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EXECUTIVE SUMMARY
Identity, Physical and Chemical Properties, Analytical Methods
A compendium is provided of aluminium compounds used in industrial settings, and as
pharmaceuticals, food additives, cosmetics and as other household products. Most aluminium
compounds are solids exhibiting high melting points. The solubility of aluminium salts is
governed by pH, because the aluminium(III)-cation (Al3+) has a strong affinity for the
hydroxide ion, which promotes precipitation. Like Mg2+ and Ca2+ ions, Al3+ in most situations
seeks out complexing agents with oxygen-atom donor sites such as carboxylate and phosphate
groups, including in biological systems. Aluminium oxides, hydroxides and oxyhydroxides
occur in numerous crystallographic forms, which exhibit different surface properties. Few
compounds of aluminium are classified in Annex 1 of the European Economic Union Council
(EEC) Directive 67/1548, with aluminium powder and sodium aluminium fluoride (cryolite)
as examples of exceptions, as well as compounds in which the anion renders them reactive
such as aluminium phosphide. And finally, the more recent analytical methods available for
the study of chemical speciation in solids and solution, and for quantitative analysis, have been
applied to the determination of aluminium and the identification of its various forms.
Sources of Human Exposure
Aluminium and its compounds comprise about 8% of the Earth’s surface; aluminium occurs
naturally in silicates, cryolite, and bauxite rock. Natural processes account for most of the
redistribution of aluminium in the environment. Acidic precipitation mobilizes aluminium
from natural sources, and direct anthropogenic releases of aluminium compounds associated
with industrial processes occur mainly to air. Certain uses lead to the presence of aluminium
in drinking water and foodstuffs.
Bauxite is the most important raw material used in the production of aluminium. Bauxite is
refined to produce alumina from which aluminium metal is recovered by electrolytic reduction;
aluminium is also recycled from scrap. Aluminium hydroxide is produced from bauxite. In
2004, primary aluminium was being produced in 41 countries, the largest producers being
China, Russia, Canada and the United States. In that year, worldwide production of primary
aluminium, alumina and aluminium hydroxide reached about 30, 63, and 5 million tonnes per
annum, respectively. More than 7 million tonnes of aluminium is recovered annually from
recycled old scrap.
The largest markets for aluminium metal and its alloys are in transportation, building and
construction, packaging and in electrical equipment. Transportation uses are one of the fastest
growing areas for aluminium use. Aluminium powders are used in pigments and paints, fuel
additives, explosives and propellants. Aluminium oxides are used as food additives and in the
manufacture of, for example, abrasives, refractories, ceramics, electrical insulators, catalysts,
paper, spark plugs, light bulbs, artificial gems, alloys, glass and heat resistant fibres.
Aluminium hydroxide is used widely in pharmaceutical and personal care products. Food
related uses of aluminium compounds include preservatives, fillers, colouring agents, anti-
caking agents, emulsifiers and baking powders; soy-based infant formula can contain
aluminium. Natural aluminium minerals especially bentonite and zeolite are used in water
purification, sugar refining, brewing and paper industries.
Aluminium has not been classified with respect to carcinogenicity; however, “aluminium
production” has been classified as carcinogenic to humans by the International Agency for
Research on Cancer (IARC) (for further explanation, please see Effects on Humans, Effects
from Occupational Exposure, Cancer). Occupational limits exist in several countries for
exposures to aluminium dust and aluminium oxide. For non-occupational environments, limits
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have been set for intake in foods and drinking water; the latter are based on aesthetic or practical,
rather than health, considerations.
Environmental Levels and Human Exposure
Aluminium may be designated as crustal in origin, and thus surface soils at uncontaminated
sites constitute a source of soluble aluminium species in surface water and aluminium-
containing particulates in sediments and ambient-air aerosols. Not surprisingly, the latter are
present extensively in air samples in agricultural communities and when road dust is extensive.
Environmental acidification is known to mobilize aluminium from land to aquatic
environments. Interestingly, aluminium levels and its various forms (species) are often similar
in source water and after its treatment with potassium alum as a flocculent during drinking
water purification.
Workers in the aluminium production and user industries, as well as aluminium welders,
experience considerable exposures to the metal and/or its compounds. In absence of
occupational exposures and chronic use of aluminium-containing antacids and buffered aspirin,
food is the major intake source of aluminium, followed by drinking water. When considering
bioavailability, namely the fraction that is actually taken up into the blood stream, food is again
the primary uptake source for individuals not occupationally exposed. However, chronic use
of antacids, buffered aspirins and other medical preparations would likely constitute the major
uptake source, even when exposed at work.
Kinetics and Metabolism
Humans—The use of 26Al as a tracer and accelerator mass spectrometry has enabled safe
studies of aluminium toxicokinetics with real exposure-relevant doses in humans. Aluminium
bioavailability from occupational inhalation exposure is ~ 2% whereas oral aluminium
bioavailability from water has been reported to be 0.1 to 0.4%. Oral aluminium bioavailability
is increased by citrate, acidic pH, and uraemia and may be decreased by silicon-containing
compounds. Oral aluminium bioavailability is also inversely related to iron status.
Oral aluminium bioavailability is greater from water than from aluminium hydroxide or
sucralfate. Oral aluminium bioavailability from aluminium hydroxide is ≤ 0.1%, and is less
with higher doses. Increased oral aluminium absorption has been suggested in Alzheimer’s
disease (AD) and Down’s subjects. Oral aluminium bioavailability from the diet has been
estimated to be ~ 0.1 to 0.3%, based on daily aluminium intake and urinary elimination. Results
of a few studies with a controlled diet and tea are consistent with this estimate.
Steady state serum to whole blood aluminium concentrations are ~ equal. Slightly > 90% of
plasma aluminium is associated with transferrin (Tf), ~ 7 to 8% with citrate, and < 1% with
phosphate and hydroxide. Normal plasma aluminium concentration is believed to be 1 to 2
μg/L. Normal tissue aluminium concentrations are greater in lung (due to entrapment of
particles from the environment) than bone than soft tissues. Approximately 60, 25, 10, 3 and
1% of the aluminium body burden is in the bone, lung, muscle, liver and brain, respectively.
Higher concentrations are seen in uraemia and higher still in dialysis encephalopathy.
Tissue aluminium concentration increases with age. Some studies have reported that the
aluminium concentration in the bulk brain samples, neurofibrillary tangles (NFT) and plaques
was higher in AD subjects than controls. Other studies have found no difference. Hair
aluminium concentration has been described but its value as an indicator of aluminium body
burden has not been demonstrated.
Greater than 95% of aluminium is eliminated by the kidney; ~ 2% in bile. Occupational
aluminium exposure increases urinary more than plasma aluminium concentration above their
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normal levels. Depending on the type and route of exposure, aluminium clearance has been
characterized as having multiple half-times and are estimated in hours, days, and years. Most
of the Al was eliminated within the first week; the terminal half-life probably represents < 1%
of the injected aluminium.
Biological monitoring of human aluminium exposure has been conducted with urine, which is
thought to indicate recent exposure, and plasma, which is thought to better reflect the
aluminium body burden and long-term exposure. However, neither is a very good predictor of
the aluminium body burden, which is better estimated by bone aluminium, the desferrioxamine
challenge test, or combined measurement of serum iPTH (parathyroid hormone) and the
desferrioxamine test.
Serum aluminium > 30 μg/L in dialysis patients has been associated with osteomalacia and
related disorders and > 80 μg/L associated with encephalopathy. Up to 5 mg/kg of
desferrioxamine once or twice weekly has been shown to be safe and effective for long-term
treatment of aluminium overload.
Animals—In studies of animals, pulmonary deposition of fly ash was 2 to 12% and was
inversely related to particle size. Oral aluminium bioavailability from water appears to be ~
0.3%. The very limited data available suggest oral aluminium bioavailability from food is less
than from water.
Oral aluminium bioavailability is increased by citrate, and to a lesser extent, other carboxylic
acids, increased solubility of the aluminium species, acidic pH, uraemia, increased dose of
soluble aluminium species, and perhaps fluoride. Oral aluminium bioavailability is decreased
by silicon-containing compounds. Oral aluminium bioavailability is also inversely related to
iron, calcium and sodium status.
Absorption of aluminium from the gastrointestinal tract (GI) appears to be primarily in the
distal intestine. There is evidence supporting several mechanisms of intestinal aluminium
absorption, including sodium transport processes, an interaction with calcium uptake, and
paracellular diffusion. Aluminium penetration of the skin is very shallow. Aluminium may be
able to enter the brain from the nasal cavity by a direct route, bypassing systemic circulation,
but convincing evidence is lacking. Absorption of aluminium from intramuscularly (i.m.)
injected aluminium hydroxide and aluminiun phosphate adjuvants is significant, and may
eventually be complete. Tissue aluminium concentration increases with age.
The volume of distribution (Vd) of aluminium is initially consistent with the blood volume,
and then increases with time. Steady state serum to whole blood aluminium concentrations are
~ equal. Greater than 90% of serum aluminium is bound to Tf. Although aluminium has been
reported in many intracellular compartments, concentrations were often greater in the nucleus.
Ferritin can incorporate aluminium.
Following i.v. injection, ~ 0.001 to 0.01% of the aluminium dose enters each gram of brain
and ~ 100-fold more each gram of bone. Brain aluminium uptake across the blood-brain barrier
(BBB) may be mediated by Tf-receptor mediated endocytosis (TfR-ME) and a Tf-independent
mechanism that may transport aluminium citrate. There appears to be a transporter that effluxes
aluminium from the brain into blood. Aluminium distributes into the placenta, foetus, milk,
hair, and can be quantified in all tissues and fluids. Greater than 95% of aluminium is eliminated
by the kidney, probably by glomerular filtration. Less than 2% appears in bile.
Aluminium clearance is characterized by multiple half-lives (t½), suggesting multiple
compartments. The terminal t½ from the lung is ~ 100 days and from the brain and other soft
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tissues > 100 days. Prolonged aluminium residence in the bone may account for the prolonged
t½ observed in most organs, including the brain.
There are no published reports of physiologically based pharmacokinetic (PBPK) modelling
of aluminium. A few models have been developed that incorporate the reported results of
toxicokinetic studies with aluminium.
Effects on Laboratory Mammals and In Vitro Test Systems
Regardless of the duration of exposure, the toxicity attributed to aluminium is dependent upon
the physiochemical properties (solubility, pH, bioavailability, etc.), type of aluminium
preparation, route of administration, and physiological status (presence of renal dysfunction).
Following oral exposure, aluminium distributes throughout the organism with accumulation
in bone, kidneys and brain being of concern to humans with evidence of renal dysfunction,
anemia or neurobehavioural alterations reported after excessive doses. The presence of
aluminium in vaccines was found to be associated with macrophagic myofasciitis (MMF) at
the site of i.m. injection. The toxicity of aluminium is affected by chelating agents and ligands
although the mechanisms underlying toxicity remain unknown. However, it should be noted
that only at excessive concentrations of aluminium are toxic manifestations seen and, hence
aluminium is considered to possess a “low” potential for producing adverse effects.
Oral administration of aluminium did not affect reproductive capacity in males or females.
Exposure to aluminium during gestation did not affect maternal health or development of the
foetuses and neonates. Further, there was no evidence of teratogenic alterations in the foetuses
of mothers fed dietary aluminium. Maternal dietary exposure to excessive amounts of
aluminium during gestation and lactation resulted in neurobehavioural abnormalities in mouse
offspring. At physiological concentrations the reproductive system does not appear to be a
target for aluminium-induced effects; and if there is exposure during pregnancy, the growth
and development of offspring of metal-treated mothers is not adversely affected.
The form of aluminium most often presented to tissues outside of the blood stream is expected
to be bound to Tf. In brain, aluminium is prone to dissociate from Tf as a soluble citrate salt.
Most cells of the central nervous system (CNS) express Tf receptor, and thus receptor-mediated
uptake would be one mechanism by which aluminium could enter cells of the brain. Free flow
endocytosis of aluminium citrate could be an alternative route of uptake. As outlined in Effects
on Laboratory Mammals and In Vitro Test Systems, Neurotoxicity, In Vivo Models,
Neuropathology, there is at least one example of human pathology which is consistent with
this mode of tissue exposure. Choroid plexus epithelia, cortical glia, and cortical neurons of
patients exhibiting dialysis associated encephalopathy (DAE) develop intracellular
argentophylllic granules that are lysosome-derived and intracytoplasmic. Uptake of
aluminium-Tf complexes via receptor-mediated endocytosis would be expected to produce just
such pathology. Whether aluminium, of any amount or speciation, escapes these compartments
to impact on intracellular processes in humans is unknown. If relatively high doses produce
pathology of such a distinctive nature, then it is reasonable to presume that lower doses of
aluminium would follow similar pathways into the nervous system of humans.
In the studies of animals, it is important to note that a few reports have documented a pathologic
accumulation of aluminium in intracellular lysosome-derived structures. Aluminium
accumulation in lysosome-like cytoplasmic granules of retinal neurons in rats exposed to very
high doses of aluminium was reported (see Effects on Laboratory Mammals and In Vitro Test
Systems, Neurotoxicity, In Vivo Models, Rodent Models of Aluminium Toxicity by Direct
Injection). Severe atrophy of the retina and loss of photoreceptors was also noted. Similarly,
another study noted intracellular accumulations of aluminium in the brain of rats feed diets
high in aluminium. For CNS it seems likely that the mode of delivery to the tissue is through
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Tf-mediated uptake. From animal studies and the clear association of aluminium exposure and
DAE, it is clear that high levels of aluminium in CNS can lead to neurotoxicity. From the
current literature it remains difficult to assess what a concentration of aluminium in serum
(chronic levels) correlates with neurotoxicity. The effects of aluminium on the developing
nervous system have also not been thoroughly addressed.
In regards to mechanisms by which aluminium could play a role in AD, there are both direct
and indirect modes of potential action. In a direct mode, aluminium could potentiate the
aggregation of molecules known to form pathologic lesions in AD. There is evidence that
aluminium can promote the aggregation of β-amyloid peptide in vitro. However, whether
aluminium would dissociate from Tf at an appreciable rate and bind β-amyloid peptide in
vivo is unclear. One study found no association between AD-like pathology and long-term
ingestion of aluminium. Indeed in this study of older patients, the incidence of AD-associated
pathology in patients with DAE was no different from controls. Although these studies would
suggest that there is little direct evidence for an association between AD and aluminium, a
study of transgenic mice that produce Alzheimer-type amyloid pathology noted that mice feed
diets high in aluminium showed increased levels of amyloid (see Effects on Laboratory
Mammals and In Vitro Test Systems, Neurotoxicity, Alzheimer’s Disease). Moreover, it is well
established in the rabbit that exposure to aluminium induces the formation of filamentous
structures containing cytoplasmic neurofilament protein (see Effects on Laboratory Mammals
and In Vitro Test Systems, Neurotoxicity, Motor Neuron Disease). Therefore, it is difficult to
determine how a life-time of exposure to aluminium might influence the development of
Alzheimer-type pathology by affecting the folding or clearance of “at-risk” proteins such as
β-amyloid, tau, and α-synuclein.
Apart from the potential that aluminium might interact directly with molecules implicated in
AD and related neurodegenerative disorders, studies in animals have revealed potential
mechanisms by which aluminium might indirectly impact on the function of the nervous
system. In Effects on Laboratory Mammals and In Vitro Test Systems, Neurotoxicity,
Alzheimer’s Disease, studies are described that reported aluminium may affect levels of
cholesterol, which has been suggested in numerous studies as a potential modulator or
Alzheimer-type amyloid formation. Effects on Laboratory Mammals and In Vitro Test Systems,
Neurotoxicity, In Vivo Models, Rodent Models of Aluminium Toxicity by Direct Injection
describes several studies that have reported elevated levels of markers of oxidative stress in
animals exposed to aluminium. These studies suggest potential mechanisms by which long-
term exposure to aluminium could be deleterious and could synergistically worsen cognitive
abilities in individuals that have pathologic abnormalities associated with AD.
However, there has not been strong evidence from animal studies that aluminium directly
modulates cognitive function. As described in Effects on Laboratory Mammals and In Vitro
Test Systems, Neurotoxicity,Behavioural Studies of Laboratory Animals Exposed to
Aluminium, there have been several studies that have examined the cognitive abilities of mice
and rats exposed to aluminium. For the most part, these studies did not report profound
cognitive impairment even when exposed to very high levels of aluminium. Therefore, it seems
unlikely that aluminium might lower the threshold for AD by blunting cognitive ability of
adults.
Outside of the nervous system, the data regarding the potential for alumimium to cause
abnormalities is mixed. There is clear evidence that sustained exposure to high levels of
aluminium can cause bone abnormalities. Aluminium is clearly deposited in bone at sites of
new growth. Bones in animals exposed to aluminium may show increased weakness and
increased brittleness. Deficiencies in calcium or magnesium may exacerbate the effects of
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aluminium. Aluminium overload leads to PTH suppression and with regards to the bone, may
be associated with altered calcium homeostasis.
Aluminium may also have negative effects on hematopoiesis. However, these effects are
relatively mild unless animals are deficient in iron. In this latter setting, there will be increased
levels of free Tf, which can then bind aluminium and compete for Tf receptor; further limiting
the amount of iron available for erythrogenesis. Aluminium may also interfere with the
metabolism of other metals. On this latter point, the strongest data, meaning most reproducible,
suggest that aluminium exposure can lead to increased excretion of phosphorous.
From the present data, however, it is difficult to determine what level of exposure poses a risk
for human health or which systems are most vulnerable. Based on projections from studies in
dogs, individuals with sustained aluminium levels in serum that are 10-fold higher than the
average range, or 1-2 μg/L, may be at increased risk for bone abnormalities. The exposure
levels at which other systems might be affected are more difficult to project, particularly when
trying to assess risk for late-onset illnesses.
Although not reported in every study, the majority of studies that utilized high doses of
aluminium reported significant reductions in weight gain, particularly in studies initiated in
young animals. The physiologic basis for this outcome is unclear, but it was reported that
animals exposed to high doses of aluminium in drinking water consumed less food. Whether
general effects of aluminium on metabolic processes depress metabolism or reduce nutritional
efficiency remains to be resolved.
Experimental aluminium inhalation has been shown to produce effects interpreted as alveolar
proteinosis and lipid pneumonia. Inhalation of aluminium had some protective effect against
quartz dust-induced fibrosis in some, but not all, studies. Intratracheal aluminium instillation
produced nodular fibrosis. Aluminium is used as an adjuvant in vaccines and hyposensitization
treatments to precipitate toxins and toxoids, enhance their antigenic properties and reduce their
rate of absorption and elimination. Aluminium can produce aluminium-species-dependent
dermal irritation.
Experimental animal studies have failed to demonstrate carcinogenicity attributed solely to
aluminium compounds. Often the response reported is associated with a tissue response to a
foreign body rather than a direct effect of aluminium exposure. This appeared to be consistent
across various routes of exposure from inhalation to intraperitoneal (i.p.) injection.
In agreement with their non-carcinogenic activity, aluminium compounds failed to show
positive results in most short-term mutagenic assays and animal experiments to determine
genotoxic potential of aluminium compounds lead to contradictory results with suggestions of
an anti-genotoxic potential.
There is little reported for aluminium compounds in the way of immunotoxicity. There may
be an altered immune response to challenge following excess aluminium exposure and this
may be influenced by the health and hormonal status of the dam with increased susceptibility
to bacterial infection seen in pregnancy.
Effects on Humans
Occupational exposure—Occupational exposure to aluminium occurs during the refining
of the primary metal and in secondary industries that use aluminium products. Several studies
have reported adverse respiratory tract effects in aluminium industry employees. Asthma-like
symptoms, known as potroom asthma, have been the most intensely investigated respiratory
effect. Wheezing, dyspnea, and impaired lung function (typically assessed by measuring forced
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expiratory volume (FEV1) and forced volume capacity (FVC)) are the primary features of this
disorder. Several cross-sectional, case-control and longitudinal studies have demonstrated
increased frequency of adverse pulmonary effects in potroom workers as compared to non-
exposed workers. The cause of potroom asthma has not been fully elucidated, but job specific
exposure measurements based on personal sampling data and analysis of plasma levels suggests
that exposure to fluorides may be an important determinant. There is some evidence to support
that individuals with hay fever and individuals with elevated eosinophil counts are at increased
risk of developing potroom asthma. Other studies did not find an association between allergic
status and the development of symptoms. The respiratory problems documented in potroom
aluminium workers are generally associated with toxic chemicals other than aluminium in the
workplace. In contrast, exposure to aluminium powder is thought to be directly correlated with
the development of pulmonary fibrosis in aluminium industry workers.
Adverse neurological outcomes as a result of occupational aluminium exposure have also been
extensively investigated. Aluminium exposure in these studies was estimated in a number of
different ways including; exposure grading for different job categories, determination of total
body burden of aluminium, number of years working in the aluminium industry, and ever v.s.
never worked in the aluminium industry. Occupational aluminium exposure was significantly
correlated with a variety of neuropyschiatric symptoms including; loss of coordination, loss of
memory, and problems with balance. Studies which specifically examined the relationship
between AD and occupational aluminium exposure did not show any significant correlation.
However, these studies are limited by methodological issues.
The occurrence of contact dermatitis and irritant dermatitis was reported in workers exposed
to aluminium alloys and aluminium dust.
Several epidemiological studies have reported an increased risk of developing lung cancer or
bladder cancer for workers in the aluminium industry, however, in all of these studies the risk
has been attributed to the exposure to the PAHs generated during aluminium production rather
than from exposure to aluminium compounds. Studies investigating the effects of occupational
exposure to aluminium are limited by many methodological issues. Rarely is a worker exposed
solely to aluminium containing compounds and exposure information is often not adequate to
rule out other toxic substances as the cause of the observed effect. Small sample sizes,
misclassification bias, selection of inappropriate comparison groups, and lack of information
to control for confounding factors are common weaknesses in these occupational studies.
Changes typical of foreign body reaction, alveolar proteinosis and wall thickening, diffuse
pulmonary fibrosis and interstitial emphysema, and some nodule formation but not to the extent
of fibrosis caused by quartz dust were associated with occupational exposure in the aluminium
industry. This was most severe in Germany during World War II, where industrial
environments were heavily contaminated with airborne aluminium flake powder. Lower
aluminium exposures contribute to Shaver’s disease, a pulmonary fibrosis seen in workers in
bauxite refining or exposed to finely divided aluminium powders; and caused pneumoconiosis,
fibrosis, and some cases of asthma.
Only one case-control study examined associations between genotype and the development of
asthma for workers employed in a potroom. However this study with very low power did not
find any association.
No reliable epidemiological studies exist to reach any conclusion on an association between
occupational exposure to aluminium and fertility or developmental effects. No clear results
have been obtained on gene-environment interactions.
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Non-occupational exposure—The neurotoxic properties of aluminium are well
established; however, the evidence surrounding the potential association between aluminium
and neurological disorders in humans is much less clear. Aluminium exposure from drinking
water has been extensively investigated in relation to the development of neurological
disorders, including AD, due to the proposed enhanced bioavailability of aluminium in this
form. The data surrounding this association is difficult to interpret due to the large variation in
study designs and the highly variable quality of these studies. The majority, but not all, of
epidemiological studies identified, reported a positive association between aluminium levels
in drinking water and risk of cognitive impairment dementia, or AD. There is some evidence
to suggest silica in drinking water is protective against the development of dementia. Fluoride
has also been identified as having a potential protective effect. Many of the studies which have
investigated the relationship between aluminium in drinking water supplies and the risk of
developing AD are limited by methodological issues. These issues include: lack of individual
exposure information, poor disease ascertainment, failure to adjust for important confounding
factors, and small sample sizes. A recent study conducted in France is methodologically
superior to the other studies conducted to date. The finding of a significant positive relationship
between drinking water aluminium levels and the development of AD in this large prospective
study, together with the finding of a positive relationship in a number of less methodologically
sound studies, suggests that the association between aluminium and AD should be further
investigated.
Regular consumers of antacids represent a unique subpopulation with heavy exposure to
aluminium. A significantly elevated odds ratio for AD for regular antacid consumers compared
to non-regular users was found; however, when only aluminium containing acids were
analyzed there was no significant association. Other studies have not found a significant
association between antacid use and AD. Little is known about the impact of aluminium-
containing antacids in human pregnancy and lactation.
Evidence surrounding the relationship between aluminium in food and the risk of AD is very
minimal. This may be a result of the difficulty in obtaining accurate exposure information in
dietary studies. One small case control study found a positive relationship between the
consumption of foods containing high levels of aluminium and the risk of developing AD.
These results have not been confirmed in a larger investigation.
There is a large body of literature, mostly in the form of clinical reports, which documents the
adverse effects of non-occupational aluminium exposure in individuals with impaired renal
function. These patients are typically exposed to aluminium through dialysate fluid or
medicinal sources. Anaemia, bone disease, and dialysis encephalopathy are the most
commonly reported complications of aluminium exposure in this population.
Contact sensitivity to aluminium is very rare. Sensitization has occurred after injection of
aluminium-adjuvant containing vaccines and pollen extracts, resulting in persistent granuloma
at the injection site. These effects are much more frequent with aluminium hydroxide than
aluminium phosphate adjuvants and more commonly seen following subcutaneous (s.c.) than
i.m. injection. Less common is sensitivity during continuous application of aluminium-
containing antiperspirants, topical aluminium application, and occupational exposure to
aluminium dust and filings which result in recurrent eczema.
Only a few epidemiological studies with no clear results have been undertaken of the possible
carcinogenic risks (such as breast cancer) of antiperspirants.
The exact genetic effects of Tf (a major transport protein for both iron and aluminium) itself
or its interaction with aluminium remains unclear and has led to contradictory results.
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As a result of inadvertent human poisoning with excessive amounts of aluminium, there are
reports of damage to bone and CNS as target organs. Further, the administration of aluminium-
containing vaccines for extended time periods was found to be associated with the development
of MMF at the injection site. In the past, individuals with impaired renal function receiving
dialysis were reported to be at greater risk for aluminium intoxication associated with
contaminated replacement fluids. However, this incidence has diminished markedly in recent
years with the use of non-contaminated fluid and replacement of high-dose antacid therapy
with alternatives. Although infants and children may be at higher risk for toxicity due to
aluminium, a causal relationship was not confirmed. Hence, it should be noted that only at
excessive concentrations of aluminium are toxic manifestations seen in human sensitive
subpopulations.
Conclusions—This report synthesizes data from relevant studies on potential health effects
of exposure to aluminium to quantify risk using the four-step process specified by the National
Research Council: 1) hazard identification, 2) exposure assessment, 3) dose-response
assessment, and 4) risk characterization.
Hazard identification qualitatively identifies adverse effects by route of exposure, and
determines whether those effects are likely in humans at some level of exposure, perhaps much
greater than exposure levels experienced in the population of interest. It is important to note
that the identification of effects that can be caused by aluminium says nothing about how likely
those effects are at exposure levels in human populations. That probability depends on the level
of exposure and the dose-response relationship. This report classified the weight of evidence
for each exposure pathway and health effect as strong, modest, limited, or having no clear
evidence (see Table 25). We concluded that there is strong evidence that aluminium can cause
irritation following exposure via either inhalation or injection. Modest evidence of an effect
exists for reproductive toxicity following oral exposure, for neurological toxicity following
either oral or injection exposure, and for bone toxicity following injection exposure. All other
effects were judged to be supported by either limited evidence or no clear evidence at all.
Exposure assessment, dose-response assessment, and risk characterization were conducted for
those effects for which the evidence was judged to be either strong or modest. The remainder
of this section describes our findings for the general population, subpopulations at special risk,
and occupationally-exposed populations.
General population
Exposure assessment quantified aluminium intake and uptake (i.e., absorption of aluminium
into systemic circulation) for a variety of pathways (see Table 26). For the general population,
intake of aluminium from food (7.2 mg/day for females and 8.6 mg/day for males) dominated
that from drinking water (0.16 mg/day) and inhalation exposure (0.06 mg/day). Antacids and
buffered aspirin can contribute on the order of thousands of mg/day to aluminium intake.
Relative contributions to uptake are ranked similarly to these intake contributions. However,
because inhaled aluminium is approximately seven times more bioavailable than aluminium
in drinking water, the contribution of inhaled aluminium to uptake (1.7 × 10-5 mg/kg b.w./day)
exceeds the corresponding contribution from drinking water (6.9 × 10-6 mg/kg b.w./day).
Uptake of aluminium in food is approximately 1 × 10-4 mg/kg b.w./day. Aluminium uptakes
from antacids and buffered aspirin amount to 3.1 × 10-1 and 4.3 × 10-2 mg/kg b.w./day,
respectively.
Relevant exposure levels of concern for the general population identified as part of dose
response assessment included: irritation following inhalation (50 mg/m3), neurological effects
due to drinking water exposure (100 μg aluminium/L water), reproductive toxicity due to oral
intake (400 mg/kg-b.w./day), and irritation following injection (1 injection). We characterized
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risk (see Table 27) by calculating a margin of exposure, or MOE (the exposure level of concern
divided by actual exposure), for each of these pathway-endpoint combinations. The MOE
values were large for local irritation following inhalation (7000) and reproductive toxicity
associated with oral intake (2900). For irritation following injection, the MOE is less than unity,
although the severity of this endpoint is limited. For neurological effects associated with
drinking water exposure, the MOE may be as small as unity. The evidence supporting this
effect, however, comes from studies that have a number of methodological limitations, a
finding that suggests the causal nature of the association is uncertain.
Subpopulations at special risk
Individuals with impaired renal function do not clear aluminium as effectively as healthy
individuals. This population can also be exposed to extremely high levels of aluminium that
are administered inadvertently via their intravenous feeds. This route of exposure may be
particularly significant because it bypasses the barrier imposed by GI absorption
characteristics. Infants, especially those born pre-term, are also vulnerable to aluminium
exposure due to immaturity of the GI wall, the BBB, and the renal system. In addition to their
added susceptibility due to compromised renal function, patients on dialysis may be subject to
higher aluminium exposure levels if dialysis or intravenous fluid becomes contaminated, a
problem that was more common in the past. Although not explicitly quantified, the
susceptibility of these populations suggests that the exposure level of concern is less than it is
for the general population. At the same time, some sensitive populations may have been
exposed to very high aluminium exposures in the past. Because of the substantial quantities of
injected fluids received by dialysis patients and their increased susceptibility, the MOE for this
pathway for this population may be less than unity.
Occupationally-exposed populations
Occupational populations can be exposed to airborne concentrations of aluminium exceeding
concentrations to which the general population is exposed by approximately three orders of
magnitude (see Table 26). Aluminium intake resulting from these exposures is estimated to be
21 mg/day, compared to 0.06 mg/day for the general population, with uptake for occupationally
exposed individuals amounting to 6 × 10-3 mg/kg b.w./day, compared to 1.7 × 10-5 for the
general population (Table 26). The resulting margin of exposure for occupationally exposed
populations is approximately 8, compared to 7000 for general population exposure to airborne
aluminium (see Table 27).
Research Needs
The following research needs were identified as important research requirements to further
improve risk assessments on aluminium:
• Studies should be conducted to quantify peak and cumulative air-borne aluminium
exposure of workers in the aluminium industry and to characterize aluminium-
containing aerosols in terms of particle composition and size. Concomitant
assessments of the bioavailability of the inhaled aerosols are crucial.
• In many occupational studies of aluminium workers, it was not known whether
respiratory tract illness was due to exposure to aluminium or other substances. There
have been very few studies of neurological effects of occupational exposure via
inhalation to aluminium and aluminium compounds (as measured in serum), and it is
not known if the very specific neurological deficits observed lead to more severe
illness such as AD. Therefore, large-scale, longitudinal, studies of occupational
exposure to aluminium and aluminium compounds via inhalation, with precise
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methods of exposure measurement, are needed to assess the risks of respiratory tract
disease and neurological effects due to aluminium and aluminium compounds.
• Further studies are needed to settle the debate over the link between aluminium and
aluminium in drinking water and neurological disorders and congnitive impairment.
Ideally, individual level data on drinking water exposure as well as other relevant risk
factors would be obtained; in the absence of this, replication of the Rondeau et al.
(2000) analysis in other study populations, with the ability to control for important
confounders and effect modifiers, is needed to assess this potential risk.
IDENTITY, PHYSICAL AND CHEMICAL PROPERTIES, ANALYTICAL
METHODS
Identity
The focus of this document is on aluminium metal, aluminium oxide and aluminium hydroxide;
however, in order to more fully understand their toxicity and related human health effects,
other pertinent studies involving aluminium compounds were reviewed. The basis for this is
that the chemistry and biochemistry of the aluminium ion (Al3+) dominate the pathways that
lead to toxic outcomes. Most aluminium compounds currently used in industry,
pharmaceuticals, food additives, cosmetics and other household products are identified in this
section (see Tables 1 and 2). Many of the compounds listed in these tables have been studied
in health-related research and are featured in the critical assessments detailed in subsequent
sections of this risk assessment document.
Tables 1 and 2 indicate that the primary identification of aluminium compounds is by the CAS
Registry Number. Other numbering systems are not as widely accepted and are thus not as
useful. For example, European Inventory of Existing Commercial Substances (EINECS)
numbers are available for aluminium (013-001-00-6), aluminium oxide (215-691-6) and
aluminium hydroxide (244-492-7) through the International Uniform Chemical Information
Database. However, most of the chemicals listed in Tables 1 and 2 are indicated as not having
been assigned such a number (ESIS, 2007). Exceptions are those compounds that exhibit high
toxicity or are widely used, such as aluminium phosphide (EINECS # 015-004-00-8) and
cryolite (15096-52-3). Note that for the three substances that form the focus for this review,
the common names assigned in the tables are the same as the EINECS names.
Purity/Impurities, Additives
Most of the substances listed in Tables 1 and 2 are generally available in high purity and thus
impurities are not an issue from a risk assessment perspective. However, it is clear that for
many of the aluminium compounds, the degree of hydration can vary. Recently, the presence
of a thin surface coating of ultrafine particles of sodium fluoride on aluminium oxide
particulates has been demonstrated for aerosols collected in an aluminium refinery (Höflich et
al., 2005;L’vov et al., 2005).
Physical and Chemical Properties
Properties of aluminium metal—Aluminium is a ubiquitous element in nature and as the
metal that has gained industrial and commercial use based upon certain physical and chemical
properties such as low specific gravity, high tensile strength, ductility, malleability, reflectivity,
corrosion resistance, and high electrical conductivity. Aluminium alloys are light, strong and
readily machined into shapes (IPCS,1997; see Sources of Human Exposure, Anthropogenic
Sources, Uses for listings of industrial and non-industrial uses).
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In spite of aluminium being highly electropositive (i.e., readily forming positive ions), it is
resistant to corrosion because of the formation of a hard, tough surface film of its oxide (Cotton
& Wilkinson, 1980). Fresh aluminium surfaces achieve this by reacting with water or molecular
oxygen. Hydrothermal oxidation of aluminium powders at 150-250°C and water vapour
pressures of 500-4500 kPa suggest that surface-adsorbed water oxidizes the aluminium with
the release of molecular hydrogen and the formation of aluminium hydroxyoxides on the
particle surface (Tikhov et al., 2003). Similarly, thermogravimetric studies of aluminium
powders have shown that oxidation with molecular oxygen generates surface layers composed
of various aluminium oxide polymorphs, specifically the γ-, θ-, and α- forms depending on the
temperature (Trunov et al., 2005) (see also Identity, Physical and Chemical Properties,
Analytical Methods, Physical and Chemical Properties, Chemical and Morphological
Speciation). Furthermore, aluminium metal is soluble in dilute mineral acids, but is inactivated
(passivated) by concentrated nitric acid; it is attacked by hot alkali hydroxides (Cotton &
Wilkinson, 1980).
Properties of aluminium compounds—Table 3 summarizes the available physico-
chemical properties of the compounds. Most of the aluminium compounds are solids exhibiting
high melting points; some are liquids. No gaseous substances were identified. Only a few of
the compounds sublimate, namely anhydrous aluminium chloride and fluoride, aluminium
nitride and sulphide, as well as the complex with 8-hydroxyquinoline. Most of the substances
are white or colourless.
The water solubility of aluminium compounds is limited except for its salts, namely the
chloride, nitrate, sulphate and chlorate (often as a corresponding hydrate). Salts of low
molecular organic acids also have some water solubility (e.g., acetate, benzoate and lactate),
as do salts containing aluminium anion complexes (e.g., ammonium hexafluoroaluminate and
tetrachloroaluminate; sodium and potassium aluminate.) As explained in Identity, Physical and
Chemical Properties, Analytical Methods, Physical and Chemical Properties, Chemical and
Morphological Speciation, pH is often a factor that can limit solubility in water. Solubility of
inorganic aluminium compounds in organic solvents is limited to those which are anhydrous
such as the bromides, chlorides, and iodides. Aluminium alkyls, alkyl halides, alkoxides and
complexes of long-chain FAs and of high molecular mass organic ligands exhibit solubility in
organic solvents.
Aluminium metal, aluminium oxide and aluminium hydroxide are nearly insoluble in water
and organic solvents, while freshly prepared aluminium metal surfaces do react with water to
form an inert protective coating. By contrast, powdered aluminium can react with water to
yield hydrogen gas (see below Identity, Physical and Chemical Properties, Analytical Methods,
Physical and Chemical Properties, Chemical and Morphological Speciation).
In terms of chemical reactivity, the following compounds are notable for their reactions with
water: aluminium alkyls, alkyl halides, hydrides; the anhydrous halides (namely bromide,
chloride and iodide); and the carbide, chlorate, nitride and phosphide. Explosive gases are
released on contact with water, specifically hydrogen (H2) from the hydrides and methane
(CH4) from the carbide. Release of toxic gases on hydration can also occur, that is chlorine
dioxide (ClO2) from the chlorate; ammonia (NH3) from the nitride; phosphine (PH3) from the
phosphide; and hydrogen sulphide (H2S) from the sulphide.
As described in Identity, Physical and Chemical Properties, Analytical Methods, Physical and
Chemical Properties, Chemical and Morphological Speciation, the Al3+ ion has a very high
affinity for the hydroxide ion, even at relatively low pH values. This is consistent with the
Class A (Hard) cation reactivity classification of Al3+, that is, it strongly prefers oxygen-
containing organic ligands over those with nitrogen or sulphur as the donor atom. Its affinity
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for the halide anions increases in the order I−<Br−<Cl−≪F− (Nieboer & Fletcher, 1996; Nieboer
et al., 1999; Nieboer & Richardson; 1980). This reactivity classification is consistent with the
stability or instability patterns towards water outlined for the aluminium compounds listed in
Tables 1-3. As a Class A (Hard) cation, the chemistry of Al3+ resembles that of Mg2+, Ca2+,
Na+ and K+. In fact, it may be viewed as a super Ca2+ or Mg2+ ion (Nieboer et al., 1999;
Nieboer & Richardson, 1980), thereby often inhibiting the biological roles of these essential
divalent cations, for example on the surface tissues of fish gills (Reid et al., 1991; Wilkinson
et al., 1993).
In biological systems, Al3+, like Mg2+ and Ca2+, seeks out carboxylate and phosphate groups
linked to macromolecules (i.e., proteins, RNA and DNA) or as constituents of low-molecular-
mass ligands such as amino acids, nucleotides, citrate, phytates, lactate, carbonate, phosphate
and sulphate (Harris, 1992). Because of the small size of the unhydrated Al3+, it can also bond
to the phenolic group of the amino acid tyrosine in proteins. Most of the Al3+ in human serum
is bound to the protein Tf (see Toxicokinetics, Distribution (Including Compartmentalization),
Human Studies, Transport in Blood), which is a recognized carrier of trivalent metal ions,
especially Fe3+ (Barker et al., 1990; Harris, 1992; Harris et al., 1996). Involvement of tyrosine
phenolate groups in the Fe3+-Tf complex is well established (DaSilva & Williams, 1991).
Under certain instances, such as in its citrate complex, Al3+ can also bind to a deprotonated
alcohol group (Feng et al., 1990).
Chemical and morphological speciation—Formally, the definition of elemental
speciation is limited to a chemical perspective; thus a chemical species is defined as: “a specific
form of a chemical element, such as a molecular or complex structure or oxidation
state” (Caruso et al., 2003; Templeton et al., 2000). However, Nieboer et al. (1999; 2005)
subscribe to a broader working definition of “speciation”, that is: “an interdisciplinary field of
activity concerned with all dimensions of the occurrence and measurement of an element in
separately identifiable forms (i.e., chemical, physical or morphological)”. The former and
more restrictive definition is employed below for the solution chemistry of Al3+, while the
latter is helpful when considering the reactivity of aluminium oxide and aluminium hydroxide
solids.
The strong dependence of Al3+ speciation on pH is illustrated by typical distribution curves in
Figures 1 and 2.
From Figure 1, it is clear that, at physiological pH of 7.4, little or no free (hydrated) Al3+ exists
in aqueous solution; the anion Al(OH)4− predominates. The distribution curve in Figure 2
illustrates the competition between hydroxide and citrate as ligand molecules. Under the
conditions indicated in the legend to Figure 2, the competition with the OH− is suppressed by
the citrate tetra-anion. At physiologic pH, the AlLH-1(OH)2- complex dominates.
The formation of aluminium fluoride complexes in fluoridated drinking water has been debated
extensively. Fluoridation of municipal drinking water supplies is a common practice for the
prevention of dental caries; fluoride is added at a concentration of around 50 μmol/L (1 mg/
L), corresponding to a pF (that is a −log[F]) of 4.3. Further, the pH of municipal water supplies
is typically 8.0 ± 0.4 (e.g., Nieboer et al., 1995). Consequently, and with reference to Figure
3, the distribution curves depicted for pH 7.5 are the most relevant. Thus, again, Al(OH)4− is
the dominant form in which Al3+ occurs, with little evidence for complexation with the fluoride
ion.
As reviewed elsewhere (see, for example, Baes & Mesmer, 1976; Cotton & Wilkinson,
1980; Nieboer et al., 1995; Stumm & Morgan, 1996; Teagarden et al., 1981), at relatively high
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concentrations of Al3+ (≥ 100 μg/L) in the pH range 5.3 to 6.5, polymerization occurs and
results in the formation of polynuclear species such as Al13O4(OH)247+.
In Human Exposure, Environmental Levels, Water, and Human Exposure, General Population
Exposures, Drinking Water, the various operationally defined forms of aluminium in surface
and drinking water are discussed, including complexes of natural organic ligands.
The reactivity of aluminium powders depends on their morphology (size, shape and surface
area), bulk density and aluminium content. For example, Ilyin et al. (2002), have demonstrated
that nanoparticles of fine aluminium powders exhibit maximal values of oxidation
(combustion) rates compared to microparticles, and this occurred at lower temperatures. Not
surprisingly, because of their thinness and corresponding high surface area, aluminium flake
powders (see Sources of Human Exposure, Anthropogenic Sources, Uses, Aluminium
Powders) also are relatively reactive. Trunov et al. (2005) and Meda et al. (2004) have reported
similar findings. Consequently fine and ultrafine aluminium powders show better promise as
propellant additives than do the more conventional-sized (of the order of 10μm) aluminium
powders. Interestingly, the combustion products of nano-sized aluminium powders are also
different, such as a higher proportion of low-temperature aluminium oxide polymorphs (Meda
et al., 2004) (see below) and product morphology. Ilyin et al. (2002) demonstrated that
combustion of spherical micro-sized aluminium powders resulted in spherical products, while
spherical fine powders produced submicron needles. As explained in the next paragraph, this
is important for human exposure characterization.
The size of aerosols is important in terms of where they are deposited in the respiratory system
and where they exert their toxic effects. In the workplace it is now common to consider three
health-related aerosol fractions (Nieboer et al., 2005; Oller & Bates, 2005; Vincent, 1995). The
inhalable aerosol fraction corresponds to the total amount of airborne particulates that enters
the body through the nose and/or mouth during breathing (aerodynamic diameters (dae) of ≤
100μm). The thoracic aerosol fraction penetrates the tracheoalveolar region of the lung (dae
< 28μm), while the respirable aerosol fraction (dae < 10μm) penetrates the alveolar region of
the lung (includes the respiratory bronchioles, the alveolar ducts and sacs). For outdoor
aeorosols, it has been customary to measure the particulate matter (PM)10 fraction, which
corresponds to the thoracic fraction but with particles larger than dae=10μm excluded (Nieboer
et al., 2005; Vincent, 2005). For a description of these differences, the reader is referred to the
review by Vincent (2005) in which the various aerosol fractions criteria are depicted
graphically as a function of aerodynamic diameter. More recently, exposure to fine particles
(dae<2.5μm) has become the focus in relation to increased rates of cardiovascular and
respiratory diseases (Dockery et al., 1993; Englert, 2004; Pope et al., 2002). Ultrafine particles
(dae < 100 nm) are also gaining in importance. Fine and ultrafine particles are included in the
respirable and PM10 fractions. It is clear from the material presented in Identity, Physical and
Chemical Properties, Analytical Methods, Physical and Chemical Properties, Properties of
Aluminium Metal and the previous paragraph that, depending on the exact industrial process
involved, aluminium powder workers have the potential of being exposed to some or all of the
aerosol fractions discussed. This also appears to be the situation in aluminium refinery workers
(Höflich et al., 2005; Skaugset et al., 2005; Thomassen et al., 2006).
Aluminium oxide (Al2O3) occurs in two major forms. α-Al2O3 [corundum; CAS No
1302-74-5] constitutes a high temperature form and is formed on heating aluminium hydroxide,
Al(OH)3, at a temperature of 1000 °C or above. It is very hard and resistant to hydration and
attack by acids; it occurs in nature as corundum (Cotton & Wilkinson 1980). γ-Al2O3 is
generated at 500°C and readily takes up water and dissolves in acids. Other minor forms
generated when heating Al(OH)3 include: χ-, κ-, δ-, θ-Al2O3 (Pearson, 1992; Trunov et al.,
2005). Recent studies suggest that the structure of the surface layers of α-Al2O3 depends on
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hydration: on the surface of a highly polished single crystal, the aluminium atom (more
correctly Al3+ ions) are exposed, while in the ideal (unrelaxed) structure the oxygen atoms
(actually oxide anions, O2-) are at the surface. On hydration, the latter are overlaid by a semi-
ordered absorbed water layer with the presence of extensive hydrogen bonding and hydroxyl
groups resulting in a relaxed structure. In fact, the hydrated surface structure appears to be in
between that of the ideal α-Al2O3 surface and that of γ-Al(OH)3. The Al3+ ions in the Al-
terminated surface are strong Lewis acids and react strongly with water, while surface hydroxyl
groups are Lewis bases that interact with metal ions (Eng et al., 2000). Surface reactivity
constitutes the basis for the use of aluminium oxide and hydroxide as industrial catalysts,
absorbents and chromatography packing materials (i.e., as stationary phases). Not surprisingly,
the reactivity of solid Al2O3 depends on its specific crystal structure and hydrophilic/
hydrophobic surface properties, and thus the degree of surface hydration (Pearson, 1992).
Gibbsite, γ-Al(OH)3 [CAS No 14762-49-3] is one of the three minerals that make up bauxite
ore; the others being Al2O3 and the oxyhydroxides boehmite [α-Al2O3 • H2O or α-AlO(OH)]
and diaspore [β- Al2O3 • H2O or β-AlO(OH)]. Of the latter, diaspore is the high temperature/
high pressure form (Pearson, 1992). Gibsite has three structural polymorphs, namely bayerite
[α-Al(OH3); CAS No 20257-20-9], nordstandite [β-Al(OH3); CAS No 13840-05-6] and
doyleite which is rather rare (Mineralogy Database, 2006). On heating the Al(OH)3,
polymorphs follow a different Al2O3 transition sequence in reaching the high temperature α-
Al2O3 form (Pearson, 1992).
In simple terms, the surface layer of a metal binary compound has exposed metal ions (and
anions) with reduced coordination number, which can behave as Lewis acids (or bases). At the
solid-solution interface, proton association and dissociation can lead to pH-dependent surface
charges and complexation. This is further complicated by specific adsorption of cations or
anions right at the solid/solution interface, with some ordering of counter-ions in a more diffuse
layer at points further into the solution (Stumm & Morgan, 1996). A zero point of charge occurs,
which is pH dependent. It is also influenced by the extent of specific ion adsorption. In addition
to surface electrostatic and complexation reactions, hydrogen-bonding and London-van der
Waals forces can be involved in the adsorption of surfactants, non-polar organic solutes,
polymers and polyelectrolytes (Stumm & Morgan, 1996).
Adsorption capacity is central to some of the major uses of Al2O3, Al(OH)3 and other
aluminium compounds (e.g., aluminium phosphate, AlPO4). Adsorption of antigens onto Al
(OH)3 and AlPO4 constitutes the basis for their use as vaccine adjuvents (Gupta, 1998). At
neutral pH, gels of these compounds have different charges, the phosphate being negative and
the hydroxide positive. This is important, relative to the charge borne by the antigen at
physiological pH. The various forces described are optimized by adjustment of the pH and
ionic strength of the medium, temperature, particle size of the adsorbent, and the surface area
of the latter (Gupta, 1998). Similarly, the natural hydrophilic surface characteristic of Al2O3
is central to its use as solid-phases in chromatography. More recently, stable surface coatings
have been developed which render the Al2O3 surface hydrophobic, which makes it even more
versatile in chromatographic applications. Al2O3 and the aluminium oxyhydroxides are used
to remove moisture from gases such as argon, alkanes, and sulphur dioxide. They are also used
to remove hydrogen fluoride (HF) from air by adsorption; fluoride ions can also be removed
effectively by them from water. Fluoride is adsorbed on to alumina at low pH values and can
be desorbed on increasing the pH. Clearly, the inhalation of particulates of Al2O3 and related
oxyhydroxides in aluminium smelting operations may constitute a delivery vehicle for
adsorbed HF (Höflich et al., 2005; L’vov et al., 2005). Finally, the use of finely divided
aluminium metal, Al(OH)3, aluminium potassium silicate and other aluminium compounds to
generate dye (colour) lakes (see Table 2) stems from the surface adsorptive forces/capacities
described.
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Classification
Of the three substances reviewed in detail in this report, only aluminium powder is classified
in Annex 1 of the European Economic Union Council Directive 67/548. Indeed, very few of
the compounds listed in Tables 1 and 3 are classified; those that are listed are recognized as
hazardous and are widely used, such as cryolite and aluminium phosphide (see Identity,
Physical and Chemical Properties, Analytical Methods, Identity).
Although aluminium (EINECS # 013-001-00-6) is not included in a priority list, it is considered
hazardous in powdered form. Aluminium powder is classified as: F; R 10,15 and the following
risk (R) and safety (S) phrases have been assigned:
R 10: flammable
R 15: contact with water liberates extremely flammable gasses
S 2: keep out of reach of children
S 7/8: keep container tightly closed and dry
S 43: in case of fire, ‘never use water’
Cryolite is on the EEC Priority List #3 and has the risk classification: T; R20/22-N; R48/23/25-
Xn; R51-53. Assigned risk (R) and safety (S) phrases are:
R 20/22: harmful by inhalation if swallowed
R 48/23/25 toxic: danger of serious damage to health by prolonged exposure through
inhalation and if swallowed
R 51/53: toxic to aquatic organisms, may cause long-term adverse effects in the
aquatic environment
S1/2: keep locked up and out of reach of children
S 22: do not breathe dust
S 37: wear suitable gloves
S 45: in case of accident, or if you feel unwell, seek medical advice immediately
(show the label where possible)
S 61: avoid release to the environment; refer to special instructions/ safety data
sheets
Aluminium phosphide is not listed on a priority list and has the classification of: F; R15/29-T;
R28,32-N; R50. The risk and safety phrases are:
R 15/29: contact with water liberates toxic, extremely flammable gas
R 28: very toxic if swallowed
R 32: contact with acids liberates very toxic gas
R 50: very toxic to aquatic organisms
S1/2: keep locked up and out of reach of children
S 3/9/14: keep in a cool, well-ventilated place away from…(incompatible materials
to be indicated by the manufacturer)
S 30: never add water to this product
S 36/37: wear suitable protective clothing and gloves
S 45: in case of accident, or if you feel unwell, seek medical advice immediately
(show the label where possible)
S 61: avoid release to the environment; refer to special instructions/ safety data
sheets.
Analytical Methods
As emphasized previously (ATSDR, 1999; IPCS, 1997; Nieboer et al., 1995; Savory et al.,
1988; Savory & Wills, 1988; Wilhelm & Ohnesorge, 1990), inadvertent contamination during
collection, storage, handling, sample preparation and analysis of body fluids and other
specimens can introduce considerable uncertainty in the determination of aluminium at the
ultratrace levels (≤ 1μmol/L or ≤ 1μmol/kg). It is therefore essential that authors provide
documented proof that adequate quality control and assurance measures were in place during
the study for which analytical results are reported.
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The analytical chemistry of aluminium has been critically reviewed (Savory et al., 1988; Savory
& Wills, 1988; Taylor & Walker, 1992) and extensively summarized (ATSDR, 1999; IPCS,
1997). Electrothermal atomic absorption spectrometry (EAAS), also referred to as graphite
furnace atomic absorption spectrometry, has traditionally been the method of choice for
biological samples and aqueous media. The newest technical development, namely
inductively-coupled plasma mass spectrometry (ICP-MS), is now a powerful alternative
because of the added capabilities of multi-elemental determinations and speed (Marchante-
Gayon et al., 1999; Rodushkin & Odman, 2001; Trentini et al., 1993; Zhu et al., 2005).
Optimization of methods and protocols for specific applications will continue for ICP-MS as
has been done for EAAS (e.g., for aluminium in bone, (Liang et al., 1991); aluminium in
cerebrospinal fluid (CSF), (Johnson & Treble, 1992); aluminium in plasma and urine by
transversely heated EAAS, (Bradley & Leung, 1994); effects of modifiers and chloride on the
determination of aluminium (Tang et al., 1995). Ion exchange, ion chromatography, and high
performance liquid chromatography have been employed in sorting out aluminium speciation
in surface water, drinking water and soil extracts (e.g., Mitrovic & Milacic, 2000; Schintu et
al., 2000; Drabek et al., 2005).
Localization of aluminium in tissues by energy-dispersive x-ray analysis and electron-probe
microanalysis (see Savory & Wills, 1988 for references) has largely replaced the earlier use of
histochemical staining employing dyes such as aluminon (Buchanan et al., 1981; Clark &
Krueger, 1985; Smith & McClure, 1982).
Limitations of the latter approach have recently been demonstrated for localizing aluminium
in maize root tissue (Eticha et al., 2005), although Ruster et al. (2002) recommended this
technique for quantifying deposition of aluminium in bone. In 1985, Verbueken et al. critically
reviewed studies that examined the localization of aluminium in histological sections, namely,
by electron probe X-ray microanalysis, secondary ion mass-spectrometry and laser microprobe
mass analysis (LAMMA). These techniques are used in conjunction with scanning electron
microscopy (SEM) or transmission electron microscopy (TEM); thus the microanalytical
results are correlated with tissue structure. Further details about these and related
microanalytical techniques are outlined by Ortner et al. (1998). Verbueken et al. (1985)
concluded that all three techniques are helpful in localizing aluminium in tissues, but LAMMA
provides the greatest sensitivity (i.e., can detect lower concentrations). Recently, accumulation
of aluminium was detected in newly-formed lamellar bone after implantation of titanium plates
containing 6% aluminium employing energy dispersive X-ray spectrometry (EDXS) in
conjunction with SEM. Similarly, the use of micro-beam proton-induced X-ray emission (PIXE
μbeam) confirmed that aluminium leaked diffusely from a titanium-aluminium-vanadium alloy
dental implant into the surrounding bone, while vanadium did not (Passi et al., 2002).
SEM, TEM, and SEM coupled with EDXS permit the determination of elements, including
aluminium, in micrometre-size particles (Ortner et al., 1998). This approach has been employed
to characterize micrometre-sized alumina (Al2O3 or related oxyhydroxides) wear debris from
artificial hip joints in wear simulations (Tipper et al., 2002), and in workplace aluminium-
containing aerosol particles (Höflich et al., 2000; 2005; L’vov et al., 2005; Nieboer et al.,
2005; Rollin et al., 1996; Weinbrüch et al., 2002).
Ellis et al. (1988) illustrated that in vivo monitoring of skeletal aluminium burden in patients
with renal failure using neutron activation analysis (NAA) was possible. However, the research
reactor required is not widely available. The promise of a portable instrument for an accelerator-
based in vivo procedure for detecting aluminium body burden by NAA has recently been
reported (Comsa et al., 2004).
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26Al is a rare radioactive isotope of aluminium and is produced in particle accelerators by
bombarding a magnesium target with deuterons. It is radioactive and has a long t½ (716,000
years) and can thus be detected radiometrically or by mass spectrometry (Priest, 1994). Whole-
body counting is possible and increases the versatility of this technique. It has been employed
in determining the human toxicokinetics, and the tissue distribution, bioavailability and GI
uptake of aluminium (Priest, 2004).
SOURCES OF HUMAN EXPOSURE
Natural Occurrence
Aluminium and its compounds are major constituents of the Earth’s crust, comprising up to
about 8% of the Earth’s surface. It is the third most abundant element (after oxygen and silicon)
and the most abundant metallic element, and is found in combination with oxygen, fluorine,
silicon, sulphur and other species; it does not occur naturally in the elemental state (ATSDR,
1999; Brusewitz, 1984; Wagner, 1999). Naturally occurring aluminium is present in silicates
such as feldspars and micas, complexed with sodium and fluorine as cryolite, and in bauxite
rock (comprising hydrous aluminium oxides, aluminium hydroxides and impurities such as
free silica) (IPCS, 1997).
Anthropogenic Sources
Aluminium is released and dispersed in the environment by natural processes and from human
activity. Natural processes account for most of the redistribution of aluminium in the
environment (ATSDR, 1999; IPCS, 1997; Wagner, 1999) as a result of the weathering of rocks
and minerals in which it is present. Mobilization from natural sources can, however, also result
from the deposition of acidic precipitation (IPCS, 1997; Wagner, 1999). Direct anthropogenic
releases of aluminium compounds occur primarily to air and these are associated with industrial
processes. Thus, the mining and processing of aluminium ores and the production of aluminium
metal, alloys and compounds can lead to the release of aluminium compounds into the
environment. The use of aluminium and its compounds in processing, packaging and storage
of food products, and as flocculants in the treatment of drinking-water may contribute to its
presence in drinking-water and food stuffs (ATSDR, 1999).
Production levels and processes
Aluminium—Bauxite, a naturally occurring, heterogeneous material, is the most important
raw material used in the production of aluminium (ATSDR, 1999; Dinman, 1983). Bauxite is
made up primarily of one or more aluminium hydroxide minerals together with various
mixtures of silica, iron oxide, titania, aluminium silicates, and other impurities in minor or
trace amounts. The commercial sources of bauxite consist mainly of gibbsite or boehmite.
Bauxite is extracted by open-cast mining (Dinman, 1983; IPCS, 1997). Nepheline and alunite
are minerals which have also been used as raw materials for production of aluminium oxide.
They are still used at some plants in the Commonweath of Independent States, but are a minor
part of world production (Kammer, 1999).
The principal method used in producing aluminium metal involves three main steps (ATSDR,
1999; Browning, 1969; Dinman, 1983; IARC, 1984):
• refining of bauxite to produce alumina (Bayer process);
• electrolytic reduction of alumina to produce aluminium (Hall-Héroult process); and
• casting of aluminium into ingots.
Aluminium is first extracted at 140 - 250°C with caustic soda from the bauxite, precipitated as
aluminium hydroxide after the removal of iron and silicon impurities, and subsequently
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converted to aluminium oxide in a calcination process. These steps encompass the Bayer
process (Sleppy, 1992). In the second stage, the aluminium oxide is dissolved in molten cryolite
(Na3AlF6) and electrolyzed at temperatures of 920-980°C at carbon electrodes to yield the pure
molten metal at the cathode and carbon dioxide at the anode (as well as some carbon monoxide
and oxygen). The electrolytic cells are referred to as pots and the work area is the potroom.
Because the anodes are consumed, they need to be replaced or generated in situ. In the first
instance, pre-bake anodes are employed, while in the second approach (referred to as the
Søderberg method) the anode is baked on site and carbon, in the form of a paste of petroleum
coke and coal tar, has to be added to the top of the pot (Abramson et al., 1989; Kongerud et
al., 1994; Staley & Haupin, 1992). Pre-baked anodes are produced in a separate department by
moulding petroleum coke and coal tar pitch binder into blocks and baking at 1000-1200°C.
Casting constitutes the final third step and is carried out in the foundry. It involves the pouring
of aluminium ingots. Note that aluminium trifluoride (AlF3) is an important additive for the
potroom electrolyte. It is prepared from Al2O3 and hydrogen fluoride (Sleppy, 1992; Staley &
Haupin, 1992).
Aluminium produced by the Hall-Héroult electrolytic reduction process may be refined to a
purity of up to 99.9% by the Badeau low-temperature electrolytic process (ATSDR, 1999;
HSDB, 1995). This process is not the only primary refining method. Other approaches have
been successfully developed, especially for the production of high purity (99.995%) aluminium
(Staley & Haupin, 1992).
Secondary aluminium refining, also referred to as smelting or more commonly recycling,
involves recycled aluminium scrap as feed. The scrap is melted in furnaces, fluxes are added,
unwanted constituents are removed in the form of dross, and other metals are added if the final
products are alloys (Healy et al., 2001). Dross forms on the surface of molten aluminium and
consists of aluminium oxide, entrained aluminium, and smaller amounts of aluminium nitride,
aluminium carbide and magnesium oxide (Staley & Haupin, 1992). This is further processed
to recover the aluminium content.
The use of carbon electrodes in the electrolytic reduction process leads to the generation of
volatile by-products including polycyclic aromatic hydrocarbons (PAH) (ATSDR 1999;
Dinman, 1983; IARC, 1984).
Aluminium oxide—Aluminium oxide is produced from of bauxite; it is crushed, ground,
and then leached with sodium hydroxide to form sodium aluminate from which the aluminium
hydrate is precipitated and then calcined to produce aluminium oxide (alumina) (ATSDR,
1999; HSDB, 1995).
Aluminium hydroxide—Aluminium hydroxide is also produced from bauxite; the ore is
dissolved in a solution of sodium hydroxide and the aluminium hydroxide precipitated from
the resulting sodium aluminate solution by neutralizing with carbon dioxide or by
autoprecipitation (ATSDR, 1999; HSDB, 1995; Sax & Lewis, 1987).
Trends in production
Bauxite: In 1992, worldwide production of bauxite was 106 million tonnes; based on a
comparison of this quantity with the quarterly average values for 1993 and 1994, production
in major producing countries appeared to be fairly constant (IPCS, 1997; World Bureau of
Metal Statistics, 1994). However, by 2003 world mine production of bauxite had reached
approximately 146 million tons (150 million tonnes) and rose to about 156 million tons (160
million tonnes) in 2004 (USGS, 2005a)1.
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Alumina: In 1992, total alumina production worldwide was 33.8 million metric tonnes; this
total production figure included 30 million tonnes for metallurgical uses and 3 million tonnes
for non-metallurgical uses (IPAI, 1993; IPCS, 1997). By 1998, alumina production reached
47.5 million tonnes (USGS, 2002) and by 2004 was close to 63 million tonnes; Table 4 shows
the production figures for different global regions for the period 2000 to 2005 (IAI, 2006a;
USGS, 2005b; USGS, 2006a).
Aluminium hydroxide: Worldwide production of aluminium hydroxide in 2004 was
estimated to be 5 million tonnes per annum (E. Nordheim, personal communication, 2006).
Aluminium: It is noted by the International Programme on Chemical Safety (IPCS) (IPAI,
1993; IPCS, 1997) that annual worldwide production of primary aluminium was 14.8 million
tonnes in 1992; by 2004 production essentially doubled to 29.6 million tonnes (Table 5).
Between 2001 and 2004 production increased by between 6 and 8% per annum. In 2004,
primary aluminium was being produced in 41 countries, the largest producers being China
(22% of world production) followed by Russia (12%), Canada (9%), the United States (8.5%),
Australia (3.8%), Brazil (5%), and Norway (4.5%) (USGS, 2004). China and Russia surpassed
the United States as the largest producers of primary aluminium in 2001 (Figure 4).
In addition to primary aluminium production, more than 7 million tonnes is produced per year
from post consumer (old) recycled scrap. Almost 100 per cent of all production scrap and over
60 per cent of all old scrap are recycled; it has been noted that the proportion of aluminium
produced from scrap (“recycled aluminium”) is rising rapidly (IAI, 2005).
The recycling of aluminium requires much less energy than that used to recover the metal from
its ores. The annual amount of aluminium recovered from purchased and tolled (new and old)
scrap was about 15 million tonnes in 2004 (IAI, 2005). The automotive industry is the largest
consumer of recycled cast aluminium accounting for about 70% of production. It was expected
that demand for secondary aluminium would increase significantly as the automotive industry
addressed the growing need for lighter vehicles (Wagner, 1999).
In 2004, the total shipments worldwide of aluminium ingots including primary and recycled
metal were estimated at 62 million tonnes; shipments of aluminium powder were estimated to
be 0.2% (75 000 tonnes per year) of this total (E. Nordheim, personal communication, 2006).
Uses
Industrial and non-industrial uses of aluminium and its compounds are summarized in Tables
6 and 7.
Aluminium—Aluminium metal is light in weight and is durable because surfaces of products
made from it are oxidized to form a thin protective coating of aluminium oxide (alumina).
However pure aluminium is extremely soft and therefore is often mixed with other metals and
elements (e.g., copper, magnesium, manganese, silicon, lithium and zinc) to form alloys which
are stronger and harder and hence of increased versatility (ATSDR, 1999; Wagner, 1999). The
tensile strength of some copper-aluminium alloys can exceed that of mild steel by as much as
50% (Wagner, 1999). Reference to the uses of aluminium thus normally relates to those for
aluminium as an alloy.
Aluminium metal and its alloys are used extensively in building construction (e.g., siding,
roofing, doors, windows), in transportation (in the manufacture of automobiles and aircraft),
1Reference states that data were not available for the United States.
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in packaging (e.g., for beverage cans), and in electrical equipment. Other uses include die-cast
motor parts, cooking utensils, decorations, road signs, fencing, beverage cans, coloured
kitchenware, food packaging, foil, corrosion-resistant chemical equipment, solid fuel rocket
propellants and explosives, dental crowns, jewellery and denture materials. Aluminium is also
used for power lines, electrical conductors, insulated cables and wiring (ATSDR, 1999; IAI,
2006b). The largest markets for aluminium are transportation (27%), building and construction
(23%), packaging (16%) and electrical equipment (10%). Transportation uses are one of the
fastest growing areas for aluminium use showing a growth rate of about 4% per annum in 1999
(Wagner, 1999). Table 8 lists the approximate distribution of the different product segments
in which aluminium is used on a global basis (E. Nordheim, personal communication, 2005)
The major markets for aluminium products in the United States in 1997 are summarized in
Table 9 (ATSDR, 1999;USGS, 1997).
Over 95% of beer and carbonated drinks are packaged in aluminium cans. Other food-related
applications of the metal are as sheet and foil for pie plates, frozen food trays and other food
packaging, cooking utensils. Consumer product and medical uses include toys, jewellery,
paints and protective coatings, and dental alloys for crowns and dentures (ATSDR, 1999;
USGS, 1997).
Aluminium powders—Aluminium powders have been used for over a century in the
production of pigments (Dinman, 1987) (see also Table 7). Today, aluminium flake powders
constitute an important component of automobile paints (Hong & Kim, 2002). They are
produced by milling of gas-atomized powder or foil scrap (Hong & Kim, 2002; James et al.,
1991; Lawley, 1986). Flake particles have unique dimensions, with the length and width
(measured in micrometres, μm) up to several hundred times its thickness (measured in
nanometers, nm). By contrast, gas-atomized particles are smooth and generally spherical or
ovoid, with the length, width and thickness being of the same order of magnitude. Sizes are in
the nm or μm range corresponding respectively to ultrafine or fine particles and microparticles
(see Identity, Physical and Chemical Properties, Analytical Methods, Physical and Chemical
Properties, Chemical and Morphological Speciation). Gas-atomization involves aspirating a
fine stream of molten metal into a high velocity air or gas jet to generate tiny droplets which,
on cooling, solidify (Dinman, 1987; Lawley, 1986; Liddiard, 1984). Aluminium particulate
powders are employed as fuel additives in propellants, explosives and pyrotechnics (Dinman,
1987; Meda et al., 2004; Trunov et al., 2005) (see also Table 6).
Other aluminium compounds—Aluminium sulphate is used in water treatment and as an
accelerator for concrete solidification (high alumina cements) (ATSDR, 1992; Helmbolt et al.,
1985; IPCS, 1997). Aluminium oxide is used in the production of aluminium; more than 95%
of alumina produced is used for this purpose (E. Nordheim, personal communication, 2005).
Aluminium oxide is also used in the manufacture of abrasives, refractories, ceramics, electrical
insulators and resistors, catalysts, paper, spark plugs, and laboratory works, light bulbs,
artificial gems, alloys, glass, heat resistant fibres, food additives (as a dispersing agent), in
hollow-fibre membrane units for water desalination and in haemodialysis (ATSDR, 1992;
1999; Bradberry et al., 1997; Helmbolt et al., 1985; HSDB, 1995; IPCS, 1997).
Aluminium hydroxide is used widely in non-prescription stomach antacids, in buffered
analgesics and other pharmaceuticals, and in antiperspirants and dentifrices, as a filler in
cosmetics, plastics, rubber and paper and as a soft abrasive for brass and plastics (ATSDR,
1999; HSDB, 1995); it is also used pharmaceutically to lower the plasma phosphorus levels in
patients with renal failure (ATSDR, 1999; Budavari et al., 1989). Aluminium hydroxide is also
the basis for producing fire retardant materials.
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Food-related uses of aluminium compounds include preservatives, fillers, colouring agents,
anti-caking, agents, emulsifiers and baking powders; soy-based infant formula can contain high
amounts of aluminium. Natural aluminium minerals especially bentonite and zeolite are used
in water purification, sugar refining, brewing and paper industries (ATSDR, 1992; IPCS,
1997).
Legislative controls
Classification and labelling—The carcinogenic risk from aluminium and its compounds
has not been evaluated by IARC. However, IARC has deemed that that there is sufficient
evidence to show that certain exposures occurring during the production of aluminium cause
cancer in humans; therefore “aluminium production” has been classified as carcinogenic to
humans (Group I) (IARC, 1987). The U.S. Environmental Protection Agency (EPA) has not
classified aluminium for human carcinogenicity (ATSDR, 1999; IRIS, 1999) and the American
Conference of Governmental Industrial Hygienists (ACGIH) has designated aluminium as a
group A4 substance (“not classifiable as to human carcinogenicity”) (ACGIH, 1996; ATSDR,
1999).
Classification and labelling requirements in the European Union (EU) are based on inherent
hazardous properties of a substance, and are laid down in Directive 67/548 (EEC, 1967) and
later amendments and adaptations. The requirement covers physico-chemical properties,
human health, and environmental toxicity. The classification is based on the results of specific
prescribed tests, generally test guidelines developed by the Organization for Economic
Cooperation and Development. Discussions regarding the classifications with respect to
considerations for either health or environment are conducted in EU expert groups which
evaluate the test data and propose the classification. This proposed classification is set out in
Directives from the Commission. The classification of aluminium compounds is summarized
in Identity, Physical and Chemical Properties, Analytical Methods, Classification.
Due to hepato-, skeletal and neurotoxicity seen in premature infants that received aluminium
as a contaminant in total parenteral nutrition solutions (see Effects on Humans, Effects from
Non-Occupational Exposure, Bone and Effects on Humans, Subpopulations at Special Risk,
Infants and Children) the U.S. Food and Drug Administration enacted a labeling requirement,
that went into effect July 26, 2004, which permits no more than 25 μg Al/L in large volume
parenterals and a statement of the exact amount of Al present in small volume parenterals (US
FDA, 2000).
Occupational exposures—The U.S. Occupational Safety and Health Administration
(OSHA) requires employers to reduce exposures to aluminium to or below an 8-hr time-
weighted average (TWA) of 15 mg/m3 for total aluminium dust or 5 mg/m3 for the respirable
fractions (NIOSH, 2005). Limits have also been set for aluminium in the workplace by the
ACGIH (1996) (ATSDR, 1999) and the National Institute for Occupational Safety and Health
(NIOSH) (2005) in the United States; these values are listed in Table 10. In general, in the
absence of occupational limits, countries in Europe also use those established by the ACGIH
(E. Nordheim, personal communication, 2005).
Occupational exposure limits for aluminium oxide (Al2O3) compiled by the Registry of Toxic
Effects of Chemical Substances (2006) are shown in Table 11. The values given in this table
for the U.S. were established by OSHA; the ACGIH has also set a TLV of 10 mg/m3
(particulate)-TWA (RTECS, 2006).
Exposures in the general environment—The Joint Food and Agriculture Organization
(FAO) / World Health Organization (WHO) Expert Committee on Food Additives and Food
Contaminants recommended a provisional tolerable weekly intake (PTWI) of 7.0 mg/kg b.w.;
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this value includes the intake of aluminium from its use as a food additive (FAO/WHO,
1989; IPCS, 1997). In 2006, the PTWI was lowered to 1.0 mg/kg b.w. citing that aluminium
compounds may exert effects on reproductive and developing nervous systems at lower doses
than were used in setting the previous guideline (FAO/WHO, 2006). In the United States, an
intermediate duration oral exposure Minimal Risk Level (MRL) of 2.0 mg/kg/day has been
developed (ATSDR, 1999; IRIS, 1999) based on neurotoxicity in mice (ATSDR, 1999; Golub
et al., 1989). No MRLs for any duration of inhalation exposure have been set for aluminium
and the EPA has not designated aluminium or its compounds as hazardous air pollutants under
the Clean Air Act; however, the EPA has regulated aluminium and certain aluminium
compounds under this Act (ATSDR, 1999).
The WHO has not proposed a health-based guideline for aluminium in drinking water because
of the limitations in the animal data; however, it has derived “practicable levels” of ≤0.1 and
≤0.2 mg/L for large and small facilities, respectively, based on optimization of the coagulation
process in water treatment plants that use aluminium-based coagulants (WHO, 2004). A health
based maximum contaminant level (MCL) has also not been promulgated for aluminium under
the U.S. Safe Drinking Water Act; a secondary non-enforceable MCL has been set at a
concentration range of 0.05 - 0.2 mg/L (ATSDR, 1999; EPA, 1979; IRIS, 1997). The EU
directive for aluminium in drinking water is 0.2 mg/L as an “Indicator Parameter” (Lenntech,
2004). Australia has also recommended a drinking water guideline value of 0.2 mg/L based on
aesthetic considerations (Queensland Government, 2002). Canada has not set a health-based
guideline. However, it is recommended in the Canadian Guidelines for Drinking Water Quality,
“as a precautionary measure”, that water treatment plants using aluminium-based coagulants
optimize their operations to reduce residual aluminium levels in the treated water to the lowest
extent possible. Where aluminium-based coagulants are used in conventional treatment plants,
the operational guidance level is <0.1mg/L (based on a 12 month running average of monthly
samples); for other types of treatment systems using such coagulants, the operational guidance
value is <0.2 mg/L (Federal-Provincial-Territorial Committee on Drinking Water, 2006).
The U.S. Association for the Advancement of Medical Instrumentation has issued a standard
in which it is recommended that water used in the preparation of dialysate solution contain less
than 10 μg/L Al in order to limit the unintentional administration of aluminium to dialysis
patients (AAMI, 1998; ATSDR, 1999). However, there is concern that unless long-term
exposure is limited to lower aluminium concentrations, there will be slow, but permanent,
exposure of a greater percentage of dialysis patients to aluminium (Fernandez-Martin et al.,
2000). These authors suggested the recommended level should be 2 μg/L.
The Kidney Disease Outcomes Quality Initiative suggested Al-based antacids could be used
in patients with chronic kidney disease who have serum phosphorus levels >7.0 mg/dL (2.26
mmol/L) as a short-term (4 weeks) therapy, and for one course only, to be replaced thereafter
by other phosphate binders and that more frequent dialysis should also be considered in these
patients (National Kidney Foundation, 2003).
In the absence of a consensus on the acceptable “safe” concentration of aluminium in plasma
to guide therapy, it was suggested that 0.5 to 1.9 μM (13.5 to 51 μg/L) be considered as
reflecting increased exposure, 2.0 to 2.9 μM (54 to 78 μg/L) excessive exposure, and > 3 μM
(81 μg/L) a toxic concentration, that perhaps warrants mobilization (Fenwick et al., 2005).
Regulations and/or guidelines that have been established for aluminium with respect to the
general environment are summarized in Table 12.
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HUMAN EXPOSURE
General Discussion
Aluminium is the third most abundant element in the Earth’s crust with oxygen and silicon
being the first and second. The respective percentages are 50, 26 and 7.5 (Williams & Fraústo
da Silva, 1996). It is therefore not surprising that soils and weathered rocks constitute the major
sources of aluminium in environmental media (Bowen, 1979). The mobilization of these
natural sources far exceeds the anthropogenic releases into air, in waste-water effluents and
industrial waste (ATSDR, 1999). The environmental mobilization, transport and distribution
of aluminium, as well as the levels observed in air, water, soils, sediments and food items have
been extensively summarized in previous monographs (ATSDR, 1992; IPCS, 1997) and in
topic-specific reviews. Rather than reproducing these efforts, only the seminal features of these
issues will be highlighted in the present chapter. However, all recent developments and topics
pertinent to human risk assessment are reviewed and discussed in detail.
Environmental Levels
Air—Prior to 1987, it was the practice to measure particulate air pollution levels as total
suspended particles (TSP) (Samet et al., 2000). TSP constitutes air-borne particles with dae
<30 μm (Cyrys et al., 2005). In 1987, annual and 24-hr standards were promulgated by the
U.S. EPA for the PM10 aerosol fraction (see Identity, Physical and Chemical Properties,
Analytical Methods, Physical and Chemical Properties, Chemical and Morphological
Speciation) of 50 and 150 μg/m3, respectively. In 1997, this agency added standards for
PM2.5, namely 15 (annual) and 65 μg/m3 (24-hr) (EPA, 1997). Both the PM10 and PM2.5
aerosol fractions have been associated with adverse health effects as reported in Identity,
Physical and Chemical Properties, Analytical Methods, Physical and Chemical Properties,
Chemical and Morphological Speciation. Reported ambient aluminium concentrations in these
fractions are summarized in Table 13. A perusal of these data indicates mean PM2.5 aluminium
levels were in the range 0.035 to 1.82 μg/m3 (excluding the arctic and Antarctica sites) and
0.58-6.97 μg/m3 for PM10. By comparison, the mean total particulate mass reported in the
PM2.5 and PM10 fractions for non-remote sites were near or often exceeded the annual
standards indicated. Detailed analyses of these data outlined in the original publications have
identified the trends and interpretations summarized in the next paragraph.
Aluminium, like silica, may be designated as crustal in origin (Laden et al., 2000; Lee et al.,
1994). Calculations of the enrichment factor (the ratio of the concentration of an element of
interest and that of a signature element in the air sample divided by the same concentration
ratio in the Earth’s crust) support this, namely values below 7.0 (Lee et al., 1994). Further
corroboration comes from principal component analysis and the general characteristic that
anthropogenic elements (e.g., sulphur and lead) accumulate predominantly in the PM2.5
fraction, while crustal elements (e.g., silicon, titanium, iron, and aluminium) occur frequently
in coarser fractions such as such as PM10 (Orlic et al., 1999). The latter was observed for the
central California data in Table 13, for which aluminium concentrations for the two agricultural
sampling stations were considerably higher in the PM10 fraction (Chow et al., 1996). Road
dust, industry and urbanization are also recognized factors in generating higher ambient
aluminium levels (Chow et al., 1996; Lee et al., 1994; 2003; Pinto et al., 1998). Finally, remote
sites well away from towns and cities exhibit the lowest aluminium air concentrations.
Examples are (see Table 13) the Sequoia and Yosemite National Parks in California (Chow et
al., 1996), the high arctic (Maenhaut et al., 1996) and Antarctica (Mazzera et al., 2001).
Precipitation—As documented in the ATSDR (1999) and IPCS (1997) monographs,
aluminium is present in measurable amounts in precipitation. This is not surprising, based on
Krewski et al. Page 25
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the observed air levels summarized in Table 13. Clearly, this source constitutes a chronic input
for surface water and soil.
Water—In terms of human health risk, dermal contact with and consumption of water are
pertinent pathways of exposure. Consequently, aluminium concentrations in surface and
drinking water are of primary interest. Further, as documented elsewhere (ATSDR, 1999;
IPCS, 1997), aluminium concentrations in marine waters tend to be considerably lower than
in fresh water. The latter, therefore, will be the focus in this section.
Environmental acidification is known to mobilize aluminium from land to aquatic
environments, and this process has been demonstrated to vary with the seasons or major storm
events (ATSDR, 1999). Anthropogenic point sources can add to the aquatic aluminium burden.
It is clear from Fig 2.1 in Identity, Physical and Chemical Properties, Analytical Methods,
Physical and Chemical Properties, Chemical and Morphological Speciation that aluminium
becomes markedly more soluble below a pH of about 5.
A study by Schintu et al. (2000) provides insight about the levels and speciation (i.e., its
chemical and physical forms) of aluminium in raw water and in water after its treatment in the
production of drinking water. It corroborates the wide variability of aluminium concentrations
and speciation in surface water and that the corresponding parameters for drinking water are
more uniform. In characterizing aluminium exposure, some recent epidemiological studies of
AD have considered aluminium speciation in their statistical analyses (e.g., Gauthier et al.,
2000). Consequently, it is relevant to explore this aspect in some detail here for raw water and
in Human Exposure, General Population Exposures, Drinking Water for drinking water.
Fractionation of water samples permits an assessment of a number of forms in which aluminium
occurs in addition to the measurement of total aluminium (operationally defined as that
dissolved at pH 1 or 2 without filtration), namely total dissolved (that dissolved at pH 1 or 2
after filtration); dissolved organic monomeric; dissolved inorganic monomeric; polymeric/
colloidal; and particulate (Driscoll & Letterman, 1995; Schintu et al., 2000). In terms of raw
water, the particulate form often dominates, with reported proportions when employing a 0.4
μm polycarbonate filter in the first fractionation step in the 54 to 74% range (e.g. Driscoll &
Letterman, 1995) and may exceed 80% for a 0.22 μm filter (Schintu et al., 2000). Average
concentrations of total dissolved aluminium after filtration; i.e., inorganic and organic
monomeric, plus colloidal and strongly-bound organic typically are 1.9-5.2 μmol/L (50-140
μg/L). These levels corresponded to 3 to 17% of the total aluminium for assessments involving
a 0.22 μm filter (Schintu et al., 2000) and 71 to 90% when employing the 0.40 μm filter
(Driscoll & Letterman, 1995). Both organic and inorganic forms appear to be present in
significant amounts in the dissolved aluminium fraction (Driscoll & Letterman, 1995; Driscoll
& Schecher, 1989; Gauthier et al., 2000; Guibaud & Gauthier, 2005; Schintu et al., 2000).
Recent studies have confirmed that, in forest soil extracts or raw water, organic ligands that
bind aluminium include citrate, oxalate and humic substances (Drabek et al., 2005; Guibaud
& Gauthier, 2005; Mitrovic & Milacic, 2000). Humic substances constitute the predominant
component of natural organic substances. They are operationally divided into three fractions:
fulvic acids, which are soluble in both acidic and alkaline solutions; humic acids, which are
soluble in alkaline solutions, but are precipitated at pH 2; and humin, which is insoluble in
water independent of pH (Turner, 1995). Carboxylic acid, alcohol and phenolic functional
groups constitute the metal-binding sites in these ligands (Stumm & Morgan, 1996; Turner,
1995). Fulvic acids provide more of these donor sites than humic acids. Respectively, the
molecular masses of the corresponding aluminium complexes have been reported for acidic
forest soil extracts to be in the 2000-4500 Da and 2700-6000 Da ranges (Mitrovic & Milacic,
2000). Further, 80 to 95% of total water-soluble aluminium was found to be in monomeric
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form (0.45 μm filter) in the forest soil extracts, with complexes of oxalate, citrate and fluoride
contributing 45 to 55%, while 30 to 40% was associated with the molecular mass fractions of
the humic substances mentioned (Mitrovic & Milacic, 2000). Drabek et al. (2005) reported
that water extracted 32.3 mg/kg of aluminium from acid forest soils as singly-charged species
[Al(OH)2+, Al(SO4)+, AlF2+, Al(oxalate)+, and Al(H-citrate)+, among others], 3.1 mg/kg as
doubly-charged species [Al(OH)2+, Al(F)2+, etc] and 3.8 mg/kg as Al3+ [Al3+ and hydroxyl
aluminium polymers].
Soil and sediment—Dermal contact with and ingestion of sediments and soils is not
expected to constitute significant exposure routes, even though the aluminium contents of these
media are substantial as mentioned in Human Exposure, General Discussion. Typical
aluminium concentrations for major sediments are 9,000 – 94,000 μg/g and 700-300,000
(median 71,000) μg/g in soils (ATSDR, 1999; Bowen, 1979; IPCS,1997; Sanei et al., 2001).
As described in the previous section, soils are a source of soluble aluminium species for surface
water and, of course, of sediment particles as well (Sanei et al., 2001). Further, aluminium
partitions from water to sediment and particulates. Consequently, soils and sediments are
determinants for the level and forms of aluminium in surface water and thus raw water as a
source for drinking water.
Terrestrial and aquatic organisms—Bioconcentration of aluminium in aquatic plants
and plants grown on low pH soils is known (Gallon et al., 2004; IPCS, 1997). Aerial deposition
appears to contribute to plant surface levels of aluminium, as illustrated for spruce needles.
Because of its high concentrations in sediments, it is difficult to interpret the aluminium
concentrations reported (IPCS, 1997) for crustaceans such as crayfish, and bottom feeders such
as carp. In other fish, little aluminium seems to be present in edible tissue, but with the gills
showing preferential accumulation (IPCS, 1997; Reid et al., 1991; Wilkinson et al., 1993). As
reviewed in Human Exposure, General Population Exposures, Food and Beverages, grains,
vegetables, legumes, and especially herbs and spices, exhibit significant tissue concentrations
of aluminium.
Occupational Exposure
Aluminium production—Exposures experienced by workers employed in aluminium
production are influenced by the industrial processes involved; an overview of the primary
refining steps and a brief introduction to secondary refining of this metal are presented in
Sources of Human Exposure, Anthropogenic Sources, Production Levels and Processes,
Aluminium.
Aluminium refinery workers can be exposed to aluminium hydroxide in the Bayer process,
and “to airborne particles of variable composition (e.g., aluminium oxides, cryolite, soot), a
number of gases (e.g., carbon oxides, sulphur dioxide (SO2), hydrogen fluoride (HF)) and
PAHs are generated” (Höflich et al., 2005) in the Hall-Héroult process (also Benke et al.,
1998). The emission of dust, including PAHs is more extensive for the Søderberg pots and
anode plants. As already pointed out (see Identity, Physical and Chemical Properties,
Analytical Methods, Physical and Chemical Properties, Chemical and Morphological
Speciation), adsorption of HF and SO2, and presumably also PAHs, onto aluminium oxide and
oxyhydroxides is an issue of concern; beryllium emissions pose an additional health risk
(Benke et al., 1998). Ultrafine particles in the 10-300 nm diameter range have also been
identified in potrooms (Höflich et al., 2005; L’vov et al., 2005; Thomassen et al., 2006). By
comparison, for secondary aluminium smelting and relative to accepted occupational exposure
limits, inhalable dust, particulate fluorides, HF, lead and aluminium appear to constitute a
health risk (Healy et al., 2001).
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Although personal measurements of exposure to dust containing aluminium oxide and other
aluminium compounds have been made in the aluminium production industry, they are not
extensively documented in the published literature. The emphasis has rather been on PAHs,
fluorides and HF measurements (Benke et al., 1998). However, the reports by Pierre et al.
(1995; 1998) provide a helpful overview. They surveyed 234 workers employed in primary
aluminium refining, 88 in secondary aluminium refining and 13 in aluminium powder
production. A summary of their findings is given in Table 14. Aluminium air concentrations
were measured as the “total” aerosol fraction. Relative to the inhalable aerosol fraction defined
in Identity, Physical and Chemical Properties, Analytical Methods, Physical and Chemical
Properties, Chemical and Morphological Speciation, “total” personal samplers undersample
particles larger than 15 μm (Vincent, 1994). Unfortunately, for most of the worker groups
surveyed, only mean values are available.
Several noteworthy trends are evident from the data in Table 14. Exposure to bauxite,
aluminium and the metal (as powder or sheets) is associated with low concentrations of water-
soluble aluminium, by contrast to exposures in the potrooms, secondary smelting, and AlF3
production. Consequently, one might expect to observe higher urinary aluminium
concentrations among workers in the latter group, which was indeed the case. Surprisingly, the
aluminium powder workers exhibited substantially higher before-shift concentrations in urine
than other workers. This observation suggests that particulates that deposited and accumulated
in the respiratory tract serve as sinks. Further, Gitelman (1995) and Gitelman et al. (1995)
conducted a survey involving 40 control subjects and 235 workers employed in 15 plants in
the USA engaged in primary and secondary aluminium refining and in the manufacture of
products (e.g., powder technologies, cables, rolling mills). Personal exposures ranged from
0.01-1.20 mg/m3, with a median of 0.025 mg/m3 for respirable fractions (<10 μm), and
0.001-3.0 mg/m3 with a median of 0.10 mg/m3 for the “total” aerosol fractions. The maxima
in their survey likely pertained to primary refining and work with powders.
The reports by Röllin et al. (1996; 2001) suggest that newer potroom technologies can
substantially reduce exposure to aluminium. In a new primary smelter, the median “total”
aluminium levels were 0.03 to 0.084 mg/m3, while in a plant using the more standard potroom
smelting approach exposures were: mean (range) in mg/m3 of 1.47 (1.25-1.66), potroom 1;
0.35 (0.20-0.57), potroom 2; and other operator, 0.036 (0.02-0.13).
An extensive survey of 7 secondary aluminium smelters in the UK found inhalable aluminium
air concentrations of 0.04 to 0.90 mg/m3, with a mean value of 0.31 mg/m3. These
measurements are comparable in magnitude to the concentrations reported in Table 14 for jobs
involving slag treatment. Healy et al. (2001) did indeed identify the slagging out of rotary
furnaces as a dusty operation. Comparable concentrations have been reported for two foundries
in South Africa: 0.17 mg/m3 for smelters; 0.027 mg/m3 for operators; and 0.58 mg/m3 for
fettlers (i.e., those lining furnaces) (Rollin et al., 1991a).
User industries—Occupational exposures in workplaces using non-powdered aluminium
metal well below its melting point (see Identity, Physical and Chemical Properties, Analytical
Methods, Physical and Chemical Properties, Properties of Aluminium Compounds, Table 3)
may be expected to be considerably lower than those in primary and secondary aluminium
refineries. By contrast, exposures in the manufacture of products involving aluminium powder
(see Tables 1 and 2 and Identity, Physical and Chemical Properties, Analytical Methods,
Physical and Chemical Properties, Properties of Aluminium Metal and Identity, Physical and
Chemical Properties, Analytical Methods, Physical and Chemical Properties, Chemical and
Morphological Speciation) are likely to be comparable to those experienced in powder
production. Similarly, workers involved in alloy production are likely to have aluminium
exposures like those associated with comparable operations described for secondary refining
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and casting in primary refining. By contrast, exposures for aluminium welders have been
reported extensively. Exposures depend on the type of welding: metal inert-gas (MIG),
tungsten inert-gas (TIG), or manual metal (MMA) welding, as well as the type of welding
electrodes (with or without flux). The following “total” aerosol fractions have been reported:
5-10 mg/m3 (Apostoli et al., 1992); 0.3-10.2 mg/m3 with a mean of 2.4 mg/m3 (Sjögren et al.,
1985; MIG); 0.2-5.3 mg/m3 with a mean of 1.5 mg/m3 (Sjögren et al., 1988; mostly MIG);
0.2-6.1 mg/m3 with a mean of 1.4 mg/m3 ((Nielsen et al., 1993; MIG and TIG); 0.17 mg/m3
(electrodes without flux) and 0.81 mg/m3 (flux-coated electrodes) (Vandenplas et al., 1998;
MMA)). The particles generated in MIG welding have a mass median diameter of about 0.4
μm, with those for TIG welding being somewhat smaller (Sjögren et al., 1985).
Physico-chemical properties (explosivity, flammability, oxidizing potential)—
The explosivity, flammability, oxidizing potential and related reactivities of aluminium and its
compounds have been noted in Table 3 and reviewed in Identity, Physical and Chemical
Properties, Analytical Methods, Physical and Chemical Properties, Properties of Aluminium
Compounds / Chemical and Morphological Speciation and Identity, Physical and Chemical
Properties, Analytical Methods, Classification.
General Population Exposures
Air—In Table 13, aluminium concentrations in the PM2.5 and PM10 aerosol fractions are
compiled. In the corresponding text (Human Exposure, Environmental Levels, Air), it was
pointed out that the mean total particulate mass found for the PM2.5 and PM10 fraction
measurements were near or exceeded the U.S. EPA’s annual standards in most instances for
non-remote sites. A perusal of the aluminium-specific data in Table 13 indicates that mean
PM2.5 concentrations were in the range 0.035-1.82 μg/m3 and 0.58-6.97 μg/m3 in the PM10
fractions. For agricultural communities, the maximum aluminium concentrations were 4.8
μg/m3 (PM2.5) and 17.3 μg/m3 (PM10), and 2.7 μg/m3 (PM2.5) and 5.4 μg/m3 (PM10) downwind
of large urban centres. As pointed out in Human Exposure, Environmental Levels, Air, the
natural crustal origin of aluminium accounts for the fact that the highest concentrations are
being observed in agricultural areas.
For systemic effects of a toxicant, uptake into the blood stream is required. Consequently, from
this perspective the PM10 aerosol fraction is more pertinent than the PM2.5 fraction. Particles
are swallowed quickly when deposited in the nasopharynx region of the respiratory tract
(inhalation through the nose) and when deposited in the oropharynx region (mouth breathing)
(NRC, 1979). Similarly, deposited particles cleared by way of mucous from the ciliated nasal
passages and the tracheobronchial tree are either expectorated or swallowed. Because
deposition in the entire respiratory system (i.e., upper and lower) is included in the inhalable
fraction (see Identity, Physical and Chemical Properties, Analytical Methods, Physical and
Chemical Properties, Chemical and Morphological Speciation), it is for this reason that the
inhalable aerosol fraction (see Identity, Physical and Chemical Properties, Analytical Methods,
Physical and Chemical Properties, Chemical and Morphological Speciation) is recommended
in the workplace when assessing potential systemic toxic outcomes (Nieboer et al., 1999;
Vincent, 1993). Relative to this, the “total” aerosol fraction discussed in Human Exposure,
Occupational Exposure would be second best, followed in order by the PM10 and PM2.5
fractions.
Food and beverages—It is clear that, in the absence of aluminium containing additives,
frequently eaten foods contain relatively low concentrations of aluminium. Mean fresh-weight
concentrations (in μg/g) typically increase in the order: beverages (1.5); fruit (2.7); fish (fresh
or tinned, 3.2); milk, dairy products (4.5); meat, sausage, offal (5.4); vegetables (5.7); sugar,
sugar-rich products (6.7); bread, cake and pastries (7.4); edible seeds (beans, peas, etc., 9.3);
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and meal, flour (9.5) (Müller et al., 1998). Items with higher mean concentrations (in μg/g fresh
weight) of which smaller amounts are ingested include: herbs (19); cocoa and cocoa products
(33); spices (145) and tea (900) (Müller et al., 1998). Steeped teas often contain 2-5 mg/L of
aluminium (Baxter et al., 1989; Jackson & Huang, 1983; Müller et al., 1998; Pennington &
Jones, 1989). Rajwanshi et al. (1997) reported concentrations double these values. Pennington
& Jones (1989) and Pennington & Schoen (1995) clearly illustrated that food items containing
aluminium additives (see Table 7) can appreciatively add to the dietary aluminium intake. They
identified the following items as contributing significantly to the estimated daily intake of 11.5
mg/day calculated for a 14-16 year old male: cornbread (36.6% of total intake); American
processed cheese (17.2%); pancakes (9.0%); yellow cake with icing (8%); taco/tostada (3.5%);
cheeseburger (2.7%); tea (2.0%); hamburger (1.8%); fish sticks (1.5%). It was suspected that
aluminium additives in processed cheese and baking ingredients were responsible. Saiyed &
Yokel (2005) have confirmed that, due to the presence of aluminium additives (e.g., baking
soda; leavening, anticaking, or emulsifying agents (Nieboer et al., 1995); also see Table 7),
certain food ingredients and items constitute major sources of dietary aluminium. Examples
are: processed cheese; pizzas; flour mixes for cakes and pancakes, and thus many baked goods
and crusts; table salt; hot cocoa mix; pickle relish; and non-dairy creamers. Although the details
are addressed in Human Exposure, General Population Exposures, Medical, aluminium intake
from antacids, buffered aspirins, and antidiarrheal agents would increase by many fold the
daily intake of this metal.
In the IPCS (1997) monograph, estimates of the average adult dietary daily intake of aluminium
are tabulated for 8 countries. These data and other reported values for adults are depicted in
Figure 5. It is clear that, since the mid 1980s, the estimates fall below 15 mg/day. As suggested
in the IPCS (1997) review, the lower values in this group likely reflect reduced use of
aluminium food additives in some of the countries. The intakes in Figure 5 estimated for or
reported in 1985 or before of 20-25 mg/day may be due to the inclusion of larger portions of
food items with additives, although analytical limitations cannot be excluded.
Intakes for infants appear considerably lower; for example, a 4-month old infant consuming
cow’s milk-based formula was estimated to take in 0.03-0.05 mg/day, compared to 0.27-0.53
mg/day when fed soya-based formula (MAFF, 1993; also see Dabeka & McKenzie, 1992; and
Pennington & Schoen, 1995). Navarro-Blasco & Alvarez-Galindo (2003) have reported
comparable findings (based on the previous PTWI of 7 mg/kg b.w., rather than the current
value of 1 mg/kg b.w.): “Standard formulae gave lower intakes amounting to about 4% PTWI;
specialized and preterm formulae resulted in moderate intake (11 to 12 and 8 to 10% PTWI,
respectively); and soya formulae contributed the highest intake (15% PTWI)”.
The daily intakes in Figure 5 derived from the Pennington & Jones (1989) and Pennington &
Schoen (1995) studies include foods that have been in contact with aluminium foil or
aluminium containers or that have been cooked in aluminium utensils. It is clear that these
storage and preparation steps contribute aluminium to daily intake, especially for acidic foods
(e.g., ATSDR, 1999;Fimreite et al., 1997;IPCS, 1997;Neelam et al., 2000;Ranau &
Oehlenchälger, 2001). However, relative to the aluminium food additives, such contributions
appear not to be appreciable, representing only a small fraction of the total dietary intake.
Drinking water—A perusal of recent reports of total and total dissolved aluminium (for
definitions see Human Exposure, Environmental Levels, Water and Table 15) in drinking water
after municipal treatment indicated that levels are generally below 7.4 μmol/L (200 μg/L).
Recently reported concentrations of dissolved aluminium and the year collected are: 1.36±1.28
μmol/L (38±35 μg/L; 1995/6; (Gauthier et al., 2000); and 2.0-3.6 μmol/L (53-96 μg/L; 1995/6;
see Table 15). Total aluminium levels are of comparable magnitude: 0.85-3.9 μmol/L (23-105
μg/L; 1993/7; (Zhao et al., 2001); 0.2-6.1 μmol/L (4-165 μg/L; c.2000; López et al., 2002);
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and a mean of 2.2 μmol/L (60 μg/L; 1999/2000; Gillette-Guyonnet et al., 2005). Compared to
the compilation for the 1980s reported by Nieboer et al. (1995) there appears to be some
moderate downward trend in the reported total aluminium concentrations.
The speciation summary provided in Table 15 illustrates that, after purification treatment,
dissolved aluminium levels are not very different from those observed for surface (raw) water
(see Human Exposure, Environmental Levels, Water). As in raw water, both inorganic and
organic forms are present. However, operational filtering processes in treatment plants using
aluminium coagulation can remove or add to the residual dissolved forms in drinking water
(Berubé, 2004;Cech & Montera, 2000;Flaten, 2001). Other operational parameters are also
known or suspected to influence the amount of dissolved aluminium in drinking water. As the
pH decreases or increases from 6, the water-solubility of aluminium increases (Driscoll &
Letterman, 1995;Driscoll & Schecher, 1989;Nieboer et al., 1995). Mean pH values of treated
drinking water typically are around 8.0, with minimum values as low as 5.3 and maxima just
above 9.0 (e.g., Nieboer et al., 1995). Further, addition of filter aids such as sulphate and non-
ionic polymers appear effective in repressing residual dissolved aluminium; and solubility
increases with water temperature (Driscoll & Letterman, 1995;Kvech & Edwards, 2002).
Interestingly, the water quality data reported by Gauthier et al. (2000) suggest that the source
of the raw water (e.g., lake, river or ground) may have some bearing. And finally, the type of
water purification technology employed is an important determinant. Consequently, and as
observed, dissolved aluminium concentrations in household water may be expected to be quite
variable.
Many of the organic and inorganic water-soluble species discussed in Identity, Physical and
Chemical Properties, Analytical Methods, Physical and Chemical Properties, Chemical and
Morphological Speciation and those shown to exist in surface waters and soil extracts (see
Human Exposure, Environmental Levels, Water) may be expected to be stable at the pH values
of drinking water.
Aluminium concentrations in bottled commercial drinking water have been reported in a small
number of instances. Rosborg et al. (2005) report a median level of total aluminium of 1.33
μmol/L (36 μg/L). Interestingly, when they compared carbonated samples from a single brand,
one contained in a plastic bottle and the other in an aluminium can, the respective
concentrations were 0.63 μmol/L (17 μg/L) and 2.7 μmol/L (72 μg/L) respectively. Gillette-
Guyonnet et al. (2005) reported that aluminium concentrations in 3 of 8 commercial mineral
waters obtained in 1992 were below the detection limit of 0.1 μmol/L (3 μg/L), while the
remainder had values between 0.2 μmol/L (5 μg/L) and 1.2 μmol/L (32 μg/L). By comparison,
levels for 6 city water supplies sampled in the same time period ranged from 0.4 μmol/L (10
μg/L) to 2.3 μmol/L (63 μg/L), and another was 2.2 μmol/L (60 μg/L) in 1999-2000. Finally,
López et al. (2002) found a mean ± SD of recoverable aluminium (that found on digestion at
120°C for 90 minutes) of 2.1±1.6 μmol/L (58±43 μg/L) in both 15 regional samples of tap
water and 11 samples of glass bottled water bought in supermarkets. By contrast, mineral water
purchased in plastic bottles had considerable higher concentrations, namely 4.5±1.2 μmol/L
(121±32 μg/L). Leaching from the plastic storage bottles was suspected in this case.
Medical—Based on the aluminium compounds added to non-prescription drugs and anti-
ulcerative drugs, the following daily doses (in mg) have been estimated: 840-5000 (antacids);
130-730 (buffered aspirins) and 830 (anti-ulcerative) (ATSDR, 1999; IPCS, 1997; Soni et al.,
2001). These intakes are massive compared to the dietary intakes discussed in Human
Exposure, General Population Exposures, Food and Beverages / Drinking Water.
Antidiarrheal agents also contain considerable levels of aluminium additives, as much as 1450
mg per dose (ATSDR, 1999). Of course, other medical uses of aluminium compounds
mentioned in Table 7 and in other sections of this document provide exposure opportunities,
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namely as astringents, antiseptics, analgesics, antimicrobial agents, vaccine adjuvants, topical
drugs, and compounds of dental materials and prosthetics, among others.
In the past, iatrogenic aluminium poisoning has been a serious issue (Savory, 1994). This was
due to the use of aluminium contaminated dialysis solutions and aluminium-based phosphate
binders in patients with chronic renal failure and, similarly, contaminated human serum
albumin and other biological products employed in i.v. therapy (see Nieboer et al. (1995) for
a detailed summary; also see Effects on Humans, Subpopulations at Special Risk). The
aluminium contamination of total parenteral nutrition solutions (see Sources of Human
Exposure, Anthropogenic Sources, Legislative Controls, Classification and Labelling) has
been mainly introduced in calcium gluconate and phosphates obtained from small volume
parenteral vials (Mouser et al., 1998).
Miscellaneous exposures
Because of the multiple uses of aluminium and its compounds (see Tables 6 and 7), employment
in workplaces where they are manufactured or used can potentially lead to exposures not
systematically documented in the scientific literature.
Physico-chemical properties (explosivity, flammability, oxidizing potential)
As described in Identity, Physical and Chemical Properties, Analytical Methods, Physical and
Chemical Properties, Properties of Aluminium Compounds / Chemical and Morphological
Speciation, and Identity, Physical and Chemical Properties, Analytical Methods,
Classification, explosivity, flammability, oxidizing potential and related reactivities are not
considered to be of primary interest with respect to assessing the health impacts of exposure
to aluminium and its compounds.
Total Human Intake From All Environmental Pathways (Combined Exposure)
Estimates of daily aluminium intakes are provided in Table 16. For an individual who is not
occupationally exposed and does not use antacids, buffered aspirin, or antiulcerative or
antidiarrheal preparations (see Human Exposure, General Population Exposures, Medical),
food is the major intake source of aluminium. If antacids, buffered aspirin, and other medicinal
preparations are used, the food contribution will be relatively insignificant. The same is true
for workers with occupational exposures, although in this case inhalation could be relatively
more important than food as a source. The potential for anti-perspirants to contribute significant
aluminium absorption through the skin has been suggested, but not well demonstrated (see
Toxicokinetics, Absorption, Studies in Humans, Dermal Exposure).
Uptake—Estimates of the bioavailability of aluminium for the various sources and pathways
are summarized in the right-hand column of Table 16. They are based on comparing aluminium
intakes by inhalation and ingestion with its urinary excretion (output), as well as toxicokinetic
studies. Details are provided in Toxicokinetics, Absorption, Studies in Humans. Food is the
primary source for uptake for individuals not occupationally exposed. However, chronic use
of antacids, buffered aspirins and other medicinal preparations would likely constitute the
major uptake source, even when exposed at work. In the absence of such medicinal usages,
occupational exposure would be expected to contribute more to the body burden than food and
drinking water.
TOXICOKINETICS
The different chemical forms in which aluminium can exist have a great impact on its
toxicokinetics and toxicodynamics. For a discussion of aluminium speciation, complexation,
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solubility, and reaction rates see Identity, Physical and Chemical Properties, Analytical
Methods, Physical and Chemical Properties.
Absorption
Animal studies
Inhalation exposure: Inhalation exposure to aluminium is known to result from cosmetic use
and from occupational and environmental sources.
The size of the inhaled particles is expected to have a profound effect on the deposition and
absorption of aluminium in the lung. Dust comprises particles from < 1 to > 100 μm in diameter;
inhalable particles are those with diameters up to 10 μm. Particles having diameters up to 10
and 2.5 μm are now classified as PM10 and PM2.5 respectively (for more details on these aerosol
fractions see Identity, Physical and Chemical Properties, Analytical Methods, Physical and
Chemical Properties, Chemical and Morphological Speciation). Ultrafine particles have
diameters < 0.1 μm. Particles can be removed from the respiratory tract by mucociliary
clearance, the movement of mucous that covers the respiratory epithelium by cilia projecting
from cells lining the respiratory tract. The mucous is moved up and out of the respiratory tract
into the upper GI tract. This process has the potential to contribute to the oral route of exposure
for substances initially deposited in the respiratory tract. Experimental studies have not isolated
the pulmonary from other absorption sites (Rollin et al., 1991b).
The only data from which one can estimate the percentage of aluminium absorbed from
inhalation exposure is from exposures in the occupational environment (see 5.1.2.1 below). As
the percentage of aluminium estimated to be absorbed during inhalation exposure is greater
than from oral aluminium intake (see 5.1.2.2 below), it seems unlikely that absorption from
the GI tract accounts for the absorption of all inhaled aluminium. There has been no estimate
of the percentage of aluminium absorbed via the intra-nasal route, so its role in relation to
pulmonary absorption cannot be delineated.
Aluminium chlorohydrate is present in many aerosol anti-perspirants. Rats and guinea pigs
were exposed to aerosolized aluminium chlorohydrate, 0.25, 2.5, or 25 mg/m3, 6 hr/day, 5
days/week, for up to 21 months (guinea pigs) or 24 months (rats). Neither animal species
showed appreciable aluminium accumulation in the brain, heart, spleen, kidney, liver or serum,
whereas significant increases in aluminium concentrations were seen in the lung of both
species, adrenal glands of rats, and peri-bronchial lymph nodes of the guinea pigs (Stone et al.,
1979).
Deposition of ~ 2 to 12% of fly ash into the lungs of rats was observed in three studies. Lung
and pulmonary deposition of aluminium were 9.8 and 7.9% for spherical monodisperse
aluminosilicate particles having a diameter of 2.2 μm (Raabe et al., 1977). Aluminium
deposition into rat lung after 7 days of exposure to power plant fly ash with a mass median
aerodynamic diameter (MMAD) of ~ 2 μm was 11.8% (Raabe et al., 1982). In another study,
the percentage of aluminium in fly ash that deposited in the lung was calculated from the
amount of aluminium in the lung of rats after exposure to 73 mg fly ash/m3 for 23 hr/day, 5
days/week for 1 month (Tanaka et al., 1983). The deposition fraction was 1.8%. Similar
exposure of rats to a fly ash that was 9.7% aluminium and had a MMAD of 3 μm at 10.4 mg/
m3 for 7 hr/day, 5 days/week for 1 month resulted in a deposition fraction of 5.1% (Matsuno
et al., 1986). The authors attributed the differences to particle diameter, noting a smaller
apparent deposition fraction with larger particles. Rabbits exposed to a mean concentration of
0.56 mg aluminium oxide/m3 for 8 hr/day, 5 days/week for 5 months showed significant
increases in aluminium concentrations in the brain, lung, and bone that were, respectively, 247,
15,800 and 122% of the values for the controls, whereas aluminium levels in the heart were
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significantly lower (70% those of controls) (Rollin et al., 1991b). Serum aluminium levels
increased during this study, although not consistently over time.
Oral administration: There has been considerable research on aluminium pharmacokinetics,
including its oral absorption. However, most of this research, including all of that carried out
prior to 1990, has been conducted using 27Al. To determine oral aluminium bioavailability,
which is very low, and to see a significant increase of aluminium in blood, urine or tissue above
the endogenous aluminium concentration, it was necessary to give very large doses of 27Al.
More recently, studies have been conducted to estimate oral aluminium bioavailability
using 26Al.
Bioavailability (fractional absorption) is the amount of a substance absorbed compared to the
amount administered. With respect to the toxicokinetics of aluminium, systemic
bioavailability, the fraction that ultimately reaches systemic circulation from where it has
access to the brain and bone, the target organs for its toxicity, is most relevant. Oral aluminium
bioavailability has been determined using several methods. Each of the methods has strengths
and weaknesses. One of the first used was the balance study in which absorption was estimated
based on the difference between intake and faecal, or urinary-plus- faecal, excretion. Estimating
aluminium absorption based on the difference between intake and faecal excretion is not
accurate for aluminium, for which oral bioavailability is very low. This approach assumes the
difference between aluminium intake and faecal excretion is that which is absorbed and
retained or excreted in the urine, which is the major route of elimination of absorbed aluminium.
Small errors in determination of aluminium in faeces can significantly influence the estimate
of bioavailability. As oral aluminium absorption is 1% or less under most conditions, with the
balance passing through the GI tract unabsorbed, it would be very difficult to accurately
determine the 1% loss of aluminium due to absorption based on the difference between oral
intake and faecal excretion. This was acknowledged by Cam et al. (1976). Therefore, the results
of studies that utilized this method (Allen & Fontenot, 1984; Cam et al., 1976; Clarkson et al.,
1972) are not considered to be reliable estimates of oral aluminium absorption. Balance studies
that estimate retention based on the difference between intake and urinary-plus-faecal
excretion tend to overestimate the bioavailability of aluminium because aluminium can be
retained on the gut wall and then be eventually excreted in faeces, but not absorbed. Therefore,
the results of a study that utilized this method (Gorsky et al., 1979) are not considered a reliable
estimate of oral aluminium absorption.
Estimating aluminium bioavailability based on urinary excretion compared to intake has been
the method most commonly used to determine aluminium bioavailability. This method has
many advantages. Collection of urine is less invasive than the sample collection requirements
for most other methods that estimate oral bioavailability, which typically include blood and/
or tissue. However, in the single dose, non-steady-state study, collection of all urine, or at least
urine collection for a sufficient duration to ensure that nearly all of the urinary aluminium
output from the dose has been obtained, is required. This is difficult when 27Al has been used
as the aluminium dose because it is necessary to distinguish urinary excretion of the aluminium
administered in the test dose from that ingested prior to the study or from other sources during
the study. The requirement for total urine collection is also a compliance issue for the human
subject. In the steady-state study, a sample collection period representing normal urinary
aluminium output should be sufficient to reduce the compliance issue. Calculation of
bioavailability assumes that all absorbed aluminium is excreted in the urine. This method may
underestimate bioavailability due to the aluminium eliminated in bile, although this is only ~
1%, (see 5.3.1.2 below), and the aluminium retained during the duration of the study. In a
human study, Stauber et al. (1999) utilized two correction factors to estimate oral aluminium
bioavailability. They collected urine for 24 hr and multiplied the amount of aluminium excreted
by 2.2 to correct for the percentage of i.v. injected aluminium found in the urine after 7 days
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(72%), and the percentage of total aluminium excreted in 7 days that was excreted in the first
day (62%).
Estimation of absorption from a single serum sample and the calculated volume of distribution
would be expected to underestimate bioavailability because this approach does not account for
aluminium that has not yet been absorbed, has distributed out of the vascular compartment, or
has been excreted. It does not assure that peak serum aluminium was sampled unless
independently determined. Underestimation of bioavailability by this method was shown by
Hohl et al. (1994) who found that peak serum 26Al suggested 0.01% bioavailability, whereas
cumulative urine 26Al estimated it to be 0.1%. Similarly, an approximate 10-fold greater
estimate of bioavailability was obtained based on urinary aluminium excretion compared with
that derived from a single (1, 4 or 24 hr) blood sample (Priest et al., 1996; 1998). The authors
concluded: “…bioavailability cannot be accurately determined from blood 26Al or 27Al levels
at a single time after administration” (Priest et al., 1996). Furthermore, an accurate estimate
of volume of distribution assumes an accurate estimate of the t½ of elimination.
The use of the product of “tissue aluminium concentrations × tissue weights” to determine
aluminium bioavailability assumes no aluminium elimination from the sampled tissues. If all
tissues are not sampled, this method results in an underestimate of bioavailability. This method
was employed by Wilhelm et al. (1992) who used bone and Zafar et al. (1997) who used liver,
kidney, spleen, femur, brain, pancreas and blood. Some other studies estimated oral
bioavailability from the sum of urinary aluminium excretion and levels of aluminium in bone
(and liver and brain) tissue, thereby partially overcoming one of the limitations of using urinary
aluminium excretion only to estimate bioavailability (Drüeke et al., 1997; Jouhanneau et al.,
1993; 1997a).
Comparison of areas under the “plasma aluminium concentration (AUC) × time curve” after
oral vs. i.v. dosing is the method generally accepted for determining the oral bioavailability of
most substances (Rowland & Tozer, 1995). This method requires repeated blood sampling,
which is a disadvantage. The use of 26Al and this method were employed by Zafar et al.
(1997) who compared the AUC after oral, to i.p., not i.v., systemic injection, and by Yokel
(2001) who compared the AUCs, or their equivalent, after oral administration of 26Al and i.v.
administration of 27Al.
It is clear that aluminium can be orally absorbed. This has been shown by studies in which
neurobehavioural changes and elevations of serum, urine and tissue aluminium following oral
aluminium dosing of animals and humans have been reported. This corrects misinformation
in 1965 stating: “… Large doses of soluble [Al] compounds taken orally will produce … no
systemic effects” and “No entity ‘chronic aluminium poisoning’ has been identified in human
beings” (Maynard, 1965).
Numerous studies have shown increased serum aluminium and/or urinary aluminium excretion
after oral administration of various 27Al-containing products; the increases have often been
seen to be influenced by the chemical form of the aluminium. These results suggest aluminium
absorption from the GI tract (Beynon & Cassidy, 1990; Gorsky et al., 1979; Haram et al.,
1987; Ittel et al., 1991a; 1991b; Kaehny et al., 1977; Knoll et al., 1984; Rauch et al., 1989;
Recker et al., 1977; Robertson et al., 1989; Tsou et al., 1991; Winterberg et al., 1987a).
However, most of the studies do not permit estimation of oral aluminium bioavailability.
In addition to elevations of serum or urine aluminium levels, numerous studies have shown
increased levels of aluminium in the brain after oral 27Al exposure, demonstrating oral
aluminium absorption. Some examples follow. Rats and dogs were fed 300 or 3000 mg
aluminium hydroxide daily in their food for 5 months. These animals exhibited a significant
elevation of brain aluminium concentrations, compared to those not receiving the aluminium
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hydroxide (Arieff et al., 1979). A significant elevation of brain aluminium was claimed after
a single administration of oral aluminium hydroxide to mice (Cutrufo et al., 1984), although
these authors did not report their actual results. Rat bone, but not brain, aluminium was
significantly elevated after consumption for 8 weeks of a diet containing 570 mg sucralfate/
kg. Sucralfate is a sucrose aluminium sulphate complex. The consumption of aluminium was
approximately 4 mg/kg/day (Burnatowska-Hledin & Mayor, 1984). Consumption, by rabbits,
of distilled water containing 0, 100 or 500 mg Al/L, introduced as aluminium chloride, for 12
weeks produced a positive correlation between aluminium exposure and aluminium in bone,
stomach, intestine and kidney, but not in brain (Fulton & Jeffery, 1990). Brain aluminium was
significantly increased in rats after 90 daily oral doses of 30 or 100 mg/kg of aluminium chloride
(Bilkei-Gorzó, 1993). Consumption by mice of drinking water containing 400 mg Al/L (as
aluminium lactate) for 6 months increased aluminium in brain and other tissues (Anghileri et
al., 1994). Mice consuming ~20 μg Al/day as aluminium hydroxide gel in their drinking water
for 105 days were reported to have 30, 60 and 340% increases in kidney, liver and brain
aluminium concentrations, respectively (Sahin et al., 1994).
On the other hand, in many studies, increased blood or tissue aluminium levels were not found
after oral 27Al administration. For example, rats consuming approximately 0, 0.01, 0.2 or 5.5
mg Al/kg/day in their drinking water, as aluminium chloride, in the absence or presence of
acetate or citrate, failed to show an increase of aluminium in bone or brain (Fulton et al.,
1989). Consumption of 0.112 mg Al/day for 20 days by one baboon did not result in increased
serum aluminium compared to a 10-day period of 0.06 mg Al/day consumption in the same
animal (Turnquest & Hallenbeck, 1991). This exposure level and duration were much smaller
than in most other studies, so the negative result from this one animal is not informative. Prior
to their report of 0.03% oral aluminium absorption from Zeolite A, Cefali et al. (1995; 1996)
did not find significant aluminium absorption from Zeolite A, sodium aluminosilicate or
aluminium hydroxide, containing 3.36, 0.90 and 27.8 mg Al/kg, respectively. Rats consuming
drinking water containing 3.8 mg Al/L (as the chloride) for 10 weeks, and a diet containing 4
to 5 mg Al/kg, had no elevation of brain, bone or liver aluminium compared to those drinking
water containing 0.05 mg Al/L (Glynn et al., 1995). Tissue aluminium concentrations
significantly decreased from 0 to 10 weeks after consumption of this diet, perhaps due to
consumption of a diet containing more aluminium prior to the study, which might have masked
any changes due to the consumption of aluminium in drinking water during the study. At the
pHs of these drinking waters, 4.3 to 4.6, speciation calculations suggested 99% of the
aluminium should be labile species, and therefore available for absorption (Glynn et al.,
1995).
In light of the evidence for oral absorption of aluminium presented in the paragraph
immediately above, it must be assumed that there was insufficient aluminium absorbed in the
studies described in the previous paragraph. Contributing to the lack of a significant increase
of aluminium could be endogenous aluminium in the organism, contamination, and variability
in the aluminium assay. The negative studies cannot be taken as proof of lack of oral absorption
or as support for the null hypothesis that aluminium is not absorbed after oral administration.
Application of accelerator mass spectrometry to quantify 26Al has enabled study of aluminium
toxicokinetics under physiological conditions. This method has been used since ~ 1990. For
example, in one study, 2 rats were given a single gastric administration of 26Al in the absence
of ligand during access to a normal diet; 2 rats did not receive 26Al. Seven days later the 26Al-
treated rats had higher brain 26Al levels than the controls (Fink et al., 1994). In a second study
by this group, using conditions that simulate drinking water, 8 rats were given a single gastric
administration of 26Al in the absence of ligand after 30 hr of no access to food; 2 rats did not
receive 26Al. Two weeks later, brain 26Al concentrations of 2 of the 26Al-dosed rats were
comparable to those of controls (3 × 10-9 of the 26Al dose), whereas brain 26Al in the other
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6 26Al-dosed rats ranged up to 100 times higher (Walton et al., 1995). The large variability is
disconcerting. These results were frequently cited as evidence supporting the hypothesis that
aluminium in drinking water contributes to brain aluminium accumulation. Assuming that a
comparable fraction of orally consumed aluminium reaches and is permanently retained by the
human brain, Walton et al. (1995) concluded that humans drinking alum-treated water (ATW)
over seven to eight decades would have ~ 1 mg Al/kg wet brain. This is greater than normal
levels of aluminium in the brain. On the other hand, these results could support the hypothesis
that aluminium in drinking water does not contribute to brain aluminium accumulation if one
uses the lowest brain aluminium level obtained after 26Al dosing, or if aluminium is not
permanently retained by the brain. Subsequent studies utilizing 26Al, reviewed below, have
clarified this issue.
Studies in animals utilizing 26Al, also reviewed below, have shown the ability of aluminium
to enter bone after oral administration.
No published information was found on buccal aluminium absorption.
In summary, there are sufficient studies in which 27Al was utilized by many different research
groups to investigate neurobehavioural endpoints or in which blood, urine and/or tissue
aluminium levels were studied following controlled administration of 27Al or 26Al, to show
that aluminium can be absorbed after oral administration. These studies also show that this
route of exposure has the potential to produce toxicity. However, many of the studies
with 27Al were conducted utilizing supra-physiological exposures or doses of aluminium. This
has led to the controversy of whether or not aluminium exposure, under normal conditions, has
the potential to produce toxicity.
Drinking water: The average daily intake of aluminium from drinking water for a 70 kg person
is approximately 160 μg, or about 2.3 μg/kg b.w./day. Studies that best model oral aluminium
bioavailability from drinking water meet two criteria. They use aluminium doses ~ 2 μg Al/kg
b.w./day, which reasonably compares with daily oral aluminium intake from water by adult
humans of ~ 2.3 μg Al/kg b.w./day, (see Human Exposure, Total Human Uptake from All
Environmental Pathways (Combined Exposure) and Evaluation of Human Health Risks,
Health Effects, Exposure Characterization) and they introduce the aluminium either as a
chemical species that might be found in drinking water, that is, as the chloride, sulphate or
hydroxide, which have the ability to release the free aluminium ion in solution, or they use
water from municipal water supplies. As noted above, by necessity, all studies with 27Al use
aluminium doses much greater than 2 μg Al/kg. The use of 26Al enables determination of oral
aluminium bioavailability after administration of ≤ 2 μg Al/kg.
Estimates of the oral bioavailability of aluminium, based on administration of 27Al chloride in
the rat, were 0.06 to 0.2% (Ittel et al., 1987) and 0.04% (Froment et al., 1989a). Administration
of 27Al as the chloride, nitrate, lactate or citrate resulted in absorption of 0.57, 1.16, 0.7 to 1.9,
and 2.18% in the rabbit (Yokel & McNamara, 1985; 1988). The difference in results obtained
in these studies may relate to the difference in physiology of the stomach of these two animal
species and/or gastric pH. The rat has a single compartment stomach whereas the rabbit’s
stomach has more than one compartment. The pH of suckling rabbit gastric juice is ~ 4 to 6.5
dropping to ~ 1.5 to 2.5 post-weaning (Beauville et al., 1966; Kaplan & Timmons, 1979; Yu
& Tsen, 1993) whereas the pH of rat gastric juice is ~ 3.2 (Cunha-Melo et al., 1983; Lysiak,
1963). The human stomach pH is typically 1 to 3. The lower pH may result in conversion of
more aluminium to monomeric species. However, as aluminium is not significantly absorbed
from the stomach (see Toxicokinetics, Absorption, Animal Studies, Oral Administration, The
Site and Mechanisms of Oral Aluminium Absorption), its chemical species would be expected
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to change as it enters the upper GI tract. Estimates based on studies utilizing 27Al suggest the
oral bioavailability of the aluminium ion is < 1%.
Several studies utilized the tracer 26Al and total aluminium doses of 0.1 to 2 μg Al/kg. However,
many of these studies had very small sample sizes and some were not well controlled. The
amount of 26Al, after administration in the absence of ligand in distilled water that was
estimated to be in the plasma of two rats 8, 24 and 48 hr after dosing was 0.0001 to 0.001%
(Jouhanneau et al., 1993). These rats had free access to food and water. When plasma
aluminium concentrations obtained by Jouhanneau et al. (1993) are compared to those obtained
at similar times from one rat after i.v. 26Al injection, in pH 5 saline solution (Meirav et al.,
1991), oral 26Al bioavailability is estimated to be 0.033% (8 hrs), 0.087% (24 hrs) or 0.2% (48
hrs). In a study in which 26Al was given to 9 rats/group, the fraction of the dose that was in
plasma 0.5 to 5 hr later was estimated (Schönholzer et al., 1997). They pooled the plasma
samples at each time point for a single 26Al analysis. The plasma 26Al area under the curve
suggested greater 26Al bioavailability in the presence of 27Al citrate + Na citrate than 27Al
citrate or 27Al hydroxide. Estimates of bioavailability based on urinary aluminium excretion
were 5.1, 0.7 and 0.1%, respectively (Schönholzer et al., 1997). Studies with aluminium
hydroxide and aluminium chloride, which may release the free aluminium ion at the low total
aluminium concentrations tested, suggested an oral aluminium bioavailability of about 0.06 to
0.1% (Drüeke et al., 1997; Schönholzer et al., 1997). Schönholzer et al. (1997) may have
underestimated aluminium bioavailability because they only collected the eliminated urine for
300 minutes after dosing and the urine in the bladder at 300 minutes. Although Jouhanneau et
al. (1997a) studied only 2 rats at each euthanasia time point, there were 8 rats/group in the
study by Drüeke et al. (1997). Jouhanneau et al. (1997a) collected total urine output for up to
720 hr. Of the total urinary aluminium output, 85% was in the first day, about 4% in the second,
an additional 5% in days 3 to 5, and 6% in days 6 to 29. They based their estimate of oral
aluminium bioavailability on the sum of the aluminium excreted in urine and that present in
bone, liver and brain. Drüeke et al. (1997) based their estimate on cumulative 48 hr urinary
aluminium excretion and on aluminium found in the skeleton at 48 hr. These studies were
conducted under conditions in which it was likely that the subjects had food in their stomachs
(Drüeke et al., 1997; Jouhanneau et al., 1997a) or, possibly, had some stomach contents. Food
and/or faeces have been found in the stomachs of rats after a 24-hr (Walton et al., 1995) and
36-hr fast (Yokel et al., unpublished results). This is partly because rats recycle faeces (the
practice of coprophagia). Therefore, it is probable that there were stomach contents in the rats
studied by Schönholzer et al. (1997) after the 16 hr overnight fast. Zafar et al. (1997)
gave 26Al (in the presence of 27Al chloride) by the oral route to 3 subjects and by i.p. injection
to 3 others and concluded that oral aluminium bioavailability was 1 to 1.6%. Based on 26Al
recovered in urine, liver, spleen and bone after an oral administration of 20 ng 26Al and 200
μg 27Al, as the chloride, oral bioavailability was estimated to be 0.133 % in control rats (Ittel
et al., 1997). Oral aluminium bioavailability was determined by concurrent administration of
oral aluminium as one isotope, 26Al (in the absence of a ligand), and i.v. aluminium (as Al
potassium sulphate) as another, 27Al (Yokel et al., 2001a). Oral aluminium bioavailability was
~ 0.28% in rats that had no stomach contents. Using the rat in situ intestinal perfusion technique,
absorption of aluminium from aluminium chloride and equimolar trisodium citrate, based on
aluminium in blood and a number of tissues, was estimated to be 0.2% (Arnich et al., 2004).
There is some evidence that fractional absorption of aluminium is dose dependent in the fasted
animal. Oral aluminium bioavailability in the rabbit dosed with 108 or 540 mg Al/kg, as
aluminium lactate, was 0.7 and 1.9% (Yokel & McNamara, 1985). Although not significantly
different, these results suggest a positive correlation between aluminium dose and
bioavailability. On the other hand, absorption of aluminium into rat blood and tissues after
perfusion of the gut with 48 or 64 mM aluminium chloride at pH 3 was not concentration
dependent (Arnich et al., 2004).
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Overall, these results suggest that oral aluminium bioavailability from water in the rat and
rabbit is in the range of 0.05 to 0.4% and most likely ~ 0.3%.
Beverages and foods: Although food comprises the primary source (> 90%) of aluminium for
the typical human (see Human Exposure, General Population Exposures, Food and
Beverages), there are very few data on oral aluminium bioavailability from foods, or beverages
other than water. The difficulties in estimating aluminium bioavailability from water
using 27Al, discussed above, apply to food. It has generally been assumed that oral aluminium
bioavailability from food is less than that from water due to the aluminium being incorporated
in high molecular weight, relatively insoluble, complexes (Glynn et al., 1995).
It has been suggested that the aluminium in tea leaves has low oral bioavailability (Glynn,
1995). In tea, 91 to 100% of aluminium is in organic complexes with a Mr > 20,000. Even at
pH 2, ~ 83% remained bound to the organic matter (French et al., 1989; Gardner & Gunn,
1991). For example, a much lower percentage (15%) of the aluminium in tea was found to be
in chemically labile species, compared with that in drinking water (61 to 75%) (Stauber et al.,
1999). Approximately 50% of aluminium in tea infusions was as soluble species, ~ 50% as
non-labile monomeric aluminium species and a small fraction as labile monomeric aluminium,
whereas > 90% of aluminium in tap waters was labile monomeric aluminium (Chen et al.,
2004). A large fraction of the aluminium in tea infusions was very strongly bound to
unidentified ligands (Alberti et al., 2003). Kralj et al. (2005) found that ~ 10 to 35% of the
aluminium in tea was negatively charged aluminium citrate. They thought the remainder was
bound to phenolic compounds. Addition of citrate increased the negatively charged aluminium
citrate species by up to 40% of total aluminium, whereas milk complexed most of the
aluminium that was not associated with citrate to protein, mainly casein. The authors suggested
that addition of citrate and milk protein would enhance aluminium absorption. Reiber et al.
(1995) suggested that a substantial portion of aluminium, regardless of the form consumed,
will be solubilized to monomeric aluminium in the stomach and subsequently converted to
poorly soluble aluminium species in the near neutral pH of the upper intestine. As the stomach
is not an important site of aluminium absorption, this implies that oral aluminium
bioavailability should be aluminium species independent. Citrate and other ligands influence
aluminium absorption, suggesting that this hypothesis is an oversimplification.
Weanling rats whose liquid source for three weeks was a diet soft drink from aluminium cans
containing 0.47 mg Al/L, had significantly higher liver and bone aluminium concentrations
than rats which drank a soft drink from glass bottles containing 0.38 mg Al/L (Kandiah & Kies,
1994). Bone aluminium was 69% higher in rats that drank the soft drink from the aluminium
cans than in rats that drank distilled water containing 0.023 mg Al/L. However, liver aluminium
concentration was significantly lower, and the concentration of aluminium in bone was non-
significantly lower, in rats that drank bottled soft drink than in those that consumed distilled
drinking water containing 0.23 mg Al/L, thereby casting doubt on the results of this study. It
is surprising that a 24% increase in aluminium intake from beverage would result in a 62, 127
and 84% increase in brain, bone and liver aluminium levels. The authors reported that the rat
ration contained 110 mg Al/kg, which is much greater than the beverages. In other studies, rat
diet has been found to contain 100, 5, and 51 mg Al/kg (Glynn et al., 1995; Gupta et al.,
1986; Yokel et al., unpublished results), mouse diet to contain 131 and 64.5 mg Al/kg
(Dlugaszek et al., 2000; Fosmire et al., 1993), guinea pig diet to contain 47 and 60 mg Al/kg
(Golub et al., 1996a; Owen et al., 1994), and rabbit diet to contain 297, 1215 and 335 mg Al/
kg (Fulton & Jeffery, 1990; Yokel & McNamara, 1985; Yokel et al., unpublished results).
No increases in blood or liver aluminium concentrations were seen in rats which consumed tea
as the only source of fluid for 28 days (Fairweather-Tait et al., 1991). In one study, it was
reported that increased tissue aluminium concentrations were attributed to the intake of
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aluminium in food. Guinea pigs that ate a test diet of sponge cake three times weekly for 3
weeks providing a total of 40 mg of aluminium, as acidic sodium aluminium phosphate (SALP)
showed a significant elevation in bone aluminium concentrations compared with those that ate
only guinea pig chow, which provided a total of 3 mg aluminium (Owen et al., 1994).
In an ambitious but not definitive study, Walton et al. (1994) orally administered various
beverages and foods to anaesthetized rats, in the absence of aluminium-treated water. Tail
blood and urine, withdrawn by needle aspiration of the bladder, were obtained prior to, and 1,
2, 3 and 4 hr after, dosing. Considering the short period of observation (4 hr) serum aluminium
is probably a better indicator of absorbed aluminium than is urinary excretion. Margarine and
8 mg of aluminium, as aluminium sulphate, increased serum aluminium levels. The aluminium
content of the margarine was not determined. The other beverages and foods tested, beer, Coca
Cola®, coffee, orange juice, tea, wine, apple, broccoli, butter, meat and Vita Wheat®, did not
appreciably increase serum aluminium levels when administered alone. This is not surprising
as the aluminium dose provided by these beverages and foods, which ranged from 0.005 to 8.6
μg, was ≤ 0.1% of the 8 mg of aluminium in the 1 mL of water which produced an elevation
of serum aluminium of 4 to 5-fold. Determination of relative oral bioavailability of aluminium
from food and water was not the objective of this study. Little can be learned from these results
concerning the oral bioavailability of aluminium from foods.
Although rigorous pharmacokinetic determination of oral aluminium bioavailability from milk
could not be determined, it was estimated to be < 1% in rabbits (Yokel & McNamara, 1985).
Weanling rats fed 1 to 2.7 gm of Al/kg diet, added as aluminium hydroxide in the absence and
presence of added sodium citrate dehydrate, were estimated to absorb 0.01 to 0.04% of the
aluminium (Greger & Powers, 1992). The percentage of aluminium absorbed was lower with
the higher dietary concentration of aluminium as the citrate, in contrast to above studies, thereby
showing a positive correlation between aluminium dose and fraction absorbed.
There are sufficient studies with reasonably similar results to estimate the oral bioavailability
of aluminium from water. Those who suggest water may be a significant contributor of the
aluminium body burden assume that aluminium in water is more bioavailable than the
aluminium in food. Some recent data support this assumption, as presented in the next
paragraph (Yokel & Florence, 2006). Diet provides most of the human’s daily aluminium
intake. Those who wish to allay any concern about drinking water as a source of aluminium
suggest that the oral bioavailability of aluminium from food and water are similar (Reiber et
al., 1995) and have provided some data to support this conclusion (Stauber et al., 1999).
The bioavailability of aluminium from selected foods has been estimated in the rat. 26Al was
incorporated into the synthesis of acidic SALP, used as a leavening agent in baked goods, and
then incorporated into a biscuit. Basic SALP, used as an emulsifier in cheese, was incorporated
into a processed cheese (Yokel et al., 2005). When rats, that had no stomach contents, ate the
biscuit containing acidic SALP, it was estimated that oral aluminium bioavailability was ~
0.1%, significantly less than from water (Yokel & Florence, 2006). Oral Al bioavailability
from the cheese containing basic SALP was ~0.1 to 0.3% (Yokel et al., unpublished results).
Comparison of oral Al bioavailability from these representative foods to that obtained from
water (~0.3%) times the contributions of food and drinking water to the typical human’s daily
Al intake (~5 to 10 mg from food and 0.1 mg from water, respectively) suggests food provides
~25-fold more Al to systemic circulation, and potential Al body burden, than does drinking
water.
The very limited data available, above, suggest that oral aluminium bioavailability from food
is less than from water.
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Drugs: Relevant published data on the oral bioavailability of aluminium species from drugs
include the use of aluminium hydroxide as an antacid and phosphate binder; sucralfate as an
antacid; aluminium lactate as a component in dental products for sensitive teeth; an aluminium
silicate product, Zeolite A, which is an inducer of osteoblast proliferation; and aluminium in
the presence of citrate. Some of the earlier work, conducted with 27Al, was reviewed by
Wilhelm & Ohnesorge (1990). Because of its poor absorption, use of large doses of aluminium
was necessitated in studies of bolus 27Al dosing to determine oral aluminium bioavailability.
The chemical species of the aluminium, when given in large doses, particularly when the
aluminium species has good buffering capacity, such as aluminium hydroxide, would not be
expected to be totally affected by the normal chemical reactions in the gut. It is less likely that
the series of chemical reactions in the gut that might produce comparable aluminium species
irrespective of aluminium species ingested, as proposed by Reiber et al. (1995), would be
relevant. Therefore, these studies might more closely reflect the absorption of the aluminium
species introduced, albeit after very high doses, assuming there is no saturation of uptake
processes.
The bioavailability of aluminium from ingested aluminium hydroxide appears to be less than
from the aluminium ion, based on studies using 27Al. In the rabbit, 0.45% of aluminium as the
hydroxide was absorbed compared with 0.57 to 1.16% from aluminium chloride and nitrate
(Yokel & McNamara, 1988). In the rat, 0.01% of aluminium from the hydroxide was absorbed
compared with 0.037% from the chloride (Froment et al., 1989a). Wilhelm et al. (1992) could
not detect aluminium absorption after an oral dose of 1 mg Al/kg, as aluminium lactate,
illustrating the necessity of using large doses in bolus 27Al dosing studies. Their estimate of
1% oral bioavailability, based on bone aluminium 17 days after oral aluminium dosing, would
be an underestimate if any bone aluminium were eliminated within that time, although there
may not have been significant bone aluminium elimination (see Toxicokinetics, Elimination
and Excretion, Animal Studies, Elimination Rate).
The absorption of aluminium from aluminium citrate is greater than from aluminium
hydroxide: 2.18 vs. 0.45% in the rabbit (Yokel & McNamara, 1988), 1.49 vs. 0.015% and 1
vs. 0.1% in the rat (Froment et al., 1989a; Schönholzer et al., 1997). Sucralfate, which, like
aluminium hydroxide, is insoluble in water but soluble in acid and base, exhibits oral
bioavailability comparable to that of aluminium hydroxide and lower than that of soluble
aluminium species. Aluminium bioavailability from sucralfate in the rabbit was 0.6%, and was
0.63% from aluminium lactate, compared with 0.57 to 1.16% from aluminium chloride and
nitrate (Yokel & McNamara, 1988). In the rat, oral aluminium bioavailability was 0.015% from
aluminium hydroxide and sucralfate, 0.037% from aluminium lactate and aluminium chloride,
and 1.49% from aluminium citrate (Froment et al., 1989a).
Cefali et al. (1996) studied aluminium absorption from Zeolite A®, an aluminium silicate
product, in dogs; they observed highly variable plasma aluminium levels during the control
phase and a small increase of plasma aluminium as a result of the treatments. They did not use
baseline-corrected data in their determination of aluminium pharmacokinetics. Therefore, one
cannot have much confidence in these results.
Factors influencing oral aluminium absorption: Oral aluminium absorption is dependent
on many factors. A summary of the reported factors affecting oral aluminium absorption in
animals is shown in Table 17. The following sections describe these effects in much more
detail.
Solubility: There is evidence of greater aluminium absorption from more soluble aluminium
species. Aluminium borate, glycinate, hydroxide and sucralfate are much less soluble in water
than aluminium chloride, lactate, nitrate and citrate and were generally less well absorbed (0.27,
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0.39, 0.45 and 0.60 vs. 0.57, 0.63, 1.16 and 2.18%, respectively (Yokel & McNamara, 1988).
Similarly, aluminium hydroxide and sucralfate are less soluble at pH 3, 6 and 7 than aluminium
lactate and chloride and were also less well absorbed (0.015 vs. 0.037%), based on urinary
aluminium excretion (Froment et al., 1989a).
pH: The chemical speciation of aluminium is known to be greatly influenced by pH (Harris et
al., 1996). The bioavailability of aluminium, to some extent, is influenced by the aluminium
species. However, Reiber et al. (1995) suggested that the human GI tract acts as a series of
reactors. They predicted that, in the stomach, all aluminium would be converted to small
molecular weight soluble species due to the predominance of the hydrated aluminium ion at
pH 1 to 2. They suggested that, when the stomach contents enter the duodenum/jejunum where
the pH increases to 4.5 to 6.8, all aluminium would be converted to hydroxides. They predicted
uniform oral bioavailability of aluminium, independent of the chemical species of the
aluminium consumed. However, this ignores the presence of ligands to compete with hydroxide
to associate with aluminium at the site of absorption. Using the in situ rat intestine preparation
with systemic and portal blood sampling, Van der Voet & de Wolff (1986-1987) found
aluminium absorption to be higher at pH 4 than at pH 7, presumably due to generation of more
soluble aluminium species. However, the predicted aluminium species at acidic pHs, in the
absence of binding ligands, are Al(H2O)63+ and Al(OH)2+ (Harris et al., 1996), which would
not be expected to permeate the gut wall by diffusion. This is consistent with the assumed
primary site of GI aluminium absorption, the upper intestine, discussed below (see
Toxicokinetics, Absorption, Animal Studies, Oral Administration, The Site and Mechanisms of
Oral Aluminium Absorption).
Carboxylic acids: Citrate and other carboxylic acids form coordination complexes with
aluminium. The co-administration of citrate with aluminium-containing drugs is relevant to
iatrogenic (medical) aluminium exposure.
The chemistry of aluminium interaction with citrate has been quite extensively studied (Harris
et al., 1996) (see also Identity, Physical and Chemical Properties, Analytical Methods, Physical
and Chemical Properties, Properties of Aluminium Compounds). Citrate can complex
aluminium, forming an electrically neutral 1:1 citrate:aluminium complex at pH 2 to 5 in the
absence of great excess of citrate. At higher pHs, this complex deprotonates, with a pKa of ~
4, to a complex with one negative charge held by a carboxylate group that is not involved in
the aluminium citrate:complex (Lakatos et al., 2001). More complex chemical species slowly
form at higher concentrations (Harris et al., 1996).
Citrate may enhance oral aluminium absorption if there is sufficient citrate present to compete
with other binding ligands for aluminium in the GI tract. Speciation calculations indicated that
citrate would solubilize ~ 97% of aluminium in the stomach (Glynn et al., 2001). Citrate is the
major small molecular weight ligand for aluminium in plasma. Formation of aluminium citrate
also enables the distribution of aluminium out of plasma, and may enhance aluminium
elimination by the kidney in the presence of renal function. However, in the absence of renal
function, citrate can significantly increase aluminium-induced toxicity, presumably by
enhancing aluminium distribution out of the blood and the resultant tissue aluminium
accumulation. However, the enhanced solubility of aluminium by citrate did not completely
account for enhanced aluminium absorption (Froment et al., 1989b). It has been suggested that
aluminium citrate is sufficiently lipid soluble from pH 2.5 to 8 to be absorbed by diffusion
(Partridge et al., 1992). Taylor et al. (1998) argued that the alkaline environment of the upper
intestine could produce insoluble aluminium species, as the aluminium citrate species would
not predominate at neutral and higher pHs. However, the typical pH of the human duodenum/
jejunum ranges from 4.5 to 6.8, which is not alkaline. Furthermore, in the presence of equimolar
aluminium and citrate, aluminium citrate-hydroxide complexes would predominate (W.R.
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Harris, personal communication, 2004). Alternatively, enhanced aluminium absorption may
require sufficient citrate to activate another mechanism of aluminium absorption. Other
hypotheses to explain the enhancement of aluminium absorption by citrate are the transport of
aluminium citrate into mucosal cells, and citrate opening the tight junctions of the intestinal
cells, as discussed in Toxicokinetics, Absorption, Animal Studies, Oral Administration, The
Site and Mechanisms of Oral Aluminium Absorption.
Numerous animal studies have shown that aluminium is more bioavailable when administered
as the citrate rather than as other chemical species (Cunat et al., 2000; Deng et al., 1998;
2000; Drüeke et al., 1997; Froment et al., 1989b; Partridge et al., 1989; 1992; Schönholzer et
al., 1997; Sutherland & Greger, 1998; Van der Voet et al.,1989; Yokel & McNamara, 1988).
It was estimated that 3.4 to 4.2% of aluminium was absorbed by rats, from aluminium citrate;
however, no direct comparison was made with aluminium dosing in the absence of citrate
(Sutherland & Greger, 1998). Numerous studies in humans have also shown enhanced
aluminium absorption in the presence of citric and other carboxylic acids (see Toxicokinetics,
Absorption, Studies in Humans, Oral Administration, Factors Influencing Oral Aluminium
Absorption, Carboxylic Acids). However, a few studies failed to find an increase of aluminium
absorption in the presence of citrate. These were conducted in subjects who received aluminium
during free food access (Jouhanneau et al., 1993; 1997a).
An increase in the citrate:26Al ratio increased oral aluminium bioavailability in one study
(Schönholzer et al., 1997). However, the increase of citrate was accompanied by an increase
of the 26Al dose and pH of the delivered solution, confounding the interpretation of the variable
that increased oral aluminium bioavailability 5-fold in this study. A citrate-induced increase
of brain and bone aluminium has been reported in many studies (Bilkei-Gorzó, 1993; Deng et
al., 1998; Domingo et al., 1991a; 1993; Ecelbarger et al., 1994a; Ecelbarger & Greger, 1991;
Fulton et al., 1989; Fulton & Jeffery, 1990; Greger & Powers, 1992; Owen et al., 1994;
Radunovic et al., 1998; Slanina et al., 1984; 1985; Testolin et al., 1996) though not in others
(Jouhanneau et al., 1997a; Van Ginkel et al., 1993). Moreover, Maitani et al. (1994) found that
citrate addition decreased tissue aluminium concentrations. It was concluded that the chronic
consumption of aluminium and citrate by gavage resulted in greater aluminium retention than
when aluminium was delivered in the diet which, in turn, was greater than when delivered in
drinking water (Greger & Sutherland, 1997). The authors suggested that the presence of other
substances in the GI tract from the diet, which would not be present when aluminium is
administered by gavage, may have modified the effect of citrate on aluminium absorption.
Concurrent acute administration of 2 mmole aluminium with 2 mmole citric, gallic,
chlorogenic, caffeic or protocatechuic acids resulted in a significant increase in rat blood
aluminium 2 hr later only with citric acid. There was no effect on liver aluminium from any
ligand, an increase of kidney aluminium with citric and chlorogenic acid, and an increase in
tibial aluminium with all but chlorogenic acid (Deng et al., 2000). Consumption by rats of a
diet containing 16 mmole/kg of aluminium chloride and carboxylic acid resulted in no
significant differences of aluminium in blood, liver, kidney or tibia; but an increase of
aluminium in brain after citric and chlorogenic acids (Deng et al., 2000). The very high
aluminium concentrations reported in blood and tissues in the control subjects reduce
confidence in these results.
Citrate may enhance oral absorption and may also enhance distribution into and out of tissues
as well as from the organism by renal elimination, in the presence of renal function, as suggested
by (Maitani et al., 1994). Citrate inhibited or produced only a small increase of aluminium
uptake into neuroblastoma and human erythroleukemia cells (Guy et al., 1990; McGregor et
al., 1991; Shi & Haug, 1990).
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Ultrafilterable species may redistribute within the organism, particularly in the presence of
reduced renal function. Quartley et al. (1993) gave rats a single oral dose of aluminium citrate;
2, 4 and 24 hr later they found elevated aluminium in all tissues but the brain. The aluminium
concentration decreased in most tissues from 2 to 24 hr, except for the bone, in which it
increased. Citrate may have enabled redistribution of the aluminium into bone.
Other short chain carboxylic acids, including acetate, oxalate, lactate, malate, tartrate,
gluconate, ascorbate, and carbonate have been similarly shown to increase aluminium
absorption or tissue aluminium accumulation in some, but not all, animal studies. However,
these substances were generally less effective than citrate (Colomina et al., 1994; Domingo et
al., 1991a; 1993; 1994; Gómez et al., 1994; Nestel et al., 1994). This may be due to the
formation of a more stable complex between aluminium and citrate than these other ligands.
Aluminium can form a complex with the dietary long chain mono-unsaturated FA, oleic acid,
but the stability of this complex has apparently not been described (Krasnukhina et al., 1971;
Lesnikovich et al., 1993). It appears aluminium does not complex with the saturated long chain
FA stearate (Ross & Takacs, 1983). No information was found on aluminium complexation
with the dietary saturated long chain FA, palmitic acid, the long chain poly-unsaturated FAs,
α-linolenic and arachidonic acids, and the long chain branched chlorophyll degradation
products, phytonic and pristonic acids. Aluminium can form a 1:1 complex with phytic acid
but the reaction is slower and less favoured thermodynamically than phytic acid complexation
with divalent cations (Evans & Martin, 1988). Insoluble aluminium-phytate complexes form
at higher aluminium:phytate mole ratios (Evans & Martin,1988).
Silicon-containing compounds: There is evidence suggesting that increased dietary intake of
silicon (Si)-containing compounds may reduce aluminium absorption and facilitate aluminium
excretion. There are also studies that did not find an effect of silicon-containing compounds
on aluminium absorption. Silicon is absorbed in the animal GI tract as monomeric silicic acid.
It can react with aluminium to form hydroxyaluminosilicate species and slowly, but eventually,
amorphous solids (Birchall et al., 1996). This was thought to reduce aluminium bioavailability,
as shown by reduced systemic aluminium absorption in fish (Birchall & Chappell, 1989) and
reduced oral aluminium absorption in humans (see Toxicokinetics, Absorption, Studies in
Humans, Oral Administration, Factors Influencing Oral Aluminium Absorption, Silicon-
Containing Compounds). Addition of sodium metasilicate to the diet was reported to reduce
brain hippocampal aluminium accumulation in 28, but not 23, month-old rats (Carlisle &
Curran, 1987). The basis for the age difference is unknown. These results have not been
independently replicated and are not considered reliable. Addition of 0.5 mM silicic acid to
water from 5 days before to 4 hr after aluminium citrate dosing by oral gavage reduced
aluminium in most tissues of rats (Quartley et al., 1993). Rats drinking water containing 59 or
118 mg Si/L (as sodium silicate with 27% SiO2) and receiving 450 mg aluminium nitrate
nonahydrate injections 5 days weekly had less brain, liver, bone, spleen and kidney aluminium
than rats not consuming silicon, suggesting that silicon-containing compounds may have
reduced aluminium absorption and/or enhanced its elimination (Bellés et al., 1998). However,
as the molar dose of silicon consumed was considerably less than the dose of aluminium
administered, the mechanism does not seem to be simply aluminium complexation by silicon.
Drüeke et al. (1997) did not find an effect of co-administered silicon dioxide and 26Al on
absorption of 26Al given with citrate to rats after eating. It is possible that there was insufficient
silicon in the presence of the food to compete with the citrate and interact with the aluminium
to influence its bioavailability.
It has been suggested, based on the very low concentrations of silicon in biological fluids, that
it is very doubtful that a monomeric aluminium silicate species plays any significant role in
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the biological chemistry of aluminium, after the aluminium has been absorbed (Harris et al.,
1996).
Fluoride: Fluoride appears to be able to increase aluminium absorption. Fluoride forms
numerous complexes with aluminium (see Identity, Physical and Chemical Properties,
Analytical Methods, Physical and Chemical Properties, Properties of Aluminium
Compounds). Speciation calculations indicated fluoride would solubilize > 60% of aluminium
in the stomach (Glynn et al., 2001). Aluminium reduced fluoride absorption (Allain et al.,
1996; Hobbs et al., 1954; Li et al., 1991; Xiao et al., 1992). The influence of fluoride on
aluminium absorption is less clear. Rats consuming a diet containing fluoride and aluminium
(chemical species not reported) had decreased levels of aluminium in liver, brain, heart, testes
and femur compared to rats consuming aluminium alone, suggesting that fluoride decreased
aluminium absorption or enhanced its clearance (Ondreicka et al., 1971). Increasing the
aluminium (as the chloride) concentration from 0 to 100 to 500 ppm decreased plasma, bone,
liver and urine fluoride concentrations in rabbits concurrently consuming fluoride in their
drinking water (Ahn et al., 1995). Increasing the drinking water fluoride concentration from 0
to 1 to 4 to 50 ppm had no significant effect on aluminium levels in plasma, urine, or liver,
although the rabbits that drank water containing 50 ppm fluoride and no added aluminium had
increased bone aluminium concentrations (Ahn et al., 1995). Sterna, obtained from another
study in which rats drank water containing 79 ppm fluoride for 2 years with no added
aluminium, showed a significant increase of aluminium (Ahn et al., 1995). Co-administration
of aluminium and fluoride to mice increased plasma aluminium 3 hr later when compared to
when aluminium chloride or aluminium phosphate was dosed. The increase was similar to that
seen with aluminium citrate. Administration of aluminium fluoride to rats increased plasma
aluminium more than did administration of aluminium chloride. The rats were given 1.87
mmole Al/kg orally by cannula as aluminium fluoride or aluminium chloride. The time course
(sampling at 20, 40, 60 and 90 min) showed aluminium from the aluminium fluoride peaked
at ~ 8 μM at ~ 40 min; aluminium from aluminium chloride peaked at ~ 3 μM at ~ 40 min
(Allain et al., 1996). In rats fed 130 or 300 mg F/kg, 300 or 1200 mg Al/kg, 130 mg Al + 130
mg F/kg, 300 mg Al + 300 mg F/kg or 1200 mg Al + 300 mg F/kg in their diet for 12 weeks,
the lower fluoride concentrations reduced, and the higher concentrations increased, aluminium
absorption (Xiao et al., 1992).
Overall, these results suggest that the presence of fluoride can enhance aluminium absorption.
Iron: Iron (Fe) status impacts on the absorption of aluminium and its accumulation in the brain;
thus aluminium absorption was generally found to increase in the presence of low amounts of
iron. Rats maintained on an iron-deficient diet had greater (0.0065%), and rats maintained on
an iron-supplemented diet had lower (0.0028%) oral aluminium bioavailability than controls
(0.0040%) (Winklhofer et al., 2000). Oral exposure to aluminium hydroxide produced a greater
increase in aluminium excretion and brain aluminium levels in iron-deficient than in normal
and iron-overloaded rats, whereas serum aluminium did not show consistent changes (Cannata
et al., 1991; Fernández et al., 1989). Similarly, oral exposure to aluminium chloride produced
non-significant increases in serum, spleen and liver aluminium concentrations in iron-deficient
rats (Brown & Schwartz, 1992). Iron deficiency significantly increased tissue aluminium levels
in rats co-administered aluminium and citrate (Brown & Schwartz, 1992). Iron depletion
increased aluminium uptake, introduced as the hydroxide, by an intestinal cell line (Cannata
et al., 1991; Fernandez Menendez et al., 1991). This is perhaps due to a similar mechanism of
GI aluminium and iron uptake, which was suggested to involve an active process mediated by
Tf, because aluminium transport was 3-fold greater as the Tf than the citrate (Cannata et al.,
1991; Fernandez Menendez et al.,1991). Divalent iron, Fe(II), but not trivalent iron, Fe(III),
increased the disappearance of aluminium, introduced as the hydroxide form, from the
intestinal lumen in the in situ rat gut preparation and decreased the appearance of aluminium
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in portal and systemic blood (Van der Voet & de Wolff, 1987b). The authors suggested that
Fe(II) may enhance Tf-mediated aluminium uptake, followed by the binding of aluminium in
mucosal cells by ferritin. However, although there was a negative correlation between the iron
status of Caco-2 cells and their aluminium uptake, both iron-depleted and iron-overloaded
Caco-2 cells showed less transport of aluminium citrate, lactate and nitrilotriacetate across the
cells than did cells with normal iron content (Alvarez-Hernandez et al., 1994), which is in
contrast to the above results. Addition of Tf failed to facilitate aluminium uptake into Caco-2
cells when the aluminium was introduced as aluminium citrate (Alvarez-Hernandez et al.,
1994). On the other hand, concurrent administration of 48 or 480 mg/kg Ferromia (sodium
ferrous citrate, tetrasodium biscitrato iron (II), E0708) with 50 mg Al/kg as aluminium
hydroxide daily 5 times weekly for 16 weeks to 5/6 nephrectomized rats did not affect serum
or tissue aluminium concentrations compared to administration of aluminium hydroxide or
aluminium citrate alone (Yamazaki et al., 1995). Similarly, iron deficient and iron overloaded
rats did not show significantly different urinary aluminium excretion following i.v. aluminium
chloride injection than controls, with the exception of less urinary aluminium excretion within
the 5 days after aluminium treatment in iron-overloaded rats (Ittel et al. 1996). Brain, bone,
liver and muscle aluminium concentrations were not different in iron-depleted vs. iron
overloaded rats after 41 days of aluminium supplementation in the drinking water and diet,
whereas spleen aluminium concentration was higher in the iron-supplemented rats (Ittel et al.,
1996). Surprisingly, urinary aluminium output was greater when aluminium chloride was given
orally with iron than saline (Ittel et al., 1996).
Nearly all of the interactions between iron and aluminium are consistent with an enhanced
aluminium uptake and retention in the presence of iron deficiency (anaemia). In contrast to
iron, zinc (Zn) deficiency did not produce measurable increases of tissue aluminium in rats
after 28 days (McNall & Fosmire, 1996).
Calcium and sodium: Like iron, calcium (Ca) status impacts on aluminium absorption and
accumulation. Dietary calcium deficiency increased the rate and extent of aluminium
absorption, when introduced as the chloride, tissue aluminium accumulation, and aluminium-
induced neuropathology in rats (Provan & Yokel, 1990; Taneda, 1984). Increased calcium
decreased aluminium uptake and its appearance in plasma in studies that used the rat everted
gut sac and in situ rat gut technique, suggesting a common uptake mechanism for aluminium,
introduced as the chloride, and calcium (Cunat et al., 2000; Feinroth et al., 1982). Based on
ionic radii, it is more likely that aluminium would compete with magnesium than with calcium.
Although there is some evidence for aluminium-magnesium competition in vivo, this has not
been well investigated.
A reduction of sodium (Na) has been reported to increase aluminium uptake. Replacement of
sodium in the perfusate of the in situ gut perfusion study with equimolar choline chloride at
pH 3 significantly (~ 50-fold) increased blood aluminium levels, suggesting a negative
interaction between sodium and aluminium on aluminium absorption, introduced as the
chloride, from the GI tract (Van der Voet & de Wolff, 1987a).
Ethanol: The results of one of two studies suggest that ethanol can affect the toxicokinetics of
aluminium, but the mechanism is not known. Rats were given saline, 10% ethanol in drinking
water, 25 mg Al/kg, as aluminium nitrate, by gastric intubation (i.g.) or 10% ethanol in drinking
water and 25 mg Al/kg i.g. for 6 days/week for 6 weeks (Flora et al., 1991). After the 6 weeks,
aluminium concentrations were significantly higher in blood and liver (24 and 76%,
respectively), and non-significantly higher in kidney and brain (28 and 31%), in the ethanol-
and-aluminium-treated group compared to the group treated only with aluminium. The amount
of ethanol consumed was not reported. If fluid consumption was typical for the rat, it would
have been 10 to 12 mL/100 g/day. The ethanol-and- aluminium-treated group also showed
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significant differences from the aluminium-only-treated group with respect to δ-aminolevulinic
acid dehydratase, zinc protoporphyrin, and glutamic oxaloacetic transaminase in blood;
glutamic pyruvic transaminase in liver; δ-aminolevulinic acid in urine; and dopamine and
homovanillic acid in brain. These effects were generally an accentuation of the aluminium
effects. However, it is not known if the elevation of blood and liver aluminium levels was due
to ethanol alteration of aluminium absorption, distribution or excretion. It is also not known if
ethanol increased aluminium toxicity or if these effects were the result of the combined toxicity
of these two agents. It has been noted that chronic ethanol ingestion compromises GI tract
integrity (Davis, 1993). The author speculated that it may increase aluminium absorption.
Results of the combined administration of ethanol and aluminium in rats suggested that ethanol
enhances the effects of aluminium, introduced as the chloride, but no information was provided
to indicate if ethanol affected aluminium toxicokinetics (Rajasekaran, 2000). However, daily
gavage with a 30% v/v ethanol solution delivering 3 g/kg and 91.8 mg aluminium lactate/kg
for 90 days did not significantly affect serum aluminium, compared to aluminium alone (Kohila
et al., 2004). There are no reports that assess directly the influence of ethanol on aluminium
absorption, distribution or elimination.
Uraemia: There is evidence that uraemia enhances aluminium absorption. The primary
documented problems with aluminium as a toxicant to bone and the brain have occurred in
persons with uraemia (see Toxicokinetics, Absorption, Studies in Humans, Oral
Administration, Factors Influencing Oral Aluminium Absorption, Uraemia). Aluminium levels
were higher in the liver, but not in other organs, of chronically uraemic rats given oral
aluminium hydroxide supplementation than in pair-fed controls (Drüeke et al., 1985).
However, this could be due to a difference in absorption, distribution and/or elimination. Blood
aluminium and/or urinary aluminium excretion were higher in uraemic, compared to normal,
subjects after oral aluminium chloride, hydroxide or lactate administration (Ittel et al., 1987;
1988; 1991a; 1991b; 1996; 1997; Olaizola et al., 1989). The lack of increase of urinary
aluminium after i.v. aluminium chloride or lactate administration to uraemic rats suggests the
increased urinary aluminium in uraemic rats is due to enhanced absorption (Ittel et al.,
1991b). The oral bioavailability of aluminium introduced as 26Al plus 27Al chloride was
estimated to be 0.133% in controls and 0.175% in uraemic (5/6 nephrectomized) rats (Ittel et
al., 1997). Reduction of renal function in rabbits, to ~ 23% of controls, increased the percentage
of aluminium absorbed from aluminium chloride, citrate and lactate by ~ 50 to 100% (Yokel
& McNamara, 1988). Systemic clearance was reduced to ~ 74% of that of controls.
Ultrafilterable serum aluminium increased, perhaps accounting for the smaller reduction in
systemic aluminium clearance than might be expected with a renal function that is 23% that
of controls. Serum aluminium concentration was lower in 5/6 nephrectomized rats but urinary
aluminium clearance was not significantly different from that of controls, suggesting a greater
free fraction of aluminium in uraemia (Ittel et al., 1997). Uraemia may increase aluminium
uptake through the paracellular pathway, indicated by increased serum and urinary aluminium
in the presence of chemically-induced intestinal mucosal atrophy and by reduced serum
aluminium when kinetin, a paracellular pathway blocker, was added to oral but not i.v.
aluminium chloride administration (Ittel et al., 1992a; 1996).
Age: It is unclear from animal studies whether age influences aluminium absorption.
Comparison of blood and urine aluminium in weanling and growing rats after oral aluminium
hydroxide administration led Olaizola et al. (1989) to conclude that there is an inverse
relationship between aluminium absorption and age. Rat brain aluminium concentration
inversely correlated with age in control rats that were 21 days, 8 months and 16 months old
(Domingo et al., 1996), in contrast to most observations in the human (see Toxicokinetics,
Distribution (Including Compartmentalization), Human Studies, Tissue Aluminium
Concentrations, Brain). After consuming aluminium and citrate in drinking water for 6.5
months, elderly rats generally had higher concentrations of aluminium in liver, kidney, spleen,
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bone and testis than the young rats (Gómez et al., 1997). In contrast, the brain aluminium
concentrations were significantly lower in old than young rats (Domingo et al., 1996). The
results of these studies are not consistent. Furthermore, none of these studies directly addressed
absorption. The differences seen could be due to distribution or elimination.
Foods and dietary components: It has been assumed that the presence of food in the stomach
inhibits aluminium absorption, due to aluminium association with organic ligands in food.
Only a few studies have directly addressed this hypothesis. The results do not consistently
show an influence of food on aluminium absorption. Some of the studies of oral aluminium
bioavailability that model aluminium exposure from drinking water restricted food access,
whereas others did not. Rodents and rabbits recycle their faeces to increase essential nutrient
absorption and usually have stomach contents 24 to 36 hr after food removal. Therefore, simply
depriving the animal of food does not guarantee that there will be no stomach contents. In some
studies, rats were dosed after a 16 or 24 hr fast (Drüeke et al., 1997; Schönholzer et al.,
1997), whereas in others free access to food was allowed (Drüeke et al., 1997). Oral aluminium
bioavailability in these studies ranged from 0.06 to 0.36%. The oral bioavailability of 26Al,
given in the absence of ligand, in rats that were deprived of food for 24 hr was 0.94% (Drüeke
et al., 1997). As stomach contents were found in rats deprived of food for ≥ 24 hr, as noted
above, it cannot be assured that there were no stomach contents in the rats in this study. In
contrast, Yokel et al. (2001b) did not find a difference in oral 26Al bioavailability, when the
Al was given in the absence of ligands, in rats exposed to a procedure that resulted in no stomach
contents compared to rats that did have chow in their stomachs. Similarly, the addition of
calcium and magnesium carbonates, designed to simulate hard water, did not affect oral
aluminium bioavailability (Yokel et al., 2001b). Walton et al. (1994) conducted an ambitious
study to assess the influence of beverages and foods on the oral absorption of aluminium given
as the sulphate, to produce alum in solution. Their results show increased peak serum
aluminium concentrations and urinary aluminium excretion after co-administration of orange
juice and, to a much smaller extent, coffee and wine. Meat and carbohydrate/cereal products
decreased aluminium absorption. However, neither the blood nor urine samples obtained
hourly for 4 hr after dosing enable determination of oral aluminium bioavailability.
Dietary components such as phytate and polyphenols, that chemically associate with
aluminium and reduce oral absorption of other minerals, may affect aluminium absorption
(Powell & Thompson, 1993; Powell et al., 1993). However, no published studies were found
that directly assessed this.
It was speculated that the species of aluminium in the GI tract, which may be present as
insoluble or soluble forms and associated with various ligands and, perhaps more importantly,
the form of mucus and interaction of aluminium with mucus, vary as a function of time since
food consumption and, perhaps, composition of the diet. This may result in variable amounts
and composition of absorbable aluminium species, contributing to the variable results in
relation to the effect of stomach contents on oral aluminium absorption.
Overall, results suggesting that food composition of the presence of food in the stomach
significantly affects oral aluminium bioavailability have been obtained in a few studies (Walton
et al., 1994; Drüeke et al., 1997; Yokel & Florence, 2006) whereas another study did not find
a significant effect of water quality or the presence of food in the stomach on oral aluminium
bioavailability (Yokel et al., 2001b).
Chemical speciation: The chemical form in which aluminium is administered can affect its
absorption (Cunat et al., 2000; Deng et al., 2000; Froment et al., 1989b; Schönholzer et al.,
1997; Yokel & McNamara, 1988). As noted above in Toxicokinetics, Absorption, Animal
Studies, Oral Administration, Factors Influencing Oral Aluminium Absorption, Carboxylic
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Acids, addition of citrate, which is believed to solubilize aluminium and perhaps open the
paracellular pathway, increased oral aluminium bioavailability in many studies. Consumption
by rats of diets for 18 days containing ~ 200 to 260 mg Al/kg diet as aluminium hydroxide,
palmatate, lactate or phosphate, or aluminium hydroxide as a reagent grade chemical, or 2
different sources of desiccated gel, resulted in some significant differences in brain, bone and
kidney aluminium concentrations (Greger, 1985). For example, aluminium hydroxide raised
brain aluminium more than aluminium palmitate and one form of aluminium hydroxide gel
raised kidney aluminium levels more than another form but resulted in lower aluminium levels
in the tibia. Using the in situ rat gut technique, significantly more aluminium appeared in the
plasma after perfusion with the citrate, lactate, tartrate and gluconate forms of aluminium,
whereas plasma aluminium was not elevated after perfusion with the chloride, nitrate, sulphate
and glutamate forms (Cunat et al., 2000).
It has been suggested that the chemical species of aluminium in drinking water in the absence
of fluoride would be primarily labile, monomolecular Al(H2O)6 below pH 5 and Al
(OH)1 to 4+2 to -1 at higher pHs (Lazerte et al., 1997). In the presence of fluoride (1 ppm; 53
μM), AlF2+ and AlF3 would be expected at pH < 6.5. At higher, pHs mixed Al(OH)xFy
complexes or Al(OH)4- would be expected (Nieboer et al., 1995). It is thought that these species
would favour aluminium absorption from drinking water compared with that from food
(Martyn et al., 1989) in which aluminium is presumed to be bound to phosphorus-rich
compounds such as phytates and casein, a phosphoprotein (Glynn et al., 1995). Glynn et al.
(1995) determined soluble and quickly reacting aluminium species (presumably species that
might be absorbed) in the presence of 4 mg Al/L, the chloride, added to simulated gastric
contents containing 40% rat feed. Less than 50% of the added aluminium was in the soluble
fraction. As nearly 100% would be expected to be labile species (Al+3, monomeric hydroxo
and sulphato complexes) under these conditions, the authors concluded that the labile
aluminium rapidly complexed to components of food. They hypothesized that foods may alter
aluminium absorption. The presence of food may change the pH. It has been suggested that
food may bind aluminium, hence reducing its bioavailability. Therefore, it has been suggested
that enhanced aluminium absorption may occur in the presence of an empty stomach, especially
during periods of fasting. This has been discussed in Toxicokinetics, Absorption, Animal
Studies, Oral Administration, Factors Influencing Oral Aluminium Absorption, Foods and
Dietary Components. There is no strong evidence to support this notion.
In a subsequent study, rats drank water containing 0, 10, 50 or 500 mg Al/L, introduced as the
chloride, for 9 weeks while consuming a diet containing 5 mg Al/kg (Glynn et al., 1999). Bone
aluminium increased above control concentrations in the rats drinking the waters containing
the higher two aluminium concentrations. In vivo fractionation of the stomach contents of these
rats showed an increase of dissolved aluminium as water aluminium concentration increased,
up to 50 mg Al/L, and the appearance of measurable quickly reacting aluminium species in
those exposed to 500 mg Al/L. The authors interpreted their results as supportive of their
hypothesis that aluminium absorption will increase when the aluminium-binding capacity of
food in the stomach has been saturated. When compared to typical drinking water aluminium
concentrations of 50 to 100 μg Al/L, these results suggest that aluminium would not be absorbed
when stomach contents are present, as the aluminium binding capacity would not be saturated.
This is not supported by several studies utilizing 26Al in much lower aluminium doses than
employed by Glynn et al. (1999). These studies found oral aluminium absorption in the
presence of stomach contents (Drüeke et al., 1997; Jouhanneau et al., 1997a; Yokel et al.,
2001b).
In contrast to the above hypothesis, Reiber et al. (1995) suggested that a substantial portion of
aluminium, regardless of the form consumed, will be solubilized to monomeric aluminium in
the stomach. They based this on studies showing solubilization of aluminium from particulate
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and colloidal sources within 2 hr at pH 1 to 2 and the average residence time in the human
stomach, which has a pH of 1.5 to 2, of 1 to 4 hr. They concluded: “…the often raised issue of
the relative bioavailability of the aluminium source would seem to be a moot point”, because
“Regardless of the consumptive form, the bulk of aluminium will be converted to
monomolecular species in the stomach” As they claimed that the stomach is impervious to
charged species, they concluded: “In a healthy stomach, however, it is unlikely that any free
or complexed aluminium can be absorbed across the stomach wall.” They claimed that the pH
of stomach contents rapidly rises to 6.2 when in the duodenum, and then to pH 7.3 after leaving
the duodenum. Because the nadir of aluminium solubility, due to aluminium hydroxide
formation, is at pH 6.2 (Harris et al., 1996), they suggested: “…more than 99.9 percent of the
consumed aluminium should ultimately be excreted in the stool as an aluminium hydroxide
precipitate, leaving less than 0.1 percent available for uptake”, explaining why only a small
percentage of oral aluminium is absorbed (Reiber et al., 1995). They recognized that this
scenario is simplistic. However, at the pH of the human intestine, ~ 6.8, the major aluminium
hydroxide species which would be formed in the absence of other ligands to associate with
aluminium would be the soluble Al(OH)4- (Harris et al., 1996), suggesting a lower percentage
of precipitated aluminium than stated by Reiber et al. (1995). If studies utilizing large doses
of 27Al are not considered, there is very little data relevant to comparative oral aluminium
bioavailability for different aluminium forms to test the suggestion of Reiber et al. (1995).
The most ambitious study of the influence of beverages and foods on oral aluminium absorption
was conducted by Walton et al. (1994). This is a non-peer reviewed report of a study in which
large sample sizes were not used. However, an issue that has not been well investigated was
addressed. They exposed anesthetized rats to 2 mL of water containing no aluminium, or 8 mg
aluminium as aluminium sulphate and/or various beverages and foods by gastric
administration. Blood was obtained from the tail, prior to and 1, 2, 3 and 4 hr after, dosing.
Urine was obtained, at the same times after dosing, by needle aspiration from the bladder.
Considering the short period of observation (4 hr), serum aluminium is probably a better
indicator of absorbed aluminium than is aluminium excreted in the urine. Administration of 8
mg aluminium in water increased peak serum aluminium about 4.5-fold and produced a urinary
aluminium concentration of 2.6 μg/L. Co-administration of orange juice, coffee and wine with
the aluminium significantly increased peak serum aluminium levels, compared to
administration of aluminium alone, approximately 17-, 2.5-, and 1.9-fold, respectively. Serum
aluminium peaked at 1 hr when given alone. The time of peak serum aluminium in the presence
of co-administered foods was not reported. Therefore, it is not known if the rates of aluminium
absorption are similar and, as a result, if the 4 blood samples obtained represent similar time
profiles of the aluminium absorbed. Urinary aluminium concentration increased approximately
10.5-, 1.3- and 1.8-fold when these three beverages were co-administered with aluminium.
Meat and Vita Wheat® biscuits (a carbohydrate/cereal product) significantly attenuated the
elevation in serum aluminium caused by aluminium dosing to 62 and 65%, when compared to
administration of aluminium alone. Urinary aluminium was attenuated by these two foods to
45 and 57%. These foods were available for 36 hr prior to their co-administration with the
aluminium, to “load the gastrointestinal tract with the single food and its breakdown
products.” In contrast, no food was available for 36 hr prior to aluminium alone or beverage
(plus aluminium) dosing. In preliminary studies, the investigators found food in the stomach
24 hr after removal of food access, so they went to 36-hr food deprivation. They did not verify
the lack of stomach contents after 36-hr food deprivation. As noted above, this does not assure
the lack of stomach contents. Co-administration of beer, Coca-Cola®, tea, apple, broccoli,
butter and margarine produced non-significant effects. Co-administration of both orange juice
and Vita Wheat® with aluminium resulted in an increase of serum aluminium levels of 9.1-
fold, an attenuation of the result seen with orange juice alone, but urine aluminium
concentration was not attenuated by the addition of Vita Wheat® to the aluminium plus orange
juice administration. No definitive conclusions can be made from this study. The results from
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co-administration of coffee and wine, which slightly increased serum and urine aluminium
levels, and meat and the cereal product, which decreased serum and urine aluminium levels,
suggest that co-administration of certain foods with drugs or foods that contain significant
amounts of aluminium warrants further study.
The site and mechanisms of oral aluminium absorption: Aluminium, like most substances,
is better absorbed from the upper intestine than from the stomach. The stomach is lined by a
thick, mucus-covered membrane. It has a much smaller surface area than the intestine. The
primary function of the stomach is digestive, whereas that of the intestine in absorptive. Ionized
molecules are usually unable to penetrate the lipid bilayer of cell membranes due to their low
lipid solubility (Benet et al., 1996). As aluminium would be expected to be present primarily
as the free ion, with associated waters of hydration, at the low pH of the stomach, non-carrier-
mediated absorption would not be predicted from the stomach. Studies with in vivo isolated
duodenal segments suggested aluminium uptake at pH 2 was due to both an aluminium-
concentration-dependent non-saturable process and a saturable process that is at least partially
vitamin D dependent, suggesting that aluminium may compete with calcium (Adler & Berlyne,
1985). Uptake of aluminium from the citrate into stomach sacs was much less than into small
bowel and colon (Whitehead et al., 1997). Plasma aluminium concentrations peaked 45 minutes
after oral citrate intake by rats (Froment et al., 1989a; 1989b). They observed a simultaneous
peak of plasma aluminium and glucose and concluded that the site of aluminium absorption is
probably the proximal small intestine (Froment et al., 1989b). The lower pH of the proximal
duodenum would be expected to result in greater aluminium absorption than more distal
intestinal segments (Greger & Sutherland, 1997).
GI aluminium absorption appears to be a two-step process, an initial mucosal cell uptake,
followed by much slower release into the blood. This was suggested by Feinroth et al.
(1982), based on results obtained with everted rat jejunal sacs and aluminium chloride. Others
reached a similar conclusion, based on results with in vivo isolated gut segments and the in
situ intestinal perfusion technique with portal and systemic blood sampling after aluminium
chloride (Adler & Berlyne, 1985; Van der Voet & de Wolff, 1986-1987) and aluminium
chloride, lactate and nitrate addition (Jäger et al., 1991), as did Cochran et al. (1990), after
aluminium chloride addition, using a duodenal perfusion preparation. It was shown that
aluminium binds to mucus glycoproteins in the GI tract (Crowther & Marriott, 1984). A much
greater loss of aluminium from the intestine than appeared in the blood was typically found in
the above studies. This loss was attributed to mucosal cell or mucous uptake of aluminium.
Support for this suggestion was provided by the finding that nearly all of the aluminium not
recovered in the perfusate effluent from the rat gut could be recovered in intestinal mucus
(Powell et al., 1994; 1999). This group found tissue aluminium uptake to be up to 1000-fold
that of aluminium transport across the gut tissue (Whitehead et al., 1997). Powell et al.
(1999) found that the association of aluminium with gelatinous mucus prevents formation of
aluminium-hydroxy precipitates. They interpreted their results to show that aluminium is
primarily associated with insoluble mucus, which, due to its slow reaction kinetics, reduces
aluminium absorption, enabling its faecal elimination (Powell et al., 1999). The finding that ~
60% of aluminium, introduced as the chloride, taken up from the in situ perfused rat intestine
was in the small intestine is consistent with this interpretation (Arnich et al., 2004).
The mechanisms mediating GI aluminium absorption have been suggested to include passive
(diffusion) and active (carrier- and vesicular-mediated) transport across intestinal cells as well
as paracellular diffusion between these cells. Support has been provided for an energy-
dependent uptake process. Dinitrophenol (DNP), cyanide, vanadate, the absence of glucose
and low temperature inhibited the uptake of aluminium, introduced as the chloride, in studies
utilizing the rat everted gut sac, isolated jejunal slice, and a duodenal perfusion technique
(Cochran et al., 1990; Feinroth et al., 1982; Provan & Yokel, 1988b). Reduced glucose in the
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in situ rat gut technique perfusate decreased aluminium in plasma (Cunat et al., 2000). In
contrast, Farrar et al. (1987) and Provan & Yokel (1988a) did not find an effect of DNP using
rat duodenal, jejunal or ileum preparations and the in situ rat gut preparation. Whitehead et al.
(1997) found no effect of ouabain, suggesting the lack of dependence on Na/K-ATPase. A
plateau of aluminium uptake, introduced as the chloride, was observed by Feinroth et al.
(1982) and Provan & Yokel (1988b), suggesting a carrier-mediated mechanism. Deleting
phosphorus from the in situ rat gut technique perfusate reduced aluminium uptake into plasma
which, the authors suggested, could be due to the role of phosphorus in cellular respiration
(Cunat et al., 2000). However, the presence of phosphorus, which causes aluminium phosphate
precipitation, has been associated with decreased aluminium absorption (Kaehny et al.,
1977).
Evidence for an interaction with calcium uptake has been obtained. Increasing calcium
perfusate concentration decreased aluminium, introduced as the chloride, uptake (Feinroth et
al., 1982) and addition of aluminium chloride to the in situ perfused duodenum decreased
calcium uptake (Adler & Berlyne, 1985). Calcium channel blockers decreased, and calcium
channel activators increased, uptake into rat jejunal slices (Provan & Yokel, 1988b) and
duodenum (Cochran et al., 1990) when introduced as aluminium chloride; however, Provan &
Yokel (1988a) did not find an effect of calcium channel blockers or a facilitator in the in situ
rat gut preparation.
It has been suggested that citrate facilitates aluminium absorption by opening the tight junctions
between GI mucosal cells, by chelating calcium, which is required for tight junction integrity,
and that the aluminium is absorbed as aluminium citrate (Froment et al., 1989b). This
mechanism of enhanced aluminium absorption was favoured by Taylor et al. (1998). However,
they found peak serum citrate concentrations 31 to 32 minutes after aluminium citrate
consumption, whereas aluminium concentrations peaked at 77 to 108 minutes, suggesting that
aluminium was not absorbed as aluminium citrate due to the faster absorption of citrate and
was not released into blood as aluminium citrate (Taylor et al., 1998).
Some evidence suggests a role for sodium transport processes. Low sodium and amiloride, a
sodium uptake blocker, increased the uptake t½ of aluminium (Provan & Yokel, 1988a). In
contrast, Van der Voet & de Wolff (1987a) found a negative interaction between sodium and
aluminium uptake. Further study by Van der Voet & De Wolff (1998) showed that the presence
of calcium, but not sodium, reduced aluminium uptake. The presence of both calcium and
sodium attenuated the calcium effect, leading the authors to speculate: “… aluminium attempts
to mimic calcium in its Na-related intestinal passage”.
Paracellular pathway blockers increased the t½ of aluminium uptake in the in situ gut
preparation (Provan & Yokel, 1988a). More support for the hypothesis that the paracellular
pathway is involved in aluminium absorption was provided by further studies which used the
in situ rat gut preparation and aluminium chloride or citrate (Froment et al., 1989a; Partridge
et al., 1992; Provan & Yokel, 1988a), inverted intestinal segments and aluminium citrate
(Farrar et al., 1987; Whitehead et al., 1997), and Caco-2 cells exposed to aluminium in the
absence of ligand or as the citrate, fluoride, hydroxide or maltolate (Zhou & Yokel, 2005).
However, paracellular pathway blockers did not affect aluminium uptake by the jejunal slice
(Provan & Yokel, 1988b), which might be expected when the endpoint is uptake into, rather
than flux across, tissue.
Tf addition to the medium vascularly perfusing an intestinal preparation increased aluminium
uptake, suggesting it facilitated entry of aluminium, introduced as the chloride, into blood,
perhaps from intestinal cells (Jäger et al., 1991). It has been suggested that Tf mediates
aluminium release from mucosal cells into blood (Greger & Sutherland, 1997). There is no
Krewski et al. Page 52
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
single unifying explanation for these results. It is probable that there is more than one
mechanism of aluminium uptake, which might be aluminium species-, pH- and intestinal
region-dependent. Multiple mechanisms would account for the lack of ability of manipulations
to totally block aluminium uptake, and perhaps the significant results obtained by some, but
not other, investigators.
Lower serum aluminium concentrations resulted from portal vein than from i.v. injections of
the same aluminium dose, as the sulfate, to rats, indicating significant first-pass pre-systemic
clearance of aluminium by the liver (Xu et al., 1992a). These results suggest that determination
of aluminium absorption based on area-under-the-curve calculations from multiple blood/
serum aluminium determinations over time might underestimate absorbed aluminium,
although this method estimates the aluminium that reaches systemic circulation and is available
for distribution to organs such as the brain.
The chemical speciation of aluminium, consumed in beer, as it passes through the upper part
of the GI tract was modelled by (Sharpe et al., 1995). The citrate concentration in beer exceeded
the aluminium concentration, resulting in the predominant aluminium species in lager, the
mouth and stomach being aluminium citrate. In the duodenum and jejunum, where the pH is
~ 6.5, the predicted predominant species was aluminium phosphate. This is the primary site of
aluminium absorption. At pH 7, neutral aluminium species exceeded charged and
“solid” (insoluble) aluminium species at total aluminium concentrations below 7600 μg Al/L,
which is well above the median aluminium concentration in the beers studied (100 μg Al/L).
Dermal—Aluminium salts precipitate proteins and have astringent properties. This has led to
their use to treat urinary bladder haemorrhage, diaper rash and prickly heat, insect stings and
bites and athlete’s foot, and use in styptic pencils and products for dermatitis (Tinea pedis); in
anti-diarrheal products and vaginal douches and as a keratolytic in anorectal preparations
(Allen et al., 2000; Knodel et al., 1996) (see also Sources of Human Exposure, Anthropogenic
Sources, Uses and Table 6).
Aluminium salts are extensively used in antiperspirants because they suppress eccrine sweating
more effectively than other metal salts (Hostynek et al., 1993). They are thought to be effective
because either they become neutralized in the sweat duct to form a gelatinous or flocculant
hydroxide precipitate, or because they denature keratin in the cornified layer that surrounds
the opening of the sweat duct. Both mechanisms predict that little aluminium would be
absorbed through the sweat duct (Hostynek et al., 1993).
Aluminium poorly penetrates the skin. In a study claimed to be the only report to that time on
penetration of aluminium salts through excised skin, it was concluded that minimal aluminium
reached the dermis following topical exposure. Abdominal and axillary human skin, 3 cm2,
was exposed for up to 23 hr to 5 mL of 20% aluminium chlorohydrate, which would have
contained ~ 280 mg aluminium. A 10 mm disk of the exposed skin contained ≤ 7 μg aluminium.
Removal of the stratum corneum (the outer layer of the skin that is 25 to 35 μm thick) by
stripping with adhesive tape resulted in no greater aluminium penetration into the dermis. The
authors noted that very little aluminium reached the dermis, the region of the sweat glands.
They attributed the low penetration to binding of unknown aluminium complexes to the outer
stratum corneum layers (Blank et al., 1958). Stripping the stratum corneum with tape restored
50% of the function of sweat glands that had been inhibited by aluminium chlorohydrate,
suggesting its site of action is quite shallow (Quatrale et al., 1981a). More, ~ 2/3, of sweat
gland function inhibited by aluminium zirconium chlorohydrate glycine complex was restored
by stripping whereas removal of the stratum corneum did little to reverse the effects of
aluminium chloride, suggesting it may have penetrated deeper into the sweat duct (Quatrale et
al., 1981a). TEM and morin stain techniques suggested that aluminium chlorohydrate collected
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in sweat ducts at the layer of the stratum corneum to completely fill the duct as an amorphous
mass (Quatrale et al., 1981b; Quatrale, 1985). Sorption, defined to include both adsorption
(onto) and absorption (into) the stratum corneum, of unbuffered aqueous solutions of 50%
aluminium chlorohydrate at pH 5 to 5.2, or aluminium chloride atomic absorption standard
reference solution at pH 3.45 to 4.16, was rapid to guinea pig stratum corneum in vitro
(Putterman et al., 1981). Desorption of aluminium chloride was more rapid than aluminium
chlorohydrate. The latter was essentially irreversibly bound to the stratum corneum, suggesting
that aluminium might not be able to be absorbed through the skin. Hostynek et al. (1993)
concluded that the avid formation of aluminium complexes with skin proteins precludes all but
very shallow penetration of the epidermis.
A few studies were conducted to assess aluminium absorption through the skin of mice.
However, a number of concerns about these studies reduces confidence in the authors’
interpretations. Anane et al. (1995) applied 20 μL of a 0.025 or 0.1 μg aluminium chloride/mL
solution to 4 cm2 of skin (0.1 and 0.4 μg/day) on the dorsal shaved surface of mice for 130
days. The total aluminium applied during this time (0.5 to 2 mg/kg) is comparable to a one day
aluminium exposure of humans using topical antiperspirants. Twenty-four hr urine samples
were obtained starting 1 day after completion of aluminium dosing. Blood and brain samples
were also obtained. A statistically significant increase was reported in urinary and serum
aluminium concentrations after both aluminium exposures, compared to those for non-exposed
mice of the same age. This suggests that a small fraction of the typical human use of a topical
antiperspirant might produce a measurable increase in urine and tissue aluminium levels.
Increases in brain aluminium levels were 19 to 124% over controls. The aluminium
concentration in the hippocampus was reported to be 2 to 3 times the rest of the brain in controls
and aluminium-exposed mice. This could be an artifact of aluminium contamination, which
would be more pronounced in a smaller sample (hippocampus) than in the rest of the brain.
Dermal exposure of mice pups from 2 to 22 days of age to 0.025, 0.05 or 0.1 μg aluminium
chloride/cm2 increased their brain aluminium levels by 5 to 24%. Using X-ray energy scanning
electron microscopy, the authors reported 11 to 120-fold more aluminium in the hippocampus
of treated mice than in those of controls, whereas atomic absorption spectrometric analysis of
aluminium showed a 1.6 to 2.2-fold increase. Absorption of aluminium, applied as aluminium
chloride, to mouse skin in vitro, was determined in a “static” culture system. Increased
aluminium was observed in the compartment that modelled sub-dermal fluid. In a similar study,
pregnant mice received dermal application of 0.4 μg aluminium chloride daily for 20 days
(Anane et al., 1997). Aluminium levels in maternal serum, amniotic fluid and foetal brain,
kidney, and liver were all reported to be statistically increased, by 63, 21, 4.5, 5.0 and 15%,
respectively, compared to controls. There is no mention in either report of methods to prevent
absorption by non-transcutaneous routes. The aluminium solution was applied over a 4 cm2
area on the back, which represents about 12% of the total body surface area of the mouse. It is
quite possible that grooming produced oral aluminium exposure. A 20 g mouse receiving a
total of 2 mg Al/kg would receive 0.04 mg of aluminium. Retention of 5 × 10-5 of the
administered aluminium by each gram of brain, as has been reported after i.v. aluminium
injection (see Toxicokinetics, Distribution (Including Compartmentalization), Animal Studies,
Central Nervous System), which corresponds to 100% bioavailability, would raise brain
aluminium levels by 2 × 10-3 mg Al/kg (2 ppm). The reported increase of brain aluminium was
18 × 10-3 mg Al/kg, suggesting > 100 % bioavailability, and therefore casting further doubt
on the validity of these findings. There is a low degree of confidence in the results and
interpretation of this work.
Intranasal—The potential for delivery of compounds to the CNS from the nasal cavity via
the olfactory neuron has been proposed. The strongest supporting data have been obtained with
manganese (Mn) (Tjälve et al., 1996). There is little evidence supporting similar transport of
other metals, such as cadmium, nickel, and mercury. For a review see Tjälve & Henriksson
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(1999). Anatomically, the olfactory system as a route of delivery to the brain is intriguing as
well as problematic for interpretation. The olfactory receptor neurons are the first-order
neurons located within the nasal cavity in the olfactory epithelium. Their cell bodies lie in the
basal two thirds of the epithelium. Several cilia extend from each cell into the mucous layer of
the epithelium. These cells are separated and partially ensheathed by supporting cells of the
olfactory epithelium. The axons of these neurons project via the olfactory nerve (the first cranial
nerve) to the olfactory bulb and synaptically terminate on the mitral and tufted cells. These
cells then relay via neurotransmitter synapses to higher order olfactory structures and to other
brain systems. Such neurotransmitter target sites include the olfactory peduncle, the piriform
cortex, the olfactory tubercle, the entorhinal cortex, and some amygdaloid nuclei. Projections
are made from these primary olfactory cortical structures to other brain regions. While this
distinct anatomical pathway exists, to serve as a direct route of exposure to the brain would
require the axonal transport of the material of concern as well as the trans-synaptic transport
from one neuron to the next within the pathway.
An alternative route from the nasal passage has been proposed, that is exposure via the CSF.
In this case, delivery would be from diffusion of the compound through the perineural fluid
around the olfactory nerve through the cribriform plate. However, it is not clear if this pathway
can mediate distribution from the nasal cavity into the brain as it has been primarily described
as a route of drainage from the CSF compartment to the nasal lymphatics (Jackson et al.,
1979; Kida et al., 1993). If a compound could diffuse by this route from the nasal cavity into
the CSF, it would be expected to initially distribute through the subarachnoid space and over
the cortical surface.
The third route of absorption from the nasal cavity is into systemic circulation by the
vasculature of the nasal cavity (Landau et al., 1994).
In the initial study to assess whether aluminium can enter the brain from the nasal cavity, Perl
& Good (1987) implanted Gelfoam® containing 0.5 mL of 15% aluminium lactate, 5%
aluminium chloride, or 15% sodium lactate into the nasal recess of rabbits. The Gelfoam®
remained in place for 1 month. Neuropathological changes and elevated aluminium were seen
in the olfactory bulb, piriform cortex, hippocampus and cerebral cortex, but not in cerebellum,
brainstem or spinal cord. However, this exposure protocol is not realistic with respect to
potential human exposure. There is concern that Gelfoam® implants containing such a high
aluminium concentration in the nasal cavity for 1 month could damage the nasal epithelia
(Lewis et al., 1994). Perl & Good (1987) suggested that a defect in the normally effective
olfactory mucosa/olfactory bulb barriers may lead to excessive aluminium exposure. Their
experimental conditions may have produced such a defect, which may not be present or as
prevalent in the normal condition. Although this study has been frequently cited, it has not
been replicated.
In a second study designed to address the possibility that aluminium can enter the brain from
the nasal cavity, rats were exposed by inhalation to 20.6 μg aluminium chlorohydrate/m3 via
nose-only exposure 6 hr/day for 12 days. The aluminium chlorohydrate was from a commercial
source (Pfaltz & Bauer) and was delivered as aerosols generated by a venturi powder dispenser.
Although particle size distribution was determined several times during the study, the results
were not reported. The rats had a significantly greater aluminium concentration in the olfactory
bulb, determined by PIXE, than in non-olfactory brain regions. Aluminium was not seen in the
brain of rats that received similar non-aluminium exposures (Divine et al., 1999). Four tissue
samples from olfactory bulbs, with 8, 7, 13 and 7 aluminium sites, had average aluminium
concentrations of 3.0, 3.8, 7.0, and 2.1 mg Al/kg, respectively. Four brain regions considered
non-olfactory bulb associated, i.e., brain stem nuclei in the region of the substantia nigra, had
2, 1, 3 and 2 aluminium sites and average aluminium concentrations of 0.7, 0.5, 1.0, and 0.6
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mg Al/kg, respectively. The average aluminium concentration and number of aluminium sites
were shown to be significantly different by Student’s t test.
Rats exposed to lipophilic aluminium acetylacetonate under conditions designed to maximize
inhalation via the nasal-olfactory system had elevated levels of aluminium in the brain (Zatta
et al., 1993). Aluminium was seen in the olfactory bulb, cortex, hippocampus, and entorhinal
area, and also in the cerebellum, which is not within the olfactory pathway. Exposure to
aluminium via deposition into the nasal cavity from which it might be absorbed may be relevant
to environmental exposures, although such exposures are most likely to be from aluminium
silicates in airborne dust, which contains very little aluminium in the exchangeable metal ion
fraction, as noted below (Lum et al., 1982). This exposure route may also be relevant to
occupational settings, such as those of potroom workers, welders and of workers exposed to
suspended aluminium particles. Although the study of aluminium chlorohydrate inhalation
may involve a route of exposure and chemical species of aluminium relevant for the human,
these studies do not model human exposure to typical aluminium species in the environment
or workplace. Furthermore, these studies provide no information on the percentage of
aluminium introduced into the nasal cavity that might, in turn, be taken up into the brain, which
may be very small based on studies with manganese and cocaine (Chow et al., 1999; Dorman
et al., 2002).
Intramuscular—There is one reported study that quantified aluminium absorption following
i.m. injection. Flarend et al. (1997) prepared 26Al hydroxide and 26Al phosphate adjuvants
(which did not contain allergens) and 26Al citrate. Two rabbits were given i.m. 26Al hydroxide,
2 rabbits were given 26Al phosphate adjuvant and 1 rabbit was given i.v. 26Al citrate. In the
first 2 days, 40% more 26Al was absorbed from 26Al hydroxide than from 26Al phosphate.
Within the first 28 days, 17% of the 26Al from aluminium hydroxide and 51% of the 26Al from
aluminium phosphate was absorbed, when compared to the area-under-the-curve for the
aluminium citrate. This is based on the assumption that the much greater (300-fold) peak blood
aluminium seen after aluminium citrate injection than after adjuvant injections does not
confound this interpretation. The authors suggested that all of the injected aluminium may
eventually be absorbed. Therefore, 100% of aluminium may eventually be absorbed from
muscle, even from insoluble aluminium species. Peak aluminium concentrations following
absorption from the i.m. route are lower than from oral and inhalation of small particles due
to the prolonged time course of i.m. aluminium absorption.
Studies in humans
Inhalation exposure—Occupational exposure to aluminium fumes, dusts and flakes has
been shown to produce elevated levels of urine aluminium and, less frequently, elevated levels
of serum and bone aluminium. Workers involved in the electrolytic production of aluminium
for an average of 3.8 years, the production of aluminium powder for 10.2 years, the production
of aluminium sulphate for 7.4 years, and in aluminium welding for 10.7 years, and a group of
patients with renal failure who were receiving dialysis, were compared with a referent group
(Sjögren et al., 1983). The dialysis patients had the highest plasma aluminium concentrations.
All of the aluminium workers, except those involved in electrolytic aluminium production, had
significantly higher serum aluminium levels than the referents. All aluminium workers had
significantly higher urine aluminium than their referents. Serum and urine aluminium
concentrations were positively correlated. Workers’ plasma and urine aluminium
concentrations were higher after a work shift compared to those before the shift and higher on
a Friday than on a Monday (Mussi et al., 1984). Plasma and urine aluminium levels increased
more after exposure to comparable concentrations of fume than dust (Mussi et al., 1984).
Although the particle sizes were not reported, it is likely that those of the dust were larger than
those of fume, the mass median diameter of which was ~ 0.4 μm (Sjögren et al., 1988). End-
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of-shift urinary aluminium concentration correlated well with environmental aluminium
concentration. The increase in urinary aluminium level was greater from inhalation of
aluminium fumes than from the slightly lower concentrations of aluminium in dust. It is not
known if inhalation exposure results in absorption across the lungs, from the GI tract after
mucociliary clearance of material from lung to stomach, and/or via the olfactory tract. It is
suggested above (see Toxicokinetics, Absorption, Animal Studies, Inhalation Exposure /
Intranasal) that absorption from the GI or olfactory tracts is unlikely to account for aluminium
absorption after inhalation exposure. Three previously unexposed volunteers and six welders
were exposed to welding fumes containing ~ 39% aluminium, as aluminium oxide (Sjögren et
al., 1985). The industrial exposures varied from 0.3 to 10.2 mg Al/m3 with a mean 8 hr TWA
value of 2.4 mg Al/m3. The urinary aluminium level in one volunteer, who had no previous
aluminium exposure and who was exposed to an 8 hr TWA of 7 mg Al/m3, showed an increase
to ~ 50 μg Al/L, and then 375 μg Al/L, 12 and 24 hr, respectively, after initiation of inhalation.
Urinary aluminium levels in the 3 volunteers increased from < 3 μg Al/L before, to > 100 μg
Al/L after, exposure (Sjögren & Elinder, 1992). The t½ of the first phase of elimination was
estimated to be ~ 8 hrs. One welder, who had been exposed for one month, had a urinary
aluminium concentration of ~ 40 μg/L during a week of exposure to ~ 1.5 mg Al/m3 ~ 7 hr
daily. Another welder who had been exposed for 19 years had a urinary aluminium
concentration of ~ 300 μg/L during a week of exposure to an 8 hr TWA of 0.5 mg Al/m3
(Sjögren & Elinder, 1992). These results suggested pulmonary absorption. The authors
estimated that ~ 0.1 to 0.3% of the inhaled aluminium appeared in urine within a few days
(Sjögren et al.,1985). Twenty-five MIG welders exposed to a median of 1.1 mg Al/m3 over
periods of 0.3 to 21 years had a median urine aluminium concentration of 82 μg/L (54 mg/kg
creatinine). After a period of 16 to 37 days of non-occupational aluminium exposure, the urine
aluminium level was 29 μg/L (29 mg/kg creatinine) (Sjögren et al., 1988). Comparison of
urinary aluminium concentration in 23 of the welders before and after the exposure-free interval
showed that it correlated with the aluminium exposure level before the exposure-free interval
whereas, after the exposure-free interval, it related to duration of occupational exposure
(Sjögren et al., 1988). The bone aluminium concentration was 18 to 29 mg/kg in two welders
after 20 and 21 years of exposure compared to 0.6 to 5 mg/kg in referents, illustrating retention
of absorbed aluminium (Elinder et al., 1991). The mean urine aluminium level of 15 workers
in an aluminium fluoride plant exposed to a mean of 0.12 mg Al/m3 was 12 μg/L, of 12 potroom
workers in an aluminium smelter exposed to a mean of 0.49 mg Al/m3 was 54 μg/L and of 7
foundry workers in the aluminium smelter exposed to a mean of 0.06 mg Al/m3 was 32 μg/L;
that for the 230 controls was 5 μg/L (Drabløs et al., 1992). Due to inter-individual variability,
these were not significant differences. However, there was a significant correlation between
weekly mean aluminium concentration in air and weekly average urine aluminium excretion.
Aluminium exposure in the aluminium fluoride plant was mainly from aluminium hydroxide
and aluminium fluoride. Exposure in the smelter potroom was mainly from aluminium oxide
and partly from aluminium fluoride and, in the foundry, from aluminium oxide and partly from
oxidized aluminium metal fume. Although urine aluminium concentrations were poorly
correlated with changes in serum aluminium, urinary aluminium and fluoride concentrations
were significantly correlated in 8 cryolite workers (Grandjean et al., 1990). Thirty-three
foundry workers who worked as smelters, die casting operators, fettlers and sand casters were
exposed for 1 to 17 (median 7) years to aluminium in dust and fumes. The exposure
concentrations for the smelters, die casting operators and fettlers averaged 0.17, 0.027, and
0.58 mg/m3, respectively. These workers had a significantly higher mean serum aluminium
than controls (16 compared to 11.3 μg/L) and non-significantly higher urine aluminium
concentrations (18.93 vs.12.90 μg/L) (Rollin et al., 1991a). However, the serum aluminium
concentration in the control group was considerably greater than the concentration now
considered to be normal, 1.6 μg/L (Nieboer et al., 1995; Roider & Drasch, 1999).
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One hundred and fifteen newly employed potroom workers, who had no previous history of
work in an aluminium industry, were followed for 36 months. Monthly determinations of
airborne aluminium in the first 18 months ranged from 0 to 2.145 mg/m3, with monthly medians
ranging from 0.001 to 0.173 mg/m3. Forty-four percent of the total inhalable aluminium was
in the respirable fraction, compared to previous determinations by this group of 52 and 87%
in two potrooms of an established plant (Rollin et al., 1996). Prior to employment in the
potroom, workers’ mean serum aluminium concentration was 3.37 μg/L. The serum aluminium
level increased steadily during the first 12 months to a mean of 6.37 μg/L and did not
appreciably increase further during the next 24 months. Smokers had higher serum aluminium
levels than non-smokers. The mean urine aluminium level before employment was 24.2 μg/L;
after 36 months of employment it was 49.1 μg/L.
Based on studies in 8 plants involving refining, casting and pressure moulding that included
119 workers, it was concluded that environmental aluminium concentration, particle size,
allotropic state, solubility and the pattern of exposure affect lung aluminium absorption
(Apostoli et al., 1992).
The absorption of aluminium from the lung can be estimated from a few studies of occupational
aluminium exposure. Daily urinary aluminium excretion by 12 aluminium welders, whose lung
aluminium burden may have been approaching a steady state, averaged 0.1 mg. Daily
aluminium deposition into their lungs was estimated to be 4.2 mg. This would suggest
absorption of ~ 2.4% of the aluminium (Sjögren et al., 1997). The site of absorption cannot be
ascertained from such data. Results from workers exposed to ~ 0.2 to 0.5 mg soluble Al/m3 in
the air (particle size not described) suggest ~ 2% absorption (Pierre et al., 1995). Fractional
absorption was similar in the workers in a second study (Gitelman et al., 1995) who were
exposed to a similar air aluminium concentration containing 25% respirable (< 10 μm diameter)
aliminium. The urinary aluminium/creatinine ratio correlated better with respirable than total
aluminium. However, fractional absorption was inversely related to air aluminium
concentration (H.J. Gitelman, personal communication, 1995). These workers showed a better
correlation between urinary aluminium excretion (which reflects absorbed aluminium) and
respirable aluminium, than total aluminium (Gitelman et al., 1995). These results suggest that
the smallest aluminium particles that can distribute to the deepest part of the lung are best
absorbed and suggest that absorption is from the pulmonary rather than GI route. The estimate
of 26Al absorption from inhalation of 26Al oxide particles which had a MMAD of 1.2 μm by
two subjects was 1.9% (Priest, 2004).
Significantly elevated urinary Al levels were seen in 10 volunteers who were exposed for 20
minutes downwind of fumaroles, suggesting respiratory Al absorption from inhalation of the
gas (Durand et al., 2004).
There are no good experimental data from which one can estimate aluminium bioavailability
from atmospheric sources. A Standard Reference Material containing urban particulate
material collected over more than 12 months near St. Louis, MO, that was thought to be
representative of an atmospheric sample obtained from an industrialized urban area, was
fractionated. Approximately 0.6% of the aluminium was in the exchangeable metal ion fraction
(Lum et al., 1982). About half was bound to iron-manganese oxides and half was organically-
bound metal ions. Absorption of 3% of the aluminium in the lung to blood was adopted (ICRP,
1981) according to Jones & Bennett (1986), but they note: “there is as yet no firm basis for
this estimate”.
Oral administration
Drinking water: The first human studies attempting to estimate oral aluminium bioavailability
utilized 27Al. These were balance studies, in which aluminium absorption was estimated from
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the difference between intake and faecal excretion. Aluminium retention was estimated from
the difference between intake and faecal-plus-urinary excretion. However, it has become
apparent that the percentage of aluminium that is orally absorbed is quite low (as noted in the
animal studies above and more recent human studies, below). Therefore, studies using these
methods are not considered reliable, as discussed above.
One of the few human studies of oral aluminium absorption that models drinking water is that
reported by Stauber et al. (1999). The 21 subjects consumed a diet that provided a total intake
of about 3 mg Al/day. They drank either 1.6 L daily of an ATW from a municipal treatment
plant that they found contained 140 μg Al/L or reconstituted soft water (RSW) that had < 1
μg Al/L, with and without sodium citrate. The ATW provided 208 to 233 (in the absence of
added sodium citrate) or 253 μg Al/day (when sodium citrate was added). The RSW provided
< 1 μg Al/day (when no sodium citrate was added) or 46 μg Al/day (when sodium citrate was
added). Oral bioavailability was estimated from the 24 hr urinary aluminium output times 2.2.
The value 2.2 was used to correct for the estimated fraction of total urinary aluminium excretion
that occurs within the first 24 hr and the fraction of absorbed aluminium that is retained (e.g.,
does not appear in the urine). This is based on the fraction of aluminium excreted in the urine
over 24 hr compared to that excreted over 7 days, which was estimated to be 0.62 by (Priest,
1993). It is also based on the fraction of aluminium administered intravenously that was found
in the urine within 7 days by Talbot et al. (1995), 0.72, suggesting the balance of the aluminium
was retained. They concluded that the oral bioavailability of aluminium from water was 0.39%
in the absence, and 0.36% in the presence, of citrate. This was based on the increase in 24 hr
urinary aluminium excretion when the subjects consumed ATW and a controlled diet compared
to RSW and the same diet, and the increased aluminium in ATW compared to RSW. The
controlled diet was given to all subjects in the same amounts for three meals, three snacks, tea
and a banana daily, delivering 1777 calories and 2.9 mg aluminium. It contained standard
amounts of specific food components, including meat, cereal, milk, tea, and cookies, each of
which was analyzed to determine its aluminium concentration. Aluminium in ATW
represented 6 to 7% of total aluminium intake. Its consumption raised urinary aluminium output
approximately 9%. Therefore, the response seen was < 10% of background urinary aluminium
excretion. A concern about this study is that one might expect the variability in the excretion
of aluminium in the urine from food to mask any ability to see an increase in urinary aluminium
output from the aluminium in water. The range of 24 hr urinary aluminium output in these
subjects was 5-fold (1.8 to 9.3 μg). However, within-subject variability must have been
considerably less for the results to produce a statistically significant difference in urinary
aluminium output after consuming the ATW compared to RSW. This is indicated by the 95%
confidence intervals (CI) that suggest considerably less variability than the 5-fold range of their
subjects. The design of this study favoured the study objectives, to measure the amount of
aluminium absorbed from water, above that contributed by food. Their study included within-
subject comparisons and a defined diet containing a low amount of aluminium for the day
before and the day of the study (3 mg vs. normal intake of 3 to 7 mg/day in Australia, according
to the authors). Glynn et al. (1995) stated that the concentration of aluminium in drinking water
has to be extremely high in relation to food to ensure that aluminium from the water is a
significant part of the total oral aluminium intake. Similar concern expressed was: “…biokinetic
studies of injected or ingested aluminium in man and animals is complicated by the
investigator’s inability to distinguish between aluminium from a test dose and that already
present in the body. Most studies of stable aluminium are, thus, of poor sensitivity.” (Priest,
1993). Apparently Stauber et al. (1999) were able to overcome this reservation. The correction
factors they used to estimate urinary aluminium output were based on two human studies
conducted by other investigators in which 26Al was used. These estimates may not accurately
predict the fraction of aluminium excreted in urine in 1 day compared to that excreted to time
infinity, and may not accurately predict the percentage retained, when that estimate is also
based on 1 vs. 7 days of observations. Although these estimates may influence the absolute
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estimate of oral bioavailability, they are less likely to influence the relative estimates of
aluminium bioavailability from water compared to that from food; this is discussed below.
A second study relevant to consumption of aluminium from drinking water involved 4 subjects
who consumed a soft mineral water containing < 1 μg Al/L, the same water with 300 μg Al/L
as Al2(SO4)3, and deionized water containing 300 μg Al/L as Al2(SO4)3 (Gardner & Gunn,
1995). Unfortunately, urine was collected only 7 hr after aluminium administration; urinary
aluminium excretion rate would not have yet returned to the pre-aluminium-treatment rate in
many cases. Therefore, the estimate of oral aluminium bioavailability, which was < 0.1%, is
below the true value.
A study of 2 humans who consumed 26Al as aluminium chloride, Hohl et al. (1994) produced
an estimate of oral aluminium bioavailability of 0.1%. The authors collected urine for 4 days
(although missing the collection of part of the sample from one of the two subjects on day 1).
Their estimate of 0.1% oral aluminium bioavailability was not corrected by the aluminium that
was retained by the subjects or excreted after the period of sample collection. The authors
suggest this would not result in a large error.
Another study that modelled aluminium consumption from drinking water employed two
subjects who consumed 26Al added to water from a public supply (Priest et al., 1998). Faeces
and urine were collected for 7 days after 26Al administration; these contained 97.6 and 100.4%
of the 26Al administered to the two subjects. These results suggest that little aluminium was
absorbed. The results also illustrate the inadequacy of the balance method to determine oral
aluminium bioavailability. The 26Al in blood obtained 1, 4 and 24 hr after oral 26Al dosing
was multiplied by the estimated blood volume of each subject. The results suggested oral
aluminium bioavailability of 0.027, 0.034 and 0.012%, based on these three sampling times.
Cumulative urine excreted suggested oral aluminium bioavailability was 0.20 and 0.14%, for
these two subjects. The authors corrected these values for the percentage of aluminium voided
in the urine in the same time period after i.v. injection (72%) (Talbot et al., 1995), as conducted
by Stauber et al. (1999). This correction resulted in an estimate of 0.22% oral aluminium
bioavailability. This is an order of magnitude greater than the results they obtained by
estimating absorption from a single serum sample and the calculated volume of distribution,
suggesting this latter method underestimates oral aluminium bioavailability.
Overall, the above results suggest that oral aluminium bioavailability from drinking water is
in the range of 0.1 to 0.5%; and most likely approximately 0.3%.
An error resulted in the introduction of 20 tons of 8% aluminium sulphate into a municipal
water supply near Camelford, England. Some of the consumers reported that the water had an
unpleasant metallic taste; others reported various symptoms (Eastwood et al., 1990). Excessive
aluminium, copper, lead and zinc were found in the water. Two of the affected individuals
showed elevated urinary aluminium output. Bone biopsies showed the presence of elevated
aluminium (Eastwood et al., 1990) that was still elevated 6 and 7, but not 18, months later
(McMillan et al., 1993). These results suggest the possibility of elevated bone aluminium in
humans with normal renal function after oral consumption of excessive amounts of aluminium.
However, only two reports were found of elevated bone aluminium in humans with normal
renal function after massive oral consumption of aluminium. One was a 49 year old male with
a 25 year history of consumption of aluminium-containing antacids whose bone aluminium
concentration, 24 mg/kg dry weight, was between that of three non-dialysis subjects at autopsy,
which averaged 6.4 mg Al/kg, and that of 3 dialyzed subjects at autopsy, which averaged 125
mg Al/kg (Recker et al., 1977). The other was a 39 year old female who consumed antacids
containing a total of ~ 18 kg of elemental aluminium over 8 years. She had stainable aluminium
on 27.6% of the bone surface (Woodson, 1998).
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Beverages and foods: Oral aluminium bioavailability from the diet was estimated to be 0.1
to 0.3% based on normal urinary aluminium excretion of 20 to 50 μg/day and a daily aluminium
intake of 20 mg (Ganrot, 1986). Daily aluminium intake is now believed to be less. Priest
(1993) estimated oral aluminium bioavailability from food to be ~ 0.1% based on a daily
aluminium intake of 15 mg, a daily urinary excretion of 0.025 mg and 5% aluminium retention
in the body. The same estimate was obtained by comparing an average daily urinary aluminium
excretion of 0.004 to 0.012 mg to average daily aluminium intake from food of 5 to 10 mg
(Nieboer et al., 1995). Based on daily dietary aluminium intake of 10 mg, a terminal t½ of
aluminium of 50 years, and aluminium body burdens of 5 and 60 mg, oral aluminium
bioavailability was estimated to be 0.14 and 1.6%, respectively (Priest, 2004).
The bioavailability of aluminium from a low aluminium diet was estimated to be 0.78%,
compared to 0.09% when aluminium, as aluminium lactate, was added to the diet, (Greger &
Baier, 1983). These results are in the range of values obtained for aluminium from drinking
water (see Toxicokinetics, Absorption, Studies in Humans, Oral Administration, Drinking
Water). The results suggest an inverse relationship between aluminium dose and oral
absorption. However different aluminium species were consumed under these two conditions.
Aluminium bioavailability was estimated based on 24 hr urinary aluminium excretion in
subjects consuming a controlled diet that included tea and RSW water (which provided
essentially no aluminium) (Stauber et al., 1999). The ~ 3 mg Al/day provided by this diet is
below typical dietary intake. Absorption of aluminium from food consumed prior to the study,
which likely provided > 3 mg Al/day, may have contributed to the urinary aluminium excretion
during the study. This would produce an over-estimation of aluminium bioavailability from
the controlled diet. The estimate of oral aluminium bioavailability from food-plus-tea in this
study was ~ 0.53%, assuming that 10% of the aluminium in the tea was available for absorption.
Based on the assumption that 100% of the aluminium in the tea was available for absorption,
oral aluminium bioavailability from food-plus-tea was estimated to be 0.28%. Therefore, the
authors concluded that oral aluminium bioavailability from water and food is comparable. They
claimed “… recent research suggesting that aluminium in food and aluminium in water have
similar bioavailabilities”, citing Priest (1993). However, Priest does not make this statement
or provide data to support, or refute, it.
Some studies found increased aluminium in the urine after tea consumption, suggesting
absorption of aluminium from the tea. Urinary aluminium concentration increased in the 12 hr
after tea consumption (Koch et al., 1988). Equal volumes of coffee or water did not increase
the urinary aluminium concentration. They did not report urine volume, or urinary aluminium
output, so it is unknown if aluminium excretion increased. However, if urine volume was
greater after consuming tea than water, as reported by Powell et al. (1993), urinary aluminium
output would have been greater following tea consumption. In the 24 hr after consumption of
2 litres of tea, presumably containing a total of 218 μmoles of aluminium, by one subject,
urinary aluminium output was 0.725 μmoles, compared to 0.14 μmoles after consumption of
water by the same subject (Powell et al., 1993). This would suggest 0.3% aluminium
bioavailability. In contrast, tea, with or without lemon juice or milk, or mineral water was
consumed one day with a defined diet, in a cross-over study. The tea contained 2.3 to 2.8 mg
aluminium and comprised about 31% of the total daily dietary aluminium intake. Blood was
obtained 11 times, from immediately before to 0.5 to 24 hr after dosing. No elevation of serum
aluminium, above the pre-treatment mean concentration of 4.2 μg/L, was seen (Drewitt et al.,
1993). Four subjects who consumed 2 litres of tea containing ~ 4 mg Al/L eliminated an average
of 0.003 mg aluminium within the subsequent 7 hr in their urine, or ~ 0.04% of the aluminium
in the tea (Gardner & Gunn, 1995). However, this is clearly an underestimate of the oral
aluminium bioavailability because urinary aluminium excretion had not yet returned to the pre-
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treatment rate in most subjects, suggesting insufficient time to follow aluminium absorption
and/or incomplete excretion of the absorbed aluminium.
It was suggested that polyphenols in tea bind most of the aluminium, thus greatly reducing its
oral bioavailability (Flaten & Odegard, 1988). Collection of ileostomy effluent from a subject
who had not consumed food orally for two weeks but had consumed tea suggested there was
no breakdown of the polyphenols from the tea (Powell et al., 1993). These results suggest that
digestion does not change the major ligand that binds aluminium in tea.
Chewing gums contain a significant amount of aluminium (0.2 to 4 mg/stick for 3 brands)
(Lione & Smith, 1982). Chewing released 2 to 21% of the aluminium, 0.01 to 0.44 mg. The
authors concluded that moderate use of chewing gums would not contribute substantially to
daily aluminium intake. However, chewing gum may exceed drinking water as a daily source
of aluminium.
Drugs: Oral aluminium bioavailability was estimated to be 0.006 and 0.007% from two studies
of a commercial aluminium hydroxide product (Linc®); estimates were based on the increase
above baseline of urinary aluminium excretion after consumption of 1, 4 or 8 tablets (Haram
et al., 1987; Weberg & Berstad, 1986). Weberg & Berstad (1986) observed an inverse
relationship between dose and oral aluminium bioavailability. They suggested that this was
due to the ability of more tablets to produce a greater increase in the pH of the intragastric
milieu, resulting in decreased solubility. However, if aluminium is primarily absorbed from
the upper intestine, where the pH is about 6 or 7, this may not be the explanation. It is unknown
if diet influenced these results, as this was not controlled or documented. Oral aluminium
bioavailability from aluminium hydroxide, and aluminium glycinate taken with aspirin, was
estimated to be 0.003 and 0.22%, respectively (Meshitsuka & Inoue, 1998; Meshitsuka et al.,
1999).
Oral aluminium bioavailability was estimated from 6-day urinary 26Al output in 2 subjects
(Priest et al., 1996). Both subjects received intragastric dosing of 26Al incorporated into
aluminium hydroxide, 26Al hydroxide in the presence of citrate, and 26Al citrate. Oral
aluminium bioavailability was estimated from urinary aluminium output, corrected for the
fraction of aluminium administered intravenously that was found in the urine within 7 days,
0.72, as demonstrated by Talbot et al. (1995), and as used by Stauber et al. (1999) above.
Estimates of the percentage of 26Al absorbed from 26Al hydroxide in the absence and presence
of citrate averaged 0.01 and 0.14%, respectively; aluminium bioavailability from 26Al citrate
was 0.52%. These limited results mirror many reports showing very low aluminium
bioavailability from aluminium hydroxide (and sucralfate) and enhancement by citrate.
Oral aluminium bioavailability from aluminium hydroxide appears to be less than from food
or water.
Factors influencing oral aluminium absorption: Studies in humans have also shown that
oral aluminium absorption is dependent on many factors, although this has been less well
studied than in animals. A summary of the reported factors affecting oral aluminium absorption
in humans is shown in Table 18. The following sections describe these effects in much more
detail.
Solubility: Oral bioavailability of aluminium from quite insoluble forms, such as aluminium
hydroxide and sucralfate, was generally reported to be quite low, e.g. ~ 0.001 to 0.007%
(Haram et al., 1987; Weberg & Berstad, 1986), whereas from drinking it water was ~ 0.22 and
0.35% (Priest et al., 1998; Stauber et al., 1999). Higher plasma levels were observed after oral
administration of sucralfate in suspension than in tablet form (Conway et al., 1994). This is
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not consistent with the notion that bioavailability is independent of the chemical species of the
aluminium (Reiber et al., 1995), a notion which does not appear to be valid.
pH: Administration of ranitidine, which increased gastric pH, reduced urinary aluminium
excretion (Rodger et al., 1991), consistent with an enhancement of aluminium absorption at
lower gastric pH. Serum and urine aluminium levels increased in pre-surgery ulcer patients
with normal renal function who had a mean gastric pH of 2.09 following administration of 30
mg/kg aluminium hydroxide, whereas the opposite was seen in post-surgery patients whose
gastric pH averaged 5.78 (Olaizola Ottonello et al., 1991). In contrast, limited observations in
patients with chronic renal failure failed to show a correlation between gastric acid secretion
and elevation of serum aluminium after oral aluminium consumption, suggesting gastric acid
secretion may not play a critical role in aluminium absorption (Beynon & Cassidy, 1990). There
are insufficient reported results to draw a firm conclusion about any effect of gastric pH on
oral aluminium absorption.
Carboxylic acids: Numerous studies in humans have shown enhanced aluminium absorption
from aluminium hydroxide in the presence of citrate, other carboxylic acids and orange juice
(Coburn et al., 1991; Fairweather-Tait et al., 1994; Lindberg et al., 1993; Mauro et al., 2001;
Nestel et al., 1994; Nolan et al., 1990; Nordal et al., 1988a; Priest et al., 1996; Rudy et al.,
1991; Slanina et al., 1986; Walker et al., 1990; Weberg & Berstad, 1986). For example, Weberg
& Berstad (1986) reported that 0.004% of 1 g of aluminium, given as an antacid, was absorbed
in the absence of citrate, compared with 0.03% when consumed with orange juice and 0.2%
when consumed with citric acid solution that delivered 0.7:1 citrate:aluminium. Similar results
have been observed in animal studies (see Toxicokinetics, Absorption, Animal Studies, Oral
Administration, Factors Influencing Oral Aluminium Absorption, Carboxylic Acids). In
contrast, co-administered sodium bicarbonate and calcium acetate were not found to increase
aluminium absorption (Mauro et al., 2001; Walker et al., 1990).
The first study of oral aluminium absorption using 26Al was conducted in one human subject
who received aluminium citrate. The results suggested ≥ 1% oral absorption (Day et al.,
1991), whereas two other studies involving 5 and 2 subjects led, respectively, to estimates of
0.015 (Edwardson et al., 1993) and 0.52% (Priest et al., 1996). However, there is a human
study that failed to find an increase of aluminium absorption in the presence of citrate. This
was conducted in subjects who received aluminium with their diet (Stauber et al., 1999).
Generally, increasing the amount of citrate consumed with aluminium hydroxide increased
blood aluminium concentrations (Taylor et al., 1992).
Although citrate can increase aluminium absorption, it has not always been reported to increase
tissue or cellular aluminium retention. Some animal studies have reported a citrate-induced
increase of brain and aluminium (as described above in Toxicokinetics, Absorption, Animal
Studies, Oral Administration, Factors Influencing Oral Aluminium Absorption, Carboxylic
Acids), whereas other animal studies and one human study have not (Sakhaee et al., 1993).
Therefore, citrate may enhance oral aluminium absorption but may also enhance its distribution
into and out of tissues as well as from the organism by renal elimination, in the presence of
renal function, as suggested by Maitani et al. (1994), and discussed below (see Toxicokinetics,
Elimination and Excretion, Animal Studies, Urinary Excretion).
The primary humic substances in water and soil are humic and fulvic acids. One healthy person
who took 1.75 g of aluminium hydroxide, adjusted to pH 2, and 1.25 gm of concentrated humic
substances, excreted more aluminium in the urine over the subsequent 50 hr than when the
aluminium was taken alone (1.4 v.s. 0.6% of the aluminium dose), suggesting humic substances
can increase aluminium absorption (Alexander et al., 1990).
Krewski et al. Page 63
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Silicon-containing compounds: Sodium silicate (100 μM) reduced the GI absorption of 26Al
(consumed in orange juice, a source of citrate) by 85% in fasted humans (Edwardson et al.,
1993). Taylor et al. (1995) cited previous studies showing an inverse relationship between
aluminium and silicon concentrations in drinking water. An earlier study showed an inverse
relationship between renal function and plasma silicon but no correlation between serum
aluminium and silicon in patients with chronic renal failure on regular haemodialysis (Roberts
& Williams, 1990). In a later study there appeared to be an inverse relationship between serum
aluminium and silicon levels in a subset of haemodialysis patients (Parry et al., 1998). Studies
of the aluminium and silicon dioxide concentrations in drinking water suggested that moderate
silicon concentration has a slight protective effect against aluminium-associated impaired
mental function (Forbes et al., 1995; Forbes & Gentleman, 1998). These results suggest that
increasing dietary silicon may reduce aluminium absorption and facilitate excretion.
Fluoride: Fluoride forms numerous complexes with aluminium (see Identity, Physical and
Chemical Properties, Analytical Methods, Physical and Chemical Properties, Properties of
Aluminium Compounds). Aluminium appears to inhibit fluoride absorption (Brudevold et al.,
1973; Hobbs et al., 1954; Li et al., 1991; Spencer et al., 1980a; 1980b; 1981; 1985; Spencer &
Kramer, 1985; Spencer & Lender, 1979).
In fluoridated drinking water, decreased pH would favour formation of aluminium-fluoride
complexes. In one survey, 19% of aluminium in treated water was complexed with fluoride,
when 58 μM (~ 1 mg/L, 1 ppm) fluoride was added (Driscoll & Letterman, 1988). Moderate
concentrations of fluoride in drinking water were found to have a slight protective effect against
aluminium-associated impaired mental function (Forbes & Agwani, 1994a; 1994b; Forbes &
Gentleman, 1998). However, there was no obvious benefit of 40 mg of fluoride given daily for
1 year to patients in the early stages of AD (D. Shore, personal communication, 1992). Although
complexation of aluminium with fluoride can be important at the more acidic pHs found
occasionally in water, there is not sufficient fluoride in plasma to form any significant amount
of binary aluminium fluoride complexes (W.R. Harris, personal communication, 2000). It is
not clear if fluoride significantly influences aluminium toxicokinetics.
Iron: Haemodialysis patients who had low or normal serum ferritin levels and were given
aluminium hydroxide for 7 days had increased serum aluminium, whereas patients with high
serum ferritin did not show an increase of serum aluminium concentration (Cannata et al.,
1984). Serum aluminium negatively correlated with serum iron, serum ferritin and Tf saturation
in chronic haemodialysis patients (Cannata et al., 1993; Huang et al., 1992). Similarly, there
was a negative correlation between serum iron and aluminium absorption in dialysis patients
(Cannata et al., 1993). These results are consistent with those of animal studies showing
enhanced aluminium absorption in the presence of iron deficiency (see Toxicokinetics,
Absorption, Animal Studies, Oral Administration, Factors Influencing Oral Aluminium
Absorption, Iron).
Calcium: Addition of calcium to aluminium hydroxide did not affect aluminium absorption
in humans with normal renal function who presumably had normal calcium status (Nolan et
al., 1990). Based on ionic radii, it is more likely that aluminium would compete with
magnesium than calcium. Although there is some evidence for aluminium-magnesium
competition in vivo, this has not been well investigated.
Uraemia: The primary documented problems with aluminium as a toxicant to bone and the
brain have occurred in persons with uraemia, who accumulate aluminium, due to their inability
to excrete it, and may develop aluminium-induced toxicity (Alfrey, 1980). There is evidence
that uraemia may also enhance aluminium absorption. Ittel et al. (1991a) found greater serum
aluminium levels in acute and chronic renal failure patients than those with normal renal
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function receiving the same daily dose of aluminium (1.18 g) as hydroxy-magnesium
aluminate, greater daily urinary aluminium excretion in the chronic renal failure patients, and
a significant negative correlation between renal aluminium excretion and creatinine clearance.
They concluded that there was an enhancement of GI aluminium absorption in the presence of
chronic renal failure. However, calculations using the biokinetic model, described in
Toxicokinetics, Pharmacokinetic Modelling, failed to find evidence for increased oral
aluminium absorption by humans with chronic renal failure (Steinhausen et al., 2004).
Age: The information related to the affect of age on aluminium absorption is from adult and
geriatric subjects. No published studies of children were found. A greater increase in blood
aluminium was seen in subjects aged > 77 than in those aged < 77 (serum aluminium 101 vs.
38 μg/L at 1 hr), who consumed ~ 4.5 mg/kg aluminium hydroxide and 3.3 to 6.5 g citrate
(citrate:aluminium, 1.6:1 to 3.2:1) after an overnight fast (Taylor et al., 1992). Comparing oral
aluminium bioavailability in the subjects < 59 with those > 59 years of age failed to reveal a
difference (Stauber et al., 1999). Taking these observations together with the results from
animal studies, (see Toxicokinetics, Absorption, Animal Studies, Oral Administration, Factors
Influencing Oral Aluminium Absorption, Urinary Excretion) there is a lack of consistent data
to be able to conclude that there is a significant effect of age on aluminium absorption,
distribution or retention.
Dementia: In a study of 20 AD subjects aged 65 to 76 (n=10) and 77 to 89 (n=10) blood
aluminium levels were compared to those of 20 controls. Subjects and controls consumed ~
4.5 mg/kg aluminium hydroxide and 3.3 to 6.5 g citrate (citrate:aluminium, 1.6:1 to 3.2:1) after
an overnight fast (Taylor et al., 1992). In the younger AD subjects, the blood aluminium was
significantly greater at 60 minutes than in control subjects (104 vs. 38 μg/L). In the older
subjects, the increase in blood aluminium levels was greater, but not statistically different, in
the controls than in patients, in contrast to the younger subjects. Aluminium absorption was
studied in AD subjects and compared to age-matched controls after consumption of a fruit
drink containing 26Al (Moore et al., 2000). The percent of aluminium absorbed in subjects,
estimated from single plasma samples obtained 1 hr after the oral aluminium consumption,
was 164% of that seen in controls. The authors attributed these differences to absorption,
although reduced renal aluminium clearance in the aged could also contribute to this difference.
The lack of consistent overall differences as a function of age or dementia status makes it
difficult to draw any general conclusion from this study. Zapatero et al. (1995) found
significantly higher serum aluminium concentrations in 17 AD subjects, compared to age-
matched controls, but no difference between 15 subjects with senile dementias and controls.
Based on greater serum and urine aluminium levels in 8 patients with dementia including the
Alzheimer’s type who were 65 to 86 years old compared to 144 controls who were 30 to 65
years old (18 and 6 μg/L and 77 and 26 μg/L, respectively), Roberts et al. (1998) claimed to
have confirmed earlier findings that patients with dementia appear to absorb more aluminium
from the diet than healthy subjects. However, the difference in the serum and urine aluminium
levels could be due to factors other than dementia, such as the significant difference in the age
of the subjects. AD appears to be associated with a higher serum aluminium concentration than
seen in controls. Nothing can be concluded from these observations to elucidate the mechanism
of this difference.
Utilizing both 27Al and 26Al in separate studies, greater aluminium absorption was seen in
subjects with Down’s syndrome than in controls, 0.14 vs. 0.030% for 27Al administered with
citrate and 0.14 vs. 0.022% for 26Al administered with orange juice (Moore et al., 1997).
However, these results are based on a single blood sample drawn 60 minutes after aluminium
administration, a method noted above in Toxicokinetics, Absorption, Animal Studies, Oral
Administration that may not very reliably estimate oral bioavailability. Down’s syndrome is
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associated with changes in neurodegeneration, particularly increased β-amyloid deposition,
that resemble AD.
Aluminium dose: Aluminium bioavailability following consumption of a commercial
aluminium hydroxide product was found to be 0.007, 0.004 and 0.001% from aluminium doses
of ~ 3.5, 14 and 28 mg/kg, respectively (Weberg & Berstad, 1986). This inverse relationship
between dose and oral bioavailablity is not consistent with results from animal studies
suggesting increased aluminium absorption with increased dose, as discussed in
Toxicokinetics, Absorption, Animal Studies, Oral Administration, Drinking Water.
Site of oral absorption: A significant increase in serum aluminium concentration was seen 30
minutes after consumption of aluminium and citrate, suggesting aluminium absorption from
an upper intestinal site (Nordal et al., 1988a). Peak serum aluminium was seen 30 minutes after
consumption of an aluminium antacid (Nagy & Jobst, 1994). Oral dosing of human subjects
with antacids and citrate produced a peak blood aluminium level ~ 4 hr later (Weberg &
Berstad, 1986) that was interpreted as support for intestinal aluminium absorption (Powell &
Thompson, 1993). Blood aluminium peaked in four subjects ~ 30 to 45 minutes after they had
consumed aluminium citrate (Nordal et al., 1988a; Taylor et al., 1992) and at 30 minutes in
one subject after oral ingestion of an aluminium-containing antacid (Nagy & Jobst, 1994).
Serum glucose also peaked 30 minutes after oral administration of 50 g of glucose (Nagy &
Jobst, 1994). Hohl et al. (1994) saw maximal serum aluminium approximately 2 hr after oral
aluminium intake, although the peak was not much higher than seen at 30 minutes, suggesting
quite rapid absorption. As concluded from studies in animals (see Toxicokinetics, Absorption,
Animal Studies, Oral Administration, The Site and Mechanisms of Oral Aluminium
Absorption), aluminium seems to be primarily absorbed from the upper intestine.
Dermal exposure—A study of 26Al chlorohydrate absorption, a primary component of
antiperspirants, which was applied once to both underarms of one male and one female subject,
revealed an average excretion of 0.012% of the applied 26Al in the urine over the subsequent
53 days (Flarend et al., 2001). Daily application of tape to the underarm area to strip away dead
skin and surface aluminium chlorohydrate followed by gentle wiping with a towelette for 6
days after its application removed 39% of the applied material. One might assume that the
aluminium chlorohydrate that was not removed by the tape and washing represents the
maximum amount of aluminium available for absorption. Based on this assumption and
assuming that 85% of the aluminium that would eventually be excreted in the urine was
excreted during the time course of this study, the results suggest that a maximum of 0.02% of
the aluminium could eventually be absorbed. Given that 50 to 75 mg of Al might be applied
daily in antiperspirants, even this very small absorption might be relevant. However, it cannot
be assured that this absorption was not from inhalation of Al that flaked off of the application
site and it is unknown if comparable aluminium absorption would occur following daily
application of aluminium chlorohydrate. This might not occur because of formation of
aluminium precipitate in the sweat gland that might impact on the potential for subsequently
applied antiperspirant to be absorbed. This study provides the best estimate to date of
percutaneous bioavailability of aluminium from antiperspirants.
A woman who applied ~ 1 g of aluminium chlorohydrate-containing antiperspirant to each
regularly-shaved underarm daily for 4 years was reported to have experienced bone pain and
fatigue (Guillard et al., 2004). Serum aluminium was 3.88 μM (105 μg/L) and 24 hr urinary
aluminium excretion was ~ 1.75 μmoles (47 μg)/day, which is elevated, but not as high as
would be expected with this serum aluminium concentration in the presence of normal renal
function. Aluminium concentrations in serum and urine before antiperspirant use were not
reported. After discontinuation of antiperspirant use, urine and serum aluminium
concentrations decreased over 7 months, her bone pain nearly disappeared and her fatigue was
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less severe. Given the extensive world-wide use of aluminium-containing antiperspirants, the
lack of other similar reports suggests that this patient was atypical, as speculated by Exley
(2004), or that the samples were contaminated.
Distribution (Including Compartmentalization)
Animal studies—Aluminium levels generally decreased in guinea pigs from gestation day
30 to post-natal day 12 (Golub et al., 1996a). Muscle aluminium was reported to increase with
age from 2 to 6 to 12 months in rats, but to decrease at 24 months (Kukhtina, 1972). Lung
aluminium increased from a mean of 1.7 and 10 mg/kg (wet tissue) in guinea pigs and rats at
6 months of age to 32 and 52 mg/kg at 21 to 24 months, respectively (Stone et al., 1979).
Aluminium levels increased with age in liver and kidney of mice, did not change in the brain
and heart, and decreased in femur and lung (Massie et al., 1988). Bone and kidney aluminium
increased with age in rats (Greger & Radzanowski, 1995). The limited data available suggest
that brain and blood aluminium concentrations increase with age. The age-related increase may
be due to reduced aluminium clearance with age, as discussed below (see Toxicokinetics,
Elimination and Excretion, Animal Studies, Elimination Rate), the large amount of aluminium
in the diet of laboratory animals, as noted above (see Toxicokinetics, Absorption, Animal
Studies, Oral Administration, Beverages and Foods) and the long t½ of aluminium (as
discussed below in Toxicokinetics, Elimination and Excretion, Animal Studies, Elimination
Rate).
It has been suggested that citrate can promote the redistribution and elimination of aluminium
from plasma. This is dependent on the presence of a significant fraction of aluminium as
aluminium citrate. In the presence of normal aluminium concentrations, Tf binds most of the
aluminium in plasma (see Toxicokinetics, Distribution (Including Compartmentalization),
Human Studies, Transport in Blood). Citrate promotion of aluminium distribution and
excretion would be favoured in the presence of aluminium concentrations that exceed the Tf
metal binding capacity. This very seldom occurs in the human, but has been produced in some
of the experimental animal studies. Alternatively, citrate may promote aluminium distribution
and excretion prior to association of the aluminium with Tf. The time course of aluminium
complexation by Tf in vivo has not been determined; however, when aluminium lactate was
incubated with Tf, the association of the aluminium with Tf was complete within 1 minute in
vitro at 37 °C (Yokel et al., 1991a). Exchange of aluminium from citrate to transferrrin at pH
7.2 to 8.9 and 25 °C occurred in three kinetic processes. The first, which might be formation
of a ternary complex of Tf, aluminium and citrate, was nearly complete within 2 minutes
(Hemadi et al., 2003). A transition time for the change of plasma aluminium association from
citrate to Tf of 4.2 minutes was tentatively used in a model of aluminium biokinetics
(Steinhausen et al., 2004) (see description in Toxicokinetics, Pharmacokinetic Modelling).
In contrast to aluminium citrate, administration of aluminium, as the lactate, chloride and
perhaps some other species, may result in clearance of the aluminium by tissues, particularly
by the reticuloendothelial organs, and sequestration, reducing renal clearance and increasing
the body burden. Tissue aluminium concentrations in rabbits 1 week after completion of a
series of 20 i.v. injections of aluminium citrate were considerably lower than after the same
molar dose of aluminium lactate (Yokel et al., 1996a). Similarly, addition of equimolar citrate
to i.p. injections of aluminium chloride significantly reduced serum aluminium compared to
the absence of citrate, whereas equimolar maltol significantly increased both serum and brain
levels of aluminium in the rat (Ogasawara et al., 2002).
Administration to dogs of aluminium, as alum, in a mixture of hashed lean beef, lard, cracker
meal, bone ash and water or biscuit prepared from flour resulted in a measurable level of
aluminium in the blood hours later, leading the author to conclude that the aluminium was
absorbed and promptly entered the blood (Steel, 1911). However, no results were reported for
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dogs that had not been treated with aluminium. Aluminium appeared in bile, lymph and urine
within minutes following an i.v. injection (Underhill et al., 1929). Most of the results of animal
studies suggest an initial Vd of aluminium consistent with blood volume. When samples were
collected over longer periods, greater Vds became evident, although much less than seen with
many xenobiotics. The Vd after i.v. and oral administration of 8.1 mg Al/kg in rats and followed
for 10 hr was 38 and 46 mL/kg (Gupta et al., 1986). Following 0.1 mg aluminium (as the
sulphate)/kg i.v. injection in the rat, Vds of 78, 47, and 42 mL/kg were seen (Pai & Melethil,
1989; Xu et al., 1991; 1992a). After i.v. injection of aluminium lactate, the initial (central
compartment) and steady-state Vds in the rabbit were reported to be 54 and 109 mL/kg after
40 μmoles Al/kg (1.1 mg/kg) and 44 and 100 mL/kg after 80 μmoles Al/kg (2.2 mg/kg) (Yokel
& McNamara, 1985). When sampling time was increased to 48 hr, initial and steady-state
Vds in the normal rabbit after i.v. injection of 100 μmoles (2.7 mg) Al/kg as the lactate were
reported to be 159 and 1175 mL/kg and 168 and 516 mL/kg in renally-impaired rabbits (Yokel
& McNamara, 1988). When blood aluminium samples were collected over 72 hr, the steady-
state Vd was found to be 1091 mL/kg (Yokel & McNamara, 1989-1990). In the dog, the initial
Vd was estimated to be 50 mL/kg after 1 mg Al/kg as the chloride given i.v., when studied over
a period of 2.5 hr (Henry et al., 1984).
The above results suggest that the initial t½ of aluminium elimination might be aluminium-
dose/concentration dependent. The t½ doubled with a 10-fold increase in the aluminium dose
in the rat (Pai & Melethil, 1989) and increased 1.8-fold with a doubling of the dose in the rabbit
(Yokel & McNamara, 1985). This could be due to greater formation of non-ultrafilterable
aluminium species (see Toxicokinetics, Elimination and Excretion, Animal Studies,
Elimination Rate).
The steady state serum to whole blood aluminium concentration ratios were ~ 0.9 to 1.1 in rats
consuming aluminium in their diet (Mayor et al., 1977). The aluminium concentration ratio in
rabbit serum and plasma compared to whole blood was ~ 1.15 to 1.2, showing nearly equal
distribution between plasma, serum and the formed elements of blood (Yokel & McNamara,
1985). Over the range of 1 to 20 μg Al/mL, blood to plasma aluminium ratios were 0.8 to 1,
also showing near equilibrium of aluminium between blood cells and plasma (Pai & Melethil,
1989).
The percentage of aluminium bound to plasma proteins was reported to be 92 to 98% in the
rat, at a serum aluminium concentration of 2000 to 10,000 μg Al/L following aluminium
chloride injection (Burnatowska-Hledin et al., 1985). Similarly, 98% of aluminium was found
to be protein bound when rat serum aluminium concentrations were 110,000 to 440,000 μg Al/
L (Gupta et al., 1986). These aluminium concentrations greatly exceed those seen in humans
and the capacity of Tf to bind aluminium. When aluminium, as the chloride, was added to
rabbit serum to give a final aluminium concentration of 100 to 32,000 μg/L, the ultrafilterable
percentage decreased as aluminium concentration increased in normal, but not renal-impaired,
rabbits (Yokel & McNamara, 1988).
Studies of the sub-cellular localization of aluminium in rat liver cells showed considerably
more in the nuclear fraction than in the mitochondrial or sub-microscopic fractions when
aluminium was introduced as the ion at pH 7, suggesting selective nuclear aluminium uptake
(Kushelevsky et al., 1976). In contrast, rat hepatocytes took aluminium into the mitochondrial
(~ 45 to 50%) and post-mitochondrial fraction (~ 40 to 45%) but only 6 to 7% into the nucleus.
There were no differences when aluminium was introduced as the chloride, nitrate or lactate
(Muller & Wilhelm, 1987). In another study, daily i.v. injection for 50 days of 1.5 mg Al/kg,
as the chloride, in piglets greatly increased serum and hepatic aluminium levels. Microanalysis
with an energy dispersive x-ray spectrometer showed aluminium and phosphate in hepatocyte
lysosomes, but aluminium was not seen in all lysosomes or in all hepatocytes (Klein et al.,
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1987). Aluminium was seen in the lysosomes of kidney cells of rats given i.p. aluminium
chloride (Linss et al., 1991; 1992). The nucleus of Caco-2 cells appeared to selectively take
up 26Al, irrespective of the chemical species of 26Al to which the cells were exposed (Zhou &
Yokel, 2005).
After repeated s.c. aluminium injections to rabbits that produced NFTs, the aluminium in the
neurons was seen in the nucleus but not the cytoplasm (Uemura, 1984). Similarly, aluminium
was seen in the nucleus (nucleolus, interchromatin granules, euchromatin, and the
heterochromatin) and cytoplasmic area (rough endoplasmic reticulum and free ribosomes) of
rabbit neurons following administration of aluminium as the powder or chloride into the
cisterna magnum or following i.v. injections of aluminium lactate (Wen & Wisniewski,
1985). The intracellular distribution of aluminium in murine neuroblastoma cells that took up
aluminium, introduced as aluminium chloride at pH 6, showed 20% to be associated with the
nuclear pellet and cell debris, 70% in the supernatant fraction from endoplasmic reticulum,
lyosomes and cytosol, and 11% with mitochondria (Shi & Haug, 1990). Aluminium-
ethylenediaminetetraacetic acid (EDTA) resulted in equal aluminium distribution in the
cytosolic and crude nuclear fractions of human neuroblastoma cells. More aluminium was
associated with protein than DNA in the nuclear fraction (Dobson et al., 1998). In contrast,
aluminium taken up by rat cerebral organotypic cultures exposed to aluminium chloride was
only seen in lysosomes (Schuurmans Stekhoven et al., 1990). A study of 26Al uptake by human
neuroblastoma cells exposed to aluminium-EDTA showed ~ 55% of the 26Al in the nuclear
fraction and the remainder in the cytoplasm. Within the nuclear fraction, ~ 81% was in the
nuclear sap, 17% associated with nuclear protein, 1.2% with DNA and 0.5% with RNA (King
et al., 1994). In neuron- and astrocyte-like cells, aluminium maltolate exposure resulted in
intranuclear and cytoplasmic vesicular aluminium accumulation, respectively. Aluminium
accumulation in astrocyte-like cells after aluminium chloride, aluminium lactate and
aluminium fluoride exposure was in small vesicles throughout the cytoplasm and nucleus
(Lévesque et al., 2000). When brain (cerebrum) was fractionated to obtain cell nuclei, ~ 27%
of the 26Al was seen in the nuclei of suckling, and 47% in those of weaned, rats (Yumoto et
al., 2003). Isolation of a nuclear fraction, and then chromatin and supernatant fractions from
the nuclear fraction, showed that ~ 89% of the nuclear 26Al was in the chromatin fraction
(Yumoto et al., 1997). Aluminium subcellular localization in many of these studies was similar
to that seen in human brain (see Toxicokinetics, Distribution (Including
Compartmentalization), Human Studies, Tissue Aluminium Concentrations, Brain), but some
results are different, suggesting that in vitro exposure of cells to some aluminium chemical
forms results in different cellular localization than occurs in vivo.
Iron status negatively correlated with tissue aluminium accumulation. It was suggested that
this may be due to competition between these two chemically-similar trivalent cations, enabling
greater Tf-mediated extravascular distribution and ferritin storage of aluminium in the presence
of low iron concentrations (Greger & Sutherland, 1997).
Ferritin isolated from the brain of rats that had received aluminium in their drinking water for
1 year had more aluminium than normal rats (115 vs. 42 mole of Al/mole of ferritin) whereas
the molar ratio of aluminium to ferritin in the liver did not increase (4.3 vs. 4.6) (Fleming &
Joshi, 1987). Horse spleen ferritin bound up to 98 mole Al/mole ferritin after incubation
exposure to aluminium citrate (30 mM) (Cochran & Chawtur, 1988). Further procedures
suggested that the aluminium was firmly bound to the ferritin, probably to the core. Horse
spleen ferritin that was reconstituted in the presence of aluminium citrate contained an average
of 120 mole Al/mole ferritin, whereas apoferritin and reconstituted ferrritin bound only 7.6
and 9.5 mole Al/mole ferritin, in an equilibrium dialysis study (Dedman et al., 1992a). The
authors concluded that aluminium can be incorporated into a growing iron core in ferritin, that
this can be explained by non-specific binding and that, once the aluminium is bound, it is
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trapped and cannot dissociate freely, but that in the presence of aluminium-complexing ligands,
such as citrate, ferritin will not sequester large amounts of aluminium. Ferritin isolated from
the brain of rats that received repeated aluminium injections, where blood and brain aluminium
were significantly increased, had 136 mole Al/mole ferritin compared to 3.6 in controls
(Sakamoto et al., 2004). Although the authors concluded that ferritin may act as an aluminium
detoxicant, they found that the ferritin-associated aluminium corresponded to 5.9% of the total
brain aluminium, suggesting it does not sequester a very large percentage of intracellular
aluminium.
Repeated aluminium administration to animals results in greater aluminium accumulation in
bone of uraemic, than renally-intact, subjects (Alfrey et al., 1985; Chan et al., 1983; Ecelbarger
& Greger, 1991; Hirschberg et al., 1985; Walker et al., 1994; Yokel & McNamara, 1988). The
bone of uraemic rats contained significantly more 26Al after a single oral administration than
did that of control rats, whereas tissues that are thought to receive aluminium by TfR-ME, the
liver and spleen, had less 26Al in uraemic, than control rats (Ittel et al., 1997). Brain aluminium
concentration was significantly elevated in only one of these studies (Alfrey et al., 1985).
Spleen and liver aluminium levels were lower in several of these studies, but liver aluminium
increased and muscle aluminium decreased in one (Hirschberg et al., 1985). Uraemia appears
to change aluminium in circulation to smaller chemical species (Yokel & McNamara, 1988),
possibly enhancing its distribution into some tissue.
After 24 hr, retention of aluminium, administered as aluminium citrate, was greater in the liver,
but less in the bone, kidney and spleen, of iron-deficient, than in those of control, rats (Greger
et al., 1994). In pregnant rats given a s.c. injection of 26Al at day 15 or 16 of gestation, 0.09%
of the dose was seen per gram liver in the dams and 0.0006% in foetal liver at gestational day
20 or 21 (Yumoto et al., 2000; 2001). There was ~ 100-fold more aluminium in the maternal
liver than in the brain of these rats, as well as in rats which were similarly injected in other
studies (see below). Placental 26Al concentrations were ~ 80 to 90% of liver concentrations.
Of the injected dose, ~ 0.2% had transferred to the foetus and a comparable mass amount had
been retained by the placenta. The liver contained ~ 5-fold more 26Al than the placenta or
foetus. Mice which drank water containing aluminium as aluminium chloride,
dihydroxyaluminium sodium carbonate or aluminium hydroxide until they had consumed 700
mg aluminium, which took 159, 182 and 239 days, respectively, had significantly greater
aluminium concentrations 48 hr after the last dose in the stomach, kidney, liver and tibia after
consuming the aluminium chloride; but only in the stomach after consuming
dihydroxyaluminium sodium carbonate and only in the tibia after consuming aluminium
hydroxide (Dlugaszek et al., 2000). These results show the influence of speciation on
aluminium kinetics.
Some studies suggest that fluoride influences aluminium distribution. Addition of fluoride to
s.c. injections of aluminium resulted in significantly higher aluminium levels in liver, spleen
and adrenals than those from aluminium-alone injections and increased aluminium-induced
behavioural toxicity, suggesting fluoride may alter aluminium distribution or some other aspect
of the fate of aluminium (Stevens et al., 1987). Addition of fluoride to the aluminium in the
drinking water of rats reduced bone aluminium levels but appeared to exacerbate the
osteomalacic lesion of aluminium-associated bone disease (Ittel et al., 1992b). Pre-treating
rabbits with 3 mg F/kg/day in their water for 9 days before intrathecal aluminium injection
tended to lower brain aluminium levels, but only significantly in the cerebellum. On the other
hand, intrathecal aluminium injection in rabbits followed by 3 mg F/kg/day in the drinking
water produced no difference in brain aluminium levels compared to those in the controls
(Shore et al., 1985).
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Although it has been suggested that AlF3 may play a role in aluminium toxicity, the fraction
of intracellular aluminium as AlF3 is < 1%, making this unlikely. Intracellular aluminium is
more likely associated with phosphate, ATP and phosphorylated proteins. Concurrent gavage
administration of aluminium, as 200 mg Al/kg, and folic acid in some rats, as 20 mg/kg, 5 days
weekly for 8 weeks, resulted in significantly less aluminium in femur, brain and kidney, but
not serum, in the rats that received the folic acid (Bayder et al., 2005). It is not clear if folic
acid reduced aluminium absorption or enhanced its elimination. Although the stability constant
of the aluminium-folate complex is quite high, (log K = 15.15 (Nayan & Dey, 1970)), the low
molar ratio of folate to aluminium of 0.006:1 suggests the results are not due to formation of
an aluminium folate complex. Dietary supplementation with vitamin E (5, 15 or 29 mg/g chow)
with i.p. injections of aluminium in the rat reduced plasma and brain aluminium compared to
the absence of vitamin E supplements, although the effect was most pronounced with the lowest
vitamin E concentration (Abubakar et al., 2004). The authors speculated that the vitamin E
effect could be due to preservation of cell membrane ion transport and membrane fluidity.
However, an effect on aluminium excretion cannot be ruled out.
To determine if there might be genetic influences on aluminium accumulation, mice from 5
inbred strains were maintained on a control diet or one supplemented with 260 mg Al/kg diet
for 28 days (Fosmire et al., 1993). C3H mice were the only strain that showed significantly
higher tibial aluminium due to aluminium in the diet, DBA the only strain that showed lower
aluminium due to aluminium in the diet and the A/J the only strain showing significantly higher
aluminium in the absence of aluminium in the diet. DBA strain mice were the only ones
showing significantly more brain aluminium due to aluminium in the diet. The bases of the
observed differences may be variation in the permeability of various barriers, such as the BBB,
as speculated by the authors, but could also be due to other factors affecting aluminium
distribution, such as absorption and elimination. No other studies were found that assessed the
potential influence of genetics on aluminium kinetics.
The α-hydroxy carboxylic acids (citric, lactic and malic) of interstitial fluids dissolve
aluminium from aluminium-containing adjuvants. Citrate solubilizes aluminium phosphate
adjuvant faster than aluminium hydroxide adjuvant (Hem, 2002).
Early studies showed a PTH-induced increase of serum and brain aluminium in rats (Mayor et
al., 1977). An increase in muscle and liver aluminium was reported in uraemic rats following
PTH and aluminium administration, whereas administration of both PTH and vitamin D to
nephrectomized rats raised aluminium in heart and muscle but decreased it in brain, bone and
liver (Hirschberg et al., 1985). An increase of aluminium in brain, bone and muscle, but not
heart, kidney, liver, spleen or serum, was reported following PTH and aluminium
administration (Costantini et al., 1989; Hirschberg et al., 1985). These results are consistent
with the effects obtained with low calcium, and a low-calcium-induced hyperparathyroidism.
In rats maintained on a calcium-deficient diet that developed hyperthyroidism but not given
supplemental aluminium, liver and bone aluminium levels were below normal, whereas they
were normal in rats given supplemental aluminium (Drüeke et al., 1985). Plasma aluminium
was above normal. Liver aluminium content was increased in rats made hyperparathyroid by
parathyroid extract treatments. However, subsequent studies failed to show an effect on
aluminium absorption following parathyroidectomy (PTX) or PTH administration (Feinroth
et al., 1982), an appreciable correlation between PTH status and aluminium absorption (Nordal
et al., 1988a), or an effect of PTX on urinary aluminium output in rats that received oral
aluminium (Ittel et al., 1987). Because PTH stimulates 1,25-(OH)2-vitamin D, a PTH effect
could be mediated by vitamin D. There is evidence suggesting vitamin D enhances oral
aluminium absorption in the rat and rabbit, as increased serum and urinary aluminium were
seen after oral but not i.v. aluminium administration (Adler & Berlyne, 1985; Ittel et al.,
1988; Long et al., 1991; 1994). Supplementation with 1,25-(OH)2-vitamin D resulted in
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decreased levels of aluminium in the rat (Drüeke et al., 1985). Repletion of 1,25-(OH)2-vitamin
D reduced bone aluminium accumulation in 5/6 nephrectomized, thyroparathyroidectomized
(TPTX) dogs; however, PTH did not produce the same effect (Malluche et al., 1987). Similarly,
1,25-(OH)2-vitamin D injections decreased bone aluminium deposition in rats treated with i.p.
aluminium injections and fluoride in their drinking water (Ittel et al., 1993a). Vitamin D has
been shown to increase aluminium levels in serum and in some peripheral tissues, such as bone,
heart, liver and muscle (Anthony et al., 1986; Burnatowska-Hledin et al., 1986; Hirschberg et
al., 1985; Ittel et al., 1990). The lack of vitamin D-induced increase of serum aluminium when
the aluminium was given i.v. suggested the vitamin D effect was on oral absorption (Ittel et
al., 1990). However, it usually decreased brain aluminium levels (Anthony et al., 1986;
Hirschberg et al., 1985). As the aluminium was given parenterally, the effect of vitamin D was
presumably on aluminium distribution or elimination.
Rabbits that consumed a cholesterol rich (1.5% cholesterol) diet had a significant elevation of
aluminium in the frontal cortex, spinal cord and kidney after 3 months (Yasui et al., 1990a).
A free radical scavenger, vinpocetine, 10 mg/day, significantly reduced the aluminium
concentrations to, or below, those of controls.
To address the hypothesis that low levels of calcium and magnesium in the environment
contributed to brain aluminium accumulation in the amyotrophic lateral sclerosis (ALS) and
parkinsonism dementia disorders (see Toxicokinetics, Distribution (Including
Compartmentalization), Human Studies, Tissue Aluminium Concentrations, Brain),
cynomolgus monkeys were maintained for 41 to 46 months on a normal diet containing 1%
calcium, a low calcium diet (0.32%), or a low calcium diet plus 150 mg aluminium and 50 mg
manganese daily (Garruto et al., 1989). Preliminary analysis of the spinal cord of one of the
animals that received the aluminium-containing diet showed aluminium, but not manganese,
accumulation. In another study, mice were fed a standard diet; a diet low in calcium and
magnesium; a diet low in calcium and magnesium and high in aluminium; or a diet low in
calcium and magnesium, high in aluminium and containing 1,25-(OH)2D3. Addition of
aluminium to the diet increased the level of brain, kidney, liver and muscle aluminium.
Addition of 1,25-(OH)2D3 enhanced aluminium accumulation in these organs (Yasui et al.,
1990b). Rats fed a calcium- and magnesium-deficient diet had a non-significant increase of
CNS aluminium, whereas rabbits fed a calcium- and magnesium-deficient diet with added
aluminium, as the lactate, did not show an elevation of CNS aluminium compared to rabbits
consuming the deficient diet without aluminium (Yase, 1980). However, few details were
reported for these two studies. In a study in rats, low amounts of calcium and magnesium
significantly increased lumbar spinal and femoral bone aluminium levels. Addition of
aluminium increased the aluminium concentration more, but the lack of a group given standard
diet with aluminium for comparison does not allow determination whether or not calcium and
magnesium deficiency increased nervous system aluminium accumulation in the presence of
elevated aluminium in the diet (Yasui et al., 1991a). Mice that consumed a low calcium, low
magnesium diet or the same diet plus aluminium, as 15.6 g aluminium hydroxide/kg diet, for
11 to 31 months, had aluminium and calcium deposition in cortical and hippocampal neurons,
shown by morin stain (Kihira et al., 2002).
Aluminium uptake into dimethylsulphoxide-induced Friend erythroleukemia cells, which are
a model system for erythroid differentiation, was linear for 96 hr when exposed to aluminium
Tf (Abreo et al., 1990). Cellular aluminium concentration did not reach the medium aluminium
Tf concentration. McGregor et al. (1991) showed that aluminium uptake by erythroleukemia
cells was aluminium Tf-concentration dependent. Aluminium uptake was not seen in these
cells when exposed to aluminium citrate (Abreo et al., 1990; McGregor et al., 1991). Similarly,
there was more aluminium in reticulocytes and an osteoblast-like cell line after exposure to
aluminium Tf than to aluminium citrate (Abreo et al., 1990; McGregor et al., 1994).
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Aluminium was taken up by hepatocytes to a greater extent when introduced as aluminium Tf
than as aluminium citrate (Abreo et al., 1991; 1997). p-Cresol, a compound that accumulates
in uraemia, increased aluminium uptake from aluminium Tf, but not from aluminium citrate
(Abreo et al., 1997), whereas the anti-oxidants N-acetylcysteine, tetramethylpiperidine 1-oxyl,
SOD, and catalase did not (Abreo et al., 2004). Aluminium appears to enter hepatocytes by a
Tf-receptor mediated process but can also enter more slowly by another mechanism(s).
Central nervous system—Oral administration of 26Al resulted in higher brain 26Al
concentrations than seen in control rats (Drüeke, 2002; Fink et al., 1994; Jouhanneau et al.,
1997b; Walton et al., 1995), demonstrating the ability of aluminium to be orally absorbed and
to distribute into the brain. There are 2 routes by which aluminium might enter the brain from
blood, through the BBB, and through the choroid plexuses into the CSF of the ventricles within
the brain and then into the brain. Aluminium can rapidly enter brain extracellular fluid (ECF)
and CSF, although its concentrations in these two fluids are less than in blood (Allen & Yokel,
1992; Allen et al., 1995; Xu et al., 1992b; Yokel et al., 1991b). Studies in which rats were
injected i.v. with aluminium as aluminium citrate, chloride or aluminium Tf or i.p. in an acidic
acetate buffer, using either 27Al or 26Al, resulted in ~ 0.0008 to 0.009% of the aluminium dose/
g brain (Allen & Yokel, 1992; Kobayashi et al., 1990; Walker et al., 1994; Yokel, 2001); in
pregnant rats injected at day 15 or 16 of gestation, the percentage was 0.00065% and in the
foetuses at day 20 it was 0.0002% (Yumoto et al., 2000; 2001).
There appears to be more than one mechanism of aluminium distribution across the BBB into
the brain though one has not been directly demonstrated. Evidence has been provided that Tf
can mediate aluminium transport across the BBB by TfR-ME of the aluminium Tf complex
(Roskams & Connor, 1990). It is also assumed that TfR-ME mediates aluminium uptake into
some peripheral tissues (see Toxicokinetics, Pharmacokinetic Modelling). The aluminium Tf
complex is the predominant aluminium species in plasma. This process would presumably
release free aluminium in brain ECF. Morris et al. (1989) reported a positive correlation
between aluminium concentration in neurons in the cortex and hippocampus and the density
of Tf receptors. I.v. injection of 26Al Tf resulted in brain 26Al concentrations (~ 0.003 % of
the injected dose/g brain) within 4 hr (Yokel et al., 2001a). TfR-ME could account for this
appearance of aluminium in the brain if the rate of aluminium transport is similar to that
reported for iron. Results of interaction between the TfR and Tf bound to two aluminium atoms
suggest that the affinity of the TfR for aluminium-saturated Tf is much lower than for iron-
saturated Tf (Hemadi et al., 2003).
Aluminium citrate was given i.v. at a rate that produced plasma concentrations in excess of the
ability of Tf to bind the aluminium (Allen et al., 1995). Under this condition aluminium citrate
was presumably the predominant aluminium species in plasma. The appearance of aluminium
in brain ECF was too rapid to be mediated by TfR-ME. This suggests a second mechanism,
independent of Tf, which can transport aluminium citrate into the brain. Brain aluminium
uptake, infused as aluminium citrate, was not influenced by a Tf receptor antibody in mice,
nor was brain aluminium uptake in hypotransferrinemic mice different from that of controls
(Radunovic et al., 1997), providing further evidence of a Tf independent mechanism of brain
aluminium entry. Decreased plasma protein binding, produced by uraemia or perhaps by
decreased Tf metal binding capacity, should favour formation of aluminium citrate and other
small molecular weight aluminium species. This was observed in partially nephrectomized
rabbits (Yokel & McNamara, 1988). This may increase brain aluminium distribution of non-
protein bound aluminium species, such as aluminium citrate.
S.c. injection of aluminium L-glutamate has been shown to result in elevated levels of
aluminium in the brain of the rat (Deloncle et al., 1995; 1999; 2001). This does not prove that
the aluminium entered the brain as aluminium glutamate, as claimed by the authors. Speciation
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calculations suggest only ~ 0.5% of aluminium would be associated with glutamate in the
human under extremely high aluminium concentrations (Daydé et al., 2003). I.p. injection of
magnesium D-aspartate with or without aluminium L-glutamate significantly decreased brain
aluminium levels compared to the absence of magnesium D-aspartate (Deloncle et al., 2002).
Although the authors suggested that D-aspartate was acting as a chelator to reduce brain
aluminium it is not clear why D-aspartate should produce an effect that is different from L-
glutamate, as they have similar complexation constants (Charlet et al., 1984), unless the isomers
of the amino acid have differential effects.
Opening of the BBB by i.v. injection of metrazole increased brain aluminium after i.p. injection
of potassium aluminium sulphate hydroxide, suggesting that aluminium entered the brain
through a paracellular pathway that might have been created by the metrazol (Wu et al.,
1999).
There appears to be a mechanism to transport aluminium out of the brain. It has been suggested
that citrate may enable aluminium transport out of the brain by a carrier-mediated process.
When aluminium citrate was infused i.v. to produce constant brain and blood ECF aluminium
concentrations, the brain ECF aluminium concentration was below that in blood ECF (Allen
et al., 1995). This suggests a mechanism at the BBB to reduce ECF brain aluminium by
transporting it into blood. The concentration of Tf in CSF, and presumably ECF, is very low.
It has been suggested that all Tf in brain ECF is iron saturated (Bradbury, 1997) providing no
ability of Tf to mediate neuronal aluminium uptake. However, the citrate concentration in brain
ECF is higher than in plasma, suggesting that 90, 5, 4 and 1% of aluminium in CSF, and
presumably brain ECF, is associated with citrate, hydroxide, Tf and phosphate, respectively,
according to calculations conducted by Harris (Yokel, 2001). It is therefore likely that
aluminium citrate is the aluminium species transported out of the brain. Aluminium citrate
transport across the BBB was assessed using microdialysis under conditions of aluminium
equilibrium between blood and brain ECF. The brain to blood aluminium concentration ratio
increased after addition to the dialysate of a metabolic inhibitor (2,4-dinitrophenol), pyruvate,
a proton ionophore (p- (trifluoromethoxy)phenylhydrazone) or mersalyl acid and when proton
availability was decreased by increasing dialysate pH. These results suggested the
monocarboxylate-1 (MCT-1) transporter mediated aluminium citrate brain efflux (Ackley &
Yokel, 1997; 1998). However, the red blood cell, which expresses MCT-1 and the anion
exchanger, did not take up aluminium citrate well, suggesting aluminium citrate is not a
substrate for MCT-1 (Yokel, 2002). Aluminium citrate uptake by an immortalized murine BBB
endothelial cell line, in the presence of various inhibitors, was suggested to be ATP- but not
Na/K-ATPase-dependent and not a substrate for a dicarboxylate carrier, but a substrate for an
organic anion transporter (Yokel et al., 2002). Using an immortalized rat BBB endothelial cell
line, it was found, in a study focusing on the glutamate transporter, that aluminium citrate
uptake was concentrative, temperature- and concentration-dependent, not sodium-dependent,
and inhibited by ligands for the sodium-independent L-glutamate/L-cystine exchanger system
Xc-. Loading the cells with these ligands enhanced aluminium citrate uptake, interpreted as a
trans-stimulatory effect, leading the authors to conclude that system Xc- is a potential candidate
for aluminium citrate uptake into the brain across the BBB (Nagasawa et al., 2005).
Brain aluminium concentration in mice consuming a commercial diet increased several fold
from 1 week to 4 weeks of age, then remained fairly constant until declining several fold from
52 to 104 weeks of age (Takahashi et al., 2001). The aluminium content of the diet was not
described. In contrast, rat brain aluminium showed no consistent changes over the same time
period (Takahashi et al., 2001), suggesting no age-related changes in brain aluminium
concentration.
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Brain aluminium concentrations in pregnant rats, given 0, 200 or 400 mg Al/kg/day during
gestation days 1 to 20, were significantly lower than in non-pregnant rats, whereas those in
liver, bone (only in non-aluminium treated rats), and kidney (only in rats that received 400 mg
Al/kg/day) were significantly higher in the pregnant rats (Bellés et al., 2001).
Neuroblastoma cells, which model human neurons, have been used to study aluminium uptake.
A human neuroblastoma cell line showed aluminium uptake with an equilibrium constant of
2.88 nM vs. 1.66 for iron and a similar t½, 3.8 min, for 50% cell internalization of the metal
(Morris et al., 1987). Mouse neuroblastoma cells took up aluminium when introduced as
aluminium Tf, at pH 7 to 8. Addition of citrate or EDTA inhibited aluminium uptake (Shi &
Haug, 1990). Aluminium uptake from a medium containing 25 μM aluminium was saturated,
achieving 5 nmole/mg cell protein. Although EDTA, citrate, tartrate, maltolate, fluoride and
8-hydroxyquinoline appeared to inhibit aluminium uptake at pH 6, they did not at pH 7.4.
Conversely, although metabolic inhibitors had no effect on aluminium uptake at pH 6, they
appeared to reduce uptake at pH 7.4. However, statistical significance was not shown (Shi &
Haug, 1990). Human neuroblastoma cells took up more aluminium when introduced as
aluminium EDTA than as aluminium citrate or aluminium maltolate. Uptake was concentrative
(Guy et al., 1990). Tf enhanced aluminium uptake into neuroblastoma cells 2-fold more than
citrate (Abreo et al., 1999).
Primary foetal rat hippocampal and human cortical neurons in culture took up aluminium
introduced as the chloride (200 μM) in the presence of 1 mM EGTA. Exposure to a divalent
cation ionophore (A23187) increased rat hippocampal intraneuronal aluminium concentration
from ~ 3 to 20 mg/kg, and aluminium influx and accumulation in human cortical neurons in
culture as well (Mattson et al., 1993; Xie et al., 1996). Explants of rat cortical neurons took up
significantly more aluminium, introduced as 340 μM aluminium lactate, aluminium lactate and
328 μM citric acid or aluminium lactate and 2 μM L-glutamic acid, than controls containing
no aluminium (Jones & Oorschot, 1998). There was no significant difference in intracellular
aluminium amount from the aluminium forms. The aluminium was in the cytoplasm and/or
cell nucleus.
Rat cerebellar cells in culture were exposed for a few minutes to aluminium, introduced as 5
mM aluminium citrate or as aluminium fluoride. Aluminium uptake was not seen in granule
cells but was observed in GABAergic neurons, that were thought to be Purkinje cells, and flat
glial cells, but not star-like (type 2) astrocytes, using synchrotron photoelectronic
spectromicroscopy (De Stasio et al., 1993; 1994).
When exposed to aluminium sulphate, rat glioma cells took up significantly more aluminium
than did those of controls, whereas murine neuroblastoma cells did not (Campbell et al.,
1999). Oligodendrocytes, the glial-forming cells in the CNS, and neurons took up aluminium
when introduced at 2.26 μM, as aluminium Tf, but not as aluminium chloride or citrate (Golub
et al., 1996b; Golub et al., 1999), consistent with the enhancement of aluminium uptake by Tf
in neuroblastoma cells. Aluminium uptake into oligodendrocytes was much greater than into
neurons.
Astrocytes, another glial cell, did not take up aluminium (Golub et al., 1999). In contrast, when
1 mM aluminium was added as the chloride, in the presence of 1 mM citrate and 1 mM calcium,
the aluminium concentration in astrocytes was greater than in granule neurons isolated from
the cerebellum and was even greater in astrocytes that had been co-cultured with neurons.
Neuronal aluminium uptake was not affected by co-culture with astrocytes (Suarez-Fernandez
et al., 1999). However, the aluminium concentration in these cells was 30 to 50 times that seen
in human brain. Aluminium accumulation in neuron- and astrocyte-like cells was significantly
increased when introduced as aluminium fluoride and in astrocyte-like cells when introduced
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as aluminium chloride. Aluminium maltolate and aluminium lactate did not significantly
increase aluminium in either cell type nor did aluminium chloride in neuron-like cells.
Exposure to up to 1 mM aluminium maltolate resulted in concentration-dependent aluminium
uptake that was generally greater in neuron- than astrocyte-like cells (Lévesque et al., 2000).
Uptake of aluminium into astrocytes from 0.1 mM aluminium associated with serine, glycine
and glutamine was significantly increased after 24 hr, but not from aluminium glutamate or
aluminium citrate exposure (Aremu & Meshitsuka, 2005). Inhibition of glutathione (GSH)
synthesis increased aluminium uptake from aluminium glutamate and from aluminium glycine
but only after 8 hr. However, it did not increase aluminium from aluminium glutamine or serine.
A non-specific inhibitor of glycine transporters (doxepin) and a selective blocker of the glycine
transporter GlyT1 (sarcosine) increased aluminium uptake from aluminium glycine. A
selective blocker (dihydrokainic acid) of the glutamine transporter GLT-1, also called EAAT2,
increased aluminium uptake from aluminium glutamine. Neither a non-specific inhibitor of
glutamate transporters (L-trans-pyrrolidine-2,4-dicarboxylic acid) nor an inhibitor of Na+/
K+-ATPase (ouabain) affected aluminium uptake. The authors concluded that neither amino
acid transporters nor Na+/K+-ATPase mediated aluminium uptake, which they suggest might
be from diffusion and one or more other mechanisms.
It is difficult to directly compare the results of these studies that had major differences in their
methods, including:
• the use of different cell types;
• the use of similar cells that were obtained from different organisms at different stages
of development; and
• greatly different, and sometimes physiologically irrelevant, aluminium exposure
conditions.
It does appear that Tf enhances uptake into neurons and that many different chemical species
of aluminium can enter neurons and glial cells. However, if there are no available binding sites
for aluminium on Tf in brain ECF, as suggested by Bradbury (1997), this mechanism may not
be very important in vivo. The mechanisms of aluminium uptake by brain cells appear to include
diffusion, TfR-ME and other, un-identified, carrier-mediated processes.
Based on brain aluminium concentration in victims of Creutzfeld-Jakob disease, which is
associated with widespread neuronal and glial pathology, that were not different from controls,
it was concluded that brain damage alone does not result in elevated brain aluminium (Traub
et al., 1981). Brain aluminium was not elevated in 20 patients who died from liver disease or
other complications of chronic alcoholism compared to 20 patients without a history of
alcoholism (Zumkley et al., 1986). Subsequent relevant studies included the
intracerebroventricular injection of 0.2 mg aluminium gluconate which resulted in significantly
more intraneuronal aluminium accumulation in the hippocampus and parietal and frontal cortex
of rats than in those of controls (Szerdahelyi & Kasa, 1988). The increase was greater in the
hippocampus and parietal than frontal cortex. Injection of the cholinotoxin AF64A six days
before intracerebroventricular aluminium gluconate injection resulted in significantly greater
intraneuronal aluminium accumulation in the hippocampus compared to injection of
aluminium gluconate alone, suggesting that neuronal toxicity enhanced aluminium uptake
(Szerdahelyi & Kasa, 1988). Aluminium uptake was enhanced in neurons exposed in culture
to glutamate and calcium, suggesting that aluminium entered during cell degeneration (Mattson
et al., 1993). Synaptosomes prepared from rat brain cortex exposed to 11 μM aluminium, from
aluminium chloride, took up ~ 2-fold more aluminium when exposed to increased lipid
peroxidation induced by 0.8 mM ascorbic acid and 2.5 μM Fe2+ (Amador et al., 1999). Infection
of rats with Japanese encephalitis virus resulted in an increased accumulation of aluminium in
the brain (Seko et al., 1986). These studies suggest stress (increased lipid peroxidation) and
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insult to the brain (induced by AF64A, glutamate and calcium and viral infection) can increase
brain aluminium accumulation. Although the mechanism is unknown, it appears to be at the
cellular level, since this effect was seen in cells in culture.
Bone—Repeated treatment of rats and rabbits with aluminium resulted in ~ 5-fold greater
elevation of aluminium levels in bone than brain (DuVal et al., 1986; Fiejka et al., 1996;
Garbossa et al., 1998b; Henry et al., 1984; Yokel, 1983). Rats consuming 50 or 500 mg Al/L
in their drinking water for 9 weeks had approximately 0.2 and 0.1 × 10-3 % of the total
aluminium intake in each gram of bone (Glynn et al., 1999). Three weeks after the i.v. injection
of 26Al in one normal rat, the percentage of the 26Al dose in each gram of bone and brain was
9 × 10-1 and 2 × 10-3, respectively, a 37-fold difference (Walker et al., 1994). The 26Al in the
bone of two mice two hr after i.v. infusion of 26Al plus citrate was 580-fold that seen in brain
(Radunovic et al., 1997). After oral ingestion of 26Al, ~ 0.25 to 0.3% of the administered 26Al
was in the skeleton after 2 (Jouhanneau et al., 1997b) and 48 hr (Drüeke et al., 1997).
Consistently more 26Al was in the skeleton and urine when it was administered with, than
without, citrate, whereas citrate inconsistently increased 26Al in brain and liver (Jouhanneau
et al., 1997b). Forty-eight hr after oral 26Al dosing of rats, 1 × 10-3 and 1 × 10-6 % of the dose
was in each gram of bone and brain, respectively (Drüeke et al., 1997). In rats orally-dosed
with 26Al, the 26Al rapidly entered the bone, peaking within hours, with no significant decrease
over the subsequent 720 hr (Jouhanneau et al., 1997b). The percentages of the dose of 26Al in
bone and brain were 2 × 10-3 and 2 × 10-6 %, respectively. Multiplying the percentage of
the 26Al dose in bone after oral 26Al dosing by 330 (to model 0.3% oral bioavailability) suggests
0.3 to 0.7% of the aluminium that reaches systemic circulation enters each gram of bone. The
result of this calculation is comparable to the one obtained by Walker et al. (1994). Comparing
this percentage of a systemic dose of 26Al that reaches each gram of bone (~ 0.5 %) to the
results summarized above for the percentage that reaches each gram of brain (~ 0.005 %)
suggests that about 100-fold more aluminium enters bone than brain after a single exposure.
Yet the steady state concentration of aluminium in bone is not 100-fold greater than in brain
of human controls (see Toxicokinetics, Distribution (Including Compartmentalization), Human
Studies, Tissue Aluminium Concentrations) and animal controls, as noted earlier in this section.
This suggests that clearance of aluminium from bone is more rapid than from brain. This is
reasonable in light of the constant turnover of bone as it remodels, whereas at least some of
the cells in the brain, the neurons, undergo very little or no turnover during the animal’s lifetime.
Based on the understanding of the cycle of heavy metals in bone, it was suggested that
aluminium is transferred to osteoclasts during bone resorption and that some may be released
from bone (Priest, 2004). Bone aluminium concentrates at the mineralization front. Potential
mechanisms of bone aluminium deposition have been suggested to be heterionic exchange with
calcium, co-precipitation with calcium and complexation with organic components of the bone
matrix (Priest, 2004).
Fluoride in drinking water (40 mg/L) markedly reduced aluminium accumulation in the bones
of uraemic rats given i.p. aluminium injections (Ittel et al., 1993a).
Other tissues and fluids—Aluminium distributes into the placenta and foetus. Injecting
aluminium into rabbits during gestation resulted in higher aluminium concentrations in their
placenta than in the tissues of 0 to 2 day old rabbits exposed in utero, which were elevated
above non-aluminium-exposed offspring (Yokel, 1985). Placental aluminium levels in mice
not treated with aluminium were non-significantly higher than in maternal tissues. Injections
(i.p.) and oral aluminium administration during gestation significantly increased placental
aluminium concentrations above those seen in placenta of saline-control animals as well as the
foetuses exposed to the aluminium (Cranmer et al., 1986). Concentrations of aluminium in the
placenta of guinea pigs that consumed a diet containing 47 mg Al/kg and in the brain, spinal
cord and liver of their newborns were similar, ~ 0.005 mmole/kg (0.135 mg/kg) (Golub et al.,
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1996a). Brain and spinal cord aluminium generally decreased from gestation day 30 to post-
natal day 12 in the offspring.
Aluminium distributes into growing hair. Injection of aluminium lactate (s.c.) into the back of
rabbits resulted in a considerable, dose-dependent, increase of the aluminium concentration
above the pre-treatment average of ~ 1 mg Al/kg hair in the hair grown over and near the region
of the injections (Yokel, 1982). Due to the very large amount of aluminium injected (0.7 to
10.8 mg Al/kg 5 days/week for 4 weeks) and the route of administration, these results cannot
be related to the human.
Aluminium distributes into milk. Milk aluminium concentration increased from 0.46 to 0.81
mg/L in cows receiving 114 mg Al/day as alum (Archibald, 1955). Aluminium concentrations
in the milk of rabbits receiving 0.4 or 0.8 mmole (10.8 or 21.6 mg) Al/kg s.c. injections 5 days
weekly for 4 weeks increased ~ 2 and 5-fold (Yokel, 1984; 1985). The increase of aluminium
in milk peaked about 8 hr after i.v. and 12 to 24 hr after oral and s.c. administration in rabbits
(Yokel & McNamara, 1985). Prior to aluminium administration, the milk/serum aluminium
ratio was 4.9. Approximately 2.4% of an i.v. dose of aluminium and 3.3% of the absorbed dose
of aluminium following a s.c. injection were found in the milk (Yokel & McNamara, 1985).
Rats were given 10 mg aluminium, as the chloride, daily i.p. from postnatal days 1 to 12
(Muller et al., 1992). Twenty-four hr after the last injection, the aluminium level in the milk
of the aluminium-treated rats was 72-fold higher than that in rats not injected with aluminium,
2.02 compared to 0.03 mg/L wet weight. AUC in aluminium-treated rats was 0.3 mg/L wet
weight. The results from both rabbit and rat showed a milk/blood ratio considerably > 1
suggesting that a process other than diffusion mediates the distribution of aluminium from
blood to milk. These studies with 27Al did not demonstrate an increase of aluminium in the
tissue of suckling offspring.
Lactating rats were given daily s.c. injections of 26Al from day 1 to day 20 postpartum. The
concentration of 26Al measured in kidney was higher than that in liver which, in turn, was
higher than that in brain and blood of suckling offspring euthanized on days 9 and 15,
demonstrating the transfer of aluminium to milk followed by its oral absorption and distribution
in the suckling offspring (Yumoto et al., 2000). Offspring of rats that were similarly treated
were weaned on day 20 and sacrificed 40, 80, 160, 320 and 730 days postpartum. Blood, brain
(cerebrum, cerebellum, and hippocampus), spinal cord, parietal bone, kidney and liver were
obtained (Yumoto et al., 2003). The amount of 26Al/g tissue in the offspring as a % of the
amount injected, on post-partum day 20, was ~ 0.02 in bone, 0.006 in liver, 0.004 in kidney,
3 × 10-5 in brain cerebrum and 3 × 10-6 in blood. The spinal cord had more 26Al/g tissue than
the 4 brain regions at postpartum day 20.
The concentration of 26Al in the milk of rats that received daily s.c. injections of 26Al from
days 1 to 20 postpartum was greater than that in any of the tissues simultaneously collected
from suckling rats (Yumoto et al., 2003). There was about 0.2 to 0.4% of the injected 26Al/g
milk. The milk was obtained from the stomachs of the sacrificed suckling rats. As the authors
did not report the amount of milk consumed or produced, one cannot determine the percentage
of injected 26Al that appeared in the milk.
Human studies
The human whole body aluminium burden has been estimated to be 80 mg (Tipton & Shafer,
1964), probably 35 to 40 mg (Alfrey, 1989) and, more recently, 30 to 50 mg (ATSDR, 1999).
Slight age-related increases in blood, bone, brain, and other soft tissues have been reported.
Aluminium concentrations increased from ~ 160 mg/kg (in ash) in the lung of 0 to 3 month
olds, to ~ 625 in 1 to 12 year olds and to > 2000 in 19 to 89 year old adults, in liver from ~ 100
in 0 to 3 month olds, to ~ 150 in 1 to 12 year olds and to ~ 550 in adults, and in kidney from
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~ 150 in 0 to 3 month olds, to ~ 300 in 1 to 12 year olds and to ~ 350 in adults (Stitch, 1957).
Similarly, median lung aluminium concentrations increased from ~ 150 mg/kg (wet tissue) in
0 to 12 year olds to ~ 2500 in ≥ 60 year olds (Tipton & Shafer, 1964), and from ~ 2 mg Al/kg
(wet tissue) in 21 to 30 year olds to ~ 40 in > 81 year olds (Roider & Drasch, 1999). Brain and
bone aluminium increases with age, as discussed in Toxicokinetics, Distribution (Including
Compartmentalization), Human Studies, Tissue Aluminium Concentrations, Brain / Bone.
Kidney, liver and spleen showed a similar trend to lung and brain, an increase with age up to
~ 40 years old, a plateau or slight decrease to age 70, then an increase later in life. Ten 32 to
46 year olds had mean hippocampal and frontal cortex aluminium concentrations of 0.014 and
0.020 mg/kg (wet tissue) whereas those of fifteen 75 to 101 year olds were 0.402 mg/kg and
0.373 mg/kg, respectively (Shimizu et al., 1994). Serum aluminium levels in 356 healthy 20
to 80 year olds increased with age with a significant linear regression of r2 = 0.067 and a mean
of 7.3 μg Al/L (Zapatero et al., 1995). In contrast, tissue aluminium levels were not found to
increase with age in 36 subjects from Denver, Colorado, U.S. or in 21 from Brisbane, Australia.
However, the ages of the subjects were not reported (Alfrey et al., 1980).
In some studies increased levels of aluminium have been found in the brain of persons who
had suffered from AD; in other studies no such increases were observed (see Table 19). More
details of some of these studies are presented in Speziali & Orvini (2003). It has been noted
that aluminium was reported to be higher in the cortex and hippocampus than in other brain
structures in normal and AD brains (Gupta et al., 2005). A review was conducted of reports of
aluminium in the brain of Parkinson’s disease subjects compared to controls. It revealed some
studies that found a significant increase in the former group. However, all of the studies were
conducted by the same research team (Speziali & Orvini, 2003).
NFT bearing neurons from AD brain showed several-fold more aluminium in the tangle than
in the nucleus which, in turn, had 1.5 to 2-fold more aluminium than cytoplasm and neuropil.
Aluminium distribution in the nucleus, cytoplasm and neuropil of tangle-free neurons was
similar (Good et al., 1992). Similarly, another group found more aluminium in the nuclei than
cytoplasm of tangle- and non-tangle-bearing neurons of Alzheimer and non-Alzheimer brains
(Lovell et al., 1993).
Iron status negatively correlates with tissue aluminium accumulation. Ferritin isolated from
the brains of 2 subjects with AD had more aluminium than that from 2 normal human subjects
(18.9 vs. 3.4 mole Al/mole ferritin) (Fleming & Joshi, 1987). After equilibrium dialysis of
ferritin isolated from human brain and liver against 20 μM aluminium, ferritin from liver had
more aluminium than from brain (Fleming & Joshi, 1987). In contrast, aluminium levels were
not found to be different in the brain cortex from normal, AD and chronic renal dialysis patients
(6.2, 8.9 and 7.2 aluminium atoms/ferritin molecule) (Dedman et al., 1992b).
Transport in blood—The concentration of aluminium in erythrocytes was found to be 110%
of that seen in healthy human plasma (Chernov et al., 1977). The aluminium concentration in
plasma from haemodialysis patients showed little difference from that in blood cells (Van der
Voet & de Wolff, 1985). These results are similar to those from animals, above, showing similar
aluminium concentrations in plasma and erythrocytes at equilibrium. In contrast, the whole
blood, serum and calculated erythrocyte Al concentrations were 15 & 17, 3 & 4 and therefore
34 & 30 μl/L in two healthy subjects, resulting in serum to erythrocyte ratios of 0.08 and 0.15
(Tamada, 2004). In a study in 15 long-term hemodialysis patients, of which 7 were taking Al
hydroxide and 8 were not, the overall serum Al to erythrocyte ratio was 0.06. Mean serum Al
was lower in those taking Al hydroxide, and averaged 32 μl/l for all patients (Sharif et al.,
2004). After ingestion of 26Al by a healthy subject, plasma 26Al concentration peaked at ~ 1.2
hr and decreased to 5% of the peak value by 24 hr, whereas erythrocyte 26Al peaked at ~ 1.2
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days, showing a 1.1 day lag. At 1.2 days, the plasma to erythrocyte concentration was 0.03
(Fifield et al., 1997). However, this is not a peer-reviewed report.
Mean AUC was 92% of that seen in whole blood of 4 renal dialysis patients whose blood
aluminium concentration was > 100 μg/L (Sjögren et al., 1983). One hr after ingestion of 26Al
citrate by one volunteer, 99% of the aluminium was in plasma (80% with Tf and 4% in a low
molecular weight fraction) and the remaining 1% was in erythrocytes. The distribution of
aluminium in blood taken 880 days after 26Al citrate injection was 86% in plasma and 14%
associated with erythrocytes (Day et al., 1994).
When plasma protein aluminium binding was determined after addition of aluminium to serum
at final a aluminium concentrations of 14 to 700 μg/L, the percentage bound increased as
aluminium concentration increased from 57 to 89% (Gidden et al., 1980). In uraemic serum,
the maximum percentage bound was found to be only 18% (Gidden et al, 1980). The aluminium
in uraemic serum containing 36 to 152 μg Al/L was reported to be 70 to 92% protein bound
(Graf et al., 1981). Aluminium in serum from normal humans, containing 8 μg Al/L was found
to be 86% protein-bound whereas aluminium in serum from uraemic humans, containing 140
μg Al/L was found to be 80% protein-bound (Leung et al., 1985). However, aluminium in
serum from normal humans, containing 8 μg Al/L was reported to be 54% protein bound
whereas aluminium in serum from uraemic humans, containing 99 μg Al/L was reported to be
67% protein-bound (Rahman et al., 1985). Perez Parajon et al. (1989) found ~ 95% of the
aluminium in serum from 8 normal subjects to be plasma-protein-bound, using conventional
ultrafiltration, and 92% in 10 normal subjects with ultramicrofiltration, the latter procedure
being more reliable. Serum from 10 uraemic patients was 87% bound to plasma proteins before
these patients received the chelator desferrioxamine (DFO), and 26% 48 hr later. Based on
binding constants, it was estimated that ~ 11% of aluminium is bound to citrate in serum
(Ohman & Martin, 1994). Using high pressure liquid chromatograpy (HPLC)-EAAS, it was
concluded that ~ 90% of the aluminium was bound to Tf (Wrobel et al., 1995). This percentage
did not change as a function of the aluminium concentration or the presence of uraemia, or as
a result of kidney transplantation. The remaining 12% was associated with a low molecular
mass entity that was thought to be citrate. DFO partially displaced the aluminium from Tf.
Using gel filtration and HPLC size exclusion (gel permeation) chromatography, serum
aluminium was studied in 3 control and 3 aluminium smelter potroom workers (Rollin &
Nogueira, 1997). The workers had a higher percentage bound as a high molecular mass complex
(91 vs. 79%), which was thought to contain Tf. Addition of aluminium to the serum samples,
to ~ 400 μg Al/L, resulted in 98 to 99% aluminium being bound in the high molecular mass
complex. Calculations suggested ~ 91% of plasma aluminium is associated with Tf, 7 to 8%
with citrate, < 1% with phosphate and hydroxide and essentially none with fluoride, glutamate
or aspartate (Martin, 1996) and as determined by Dr. Wesley R. Harris (in Harris & Messori,
2002; Yokel & McNamara, 2001). Aluminium complexation with citrate in plasma has been
demonstrated (Bell et al., 1993). Results of calculation of the ultrafilterable fraction of
aluminium in healthy humans and patients with chronic renal failure using the biokinetic model
described in Toxicokinetics, Pharmacokinetic Modelling suggested it was 0.06 and 0.11,
respectively (Steinhausen et al., 2004). This is relevant to all data reported in this review, with
the exception of some 27Al studies where plasma aluminium levels exceeded the aluminium
binding capacity of Tf (about 1200 μg/L). Analytical speciation studies suggest that the
ultrafilterable species are citrate, phosphate, and citrate-phosphate aluminium complexes
(Sanz-Medel et al., 2002). It does not appear that albumin binding of aluminium is
physiologically important. Most recent studies concluded that Tf is the sole plasma protein
which binds aluminium. Non-protein bound aluminium in plasma is believed to be associated
with citrate and, to a lesser extent, phosphate. Therefore, aluminium distribution from blood
to tissues probably involves aluminium Tf or aluminium citrate. Aluminium citrate readily
distributes out of blood. After i.v. injection of aluminium as the citrate to one subject, > 50%
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of the aluminium had distributed out of the blood within 15 minutes (Priest, 1994). The effects
of citrate on brain and/or bone aluminium concentrations and uptake of aluminium into cells
have been inconsistent. Citrate forms a small molecular weight complex with aluminium that
appears to enhance aluminium distribution and elimination compared to aluminium Tf (Maitani
et al., 1994). In the presence of renal function, citrate may enhance aluminium clearance; in
the absence it may enhance the accumulation of aluminium in tissues.
Calculations show that insignificant amounts of aluminium fluoride species will form in the
presence of normal plasma fluoride (~ 100 μg/L) and normal or elevated plasma aluminium.
This suggests fluoride is unlikely to affect aluminium distribution or elimination, unless it is
involved in mixed ligand complexes containing aluminium and other ligands (W.R. Harris,
personal communication, 2000). Similarly, silicon concentrations in biological fluids are very
low. It was suggested that monomeric aluminium silicate species are quite unlikely to play any
significant role in the biological chemistry of aluminium after the aluminium is absorbed
(Harris et al., 1996). An inverse relationship was noted between serum aluminium and silicon
in patients in one haemodialysis centre, raising the possibility that silicon influences aluminium
distribution and/or elimination (Parry et al., 1998).
Plasma aluminium concentrations—Many older studies report aluminium
concentrations that were subsequently believed to be elevated due to contamination (Versieck
& Cornelis, 1980). A review of the aluminium concentration in normal human plasma or serum
by these authors from 12 reports published in 1980 to 1985 showed mean values ranging from
0.07 to 0.38 μM (1.9 to 10.3 μg/L), and an overall median of 0.23 μM (6.2 μg/L) (Versieck &
Cornelis, 1989). Eleven reports of blood, serum or plasma aluminium in healthy humans,
published from 1986 to 1992 showed a range of 0 to 0.22 μM with an overall median of ~ 0.12
μM (3.2 μg/L). The authors concluded that the true value of aluminium in healthy control
human serum/plasma is 0.04 to 0.12 μM (Nieboer et al., 1995). A literature review of studies
published the previous 30 years suggested the reference value was 0.5 to 8 μg/L in plasma and
serum and 2 to 8 μg/L in whole blood (Caroli et al., 1994). House (1992), summarized 24
previous reports of plasma and serum aluminium concentrations in normal subjects, determined
by EAAS, from 1974 to 1991. The results showed a reduction over time to a mean of ~ 27
μg/L around 1990, which is well above the currently accepted normal value. It was suggested
that healthy human serum contains 1.6 μg Al/L (Valkonen & Aitio, 1997). Plasma aluminium
in 71 office employees did not show a normal distribution. Most values were ≤ 2.7 μg/L, with
a mean of 2.67 μg/L (House, 1992). Variables that affected the aluminium concentration were
the batch in which the sample was analyzed (thought to reflect sample contamination), sex
(males > females), antacid use and cola consumption. It has been suggested that the upper limit
of the normal range is 6 μg/L (Daniela et al., 2002). Median blood aluminium was 3.2 μg/L in
67 office workers who had not been exposed to aluminium (Liao et al., 2004). Serum aluminium
in a control group was 0.99 ± 0.97 μg/L (range 0.03 to 3.12 μg/L), whereas the values were
4.75 ± 9.23 μg/L (range 0.5 to 45.1 μg/L) in dialyzed patients (Razniewska, 2005). Serum
aluminium in normal newborns was reported to average 5.17 μg/L (Sedman et al., 1985) and
8 to 12 μg/L (Litov et al., 1989). In premature infants who received i.v. therapy, the plasma
aluminium concentration averaged 37 μg/L (Sedman et al., 1985). Mean plasma aluminium
concentrations in pre-term infants born at gestational age 28 to 32 weeks, pre-term infants born
at gestational age 33 to 36 weeks, and full-term (mean 39 weeks) were 0.49, 0.39 and 0.29
μM (13.2, 10.5 and 7.8 μg/L), respectively (Bougle et al., 1992). Plasma aluminium averaged
0.59 μM (15.9 μg/L) in those that received parenteral nutrition compared to 0.33 μM (8.9 μg/
L) in those that did not (Bougle et al., 1992).
The mean AUC in 44 haemodialysis patients who were receiving aluminium therapy was 32
μg/L compared to 10.8 μg/L in 32 not receiving aluminium (Fenwick et al., 2005). Serum Al
concentration was reported to be significantly higher in patients with spontaneous
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pneumothorax (184 μg/L) than controls (27 μg/L) (Han et al., 2004). However, these values
from the healthy individuals are an order of magnitude above what is accepted as the true value
of serum aluminium, reducing confidence in this study.
A seasonal variation of aluminium in serum was seen, with higher levels in the autumn, which
was speculated to be due to a water-borne factor (Nordal et al., 1988b).
Tissue aluminium concentrations—Aluminium is unequally distributed throughout the
body in normal and aluminium-intoxicated humans (Alfrey et al., 1980; Di Paolo et al.,
1997). Tissue aluminium concentrations in normal adults at steady state (in mg/kg wet weight
unless otherwise stated), were 20 in lung, 1 to 3 in bone (based on dry weight), 1 in liver and
spleen, 0.5 in the kidney, 0.45 in the heart, 0.4 in muscle, 0.35 in brain and ~ 0.002 in blood
(Nieboer et al., 1995). Similar reference values, of 2.21 to 15.3 mg/kg in the lung, 1.0 to 2.45
mg/kg in the liver and 0.55 to 1.31 mg/kg in the kidneys were obtained from a review of
literature published in the prior 30 years (Caroli et al., 1994). With increased age and
accumulation of aluminium, late life aluminium body burden has been estimated to be 25 to
50 mg in bone, 20 mg in lung, and 9 to 24 mg in soft tissue (Keith et al., 2002). Based on typical
organ weights for a 70 kg adult, ~ 58, 26, 11, 3, 0.95, 0.3, 0.25 and 0.2% of the body burden
of aluminium would be in the bone, lung, muscle, liver, brain, heart, kidney and spleen,
respectively. The higher concentration in lung of normal humans may reflect entrapment of
airborne aluminium particles whereas the higher concentrations in bone, liver and spleen may
reflect aluminium sequestration. Skin, taken from the back of 11 chronic haemodialysis
patients, had greater aluminium concentration than from 9 controls (1.02 vs. 0.26 mg/kg)
(Subra et al., 1991). Skin and serum aluminium concentrations were greater in the patients who
had received haemodialysis for a longer time (averages of 156 vs. 49 months) (Subra et al.,
1991). It has been suggested that up to 14% of the body burden of aluminium is in the skin,
but the potential contribution of contamination to this value has been raised (Priest, 2004).
Because of its very low bioavailability by most routes of exposure and the effective urinary
clearance of aluminium from blood, human tissue and fluid, aluminium concentrations are low
compared to aluminium concentrations in most exposure sources.
Victims of the dialysis encephalopathy syndrome showed elevated aluminium exposure in all
tissues (Alfrey et al., 1980). The respective mean aluminium concentrations, in mg/kg dry
defatted tissue, in controls, non-dialyzed uraemic patients, dialyzed uraemic patients and
dialyzed uraemic patients with encephalopathy were 4.1, 25.5, 161 and 301 in liver; 3.0, 35.3,
243 and 493 in spleen; 4.5, 27.4, 116 and 281 in bone; 1.1, 6.9, 22.5 and 42.7 in heart; 1.2, 2.6,
9.1 and 14.9 in muscle; 55, 75, 90 and 215 in lung; and 2.4, 4.1, 8.5 and 24 in brain grey matter.
In a more recent episode of aluminium intoxication in dialysis patients, 10 of 17 patients
exposed to dialysate prepared from tap water containing 650 μg Al/L died. The serum
aluminium concentrations of those that died and those that did not averaged 808 and 255 μg
Al/L, respectively. Tissue aluminium concentrations in 4 of the victims were above reference
values: liver 4.7 to 51.7 (reference < 2), bone 7.5 to 88.7 (reference < 2) and cerebral cortex
1.09 to 1.78 (reference 0.14 to 0.22) mg Al/kg.
Two male twins, 32 weeks at birth, received 2500 and 5350 mg total aluminium orally as
antacids and 2.96 and 3.2 mg in total parenteral nutrition (TPN) solutions over 5 months. When
they died at age 149 and 157 days, their bone, brain, liver, and lung, and in one of the two,
kidney, aluminium concentrations were greater than the average values from infants that had
not received i.v. fluids or TPN solution for more than 21 days (Bozynski et al., 1989).
Considering oral aluminium bioavailability of 0.1%, ~ ½ to ⅔of the aluminium that reached
systemic circulation was from the antacids. They received comparable amounts of aluminium
from the TPN solution but the twin that received ~ 2-fold more from antacids had higher
aluminium concentrations in all organs but the brain.
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Aluminium, as the phosphate, was shown to be elevated ~ 10-fold in the synovial fluid, synovial
membrane and articular cartilage of 28 chronic haemodialysis patients, some of whom took 5
to 15 g of aluminium hydroxide daily, compared to patients who had not taken aluminium
(Netter et al., 1984; 1988). Speciation calculations indicate that a major aluminium species in
synovial fluid is the citrate (Silwood & Grootveld, 2005).
Lung, liver and brain aluminium concentrations were greatly elevated (~ 20-, 120- and 20-fold)
in a worker who developed fibrosis and encephalopathy after exposure to aluminium powder
for 13.5 years (McLaughlin et al., 1962). Aluminium levels were elevated in the lung, liver,
spleen and hilar lymph node of a stone mason (Teraoka, 1981).
Gastric mucosal membrane aluminium concentration was elevated in aluminium-consuming
patients with normal renal function and those with renal insufficiency who were predialysis
and those receiving dialysis, compared to patients with normal renal function who were not
consuming aluminium-containing antacids (Zumkley et al., 1984a). The increases paralleled
increases in plasma aluminium, and were attributed to consumption of aluminium antacids.
In a case of Wilson disease, increased urinary clearance of aluminium as well as copper and
increased aluminium content of the liver was observed (Yasui et al., 1979).
The observations of increased serum aluminium during acute infection and concurrent
neurological dysfunction and some deaths suggest infection in humans who have a significant
body burden of aluminium causes aluminium release from its storage sites (Davenport et al.,
1988; Fenwick et al., 2005).
Brain: A review of the literature on the reports of aluminium concentrations in various brain
regions led the authors to conclude that aluminium is generally higher in grey than white matter
(Speziali & Orvini, 2003). Human brain aluminium concentration correlated positively with
age in several studies. Brain aluminium concentrations in 3 subjects aged 25, 43 and 65
averaged 1.59 mg/kg (dry tissue) and 2.74 mg/kg in 6 subjects aged from 75 to 99 years
(McDermott et al., 1979). Brain aluminium levels in 7 subjects from premature to 6 months
old were ~ 0.3 mg/kg (wet tissue), increasing as the age of subjects increased, to ~ 0.7 mg/kg
in 4 subjects 80 to 99 years old (Markesbery et al., 1984). Similarly, brain aluminium levels
increased from ~ 0.2 mg Al/kg (wet tissue) in 21 to 30 year olds to ~ 0.55 mg/kg in > 81 year
olds (Roider & Drasch, 1999). Ten adults 32 to 46 years old were compared to fifteen adults
75 to 101 year old. The aluminium concentrations in the hippocampus and frontal lobe were
0.014 and 0.020 vs. 0.40 and 0.37 mg Al/kg, wet weight, respectively (Shimizu et al., 1994).
The increase in brain aluminium concentrations with age could be due to increased exposure
with age, a decreased ability to remove aluminium from the brain with age, or very slow, or
no, elimination of aluminium from the brain. Patients who had elevated aluminium intake and
who received haemodialysis before successful renal transplantation up to 8 years prior to death
had elevated post-mortem aluminium levels in the brain (McDermott et al., 1978; Reusche et
al., 1996), suggesting accumulation of aluminium during haemodialysis that was slowly, or
not, cleared after establishment of renal function. Using morin, aluminium was visualized in
the disintegrating NFT and senile plaque amyloid core of non-demented elderly subjects. In
normal brain tissue, aluminium was seen in the wall of the capillary vessels of the BBB,
perivascular glial supporting tissues, nuclei of astrocytes, and nuclei and nucleoli of neurons
(Shimizu et al., 1994). However a study of only 4 subjects who died between 58 to 74 years
of age and who had a mean brain aluminium concentration of 0.54 mg/kg wet weight failed to
find an association between age and brain aluminium concentration (Jacobs et al., 1989). The
aluminium concentration in 12 brain regions obtained from 8 neurologically normal subjects
was reported to range from a mean of 58 mg Al/kg, wet weight, in the pons to 196 mg Al/kg
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in temporal cerebrum (Rajan et al., 1997). These very much higher values do not appear to be
correct, perhaps due to contamination or incorrect reporting of the units.
Neuromelanin from human brain was reported to contain 220 mg Al/kg, dry weight (Zecca et
al., 1994).
Patients who received brain surgery for a tumour after consuming an aluminium-rich antacid
for 10 days had 2-fold higher brain aluminium concentration than patients consuming an
antacid low in aluminium (Winterberg et al., 1987a), demonstrating aluminium absorption and
distribution into the human brain in the presence of normal renal function.
A case of generalized amyloidosis showed greater brain aluminium accumulation than seen in
the control or parkinsonism groups, 89.5 mg/kg vs. 17.7 mg/kg and 31.8 mg/kg, respectively
(Yasui et al., 1980).
The CNS shows lower aluminium concentrations than many other tissues, even in the presence
of overt neurotoxicity. Increased brain aluminium concentrations of ~ 4- to 6-fold in rabbits
and somewhat higher increases in victims of dialysis encephalopathy syndrome were
associated with neurotoxicity (Alfrey, 1980; Crapper et al., 1976; Yokel, 1983). Results of the
many studies of aluminium concentration in bulk brain samples and sub-cellular sites of AD
victims inconsistently show elevated aluminium (see Tables 19, 20 and 21). The magnitude of
elevation of bulk brain aluminium, when reported, is generally a few-fold or less in AD victims
than in controls. The inconsistent findings of a small increase in brain aluminium in AD in
relation to the small increase in bulk brain aluminium sufficient to produce neurotoxicity has
hindered the resolution of the role of aluminium in AD. If aluminium is elevated in AD brain,
it is not reflected in CSF aluminium, which has generally not been found to be elevated
(Jagannatha Rao et al., 1999; Kapaki et al., 1993). CSF aluminium concentration was reported
to be higher in patients with virus nephro infections, residual manifestations from brain and
spinal cord trauma, and pain syndromes, than in controls. Blood serum aluminium
concentrations were also reported to be elevated in those with residual effects of brain and
spinal cord trauma (0.014 and 0.012% aluminium in the ash vs. 0.0088% in controls) (Del’va,
1962).
The indigenous people of several western Pacific foci, the Chamorro on Guam, Japanese on
the Kii peninsula of Honshu Island, Japan and the Auyu and Jakai of southern West New
Guinea, developed two syndromes having features of ALS and a parkinsonism-dementia (PD).
From the time this variant of ALS was first identified in 1945 until 1960, its incidence was 50
to 150 times higher than elsewhere in the world (Kihira et al., 2004). It was suggested that a
high aluminium and low calcium and magnesium concentration in the environment contributed
to these syndromes (Yase, 1972). Although the manganese concentrations in the soil, river and
drinking water were greater in ALS than control areas, the manganese content of plants, crops,
livestock and fish was not (Iwata et al., 1976). A specific localization of manganese, aluminium
and calcium was observed in the spinal cord of ALS patients (Iwata et al., 1976). Food was
not found to be high in aluminium and low in calcium, but the soil was high in aluminium
(McLachlan et al., 1989). The aluminium, and calcium, concentration in the brain of victims
of ALS has been reported to be greater than in controls, whereas magnesium was not elevated,
using neutron activation analysis (Yoshimasu et al., 1976; 1980). Brain aluminium
concentrations averaged 33.1 mg/kg in 6 ALS cases and 36.8 mg/kg in 4 PD cases compared
to 17.7 mg/kg in controls, determined by neutron activation analysis. Aluminium in the ALS
and PD groups was statistically greater than in the controls (Yase, 1980). Calcium was also
elevated in the ALS and PD subjects. X-ray microanalysis showed similar calcium, aluminium
and manganese distribution in spinal cord of ALS patients (Yase, 1980). Using EAAS, Traub
et al. (1981) found elevated brain aluminium levels in two Guamian ALS cases to be 1.7 and
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8.9 and in two Guamian PD cases to be 2.0 and 3.9 mg/kg, compared to an average of 1.38
mg/kg in 4 normal subjects. Aluminium, silicon, calcium, vanadium, iron and zinc were
reported to be elevated in the frontal cortex of humans with ALS compared to normal subjects
and patients with parkinsonism (Mizumoto et al., 1983).
Aluminium was significantly increased in 26 CNS regions in 2 of 6 patients with ALS compared
to those in 5 patients without neurological abnormalities. Mean concentrations were 88 and
136 in the two cases vs. 26 and 23 mg Al/kg dry weight in the other 4 cases and controls,
respectively (Yasui et al., 1991b; 1991c).
Using SEM with energy dispersive spectrometry, NFT-bearing neurons from ALS-PD and
non-afflicted patients were found to have a high aluminium concentration (Perl et al., 1982).
Aluminium and calcium were co-localized in the NFT-bearing neurons. Using wavelength
dispersive spectrometry coupled with electron beam X-ray microprobe analysis, aluminium
and calcium were found to be co-localized in the NFTs of two Guamian PD patients but not
in the non-NFT-containing regions of either the PD patients or two control lifelong Guamian
residents (Garruto et al., 1984). Semi-quantitative estimates of the highest concentrations were
7200 and 500 mg/kg calcium and aluminium, dry weight, respectively. Garruto & Yase
(1986) compared silicon distribution in 5 Guamian Chamorros who had PD and in 2 who had
ALS with 2 Guamian and 2 Caucasian normal controls and found a similar distribution,
estimated to be up to 3000 mg/kg, with no detectable silicon in the controls. The average brain
aluminium concentration was higher in 6 Guam PD cases than 7 Chamorro controls (179 vs.
57 mg/kg dry weight) (Yoshimasu et al., 1985). Aluminium and calcium were seen in the
cytoplasm of hippocampal neurons bearing NFTs, using laser microprobe mass spectroscopy
(Perl & Pendlebury, 1986). Aluminium and calcium were found to be associated with NFT-
bearing hippocampal neurons of PD patients, using secondary ion mass spectrometry (Linton
et al., 1987). Using histochemical staining, aluminium was visualized in the hippocampus,
spinal cord and frontal cortex in most of 3 Guamian patients with ALS and 5 with PD who had
NFTs but not in the 5 neurologically and neuropathologically normal Guamian or Caucasian
patients (Piccardo et al., 1988). Staining was observed in the cytoplasm, nucleoli, neuropil,
white matter and some endothelial cells and walls of cerebral vessels. X-ray microanalysis
confirmed the presence of aluminium.
Using neutron activation analysis, aluminium levels were reported to be higher in 3 Guamian
cases than in 4 non-demented controls. The Guamian cases also had high calcium levels in
grey and white matter and low zinc levels in grey matter (Yoshida et al., 1993). Using PIXE,
extremely high aluminium concentrations were reported in lumbar spinal cord and
hippocampus of patients with ALS from Guam and the Kii peninsula of Japan, compared with
those in cases with sporadic ALS and in controls (Yoshida et al., 1997; Yoshida, 1999).
Aluminium concentrations negatively correlated with calcium and magnesium contents in the
birthplace area’s rivers (Yoshida et al., 1997) and positively correlated with iron and copper,
and negatively correlated with zinc, in the neural tissue (Yoshida, 1999).
Toenail aluminium concentrations, measured as an indicator of metal exposure, were not
different between 22 patients with ALS and 40 controls. Median values were 34.5 and 37.5
mg Al/kg, respectively (Bergomi et al., 2002).
Aluminium levels in 4 cases of Parkinson’s disease were compared to those in the 5 patients
without neurological abnormalities in the above cited studies and were found to be significantly
higher in the hippocampal gyrus, caudate nucleus, globus pallidus and substantia nigra as well
as in the liver, kidney and spleen (Yasui et al., 1992). Magnesium, but not calcium, levels were
significantly decreased in these same brain regions, and others as well. However, aluminium
was not significantly different in the frontal cortex, caudate nucleus, substantia nigra, and
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cerebellum of 9 Parkinson’s disease patients or 15 patients with other chronic neurological
diseases compared to 12 controls (Uitti et al., 1989).
Bone: Aluminium concentrations, on a dry weight basis, in the bone of normal humans were
a few-fold higher than those in the brain (Alfrey et al., 1980; Di Paolo et al., 1997), ~ 1 to 3
mg/kg (Nieboer et al., 1995). Human bone aluminium concentration significantly increased
with age in a study of one hundred seventy-two 16-98 year old subjects. It was <0.4 μg/gm dry
bone weight in quartile 1 compared to >1.7 in quartile 4 (Hellström et al., 2005). Aluminium
contamination in parenteral nutrition solutions in patients with normal renal function led to
stainable bone aluminium and osteomalacia (Ott et al., 1983). Oral consumption of aluminium
in drinking water and aluminium carbonate by people with normal renal function led to
detectible bone levels of aluminium (Eastwood et al., 1990; Recker et al., 1977). Bone
aluminium concentrations averaged 6.4 mg/kg dry bone weight in 3 non-dialysis and 125 mg/
kg in 3 dialysis patients (Recker et al., 1977) and 5.6 and 102 mg/kg fresh weight in 2 controls
and 4 patients with dialysis osteomalacia (Zumkley et al., 1984b). Consumption of a total of
~ 18 kg of elemental aluminium in antacids by a 39 year old female with normal renal function
over 8 years led to stainable aluminium on 27.6% of the bone surface, elevated serum and
urinary aluminium, and phosphate-depletion-induced osteomalacia that was attributed to
aluminium (Woodson, 1998).
Dialysis patients had an average increase of brain and bone aluminium concentrations of 5 and
10-fold, respectively (Alfrey et al., 1980; Di Paolo et al., 1997). Those with dialysis
encephalopathy had brain and bone aluminium concentrations about 10- and 85-fold higher
than those of controls, respectively (Alfrey et al., 1980). Considerably more aluminium enters,
and resides in, the human skeletal system than in the CNS, due to the larger mass of the former.
Aluminium was found to be localized at the mineralization front and osteoid of bone (Boyce
et al., 1981; Cournot-Witmer et al., 1981; Ott et al., 1982; Schmidt et al., 1984). The aluminium
was within 2μm of the calcified bone/osteoid interface at a concentration 20 to 40-fold greater
than the whole bone aluminium concentration (Boyce et al., 1981).
Six patients who received aluminium-contaminated TPN solutions for 6 to 72 months had bone
aluminium concentrations of 14 to 265 mg/kg, well above the normal range, as well as elevated
plasma aluminium (98 to 214 μg/l) and urinary aluminium outputs (Klein et al., 1982). Bone
aluminium concentration averaged 2 mg/kg dry weight in infants who received limited i.v.
therapy compared to 20 in infants who received ≥ three weeks of i.v. therapy (Sedman et al.,
1985).
As bone is a major site of aluminium storage, prolonged urinary aluminium excretion may
reflect a prolonged t½ of aluminium in bone. A t½ of 7 years was estimated in one human who
had received an i.v. injection of 26Al citrate 3.2 years earlier (Priest et al., 1995). An updated
estimate in this individual, based on whole-body monitoring collected up to 3000 days after
the injection, suggests the t½ is ~ 50 years (Priest, 2004). This prolonged whole-body t½ may
largely reflect the t½ of aluminium in bone.
Clinical evidence suggested that PTH had a protective effect against aluminium-induced bone
disease, and encephalopathy (Cannata et al., 1988). Bone aluminium did not correlate with
PTH levels in uraemic patients (Alfrey et al., 1979). Subtotal PTX of 10 dialysis patients who
had refractory secondary hyperparathyroidism resulted in a significant increase of bone
aluminium in 6 of the 7 consuming aluminium (De Vernejoul et al., 1985). These results are
not consistent with observations in animals (see Toxicokinetics, Distribution (Including
Compartmentalization), Animal Studies).
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Aluminium-containing implants have been implicated as a cause of encephalopathy, associated
with elevated CSF, serum and urine aluminium concentrations (Hantson et al., 1994; Renard
et a., 1994). Using PIXE, it was shown that aluminium uniformly leaked from the site of an
implanted aluminium-containing alloy into surrounding bone (Passi et al., 2002).
It has been suggested that the accumulation of aluminium in bone and liver protects patients
from the toxic effect of aluminium in other organs (Berend et al., 2001).
Hair: Hair has been used to estimate the body burden and to indicate excessive exposure to
metals since the 1960s (Villain et al., 2004). For example, hair has been shown to reflect
methylmercury exposure (Johnsson et al., 2005) and to have a 1:270 ratio with blood mercury
(IPCS, 1990). The validity of hair to predict the aluminium body burden has not been well
established. There can be additional problems with the analysis of hair for metals; procedures
for collection have not been standardized. Although hair has been shown in some studies to
correlate with other indicators of body burden, it is seldom the preferred tissue for this purpose;
commercial panels that test hair for multiple metals have questionable validity (Kales &
Goldman, 2002; Villain et al., 2004).
Aluminium was shown to be taken up into human hair from aqueous solution (Wilhelm et al.,
1989a). Normal hair aluminium concentration was reported to be < 0.24 to 67 mg/kg in 194
people (Imahori et al., 1979); 6.5 mg/kg in English samples (Alder et al., 1976); 3.7 for US,
8.8 mg/kg for rural Japan, 11.9 mg/kg for Hong Kong and 13.6 mg/kg for samples from Tokyo
(IAEA, 1978) and 15 to 18 mg/kg in samples obtained in Kentucky, US, depending on the
method used to wash the samples to remove surface contamination (Yokel, 1982). A reference
value for aluminium in hair of 0.1 to 36 mg/kg was derived from a literature review of studies
published in the prior 30 years (Caroli et al., 1994).There are a few cases reporting elevated
hair aluminium in children with emotional problems (Rees, 1979), but the results could be due
to contamination. Unexpectedly high aluminium concentrations were observed in the hair of
patients with neurological and other disorders, which was thought to be due to dolomite in
many of the cases (Roberts, 1981).
The aluminium concentration in hair of 6 control subjects was reported to be 97 ± 25 mg/kg,
118 ± 46 mg/kg in 11 haemodialysis patients and 370 ± 266 in 8 non-dialyzed chronic renal
failure patients (Tsukamoto et al., 1979). Hair aluminium concentration positively correlated
with AUC and duration of dialysis. Similarly, hair aluminium concentrations were higher in
non-dialyzed and dialyzed chronic renal failure patients than in controls, whereas
haemofiltered chronic renal failure patients did not have higher concentrations of hair
aluminium (Marumo et al., 1984). The elevated aluminium concentrations were attributed to
the use of aluminium-contaminated dialysate. Hair aluminium was 10.5 mg/kg in 22 male and
10.1 in 29 female long-term haemodialysis patients who had elevated plasma and bone
aluminium concentrations (Winterberg et al., 1987b). There was a significant correlation
between hair and bone aluminium in the males, but not the females. Hair aluminium in 18
chronic haemodialysis patients who received an average of 6.3 kg of an aluminium-containing
phosphate binder that released aluminium averaged 15.4 mg/kg compared to a hair
concentration of 10.5 mg Al/kg in a group of 18 chronic haemodialysis patients who received
an average of 6.6 kg of an aluminium-containing phosphate binder that released less aluminium
(Winterberg et al., 1987b). The latter group of patients had lower aluminium in their plasma
(34.6 vs.101.4 μg/L) and bone (11.6 vs. 26.2 mg/kg). Higher hair aluminium concentration
was seen in 39 haemodialyzed patients (6.1 ± 2.8 mg/kg), than in 49 control subjects (3.4 ±
1.6) mg/kg (Chappuis et al., 1988). Hair aluminium did not correlate with serum or bone
aluminium, leading the authors to conclude that hair aluminium levels do not predict
aluminium-induced osteomalacia (Chappuis et al., 1989). The aluminium hair concentration
of 12 home haemodialysis patients tested before introduction of water treatment by reverse
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osmosis was above that in controls, whereas it was not elevated in 16 patients undergoing
continuous ambulatory peritoneal dialysis (Wilhelm et al., 1989b). Because hair aluminium
concentration did not relate to daily or cumulative aluminium intake or to bone or plasma
aluminium concentrations, the authors concluded that hair aluminium is of very limited value
for diagnosis of aluminium exposure.
The concentration of aluminium in the hair of 10 AD patients averaged 7.5 mg/kg compared
to 6.2 in 10 age-matched controls (Shore & Wyatt, 1983). In another study, hair aluminium
concentration in 35 cases of AD was significantly lower than in 71 comparably-aged controls
(Kobayashi et al., 1989). There was no significant effect of age on hair aluminium levels in
either group (Kobayashi et al., 1989).
Milk: A literature review of studies published the previous 30 years suggested the reference
value was 39 to 250 μg/L (Caroli et al., 1994). Another review concluded the value was 4 to
65 μg Al/L (American Academy of Pediatrics, 1996). Other studies reported means of 30 μg/
L (Weintraub et al., 1986), < 5 to 45 (median 14) μg/L (Koo et al., 1988), 49 μg/L (Simmer et
al., 1990), 3 to 79 μg/L (Baxter et al., 1991), a median of 161 μg/kg (Coni et al., 1990), a mean
of 40 μg/L (Bougle et al., 1992), 9.2 μg/L (Hawkins et al., 1994), a mean of 86 μg/L (Vinas et
al., 1997) and a median of 67 μg/L (Krachler et al., 2000). One report found a mean of 380
μg Al/L (Mandic et al., 1995) and another a mean of 350 μg Al/L (Bergerioux & Boivert,
1979); these two values are suspect compared to the others. Speciation calculations suggest ~
88% of aluminium in human (and bovine) milk at pH 6.8 is Al(citrate)(OH)2-2 and 11% is Al
(citrate)(OH)-1, suggesting to the authors that little would be absorbed due to the net charge
(Findlow et al., 1990). However, this assumes no change in speciation in the GI tract.
Elimination and Excretion
Animal studies
Urinary excretion: The primary organ for aluminium elimination is the kidney, which is
believed to eliminate > 95% of excreted aluminium. Dietary intakes of 3.5 to 11.5 mg Al/day
result in a daily excretion of 4 to 12 μg (Nieboer et al., 1995). Many of the reported rates of
aluminium clearance are consistent with the glomerular filtration rate (GFR) when the free
fraction is considered. Kovalchik et al. (1978) found renal aluminium clearance to be 50% of
inulin clearance (GFR) in the dog, over a range of plasma aluminium concentrations of 80 to
600 μg /L. As this range is below the saturation of Tf by aluminium, the aluminium should be
≥ 90% bound to Tf. An aluminium clearance of 116 mL/hr was reported in 18 to 24 kg dogs,
or ~ 5.5 mL/kg/hr, after an i.v. aluminium injection that produced blood aluminium
concentrations decreasing from ~ 19,000 to ~ 14,000 μg /L (Henry et al., 1984). These are well
above the saturation of Tf. The authors found that the renal contribution to plasma aluminium
clearance correlated well with GFR in the dog. Systemic clearance in the rabbit was found to
be 53 and 72 mL/kg/hr, consistent with GFR, based on the GFR and the free fraction of
aluminium in plasma (Yokel & McNamara, 1985; 1988). A renal aluminium clearance of 36
to 60 mL/hr was seen in ~ 0.2 kg rats after an aluminium chloride infusion that produced a
serum aluminium concentration of 2000 to 10,000 μg/L (Burnatowska-Hledin et al., 1985).
Renal aluminium clearances of 49.6, 44.4 and 41.8, and of 18.4, 18.4 and 17.2 mL/kg/hr were
reported after 0.1 or 1 mg Al/kg injections in the rat, respectively, that resulted in serum
aluminium concentrations of several thousand decreasing to several hundred μg /L and ~
20,000 to 30,000 decreasing to ~ 8000 μg /L (Pai & Melethil, 1989; Xu et al., 1991; 1992a).
The lower clearance with the greater aluminium concentration may be due to formation of non-
ultrafilterable aluminium species.
Several animal studies suggested that aluminium clearance decreases and t½ increases with
increased aluminium concentration. For example, renal aluminium clearance in the rat after an
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i.v. injection of aluminium (8.1 mg/kg) that produced serum aluminium concentrations of
110,000 to 400,000 μg Al/L, was reported to be 4.3 mL/kg/hr (Gupta et al., 1986). Similarly,
renal aluminium clearance was reported to decrease from 78 to 3.6 mL/hr as aluminium plasma
concentration increased from 40 to 12,400 μg/L (up to 460 μM Al) (Hohr et al., 1989). This
may be due to the formation of non-filterable aluminium complexes or aggregates at the higher
aluminium concentrations, reducing the plasma filterable aluminium fraction (Lote et al.,
1992; Xu et al., 1991; Yokel & McNamara, 1988). The very high aluminium concentrations
achieved by Gupta et al. (1986) of 4075 to 16,300 μM far exceed the Tf and citrate aluminium
binding capacities of ~ 45 and 100 μM aluminium. It is likely that the aluminium was no longer
in solution due to binding by phosphate, which is 1100 μM in serum, or that the aluminium
was present as aluminium hydroxides.
The mechanisms of renal aluminium handling are not well understood. Burnatowska-Hledin
et al. (1985) interpreted results of their micropuncture studies to suggest that most of the filtered
aluminium was reabsorbed. In contrast, Monteagudo et al. (1988) interpreted their results to
suggest aluminium excretion in the distal nephron. Micropuncture of Bowman’s space, the late
proximal convoluted tubule, and early distal tubule was used to determine aluminium
concentration vs. arterial blood and urine in the rat. Aluminium was given in a 3% sodium
citrate solution i.v. as doses that produced plasma concentrations of 2.9 to 10 mg/L, a
supraphysiological concentration that would exceed the ability of Tf to bind the aluminium,
which presumably was present in plasma as the citrate. The results suggested aluminium citrate
is filtered at the glomerulus and ~ 25% reabsorbed in the loop of Henle (Shirley et al., 2004).
Evidence has been provided that citrate may enhance renal aluminium elimination (Van Ginkel
et al., 1990). Lote et al. (1992) found that citrate increased the percentage of aluminium that
was ultrafilterable, probably due to formation of aluminium citrate, and enhanced excretion.
Others have reported that citrate increased urinary aluminium excretion (Cochran et al.,
1994; Maitani et al., 1994), although Cochran et al. (1994) did not find an increase in the
ultrafilterable fraction. Urinary silicon and aluminium excretion correlated well, suggesting
they may be cleared by a common pathway or as a complex, such as a hydroxyaluminosilicate
(Bellia et al., 1994).
Biliary excretion: Biliary aluminium excretion has been reported to account for 0.2% of total
aluminium elimination in the dog (Kovalchik et al., 1978), 1.5% in the rabbit (Yokel et al.,
1996b), < 0.5 and 1.3% in the rat in the first 12 hr (Xu et al., 1991) and 0.7% in the rat (Yokel
et al., unpublished results). These values are in agreement with some of the results from the
human (see Toxicokinetics, Elimination and Excretion, Human Studies, Biliary Excretion).
Bile aluminium concentration did not increase with increasing oral aluminium doses of 0, 0.2,
0.4 and 0.8 mmole as the lactate given to rats with an average weight of 191 g, suggesting that
the higher doses exceeded the ability to excrete aluminium in the bile (Sutherland et al.,
1996). Enterohepatic recirculation of aluminium has not been investigated. Considering the
very low percentage of aluminium absorbed from the GI tract, it is anticipated that
enterohepatic recirculation would not be great. A significant increase of biliary excretion of
aluminium and Tf was seen in rats that received 5 mg Al/kg i.v. for 14 days (Klein et al.,
1993). These results suggest aluminium bound to Tf may be taken up by hepatocytes and, if
excreted as a complex, might be well absorbed because Tf may facilitate aluminium absorption
(Jäger et al., 1991).
Elimination rate: Clearance of aluminium from the lung of rats that inhaled fly ash was very
slow. The lung concentration decreased from a mean of 53 mg Al/kg immediately after a one-
month aluminium exposure, to 27 mg Al/kg six months later, and to 25 mg Al/kg ten months
later (Matsuno et al., 1986). The slow clearance was attributed to the solubility of the aluminium
in the fly ash. Similarly, after 20 weekly intratracheal installations of 1 mg Al/kg as 1.2 μm
MMAD aluminium oxide, only 9% was cleared from the lungs in the subsequent 19 weeks
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(Schlesinger et al., 2000). A more rapid clearance of 1 to 5 μm diameter coal fly ash particles
from mouse lungs after intratracheal administration was described. The aluminium
concentration decreased from 980 mg/kg at 1 wk to 519 mg/kg 15 weeks later (Ogugbuaja et
al., 2004).
Following inhalation of particles of Montmorillonite (a complex aluminium magnesium
silicate clay) by dogs, rats and mice, initial clearance was primarily by the GI tract. Long-term
clearance of particles in dogs was predominantly to lung-associated lymph nodes in rats and,
in mice, by mechanical clearance by the GI tract (Snipes et al., 1983). The t½ for the clearance
of particles that went to the lung-associated lymph nodes of dogs was 3500 days and, from the
GI tract, was 6900 days. For mice and rats, the long-term t½s were 490 and 690 days,
respectively.
The aluminium concentration was determined in the reactive zone of muscle, which contained
macrophage aggregation and lymphoid infiltration, 3 and 6 months after a single i.m. vaccine
injection to Cynomolgus monkeys (Macaca fasciculata). The vaccines contained aluminium
oxyhydroxide-adjuvated or aluminium phosphate-adjuvated diphtheria and tetanus. At 3
months, the aluminium concentration was 14,280 and 2860 mg Al/kg and at 6 months 11,000
and < 150 mg Al/kg, following the aluminium oxyhydroxide-adjuvated or aluminium
phosphate-adjuvated vaccine injections, suggesting more rapid dissolution of aluminium from
aluminium phosphate than from aluminium oxyhydroxide adjuvant (Verdier et al., 2005).
These results are consistent with the more rapid absorption of aluminium from aluminium
phosphate than from aluminium hydroxide reported in rabbits (see Toxicokinetics, Absorption,
Animal Studies, Intramuscular).
The rate of aluminium elimination from the entire organism has been determined in animals
and humans. The apparent t½ increased with increased duration of sampling after acute
aluminium loading of rabbits, suggesting the presence of one or more compartments with very
long t½ s. The t½ of aluminium elimination, based on studies in which samples for aluminium
determination were collected for ≤ 24 hr, were initially reported to be 1.35 hr in the rat after
i.v. injection of aluminium chloride (Wachi & Aikawa, 1975); 5.3 hr after i.v. injection of 8.1
mg Al/kg to the rat, based on sampling to 10 hr (Gupta et al., 1986); 1.2, 1.3, and 1.08 and 2.4,
2.1 and 4 hr after i.v. injection of 0.1 or 1 mg aluminium (as the sulphate)/kg in the rat, based
on sampling to 24 hr (Pai & Melethil, 1989; Xu et al., 1991; 1992b); ~ 2 hr from blood after
oral aluminium (0.25 to 1 mmole/kg) and citrate (~ 3.4 mmole/kg) and 4.5 to 7.5 hr from liver
based on sampling up to 6 hr in the rat (Sutherland & Greger, 1998). Similar values were
obtained in the mouse; 1.5 hr after i.p. injection of 54 mg Al/kg as aluminium gluconate or
lactate with sampling up to 1.5 hr (Leblondel & Allain, 1980). Similar results were also
obtained in rabbits: 2.1 and 3.8 hr after injection of 40 and 80 μmoles Al/kg (1.1 and 2.2 mg
Al/kg) as the lactate in lactating rabbits and 8.6 hr after injection of 40 μmoles Al/kg to 17 to
21 day old suckling offspring with sampling up to 24 hr (Yokel & McNamara, 1985). Studies
in the dog also provided similar results: ~ 1.5 to 2 hr after 1 or 2 mg aluminium, as the chloride
given i.v., when studied up to 2 hr (Kovalchik et al., 1978) and 4.6 hr after i.v. injection of 1
mg aluminium (as the chloride)/kg and sampling to 2.5 hr (Henry et al., 1984). When sampling
time increased, longer t½ were observed. When blood was obtained to 48 hr, t½ of 27 and 14
hr were seen in normal and renal-impaired rabbits, respectively, that received 100 μmoles Al/
kg (2.7 mg Al/kg) as the lactate (Yokel & McNamara, 1988). A similar study, in which blood
was obtained to 72 hr, resulted in a t½ of 43 hr in normal rabbits (Yokel & McNamara,
1989-1990). An initial t½ of 102 to 119 minutes was reported in rats after an oral aluminium
dose, but samples were only obtained up to 360 minutes later (Sutherland & Greger, 1998),
precluding the ability to observe longer t½.
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To determine the t½ of aluminium elimination from organs, adult rabbits were given a single
i.v. infusion of 200 μmoles Al/kg (as the lactate) over 6 hr and then terminated up to 128 days
later. The t½ of aluminium was estimated to be 113, 74, 44, 42, 4.2 and 2.3 days in spleen,
liver, lung, serum, kidney cortex, and kidney medulla, respectively. Another t½ in the kidney
greatly exceeded 100 days (Yokel & McNamara, 1989). The whole organism elimination t½
was estimated to be 8 to 24 days in serum, kidney, muscle, liver, tibia and spleen of rats (Greger
et al., 1994). The brain aluminium t½ was not determined in either of these studies; this has
been done using 26Al (see below). The aluminium concentration in rat tibia, kidney and brain,
above that in controls, produced by 30 days of aluminium oral administration, decreased by
88, 85 and 66% respectively (Rahnema & Jennings, 1999), suggesting corresponding
elimination t½ of ~ 10, 11 and 18 days. Liver aluminium concentration increased during the
30 days after completion of aluminium administration.
The t½ of aluminium elimination significantly increased following an i.v. injection of 1 mg Al/
kg compared to injection of 0.1 mg/kg (Xu et al., 1991). This can be explained by the much
lower percentage (5%) of the 10,000 μg Al/L in the plasma that was ultrafilterable after the 1
mg Al/kg injection compared to a greater percentage of ultrafilterable aluminium (22%) of the
1000 μg Al/L in the plasma achieved after the injection of 0.1 mg Al/kg (Xu et al., 1991).
Aluminium persists for a very long time in rat brain following systemic injection of very small
doses of 26Al. Rat brain 26Al increased slightly from days 5 to 35 after an i.p. 26Al injection
(Kobayashi et al., 1990), suggesting a lack of brain aluminium elimination. However, the
possibility of 26Al precipitation and delayed absorption from the peritoneal cavity, the small
number of subjects (single rats 10, 15, 25 and 35 days and 2 rats 5 days after dosing) and the
lack of a non-26Al dosed group to control for cross-contamination, are of concern. A subsequent
study found no decrease in brain 26Al concentration up to 270 days after 26Al injection (Yumoto
et al., 1997). When 26Al was given i.v. to rats that were euthanatized 0.17 to 256 days later,
the t½ of brain aluminium was estimated to be ~ 150 days (Yokel et al., 2001a). As brain
samples were not obtained for at least 3 t½, this estimated terminal t½ of aluminium in the brain
is not expected to have a high degree of accuracy. Offspring of rats that were given 26Al
injections daily from day 1 to 20 postpartum were weaned on day 20 and sacrificed on days
40, 80, 160, 320 or 730 postpartum. Aluminium concentrations decreased over the 730 days
in all tissues (Yumoto et al., 2003). At postpartum day 730, brain 26Al had decreased to ~ 20%
of that seen at weaning (day 20 postpartum). The authors did not determine the t½ of aluminium
elimination. Calculations conducted for the current review using RSTRIP (Fox & Lamson,
1989) suggest the elimination t½s were ~ 13 and 1635 days in brain. There is little published
information on allometric scaling of metal elimination rates that could be used to extrapolate
these results from the rat to the human. 150 days is ~ 20% of, and 1365 days exceeds, the rat’s
normal life span. For comparison, the whole-body t½ of aluminium in the human was estimated
to be 50 years (Priest, 2004) (see Toxicokinetics, Elimination and Excretion, Human Studies,
Elimination Rate).
After weanling rats were given a single oral dose of 0.8 mmole aluminium, as lactate, with
0.75 mmole citrate, the aluminium t½ was found to be 16 to 24 days in bone, liver, muscle, and
spleen and 8 days in kidney (Greger et al., 1994). The t½ of aluminium elimination from tibia
and kidneys positively correlated with the age of rats that received a single gavage of 0.8 mmole
aluminium given with 0.75 mmole citrate and were sacrificed 1 to 44 days later (Greger &
Radzanowski, 1995). The half lives of aluminium in rats that were 2, 8 and 19 months at dosing
were 38, 58 and 173 days in tibia and 9, 12, and 16 days in kidneys. The estimate of the tibial
aluminium t½ cannot be considered very definitive because results up to ~ 3 t½ are required
for good t½ determination. These results suggest bone aluminium levels should increase with
age due to continuous exposure. The t½ of aluminium was significantly greater in liver, muscle
and serum of anaemic rats (Greger et al., 1994).
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Following a single i.p. injection of 26Al and euthanasia up to 270 days later, liver 26Al was
found to decrease considerably from day 5 to 25, then to remain rather constant before
beginning to increase from day 75 to 270 (Yumoto et al., 1997). Blood 26Al decreased
dramatically from ~ day 35 to 75 then remained fairly constant to day 270.
No decrease of bone aluminium concentration was seen over 6 weeks following aluminium
loading in rats that had undergone 5/6 nephrectomy prior to aluminium exposure (Elorriaga et
al., 1992). Nor was there an observable decrease of aluminium in bone, liver or brain in rats
up to 30 days after oral 26Al administration (Jouhanneau et al., 1997b). Calculations conducted
for the current review using RSTRIP, of the t½ of aluminium elimination in the bone of
offspring of rats that were given 26Al injections daily from day 1 to 20 postpartum from the
results of Yumoto et al. (2003) suggest t½ of ~ 7 and 520 days in parietal bone. After 730 days,
the amount of 26Al remaining in the liver and kidneys was ~ 2% of that seen at weaning. For
liver and kidney, the t½ were ~ 5 and 430 days and ~ 5 and 400 days, respectively. In blood
the values were ~ 16 and 980 days.
Aluminium has been found at the site of s.c. aluminium adjuvant injection to mice and guinea
pigs up to 1 year later (Gupta, 1998).
The t½s of aluminium elimination from liver, bone and kidney after a single oral dose of 0,
0.25, 0.5 or 1 mmole Al/kg in rats did not provide any evidence that aluminium elimination is
aluminium-concentration dependent (Sutherland & Greger, 1998).
Chelators can increase aluminium clearance into urine, bile and dialysate (Yokel et al.,
1996a; 2002). Citrate and perhaps silicon appear to form small molecular weight species with
aluminium that can be excreted in the presence of adequate renal function, potentially
protecting against the accumulation and toxicity of absorbed aluminium.
Human studies—The primary route of aluminium elimination is via the kidneys, and
secondarily via bile. Sweat collected during exercise from 15 normal healthy subjects had a
mean aluminium concentration of 15 μg/L, which was similar to their laboratory adult reference
values for UK residents of 11 μg/L (Omokhodion & Howard, 1994). Saliva aluminium
concentrations in 6 children aged ~ 10 from North Italy averaged 54 μg/L, with a median of
43 μg/L (Sighinolfi et al., 1989). Speciation calculations suggested 94% of aluminium in saliva
would be associated with phosphate (Duffield et al., 1991). There are no reports addressing
whether aluminium in sweat or saliva reflects aluminium exposure or body burden.
Seminal fluid aluminium concentrations have been reported to average 3.3 mg/kg in 50 subjects
(Yamamoto et al., 1959), 0.54 mg/kg in 27 refinery and polyolefin factory employees and 0.87
mg/kg in 45 sperm donor candidates (Hovatta et al., 1998). Although there was no significant
difference between the controls and industrially-exposed subjects for seminal plasma
aluminium concentration, spermatozoa aluminium was significantly higher in the controls than
the industrially-exposed subjects (2.52 vs. 0.93 mg/kg) (Hovatta et al., 1998). The seminal
AUC in 64 apparently healthy 21 to 35 year old men was significantly higher in those with
low sperm viability, averaging 1.01, 0.59 and 0.18 mg/L in the 18, 26 and 20 subjects with
low, medium and high sperm viability, respectively (Dawson et al., 1998). Seminal plasma
aluminium concentrations averaged 0.46, 2.0, 1.53 and 0.27 mg/L in 50 adults working in a
medical centre, metal ore smelter, petroleum refinery and chemical plant, respectively (Dawson
et al., 2000). The authors did not report aluminium in other biological fluids or tissues or the
work environment to show if seminal plasma reflects body burden or occupational exposure.
Urinary excretion: The kidneys excrete > 95% of eliminated aluminium, presumably as the
citrate. The urinary excretion time of aluminium, as the citrate, into the urine was calculated
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using the biokinetic model described in Toxicokinetics, Pharmacokinetic Modelling to be 0.4
hr in healthy, and 1.7 hr in patients with chronic renal failure, respectively (Steinhausen et al.,
2004).
It has been concluded that humans who consume a normal diet, take no medications containing
aluminium, and who have normal renal function excrete 0.15 to 0.45 μmole (4 to 12 μg)
(Nieboer et al., 1995), < 20 μg (Wilhelm et al., 1990) and < 50 μg Al/day in urine (Greger &
Sutherland, 1997). Other studies reported 24 hr urinary Al excretion of ~ 0.2 μmoles in 21 to
34 year olds (Reffitt et al., 1999) and 0.7, 1.7 and 2 subjects averaging 22, 48 and 69 years old
(Morie et al., 1996). Based on published studies during the preceding 30 years, a reference
value of 2.3 to 110 μg/L was established (Caroli et al., 1994). Mean serum and urine aluminium
levels in 44 non-exposed persons who did not use antacids were 0.06 and 0.33 μM (1.6 and
8.9 μg/L) (Valkonen & Aitio, 1997). Median urine aluminium concentration was 3.3 μg/L in
67 office workers who had not been exposed to aluminium (Liao et al., 2004). Mean urinary
aluminium excretion/mmole of creatinine was 0.80, 0.78 and 0.77 μmole in pre-term infants
born at gestational age 28 to 32 weeks, pre-term infants born at gestational age 33 to 36 weeks,
and full-term infants (mean 39 weeks), respectively (Bougle et al., 1992). Urinary aluminium
excretion averaged 0.76 μmole/mmole creatinine in those that received parenteral nutrition
compared to 0.47 μmole/mmole creatinine in those that did not (Bougle et al., 1992).
Following oral consumption of 27Al-containing antacids, urinary aluminium levels increased
to a greater extent than did those of serum aluminium, suggesting urine is a better indicator of
current or very recent aluminium exposure. For example, after consumption of 2.2 g aluminium
in antacids, serum aluminium concentration increased 1.3 to 2.8-fold and urine aluminium
concentration increased 3 to 34-fold (Kaehny et al., 1977). The increases in both serum and
urinary aluminium were less with an aluminium phosphate product than with aluminium
hydroxide-, aluminium carbonate- and dihydroxyaluminium aminoacetate-containing
products. Similarly, after aluminium-containing antacid consumption, serum aluminium
concentration increased ~ 2.4-fold and urine aluminium concentration increased ~4.5-fold
(Gorsky et al., 1979). Urine concentration increased to a greater extent and remained elevated
for a longer time than did serum aluminium concentration after oral administration of
aluminium (Williams et al., 1986). Increasing aluminium antacid dose increased urinary, but
not serum, aluminium levels (Nagy & Jobst, 1994).
Nine patients who received aluminium contaminated TPN solutions for 6 to 72 months had
daily urinary aluminium outputs of 90 to 3830 μg, well above the normal range, as well as
elevated plasma aluminium (23 to 214 μg/L) and bone aluminium concentrations (Klein et al.,
1982).
Recent occupational aluminium exposure has been reported to cause increased urinary, and
sometimes serum, aluminium levels. Occupational exposure to aluminium fumes and dusts
produced a marked increase in urinary, but very little increase in serum, aluminium levels
(Mussi et al., 1984). Occupational exposure of 235 workers to median respirable and total
aluminium at concentrations of 25 and 100 μg/m3, respectively, was associated with only
borderline changes in serum aluminium but significantly higher pre- and post-shift urine
aluminium levels than seen in those of 44 controls (Gitelman et al., 1995). Mean plasma
aluminium concentrations were 4.6 to 25.1 μg/L in potroom workers from 1981 to 1989
compared to 1.8 μg/L in 24 controls in 1988 (Schlatter et al., 1990; Schlatter & Steinegger,
1992). Although serum aluminium levels did not change in response to occupational aluminium
inhalation, there was a significant correlation between mean weekly aluminium concentrations
in air and excretion in urine (Drabløs et al., 1992). Median plasma and urine aluminium
concentrations were 4.3 and 7.3 μg/L, respectively, in 30 non-exposed controls, whereas
workers exposed an average of 151 months to aluminium powder with a mean ambient air
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concentration of 12.1 mg/m3 had values of 8.6 and 110 μg Al/L (Schmid et al., 1995), showing
a greater elevation in urine than blood from the exposure. Similarly, median serum and urine
aluminium concentrations were 0.18 μM (4.9 μg/L) and 2.4 μM (65 μg/L), respectively,
suggesting greater urine than serum elevation above accepted levels in healthy humans
(Hanninen et al., 1994). Blood and urine aluminium positively correlated in 103 exposed
workers, but exposure did not significantly increase either (Liao et al., 2004). Workers exposed
to mean concentrations of 0.036, 0.35 or 1.47 mg Al/m3 showed significant, and exposure-
dependent, increases of urine aluminium (33, 67 and 133 μg/L, respectively, compared to
controls which had 24 μg Al/L), but only the group exposed to the highest concentrations of
aluminium showed significantly elevated serum aluminium levels (4.1, 4.8 and 7.2,
respectively, compared to the control of 4.8 μg Al/L). These results suggested to the authors
that only urinary aluminium is a practical index of exposure to aluminium above 0.35 mg Al/
m3 (Rollin et al., 1996). By studying aluminium potroom workers before and after occupational
exposure, Rollin et al. (1996) found an increase in serum aluminium concentration from 3.3
μg/L before exposure to ~ 6 μg/L after 1 year when it reached a plateau, and a continual increase
of urinary aluminium from 24 μg/L before to ~ 48 μg/L after 2.5 years. In this study, the average
of the median airborne aluminium concentrations was only 0.04 mg Al/m3, and the respirable
fraction only 44% (Rollin et al., 2001). Similarly, three workers were exposed for 6 months to
dust containing 3.3 Al/m3 in the air or for 4 months to fumes containing 3.9 mg Al/m3. They
showed no consistent elevation of plasma aluminium above that of 10 non-occupationally
exposed healthy subjects (mean 6.6 μg/L), whereas urine aluminium was consistently elevated
after a work shift, averaging 97 μg Al/L, compared to the beginning of the shift, which averaged
46 μg Al/L. Urine aluminium was much above that of the controls, which averaged 4.6 μg Al/
L (Mussi et al., 1984). Forty-four aluminium welders who had an average of 11.4 years of
exposure, which averaged 5.6 and 4.5 mg Al/m3 in 1999 and 2001, had median urinary and
plasma aluminium concentrations of 130 to 153 and 9.6 to 14.3 μg/L, respectively (Buchta et
al., 2005). Plasma aluminium concentrations increased on average ~ 20 to 35% after, compared
to before, a shift, but urinary aluminium concentrations did not increase.
There are a number of studies in which urinary, but not serum, aluminium was measured. The
median urinary aluminium concentration in workers exposed to aluminium fumes and dusts
in Finland from 1992 to 1997 was ~ 0.8 μM (~ 22 μg/L), compared to the upper reference limit
for controls of 0.6 μM (16 μg/L) (Kallio et al., 1999). Sixty-seven workers with 2 to 34 years
work history exposed to a mean of 0.35 to 0.4 mg aluminium oxide/m3 had a mean urinary
aluminium concentration of 42.9 μg/L compared to 20.3 μg/L in 57 controls (Sinczuk-Walczak
et al., 2003). Twenty male electrolyzers in the electrolysis department of an aluminium foundry
who were exposed to aluminium oxide had a mean urinary aluminium concentration of 56.8
μg/L whereas 55 others in the same department who were crane operators, metallic chargers,
locksmiths, and wireman had mean values of 25 to 35 μg/L (Trzcinka-Ochocka et al., 2005).
Urinary aluminium concentrations in the control group of 57 wood-shop workers in the same
foundry averaged 20 μg/L. A positive relationship was found between urinary aluminium
concentrations after a work shift, air aluminium concentrations and duration of exposure
(Elinder et al., 1991; Sjögren et al., 1988).
Most urine aluminium outputs have been reported as concentration or daily output, and have
not been normalized to creatinine. Schlatter & Steinegger (1992) noted that urinary aluminium
clearance is dependent on urine production whereas creatinine clearance is quite constant,
making normalization of urine aluminium output to creatinine clearance not appropriate.
Two, five and 11 months after discontinuation of consumption of 6 g aluminium taken as an
antacid over 8 years by a 39-year-old female, urinary aluminium levels were 270, 93 and 49
μg/L, respectively (Woodson, 1998). Serum aluminium 11 months after discontinuation of
aluminium consumption was 68 μg/L, which is also considerably above normal. Two
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aluminium welders with 20 and 21 years of exposure had urinary aluminium levels of 107 and
351 μg Al/L (Elinder et al., 1991). Urinary aluminium was also elevated for years after
termination of this occupational aluminium exposure.
Median urine aluminium was 2.4 μM (65 μg/L) in MIG welders exposed for 4 years (Hanninen
et al., 1994), 22 μg/L in workers exposed > 10 years (Sjögren et al., 1996a), 40 μg/L in
aluminium welders exposed for 8 years (Bast-Pettersen et al., 2000), 22 μg/L in aluminium
welders with 15 years exposure (Iregren et al., 2001), and 58 μg/L in 1999 and 52 μg/L in 2001
in aluminium welders with > 6 years exposure (Buchta et al., 2003). Akila et al. (1999) studied
two groups of aluminium welders who had mean urinary aluminium concentrations of 2.25
and 9.98 μM (61 and 270 μg/L). The mean serum aluminium concentration in 55 workers in
an aluminium factory was reported to be 72.7 μg/L compared to 31.1 μg/L in 30 controls (San
et al., 1997). Although significantly elevated in the aluminium workers, the control values are
well above the normal range, suggesting these values may not be accurate.
Citrate did not increase urinary aluminium levels in the absence of concurrent aluminium
administration (Nordal et al., 1988a). Humans consuming 5 mg of fluoride showed increased
fluoride and aluminium in urine. Aluminium may have come from endogenous stores (Chiba
et al., 2002).
Renal aluminium and silicon excretion following renal transplantation in 15 patients generally
correlated, suggesting clearance by the kidney by a similar mechanism or as a complex, such
as a hydroxyaluminosilicate species (Bellia et al., 1994). Renal excretion of aluminium,
following consumption of 600 μmole silicic acid and 2.67 μmole of aluminium in beer, peaked
at the same time as silicon (Bellia et al., 1996). Administration of 600 μmole silicon in water
following 26Al administration accelerated the decline in serum 26Al (Bellia et al., 1996); an
effect similar to that produced by citrate (Birchall et al., 1996). It was suggested that this
resulted from complexation with silicate in urine to form hydroxyaluminosilicate species,
which restricted aluminium reabsorption (Birchall et al., 1996). Two subjects were given
oral 26Al together with 30 or 540 μM silicon (as a high-silicate mineral water). One was also
given 4 and the other 50 mM citrate. They seemed to show more rapid renal aluminium
clearance in the first day after they received the higher silicon dose (King et al., 1997). The
appearance of 26Al increased in the urine of the subject that received the higher silicon dose
and the lower citrate dose whereas less 26Al was eliminated in urine in the subject who received
the higher silicon dose and the higher citrate dose. It is unknown if these effects would be seen
in more than the one subject tested and if they are due to an effect of silicon on aluminium
absorption and/or elimination. In a cross-over study, 3 humans consumed 26Al citrate, 26Al
citrate with monomeric silica (orthosilicic acid), which is ~ 50% absorbed and excreted in the
urine, or 26Al citrate with oligomeric silica, a polymer of silicic acid that has a much higher
binding constant with aluminium, that is not detectably absorbed or excreted. Serum 26Al was
lower following oligomeric silica and 26Al ingestion compared to the other two conditions
(Jugdaohsingh et al., 2000). These results may explain the differences in the studies of silicon-
containing compounds on aluminium absorption and elimination.
In dialysis patients a DFO test (5 mg/kg body weight given i.v.) was recommended for assessing
the aluminium burden. If plasma aluminium increased by more than 50 μg/L it indicated that
there is a high probability of aluminium-related bone disease. Bone biopsy is however needed
for definitive diagnosis (Cronin & Henrich, 2004).
Biliary excretion: The concentration of aluminium in bile was greater than in urine before
oral aluminium consumption (mean ~ 63 and 24 μg Al/L). Both increased comparably (~ 4 to
6-fold) suggesting to the authors that bile is an important route of aluminium elimination
(Williams & Fraústo da Silva, 1996). It can be noted that the daily output of bile and urine are
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comparable, ~ 1 to 2 litres, supporting the notion that bile might be a significant route of
aluminium elimination (Nieboer et al., 1995). Based on faecal 26Al after an i.v. 26Al citrate
injection, biliary aluminium excretion was reported to account for 2.1% of the eliminated
aluminium in one human (Priest et al., 1995). During the first 5 days after i.v. 26Al citrate
injection in seven humans ~ 1.5% of the injected dose appeared in the faeces and ~ 70% in
urine (Priest, 2004). Approximately 9 years after injection, only 1% of the 26Al being excreted
in urine and faeces was in faeces (Priest, 2004). The aluminium concentration in bile of dialysis
patients was ~ 30-fold higher than in controls (Di Paolo et al., 1997). The discrepancy between
the reports of Williams et al. and Priest et al. could be due to enterohepatic recirculation.
However, reports from animal studies have not shown a large percentage of aluminium in the
bile. If bile was an effective route of aluminium elimination, it would be expected to reduce
aluminium in severely renal impaired and anephric patients, which does not appear to be the
case.
Elimination rate: Multiple aluminium t½ have been seen, suggesting that there is more than
one compartment of aluminium storage from which aluminium is eliminated. Typically, as the
duration of sampling after exposure was increased, longer t½ were observed.
The t½ of aluminium elimination positively correlated with the duration of exposure (Ljunggren
et al., 1991). Tissue aluminium concentrations were elevated in non-dialyzed uraemic patients
(Alfrey et al., 1980), suggesting uraemia facilitated tissue aluminium retention. Based on an
estimated human body burden of 60 mg aluminium, a daily dietary intake of 20 mg and
absorption of 1%, Jones et al. (1988) calculated a mean retention time of aluminium in the
human of 300 days and a t½ of 210 days. This calculation assumed steady state conditions and
was based on a single compartment or one compartment that is responsible for a majority of
the aluminium body burden. Elimination t½ s of hours, weeks and years were seen after
termination of short-term inhalation exposure, < 1 year exposure and upon retirement,
respectively (Ljunggren et al., 1991). The aluminium elimination t½ positively correlated with
exposure time (Ljunggren et al., 1991). These results are consistent with more than one
compartment of aluminium storage. This kinetic behaviour might result from retention of
aluminium in a depot from which it is slowly eliminated. This depot is probably bone which
stores ~ 58% of the human aluminium body burden. Slow aluminium elimination coupled with
continued exposure would be predicted to produce an increasing body burden with age, as
noted above.
Multiple phases of elimination were seen in a study in which one human received i.v.26Al
citrate suggesting multiple compartments of aluminium distribution. About 85 to 90% of the
aluminium was eliminated in < 24 hr. Four percent of the injected 26Al remained after 3.2 years
(Priest et al., 1995) and ~ 2% after 9.2 years (Priest, 2004). Calculations based on results up
to 14 years after the injection suggested at least three components of the aluminium elimination
with t½s of 1.4, 40 and 1727 days, and a retention t½ of ~ 50 years (Priest, 2004). This unusual
kinetic behaviour might result from retention of an aluminium species other than that
administered, creating a depot, probably in bone, from which the aluminium is slowly
eliminated. Slow aluminium elimination coupled with continued exposure predicts an
increasing body burden with age.
Following the consumption of aluminium-contaminated drinking water in Camelford,
Cornwall, England, stainable bone aluminium was seen in 2 people six and seven months later
whereas no stainable aluminium was seen 19 months later (Eastwood et al., 1990). Aluminium
was not elevated, as determined by EAAS, at either time (McMillan et al., 1993).
The t½ of the first phase of urinary aluminium elimination in 3 previously non-exposed
volunteers exposed to aluminium welding fumes for 1 day was 8 hr (Sjögren et al., 1985). In
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5 aluminium welders exposed < 1 year to aluminium fumes, the t½ was estimated to be 8 to 9
days, whereas in workers exposed > 10 years it was ≥ 6 months (Sjögren et al., 1988). The
t½ of aluminium elimination in two welders after 20 and 21 years exposure was ~ 3 years,
based on daily urinary aluminium excretion compared to the estimated body burden of
aluminium which, in turn, was based on bone aluminium concentration (Elinder et al., 1991).
This group calculated a t½ of 9.8 years for aluminium elimination based on urine aluminium
concentrations of 1 welder (Sjögren et al., 1996b). Aluminium t½ were estimated from urinary
aluminium after termination of occupational aluminium exposure of 9 to 50 years duration.
Elimination t½ of 0.7 to 7.9 years were estimated, based on a few samples per subject
(Ljunggren et al., 1991). These t½s might be underestimates.
The t½ of aluminium elimination in dialysis patients receiving aluminium hydroxide was found
to be 85 days, when studied to 900 days (Schulz et al., 1984). In patients undergoing
plasmapheresis therapy who received 32 μg Al/kg, the t½ was determined to be 14 hr, when
studied to 5 days (Wilhelm et al., 1987).
Priest et al. (1995) provided a formula to predict the aluminium body content (Bτ) as a function
of time with repeated daily aluminium exposure, Bτ = 0.52(τ0.68-1), where τ = time in days
after the start of the exposure, and Bτ is expressed as a multiple of the daily systemic aluminium
intake. Modification, using more recent data, suggests the aluminium body burden after long
term (years) of fairly constant aluminium intake would be ~ 400 times the daily aluminium
intake (Priest, 2004).
As discussed in Toxicokinetics, Distribution (Including Compartmentalization), Human
Studies, Tissue Aluminium Concentrations, Brain, brain aluminium levels have been reported
to increase with age. Slow, or no, brain aluminium elimination and continued aluminium
exposure would produce an increasing aluminium burden with age, as has been seen in the
human. Assuming the t½ of brain aluminium in the human to be 20 to 50 years, the amount of
aluminium that would accumulate in the brain after 60 years of daily consumption of 300 μg
aluminium, assuming that 5 × 10-3 % of each dose enters each gram of brain and resides therein
with a t½ of ≥ 20 years, would equal or exceed the amount seen in the normal 60 year old
human. One might then conclude that normal concentrations of aluminium in drinking water
would significantly contribute to elevated brain aluminium concentrations, and therefore could
pose a potential health hazard.
Zapatero et al. (1995) found that serum aluminium concentration positively correlated with
age in 356 healthy adults. This could not be attributed to the age-related decrease of renal
function. It is unknown if it relates to the long t½ of aluminium in one or more compartments
in the human so that steady state is not reached in a lifetime, to age-related increased absorption,
or to other factors. In a previous study, Naylor et al. (1990) failed to find a correlation between
age and serum, whole blood, urine or hair aluminium concentrations, in 76, 42, 42, and 42
subjects, respecively.
As noted above, injection of 26Al in animals increased 26Al in bone ~ 100-fold more than in
brain, yet steady state bone aluminium concentration is < 100-fold greater than that in the brain.
This suggests aluminium clearance from bone is more rapid than from brain, which is
reasonable considering bone turnover and lack of neuron turnover. The elimination t½ of
aluminium from human brain is predicted to be very long.
There are no reported determinations of retention time in specific tissues in humans. No
publications of studies of bone aluminium concentration in normal humans as a function of
age were found.
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Biological Indices of Exposure, Body Burden and Organ Concentration
Human tissue and fluid aluminium concentrations are low compared to those in most exposure
sources due to its very low bioavailability by most routes and effective urinary clearance.
Biological monitoring of human exposure to aluminium has been conducted with urine, which
has been thought to indicate recent exposure, or serum, which has been thought to better reflect
the aluminium body burden and long-term exposure (Alessio et al., 1989; Apostoli et al.,
1992; Nieboer et al., 1995). However, neither is a very good predictor of the aluminium body
burden.
As noted in Toxicokinetics, Distribution (Including Compartmentalization), Human Studies,
Plasma Aluminium Concentrations, the serum aluminium level in normal humans has been
reported to be ~ 1 to 2 μg/L. In dialysis patients, it was noted that > 30 μg Al/L serum has been
associated with osteomalacia and related disorders (Nieboer et al., 1995). This conclusion was
based on serum or plasma aluminium levels of 30 to 575 μg Al/L in 11 patients with
osteomalacia and 27 to 160 μg Al/L in 11 patients with osteitis fibrosa (Cournot-Witmer et al.,
1981), 65 to 360 μg Al/L in 18 patients with osteomalacia (Parkinson et al., 1981), 22 ± 12
μg Al/L in 18 patients with renal osteodystrophy (Gokal et al., 1983), 224 ± 22 μg Al/L in 40
patients with aluminium-related bone disease and 75 ± 13 μg Al/L in 21 patients with osteitis
fibrosa (Norris et al., 1985) and 138 to 497 μg Al/L in 7 patients with moderately severe
osteomalacia (Smith et al., 1987). It was noted in dialysis patients that concentrations > 80
μg Al/L serum have been associated with encephalopathy (Nieboer et al., 1995). This
conclusion was based on serum aluminium concentrations of 89 to 486 μg Al/L in 17 patients
(Parkinson et al., 1981) and 175 to 700 μg Al/L in 10 patients (McKinney et al., 1982). Ten
dialysis patients who died with acute encephalopathy associated with aluminium
contamination of the dialysate had a mean serum aluminium concentration of 808 μg/L.
Seventeen patients who were similarly exposed but did not develop encephalopathy or die had
a mean of 225 μg Al/L (Berend et al., 2001).
It has been suggested that the serum aluminium concentration should be kept below 30 μg/L
(Razniewska, 2005). Psychomotor function in long-term dialysis patients whose mean serum
aluminium was 59 μg Al/L was significantly impaired compared to that in controls (Altmann
et al., 1989). Others suggested that a level of 40 to 50 μg Al/L warrants discontinuation of
aluminium gels, 60 μg Al/L might indicate increased body burden, and > 100 μg Al/L indicates
potential encephalopathy and the need for increased monitoring in dialysis patients. An AUC
> 100 or 150 μg/L could present a risk of aluminium toxicity in these patients (Alfrey, 1986)
and overt aluminium toxicity has been seen when the serum aluminium concentration was >
200 μg/L (Berend et al., 2002; Spencer, 2000). Mild neurophysiological and
neuropsychological adverse effects were seen in MIG welders. The body burden threshold
associated with these detrimental effects was estimated to be ~ 4 to 6 μM (108 to 162 μg/L) in
urine and 0.25 to 0.35 μM (7 to 9 μg/L) in serum (Riihimaki et al., 2000).
Although the serum aluminium level increases with increased aluminium body burden, it does
not directly reflect the aluminium body burden from long-term exposure. This is better
measured by bone aluminium, the DFO challenge test, which has a high rate of false negative
results, or the combined measurements of serum iPTH and the DFO test (Cannata-Andia &
Fernadez-Martin, 2002; Mazzaferro et al., 1992; Pei et al., 1992). The peak and increment in
serum aluminium after the DFO test in 28 chronic dialysis patients correlated significantly with
bone aluminium (De Vernejoul et al., 1989) and in 11 other chronic dialysis patients correlated
significantly with skin aluminium (Subra et al., 1991), suggesting utility of this test to indicate
the aluminium body burden. Five mg/kg of DFO or less once or twice weekly has been shown
to be safe and effective for long-term treatment of aluminium overload, and is as effective
when given 1 hr before as after dialysis (Barata et al., 1996; Berend et al., 2002; Cannata-Andia
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& Fernadez-Martin, 2002). The serum aluminium increase in response to mobilization of
aluminium from storage sites, such as produced by DFO, is used to test for aluminium body
burden. A positive correlation was found between the oral dose of aluminium in a phosphate
binder and bone aluminium content, but not with serum aluminium during the 6 months before
the determination of aluminium in bone (Channon et al., 1988).
Conventional x-rays have not been shown useful to reveal aluminium-induced pneumoconiosis
(Kraus et al., 2000; Letzel et al., 1996; Saia et al., 1981). High-resolution computed tomography
was shown to reveal aluminium-induced lung fibrosis changes (Kraus et al., 2000).
A method using in vivo neutron activation analysis to measure aluminium in the bones of the
hand has been developed and is ready for pilot studies in human subjects (Pejovi-Mili et al.,
2005).
Pharmacokinetic Modelling
There are no published reports of physiologically based pharmacokinetic (PBPK) modelling
of aluminium. The International Commission on Radiological Protection concluded that the
t½ would be 100 days, based on 61 mg of aluminium in the human body (21 mg in the skeleton),
daily intake of 45 mg in food and fluids, fractional absorption of 0.01 from the GI tract and
from inhalation, and distribution of 30% of the aluminium that leaves systemic circulation to
bone and 70% to all other organs and tissues (ICRP, 1975). Much of the data obtained during
the past 40 years are different from the assumptions used in this prediction. A model with a
plasma and two tissue compartments was developed based on t½s of 10.5 and 105 hr, that fit
plasma and urine 26Al after 26Al citrate ingestion reasonably well (Fifield et al., 1997; Priest,
2004). Similarly, an 8 compartment model was based on the results obtained during 10 years
after 26Al citrate ingestion by one human subject. The model assumes distribution of 60, 24,
7.5, 5.25, 2.2 and 1.25% of the aluminium from blood and ECFs into urine, soft tissues
including liver, a rapidly exchangeable bone surface pool, a slowly exchangeable bone surface
pool, cortical bone mineral and trabecular bone mineral, respectively. The compartmental t½s
were calculated to be 1.43, 6, 45, 10500 and 500 days for the five non-urine compartments,
respectively (Priest, 2004). Based on 26Al in blood and urine samples after a single oral 26Al
administration to 3 healthy and 2 subjects with renal failure and i.v. in 3 healthy human subjects,
Kislinger et al. (1997) developed a tentative open compartment model to describe aluminium
biokinetics. The model has a central compartment that incorporates separate plasma and
interstitial fluid compartments, each with sub-compartments for aluminium Tf and aluminium
citrate. It has three peripheral compartments. One is for bone connected to the interstitial citrate
compartment since the authors stated that studies in rats have shown that bones are supplied
with aluminium by citrate. A second compartment represents muscles and organs including
liver, kidneys and spleen connected to both central Tf compartments (plasma and interstitial
fluid) as those organs receive aluminium from Tf. The third peripheral compartment is of
unknown identity and was arbitrarily connected to the two central Tf compartments.
Aluminium input was represented from a duodenal compartment into both the blood plasma
Tf and citrate compartments. Output is described from plasma citrate into urine and a minor
pathway from plasma Tf into the residual (beyond duodenal) intestinal tract into the stool.
Compartment volumes and transport rates between compartments were determined based on
the results of 8 subjects. In another report from the same group, Nolte et al. (2001) presented
this model again, modifying the percentage of aluminium bound to citrate in plasma from 20%
in the previous model to 6% and assigning the two peripheral non-bone compartments to liver
and spleen that receive aluminium from plasma Tf and muscles, heart and the kidneys that
receive aluminium from interstitial fluid Tf. Incorporating values reported from studies of
aluminium in healthy individuals and renal failure patients, and from healthy and
nephrectomized rats as well as rats in iron deficiency and iron overload, they calculated
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compartment volumes and transport rates between compartments. The same group reported
the addition of one subject who received i.v. aluminium citrate, bringing the total to 6 healthy
and 2 chronic renal-failure subjects who received 26Al either orally or i.v. Urine samples were
obtained for up to 9, and blood for up to, 512 days. Again drawing on much of the published
literature, the model was tested (Steinhausen et al., 2004) and the results were found to agree
well with model predictions.
EFFECTS ON LABORATORY MAMMALS AND IN VITRO TEST SYSTEMS
Single/Acute Exposure
The acute toxicity of aluminium metal and aluminium-containing compounds is relatively low
(Appendix A). The reported oral LD50 values of aluminium compounds from toxicological
animal studies are between 162 and 980 mg/kg b.w. (IPCS, 1997). The acute toxicity is
dependent upon factors such as the solubility and bioavailability of the aluminium compounds,
the route of administration, and the physiological status (renal function) of treated animals.
Because aluminium hydroxide and aluminium oxide are poorly absorbed after GI, respiratory,
dermal or i.v. administration (Flarend et al., 1997; Hem, 2002; Priest, 2004; Priest et al.,
1996; Schönholzer et al., 1997) (see also Toxicokinetics, Absorption), it is expected that these
compounds also produce low acute toxicity when administered by these routes. The i.p.
LD50 (mouse) for aluminium oxide is >3600 mg/kg body weight (Filov, 1988) which suggests
that aluminium oxide produces low acute toxicity. Aluminium hydroxide toxicity is
predominantly seen in uraemic animals after i.p. injection and is manifested by symptoms of
lethargy, periorbital bleeding, anorexia, and subsequently death (Berlyne et al., 1972a).
Increased aluminium plasma levels and excessive aluminium deposition in the brain, liver,
heart and muscle have also been documented following aluminium hydroxide overload
(Berlyne et al., 1972a; Thurston et al., 1972).
Intratracheal/intrapleural exposure
Intratracheal instillation of aluminium compounds in laboratory animals has been used as a
simple and relatively inexpensive method for screening aluminium for fibrogenicity or other
types of pulmonary toxicity, including carcinogenesis. Experimental studies to evaluate
fibrogenic potential in rats i.e., the ability to induce pulmonary fibrosis of 4 different types of
aluminium fibres including alpha (uncalcined form) and gamma alumina (calcined form)
following single intratracheal injections, were performed by Dalbey & Pulkowski (2000). Six
months after dosing, pulmonary function tests (functional residual capacity, deflation pressure-
volume curves, maximal forced deflation, single breath carbon monoxide diffusion capacity,
and pulmonary resistance) and histopathological evaluation were performed. Rales were noted
during the first week of instillation in aluminium treated groups, but not in the groups given
glass beads or quartz. Standard lung volume and maximal forced exhalation parameters were
decreased at 6 months after instillation in aluminium treated groups as compared to animals
injected with saline and glass beads (controls). Single-breath carbon monoxide diffusing
capacity was significantly decreased in aluminium treated animals compared to both types of
controls which indicated the presence of a physical barrier between the air in the alveoli and
the blood. The weight of the postcaval lung lobe was significantly increased for all groups
administered aluminas, and the most marked increase was seen in the quartz group. The
histopathological changes were similar in all treated groups and consisted of areas of
granulomatous inflammation with early collagenization (fibrosis). The presence of
multinuclear giant cells and the infiltration of macrophages were suggestive of a foreign body
type reaction. Interstitial fibrosis was also apparent and was characterized by a thickening of
alveolar walls with collagen. Both groups treated with uncalcined aluminas tended to have a
higher incidence and severity of granulomas with fibrosis. Although minor pulmonary changes
were noted in the aluminium treated groups, these effects were significantly less pronounced
Krewski et al. Page 100
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
than the changes induced by the instillation of the positive control (quartz). Results are
consistent with previously published work (Ess et al., 1993; King et al., 1955; Stacy et al.,
1959) and point to the variation in responses to material within the class of alumina compounds.
In interpreting these results, it must be considered that large doses were instilled with the intent
of overloading normal clearance mechanisms in the lung to exaggerate any reaction that might
occur. The dose of 50 mg is equivalent to about 30 mg/g lung, well above the 1 mg/g generally
associated with the onset of overloading during long-term studies (Oberdorster et al., 1992).
Influx of alveolar macrophages (AM), accumulation of particles, inflammation, and fibrosis
are changes which would be expected following the administration of a large dose of relatively
insoluble particles producing low toxicity to rats. The main goal of these instillations was to
rank several alumina samples for their general potential to induce pulmonary fibrosis.
Lindenschimdt et al. (1990) examined the effects of aluminium on the development of
pulmonary fibrosis and histological changes/inflammatory responses in the lungs of rats
instilled with 1 or 5 mg Al2O3/100 g body weight. A dose-dependent minimal and generally
transient increase in inflammatory responses was measured in the bronchoalveolar lavage fluid
(BALF) including; activity of lactate dehydrogenase (LDH) an index of cell membrane
damage; beta-glucurnidase and N-acetylglucosaminidase, markers of macrophage/
polymorphonuclear membrane damage; and levels of total protein, an index of potential fibrotic
activity and/or vascular damage. Increase in total cells at this dose was primarily due to
elevation in neutrophils and lymphocytes. At low dose, the only significant change was an
increase of neutrophils on day 1 which returned to the control level by day 7. The changes
observed at high doses returned slowly to normal values during the 2-month study period.
Although intratracheal instillation is not the normal route of exposure, the minimal and
generally transient changes induced by Al203 are consistent with the lack of significant lung
toxicity found in both humans and animals. Significant pathologic response at high doses might
be due to the overload phenomenon of aluminium oxide dust (~9.1 mg/g lung tissue). Morrow
(1996) showed that deposition of large amounts of inert dust in the lungs (> 1-2 mg/g lung
tissue) resulted in inhibition of phagocytic removal of dust, leading to a delayed clearance from
the lung.
Tornling et al. (1993) administered intratracheal instillations of aluminium oxide (primary
alumina), aluminium oxide with adsorbed fluorides (secondary alumina), and saline to three
different groups of rats. The alumina dust (40 mg) was suspended in saline. BALF was obtained
and histological examination of the lungs was performed 1, 4, and 12 months after exposure.
No signs of fibrosis were found in any of the animals. No significant changes in alveolar cell
concentrations were noted for the group treated with primary aluminium; however the
secondary aluminium group exhibited increased concentrations of macrophages and
neutrophils one month and one year after exposure. This suggests that fluoride plays an
important role in early changes to alveolar cell populations. One year after exposure both the
aluminium treated groups exhibited significantly raised concentrations of fibronectin, which
indicates that alumina, not fluoride, is essential for this observed effect. The biochemical
properties of fibronectin support the formation of an extracellular matrix network, and therefore
fibronectin may be an early marker of fibrosis. Due to the administration of aluminium by
intratracheal instillation, which is not a physiological route, the results observed in this study
need to be confirmed by further investigations in which inhalation is used as a route of exposure.
Instillation may have led to pulmonary overload which could have contributed to the
development of the observed effects.
Pigott & Ishmael (1992) assessed the effects of a single intrapleural injection (0.2 mL
suspension/20 mg suspended solids) of refractory alumina fibres (Saffil fibres) obtained
immediately after manufacturing or, later, after extensive thermal ageing. The potential for
these fibres, which had different diameters, to result in the development of mesotheliomas in
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groups of rats was examined. No mesothelioma was detected in any of the rats dosed with the
Saffil fibres, or in the negative controls. Malignant mesothelioma was diagnosed in 7 rats in
the asbestos group (positive control) and in 3 rats in one of the aluminosilicate groups.
However, it must be considered that intra-cavity injections result in a high deposition of the
test material directly on the target tissue. This does not reflect inhalation exposures in which
the fibres must first be deposited in the alveolar region of the lung and penetrate lung tissue
before it reaches the pleural space. The increased mesothelioma proliferation and malignant
mesotheliomas detected in the aluminosilicate B group as compared to the aluminosilicate A
group is likely a reflection of the size of the fibres. Coarse fibres were found to be more irritating
than fine fibres. The results of this study suggest that Saffil alumina fibres are inert and are not
associated with mesothelioma induction. This study supports the results from a previously
conducted inhalation study (Pigott et al., 1981).
After a single intrapleural instillation of Al(OH)3 at a dose of 0.3 g/mL saline to rats there was
an increase in chest wall elastic properties and viscoelastic pressure accompanied by pleural
inflammation after 7 days (Albuquerque et al., 2002). The pleural adherence was associated
with a marked increase in the type I/type III collagen ratio after 30 days. Histological
examination demonstrated no significant differences in lung parenchyma in the aluminium
hydroxide treated and control groups.
In vitro studies—Gusev et al. (1993) and Warshawsky et al. (1994) conducted in vitro studies
to examine the effects of aluminium on lung cell related functions. Gusev et al. (1993) showed
that phagocytosis of alumina dust by rabbit AM did not produce exogenous generation of
superoxide radicals and hydrogen peroxide as measured by nitroblue tetrazolium reduction in
resting and stimulated cells when compared to quartz dust. Alumina dust exerted no effect on
hydrogen peroxide generation and substantially decreased the level of superoxide radical
generation by human granulocytes. Warshawsky et al. (1994) also conducted a study to assess
the role of AM after exposure to aluminium oxide. The cytotoxicity of aluminium oxide
particles (median size was equal or less than 0.36 μm and surface area 198.4 m2/g) to hamster
and rat AM in vitro was measured at 0.1-0.5 mg/L ×106 cells at 24 and 48 hr using trypan blue
exclusion procedures. The viability of the hamster AM in the presence of aluminium oxide up
to the highest concentration was similar to control. After 24 and 48 hr, the viability of the AM
was approximately 80 and 70%, respectively. Results demonstrated that aluminium oxide
showed no changes in AM viability under in vitro conditions.
Oral exposure
As discussed in Toxicokinetics, Absorption, Animal Studies, Oral Administration, the oral
bioavailability of silicon and aluminium from Zeolite A (30 mg/kg), sodium aluminosilicate
(16 mg/kg), magnesium trisilicate (20 mg/kg), and aluminium hydroxide (675 mg) in dogs was
examined by Cefali et al. (1995). Twelve female dogs received a single oral dose of each
compound at one-week intervals. One of the 12 dogs receiving aluminium hydroxide displayed
frothy emesis, and two dogs excreted soft stool.
Intracellular binding of aluminium was examined in the mucosa of the stomach, duodenum,
jejunum and ileum of adult rats following a single oral administration (300 mg/kg) of
aluminium hydroxide (More et al., 1992). A second group of rats received a daily oral
administration of Al(OH)3 (300 mg/kg) for 5 days. No marked differences in body weight and
no microscopic lesions in the GI tract (body and antrum of the stomach, duodenum, jejunum
and ileum) were observed in either group of animals. Six hr after single Al(OH)3
administration, aluminium deposits were observed in the gastric lumen, in the duodenum, and
in the lumen of both the jejunum and ileum. After repeated administration, the presence of
aluminium-reactive deposits was noted only in the lumen of the stomach (at the bottom of the
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antral glands) and in the lumen of the intestine from day 3 to day 7. Other data (discussed in
Toxicokinetics, Absorption, Animal Studies, Oral Administration, The Site and Mechanisms of
Oral Aluminium Absorption) have demonstrated that aluminium absorption occurs in the small
intestine by a paracellular pathway process via the tight junctions (Garbossa et al., 1998b;
Provan & Yokel 1988a). The results also suggest that after repeated administration of large
oral doses, aluminium accumulates in the antral mucosa of the stomach and is released slowly
in the digestive tract.
Injection
Aluminium hydroxide is one of the adjuvants most commonly used in routine human vaccines
against hepatitis B virus (HBV), hepatitis A virus, and tetanus toxoid (TT) and in veterinary
vaccines (see also Effects on Humans, Effects from Non-Occupational Exposure, Irritation,
Irritation after Injection of Aluminium-Adsorbed Proteins (Vaccines and Hyposensitization
Regimens)). Although it has been investigated since 1926, the mechanisms of action of
aluminium adjuvants are not yet fully understood. It is likely that aluminium adjuvants induce
immune activation which includes interleukin (IL) -1 production by monocytes, induction of
eosinophilia, compliment activation and increased specific and non-specific immunoglobulin
(Ig) G1 and IgE antibody responses (Gupta & Siber, 1995; HogenEsch, 2002; Jensen & Koch,
1988; Larsen et al., 2002; Norimatsu et al., 1995; Shi et al., 2001). Limitations of aluminium
adjuvants for human vaccination include local reactions, augmentation of IgE antibody
responses, ineffectiveness against some antigens and inability to augment cell-mediated
immune responses, especially cytotoxic T-cell responses (Gupta, 1998).
Gherardi et al. (2001) administered a single i.m. injection of an aluminium hydroxide-
containing HBV vaccine (GenHevac, 250 μL) to rats in an attempt to reproduce lesions
characteristic of MMF (also see Effects on Humans, Case Reports). The aluminium hydroxide-
containing vaccine induced a large necrotic area containing damaged muscle fibres and
neutrophils, surrounded by abundant lymphocytes and macrophages (days 7-15), that
progressed to a mature lesion (21 and 28 days). The focal infiltration of densely packed PAS-
positive macrophages, without giant cell formation or muscle fibre damage, was similar to the
macrophage infiltrate seen in MMF. Crystalline inclusions similar to those of MMF were
detected by electron microscopy. It was proposed that aluminium hydroxide forms a deposit
which damages the injected tissue, subsequently eliciting a signal from stressed cells. This
signal attracts inflammatory and antigen presenting cells and the aluminium hydroxide deposit
is then subject to phagocytosis (Balouet et al., 1997; IPCS, 1997; Schijns, 2000). Phagocytized
aluminium hydroxide increases survival of macrophages and enhances the effects of
granulocyte/monocyte stimulating factor (Hamilton et al., 2000). A number of aluminium
loaded macrophages accumulate locally, resulting in the characteristic granuloma formation,
while others migrate to the regional lymph nodes (IPCS, 1997). A recent study in monkeys
showed that macrophage accumulation persisted more that 1 year after injection (Verdier et
al., 2005). A residence time longer than 6 months was observed in rats (Gherardi et al.,
2001).
Verdier et al. (2005) evaluated the local reaction and aluminium concentration following i.m.
injection of aluminium adjuvant vaccines in Cynomolgus monkeys. Two groups of 12 male
monkeys received a single i.m. injection of either aluminium phosphate adjuvant diphtheria-
tetanus vaccine or aluminium hydroxide adjuvant diphtheria-tetanus vaccine. Four monkeys
from each of the two groups were sacrificed 85, 169, or 366 days after the single i.m. injection,
and macroscopic examination of the injected site was performed to detect any sign of local
intolerance. Macrophage aggregation was graded as moderate to marked and was accompanied
by a lymphoid infiltration in all cases following the initial sacrifice. Analysis of the injection
site revealed high aluminium content for both aluminium treated vaccine groups; however, the
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aluminium concentration of the reactive zones of animals treated with aluminium hydroxide
was 4 times higher than in those treated with aluminium phosphate. The size of the
inflammatory lesion was greater in the monkeys given the aluminium hydroxide adjuvant. Six
months after the vaccine injection 3 out of 4 monkeys exhibited appreciable lesions composed
primarily of macrophages. One of the lesions had an extensive cyst-like structure which
contained degenerate macrophages. Two of 4 monkeys in the aluminium hydroxide group had
persistent macrophages aggregations with associated minor lymphocytic infiltrations one year
following the injection. The histological appearance and persistence of the lesion observed at
the injection site is similar to the lesions observed in human cases of MMF. Therefore these
results suggest that this type of lesion is a usual reaction following the injection of an aluminium
adjuvant vaccine by the i.m. route, and can occur in normal healthy animals following the
administration of both aluminium phosphate and aluminium hydroxide containing vaccines.
A field trial involving 45 pigs was conducted to validate the hypothesis of aluminium-induced
granulomas (Valtulini et al., 2005). The animals were randomly allocated to receive the same
aluminium hydroxide adjuvant vaccine which induced the formation of nodules in the muscles
of pigs from one particular farm; the adjuvant alone, distilled water, or the adjuvant and distilled
water. The pigs were injected twice i.m. and slaughtered at about 165 kg weight. Granulomas
located within muscular tissue were observed for all the aluminium containing vaccine groups;
granulomas were not detected in any of the pigs who received only water. Granulomas were
characterized by aggregates of macrophage-derived epithelioid cells, with some containing
oval nucleus, a pale pink cytoplasm, and indistinct cell borders. These cells were surrounded
by an infiltrate of mixed inflammatory cells, including large multinucleated giant cells,
macrophages, lymphocytes, plasma cells and eosinophilic elements. In most samples, multiple
granulomas were joined by a unique fibrous shell. X-ray microanalysis and atomic absorption
revealed the presence of considerable amounts of Al, both within and outside the cells. These
results indicate that high amounts of aluminium hydroxide have the potential to produce
granuloma formulation.
Administration of endotoxin and aluminium hydroxide adjuvant (0.85 mg) s.c. to Sprague-
Dawley rats demonstrated that aluminium hydroxide was able to protect animals from the
adverse effects of a 15 μg/kg dose of endotoxin. Shi et al. (2001) suggested that the
detoxification of endotoxin by Al-containing adjuvants occurs due to the irreversible binding
of endotoxin to the surface of Al. These results suggest that all of the surface aluminium in the
aluminium hydroxide adjuvant was able to covalently bind to the phosphate groups of
endotoxin, and absorption of endotoxin was subsequently inhibited due to phosphate binding.
The pro-inflammatory cytokines tumor necrosis factor (TNF)-α and IL-6 were not detected in
the serum of animals receiving endotoxin with the aluminium hydroxide adjuvant (Shi et al.,
2001).
Dermal exposure
The comparative irritancy of several aluminium salts was assessed by Lansdown (1973) in
three different species. Groups of 5 mice, 3 rabbits and 2 pigs were treated daily for 5
consecutive days with applications of 10 % w/v aluminium chloride, aluminium nitrate,
aluminium chlorhydrate, aluminium sulphate, aluminium hydroxide (the pH of the solution
was highest at 7.2 among these chemical species of Al tested) or basic aluminium acetate.
Twenty-four hr after the final treatment with aluminium hydroxide, signs of erythema,
thickening, scaling hyperkeratosis, acanthosis, microabsecesses and the presence of aluminium
in keratin were not observed. After single dermal application of aluminium hydroxide (10%)
on mouse, rabbit and pig skin no signs of dermal irritation or inflammation were found
(Lansdown, 1973).
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Repeated Exposure
Inhalation/intratrachael exposure—The fibrogenic potential of very fine metallic
aluminium powder was investigated by Gross et al. (1973). Three different types of aluminium
powder were tested. Pyro powder and flaked powder were composed of flake-like particles,
and the atomized powder consisted of atomized spherical particles. Aluminium oxide dust was
used as a negative control. Two chambers, containing 30 rats and 30 hamsters each, were held
at dust concentrations of 100 mg/m3 of the pyro powder and the atomized metal powder
respectively, two additional chambers were held 50 mg/m3 of the respective powders. Six
chambers, each containing 30 rats and 15 guinea pigs, were maintained at dust concentrations
of 15 and 30 mg/m3 respectively, for each of the three types of metallic aluminium powders.
The animals were exposed for 6 hr daily, 5 days each week, for 6 months for the 50 and 100
mg/m3 groups, and for 12 months for all other animals. An additional group of 30 rats and 30
hamsters was exposed to aluminium oxide dust at an average concentration of 75 mg/m3 for
6 months, and 30 rats and 12 guinea pigs were exposed to aluminium oxide at a concentration
of 30 mg/m3 for one year. Intratracheal injection of the aluminium powders at different dose
levels was also conducted. Pulmonary fibrosis was not apparent following inhalation of the
aluminium powders in hamsters and guinea pigs; however scattered small scars resulted from
foci of lipid pneumonitis in rats. All three species of animals developed alveolar proteinosis,
the severity and extent of which were not consistently or clearly related either to the type of
aluminium powder or to the severity of the dust exposure. The alveolar proteinosis resolved
spontaneously and the accumulated dust deposits cleared rapidly from the lungs after cessation
of exposure. Intratracheal injection of large doses of aluminium powders into rats produced
focal pulmonary fibrosis; no fibrosis occurred in the lungs of hamsters following intratracheal
injection. The results of this experiment indicate that inhalation of fine metallic aluminium
powders does not produce fibrogenic effects, and that intratracheal injection of these powders
is likely an artefact of the injection itself.
Christie et al. (1963) examined the pulmonary effects of aluminium in rats and hamsters (see
also Effects on Laboratory Mammals and In Vitro Test Systems, Irritation, Inhalation
Exposure). Inhalation exposure to 100 mg/hr aluminium, in the form of powder, or 92 mg Al/
per 2 hr, as a fume, each day for 9-13 months showed a significant retention of aluminium in
the lungs of both groups of animals. The aluminium retention in the lungs in rats and hamsters
exposed to fume was much greater than when exposed to powder. Following exposure to fresh
air, aluminium oxide was cleared rapidly from the lungs of the both powder and fume groups.
Weight of wet lung, ash and aluminium oxide content of lungs in exposed animals increased.
The initial pulmonary tissue response was proliferation of macrophages within alveolar spaces
as well as lipoid pneumonia. The focal aggregates of macrophages were located around the
small bronchioles and small pulmonary arterioles; lymphoid hyperplasia was observed. After
chronic exposure to aluminium powder, rats showed focal deposits of hyaline in alveolar walls,
and focal areas of lipoid pneumonia developed in hamsters.
The pulmonary reaction to inhalation exposure of refractory alumina fibre (Saffil fibres), either
as manufactured or in a thermally aged form, was assessed in rats (Pigott et al., 1981). Animals
were exposed to the fibres 5 days a week, for a 6 hr period, for a duration of 86 weeks.
Pulmonary reaction to both forms of alumina fibre was minimal. Focal necrosis and
regeneration of olfactory epithelium was seen in the nasal cavity in 2 Saffil fibre treated
animals, and the appearance of aluminium fibres in the mediastinal lymph nodes indicated that
fibres and particles may also have been transported via macrophages into the lymphatic system.
Benign and malignant pulmonary tumours were confined to the rats in the positive control
group which were dosed with asbestos. The results of this study indicate that inhalation of
refractory alumina fibres is not associated with an increase in pulmonary or other tumours.
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Ess et al. (1993) studied the fibrogenic effect of intratracheal instillation of 7 alumina samples
in rats. Five of the samples were used for aluminium production, one sample was a chemical
grade form of alumina characterized by small particle diameter and high chemical purity, and
the last sample was a laboratory-produced alumina. Quartz was used as a positive control
because of its well-known fibrogenic activity. The alumina samples were administered at a
total dose of 50 mg by 5 injections given over a period of 2 weeks. Groups of 5 animals were
sacrificed at 60, 90, 180, or 360 days after exposure. Histopathological examinations were
carried out on all animals and bronchoalveolar lavage was performed to assess inflammatory
reactions. Fibrogenic potential was not detected for any of the 5 aluminas used for primary
aluminium production, while it was reported that the other 2 samples induced fibrotic lesions.
A correlation between cytological and biochemical parameters studied in BALF and the
fibrosis determined by histology was not noted for the alumina-treated animals. A persistent
inflammatory alveolar reaction was seen in the animals instilled with the alumina samples,
which was less severe than the reaction produced by the instillation of quartz. The route of
administration needs to be considered in interpreting these results. Intratracheal instillation
may have overloaded clearance mechanisms; however this cannot account for differences of
intensity between samples which were administered at the same dose.
There are a number of limitations in these studies. First, most studies do not demonstrate a
dose-response relationship. Few data are available concerning exposure conditions and the size
of the ambient aerosol. Some studies were of relatively short duration compared with the life-
span of the animals employed; consequently, although no adverse effects were reported in
nearly all cases, it is not possible to assess how much, if any, of the compound was deposited
in the lungs and whether the time-span of the experiment may have been too short to
demonstrate delayed effects.
Oral exposure
Several repeated dose toxicity studies have been conducted in order to assess the effects of oral
exposure to aluminium hydroxide on clinical signs, food and water consumption, growth,
haematology and serum chemistries, tissue and plasma concentrations of aluminium, and
histopathology.
In a study conducted by Hicks et al. (1987) there were no treatment-related effects in rats fed
up to 288 mg Al/kg b.w./day as aluminium hydroxide in the diet for 28 days.
Berlyne et al. (1972a) investigated the effects of repeated oral, s.c., and i.p. aluminium
hydroxide administration in normal and uraemic rats. Groups of nephrectomised rats were
administered 1 or 2% AlCl3 or Al2(SO4)3 in the drinking-water or oral Al(OH)3 (150 mg of
elemental aluminium/kg/day) by gavage. Groups of non-nephroctomised rats received the
same treatments. The duration of the treatment was not indicated. Groups of nephrectomized
and normal rats also received i.p. and s.c. injections of Al(OH)3. The clinical signs of
intoxication in nephrectomized animals observed following i.p. administration (90 mg/kg b.w.)
included periorbital bleeding, lethargy, anorexia and death. Plasma, liver, muscle, heart, brain,
and bone levels of aluminium were markedly elevated in the i.p.-treated group. S.c. injection
was apparently less toxic, resulting in no mortality, but periorbital bleeding occurred in
nephrectomized animals. Aluminium levels were elevated in all tissues, the highest
concentration being in the brain. Administration of high doses of aluminium chloride (180 mg/
kg b.w.) and aluminium sulphate (300 mg/kg b.w.) in drinking water to nephroectomized rats
produced periorbital bleeding and 100% death in treated animals. Periorbital bleeding was
noted for the rats which received drinking water supplemented with Al(OH)3. In normal rats
only aluminium sulphate produced periorbital bleeding in 3 of 5 rats, but no mortality.
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Thurston et al. (1972) examined aluminium deposition in the tissues of rats following dietary
aluminium hydroxide exposure in order to assess whether the toxicity of this compound was
modified when hypophosphatemia was prevented. Weanling rats (6 per group) were assigned
to either a whole meal diet; a whole meal diet with aluminium hydroxide (3.2 g/kg) added; or
a whole meal diet with added aluminium hydroxide (3.2 g/kg) plus 10 g/kg disodium hydrogen
phosphate. An additional group underwent partial nephrectomy and was assigned to the whole
meal diet with added aluminium hydroxide.
The duration of the experiment was 4 weeks; after the treatment the animals were sacrificed,
blood samples were taken and a complete post-mortem examination was conducted. Animals
in the aluminium hydroxide group exhibited a significant impairment of growth, while animals
receiving both aluminium hydroxide and the phosphate supplement showed a normal rate of
growth. The adverse effects on growth were more severe in uraemic rats but the pattern was
the same for aluminium hydroxide treated and untreated animals. Skeletal aluminium content
was raised in the normal animals given aluminium hydroxide or aluminium hydroxide and
phosphate; however, the uraemic animals showed the most marked increase in skeletal
aluminium levels. These results suggested that some aluminium accumulation is seen following
oral exposure but that adverse effects are not exhibited if hypophosphatemia is avoided.
The accumulation of aluminium in bone and various regions of the CNS in rats treated with
aluminium hydroxide (100 mg/kg b.w./day) or aluminium citrate (100 mg/kg b.w./day) i.g. for
either 4 or 9 weeks (6 times a week) was studied by Slanina et al. (1984). However, a decrease
in weight gain was observed after 4 weeks of aluminium hydroxide treatment indicating the
presence of subacute adverse effect.
Subchronic oral administration (18 days) of aluminium hydroxide (271.3 μg Al/g diet) resulted
in significantly increased tibia weight compared to rats fed aluminium phosphate (272 μg/g),
aluminium lactate (262 μg/g), or aluminium palmitate (268 μg/g) (Greger et al., 1985).
Body weight of weanling and adult rats was not affected after repeated oral exposure to high
doses of aluminium hydroxide mixed with sucrose in the diet (2000 ppm for 67 days) (Sugawara
et al., 1988). Rats were fed test diets that had been supplemented with aluminium hydroxide
at levels of 989 and 1070 μg Al/g diet. An additional group of rats was fed a control diet
containing 26 μg Al/g. No aluminium-induced anaemia or hypophosphatemia was observed
in young or adult rats and serum aluminium did not exceed the normal level. Aluminium
concentration in the intestinal tract mucosal membrane increased significantly but no effect on
inflammatory infiltration or necrosis was noted in the intestine. Serum and hepatic triglyceride
levels and adipose weight were decreased significantly in young rats, but neither serum
cholesterol nor phospholipid levels was affected by aluminium ingestion. In the adult group,
aluminium hydroxide produced a decrease in only hepatic glycogen content (Sugawara et al.,
1988).
The body burden of aluminium in weanling rats fed one of 4 diets for 29 days was assessed by
Greger & Powers (1992). Rats were assigned to receive a diet containing 40 μmol Al/g diet
with or without citrate, a diet containing 100 μmol Al/g diet with citrate, or a control diet
containing 0.39 μmol Al/g diet. Rats were injected with DFO or buffer 24 hr prior to sacrifice.
Rats fed Al-supplemented diets accumulated significantly more metal in their tissues than rats
fed the basal diet, the accumulation was greatest in the rats fed aluminium with citrate.
Haematocrit levels following oral aluminium exposure were inversely correlated to tissue
aluminium concentrations. It was expected that DFO might mobilize aluminium from tissues
subsequently increasing serum and urinary aluminium levels proportionately to bone
aluminium concentrations. However, the changes induced by DFO were small and the elevated
serum and urine aluminium concentrations were not more correlated to the body load of Al,
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as indicated by tibia aluminium concentrations. It was estimated that approximately 0.01 to
0.04% dietary aluminium was absorbed. Aluminium hydroxide added to the diet (0.05%) of
rats during the 30 days did not affect vitamin A bioavailability (Favaro et al., 1994). Hicks et
al. (1987) found no treatment related effects in rats fed up to 302 mg Al/kg bw as aluminium
hydroxide for 28 days.
Oral administration of high doses of aluminium hydroxide (1513, 2697 or 3617 mg/kg) in rats
for 30 days did not produce any clinical signs or gross symptoms of intoxication, or any
significant differences in body weight and food intake. However, in treated animals,
behavioural changes (memory and learning ability disturbances) associated with elevated brain
aluminium content were observed (Thorne et al., 1986).
Dlugaszek et al. (2000) examined the effects of long term exposure to aluminium in drinking
water, including the distribution of the ingested aluminium and changes in the tissue levels of
essential elements. Aluminium was administered in drinking water as aluminium chloride,
dihydroxy aluminium sodium carbonate, or aluminium hydroxide. Animals in the Al(OH)3-
treated group exhibited an increase in Mg concentration in bones, a decreased Fe concentration
in the stomach, and a decline of copper in the kidneys and liver. The group which received
AlCl3 exhibited the highest elevation of aluminium in the tissues following oral exposure.
Bilkei-Gorzo (1993) investigated neurotoxic effects following daily oral administration (90
days) of insoluble aluminium hydroxide (300 mg/kg Al(OH)3), water soluble AlCl3 (30 or 100
mg/kg) and chelated aluminium hydroxide (100 mg Al(OH)3/kg + 30 mg citric acid/kg) in rats.
The ability to learn (determined by the number of runs necessary to learn the labyrinth) was
affected in all aluminium treated groups; the learned performance was altered to a greater extent
in the Al(OH)3 and AlCl3 treatment groups. The aluminium content of the brain was elevated
in each treatment group; however, the elevation was highest in the groups treated with soluble
aluminium compounds. Similarly, all treatments resulted in elevated acetylcholinesterase
activity, with significant increases in the AlCl3 group, and in Al(OH)3 chelated to citric acid.
No relevant differences in body weights, general conditions, or water and food intake were
noted between control and treated groups. These results suggested that, although water-soluble
aluminium compounds exhibit greater neurotoxicity, the highly insoluble aluminium
hydroxide compound appeared to be absorbed subsequently producing some effect on nervous
system functions.
Ecelbarger et al. (1994b) conducted a study to assess the impact of chronic exposure to dietary
aluminium on aging rats. Male rats were fed diets containing 0.4 or 36.8 μmol Al/g diet in the
form of aluminium hydroxide for 8 months until they reached 23 months of age. One day prior
to sacrifice, one-half of the rats in both treatments were i.p. injected with DFO, and the
remaining rats were injected with saline in order to investigate the usefulness of DFO for
estimating body burden of Al. The rats exhibited little evidence of aluminium toxicity as body
weight, feed intake, or changes in the relative size of tissues did not appear to be affected by
the treatments.
The possible relation between aluminium intake, levels of aluminium in the brain, and dementia
was investigated in rats and dogs following chronic oral aluminium hydroxide exposure (Arieff
et al., 1979). Clinical signs of intoxication were not apparent in rats with normal renal function
(n=10) or rats with chronic renal failure (n=14) exposed to an oral daily dose of 300 mg
aluminium hydroxide, for 5 months. Brain Al3+ was significantly greater than normal for both
groups of rats, the most marked increase being in the group with renal failure. The effects of
aluminium were also investigated in two groups of mongrel dogs. One group of dogs received
a diet which included 3 g of added aluminium hydroxide daily for 5 months, while the other
group received the same diet without Al. In the aluminium loaded dogs the content of Al3+ in
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the cerebral cortex was significantly greater than in that of the controls. Electroencephalograms
(EEG) were conducted in the exposed dogs and the results for the aluminium treated dogs were
within the normal range. It must be considered that the number of animals in each treatment
group was not clearly reported.
A significant increase in tubular phosphate reabsorption with an increase in the apparent
velocity of maximal tubular transport was reported in rats following aluminium i.v.
administration (Mahieu et al., 1998). Proximal tubule damage was reported in rats (Ebina et
al., 1984) and rabbits (Bertholf et al., 1989) following i.v. administration of aluminium. Rats
consuming a high aluminium diet (36.8 μmol Al/g diet) for 8 months excreted significantly
more protein in urine which is indicative of renal damage (Ecelbarger et al., 1994b).
Studies on the effects of oral administration of aluminium on pregnant animals and their
offspring are presented in Effects on Laboratory Mammals and In Vitro Test Systems,
Reproductive and Developmental Toxicity.
Injection
Repeated s.c. injection of aluminium hydroxide for 5 or 10 months to rabbits and guinea-pigs
did not induce any apparent symptoms or visceral alterations. Limited local lesions
characterized by the presence of monocytes and macrophages were observed (Levatidi et al.,
1968).
S.c. implants of aluminium foil induced subcutaneous tumours in 8 of 18 rats (O’Gara &
Brown, 1967). Histologically, the tumours were fibrosarcomas, rhabdomyosarcomas, or
combination of these types. One fibrosarcoma had metastasized to the lungs. The significance
of aluminium in tumour induction is unknown as the smooth surface of the aluminium implant
may be responsible for the induction of the observed lesions.
Mahieu et al. (2000) examined the effects of chronic i.p. administration of aluminium
hydroxide on haematological parameters in rats. Male rats received 80 mg/kg body weight
aluminium hydroxide three times a week for 6 months. Control rats were injected with saline
solution for the same period. Animals in the aluminium treatment group developed a
progressive microcyotosis which became more prominent with time. Significant decreases in
mean corpuscular haemoglobin and mean corpuscular volume were noted throughout the
duration of the experiment. The haematocrit levels were significantly reduced during months
1, 3, or 4 for the treated animals. The haemoglobin levels of aluminium-treated animals
decreased in months 3 and 4 and then began to increase in months 5 and 6. These results suggest
that chronic i.p. aluminium administration may interfere with different stages of red blood cell
synthesis. Persistent exposure appears to trigger a compensating mechanism leading to restored
haematocrit and haemoglobin concentrations, with persistence of microcytosis and depressed
mean corpuscular haemoglobin levels.
Bazzoni et al. (2005) studied the effect of repeated i.p. injection of aluminium hydroxide on
red blood cell parameters in rats. Male rats were injected with 80 mg/kg body weight of
aluminium hydroxide 3 times a week, for a duration of 3 months. A control group of rats was
injected with saline at the same frequency and volume. Significant decreases in haematocrit
and haemoglobin concentrations were noted in the treated rats as compared to controls. The
treated animals showed a high quantity of abnormally shaped (stomatocytes) erythrocytes
which became more resistant to haemolysis, and the rigidity index was also substantially higher
in the aluminium treated rats. It was reported that the observed effects may have been due to
aluminium induced alterations in the mechanical properties of red blood cells resulting in
disorganization of the erythrocyte membrane. These alterations likely result in a reduction of
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the viability of the circulating red blood cells which may lead to anaemia in aluminium
intoxicated animals.
Effects of chronic parenteral aluminium administration on parameters of renal function, P and
Ca movements at the tubular level, and the possible proximal cell mechanisms were studied
by Mahieu et al. (1998). Rats were treated with an 80 mg/kg body weight i.p. dose of aluminium
hydroxide (three times per week for 6 months). Control rats received saline for the same
duration and frequency. Treated rats showed a significant decrease in asymptotic weight gain
and in the initial efficiency of food conversion compared to the controls. Treated rats also
exhibited a significant decrease in the haemoglobin level, haematocrit index, and serum Fe
concentrations in the peripheral blood compared to control rats. The Ca balance in treated rats
was significantly less than in the control group and was accompanied by a significant increase
in Ca excreted in faeces, correlated with less intestinal absorption. Accumulation of aluminium
on the surface of the trabecular bone and a reduction in the skeletal Ca mass (without any
changes in the bone Ca resorption rate), were observed in all treated rats; however, there were
no differences when expressed as per 100 g body weight. The reduction in bone turnover was
accompanied by a lower recovery velocity from calcemia in the aluminium treated group. The
fractional reabsorption of P and sodium was significantly lower in treated animals compared
to controls. There did not appear to be any significant differences in the acid-base balance nor
in the Ca and P concentrations in the plasma between treated and control animals. It was
postulated that aluminium exposure interferes with P excretion by decreasing PTH or by
diminishing the affinity for PTH receptors at the level of the renal tubule. These results are in
agreement with other studies which demonstrated that aluminium is a potent inhibitor of PTH
secretion (Morrisey et al., 1983; Morrissey & Slatopolsky, 1986). Smans et al. (2000) reported
that aluminium inhibited PTH secretion in vivo, implying potential for lowered Ca release from
the bone to blood.
Cointry et al. (2005) examined aluminium effects on the diaphyseal structure and biomechanics
of rat bones. After subchronic i.p. injection of 27 mg Al(OH)3 in 20% glycerol/water solution
for a duration of 26 weeks, blood aluminium levels were significantly higher in treated rats. A
significant difference was observed between tibial aluminium concentrations in control vs. Al-
treated rats. A significant delay in femur length growth was noted in treated animals. The
volumetric bone mineral density and cortical bone material properties (elastic modules and the
stress at the yield point) were significantly reduced in treated animals compared to controls.
The bone geometric and structural properties were unaffected by treatment. The serum Ca and
P levels were not affected by aluminium treatment. No changes were observed in urine volume
(diuresis) and urinary excretion of Ca and Pi. No significant differences were noted in the body
weights of treated and control groups at the end of the study (Cointry et al., 2005).
An aluminium-induced inhibition of bone mineralization (Cointry et al., 2005) is consistent
with other studies showing similar aluminium effects on bone mineralization in vitro and in
vivo (Ballanti et al., 1989; Bellows et al., 1995; Blumenthal & Posner, 1984; Chan et al.,
1987; Mjoberg et al., 1997; Posner & Blumenthal, 1985). Potential mechanisms proposed
include; changes in the biosynthesis of collagen, increased collagen cross-links, altered
osteocalcin levels (Blahos et al., 1991; Chan et al., 1987; Mjoberg et al., 1997), and
physicochemical dissolution of mineral crystals (Bushinsky et al., 1995). Different
combinations of these effects were described as aplastic bone disease (Ballanti et al., 1989;
Malluche, 2002) and osteomalacia (Galceran et al., 1987; Lieuallen & Weisbrode, 1991;
Malluche, 2002; Mjoberg et al., 1997; Quarles et al., 1985). Chronic oral or parenteral
aluminium hydroxide administration was found to produce aluminium accumulation in bone
and on the bone surface accompanied by a decrease of P and Zn concentrations in tibias
(Berlyne et al., 1972a; Ecelbarger et al., 1994b; Greger et al., 1985; Greger & Donnabauer,
1986; Greger & Powers, 1992; Mahieu et al., 1998; Thurston et al., 1972).
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Fiejka et al. (1996) conducted a study to determine the compartmentalization of aluminium in
mice following i.p. injection of aluminium hydroxide. One group of mice (n=30) received
aluminium hydroxide containing 1 mg of elemental aluminium every two weeks; another group
(n=30) received an injection of aluminium hydroxide which contained 0.1 mg elemental
aluminium 5 days a week. Controls were treated with saline. Ten animals from each group
were sacrificed 48 hr after a cumulative dose of 2, 4 or 6 mg of elemental Al. In the liver the
development of aluminium containing granulomas represented by swollen macrophages and
multinucleated giant cells were observed; the number of granulomas increased with the
aluminium dose. These results suggest that the physiochemical nature of the Al(OH)3 is an
important factor in the development of this type of foreign-body response (Fiejka et al.,
1996).
Histochemical and immunochemical studies were carried out after repeated
intracerebroventricular aluminium injections (5.4 or 0.68 μg/day for 5 days) in the adult rat
brain in animals allowed to survive for a period of either 1 or 6 weeks. Platt et al. (2001)
demonstrated that aluminium concentrated in the white matter of the medial striatum, corpus
callosum, and singulate bundle. Inflammatory responses and damage in the singulate bundle
was noted in Al-treated animals which led to a severe anterograde degeneration of cholinergic
terminals in the cortex and hippocampus. These findings suggested that the enhancement of
inflammation and interference with cholinergic signalling may be the modes of action through
which aluminium results in learning and memory deficits in mammals (Platt et al., 2001).
The injection of 0.3 ml of a 1% suspension of aluminium (metallic) powder into the CSF
(cisterna magna) of adult rabbits induced a slowly progressing encephalopathy characterized
by alterations of posture, myoclonic jerks and muscle weakness (Bugiani & Ghetti, 1982). The
presence of neurons with neurofibrillary degeneration (NFD) and proximal axon swelling was
observed between 1 and 81 days after injection. In some animals, large axons with thin or no
myelin sheath were also observed. In treated animals pathological changes in the peripheral
nerves and muscles were also found. The neuropathological investigation confirmed that the
vulnerability of the brain to aluminium is a time-related event. Within the observed time
interval (1-81 days), NFD developed in every nuclear complex of the CNS other than the
striatum and the amygdala. The factors regulating the time related degeneration of adult rabbit
neurons resulting from exposure to aluminium were not clarified by this study. No relation was
found between the chronology or the topography of the NFD and the size of the cell bodies,
the site of the injection, and the distance from the subarachnoid space and the ventricles
(Bugiani & Ghetti, 1982). These data are consistent with other studies which have demonstrated
that aluminium salts induce an encephalopathy with NFD after subarachnoid injection in
receptive animals (rabbits, cat, ferret) (Crapper et al., 1973; Klatzo et al., 1965; Wisniewski &
Kozlowski, 1982). Although the mechanism by which aluminium induces the accumulation
of neurofilaments is unknown, it has been demonstrated that these neurofilaments are
morphologically identical to filaments that accumulate following the administration of tubulin-
binding agents. These compounds bind to tubulin, induce a disruption of microtubules (Ghetti
& Ohcs, 1978; Remillard et al., 1975) that is followed by the accumulation of filaments in the
cell pericarion, in dendrites and proximal axonal segments.
Reproductive and Developmental Toxicity
Developmental toxicity—It is noteworthy that the reproductive consequences of
aluminium occur only at excessively high non-environmentally amounts. The high amount of
aluminium plays a key role in chemical-induced alterations in reproductive function and
consequent mammalian development. Various investigators have demonstrated an adverse
effect on reproductive capacity due to the chemical species of aluminium ingested (Domingo,
1995; Golub & Domingo, 1996). Embryotoxic and adverse developmental effects were found
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in rats and mice following administration of aluminium nitrate (Albina et al., 2000; Paternain
et al., 1988), aluminium chloride (Colomina et al., 1999; Cranmer et al., 1986; Misawa &
Shigeta, 1993) or aluminium lactate (Golub et al., 1987; Gonda et al., 1996; Poulos et al.,
1996), although these effects may be directly related to aluminium exposure or the result of a
secondary consequence (e.g., maternal toxicity, systemic toxicity). These forms of aluminium
are water soluble, and are therefore absorbed to a greater extent than non-soluble aluminium
forms, such as Al(OH)3 (Colomina et al., 1994; Domingo, 1995).
The embryotoxic and teratogenic potential of Al(OH)3 administered orally to pregnant mice
was investigated by Domingo et al. (1989). Mated female mice were administered 0, 66.5, 133
or 266 mg/kg b.w. of Al(OH)3 daily from gestation days 6 through 15. No signs of maternal
toxicity were observed in any group as evidenced by changes in maternal weight gain or gross
signs of abnormalities. The number of implantations, number of resorptions, number of live
and dead foetuses, and body weights of foetuses were not significantly affected by any dose
of aluminium hydroxide administered. The foetuses of Al-treated dams did not exhibit any
significant differences in the number and type of external malformations, internal soft-tissue
defects or skeletal abnormalities as compared to controls. Domingo et al. (1989) proposed that
the lack of any apparent demonstrated embryo/foetal toxicity of Al(OH)3 in mice was likely
due to the low GI absorption of this compound as compared to other forms of aluminium. A
similar study was also conducted by Gómez et al. (1990). Higher doses of Al(OH)3 were used
in order to evaluate the potential of Al(OH)3 to induce adverse developmental effects in rats.
Al(OH)3 was administered by gavage at dose levels of 0, 192, 384, and 768 mg/kg b.w./day
to pregnant rats from day 6 through 15 of gestation. No significant maternal or developmental
toxicity was observed at any Al(OH)3 dose level administered.
Although based on the studies by Domingo et al. (1989) and Gómez et al. (1990) Al(OH)3
alone did not produce adverse reproductive effects, other studies showed that concurrent
ingestion of Al(OH)3 with other dietary constituents such as ascorbic acid results in an increase
in the GI absorption of aluminium (Colomina et al., 1994; Domingo et al., 1991b) (see also
Toxicokinetics, Absorption, Animal Studies, Oral Administration, Factors Influencing Oral
Aluminium Absorption). Gómez et al. (1991) assessed in rats the influence of citric acid on the
embryonic and/or teratogenic effects potentially induced by high doses of Al(OH)3. Three
groups of pregnant rats were administered daily doses of Al(OH)3 (384 mg/kg b.w.), aluminium
citrate (1064 mg/kg b.w.), or Al(OH)3 (384 mg/kg b.w.) concurrently with citric acid (62 mg/
kg b.w.) on gestational days 6-15. A fourth group received distilled water and served as a
control group (n=17). Maternal and foetal body weights were significantly reduced in the group
treated with Al(OH)3 and citric acid. There were no significant treatment-related differences
on pre- or post-implantation sites, number of live foetuses per litter, or gender ratio. Although
no significant differences in the number of malformations were detected between any of the
groups (data not shown), delayed sternabrae and occipital ossification was observed in the
foetuses treated with Al(OH)3 and citric acid as compared to the control group (p < 0.05).
The potential influence of lactate on developmental toxicity attributed to high doses of Al
(OH)3 was also evaluated in mice (Colomina et al., 1992). Oral daily doses of Al(OH)3 (166
mg/kg b.w.), aluminium lactate (627 mg/kg b), or Al(OH)3 (166 mg/kg b.w.) concurrent with
lactic acid (570 mg/kg b.w.) were administered to pregnant mice from gestational day 6 to15.
An additional group of mice received lactic acid alone (570 mg/kg b.w.). A control group
received distilled water during the same period. Concurrent administration of Al(OH)3 with
lactic acid resulted in significant reductions in maternal weight compared to the control group
of mice who received distilled water without the addition of aluminium lactate or lactic acid.
In the group given lactate only, a quantitative rise in the concentration of aluminium was
detected in whole foetuses; however this was not statistically different from the mean levels
found in the control group. Aluminium lactate administration resulted in significant decreases
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in foetal body weight accompanied by increases in the incidence of cleft palate and delayed
ossification. Although not statistically significant, the incidence of skeletal variations was
higher in the concurrent Al(OH)3 and lactic acid group compared to the control group. No other
signs of developmental toxicity were detected in this group.
In a similar experiment, Colomina et al. (1994) assessed the concurrent ingestion of high doses
of Al(OH)3 and ascorbic acid on maternal and developmental toxicity in mice. Three groups
of pregnant mice were given daily doses of Al(OH)3 (300 mg/kg b.w.), ascorbic acid (85 mg/
kg b.w.), or Al(OH)3 concurrent with ascorbic acid (85 mg/kg b.w.) from gestational day 6 to
15. A fourth group of animals received distilled water and served as the control group. No
embryotoxic or foetotoxic effects were detected in any group. Gross, internal, or skeletal
malformations did not vary according to treatment group. The number of resorptions, dead and
live foetuses, percent implantation loss, and foetal body weight did not differ between among
the control and treated groups (Colomina et al., 1994). Placenta and kidney concentrations of
aluminium were significantly higher in mice receiving Al(OH)3 and Al(OH)3 plus ascorbic
acid compared to controls. In contrast, Gómez et al. (1990) found no significant differences in
placental concentrations of aluminium in rats administered higher doses of Al(OH)3 alone.
Competition between aluminium and other essential trace elements was proposed as one of the
possible mechanisms to explain adverse reproductive outcomes related to aluminium toxicity
including delayed ossification, foetal malformations and reduced weight gain (Bellés et al.,
2001). Bellés et al. (2001) examined in rats the effect of oral Al(OH)3 on the accumulation and
urinary excretion of Ca, Mg, Mn, Cu, Zn and Fe. Three groups of rats were given either 0, 200
or 400mg/kg b.w./day Al(OH)3 from gestational day 1 to 20. Three groups of non-pregnant
female rats also received the same doses of Al(OH)3 for 20 consecutive days. Urinary
concentrations, as well as samples of liver, bone, spleen, kidney and brain removed post-
sacrifice, were analyzed for Al concentrations, as well as levels of Ca, Mg, Zn, Cu, and Fe.
Treatment with oral doses of Al(OH)3 did not produce any overt signs of toxicity in pregnant
or non-pregnant rats; however, there were differences in the pattern of metal tissue distribution.
In pregnant rats, the highest aluminium concentration was found in kidneys while, in non-
pregnant animals, the brain had the highest level of aluminium. In the non-pregnant control
group, the highest tissue accumulation of aluminium was also in brain. The hepatic and renal
concentrations of several essential elements, as well as the levels of calcium in bone and copper
in brain, were significantly higher (p < 0.05) in the treatment groups as compared to the control
group for the pregnant rats. In contrast, fewer differences between hepatic, renal and bone
concentrations of the elements examined were found between the treatment and control groups
of the non-pregnant animals. These results suggest that pregnancy may be a period of enhanced
susceptibility for aluminium accumulation and subsequent toxic outcome.
Donald et al. (1989) and Golub et al. (1991) evaluated developmental neurobehavioural
toxicity. Donald et al. (1989) conducted a study which demonstrated that elevated dietary
exposure of mouse dams to aluminium during gestation and lactation resulted in persistent
neurological defects during the post weaning period in offspring. Pregnant mice were assigned
to receive a diet containing 25, 500, or 1000 μg aluminium lactate/g diet. The experimental
diet commenced on day 0 of gestation and continued throughout pregnancy and lactation. Four
pups from each litter were selected for further neurobehavioural assessment after weaning.
These pups were fed a control diet containing 25 μg aluminium lactate/g. Neither maternal nor
reproductive toxicity was detected. Neurobehavioural maturation of the pups was tested on
days 8 through 18 with the Wahlsten test battery which included: forelimb and hindlimb grasps,
fore- and hindpaw placement on sticks of two widths, vibrissae placing, visual placing, auditory
and air puff startle, eye opening, screen grasp, screen cling, and screen climb. The only
difference among the aluminium groups in terms of pup toxicity prior to weaning was poor
performance in a climbing test in the 1000 μg Al/g diet group. Several significant differences
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in neurological signs were exhibited between weanlings whose dams were fed control or high
aluminium diets; some of these manifestations persisted after a 2 week recovery period from
the diet. Foot splay, forelimb and hindlimb grip strengths, and thermal sensitivity (tail removal
latency) were associated with higher maternal dietary aluminium levels. These results
suggested that maternal dietary exposure to excess aluminium during gestation and lactation
resulted in neurobehavioural toxicity in weanling mice even in the absence of maternal toxicity.
In a similar experiment, Golub et al. (1991) fed pregnant mice a diet of either 25 (control) or
1000 (high) μg aluminium lactate/g from conception through lactation. Litters were fostered
either within or between groups at birth to create the following 4 groups related to the
aluminium concentration of the maternal diet: (1) control during gestation and lactation, (2)
high aluminium during gestation, control during lactation, (3) control during gestation, high
aluminium during lactation, (4) high aluminium during both gestation and lactation. Forelimb
grasp strength was influenced by high aluminium exposure during gestation, negative geotaxis
was influenced by exposure during lactation, and hindlimb grasp and temperature sensitivity
were affected by exposure during both gestation and lactation. Although aluminium exposure
during gestation or lactation did not influence brain and liver aluminium concentrations,
exposure during lactation resulted in significantly lower manganese and iron concentrations
in the liver, and significantly less manganese concentrations in the brain of the pups at weaning.
These results demonstrated that high maternal dietary aluminium intake, during both gestation
and lactation, might result in neurodevelopmental adverse effects and altered essential trace
element metabolism in offspring.
It has been suggested that maternal stress during pregnancy could enhance aluminium-induced
developmental toxicity in mouse and rat offspring (Colomina et al., 1998; 1999; 2005; Roig
et al., 2006). Colomina et al. (1998) administered i.p. injections of AlCl3 at 37.5 and 75 mg/
kg/day to two groups of pregnant mice on days 6-15 of gestation who were also subjected to
restraint for 2 hours/day. AlCl3 was also administered at the same frequency and doses to two
groups of mice who were not restrained. Foetal weight was significantly lower (p < 0.05) in
the groups whose dams were concurrently exposed to aluminium (37.5mg/kg and 75mg/kg)
plus restraint, and in the group exposed to 75 mg/kg without restraint, as compared to those in
the group subjected to restraint only. A significant increase (p < 0.05) in the number of litters
with skeletal anomalies, as well as the total number of litters with internal and skeletal defects,
was observed in the group exposed to 75 mg AlCl3/kg/day plus maternal restraint as compared
to any of the other groups.
In a more recent study, Colomina et al. (2005) did not detect a significant influence of maternal
restraint on the postnatal developmental and behavioural effects in the offspring of rats exposed
parentally to aluminium nitrate nonahydrate in drinking water. In this study, female rats were
exposed to 0 (control group), 50, or 100 mg/kg/day of aluminium (as aluminium nitrate
nonahydrate) in drinking water with citric acid (355 or 710 mg/kg/day) for a duration of 15
days. The female rats were then mated with untreated males and aluminium exposure was
maintained throughout the gestational, lactational, and post-weaning periods. Half of the
animals in each group were restrained for 2 hours/day on days 6-20 of gestation. No significant
differences were noted in the activity of the offspring (postnatal day 30) measured in an open
field test between animals with prenatal aluminium exposure, alone or plus restraint, as
compared to the control group. Rats exposed to 100 mg/kg/day all through their life following
prenatal restraint stress showed improved performance in a passive avoidance task. A
significantly improved performance in a water maze test was also noted for rats exposed to
50mg/kg/day of aluminium as compared to the non-aluminium exposed groups. Maternal
restraint did not appear to affect the water maze performance for rats also exposed to
aluminium.
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Roig et al. (2006) investigated the long-lasting neurobehavioural effects of prenatal restraint
stress and oral aluminium exposure in rats. Pregnant females were orally exposed to 0, 50, and
100 mg/kg/day of Al. Each Al exposed group was divided into two subgroups, one of these
groups was subjected to restraint stress for 2 hours/day on gestation days 6-20. The offspring
of the treated females received the same Al treatment until the time of sacrifice at 1 or 2 years
of age. An open field test and a water maze test were conducted to assess behavioural
performance of the offspring one or two years after birth. Prenatal restraint did not appear to
modify behavioural performance in the rats. In addition, brain aluminium accumulation was
significantly higher (p < 0.05) in rats exposed to 100mg/kg/day aluminium, without prenatal
restraint, in all brain structures analyzed (cortex: 31.7 ug/g, olfactory bulb: 28.1 ug/g,
cerebellum: 36.3 ug/g, striatum: 51.1 ug/g, hippocampus: 79.7 ug/g, and brain stem: 26.7 ug/
g), as compared to rats who experienced prenatal restraint and were exposed to the same dose
of aluminium (cortex: 0.8 ug/g, olfactory bulb: 9.1 ug/g, cerebellum: 2.6 ug/g, striatum: 7.1
ug/g, hippocampus: 4.2 ug/g, and brain stem: 3.1 ug/g). Therefore, prenatal restraint stress
appeared to prevent aluminium accumulation.
Until the actual delivered dose to the foetus, the suckling pup, and to the target organs is well
characterized, any determination of a vulnerable window of effect or comparison of animal to
human data will remain limited.
Reproductive toxicity—To our knowledge no studies have been conducted to assess the
reproductive toxicity of Al(OH)3 or Al2O3 in male mice; however, adverse reproductive effects
were documented following i.p. injections of aluminium nitrate to male mice. Llobet et al.
(1995) administered i.p. aluminium nitrate injections to adult male mice at doses of 0, 50, 100
or 200 mg/kg b.w./day for 4 weeks before mating with untreated females. The pregnancy rate
was significantly reduced for the 100 and 200 mg/kg b.w./day dose groups compared to
controls. Testicular and epididymal sperm counts were significantly decreased in the group
administered 200 mg/kg b.w./day aluminium nitrate and the count of spermatids was
significantly reduced at 100 mg/kg b.w./day. In the 100 and 200 mg/kg b.w./day groups
histological changes, including necrosis of spermatocytes/spermatids, were noted in 5 and 6
mice, respectively. Histological lesions were not detected in the control mice or in the group
that received 50 mg/kg b.w./day aluminium nitrate.
In another study, focal necrosis of the testes and destruction of spermatozoa was observed
following a single intratesticular injection on 4.3 mg Al/kg (as aluminium sulphate) to rats
(Kamboj & Kar, 1964). A proliferation of interstitial cells and a reduction in the number and
motility of spermatozoa was observed following chronic exposure (6 months) of an oral dose
of 2.5 mg/kg (as aluminium chloride) in rats (Krasovskii et al., 1979).
Protective treatments on aluminium-induced developmental effects
Albina et al. (2000) conducted a study to determine if a chelating agent, deferiprone, could
protect against aluminium-induced maternal and developmental toxicity in mice. Pregnant
mice were randomly divided into 5 groups. One group was administered 1,327 mg/kg b.w. of
aluminium nitrate nonahydrate by gavage on gestation day 12, a second group was given 24
mg/kg b.w./day of deferiprone on days 12-15 of gestation, and a third group was given 1,327
mg/kg b.w. of aluminium nitrate nonahydrate on gestation day 12 followed by deferiprone (24
mg/kg b.w. at 2, 24, 48 and 72 hr following aluminium exposure. The controls received sodium
nitrate or deionised water. Administration of deferiprone alone did not produce any apparent
signs of developmental toxicity. Aluminium-induced maternal toxicity included significant
reductions in body weight gain, absolute liver weight and food consumption compared to
controls. Administration of deferiprone did not offer protection against these aluminium
induced maternal effects. In contrast, deferiprone administration following aluminium
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exposure resulted in a more pronounced decrease in maternal weight gain and corrected body
weight change. Developmental toxicity was manifested by delayed ossification of a number
of bones in the aluminium treated groups compared to controls. The group treated with
aluminium nitrate and deferiprone exhibited a higher number of litters with foetuses showing
skeletal deficiencies. These results suggested that deferiprone is not an effective agent to protect
against aluminium-induced developmental toxicity and might increase the severity of
aluminium-induced maternal and developmental adverse effects in mice.
Silicon-containing compounds were shown to limit absorption of ingested aluminium
(Edwardson et al., 1993). Therefore, it was proposed as exerting a protective effect against
aluminium-induced toxicity (see also Toxicokinetics, Absorption, Animal Studies, Oral
Administration, Factors Influencing Oral Aluminium Absorption, Silicon-Containing
Compounds). Bellés et al. (1999) conducted a study to test this hypothesis. Aluminium nitrate
monohydrate was administered to three groups of pregnant mice by gavage (398 mg/kg b.w./
day) on gestation days 6-15. These animals received silicon in drinking water at concentrations
of 0, 118 or 236 g/L on days 7-18 of gestation. Three additional groups of pregnant mice
received 270.6 mg/kg of sodium nitrate and the same concentrations of silicon in drinking
water as the aluminium-treated groups. The percentage of aluminium-induced deaths,
abortions and early deliveries was significantly reduced in the group administered 236 mg/L
silicon. However, no significant differences were noted at 118 or 236 mg/L silicon on
aluminium induced foetotoxicity.
Neurotoxicity
The scientific literature is replete with reports linking (or dissociating) various chemical forms
of aluminium with neurotoxicity and neurodegeneration. Interested readers can gain a grasp
of the literature and the differing views as to the potential mechanisms of aluminium toxicity,
through a number of existing reviews and hypotheses papers (Atchison, 2003; Becaria et al.,
2002; Campbell, 2002; 2004; Campbell & Bondy, 2000; Domingo, 1996; Elmore et al.,
2003; Emmett, 2004; Exley, 1999; 2005; Flaten, 2001; Gupta et al., 2005; Kagan et al.,
2002; Kumar, 1999; Oteiza et al., 2004; Priest, 2004; Rao et al., 1998; Reinke et al., 2003; Rob
et al., 2001; Shin et al., 1995; Savory et al., 2003; Sim & Benke, 2003; Solfrizzi et al., 2003;
Soni et al., 2001; Szutowicz, 2001; Tanaka, 2004; Van Landegham et al., 1998; Yokel,
2000). Here, we will focus on some of the literature from the last 10 years that addresses the
potential for aluminium to cause neurotoxicity and/or provides insight into the mechanisms of
toxicity.
In examining the literature on in vivo studies, it is useful to consider several factors in
determining whether a given study may provide significant insight. For studies in animals, the
over-riding considerations are dose, mode of administration, speciation of the metal, and
measures of outcome. Human Exposure, Total Human Uptake from All Environmental
Pathways (Combined Exposure) summarizes the most common sources of human exposure to
aluminium. For the majority of individuals, these various sources of exposure result serum
concentrations of 1-2 μg of aluminium per Litre of plasma. It is notable that daily doses can
be much higher in individuals who use aluminium-based antacids (Lione, 1983). Typically,
toxicological studies in rodents utilize doses that are 10-20 times the anticipated human dose.
This calculation is based on increased metabolic rates for rodents and is meant to account for
differences in the metabolism of the toxin. Therefore, one potential approach to relate
experimental studies in rodents, which are most commonly used, to humans is to assume that
studies in rodents that achieve serum levels of >10-20 μg/L would mimic normal environmental
exposure levels of humans. Studies that achieve higher concentrations of aluminium in serum
could be viewed as challenging the animal to determine the toxic potential of the metal.
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Investigators have used a variety of routes of exposure, including oral, i.v. injection, and i.p.
injection. A variety of aluminium salts have been used in these studies. As discussed in
Toxicokinetics, soluble aluminium salts that are introduced into the body are subject to re-
speciation with most aluminium in serum being bound to Tf, a minority found as aluminium
citrate, and smaller amounts bound to other molecules. Aluminium citrate is usually excreted
by the kidney rather quickly, and thus one could expect that Tf would be the major carrier of
aluminium into the brain. In CSF, which has higher concentrations of citrate, aluminium
dissociates from Tf with the majority bound to citrate. In studies where soluble aluminium salts
have been given orally or by injection (i.p. or i.v.), the most likely species of aluminium in
brain would be bound to Tf and citrate. In studies where aluminium has been injected directly
into the brain there would be also be re-speciation but there would be opportunity for exposure
to novel aluminium salts. For the purposes of review, studies involving oral and i.p, or i.v.,
injection methods of exposure are probably most informative regarding potential effects in
humans. Studies in which aluminium salts have been injected directly into the brain have a
greater probability of producing non-physiologic effects.
Alzheimer’s disease
Studies in both cell culture models and in vivo have clearly established the potential for
aluminium to cause significant neurotoxicity. Likewise, well documented cases of
encephalopathy associated with long-term dialysis establish a connection between aluminium
and neurotoxicity in humans. One of the first proposed consequences of aluminium exposure
in humans was an elevated risk of developing AD. AD is defined by both clinical and pathologic
symptoms. Clinically, the symptoms include loss of cognitive ability, psychiatric symptoms,
and emotional changes, progressing to profound motor dysfunction and death. Pathologically,
AD is defined by the presence of senile plaques, composed of fibrillar extracellular deposits
of amyloid β peptide, and NFTs, composed of fibrillar intracellular accumulations of
hyperphosphorylated tau protein. Several disorders can produce clinical symptoms that overlap
with, or duplicate, the clinical symptoms of AD, including frontotemporal dementia and
vascular dementia.
The scientific literature contains numerous reviews that discuss the extant literature regarding
AD and aluminium exposure. The initial lines of evidence linking AD to aluminium exposure
were numerous reports of elevated levels of aluminium in the brains of AD patients and an
association of aluminium with disease-specific lesions (amyloid senile plaques and NFTs).
However, subsequent studies utilizing more sophisticated technology demonstrated that
aluminium levels are not particularly elevated in the brains of AD patients, and aluminium is
not disproportionately distributed to senile plaques or NFT (Lovell et al. 1993; Xu et al.,
1992c) (see Tables 19-21). A well controlled study by Makjanic et al. (1998), demonstrated
that the detection of aluminium in tissues from AD patients may partially result from methods
of tissue preparation as measures of aluminium in frozen-untreated tissue preparations failed
to detect aluminium (<20 ppm) (Makjanic et al., 1998). Studies of a very limited number of
autopsied brains suggested that aluminium may preferentially accumulate in lipofuscin
granules (Tokutake et al., 1995), which are a common pathology in the aged, and thought to
represent remnants of lysosomes that contain undigestable-material.
In regard to animal studies designed to directly test the potential role of aluminium in the
development of AD-related pathologies, Pratico et al. (2002) utilized a transgenic mouse model
of Alzheimer amyloid pathology. Animals were fed diets enriched in aluminium (dose and
chemical form not clarified in the publication) to determine whether aluminium induced
changes in the rate or severity of amyloid deposition in this model. The authors reported
significant increases (~ 2-fold) in brain loads of soluble and insoluble amyloid peptide and in
the levels of isoprostane 8,12-iso-iPF2α-VI, which was examined as a marker of lipid
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peroxidation. Huang et al. (1997) also reported increases in the expression of the precursor to
amyloid peptide, termed amyloid precursor protein (APP), in cervical spinal cords of rabbits
given intracisternal injections of aluminium maltolate (2.5 mmole). Intracellular accumulations
of APP immunostaining in neurons of the medulla have also been reported by Zhang et al.
(2004), who described increased numbers of neurons immunoreactive for APP in the cortex
and hippocampus of rats given aluminium chloride in drinking water (3 mg/mL) for 90 days
(Zhang et al., 2003). Together, these data suggest that aluminium may modulate the expression
and, or, processing of APP. If a life-time of constant exposure results in sustained elevations
in APP expression or production of amyloid peptide, then increases in amyloid peptide could
accelerate the rate of senile plaque formation and hasten the onset of AD (Jankowsky et al.,
2004).
In a study in which rats were given large doses of aluminium sulphate by oral gavage, El-
Rahman (2003) reported histological changes that resemble those found in AD patients.
Animals were given daily doses of aluminium ranging from 4.59 to 17 mg/100 g b.w./day for
35 days. The brains of animals receiving the highest doses were reported to have developed
both classic amyloid deposits and NFTs in the cortex. The report, however, did not quantify
the prevalence of either pathology and relied on histological stains, rather than antibody
immunostaining, to define pathology. The highest dose in this study would equate to a daily
exposure for humans of 170 mg/kg b.w./day. Unfortunately, serum levels of aluminium were
not reported, making if more difficult to assess exposure to tissue. Although this dose is far
and above normal exposure levels, humans who take aluminium-containing antacids may be
exposed to between 15 and 50 mg/kg b.w./day (Lione, 1983). Therefore the dose used in this
study was within the 10 to 20-fold excess that is routinely used in rodent toxicological studies.
If replicated, and examined with more precise methods, this study could be construed as
evidence that very high exposure to aluminium could lead to AD-related pathologic changes
in the brain.
Another potential mechanistic connection between aluminium and AD comes from work of
Silva et al. (2002) who examined cholesterol levels in the brains of rats fed high doses of
aluminium (1 g per day for 10 days or 0.03 g per day for 4 months). Under both conditions,
there were significant and robust changes in the ratio of cholesterol to total phospholipids.
There were also robust diminutions in membrane fluidity, attributed to the loss of cholesterol.
Recent studies from a number of laboratories (Refolo et al., 2000; Smith et al., 2001)
demonstrated that the proteolytic generation of amyloid peptide (the principal component of
senile plaques in AD patients) is elevated by hypercholesterolemia. The findings by Silva noted
above would suggest that aluminium exposure might indirectly reduce amyloid production.
However, such beneficial effects could be offset by the reported ability of aluminium to
increase the rate at which amyloid peptides (Kawahara et al., 1994; 2001; Mantyh et al.,
1993), and other pathogenic proteins such as α-synuclein (Uversky et al., 2001), to assemble
into more stable and pathologic fibrillar structures. Additionally, regardless of whether there
is a direct action of aluminium on CNS membranes or an indirect metabolic consequence of
aluminium exposure, changes in membrane fluidity and cholesterol content could account for
the numerous reports of deleterious effects of aluminium on neurotransmitter systems and
synaptic function (Csoti et al., 2001; Dave et al., 2002; El-Rahman, 2003; Nayak & Chatterjee,
2001; Wang et al., 2002; Zatta, 1997; Zhang et al., 2004).
The most convincing data to dissociate AD from aluminium exposure are detailed histological
analyses of patients who have undergone long-term haemodialysis and succumbed to
encephalopathy. To control serum phosphorus levels, patients take high doses of hydroxyl-
aluminium gel over long periods, leading to elevated levels of aluminium in many tissues at
autopsy. The brains of these patients have characteristic accumulations of aluminium in sub-
cellular compartments of both neurons and glia (Reusche et al., 2001a). Morphologically, these
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structures are most commonly ovid in nature, intracellular, and appear to be lysosome-derived.
In rare cases, where pathologic changes that meet criteria for diagnosis of AD in patients with
dialysis-encephalopathy (one case out of 127 analyzed), the pathology associated with each
disorder remains morphologically distinct (Reusche, 1997). Importantly, in the study by
Reusche et al. (2001a), there was no association between AD-like pathology and long-term
ingestion of aluminium. The most informative group of patients included 10 who received high
doses of aluminium (> 500 g total intake over at least 5 years), for whom the frequency of AD-
related pathology was no greater than controls. Moreover, in patients over 60 years of age the
degree of AD-related pathology (subclinical levels) in dialysis patients was similar to that in
controls. Collectively, these studies in humans support the view that exposure to aluminium
poses no direct risk for development of AD. However, caution in over-stating the importance
of the data from DAE patients is warranted given the rather small number of highly definitive
cases. The animal studies cited above suggest that a life-time of exposure to low doses of
aluminium, or exposure to a single-high-dose, might pose a risk for developing AD or
contribute to the aetiology of a subset of cases.
Motor neuron disease
It has been known since 1965 that the rabbit is uniquely vulnerable to aluminium toxicity and
produces both clinical and pathologic features of motor neuron disease (Klatzo et al., 1965).
Intracisternal (directly into CSF) injection of aluminium salts (chloride, phosphate, maltolate)
can be used to cause both acute and chronic neurotoxicity. Single high doses of aluminium (1
mg) cause rapidly progressing motor neuron dysfunction with hindlimb paralysis, whereas
repeated low dose injections (100 μg) can induce a chronic motor dysfunction (for review see
Savory et al., 2001). Detailed neuropathological studies of the chronic rabbit model have
defined the similarities and differences between aluminium intoxication in the rabbit and
human disease. First and foremost, aluminium intoxication in the rabbit is reversible.
Symptoms and pathology associated with chronic low dose aluminium intoxication can be
ameliorated if aluminium exposure is reduced at the first signs of symptoms. In humans, motor
neuron disease is progressive and almost uniformly fatal. Pathologically, the major
resemblance between aluminium intoxication in the rabbit and human disease is the appearance
of intracellular inclusions in motor neurons of the spine and brain stem. These inclusions are
formed by filamentous aggregations of neurofilament protein (He & Strong, 2000a; Wakayama
et al., 1996). Absent from the rabbit model are significant numbers of inclusions that are
immunoreactive with cystatin C, ubiquitin, and tau (Wakayama et al., 1996). Also
conspicuously absent is evidence of astrocytic gliosis and activation of microglia, both of which
are hallmarks of human ALS (He & Strong, 2000a; 2000b; Wakayama et al., 1996). In a chronic
aluminium intoxication model, Ghribi et al. (2002) found evidence of caspase-3 activation, an
important step in programmed cell death; however, others failed to detect the definitive marker
of apoptosis, DNA fragmentation (He & Strong, 2000a), despite ~50% losses in the numbers
of lumbar spinal motor neurons. Relevant to AD, Muma & Singer (1996) reported alterations
in tau protein phosphorylation and accumulation, the principal component of NFT pathology
of AD, in the spinal motor neurons of rabbits chronically given moderate intracisternal doses
of aluminium (~ 200 μg of elemental aluminium). Notably, DAE patients do not show increased
levels of neurofibrillary pathology (see below).
In vivo models
Neuropathology—The pathology of DAE patients provides insight into potential
mechanisms of aluminium neurotoxicity and its transport into the nervous system. As discussed
above, Reusche et al. (1997) noted an abundance of intracellular argentophyllic (silver binding)
granules in the brains of DAE patients, which are most commonly ovid, intracellular, and
lysosomal in appearance. LAMMA revealed high concentrations of aluminium in the
cytoplasm of cells exhibiting these structures. One of the major carriers of aluminium in the
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serum and interstitial fluids is Tf (see Toxicokinetics, Distribution (Including
Compartmentalization), Human Studies, Transport in Blood). At physiological pH, aluminium
in serum is bound to transferrrin, although less tightly than Fe would be bound. In CSF, higher
concentrations of citrate result in significant re-speciation to aluminium citrate (Yokel,
2001). Uptake of Tf by neural cells involves receptor-mediated endocytosis via the Tf receptor.
Indeed, in the CNS, Tf-mediated uptake has recently been used as a molecular means of
introducing novel compounds or proteins into the brain. Importantly, receptor-mediated
endocytosis would be expected to deliver material to the endosomal and then lysosomal
compartments. Hence, in DAE patient, the subcellular distribution of aluminium in neural cells
(neurons and cells of the choroid plexus) is consistent with a mode of exposure that involves
Tf-mediated delivery to the nervous system. The extent to which aluminium citrate is taken up
by neural cells is unclear.
Rodent models of aluminium toxicity by direct injection—To bypass limitations of
absorption, some investigators have directly i.p. injected aluminium-salts. Esparza et al.
(2003) injected rats with aluminium lactate at concentrations of 5 mg/kg/day and 10 mg/kg/
day for 8 weeks (5 injections per week) and then assessed markers of oxidative stress and
cognitive function (see below). The estimated exposure would be >1000 times normal. Levels
of aluminium in cortex, hippocampus, cerebellum and liver were measured, with only
cerebellum and liver showing significant accumulations of aluminium. Levels of aluminium
in serum were not reported. Significant reductions in the levels of manganese and copper were
found in brain, with no change in Fe in any organ. In this model, the hippocampus showed the
largest number of changes indicative of oxidative stress, including increased GSH, increased
measures of lipid peroxidation (thiobarbituric acid reactive substances (TBARS)), increased
levels of oxidized glutathione (GSSG), and increased SOD levels. In the liver, the levels of
GSH were similarly increased, however, paradoxically, the levels of lipid peroxidation were
lower than control. Importantly, the magnitude of the changes in these markers never
approached the level of 2-fold and most were less then 50%.
A follow up study by these investigators (Gómez et al., 2005) utilized a similar paradigm of 7
mg/kg/day i.p. injections of aluminium lactate into rats for 11 weeks (5 injections per week),
focusing on oxidative markers in the hippocampus. The most robust evidence of general
toxicity included 30% reductions in body weight. The levels of aluminium in hippocampus
increased ~5-fold, to 22 μg/g. While this study reported a similar elevation in TBARS (~ 2-
fold), increases in GSSG were not detected. Slight elevations (~50%) in mitochondrial
superoxide dismutase (SOD) mRNA, an important antioxidant enzyme that is induced by
oxidative stress, were noted.
Platt et al. (2001) examined the impact of aluminium on CNS integrity by direct
intracerebroventricular injection, via cannula, of 5.4 μg of aluminium chloride for 5
consecutive days; followed by either 7 days or 6 weeks of no treatment before sacrifice.
Interpretation of the study is somewhat confounded by damage to the brain resulting from
instillation of the cannula and from disruption of the BBB, however several findings were
revealing. Aluminium was found to distribute readily along white matter tracts and resulted in
activation of both astrocytes and microglia at sites distal to the injection site. Although not a
mimic of chronic exposure from drinking water or food sources, these data suggest that acute
exposure of neural tissues to aluminium salts elicits responses indicative of neurotoxicity.
Overall, however, the reported increases in markers of oxidative stress were of a relatively low
magnitude.
In another example of acute toxicity, Sreekumaran et al. (2003) examined several parameters
of neuronal morphology following a one-time injection of 8 mg/kg aluminium chloride into
CSF, via the cisterna magna of rats. Following a 30 day survival, animals were sacrificed and
Krewski et al. Page 120
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
tissues were prepared for Golgi impregnation to reveal dendritic and axonal structure.
Significant reductions (averaging 30 to 40%) in axonal length and dendritic branching were
noted in the treated group.
Yang et al. (2004) reported evidence of apoptotic cell death in the CNS of rats given a single
injection of aluminium maltolate (100 μl of 500 μM solution). In a small number of animals
(n = 4), 5 days after injection, TUNEL positive cells were detected in hippocampus along with
biochemical evidence of DNA fragmentation. Biochemical evidence of caspase activation
(caspase 3 and 12) was also reported. The study did not identify which type of cell(s) in the
hippocampus were affected.
Dramatic evidence of aluminium toxicity in retina of rats was reported by Lu et al. (2002).
Chronic i.p. injection of 12 mg of aluminium chloride for 16 weeks resulted in severe atrophy
of the retina with losses of photoreceptors. Interestingly, in this model, the location of
accumulated aluminium mimicked that seen in DAE patients. Aluminium was concentrated in
cytoplasmic granules that resemble lysosomes. There was no report of neurofibrillary
pathology or discussion of mechanisms of cell death.
Miu et al. (2003) studied rats given i.p. injections of aluminium gluconate 85 ug/100 g body
weight 3 times a week for 6 months. At sacrifice, the authors showed evidence of reductions
in neuronal density in the hippocampus, intracellular accumulations of aluminium in dense
granules, and thickening of meningeal blood vessels. Serum levels of aluminium were
measured at 3 intervals, recording levels of 86.8, 38.9, and 69.7 μg/100 mL of serum (mean
values for n=12). These levels were roughly 5 to 40-fold higher than controls. The average
level of aluminium in human serum ranges from 1-2 μg/L. Hence the levels in these rats were
about 3 to 8-fold the normal human level.
In a parallel study, using the same method of dosing and concentration of aluminium gluconate
for 12 weeks, Miu et al. (2004) reported finding similar lesions in addition to changes in myelin
structure and evidence of mitochondrial swelling in hippocampal neurons. None of these
pathologies was quantified however.
A key issue in the foregoing studies, however, relates to the speciation of aluminium and
mechanisms of uptake by neural cells. The pathologic distribution of aluminium in DAE
patients, and in some of the animal studies described above, are consistent with Tf-receptor-
mediated endocytosis. Free-flow endocytosis of aluminium citrate could produce a similar
pattern. Indeed, the pattern of aluminium accumulation in patients suffering from DAE,
membrane delineated lysosomal-like structures, is consistent with an endocytic mechanism of
uptake. It is unclear as to whether acute exposure to high levels of aluminium salts by direct
injection into CNS reasonably simulates the exposures which result from long-term low level
intakes via the oral route. In some of the acute exposure studies, aspects of human
neurogenerative disease are produced. However, as described above, pathologic analyses of
DAE patients do not reveal the pathologies found in AD and other neurodegenerative diseases,
including neurofibrillary pathology, symptoms of motor neuron disease (as occurs in rabbits),
or senile plaques. Overall, the connection between aluminium exposure and neuropathologic
features of human disease is not particularly strong, though some resports of positive
associations continue to foster debate.
Rodent models of aluminium toxicity by oral exposure—Aluminium has been
implicated in the aetiology of ALS in Kii peninsula of Japan and the islands of Guam. In these
environments, the levels of aluminium and manganese in drinking water are high while the
levels of calcium and magnesium are low (for review see Garruto, 1991). Kihira et al.
(2002) reported that mice feed diets high in aluminium (1.56 g/100 g) and low in Ca/Mg (50%
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reduction from control diet) developed pathologic features of human disease (Kihira et al.,
2002), including neuronal accumulation of tau immunoreactivity in a pattern resembling pre-
tangles of AD. Reductions in the density of cortical neurons were also noted in mice on low
calcium/magnesium diets and in mice on the aluminium + low Ca/Mg diet. Mice given high
doses of aluminium alone showed no evidence of neuronal loss. No symptoms of motor neuron
disease were noted and animals exhibited near normal lifespans. Lowering Ca and Mg in diet
induced a greater number of abnormalities in general health and appearance than Al laced diets
(with or without manipulation of calcium/magnesium levels). Intracellular accumulations of
aluminium were noted. Although it is possible that the levels of other minerals in the diet could
influence the toxicity of aluminium, the most informative outcome of this study was that
chronically high doses of aluminium did not result in obvious neurodegeneration, profound
neuropathology, or clinical symptoms relevant to motor neuron disease. The average 25g
mouse consumes about 5 g of food per day (formulated to contain 15.60 mg/g of aluminium).
Therefore, the estimated consumption of aluminium by these animals would be about 3 g/kg/
day, a dose nearly unattainable in humans. Despite this extremely high dose for a prolonged
period, these animals developed relatively few phenotypes related to human neurological
disease.
In a study of chronic exposure to aluminium in diet (rats fed 32 mg aluminium sulphate per
day for 5 weeks), no evidence of apoptotic cells (TUNEL positive) was noted in cerebral cortex
(Rodella et al., 2001). Similarly, the relative density of neurons in cortex was not obviously
diminished. The authors did report that the density of NADPH-diaphorase positive neurons in
cortex was diminished by 50%, but a better validation of such a reduction could be made by
unbiased stereological assessments of these neurons (Gundersen et al., 1988).
Swegert et al. (1999) examined the effects of aluminium exposure on oxidative metabolism in
rats given diets supplemented with aluminium chloride at an estimated dose of 20 mg/kg/day,
which is approximately 20 times higher than the maximum amount normally consumed by
humans from food. Animals were treated for 90-120 days at which time tissues were harvested
and mitochondria were isolated for further study. Thirty to forty percent reductions in
mitochondrial respiration rates were noted in brain mitochondria, with a paradoxical increase
(~2-fold) in respiration rates in heart.
Flora et al. (2003) reported similar changes in oxidative markers in rats given aluminium nitrate
in water at a concentration of 0.2% (2 g/l) for 8 months. Levels of aluminium in blood increased
from ~3 μg/dL to >20 μg/dL. In brain, the levels increased from ~8 μg/dL to ~16 μg/dL. Indices
of lipid peroxidation (TBARS) and the levels of GSSG were increased in brain. Again,
however, the magnitude of changes in these measures was less than 2-fold with only very
modest increases in the levels of GSSG.
Golub et al. (2000) fed mice defined diets containing 1000 μg/g of aluminium lactate from
conception to sacrifice at 24 months of age (~ dose 100 mg/kg/day). Several parameters were
analyzed (see below for discussion of cognitive behaviour), but relevant to this section was an
absence of evidence for oxidative stress (no increase in TBARS). Surprisingly, however,
despite the high dose of aluminium in the diet, the levels of accumulated aluminium in the
brain were not significantly greater than that of controls.
Collectively, these studies establish that dietary aluminium intake can lead to accumulation of
aluminium (speciation uncertain) in the brain of rats and mice. Modest increases in measures
of oxidative stress have been noted, but evidence of significant neuropathology related to
aluminium intake was not consistently noted. The level of sustained oxidative injury that is
required to produce neuropsychological abnormalities is unknown, few of the oxidative
markers measured in the foregoing studies increased as much as 2-fold.
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Behavioural studies of laboratory animals exposed to aluminium
Before reviewing the literature concerning the cognitive behaviour of laboratory animals
exposed to aluminium, it is worth noting that there are detailed longitudinal studies of humans
exposed to elevated levels of aluminium in the workplace. Buchta et al. (2003) examined a
battery of neuropsychological and motor skills in a large cohort of auto manufacturing workers.
They recorded average urine levels of aluminium of 70 μg/L, which compares with 1-2 μg/L
in most individuals (Buchta et al., 2003). Individuals who had experienced at least 6 years of
exposure were selected for analysis and their results were compared with those of co-workers
of similar age, gender, and education who worked in other areas of manufacturing. The only
measure by which the workers exposed to aluminium could be distinguished was a small
reduction in reaction time (speed to respond to a question or perform a motor task). In all other
cognitive measures including intelligence quotient (IQ), verbal intelligence, and the European
Neurobehavioral Evaluation System, workers exposed to aluminium were no different from
control populations (Buchta et al., 2003). Thus in humans, exposure to significant levels of
aluminium does not lead to robust changes in cognitive function. However, the above study
did not assess the levels of aluminium in blood, which would indicate absorption. Though there
are clearly too few human studies, much of the data from studies in adult animals also suggests
aluminium exposure does not lead to significant reductions in cognitive function.
As mentioned above, a lifelong exposure of Swiss Webster and C57BL/6J mice to high doses
of aluminium (~100 mg/kg/day in feed) was utilized as a paradigm by Golub et al. (2000).
With the caveat that brain levels of aluminium were not elevated in the treated mice, suggesting
poor absorption, there were little or no deleterious effects of the aluminium-laced diet on
several behavioural measures, including grip strength (slight reduction ~10%), temperature
sensitivity (slight increase), and spatial reference memory. In the latter task, data from the
C57Bl/6J mice are most informative where no adverse impact on acquisition or retention of
memory was noted. A prior study by Golub et al. (1995) fed Swiss Webster mice food
supplemented with either 500 μg or 1000 μg/g aluminium lactate (calculated dose 200 mg/kg/
day) from conception to sacrifice at 150-170 days of age. In several measures of cognitive
function, mice fed the aluminium laced diet performed as well as controls. However, 10 to
15% reductions in fore and hindlimb grip strength were noted.
Similarly, although Esparza et al. (2003) reported increased levels of several oxidative markers
in the brains of rats given high doses of aluminium (5 and 10 mg/kg/day by i.p. injection), no
changes in performance in a passive avoidance task were noted in animals treated with either
dose. The classic passive avoidance task involves an electric shock deterrent in which rats are
required to remember that the more preferred location (a dark enclosure next to the lighted
open space) is associated with shock. Retention of the memory is usually tested 24 hr after
conditioning. Hence the task is a measure of memory function.
In contrast to the results of the study by Esparza et al. (2003), Zhang et al. (2003) reported
dramatic reductions in performance in passive avoidance in rats exposed to aluminium through
drinking water. In the latter paradigm, aluminium chloride was provided through drinking
water at a concentration of 3 mg/mL for 90 days. Serum levels of aluminium were not reported.
Interestingly, in this study, an extract of Dispsacus asper (a herbal medicine) and vitamin E
were shown to alleviate the memory deficits. The authors suggested that the anti-inflammatory
and/or anti-oxidant properties of these drugs contributed to the improvements.
Domingo et al. (1996) examined passive avoidance in rats provided drinking water containing
aluminium nitrate at concentrations that would equate to doses predicted to be 50 and 100 mg/
kg/day for 6.5 months. No effects of the high aluminium exposure on measures of spontaneous
motor activity or learning in passive avoidance tasks were noted.
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Struys-Ponsor et al. (1997) studied rats given i.p. injections of 667 μg of aluminium gluconate
3 times per week for 60 days prior to assessment of spatial memory in a radial water maze task.
Although a slowing of reaction time was noted, there were no statistically significant deficits
in the ability of the aluminium-injected animals to perform the task.
Two studies by Miu et al. (2003; 2004), the pathological findings of which are described above,
also assessed neuropsychiatric parameters. The 2003 work reported slight reductions in
performance in a passive-avoidance memory task and in a spatial reference memory task. The
latter work (2004) reported changes in behaviour in open fields which were interpreted as
reductions in spontaneous activity and emotional responses.
Overall, the data on neuropsychological measures in rodents given high doses of aluminium
by oral routes are not suggestive of profound toxicity. However, none of these animal studies
is able to reproduce life-time exposures that could occur over the life-span of humans. It is
clear that humans with compromised renal function develop neuropsychological symptoms
upon exposure to elevated levels of aluminium. However, from the study of individuals
exposed occupationally to aluminium fumes, humans with normal kidney function seem to
tolerate high levels of exposure relatively well (see above). The degree to which the chemical
form of aluminium, the route of exposure, and the age/health of the individual could modulate
the neurotoxicity of aluminium is uncertain and has not been extensively modeled in animals.
Effects on Bone
The bone constitutes a primary site for the deposition of aluminium (Mahieu et al., 2004) (see
also Toxicokinetics, Distribution (Including Compartmentalization), Animal Studies, Bone).
Elevated aluminium levels in humans, primarily in individuals with impaired renal function,
have been associated with several bone disorders including osteomalacia (excess
unmineralized osteoid) and aplastic bone disease which is characterized by normal or decreased
osteoid (Firling et al., 1999). The mechanism by which aluminium exerts its effects on bone
tissue has not been fully elucidated (Cointry et al., 2005). Experimental evidence in a number
of different animal models has led to a variety of proposed ways in which aluminium might
influence new bone development. It has been suggested that aluminium may directly interfere
with osteoblast activity thereby influencing the production or mineralization of osteoid (Firling
et al., 1999). Bone formation may be impaired due to aluminium induced reductions in the total
number of osteoblasts (Sedman et al., 1987). Direct physiochemical inhibition of
mineralization sites has also been proposed as a potential mechanism (Firling et al., 1999).
Aluminium-induced alterations in the PTH-calcium axis have also been extensively
investigated with respect to aluminium-induced bone toxicity (Mahieu et al., 2004). One of the
functions of the PTH is to stimulate bone resorption by increasing osteoblast activity (Quarles,
1990). It has been proposed that aluminium impairs the secretion of this hormone from
parathyroid glands (Morrisey et al., 1983). Numerous studies, using a variety of animal models,
have been conducted to investigate the effects of aluminium on bone. In interpreting the results
of these studies, it is important to consider the difference in bone remodelling physiology
between species. It is thought that larger animals such as the dog and pig approximate the bone
physiology of humans more closely than rats and mice (Quarles, 1990). The route of aluminium
administration and the duration of the study period may also have had significant impacts on
the overall results of these studies. It should also be noted that the use of large doses of
aluminium in some of these experimental studies may have resulted in a generalized toxicity
to the animals, which could complicate the interpretation of aluminium-induced bone toxicity
endpoints (Quarles et al., 1988). Some of the in vitro and animal studies investigating the effects
of aluminium and bone have been reviewed and are summarized below.
PTH is considered to enhance osteoblast-directed osteoclast activity, and it has been proposed
that aluminium may inhibit the production or secretion of this hormone (Jeffery et al., 1996).
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Morrissey et al. (1983) used dispersed bovine parathyroid cells to determine if aluminium
directly affects PTH secretion. Digested bovine parathyroid glands were placed in media
containing varying concentrations of aluminium, ranging from 0.5 to 2.0 mM. The incubations
were terminated after 2 hr and the amount of hormone secreted into the medium was determined
by radioimmunoassay. The secretion of PTH decreased with increasing amounts of aluminium.
Hormone secretion decreased by an average of 68% in cells incubated with 2.0 mM aluminium
compared to the cells incubated in the absence of aluminium. To examine if there was an
irreversible toxic effect of aluminium with respect to PTH secretion, the cells were incubated
for 1 or 6 hr with 2.0 mM aluminium, washed with low calcium buffer, and re-incubated in
media without aluminium. Hormone secretion appeared to be restored and was comparable to
that of cells which had not been incubated with aluminium. Cells were also incubated with
radio-labelled leucine to examine the effect of aluminium on the biosynthesis of proparathyroid
hormone, PTH, and parathyroid secretory protein. Examination of the incorporation of this
radio-labelled amino acid into these proteins revealed that the biosynthesis of these compounds
was not affected by aluminium incubation. Therefore, the results of this study suggest that
aluminium directly affects the secretion of protein from parathyroid cells.
Ellis et al. (1979) investigated the effects of aluminium on bone toxicity in a group of 20 rats
given daily i.p. injections of aluminium chloride for periods of up to three months. Sixteen rats
received daily i.p. injections of 0.27 mg Al/day (as aluminium chloride), increasing gradually
to a dose of up to 2.7 mg Al/day. The periods for the injections ranged from 48 to 85 days and,
in 5 animals, no further injections were given after 63 or 84 days of treatment until sacrifice,
27 or 49 days later. The total dose of aluminium ranged from 38 mg to 109 mg. Four controls
were i.p. injected with saline. The whole femur bone aluminium content was higher in the 16
rats given aluminium chloride (176 ± 8.2 ppm/ash compared with the controls (15.4 ± 4.7
appm). A mineralization defect of bone was detected in the rats after 53 days of aluminium
treatment, and this increased in severity as the injections were continued. This was marked by
an excess of osteoid on the surface of normally mineralized cartilage at the usual site of
endochondral ossification. The excess osteoid was typical of osteomalacia with abnormally
wide seams and no calcification front. Endochondral ossification was restored to normal, but
osteomalacia persisted for up to 49 days after the cessation of treatment.
Chan et al. (1983) investigated the effects of i.p. aluminium chloride (1.5 mg/kg/day) for a
duration of 9 weeks in normal (n=16) and uraemic (n=23) rats. Eight rats in the nonuraemic
group and 10 rats in the uraemic group received the aluminium treatment, while no injections
were given to the remaining control animals. At the end of the treatment period, the rats were
euthanized and tissue aluminium, serum vitamin D metabolites, and quantitative bone histology
were measured. Bone aluminium concentrations were higher in uraemic rats (121 ± 27 mg/kg)
than in normal rats (47 ± 4 mg/kg), and liver aluminium values were higher in the normal group
(175 ± 47 mg/kg) than in the uraemic rats (100 ± 36 mg/kg). Aluminium did not appear to have
an effect on the levels of any vitamin D metabolites; however, serum concentrations of 25-
hydroxyvitamin D and 24,25-dihydroxyvitamin D were reduced as a direct result of uraemia.
The nonuraemic aluminium treated animals did not exhibit any significant skeletal changes as
compared to the controls. Marrow fibrosis and osteomalacia developed in some of the uraemic,
non-aluminium treated animals. However, osteomalacia as defined by (1) an increase in osteoid
area (29 ± 13% uraemia + aluminium vs. 3 ± 6% uraemia, no aluminium), (2) an increase in
osteoid surface (42 ± 16% vs. 7 ± 11%), and (3) an abnormal pattern of tetracycline uptake at
the calcification front, was more severe in uraemic animals treated with aluminium than in
untreated uraemic animals.
Robertson et al. (1983) conducted a study to investigate the effects of aluminium on bone
histology and PTH levels, and to determine if chronic renal failure accentuates aluminium
toxicity. Male Wistar rats were divided into 5 groups. The first group (n=5) received a low
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dose of aluminium (i.p. injection 0.1 mg aluminium as aluminium chloride 5days/week), the
second group (n=5) received a high dose of aluminium (i.p. injection of 1.0 mg aluminium as
aluminium chloride 5 days/week); the control group (n=4) was administered an i.p injection
of an equal volume of diluent over the same injection schedule. One group (n=6) of rats
underwent partial nephrectomy and received an i.p injection of diluent, and another group (n=5)
underwent partial nephrectomy and received an i.p. injection of 1.0 mg aluminium as
aluminium chloride 5 days/week. The treatment lasted for 120 days for the control and low
dose aluminium group, but for a shorter period (between 90-100 days) for the other three groups
due to the need for early sacrifice as a result of high attrition in these groups. The trabecular
bone of the ischium and the iliac wing was obtained from each animal and examined
histologically; the bone mineralization process was evaluated by double tetracycline labelling.
There were no differences in bone parameters between the low dose aluminium group and the
controls. In the other three groups, the relative osteoid volume (p < 0.02) and the osteoid seam
width (p < 0.001) were significantly increased as compared to the controls. These parameters
are indicators of osteomalacia. The number of osteoclasts/mm2 increased in nephrectomized
rats not exposed to aluminium (p < 0.02) and decreased (p < 0.05) in rats with normal renal
function exposed to high doses of aluminium. The number of osteoclasts/mm2 was not
significantly different from that of the control level for the aluminium treated nephrectomized
rats. Animals with normal renal function given the high dose were the only group to exhibit a
decrease in PTH level, which may explain the reduced osteoclast numbers in this group.
However, the increase in osteoclasts/mm2, as compared to controls (8.13 ± 2.92 vs. 3.93 ± 100
osteoclasts/mm2), in the non-exposed renal failure group, compared to the reduction of
osteoclasts in the exposed renal failure group (2.34 ± 1.38 osteoclasts/mm2 vs. 3.93 ± 100
osteoclasts/mm2), indicates that aluminium may have a direct toxic effect on osteoclastic
activity.
Cortical bone growth was measured in rats given aluminium to study the early effects of
aluminium on bone (Goodman, 1984). Thirty weanling male rats were assigned to one of three
groups: control (n=10), experimental (n=10), or basal (n=10). Rats in the experimental group
were given i.p. injections of aluminium chloride (2 mg aluminium, 5 days per week); animals
in the control group received an injection of saline vehicle at the same frequency, and the basal
animals did not receive any treatment. The treatment period lasted for 44 days. Bone growth
was assessed over two consecutive periods of 28 and 16 days in the control and experimental
rats, using tetracycline labelling of bone. Rats in the basal group were sacrificed on the first
day of the experimental period. Histological measurements in sections of bone obtained from
the basal group were interpreted to represent the status of the bone at the beginning of the bone-
labelling period in rats from the control and experimental groups. Bone (0.017 ± 0.004 mm3/
day) and matrix formation (0.017 ± 0.004mm3/day) in the experimental group remained at
control levels (bone formation: 0.020 ± 0.004, matrix formation 0.02 ± 0.004 mm3/day) during
the first period of assessment (28 days after treatment initiation); however, both these
measurements were significantly lower (p <0.01) than control values at the end of the entire
44 day study (bone formation: 0.014 ± 0.003 mm3/day vs. 0.022 ± 0.003mm3/day, matrix
formation:0.014 ± 0.003mm3/day vs. 0.022 ± 0.003mm3/day). Bone and matrix apposition at
the periosteum in aluminium treated animals was significantly reduced (p < 0.0001) from
control levels at the end of the 44 day treatment period, but was not significantly different at
the assessment following 28 days of treatment. Aluminium treatment did not induce a state of
osteomalacia as no significant effect on the osteoid width or the mineralization front width was
apparent. The results of this study indicate that aluminium reduces bone and matrix formation
early in the course of aluminium exposure, prior to the development of histologically apparent
osteomalacia. Aluminium may affect matrix synthesis by reducing the total number of active
osteoblasts or diminishing the cellular activity of individual osteoblasts.
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Goodman et al. (1984a) examined the effect of short-term (4 week exposure) aluminium
administration on bone growth and histology, and evaluated the role of renal insufficiency in
mediating the skeletal effects of aluminium. Thirty rats underwent partial nephrectomy and
were assigned to one of three groups: control, aluminium-treated, or basal control. Thirty
additional rats with intact renal function were divided into the same treatment assignments.
Aluminium treated rats received i.p. injections of aluminium chloride (AlCl3) in saline 5 days/
wk for 4 weeks; the aluminium dose was 2 mg/day. Control rats received injections of saline
only, according to the same treatment schedule. Bone growth, bone formation, mineralization,
and resorption were measured using double tetracycline labelling of bone. Total bone and
matrix formation and periosteal bone and matrix formation were reduced in both
nephrectomized and normal renal function rats treated with aluminium as compared to the
respective controls. Periosteal bone and matrix formation were similarly reduced in both
groups. There was no difference in bone parameters between the control rats of the
nephrectomized group as compared to the normal renal function control rats; however, total
bone, total matrix, periosteal bone, and periosteal matrix formations were all less in the
nephrectomized aluminium treated rats as compared to the non-nephrectomized aluminium
treated rats. Resorption surface was greater in both aluminium- (1.70 ± 0.41mm vs. 1.33 ± 0.34
mm) and nephrectomized-aluminium-treated (1.87 ± 0.6 mm vs. 165 ± 0.43 mm) rats compared
to the respective controls, and resorptive activity at the endosteum was greater (p < 0.05) in
the nephrectomized aluminium treated group (12.2 ± 6.3 μm/d) than in the controls (7.9 ± 4.9
μm/d). Serum calcium and phosphorus concentrations were similar in aluminium-treated and
control animals, suggesting that PTH secretion was not substantially affected by aluminium
administration. Osteomalacia was not detected, but it should be considered that the duration
of this study may not have been of sufficient length for this condition to develop. The results
of this study suggest that aluminium exerts is toxic effects on bone by acting directly to reduce
new bone and matrix synthesis. In addition, it appears that aluminium may act to increase bone
resorption. The enhanced effect of aluminium in nephrectomized rats may be a result of
increased aluminium accumulation due to an impaired ability to excrete the metal; however,
aluminium in bone was not quantified in this study.
In order to investigate the effects of aluminium on the vitamin D-dependent mineralization
process, aluminium chloride (1 mg/kg) was administered i.v. 3 times per week for 3 weeks to
normal (n=5) and vitamin D-deficient (n=5) beagle puppies (Quarles et al., 1985). Vitamin
deficiency was induced in the 5 dogs by providing a diet deficient in vitamin D and calcium
for a period of 15 weeks before treatment initiation. Bone biopsies and plasma were obtained
before and after the 3 week treatment period in each group. In the next phase of this study,
aluminium chloride administration was continued at a lower dose (1 mg/kg twice a week) and
both groups received the diet fortified with calcium and vitamin D. This phase of the study
lasted for 11 weeks. The vitamin D deficient dogs displayed biochemical and bone biopsy
evidence of osteomalacia before administration of aluminium. Plasma phosphorus, PTH, and
25-hydroxyvitamin D concentrations did not appear to be affected by the 3 weeks of aluminium
administration in either group. However, bone aluminium content increased to a greater extent
in the vitamin D-deficient dogs (390 ± 24.3 μg/g) than in the normal dogs (73.6 ± 10.6 μg/g).
After 3 weeks of aluminium treatment, the bone histology in both groups revealed changes
consistent only with aging. Provision of a calcium/vitamin D replete diet to the deficient dogs,
and reduction of aluminium dosage for 11 weeks resulted normalization of their plasma
biochemistry and healing of the osteomalacia. The bone aluminium content of the non-vitamin
D deficient dogs increased during the additional 11 weeks of aluminium exposure to 151.0 ±
11.3 μg/g as compared to a bone aluminium content of 73.6 ± 10.6 μg/g after 3weeks of
exposure. In contrast, the bone aluminium content in the vitamin D deficient dogs decreased
from 390 ± 24.3 μg/g to 173.5 ± 5.6 μg/g at the end of the additional 11 weeks of exposure.
Histochemical staining for bone aluminium revealed no apparent aluminium in the normal
group and, in the vitamin-D deficient group, there was identifiable aluminium at the
Krewski et al. Page 127
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
mineralization fronts after the 3 weeks of treatment. At the end of the 11 weeks of additional
exposure staining for aluminium was detectable only in the cement lines, indicating that
mineralization occurred over the previous sites of aluminium deposition. The results of this
investigation indicate that aluminium accumulates preferentially in pre-existent osteomalacic
bone and localizes at the calcification front (osteoid-bone interface). The presence of
aluminium at the calcification front did not impair vitamin D-dependent mineralization as
remineralization occurred in the bones of the osteomalacic pups following vitamin-D repletion.
Osteomalacia did not occur in the normal pups; however, this does not eliminate the possibility
that aluminium administration at higher doses or for prolonged periods might cause bone
toxicity in these animals. Therefore, although aluminium may have the potential to cause
osteomalacia, its presence at mineralization fronts does not appear to be the mechanism through
which this occurs.
Alfrey et al. (1985) studied aluminium compartmentalization in rats with an induced state of
uraemia or hypoparathyroidism. Seventy four male rats were divided into two main study
groups. The first group consisted of 10 animals that underwent selective PTX, 10 animals were
rendered uraemic by uninephrectomy, 11 animals underwent both nephroctomy and PTX, and
8 animals served as controls. 1,25(OH)2D3 was administered to normalize serum calcium
levels. All animals received 1.5 mg/kg aluminium (as AlCl3) by i.p. injection 5 days/wk for
79 days. There was a significantly greater (p < 0.001) trabecular bone osteoid area (percent
total bone area) in the PTX uraemic group than in the uraemic group (45 ± 9.7% compared to
13.4 ± 10.6%). Plasma calcium levels were significantly higher in the uraemic PTX group
(10.7 ± 0.9 mg/dL) and lower in the control PTX group (9.0 ± 0.5 mg/L) than in their respective
controls (9.9 ± 0.6 g/L: uraemic group; 9.8 ± 0.3 mg/L: control group), and phosphorus levels
were significantly higher in both the PTX uraemic group (9.3 ± 1.5 mg/L) and PTX control
group (8.1 ± 0.6mg/L) as compared to the controls (5.9 ± 0.3mg/L). The second study group
was comprised of 35 uraemic rats; 8 of these rats had previously undergone selective PTX and
were given 1,25(OH)2D3. The uraemic PTX animals and 8 of the uaremic animals received
1.5 mg AlCl3/kg by i.p. injection 5 days/week for 35 days, and were killed at the end of this
treatment period. Aluminium injections were discontinued in the remaining animals, and nine
underwent selective PTX at this time. These animals were followed for an additional 30 days.
Bone aluminium levels in the animals killed after 35 days were lower (p < 0.05) in the PTX
uraemic group than in the uraemic control group (37 ± 7.6 and 47 ± 7.6 mg/kg, respectively).
The bone aluminium levels in the uraemic group that underwent PTX after aluminium loading
(53 ± 8 mg/kg) and in the uraemic group (48 ± 5.7 mg/kg) 30 days after aluminium
discontinuation were not significantly different. The results of this study suggest that PTX
affects the compartmentalization of aluminium in bone, especially in animals in a uraemic
state. It also appears that PTX may intensify aluminium-induced osteomalacia as the PTX
group had significantly greater bone osteoid area than the uraemic group of rats.
Galceran et al. (1987) conducted a study to further characterize the mechanism of aluminium
induced osteomalacia. One group of dogs (n=7) was treated i.v. with 0.75 mg aluminium, 5
days a week for 3 months; 7 additional dogs served as controls. At the end of the treatment
period, the dogs were killed, and the tibiae were obtained and perfused in vitro. PTH and
methylxanthine (an inhibitor of phosphodiesterase) were added to the perfusate. The serum
aluminium level was 20.4 ± 2.3 μg/L before treatment, and rose significantly to 206.2 ± 28.3
(p < 0.01) after aluminium administration. No significant difference in PTH levels was detected
before and after aluminium treatment. Because PTH acts to stimulate cAMP release from bone,
cAMP levels were measured in both groups before and after PTH administration to examine
the effect of aluminium on this process. Although the basal cAMP secretion was the same in
both groups of dogs, cAMP increased to a peak of 188.2 ± 30.6 pmol/min in the normal dogs
vs. 113 ± 8.15 pmol/min in the aluminium treated dogs after PTH was added to the perfusate
(p < 0.05). Examination of bone biopsies taken before and after aluminium administration
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revealed that the number of osteoblasts had decreased 8-fold (p < 0.01) following aluminium
treatment. Aluminium treatment led to an increase in the percent total osteoid surface (44.3 ±
4.7% vs. 22.1 ± 4.1%), decreased mineral apposition rate (0.5 ± 0.4 μm/day vs. 1.3 ± 0.2 μm/
day), and aluminium deposition at the mineralization front. Despite the decrease in osteoblast
number, the histological features of the post aluminium treatment biopsies indicated that
aluminium stimulated osteoblastic activity at some point during its administration. This was
apparent from the presentation of new woven bone formation in two dogs, and a layer of newly
deposited lamellar bone covering all trabecular surfaces in another. Aluminium also appeared
to stimulate the activity of fibroblasts as indicated by the presence of extensive marrow fibrosis
in five of the treated dogs. These data support the possibility that aluminium is capable of both
stimulating and suppressing matrix synthesis at different times throughout the exposure period.
Although the levels of PTH were similar in the aluminium exposed and control animals, the
decreased generation of cAMP following the addition of PTH to the perfused bones of the
aluminium treated group suggests that aluminium may cause bones to be resistant to the effects
of PTH.
Sedman et al. (1987) examined the effects of i.v. aluminium injections for a duration of 8 weeks
on various bone parameters in growing piglets. Four piglets were administered 1.5 mg AlCl3/
kg/day parenterally, and 4 control piglets received daily injections of deionised water for the
same period. Quantitative bone histology and measurements of bone formation were assessed
at three skeletal sites (two in the proximal tibia and one in the distal femur) in both the
experimental and control groups. Bone aluminium was significantly higher (p < 0.001) in
experimental animals (241 ± 40 mg/kg) as compared to the controls (1.6 ± 0.9 mg/kg).
Osteomalacia, as defined by histological criteria, was documented in all aluminium-treated
animals. The rate of mineralized bone formation was also lower in the aluminium-treated group
compared to that in the controls at all three sites. However, it was found that, at sites of
continued osteoblastic activity, total osteoid production did not differ between the two groups.
These results suggest that bone mineralization is inhibited by aluminium via a decrease in the
number of active osteoblasts rather than by an inhibition of the calcification of osteoid.
Ott et al. (1987) conducted a study to investigate the development and reversibility of
aluminium-induced bone toxicity in weanling and adult rats. Four groups of weanling rats and
one group of adult rats were used in this study. Each group consisted of 18 rats. Half the rats
in each group received daily i.p. injections 10mg Al/kg as aluminium chloride. The other half
of the group was given normal saline solution. Weanling rats were sacrificed after 3, 6, or 9
weeks of treatment. The remaining group of weanling rats received injections for 9 weeks, and
was allowed to recover for 3 weeks. The adult group received aluminium treatment for 9 weeks.
The effects of aluminium on blood serum levels of various compounds, and on aluminium
bone content, and rate of bone formation were assessed after intervals of 3, 6, and 9 weeks.
The calcium, phosphate, creatinine, and PTH levels were similar in aluminium-treated rats and
controls. Aluminium was detectable by histochemical stain after 6 weeks in the aluminium
treated animals; however, other bone parameters did not differ significantly at this time between
the treated animals and the controls. A decrease in bone formation (measured by tetracycline
labelling) on trabecular and endosteal surfaces was apparent by 9 weeks in the aluminium
exposed groups. The weanling rats had a bone formation rate of (0.15 ± 0.2 mm2/100 days vs.
0.46 ± 0.14 mm2/100 days) which was significantly lower (p < 0.02) than the rate in the controls,
while the adult rats had a rate of (0.04 ± 0.06 mm2/100 days) vs. (0.23 ± 0.12 mm2/100 days)
in the controls. One group of rats was allowed to recover for 3 weeks without any aluminium
administration. The bone formation rate in the younger group was similar to that of the controls
after 3 weeks of recovery. Adult rats showed signs of early osteomalacia as evidenced by an
increase in the length (4.75 ± 2.3 vs. 2.15 ± 1.5% surface) and width (18.4 ± 9.7 vs. 4.8 ± 1.3
μm) of the trabecular osteoid as compared to the controls. In this study it appeared that
aluminium administration led to decreased rates of bone formation in rats despite normal
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calcium and parathyroid levels, and normal renal function. It is possible that aluminium induced
decreased bone formation by inhibiting osteoblast formation or activity.
Quarles et al. (1988) conducted a study to define the primary effects of aluminium on bone in
the mammalian species, and to examine the dose/time-dependent actions of aluminium on
bone. Two year-old beagles were assigned to one of three treatment regimens. The first group
(n=6) received 0.75 mg Al/kg as aluminium chloride i.v. three times per week, the second
group (n=6) received 1.20 mg Al/kg at the same dosing schedule, and the third group (n=6)
received sodium chloride i.v. and served as controls. The treatment period lasted for 16 weeks.
Transcortical bone biopsies were taken from each group after 8 weeks and 16 weeks. In both
the low and high dose aluminium groups, serum aluminium levels were significantly elevated
compared with those of controls, but calcium, or PTH levels were not altered by treatment.
Bone biopsies taken at 8 weeks in the low dose group displayed characteristics of a low turnover
state, as marked by a reduction of bone resorption (2.6 ± 0.63% vs. 4.5 ± 0.39%) and osteoblast–
covered bone surfaces (2.02 ± 0.51% vs. 7.64 ± 1.86%) as compared to the controls. The
mineralized bone formation rate was also found to be significantly decreased. Biopsies taken
at week 16 of aluminium administration in the low dose group displayed evidence of de
novo bone formation, as well as an increase of bone volume (38.9% ± 1.35 vs. 25.2% ± 2.56)
and trabecular number (3.56/mm ± 0.23 vs. 2.88 ± 0.11) compared to the controls. The 16 week
biopsies displayed a persistence of inactive osteoid marked by a diminished mineralization
front in the low dose group compared to the controls (46.0 ± 4.2% vs. 71.9 ± 2.92%). The bone
biopsies obtained from the high dose aluminium group at 8 weeks displayed changes similar
to those exhibited after 16 weeks of the low dose treatment. De novo bone formation was
evidenced by an increase in trabecular number as compared to the controls (3.41 ± 0.18/mm
vs. 2.88 ± 0.11/mm) and increased bone volume (36.5 ± 2.38% vs. 25.2 ± 2.56%). Poorly
mineralized woven bone accounted for a large proportion of the newly synthesized tissue,
comprising 11.5 ± 4.6% of the bone volume. High dose treatment for 16 weeks further enhanced
bone volume (50.4 ± 4.61%) and trabecular number (3.90 ± 0.5/mm). The woven osteoid
volume at 16 weeks decreased to 2.43 ± 0.96% of the total bone volume, indicating that
heterogeneous calcification of this tissue was more complete. The observation of histological
changes similar to those observed in disorders characterized by low bone turnover in the low-
dose aluminium group after 8 weeks, combined with the observation of new bone formation
and stimulation of cellular activity after longer treatment, suggests that aluminium may exert
both inhibitory and stimulatory effects on osteoblasts.
To further examine the influence of osteoblast function on aluminium-induced of de novo bone
formation, Quarles et al. (1989) compared the effects of aluminium in TPTX beagles (n=4)
with beagles which underwent thyroidectomy but had intact parathyroid glands (n=4). The
animals underwent TPTX as a means to reduce osteoblast number and activity. The treatment
procedure began 2 months after surgery, when sufficient time had elapsed to achieve a new
steady state of bone remodelling activity. 1.25 mg AlCl3/kg was administered to both groups
of animals by i.v. three times per week for 8 weeks. The TPTX animals received supplements
of calcium carbonate and calcitrol in order to maintain normal plasma 1,25-dihydroxyvitamin
D levels as well as normocalcemia. Both groups were administered thyroxine to sustain normal
free thyroxine concentrations. Although both groups of animals received the same aluminium
treatment, TPTX beagles exhibited a significantly higher (p < 0.05) serum aluminium level
(2386.1 μg/L) as compared to the controls (1087.0 μg/L). Aluminium administration did not
alter the plasma calcium, creatinine, or PTH from baseline levels in either group of animals.
Bone biopsies taken from the control animals after 8 weeks of treatment displayed evidence
of de novo bone formation as compared to baseline bone parameters. This was evidenced by
an increased bone volume (47.0 ± 1.0 vs. 30.4 ± 09%) and trabucular number (4.1 ± 0.2 vs.
3.2 ± 0.2/mm). Deposition of poorly mineralized woven bone accounted for much of the
enhanced bone volume (9.9 ± 2.7%). TPTX animals demonstrated significantly less evidence
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of bone formation. Bone volume (35.5 ± 1.7% vs. 27.7 ± 1.9% at baseline) and woven tissue
volume (1.4 ± 0.8% vs. 9.85 ± 2.66%), as well trabecular number (3.3 ± 0.1/mm vs. 4.2 ± 0.2/
mm) were significantly less than those of the aluminium treated non-TPTX controls. It appears
that the diminished functional osteoblast pool in the TPTX beagles limited the ability of
aluminium to stimulate neo-osteogenesis.
Bellows et al. (1999) examined the effects of aluminium on osteoprogenitor proliferation and
differentiation, cell survival, and bone formation in long-term rat calvaria cell cultures. The
cells obtained from foetal rats were incubated in medium with or without aluminium added.
The aluminium treated cells were incubated at various concentrations ranging from 1 uM to 1
mM of aluminium for up to 19 days. The numbers of mineralized and unmineralized bone or
osteoid nodules in each culture dish were quantified by in situ staining. Alkaline phosphatase
activity, cell viability, and cytotoxicity were also determined. Nodule formation was
significantly increased (p < 0.001) by 30-1000 μM aluminium incubation, in a dose dependent
manner, at 11 days but not at 17 days. Control and aluminium-treated cultures appeared similar
with respect to nodules and cell layers at day 13 of culture. However, at day 17 of culture,
aluminium concentrations of 30 μM and above resulted in reduced cellularity and an increased
fibrilar appearance of the matrix that had formed outside of, or adjacent to, nodules. Aluminium
also increased alkaline phosphatase activity at all time points in a dose-dependent manner.
Significantly fewer viable cells were present in the 300 μM aluminium-containing cultures
after 13 and 17 days. The results of this experiment indicate that aluminium has a stimulatory
effect upon existing osteoprogenitor cells leading to an accelerated rate of osteoblastic
differentiation and nodule formation, while inhibiting nodule mineralization. The
concentration of aluminium at which this effect occurred resulted in decreased cell viability
and enhanced cytotoxicity.
The effect of aluminium administration on bone, in a model of osteopoenia induced by chronic
acid overload in rats with normal renal function, was examined by Gomez-Alonso et al.
(1999). Thirteen male rats with induced osteopoenia were divided into two groups. The first
group (n=8) received 10 mg/kg of AlCl3 i.p. 5 times per week for 4 months, the second group
(n=5) did not receive any aluminium treatment. At the end of the experiment, both tibias from
each animal were extracted for the determination of aluminium content, in vitro bone
densitometry, and histological analysis. Bone mineral density, measured at the proximal end
of the tibia, was found to be significantly higher (<0.05) in the aluminium-treated group (0.292
± 0.01 g/cm2) as compared to the controls (0.267 ± 0.02 g/cm2). Histomorphometric analysis
showed a significant increase (p < 0.01) in bone volume (18.59 ± 5.66% vs. 7.69 ± 3.08%),
cortical thickness (0.52 ± 0.06 mm vs. 0.36 ± 0.07 mm), osteoid thickness (14.05 ± 4.72 μm
vs. 5.25 ± 090 μm), and osteoclast number (2.44 ± 0.52 N Oc/mm2 vs. 1.30 ± 0.01 N Oc/
mm2) in the aluminium-treated group as compared to the controls. No significant differences
in serum calcium, phosphorus, creatinine, hydroxyproline, or PTH were apparent between the
aluminium-treated and control animals. There was no evidence of osteomalacia in the
aluminium-treated rats. These findings indicate that aluminium is able to induce bone
formation in rats with normal renal function even when osteopoenia is present.
Firling et al. (1999) examined the influence of aluminium citrate administration on tibia
formation and calcification in the developing chick embryo. Tibia formation and mineralization
were assessed by radiology, total bone calcium content, calcium incorporation rate, collagen
synthesis rate, bone alkaline phosphatase activity, and serum levels of osteocalcin, procollagen
carboxy-terminal propeptide, and PTH. The chick embryos derived from White Leghorn strain
eggs were divided into three treatment groups (aluminium citrate, sodium citrate, sodium
chloride), and were treated acutely or chronically. Acutely treated embryos received 100 μL
of 60 mM aluminium citrate, 60 mM sodium citrate or 0.7% sodium chloride via injections
into the air sac of the egg on day 8 of incubation. Chronically treated embryos received a daily
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25 μL dose of the solutions beginning on day 8. The embryos were incubated for an additional
2 to 8 days following treatment. Radiographic analysis of the tibias and femurs of the embryos
revealed that the mineralization of the aluminium treated animals was less dense and restricted
to a shorter length of the mid-diaphysis as compared to the other two groups. The bone calcium
content of embryos acutely or chronically administered aluminium and incubated for 10 to 12
days was significantly lower (p < 0.05) compared to that of the other treatment groups. The
calcium content of tibias from embryos chronically treated with aluminium remained lower
than the controls for 12 day and 16 day embryos while, by day 14, there were no significant
differences in the total calcium content from acutely treated embryos compared to the controls.
Significantly higher (p < 0.05) levels of alkaline phosphatase activity were found in the tibias
collected from embryos chronically treated with aluminium incubated from 12 (2.16 units/
tibia/hr vs. 1.32 units/tibia/hr) to 16 days (10.38 units/tibia/hr vs. 6.78 units/tibia/hr) as
compared to the sodium chloride control group. Aluminium did not have a significant effect
on the rate of tibia collagen, non-collagenous protein synthesis or serum levels of procollagen
carboxy terminal propeptide, osteoclacin or PTH. The lack of change in these parameters
suggests that embryonic osteoblast number and activity is not markedly diminished by
aluminium exposure at these doses. The authors suggested that the observed under-
mineralization of the tibias in the aluminium treated embryos may be a manifestation of the
production of defective osteoid, an inhibited terminal maturation of osteoblasts, or
physiochemical inhibition of mineralization nucleation sites.
Zafar et al. (2004) investigated the effect of chronic exposure to dietary aluminium on calcium
absorption and calbindin concentrations in male weanling rats fed various levels of calcium
and aluminium for 3 and 6 week periods. One group of rats (n=40) was fed a calcium adequate
diet, three other groups of 40 animals each were fed a calcium-deficient diet with 0, 0.05 or
0.1% aluminium, as aluminium chloride. After 3 weeks, 20 rats per group were fasted overnight
and 10 rats per group were given an oral dose of 25 mg calcium labelled with 6 μCi 45Ca by
gavage. The other 10 rats in each group were given 6 μCi 45Ca as an interperitoneal injection.
Rats were anaesthetized the following day, blood was collected and the femurs were obtained.
The remaining animals (20 per group) were switched to a calcium adequate diet containing the
same level of aluminium they had been fed previously, and were maintained on these new diets
for another 3 weeks. No difference in 45Ca absorption was observed among the 4 groups at
either 3 or 6 weeks. Aluminium supplementation at 0.05 and 0.1% of the diet reduced calbindin
concentrations (compared to the group receiving a calcium deficient diet without aluminium).
Total bone calcium decreased with aluminium supplementation. The bone calcium content was
significantly different (p < 0.05) in the calcium deficient-no aluminium group, and in the
calcium deficient groups supplemented with 0.05 and 0.1% aluminium, as compared to the
calcium adequate group at both 3 and 6 weeks of treatment. In addition, the bone calcium
content was significantly lower (p < 0.05) in the calcium deficient, 0.1% aluminium group as
compared to all the other groups. Aluminium treatment reduced the breaking strength
parameters of the bones from rats on the calcium-deficient diets. When the animals were
switched to a calcium adequate diet for 3 weeks, there were no differences in the resistance to
breaking due to aluminium intake. The results of this study suggest that dietary aluminium has
detrimental effects on bone quality when calcium is deficient.
Cointry et al. (2005) analyzed the effects of aluminium accumulation on whole-bone behaviour
in rats. Rats (n=14) received i.p. doses of 27mgAl/day, as aluminium hydroxide (Al(OH)3),
for a period of 26 weeks. Fourteen control rats received a 20% glycerol/water solution at the
same dosing schedule. At the end of the experimental period, the left tibiae was obtained from
each animal for bone ash determination. Both femurs from each animal were also dissected
and examined for the volumetric mineral density of the cortical bone region and for cross-
sectional properties of the cortical bone region. Mechanical testing of the femurs was also
conducted. The Young’s modulus of elasticity (a measure of stiffness) was calculated, as well
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as the stress of the cortical tissue at the yield point, which is an indicator of the tissue’s ability
to support loads before any crack initiation. Aluminium concentration was significantly higher
(p < 0.001) in the tibias of treated animals (103 ±18 μg/g) as compared to those of control
animals (6 ±1 μg/g). The volumetric bone mineral density was significantly reduced in the
treated animals with respect to the controls. Up to the yield point, the structural stiffness and
strength of the bones did not differ between groups; however, an aluminium-induced
impairment of the ability to resist loads beyond the yield point was observed. Treatment had
a negative impact on the bending stiffness (Young’s elastic modulus) and the yield stress of
cortical bone. These parameters were decreased by 18 and 13% respectively in treated animals
as compared to those of controls (p< 0.05). The cortical second moment of inertia, which is a
measure of the architectural efficiency of the cortical bone, was significantly improved in
aluminium-treated rats (+10% change, p <0.01) as compared to that of the control group. This
suggests that an adaptive response to aluminium treatment may have caused an improvement
of the spatial distribution of the available cortical tissue resulting in an enhanced ability of the
bone to resist anterior-posterior bending. The results of this study suggest that the apparent
adaptive response of the bone to aluminium may have maintained normal stiffness and strength,
but aluminium may have reduced the ability of the bone to resist loads beyond the yield point,
or the ultimate strength of the bone.
Mineral Metabolism
The effects of aluminium on metabolic parameters in humans are not well understood. There
have been relatively few studies of the effects of occupational exposure to aluminium on
mineral metabolism. Ulfvarson & Wold (1977) examined the levels of trace metals in the blood
of welders of aluminium and stainless steel. Although the authors did not report the levels of
aluminium in blood, which would have been useful in gauging exposure, other studies of
aluminium welders have noted relatively high levels of exposure (Buchta et al., 2003). In the
study by Ulfvarson & Wold (1977), the levels of lead, strontium, rubidium, bromine, gallium,
zinc, copper, cobalt, iron, manganese, chromium, calcium, potassium, sulphur, phosphorus,
silicon, and magnesium in the blood of aluminium welders were not statistically different from
the levels of controls. However, significant variability in the data was noted. Little is known
regarding the effects of aluminium on other metabolic parameters in humans.
Most of the data on the effects of aluminium on trace metal, and general, metabolism originates
from studies on animals given aluminium by various routes. There is clear evidence that
aluminium can influence iron metabolism in the context of haematopoiesis (see Effects on
Laboratory Mammals and In Vitro Test Systems, Effects on Haematopoieses). However, as
described below, alterations in iron levels in solid organs have also been noted, but with
inconsistent outcomes. Studies of the metabolism of trace metals have yielded similarly
conflicting outcomes. There have also been reports of alterations in a variety of metabolic
pathways in response to aluminium exposure.
Non-haem iron and trace metals
Golub et al. (1995) reported that mice fed diets containing as much as 1 mg Al/g for 150 days
had small, but statistically significant, reductions in the levels of iron in spinal cord and liver.
The calculated dose of aluminium exposure in this experiment was 200 mg/kg b.w./day, which
is about 100-fold greater than dietary exposure in humans. Animals exposed to these levels of
aluminium had no significant differences in body weight.
Ward et al. (2001) injected rats (i.p.) with aluminium gluconate (2 mg/kg b.w.) 3 times a week
for 8 weeks and then examined iron levels in liver, kidney, heart, spleen, and brain. Two to
three-fold increases in tissue iron levels were noted in liver, spleen, and brain. Blood levels of
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aluminium were not reported, but the levels of aluminium in liver and spleen were recorded
as 100 ng/mg protein and 150 ng/mg protein, respectively, indicating substantial exposure.
Han et al. (2000) examined non-haem iron levels in kidney, liver, and intestine of chicks fed
diets containing 0.15 and 0.3% (by weight) aluminium for 3 weeks. Chicks receiving the higher
dose of aluminium were reported to have gained 28% less weight. Levels of iron in liver were
reduced by 40%, with 30% reductions in iron levels in intestine.
Esparza et al. (2003) examined the levels of manganese, iron, and copper in the brain and liver
of rats given i.p. injections of aluminium lactate (5 mg/kg b.w.) 5 days per week for 8 weeks.
Rats exposed to this level of aluminium showed 5-fold increases in aluminium levels in liver
(8.45 μg/g compared to 48.35 μg/g) with a 2-fold increase in cerebellum (5.49 μg/g compared
to 12.51 μg/g). The cortex and hippocampus of brain showed trends towards increased
aluminium accumulation, but were not statistically different from those of controls. In liver,
manganese levels were reduced by 40% with no alterations in iron or copper levels. In
cerebellum, there were no statistically significant changes in the levels of any of these metals
while, in cortex and hippocampus, the levels of copper were reduced 25 to 40%. Cortex also
showed 25% reductions in manganese. Animals injected with aluminium lactate gained 25%
less weight than control animals injected with vehicle.
The levels of copper, zinc, and manganese have been measured in the serum of rabbits exposed
to aluminium by s.c. injection of aluminium sulphate (600 μmol aluminium/kg b.w./day) five
times per week for 3 weeks (Liu et al., 2005). The total aluminium exposure per rabbit for the
entire study was 243 mg/kg b.w. Aluminium levels in serum increased from 0.25 μg/mL to 1.3
μg/mL after 21 days of treatment before levelling to 1.2 μg/mL by day 42 of treatment. There
were no statistically significant changes in the levels of zinc, copper, or manganese in serum
after either 21 days or 42 days of treatment. The authors reported weight loss in the aluminium-
treated group but did not specify the degree of loss.
Fattoretti et al. (2004) examined the levels of copper, zinc, and manganese in the brains of rats
exposed to aluminium through drinking water (2 g AlCl3 /L) for 6 months beginning at the age
of 22 months. Serum levels of aluminium were not reported, making it difficult to assess the
level of exposure. The authors sampled 3 domains of the brain; fore- and mid-brain together,
pons and medulla together, and cerebellum. In cerebellum, there was no significant change in
the levels of any metal. The authors reported accumulations of aluminium in fore- and mid-
brain (94% increase) with increases in copper, zinc, and manganese (32, 41, and 50%,
respectively). Pons and medulla showed 53% increases in aluminium accumulation with 46,
46, and 41% increases in copper, zinc, and manganese, respectively.
Sanchez et al. (1997) described an analysis of calcium, magnesium, manganese, zinc, copper,
and iron levels in rats of 3 age groups exposed to aluminium in drinking water. The doses used
were 50 and 100 mg/kg b.w./day of aluminium nitrate with added citrate at 355 and 710 mg/
kg/day, respectively, to increase absorption of the metal. The ages at which studies were
initiated were at 21 days, 8 months, and 16 months. Studies were terminated after 6.5 months
of exposure and the levels of each trace element were measured in liver, bone, testes, spleen,
kidney, and brain. The authors did not report the levels of aluminium in serum or bone, so it
is difficult to assess the relative exposures of the animals. The amounts of aluminium in the
water were roughly 10,000 times the average exposure level of humans and the addition of
citrate would likely have increased absorption. Under these conditions, for each trace element,
there were statistically significant effects of aluminium for multiple tissues; however, there
were not always dose-dependent responses and the response of young vs. older animals
sometimes differed. Among the most striking changes were the 25 to 50% reductions in calcium
levels in kidney and brain of the mid and old age groups given the highest dose of aluminium.
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In young animals given the highest dose, however, the levels of calcium in these organs were
~2-fold higher than in those of controls. The testes of older animals also showed 2 to 3-fold
increases in calcium levels. The data on copper levels showed significant fluctuations among
age and treatment groups. The most robust finding was that, in young animals exposed to both
doses of aluminium, the level of copper was reduced 30 to 50% in both kidney and brain.
However, in older animals there were no changes in these organs. Magnesium, manganese,
iron, and zinc levels fluctuated less among age and treatment groups in the various tissues, and
there was less definitive evidence that aluminium caused consistent changes the amount of
these elements in the tissues examined. There was evidence of a robust and consistent effect
on levels of manganese in spleen, where, in all age groups, the highest dose of aluminium
correlated with the highest tissue levels of manganese. There was also evidence of an effect
on iron levels in spleen of young animals given the highest dose (30% increase in iron) and in
kidney of older animals (25% reduction).
The authors also examined urinary excretion of trace metals at 2 time points within the
treatment (at 3 and 6.5 months). The most robust and consistent changes in excretion were
noted for zinc with a 3-fold reduction in excreted zinc at both doses in middle-aged group. In
all other groups and for all other elements, the changes were either far less robust or inconsistent
across age and treatment groups.
Yasui & Ota (1998) examined the levels of magnesium and calcium in serum, spinal cord, and
bone in rats fed diets low in calcium (3 mg/100g diet) and high in aluminium (194 mg/100g
diet) as aluminium lactate. Control diets contained 1250 mg/100g diet calcium and 10 mg/100g
diet aluminium. After 60 days of exposure, the levels of aluminium in serum increased from
0.25 μg/dL to 1.25 μg/dL. Control diet low in calcium had no effect on aluminium levels and
only slightly lowered serum levels of calcium. By contrast, there was a 2-fold reduction in
serum calcium levels in animals exposed to both low calcium and high aluminium. None of
the diets affected serum levels of magnesium. In spinal cord, the combined low calcium/high
aluminium diet led to very modest reductions in the levels of magnesium (~10% reduction).
However, in lumbar vertebra, magnesium levels were reduced by 25% on the combined diet.
Diets low in calcium had no effect in either tissue. The authors did not comment on whether
these diets affected weight gain.
In a study of much shorter duration (18 days) in which lower doses of aluminium were used
(~270 μg/g of food), Greger et al. (1985) examined the levels of phosphorus, calcium,
magnesium, iron, manganese, zinc, and copper in bone, kidney, and liver of rats exposed to
aluminium in diet. Two food formulations provided trace metals at levels that were at the
minimum requirement and at 2-3 times the minimum requirement. The chemical form of
aluminium was varied, using aluminium palmitate, aluminium lactate, aluminium phosphate,
and aluminium hydroxide. No significant differences in levels of aluminium accumulation in
bone were noted among the different chemical forms of exposure (control 1.9 μg/g; treated
13-15 μg/g). The authors found no significant changes in the levels of any of the studied
minerals in the tissues examined in animals exposed to aluminium by any of the methods.
Boudey et al. (1997) examined the effects of low doses of aluminium on growth rates and
calcium metabolism of young weanling rats; an additional variable in the study included
reductions in calcium levels. Animals were given control diets (8.4 mg Al/kg b.w. or
supplemented diet (10.6 mg Al /kg b.w.), with or without altering calcium levels (7.6 g Ca /kg
b.w. vs. 0.4 g Ca/kg b.w). Animals exposed to the higher dose of aluminium in calcium deficient
diets weighed 40% less at the end of the 90 day study. Aluminium levels in brain, liver, and
bone were approximately 3-fold higher than those of animals given diets containing normal
levels of calcium and the lower dose of aluminium. The authors also noted that, in the presence
of normal levels of calcium, the higher dose of aluminium caused 25 to 40% reductions in the
Krewski et al. Page 135
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
levels of calcium in bone, liver, and brain. One conclusion of the study was that young animals
may be more sensitive to the effects of aluminium if diets are deficient in calcium.
In comparison to these outcomes, Julka & Gill (1996) reported that young (100-150 g) rats
exposed to very high doses of aluminium by i.p. injection (10 mg/kg b.w. per day) for 4 weeks
had elevated levels of calcium (2 to 3-fold) in cortex and hippocampus of brain. Other
physiological consequences related to calcium included decreased (~40%) calcium influx in
isolated synaptic preparations from the aluminium-treated animals and reduced ability of
calmodulin to stimulate cAMP phosphodiesterase (~25% reduction in activity).
Mahieu & Calvo (1998) examined renal function in rats exposed to aluminium by i.p. injection
of aluminium hydroxide (80 mg/kg b.w., 3 times per week, for 6 months). After 6 months of
exposure, aluminium levels in serum reached 800 μg/L as compared to controls (10 μg/L).
These exposure levels are 400 to 800-fold higher than typically found in human serum (see
Effects on Laboratory Mammals and In Vitro Test Systems, Neurotoxicity). Deposition of
aluminium in trabecular bone was also observed, indicating significant exposure levels. Similar
to results of other studies, the authors reported that treated animals showed reductions in weight
(25%) and reduced efficiency of nutrient utilization. No obvious loss of renal function was
noted; there were significant reductions in the excretion of phosphorus (40% less) with
significant increases in calcium excretion. The suggested mechanism for the effects on renal
function involved loss of PTH response, either by lower release of the hormone or reduced
receptor sensitivity.
In another study of renal function, Braunlich et al. (1986) reported that aluminium exposure
(i.p. injection of 0.5 mg/kg b.w., 5 times weekly for 12 weeks) led to increased urine output
(45%) and increased sodium excretion (57%). Notably, the dose used in these studies was more
in line with what would be used to achieve 10-fold increases in aluminium loads in rodents.
Mahieu et al. (2004) examined the intestinal absorption of phosphorus and its subsequent
deposition in bone in rats exposed to aluminium. Animals were injected i.p. with aluminium
lactate (5.75 mg/kg b.w.) 3 times per week for 3 months. By the end of the study, serum levels
of aluminium were reported to be 600 μg/dL as compared to 10 μg/dL in controls. Slight
reductions in body weight (10%) at 3 weeks of treatment were noted. In serum, there were no
differences in calcium or phosphorus levels between control and treated groups at any age
tested. At 1, 2, and 3 months of exposure, 25 to 30% reductions in the level of phosphorus
excreted in urine were noted. Small, but statistically significant, reductions in the levels of
phosphorus absorbed by the intestine were also noted. Similar reductions, small but statistically
significant, in calcium absorption were also reported. Slight increases in calcium urinary
excretion were detected along with 10% reductions in calcium levels in bone. A significant
increase in the bone accretion of phosphorous (32P deposited/32P absorbed) was also noted in
treated animals as compared to controls (27% increase). Bone calcium was significantly (p <
0.03) reduced in treated rats (10% decrease). These findings indicate that phosphorous
metabolism may be modified by aluminium through direct action on the intestine, kidney, and
bone.
General metabolic effects
There are several reports that provide evidence that aluminium may have effects on multiple
metabolic pathways. There have been two studies on the effects of aluminium on metabolic
enzymes. Rats exposed to 100 μM aluminium chloride in drinking water (2.6 μg Al/mL) for
12 months showed 2-fold elevations in aluminium in brain with reductions in the activities of
hexokinase and glucose-6-phosphate dehydrogenase (G6PDH) (73 and 80% of normal) (Cho
& Joshi, 1989). Reductions in erythrocyte activities of G6PDH and glutathione reductase (82%
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of normal for each) were reported in rats injected i.v. with 5 mg AlCl3/kg for 3 consecutive
days and then harvested at 4 weeks post treatment (Zaman et al., 1993).
Another study examined nutritional effects of aluminium in drinking water (administered as
aluminium nitrate at doses of 360, 720, 3600 mg/kg b.w./day) for 100 days (Domingo et al.,
1987). Young female rats exposed to the highest dose gained 50% less weight than animals on
lower doses or the controls. The largest difference in weight gain occurred in the first weeks
of the study. Animals on the highest dose drank less water, consumed less food, and showed
less urine and faecal output. No changes in blood uric acid, cholesterol, glucose, creatine, or
urea levels were detected in any treatment group.
Gonzalez et al. (2004) reported that rats given aluminium hydroxide by i.p. injection (27 mg/
kg b.w.) 3 times per week for 3 months show 25% reductions in bile flow, 39% reductions in
bile salt output, 43% reductions in bile cholesterol output, and 38% reductions in total bile
protein output. These effects were correlated with 40% reductions in the expression of
multidrug-resistance-associated protein 2, which is the main multi-specific organic anion
transporter of the bile duct. Plasma concentration of aluminium in these animals reached 750
μg /L (controls 9 μg/L), indicating very significant exposure. No change in weight was detected
in the treated animals.
Effects on Haematopoiesis
One of the most common abnormalities associated with renal failure and haemodialysis is
anaemia. Many patients with this disease receive high doses of hydroxyl aluminium gel over
long periods to control serum phosphorus levels. As described above in Effects on Laboratory
Mammals and In Vitro Test Systems, Neurotoxicity, the majority of aluminium found in serum
is bound to Tf, which is responsible for the transport of iron. As described below, Tf and iron
are crucial regulators of erythropoiesis; thus an immediate suggestion of a mechanism behind
anaemia in patients afflicted with renal failure is evident that implicates aluminium.
However, in the majority of these patients, treatment with erythropoietin, a hormonal stimulator
of haematopoiesis, is effective in restoring haematocrits (percentage of cells in whole blood
that are red blood cells), at least partially (Eschbach et al., 2002; Sakiewicz & Paganini,
1998). In most patients, one physiological basis of anaemia stems from compromised
production of erythropoietin by diseased kidneys, leading to chronic anaemia. The condition
is often exacerbated by iron deficiency, which can arise from decreased red blood cell t½,
chronic loss of blood, decreased uptake, and other nutritional deficiencies (Drüeke, 2001;
Sakiewicz & Paganini, 1998; Winearls, 1998). In the majority of haemodialysis patients,
treatments with erythropoietin and iron supplements are sufficient to raise haematocrits to
levels >30% of normal, a level that alleviates most symptoms of anaemia. Although some
patients are hyporesponsive to erythropoietin, the levels of iron-saturated Tf and aluminium
do not provide a correlative explanation (Eschbach et al., 2002); unresponsive patients do not
have higher serum levels of aluminium or lower levels of iron saturated Tf. Thus, in patients
who are exposed to high levels of aluminium, the physiological basis for anaemia is complex
and involves, at least in part, a loss of hormonal stimulation. However, as outlined below, there
are both cell culture and animal model data to indicate that aluminium has the capacity of
perturb haematopoiesis and thus effects on this system should be considered in assessing
aluminium toxicity.
In vivo animal studies
The effects of aluminium on haematopoiesis have been investigated in various animal models.
In these studies, aluminium exposure has been accomplished by both oral and injection routes.
Data from selected studies involving direct injection of aluminium salts will be summarized
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first. As a point of reference, the average human exposure to aluminium in drinking water, is
~ 2.3 μg/kg b.w./day, with steady-state serum levels of aluminium averaging ~2 μg/L in most
individuals (see Effects on Laboratory Mammals and In Vitro Test Systems, Neurotoxicity).
Chmielnicka et al. (1996) exposed rats to high doses of aluminium chloride (4 mg/kg b.w./day)
for 21 days by i.p. injection. Although the levels of aluminium in serum were not reported, this
exposure level equates to 800 μg/kg b.w./day of elemental aluminium. At 3, 7, 14, and 21 days
of exposure, the authors measured platelet counts, red blood cell counts, serum levels of iron,
total haemoglobin levels, and haematocrits. No significant changes in platelet or red blood cell
counts were noted at any age. By 21 days of exposure, small, but statistically significant,
decreases in total haemoglobin and haematocrit were reported. The most robust effect
identified was a 25 to 30% reduction in the level of iron in serum.
Farina et al. (2002) exposed rats to aluminium sulphate (50 μmol/kg b.w. = 2.6 mg of
aluminium/kg b.w.) through i.p. injections 5 times a week for 3 months. The levels of
aluminium in serum were not reported. At the end of the exposure period, the authors reported
finding several indications of toxicity to the haematopoietic system, including 32% reductions
in total haemoglobin levels, 24% reductions in haematocrit, and 30% reductions in serum levels
of iron. However, total iron-binding capacity of serum from exposed animals was not
statistically different from controls.
I.p. injections of aluminium hydroxide (80 mg/kg b.w. – 3 times per week) have also been used
as an experimental model of chronic exposure to aluminium. Mahieu et al. (2000) studied
animals exposed for up to 28 weeks, while Bazzoni et al. (2005) examined animals treated for
12 weeks. Serum levels of aluminium were not reported in these studies and thus the sustained
body burden is not known. The elemental aluminium content of this exposure was calculated
to be ~27 mg/kg b.w. at each injection. Several haematological factors were measured in each
study. Mahieu et al. (2000) noted progressive decreases in mean corpuscular volume
(microcytosis) to a maximum of 28% reductions. However, minimal reductions in red blood
cell counts and haematocrit were reported. Modest reductions in total haemoglobin (20%
reduction) and small increases in red blood cell fragility were reported. Bazzoni et al. (2005)
reported 20% reductions in total haemoglobin with 7% reductions in haematocrit. This latter
study reported significant increases in red blood cells with deformed morphology (not
quantified) with slight increases in fragility. Bazzoni et al. (2005) also reported that red blood
cells in the treated animals were 3 times more rigid and less prone to aggregate.
Farina et al. (2005) conducted a second study of rats exposed to aluminium citrate (30 mM
aluminium sulphate with 35 mM sodium citrate) in water for a total of 18 months. The daily
exposure to aluminium was estimated to be 54.7 mg/kg b.w. Citrate would be expected to
increase absorbance; however serum levels of aluminium were not reported. The authors
reported that chronic exposure at this level led to reductions of 20% in red blood cell counts,
13% in haematocrit, 15% in total serum haemoglobin, and 40% in total levels of iron in serum.
However there was no change in total iron binding capacity and no increase in red blood cell
fragility. Turgut et al. (2004) exposed mice to aluminium for 3 months through drinking water
containing aluminium sulphate. The estimated dose was 877 μmol/kg b.w./day = 47 mg of
aluminium/kg b.w./day. Serum levels of aluminium were not reported. Reductions in serum
haemoglobin (14%) and haematocrit (13%) were described. The levels of iron in serum were
elevated by 59% with a small increase in the levels of Tf.
Garbossa et al. (1998a) have reported evidence that aluminium exposure may have direct
effects on erythroid differentiation, which may account for the reductions in red blood cell
counts and haematocrit in animals exposed to aluminium. Garbossa et al. (1998b) conducted
a study in which rats were exposed to aluminium citrate at two levels by two routes for 15
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weeks; 1 μmol/g b.w./day by oral gavage 5 days/week and by drinking water containing a 100
mM solution (estimated exposure 14-17 μmol/g b.w. day). Serum levels of aluminium were
measured in this study with the dose given by oral gavage leading to serum aluminium levels
of 2.9 μmol/L (78 μg/L), as compared to controls with 0.8 μmol/L (21.5 μg/L). The serum
levels of aluminium in animals exposed through drinking water were 3.6 μmol/L (97 μg/L).
The authors reported that animals given aluminium in drinking water had reductions in
haematocrit (11%), increased osmotic fragility of red blood cells (20% more fragile), and 24%
reductions in red blood cell t½. At both the lower and higher dose, there were reductions in the
ability of isolated bone marrow stem cells to differentiate into erythrocytes after exposure to
erythropoietin (colony-forming units – erythroid). In a later study by the same group, Vittori
et al. (1999) exposed rats to aluminium via drinking water containing 80 mM aluminium citrate
for 8 months. At the end of the study, the serum level of aluminium in the treated rats was 205
μg/L (range 120-790 μg/L) whereas the level in control animals was 15 μg/L (range 5 to 90
μg/L). These levels are between 10 (control) and 200 (treated) times the average level of
aluminium in human serum (1-2 μg/L - see Effects on Laboratory Mammals and In Vitro Test
Systems, Neurotoxicity). At this high exposure level, very significant reductions in
erythrogenesis were found ~60% reduction in erythroid colony forming units (CFU-E) and
decreased uptake of iron (~30% reduction). The authors also reported significant increases in
abnormal red blood cell morphology.
In vitro studies
Studies of the effects of aluminium on erythroid cell differentiation have suggested potential
mechanisms by which aluminium could impact haematopoiesis. In a study by Vittori et al.
(1999), direct evidence that aluminium inhibits erythroid differentiation was reported.
Erythroid progenitor cells were concentrated from human blood and exposed to 100 μmol
aluminium citrate (8 mg/L elemental aluminium) for 10 days and induced to differentiate with
erythropoietin. The authors reported 30% reductions in CFU-E activity. However, in a similar
study, Mladenovic (1988) reported that aluminium at levels of 1,035 ng/mL (1.035 mg/L) in
medium did not significantly diminish CFU-E. However, if Tf was added to the medium along
with aluminium, then CFU-E was diminished by 90%. If Tf was first saturated with iron,
aluminium had no effect. The negative effects of Tf-aluminium were not overcome by adding
excess levels of erythropoietin. One conclusion that could be drawn from this study was that
a primary effect of aluminium on erythroid differentiation was mediated by competition for
the Tf receptor. If excess Tf saturated with aluminium is present, then erythroid differentiation
is inhibited by the binding of aluminium-metallated-Tf (aluminoxamine) to its receptor.
However, the affinity of Tf for iron is 5 orders of magnitude greater than its affinity for
aluminium. Hence excess aluminium alone cannot displace the iron from Tf-iron complexes
that pre-exist in culture medium. Adding demetallated Tf to the medium allows aluminium to
bind and thus creates the opportunity for Tf-aluminium-complexes to compete for binding to
the Tf receptor. The extent to which a similar scenario may occur in vivo depends upon the
levels of free Tf in serum at the time of aluminium exposure and on the level of iron in the
serum. If sufficient iron is present, then aluminium binding to Tf would be less favoured.
Individuals with iron deficiency could therefore be at greater risk for developing
haematopoietic abnormalities upon exposure to aluminium.
Direct effects of aluminium salts on the morphology of red blood cells have been reported
(Suwalsky et al., 2004; Vittori et al., 2002; Zatta et al., 1997). However, as outlined above in
Effects on Laboratory Mammals and In Vitro Test Systems, Neurotoxicity, most studies of
aluminium metabolism indicate that most of the aluminium, absorbed from drinking water or
food, present in plasma would be bound to Tf. Thus, the amount of soluble aluminium salts
that red blood cells would be exposed to is limited. However, Tf-mediated delivery of
aluminium to erythroid progenitors does provide a means to expose these cells directly to the
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metal. Vittori et al. (2002) noted that red blood cells exposed to aluminium citrate in vitro
acquired abnormal morphology and showed increased degradation of a protein involved in
maintenance of cell shape (band 3 protein). Suwalsky et al. (2004) similarly reported that red
blood cells exposed to aluminium fluoride in vitro developed abnormal morphology.
Irritation
Oral exposure—There are reports of animal studies in which aluminium was given in large
amounts orally for a considerable period of time that do not mention GI irritation, corrosion
or sensitivity. These GI effects were not specifically examined in many of these studies and it
is not known whether such effects were considered at all in these studies. Generally, the only
adverse effect observed in most of the studies was a decrease in body weight gain. Some
examples follow. Gross necropsy of male Sprague-Dawley rats fed diets containing 7000 to
30,000 mg/kg basic SALP, which is used as emulsifying agent, equivalent to 67 to 288 mg Al/
kg b.w./day, for 28 days, showed no evidence of GI irritation (Hicks et al., 1987). Beagle dogs
fed 80 mg Al/kg b.w./day as basic SALP for 26 weeks demonstrated histopathological changes
in the liver and kidney that were attributed to reduced food intake, but no adverse effects on
the stomach were noted (Pettersen et al., 1990). Male and female beagle dogs fed acidic SALP,
a leavening agent, in a diet containing 0.3, 1.0 or 3.0% SALP for 6 months, showed no evidence
of GI irritation on gross autopsy and histopathological examination (Katz et al., 1984). These
SALPs are not very soluble, except in dilute HCl, which might be achieved in the stomach.
Male Weizman Institute strain rats given 1% aluminium chloride or sulphate in their drinking
water demonstrated periorbital bleeding after an unspecified period of exposure, but were not
noted to demonstrate GI irritation. However, histology may not have been conducted on the
GI tract (Berlyne et al., 1972b). Female Sprague-Dawley rats were given drinking water
containing aluminium nitrate (375, 750 or 1500 mg/kg b.w./day, equivalent to 27, 54 and 108
mg Al/kg b.w./day, respectively) for 28 days; mild histological changes occurred in the liver
and spleen but no histological changes in the presence of elevated aluminium were seen in the
stomach or small or large intestine (Gómez et al., 1986).
In contrast to the above reports that were negative for aluminium-induced GI irritation, male
albino rats given a single daily gavage dose of aluminium sulphate (17 to 172 mg/kg b.w./day)
or potassium aluminium sulphate (29 or 43 mg Al/kg b.w./day) for 21 days demonstrated
gastric mucosal layer thickening, hyperplasia and ulceration after exposure to 86 and 172 mg/
kg b.w./day aluminium sulphate, but not to lower doses (Roy et al., 1991). It therefore appears
that aluminium has the potential to produce irritation in rats after oral administration when high
concentrations of soluble aluminium salts are administered (see Effects on Laboratory
Mammals and In Vitro Test Systems, Single/Acute Exposure and Effects on Laboratory
Mammals and In Vitro Test Systems, Repeated Exposure for more information on the effects
of oral exposure to aluminium in mammals).
Inhalation exposure—The pulmonary response to various species of aluminium has been
studied in animals after inhalation exposure and after intratracheal instillation (see Effects on
Laboratory Mammals and In Vitro Test Systems, Irritation, Intratrachael Exposure). Many of
these studies were conducted to better understand the adverse effects observed in humans
exposed to very high levels of air-borne aluminium, and other materials, in industrial settings
during the Second World War, and the postulated protective effect of inhaled aluminium
against quartz dust-induced pulmonary fibrosis; this practice started in the mid-1940’s and
continued for at least 10 years (see Effects on Humans, Effects from Occupational Exposure,
Irritation, Inhalation Exposure). Various species of aluminium caused responses described as
typical of foreign body reaction, alveolar proteinosis and wall thickening, some nodule
formation, but not the extent of fibrosis caused by quartz dust.
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Rabbits exposed to aluminium dust 1 to 2 hr daily for 20 to 40 days showed increased
connective tissue in their lungs (Goralewski, 1939). In studies by Jötten & Eickhoff (1942),
inhalation of finely powdered aluminium dust by rabbits caused few lung changes and no
fibrosis. However, addition of a pneumococcal infection resulted in a diffuse sclerosis, collagen
formation and rapid death, suggesting that aluminium somehow enhanced the toxicity of the
infectious agent.
Exposure of rabbits to aluminium dusts resulted in three phases of pulmonary change, an initial
exudation of leukocytes for a few hr or days, several months of an intermediate monocytic
phase, and a final foreign body granulomatous phase that developed after several months of
exposure (De Marchi, 1947). These are changes associated with a foreign body reaction (Chen
et al., 1978; De Vuyst et al., 1987). Rats and guinea pigs were exposed to arc-produced fumes
of pure aluminium oxide (alumina), silica, or “stack dust” (a mixture of alumina, silica and
other oxides) for 18.3 hr daily for 6 months. Six months after completion of exposure, their
lungs contained 1 to 11% of fume material. The alumina-exposed animals exhibited nodule-
like collections of endothelial cells, fibroblasts and mononuclear leucocytes, similar to silicotic
nodules (MacFarland & Hornstein, 1949). Inhalation of aluminium hydrate by guinea pigs led
to hypertrophic reticular pneumonia and a histiolymphoid reaction as a general response to this
insult and formation of nodules in the alveoli, demonstrating the harmfulness of this aluminium
species (Jullien et al., 1952).
To assess the role of paraffin, which was used to coat aluminium dust during its production,
in the toxicity associated with aluminium production, rabbits were exposed to paraffin-coated
aluminium dust. They developed an interstitial fibrosis that began to appear about 75 days later,
which was less frequent and severe than seen in rabbits exposed to uncoated dust (Van
Marwyck & Eickhoff, 1950). These results did not support the hypothesis of Perry (1947) (see
Effects on Humans, Effects from Occupational Exposure, Irritation, Inhalation Exposure) that
paraffin substances coating the aluminium are the cause of aluminium-induced fibrosis, but
are consistent with the hypothesis of Corrin (1963a) (see below).
Inhalation of 40 to 120 mg/m3 of boehmite, a gelatinous aluminium oxide, or 21 to 33 mg/
m3 aluminium oxide, considered to be gibbsite, by guinea pigs 8 hr daily, 6 days weekly for
14 months apparently did not produce adverse pulmonary alterations (Gardner et al., 1944).
The authors did note that this inhalation unfavourably influenced the resistance to tuberculosis,
consistent with the response to concurrent exposure to finely powdered aluminium dust and
pneumococci (see above).
Aluminium oxide exists in many chemical species (see Identity, Physical and Chemical
Properties, Analytical Methods, Physical and Chemical Properties, Properties of Aluminium
Compounds). The γ transitional form was believed to be the most biologically active
(Klosterkotter, 1960). Mice and rats were exposed to a relatively well-defined γ transitional
form of aluminium oxide having an average particle size of 0.005 to 0.04 μm and a surface
area of 95 m2/g, although these particles aggregated during the experiment. Exposure was to
33 g/m3 by inhalation 5 hr daily for 285 days or by intratracheal instillation of a single dose of
35 mg of γ-Al2O3 suspended in 1 mL of tap-water. It was noted by the experimenters that this
very high level inhalational exposure could not be tolerated and would be avoided by industrial
workers. Inhalation exposure resulted in some deaths, some connective tissue thickening in the
alveolar walls and bronchioles with mild collagenous fibrosis, but not the collagenous nodules
seen in silicosis. These effects have been interpreted as alveolar proteinosis, a non-specific
response to pulmonary dust exposure (Dinman, 1988).
Wistar rats and hamsters inhaled a powder composed of 20% aluminium and 80% aluminium
oxide, 0.05 to 7 μm particle width, which was introduced hourly during an 8 hr day for 3 to 19
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months (Christie et al., 1963). Increased exposure duration produced enlarged lungs covered
by slightly thickened pleura with sub-pleural plaques. This progressed to consolidated areas
surrounding the small bronchioles. Cystic spaces, usually sub-pleural, were seen after 9
months. They were surrounded by firm, fibrous plural walls and filled with pulpy material.
Microscopic examination revealed diffuse alveolar catarrh, large macrophages, eosinophilic
foamy vacuolated cytoplasm, some thickening of the alveolar walls which were lined by
proliferation macrophages, foreign body giant cells, granulomas formed by histiocytes (tissue
macrophages), and foreign body giant cells with large lipoid clefts. This constellation of effects
was considered to be a lipid pneumonia. Acute inhalation of aluminium oxide particles,
produced by a Wright dust constant feed generator, with a mean count size of 0.2 μm, and
maximum size of 1 μm, as 0.38 or 0.58 mg/L (380 or 580 mg/m3), for 30 minutes by guinea
pigs caused a constriction of pulmonary air flow (Robillard & Alarie, 1963a). In contrast,
inhalation of aluminium oxide at a concentration of 0.38 mg/L (380 mg/m3) by rats for 3, 7 or
15 minutes produced a time-dependent lung dilatory effect, the opposite to that seen in the
human, guinea pig, dog and cat (Robillard & Alarie, 1963b).
Three metallic aluminium powders were introduced at dust concentrations of 15, 30, 50 or 100
mg/m3 into chambers containing rats, guinea pigs or hamsters 6 hr daily, 5 days weekly for 6
months. The powders were; pyro coated, flake-like particles (4% < 1 μm, 87% 1 to 4 μm and
8.5 % > 4 μm; mean 2.5 μm diameter), flake-like particles (19% 1 to 4 μm and 71 % > 4 μm;
mean 4.8 μm diameter), and atomized spherical particles (1.5% < 1-4 μm, 96% 1 to 4 μm and
3 % > 4 μm; mean 2.2 μm diameter) (Gross et al., 1973). The response among all 3 animal
species was alveolar proteinosis, characterized by generalized alveolar epithelial reactions, the
appearance of pneumocytes, and occasional macrophages, but no fibrosis.
Male Syrian golden hamsters were exposed by inhalation to a propylene glycol complex of
aluminium chloride hydroxide, which was used in some antiperspirants. Exposure was to 164
mg/m3 of the complex, for 6 hr on the first day and for 4 hr on the second and third days. The
animals demonstrated acute bronchopneumonia and moderate thickening of the alveolar walls.
Rabbits exposed to 212 mg/m3 of the complex for 5 days showed similar effects. Exposure of
hamsters to 52 mg/m3 of the complex 6 hr daily 5 days weekly for 30 exposures demonstrated
persistent numerous foci of macrophages and heterophils, especially at the bronchioalveolar
junction (Drew et al., 1974). Fisher 344 rats and Hartley strain guinea pigs received inhalation
exposure to large (2.45 to 3.09 μm mean mass equivalent aerodynamic diameter) aluminium
chlorhydrate particles, 0.25, 2.5 or 25 mg/m3 6 hr daily, 5 days weekly for 6 months. This
resulted in multi-focal granulomatous pneumonia characterized by proliferation and infiltration
of mononuclear inflammatory cells and foci of giant macrophages in the alveoli, often
containing vacuoles of fibrillar basophilic material, and granulomatous lesions in peribronchial
lymph nodes, evidence of active phagocytosis and necrosis (Steinhagen et al., 1978; Stone et
al., 1979). Rats exposed to aluminium chloride and aluminium fluoride dusts by inhalation,
1.3 to 1.8 mg/m3 for over 5 months, showed that aluminium affected AM integrity and
increased lysozyme, alkaline phosphatase, and initial protein levels in lung lavage fluid,
suggesting effects on Type II alveolar cells. This was considered to be an adaptive response to
the dusts (Finelli et al., 1981). Inhalation exposure of male Fischer 344 rats for 4 hr to
aluminium flakes, at aluminium concentrations of 10, 50, 100, 200 or 1000 mg /m3,
demonstrated an influx of polymorphonuclear neutrophils into bronchopulmonary lavage fluid
that persisted for 6 months post-exposure, an indication of a continued irritant response.
Multifocal microgranulomas in lungs and hilar lymph nodes were also seen (Thomson et al.,
1986).
Clinical observations of uncontrolled studies suggested inhalation of aluminium dust was
beneficial in the treatment of silicosis and did not produce apparent adverse effects (see Effects
on Humans, Effects from Occupational Exposure, Irritation, Inhalation Exposure). This
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treatment was based on the theory that silica exerted its toxicity following its dissolution to
silicic acid. Aluminium was found to coat the silica particles with a thin film of hydrated
gelatinous aluminium oxide, reducing particle solubility (Crombie et al., 1944). Denny et al.
(1937;1939) found that exposure to 1% metallic aluminium powder and quartz dust for 6
months protected against quartz-induced silicosis in the rabbit. They then exposed rabbits to
freshly ground, fine particulate metallic aluminium dust particles, (the majority with diameter
< 3 μm), at an average airborne particle concentration of 7 × 109 /m3 for 12 hr daily for 14
months. This resulted in a dried lung aluminium concentration of 2,700 to 12,000 mg/kg. The
authors observed no harmful effects other than occasional thickening of the alveolar walls that
consisted of alveolar epithelial proliferation. Concurrent exposure to admixtures of quartz and
0.5 to 3% aluminium dusts resulted in fibrosis in some animals that had < 1% aluminium in
their lungs, but no fibrosis was seen in rabbits whose lungs had hydrated aluminium oxide.
Aluminium was visualized by aurine. Similarly, exposure of rabbits for 40 minutes to
aluminium dust containing 7 × 109 particles/m3 before or after being exposed to quartz dust
(20 × 109 particles/m3) for 12 hr daily protected against quartz-dust induced fibrosis. Exposure
of guinea pigs to 2 types of hydrated aluminium oxide (aluminium hydroxide) for ≥ 1 year
produced no adverse effects on the lungs, but did have a protective effect against silicosis
(Gardner et al., 1944). Dworski (1955) described a series of studies, begun by Gardner and
continued by others, on the effects of colloidal aluminium hydroxide, powdered aluminium
hydrate and metallic aluminium powder on normal animals, on the prevention of quartz dust-
induced-silicotic reaction and on the treatment of pre-established silicotic lesions. A beneficial
effect was attributed to aluminium when given before, or with, quartz, irrespective of the route
of quartz or aluminium administration, when the quartz and aluminium distributed to the same
location. Some retardation of not-yet-mature silicotic lesions was observed, but aluminium did
not affect fibrotic lesions. Metallic aluminium powder produced less effect and lower tissue
aluminium concentrations. One observation related by the author of unintended aluminium
exposure producing less than expected toxicity from quartz exposure during the course of their
studies undermines confidence in the experimental control of these studies. Addition of 2%
metallic aluminium powder, as used by Denny et al. (1937;1939), to quartz dust delayed the
development of nodular retilulinosis and collagenous silicosis, which occurred by ~ the
200th and 300th days in the absence of aluminium, and by ~ the 300th and 400th days in the
presence of aluminium, respectively (King & Wright, 1950). Addition of aluminium at a
concentration of 4 mg/m3 as McIntyre powder to an inhaled dust mixture of 75% finely ground
lean coal and 25% Dörentrup quartz powder, ~ 45 mg/m3 with a particle count of ~ 2. 5 ×
109/m3, did not reduce the development of fibrosis or have any other beneficial effects (Weller
et al., 1966). When the aluminium dust was inhaled after the coal-quartz dusting, further cellular
granulomas reactions were seen. The authors concluded from studies of inhalation of the
aluminium dust alone that it cannot be considered totally inert. Aluminium salts were shown
to be beneficial in rats exposed to pure quartz or coal-quartz. The aluminium aerosols showed
no toxicity (Le Bouffant et al., 1975). Aluminium lactate alone produced no significant effects.
Treating quartz with aluminium lactate reduced the inflammatory response and attenuated
oxidation and proteolysis of fibronectin (Brown et al., 1989). Exposure of sheep with silica-
induced silicosis to 100 mg aluminium lactate aerosol in saline monthly for the first year, and
weekly for the next 2 years, starting 1 year after radiographic evidence of silicosis, produced
no benefit (Bégin et al., 1995).
Many, but not all, of the studies aimed at assessing the potential protective effect of aluminium
against fibrosis induced by quartz dust reported beneficial effects, as reviewed above. It was
often noted that the aluminium alone had little toxicity.
Zeolite (hydrated alkali aluminium silicate) inhalation produced respiratory disease in rats
(Gloxhuber et al., 1983).
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Inhalation of power plant fly ash, which had a MMAD of ~ 2 μm, at concentrations of up to
4.2 mg/m3, 8 hr/day for 180 consecutive days, produced no significant adverse effects in rats
(Raabe et al., 1982). However, the increased number of macrophages found in the lung was
interpreted as a natural response to inhaled particles.
Aluminium starch octenylsuccinate is used in cosmetic formulations as an anti-caking and
viscosity-increasing agent. Rats exposed to 200 g/m3 for 1 hr showed no gross changes from
1 hr to 14 days later (Nair & Yamarik, 2002).
Intratracheal exposure—Implantation of a fine, pure aluminium wire in the lungs of Swiss
mice produced interstitial infiltration of lymphocytes, macrophages, and diffusely spreading
fibrosis (Greenberg, 1977). The author thought the effects were more extensive than those
produced by powdered aluminium and suggested that metallic aluminium might act as an
antigen in a hypersensitivity reaction and that aluminium-induced pulmonary fibrosis may be
an expression of tissue immunity.
Intratracheal administration, rather than inhalation, of aluminium has been employed in many
studies. Intratracheal injection of a rather coarse form of metallic aluminium powder produced
an extensive foreign-body granuloma in rats (Belt & King, 1943). Intratracheal injection of
stack fume dust, a causative agent in Shaver’s disease, to guinea pigs produced a rather abruptly
developing fibrosis 8 to 12 months later (Pratt, 1950).
Intratracheal instillation of 100 mg of the same gelatinous, hydrated aluminium oxide (laths
of 200 to 400 Å length and 50 to 100 Å width, or aggregates, 300 m2/g surface area) studied
by Gardner et al. (1944) resulted in extensive confluent nodular and diffuse confluent grade 5
fibrosis after 270 days (King et al., 1955). Similar intratracheal application of fumes,
comprising largely amorphous spherical particles of 0.02 to 0.5 μm with a surface area of 10
m2/g, from a corundum furnace produced mild, grade 2 to 3 fibrosis. Introduction of 50 mg of
aluminium phosphate, in the form of thin tablets of 0.5 to 5 μm diameter and having a surface
area of 1 m2/g, produced moderate, grade 3, fibrosis after 390 days (King et al., 1955). Further
studies were conducted by this group in hooded rats given intratracheal instillation of various
aluminium forms. Fourteen mg of aluminium hydroxide resulted in the development of firm,
discrete, rarely confluent lung lesions and collagenous fibrosis. Fifty mg of aluminium oxide,
aluminium phosphate or the equivalent dose as aluminium hydroxide were similarly injected.
The aluminium oxide studied was the same as used by others (Gardner et al., 1944).
Intratracheal instillation produced numerous white patches, often confluent, as early as 60 days
after exposure. After 180 days there were firm fibrotic areas and, at day 210, almost the entire
lung was a dense mass of fibrous tissue that progressed to a mass of confluent collagenous
tissue. Aluminium hydroxide produced firm, confluent, fibrotic patches in the lungs after 150
or more days. Aluminium phosphate produced similar effects, although less severe than seen
with aluminium oxide, whereas catalytically inert α-aluminium oxide did not produce adverse
lung effects (Stacy et al., 1959). Similar experiments with powdered metallic aluminium
(amorphous, 0.05 to 1 μm diameter) resulted in nodular fibrosis in hooded rats, similar to
changes produced by quartz dust (King et al., 1958). The intratracheal administration of 35 mg
of aluminium oxide produced slight (grade 1 to 2) fibrosis 150 days later, and grade 2 to 3
fibrosis 180 days later (Klosterkotter, 1960).
An intratracheal injection of 100 mg of stamped, thin, flake-like, aluminium particles (50% <
1 μm, 47% 1 to 5 μm and 3% > 5 μm) in 1 mL saline to Wistar rats produced nodules, enlarged
hilar lymph nodes, macrophage infiltration, the development of collagen fibres and fibrosis
over months. In contrast, instillation of granular aluminium (11% 1 to 5 μm, 17% 5 to 10 μm
and 72% > 10 μm) resulted in a small number of macrophages and occasional collagen fibres
after many months, but very little fibrosis (Corrin, 1963a).
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Intratracheal installation of 2 to 100 mg of coated, flake-like particles or atomized spherical
particles or 2 to 24 mg of the flaked powder to rats and hamsters resulted in dose-dependent
collagenous fibrosis which was not seen below a dose of 24 mg (Gross et al., 1973).
Rats were given a single intratracheal instillation of a saline suspension of potroom dust from
an aluminium reduction plant. Seven days after instillation of 0.5 mg dust, changes were seen
at the pulmonary surface. After a 5 mg dose, marked changes were seen at the pulmonary
surface and in lung tissue. There was a 16 to 20-fold increase in the number of
polymorphonuclear leukocytes in the lung. By contrast, 5 mg virginal (primary) aluminium
oxide caused an 8-fold increase which was interpreted by the authors as a standard response
to a nuisance dust. Twenty-two weeks after a single intratracheal instillation of 5 mg of potroom
dust or virginal aluminium oxide, all parameters measured had returned to control levels. The
acute irritation and inflammation produced in rat lung suggested that this type of dust may have
produced similar effects in human lung, thus contributing to the acute respiratory symptoms
experienced by some potroom workers (White et al., 1987).
Dinman (1988) reviewed the experimental studies of the toxicity of aluminium oxide in the
lung and concluded that the catalytically-active low temperature forms of aluminium oxide
and the forms that are not catalytically-active and defined as γ can produce irreversible
fibronodular changes, but only after intratracheal instillation. He termed this “alumina-related
pulmonary disease”. He noted a positive correlation between the surface area of the aluminium
oxide particles and the fibronodular response.
The ability of 7 aluminium oxide samples to produce lung cytotoxicity, measured by LDH and
polymorphonuclear neutrophils in BALF, was tested in rats by comparing the intratracheal
instillation of a total of 50 mg of aluminium oxide, with that of 25 mg of quartz, each given in
5 instillations over 2 weeks (Ess et al., 1993). The samples were smelter grade aluminas
obtained from industries involved in aluminium production and a chemical grade and a
laboratory produced aluminium oxide. They had median particle diameters of 1.3 to 12 μm
except for the chemical grade that had a median diameter of 0.008 μm. Increased lung
cytotoxicity was seen as surface area increased and α-content decreased. I.p. injection of 5 mg
of the smelter grade aluminas in mice produced nodules, but no fibrosis. The BALF of rats
given a single intratracheal instillation of 40 mg of potroom aluminium oxide was studied 1,
4 and 12 months later (Tornling et al., 1993). Compared to controls, there was a significant
decrease of lymphocytes at 1 month, a significant decrease of albumin at 4 months and a
significant increase of fibronectin at 12 months. The authors suggested that the increase of
fibronectin might contribute to the inflammatory reaction and build up of an extrcellular matrix
network. Rats were given a single intratracheal instillation of 20 mg of either condensed
aerosols/dusts collected from a foundry or pure chemical grade α-alumina. They were
suspended in 0.5 mL of saline. Before installation, samples were passed through a 36 μm
diameter strainer (Halatek et al., 2005). Multiple endpoints were determined in the BALF 3, 6
and 9 months later. Clara cell protein 16 (CC16) was significantly lower in rats that received
α-alumina 3 months after instillation and in rats that received foundry aluminium 6 months
after instillation, compared to controls. Hyaluronic acid was significantly increased only in the
rats terminated 6 months after α-alumina instillation. Nine months after treatment, neutrophils
increased ~ 3-fold in rats given foundry aluminium and ~ 5-fold in those given α-alumina.
Lung weights increased in the α-alumina-treated rats but not those that received foundry
aluminium. Three months after α-alumina instillation macrophage accumulation was seen;
after 6 and 9 months granuloma-like structures were observed. Six months after foundry
aluminium instillation, young forms of lymphocytes, macrophages and fibroblasts were seen;
after 9 months interstitial fibrosis was observed. The authors concluded that foundry aluminium
can cause irritation and inflammation in the rat lung and that a lowering of CC16 was the most
sensitive biomarker for this damage.
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Some of the studies of the potential for aluminium to protect against quartz dust-induced
pulmonary fibrosis employed intratracheal aluminium administration. Intratracheal
insufflation in rats of 150 mg of quartz dust mixed with 3 mg of powdered aluminium in 1.5
mL milk-saline as a vehicle resulted in silicotic nodules in the presence of 1% aluminium in
the lung in nearly all subjects, showing that aluminium failed to prevent experimentally-
induced silicosis (Dworski, 1955). Similarly, aluminium alone (20 to 50 mg) produced an
extensive foreign body reaction seen at ~ 16 months (Belt & King, 1943). Administration of
400 mg of a mixture of 98% quartz and 2% of the aluminium dust used by Denny et al.
(1937; 1939) in 4 mL saline into the lungs of rabbits reduced lesions and collagen formation
up to 1 year later and to a greater extent than when only quartz was administered (Belt & King,
1943; King et al., 1945). King et al. (1958) conducted further studies in hooded rats given
intratracheal instillation of various aluminium forms. Powdered metallic aluminium given
intratracheally in large amounts relative to quartz, which was given similarly, did not reduce
quartz-induced fibrosis (King et al., 1958). Intratracheal administration in sheep of 100 mg
quartz produced sustained increases in bronchoalveolar lavage cells, an alveolitis at 60 days,
and early nodular silicotic lesions at 10 months. This was attenuated by treating the quartz with
11 or 100 mg aluminium lactate, which was believed to mask some of the active sites on the
silica (Bégin et al., 1986; 1987; Dubois et al., 1988). Monthly inhalation of 100 mg aluminium
lactate after intratracheal instillation of 100 mg quartz or instillation of 100 mg aluminium
lactate-treated quartz enhanced pulmonary quartz clearance compared to when only quartz was
inhaled (Dufresne et al., 1994).
I.v. and i.p. administration of an aluminium dextran complex, Mr = 150,000, protected against
the development of silicotic nodules in the liver of mice injected i.v. with silica dust (James et
al., 1960).
Aluminium species used in pharmaceuticals and cosmetics have been tested for pulmonary
irritation and toxicity. Intratracheal installation of kaolin (hydrated aluminium silicate) in rats
produced pulmonary toxicity manifested as fibrosis (Martin et al., 1975). Bentonite (hydrated
colloidal aluminium silicate) given intratracheally to rats produced an increase in
polymorphonuclear lymphocytes in the lung (Sykes et al., 1982), inflammation, and
bronchopneumonia progressing to necrosis and storage-focal tissue reaction (Tatrai et al.,
1983), elevated macrophages and acid phosphatase activity (Tatrai et al., 1985) and increased
phospholipid (Adamis et al., 1986). Intratracheal montmorillonite (an aluminium magnesium
silicate clay) produced dose-dependent interstitial fibrosis (Schreider et al., 1985). Intratracheal
zeolite administration produced pneumoconiosis in rats (Kruglikov et al., 1990) and a storage
type reaction that progressed to mild pulmonary fibrosis (Tatrai et al., 1991).
Single intratracheal administration of attapulgite (hydrated magnesium aluminium silicate) or
Fiberfrax (an aluminium silicate) in rats produced granulomas accompanied by multinucleated
giant macrophages and enhanced IL-1-like activity. Additionally, early fibrosis was seen after
Fiberfrax exposure, and irreversible fibrosis 8 months following attapulgite administration
(Lemaire, 1991; Lemaire et al., 1989).
Rats that inhaled refractory aluminium oxide fibre as manufactured, or after thermal aging for
86 weeks, showed minimal pulmonary reaction (Pigott et al., 1981). When 20 mg of these
refractory aluminium oxide fibres were given by an intrapleural injection, they did not produce
the malignant mesothelioma produced by aluminosillicate and asbestos fibres (Pigott &
Ishmael, 1992).
Dermal application
Aluminium was applied in 0.5 mL solution as 2.5, 5, 10 and 25% aluminium chloride, or 10
or 25% aluminium chlorhydrate to 2 cm2 of shaved skin on the back of TF1 strain mice for 5
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consecutive days. Aluminium was similarly applied for 5 days to mice, New Zealand rabbits
and white strain pigs (1 mL of solution to 4 cm2) as 10% aluminium chloride, nitrate,
chlorhydrate, sulphate, hydroxide (in suspension) and basic acetate (in suspension), and as 25%
aluminium chlorhydrate. The 10% solutions of aluminium chloride and nitrate produced
epidermal changes that included slight to severe hyperplasia with focal ulceration, epidermal
damage, dermal inflammatory cell infiltration, hyperkeratosis, acanthosis, microabscesses,
aluminium deposition and abnormal keratin (Lansdown, 1973). The other 4 aluminium forms
did not produce these changes. The author suggested that the aluminium ion interacted with
keratin to denature it, making the stratum corneum more permeable, thereby allowing
aluminium penetration through the stratum corneum to cause toxicity to the epidermal cells.
Magnesium aluminium silicate was a weak primary skin irritant in rabbits (CFTA, 1970).
Therefore, aluminium can produce dermal irritation that is aluminium species-dependent.
Injection
The i.p. injection of ground aluminium phosphate in rats produced extensive fibrosis in the
peritoneal cavity (Evans & Zeit, 1949). Zeolite injection produced a peritoneal fibrosis (Suzuki
& Kohyama, 1984). Sub-plantar injection of bentonite produced granulomas in rats (Marek &
Blaha, 1985).
Aluminium is used as an adjuvant in vaccines and hyposensitization treatments for allergies.
Precipitation of toxins and toxoids by alum was found to enhance their antigenic properties
and reduce the rate of absorption and elimination of the antigen (Glenny et al., 1926; 1931).
However, an in vitro study demonstrated that proteins present in interstitial fluid that have a
larger adsorption coefficient can displace aluminium-adsorbed proteins with a smaller
coefficient, with > 50% protein displacement within 15 minutes. It has been suggested that this
result does not support the proposed mechanism of aluminium-enhanced antigenicity by
producing a persistent depot of antigen (Heimlich et al., 1999). In addition to delaying release,
aluminium strengthens the immunological properties of weak antigens to improve antibody
response, as shown by addition of aluminium hydroxide to triple vaccine, 2.5 mg in the 0.5
mL injection. This reduced toxicity and increased potency in laboratory tests, and reduced
reactions in children. However it produced s.c. nodules (Butler et al., 1969) (see also Effects
on Humans, Effects from Non-Occupational Exposure, Irritation, Irritation after Injection of
Aluminium-Adsorbed Proteins (Vaccines and Hyposensitization Regimens)). Aluminium
adjuvants may also increase antigenicity by increasing the production of a local granuloma
which contains antibody-producing plasma cells (White et al., 1955); by increasing the
immunogenicity of the aluminium-antigen complex; by increasing antigen specific as well as
total IgE antibodies (Gupta, 1998); and by stimulating the body’s immune competent cells
through activation of complement, induction of eosinophilia, and activation of macrophages,
lymphocytes and lymph nodes (Gupta, 1998; Hunter, 2002). Aluminium hydroxide-stimulated
macrophages contain aluminium and differentiate into mature, specialized antigen-producing
cells that express surface molecules similar to those seen in cultured dendritic cells, including
HLA-DRhigh, CD-86high, CD14-, and CD83 (Rimaniol et al., 2004). These effects seem to be
aluminium-dependent, because aluminium, phosphate-adsorbed TT produced a prolonged
synthesis of specific IgE, whereas calcium phosphate adsorbed TT did not (Vassilev, 1978).
This is discussed further in Effects on Humans, Effects from Non-Occupational Exposure,
Irritation, Irritation after Injection of Aluminium-Adsorbed Proteins (Vaccines and
Hyposensitization Regimens).
There is other evidence for aluminium induction of the immune system. I.p. administered
ovalbumin-adsorbed-aluminium silicate enhanced IgE antibody production (Fujimaki et al.,
1984). Aluminium silicate is a component of fly ash. IgE and IgG production were increased
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by intratracheal instillation of ovalbumin adsorbed onto 0.02 or 0.2 mg of aluminium silicate,
or onto alum or kaolin (Fujimaki et al., 1986).
Aluminium phosphate-precipitated toxoid prolonged the response to the toxoid in rabbits and
guinea pigs, producing granulomas and antibody-containing cells 4 to 7 weeks after injection
(White et al., 1955). The intradermal injection of alum-precipitated antigens produced lymph
node infiltration of histiocytes (Turk & Heather, 1965). Intradermal injection of aluminium
chlorhydrate into guinea pigs produced granulomas consisting of aggregations of
undifferentiated macrophages that followed lymph drainage to the regional lymph nodes where
they collected (Gaafar & Turk, 1970). Intradermal injection of 0.1 mL of alum-precipitated
protein or aluminium hydroxide emulsion into Hartley guinea pig ears produced histiocyte
infiltration within 4 days, persisting up to 28 days, that was mainly localized in close proximity
to the entrance to the afferent lymphatics (Gaafar & Turk, 1970). I.m. injection of aluminium
hydroxide or aluminium-adsorbed TT (0.1 mL containing 0.05 mg aluminium) in mice
produced interstitial oedema and degenerative/necrotic changes and polymorphonuclear
leukocyte infiltration at 24 hr. This acute reaction decreased over 72 hr when macrophage
infiltration began, leading to a chronic granulomatous reaction beginning 1 to 2 weeks later
that peaked at 8 and persisted for 16 to 20 weeks (Goto & Akama, 1982). Intradermal injections
of 0.05, 0.5 or 5 mg aluminium chlorhydrate or zirconium aluminium glycinate (ZAG) or 0.065,
0.65 or 6.5 mg of aluminium hydroxide were given to Hartley strain guinea pigs. The
aluminium hydroxide injections produced granulomas after the higher 2 doses. Those produced
by 6.5 mg aluminium hydroxide persisted for longer than 28 days. These granulomas
demonstrated undifferentiated macrophages and occasional giant cells around the injection.
There was little evidence of infiltration and none of fibrosis. Aluminium chlorhydrate and ZAG
injections produced skin thickness increases that reached a maximum at 28 days, and
granulomas consisting of shredded bundles of basophilic collagen, giant cells and histiocytes
which were pleomorphic, strongly hyperchromatic and sometimes phagocytic, followed by
intense fibrosis (Turk & Parker, 1977). The authors suggested aluminium induced persistent
nodule formation by a nonallergic direct toxic effect (foreign body reaction). I.m. injection of
aluminium hydroxide-adsorbed TT into mice produced muscle fibre necrosis and eosinophil
infiltration 4 days later (Walls, 1977). When aluminium chlorhydrate or ZAG were injected
into the toe pad of New Zealand rabbits twice weekly for 6 weeks for a total dose of 1.4 mg,
foreign-body granulomas, but not positive skin reactivity, were induced (Kang et al., 1977).
Intradermal injection of 0.25 mL of vaccine containing ~ 0.3 mg aluminium into the backs and
sides of rabbits produced s.c. nodules at all sites 8 days later, which persisted in most rabbits
for 56 days and in 1 for 72 days (Pineau et al., 1992). The nodules had greater aluminium
concentration than did normal skin. The infiltrate intensity and aluminium concentration in the
nodules positively correlated. However, this is not the typical route for such injections.
Aluminium hydroxide gel and suspension (aluminium concentration, 1 or 3 mg/mL) were
injected i.m. (0.5 mL) or s.c. (1 mL) as 3 mg aluminium with ovalbumin into the hind legs of
Hartley strain guinea pigs. The aluminium hydroxide gel produced granulomatous
inflammatory reactions characterized by macrophages with foamy cytoplasm, small
lymphocytes and giant cells at the injection sites. These effects persisted at least 8 weeks (Goto
et al., 1997).
Aluminium compounds are the only adjuvants widely used in routine human vaccines and are
the most commonly used adjuvants in veterinary vaccines. Two production methods have been
used. One is the addition of alum to the antigen to form a precipitate of protein aluminate,
termed alum-precipitated vaccines, which are similar in composition and physicochemical
characteristics to aluminium phosphate adjuvants. The second is the addition of the antigen
solution to preformed aluminium hydroxide, aluminium phosphate, mixed aluminium
hydroxide and phosphate, or gamma aluminium oxide to produce aluminium-adsorbed
vaccines (Clements & Griffiths, 2002; HogenEsch, 2002). Aluminium hydroxide (chemically:
Krewski et al. Page 148
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
crystalline aluminium oxyhydroxide) and aluminium phosphate (chemically: aluminium
hydroxyphosphate) are most commonly used (Hem, 2002). The former has an isoelectric point
of 11.4 and is positively charged in interstitial fluid, at pH 7.4, thereby adsorbing negatively
charged antigens by electrostatic attractive forces. Aluminium phosphate has an isoelectric
point between 4.5 and 6, is negatively charged at neutral pH and this adsorbs positively charged
antigens. Rational selection of the aluminium form is based on the charge of the protein to be
adsorbed.
When aluminium starch octenylsuccinate was prepared in suspension and injected
intracutaneously into a depilated site on the back of guinea pigs and rabbits, thrice weekly the
first week and weekly for 7 more weeks, no abnormal skin reactions were observed (Nair &
Yamarik, 2002). Subarachnoid (cisternal magna) injection of kaolin into foetal lambs and
monkeys produced a fibrotic reaction and inflammatory cell response of the meninges and
infiltration of kaolin-containing macrophages into the subarachnoid space (Edwards et al.,
1984).
Ophthalmic exposure—With respect to studies relevant to industrial aluminium exposure,
instillation of aluminium sulphate, potash alum, and ammonium alum into the eye resulted in
conjunctivitis and purulent ophthalmitis (Grekhova et al., 1994).
Of relevance to the potential effects of human exposure to aluminium in cosmetics, instillation
of aluminium starch octenylsuccinate, 70 mg in 0.1 mL, into the conjunctival sac of rabbits
produced a slight reddening of the conjunctiva that was seen from 1 to 24 hr later; this was
considered “unlikely” to be an ocular irritant in humans (Nair & Yamarik, 2002). When placed
in the eye of rabbits as an eye shadow containing 15% of this aluminium form, the irritation
potential was considered mild by the Draize classification system (Nair & Yamarik, 2002).
Formulations containing 1 and 2.5% of this aluminium form were considering non-irritating
in the chorioallantoic membrane vesicular assay (Nair & Yamarik, 2002). Magnesium
aluminium silicate caused minimal eye irritation in a Draize eye irritation test (Hazelton
Laboratories, 1968). Bentonite caused severe iritis after injection into the anterior chamber of
the eyes of rabbits. When injected intralamellarly, widespread corneal infiltrates and
retrocorneal membranes were recorded (Austin & Doughman, 1980).
Implantation exposure—Discs of synthetic auditory ossicle composed of aluminium oxide
were implanted s.c. in the interscapular region of 16 rats and removed 1, 3, 7 and 14 days later.
After 1 day, this resulted in an acute inflammatory reaction in which macrophages and
neutrophils predominated and that almost disappeared after 7 days. Fibrosis began to be
observed at 3 days (Ye et al., 1998).
In vitro test systems
Many reports are cited in Effects on Laboratory Mammals and In Vitro Test Systems, Irritation,
Inhalation Exposure / Intratrachael Exposure, and Effects on Humans, Effects from
Occupational Exposure, Irritation, Inhalation Exposure of the ability of aluminium to cause
pneumoconiosis, an inflammation of the lung that can progress to fibrosis, which is typically
caused by inhalation of dust. There are also many reports of negative findings. The discrepancy
may be due to the chemical form (species) of the inhaled aluminium, granular vs. flake-like
particles. In this section, studies addressing the mechanism(s) of action of these irritant effects
are discussed.
Corrin (1963a;1963b) noted that aluminium reacts with water but is not able to do so when
coated with inert aluminium oxide. Granular aluminium coated with aluminium oxide is
produced without use of lubricating agents, such as spindle oil and stearine. The author
attributed many of the reports of negative effects to exposure to aluminium oxide or aluminium
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oxide-coated aluminium. The author also found that spindle oil- or stearine-coated aluminium
powder reacted with water, presumably forming reactive aluminium hydroxide, whereas
stearine-coated aluminium powder did not, and noted that the substitution of mineral product
for stearine coincided with the onset of aluminium-induced pneumoconiosis. The explanation
offered was that respirable aluminium particles that can react with water in the lung can be
toxic.
Aluminium oxide was shown to release histamine from rat peritoneal mast cells (Casarett et
al., 1968). The greatest effect, seen with 4.4 μm maximal median diameter particles at pH 6.8,
was comparable to that see with iron oxide but less than seen with chromium oxide. This may
contribute to bronchoconstriction caused by inhaled aluminium particles. Four clays containing
aluminium silicate (montmorillonite, bentonite, kaolinite and erionite), caused lysis of human
umbilical vein endothelia, N1E-115 neuroblastoma and ROC-1 oligodendroglial cells (Murphy
et al., 1993). The authors suggested these clays might disrupt the BBB, allowing their entry
into the brain. Exposure of mouse peritoneal macrophages, human type II alveolar tumour
(A549) cells and Chinese hamster V79-4 lung cells to 11 minerals, including short and long
fibres of attapulgite (a hydrated magnesium aluminium silicate) revealed some dusts that were
non-toxic to all three cell types, some that were toxic toward mouse peritoneal macrophages,
as shown by LDH release, and some that were toxic to all 3 cell types, additionally causing
increased diameter of the A549 cells and reduced survival of 79-4 cells (Chamberlain et al.,
1982). The results suggest differential sensitivity of cells to toxicity produced by these dusts
and that long-fibred dusts are more toxic than short-fibred dusts. Exposure of rabbit AM to
hydrated aluminium silicate resulted in toxicity, as evidenced by reduced viability and ATP
(Hatch et al., 1985). Hydrated aluminium silicate caused concentration-dependent haemolysis
of erythrocytes (Woodworth et al., 1982). Murine neuroblastoma cells exposed to hydrated
aluminium silicate showed an increase in membrane electrical conductance and loss of
excitable activity, as evidence of toxicity (Banin & Meiri, 1990).
Immunotoxicity/Immunosuppression
The immune system and its reactions involve interactions between various cell types and
soluble mediators. These responses can be clustered into innate (natural and non-specific) and
acquired (adaptive) responses for which the reaction is directed to an antigenic determinant or
epitope. Non-specific responses involve effector cells such as macrophages, natural killer cells,
granulocytes, and mediator systems such as the complement system. Biologically, components
of the immune system are present throughout the body and interactions between the immune
system and other organ systems are a normal component of immunoregulation. While a number
of metals have been demonstrated to have immunotoxic properties, little has been reported for
aluminium (IPCS/WHO, 1996). In addition, aluminium hydroxide has been used as an adjuvant
in many human vaccines (Roit et al., 1998) (see Table 7). Vaccine efficiency is enhanced by
aluminium’s capacity to absorb antigen particles forming granulomas in the point of injection.
Early studies suggested altered immune responses following excess aluminium exposure.
Pregnant Swiss-Webster mice exposed to aluminium (500 or 1,000 μg Al/g diet; as aluminium
lactate) showed a lower resistance to bacterial Listeria monocytogene infection while non-
pregnant mice showed the reverse (Yoshida et al., 1989). Acute injection of aluminium (1-10
mg/kg body weight to non-pregnant mice) resulted in a lower mortality rate to L.
monocytogenes as compared to controls (Yoshida et al., 1989). In these studies, the offspring
showed no differences in mortality rates. However, Golub et al. (1993) suggested that excess
aluminium exposure (1000 μg Al/g diet; as aluminium lactate) in Swiss Webster mice from
conception to 6 months of age resulted in alterations in immune effector cell function. Splenic
lymphocytes showed a depressed response to concanavalin A. When the spleen weight was
measured in mice fed 1000 ppm in the food from weaning to adulthood (4 week and 8 week
exposures) no changes were detected relative to controls (Golub & Keen, 1999). Based upon
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these studies, Tsunoda & Sharma (1999) examined pro-inflammatory cytokine mRNA levels
in the brain and immune organs of mice following a 1-month exposure to 125 ppm aluminium
ammonium sulphate in the drinking water. Isolated splenic macrophages and lymphocytes
showed no aluminium-related changes in the basal mRNA levels of TNFα, IL-1β, or IFNγ.
However, the authors suggested that, while low and somewhat variable, basal mRNA levels
for TNFα were increased in the brain of aluminium exposed mice (Tsunoda & Sharma,
1999).
Effects on the Endocrine System
With the exception of experimental studies in which the effect of aluminium exposure on the
reproductive system has been examined (Effects on Laboratory Mammals and In Vitro Test
Systems, Reproductive and Developmental Toxicity, Reproductive Toxicity), those designed to
examine adverse effects on the endocrine system have been limited to the parathyroid response
given that aluminium overload leads to PTH suppression.
Many of the PTH receptors of interest for aluminium toxicity are present in both the bone and
kidney; thus, much of the data with regard to the effect of aluminium exposure on the bone
discussed in Effects on Laboratory Mammals and In Vitro Test Systems, Effects On Bone is
related to the alterations in serum PTH levels and calcium homeostasis. For example, Pun et
al. (1990) demonstrated that lower concentrations of aluminium (4μm and 40 μM) inhibited
the cyclic AMP response to PTH challenge via a decrease in PTH receptor binding in both
clonal osteoblastic UMR-106 cells and in dog renal cortical membrane. Bourdeau et al.
(1987) examined the endocrine response of porcine parathyroid gland tissue slices to
aluminium at concentrations of 20 to 500 ng/mL. High concentrations of aluminium inhibited
induced PTH release in a calcium-dependent manner. Gonzalez-Suarez et al. (2003) reported
that 8 weeks of exposure to aluminium chloride (AlCl3) (i.p. daily) reduced serum PTH levels
and cell proliferation in the parathyroid glands, yet did not alter serum phosphorus levels, cell
apoptosis or the calcium sensing receptor expression in young adult male Wistar rats surgically
nephrectomized (7/8th tissue excised). In a similar study, Diaz-Corte et al. (2001), surgically
nephrectomized adult male Wistar rats maintained on a high dietary phosphorus intake received
2 daily ip. injections of AlCl3 five weeks after surgery and examined 2 weeks post-injection.
While significant decreases in serum PTH levels and mRNA levels for PTH in the parathyroid
gland were seen in the aluminium-injected group, no differences were seen in serum calcium
and phosphorus levels, renal function or body weight. Similar decreases in plasma PTH
concentrations have been reported in cats with stable chronic renal failure when maintained
on a diet restricted in phosphorus and protein with aluminium hydroxide included as an
intestinal phosphate binding agent (Barber et al., 1999).
Genotoxicity and Mutagenicity
Aluminium compounds have produced negative results in most short-term mutagenic assays.
As early as 1976, aluminium (Al2(SO4)3) had been shown to decrease DNA synthesis without
affecting replication fidelity (Sirover & Loeb, 1976). At concentrations from 20 μM to 150
mM, the accuracy of DNA synthesis in vitro was maintained. In a rat osteoblast cell line, UMR
106, DNA synthesis as determined by 3H-thimidine incorporation was shown to be decreased
in the absence of an increase of protein synthesis as determined by 3H-leucine incorporation
by exposure to 30 μM aluminium (Blair et al., 1989). Aluminium concentrations of 0.01 mM
to 0.1 M, as AlCl3, showed no potential to induce depurination of DNA as measured by the
release of adenine or guanine in calf-thymus DNA (Schaaper et al., 1987). Calf-thymus DNA
was used by Ahmad et al. (1996) to examine alterations in DNA binding by AlCl3 (0.6-25
mM). These authors reported that aluminium was bound to the backbone PO2 group and the
guanine N-7 site of the G-C base pairs by the process of chelation.
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In bacteria, aluminium compounds have been considered, in general, to be non-mutagenic.
Aluminium showed no mutagenic activity as measured by the Rec-assay using Bacillus
subtilis (Nishioka, 1975). At concentrations of 1 to 10 mM, Al2O3, AlCl3, and Al2(SO4)3 were
also negative in the Rec-assay with the Bacillus subtilis H17 rec+ and M45 rec- strains (Kada
et al., 1980; Kanematsu et al., 1980). Both aluminium and hydrated aluminium chloride
(AlCl3-6H2O) at concentrations ranging from 10 to 100 nM per plate failed to induce reverse
mutations in the Salmonella typhimurium TA102 strain as identified by his gene mutations
(Marzin & Phi, 1985). Positive results have been obtained in studies using dye-alumina
complexes; however these (positive) results have been attributed to impurities in the complexes
rather than an effect of aluminium (Brown et al., 1979). The absence of mutagenic effects of
aluminium compounds on various bacterial strains including Salmonella typhimurium and
Escherichia coli demonstrated in these early studies has been supported by the findings of more
recent studies (Ahn & Jeffery, 1994; Gava et al., 1989; Marzin & Phi, 1985; Olivier & Marzin,
1987; Prival et al., 1991; Seo & Lee, 1993; Shimizu et al., 1985; Venier et al., 1985; Zeiger et
al., 1987). In their assessment of mutagenicity, Ahn & Jeffrey (1994) failed to find positive
findings with aluminium chloride (0.3 and 3.0 ppm) using the biological endpoint of his
mutation induction in the absence of S9 metabolic activation in the TA98 strain. No induction
of his mutations were seen by Marzin & Phi (1985) in the 102 strain exposed to aluminium
chloride hexahydrate (10-100 nmol/plate), and by Gava et al. (1989) in the TA104, TA92,
TA98, TA1000 strains exposed to aluminium acetylacetonate (1.9-48 μmol/plate), aluminium
lactate (1.8 - 5.5 μmol/plate), or aluminium maltolate (0.5-3.7 μmol/plate). The Salmonella
typhimurium strain, TA104, showed a his gene mutation to aluminium acetylacetonate (1.8 –
48 μmol/plate); however, negative responses were reported when comparisons were made
between the absence and presence of S9 metabolic activation. Shimizu et al. (1985) showed
no positive response to aluminium fluoride (0.02-119 μmol/plate) in TA98, TA100, TA1535,
TA1537, and TA1538 strains. Zeiger et al. (1987) showed similar results in the TA98, TA100,
TA1535, and TA1537 strains following exposure to sodium aluminium silicate (0.96 - 38.5
μmol/plate). Prival et al. (1991) showed no positive responses to sodium aluminium silicate
(0.36 - 108.1 μmol/plate) or calcium aluminosilicate (0.033 - 10 mg/plate) in TA98, TA100,
TA1535, TA1537, and TA1538 strains. Studies with Escherichia coli (WP2 strain) have shown
negative responses in trp mutations with aluminium chloride (0.8 mol) (Seo & Lee, 1993);
aluminium fluoride (12 nmol-1.6 mmol/plate) (Shimizu et al., 1985); calcium aluminosilicate
(0.33-10 mg/plate), and sodium aluminium silicate (0.96.1 μmol/plate) (Prival et al., 1991).
Using the SOS chromotest, Raabe et al. (1993) evaluated the genotoxicity potential of 36
characteristic waste products resulting from aluminium plasma etching. While a majority of
the products show some genotoxic activity, a correlation between the organic constituents and
biological effect could not be established. Using the common soil bacterium Rhizobium, Octive
et al. (1991) reported preliminary findings showing no change in cell survival following an 18
hr exposure to 50 mM aluminium in both RDG 2002 and NZP2037 strains. In each strain,
exposure to rafampicin for 3-14 days decreased cell growth; the data suggested a slight
resistance in the RDG 2002 strain exposed to aluminium.
Studies have shown that aluminium compounds can inhibit cell division and produce
chromosomal aberrations in plants. The relevance of data derived from plant studies to assess
the carcinogenic potential in mammalian systems has come under question given that metal
salts of various carcinogenic potential can give similar results in short-term plant assays
(Léonard & Gerber, 1988). An early study by Gelfant (1963) showed that mammalian cell
division can be inhibited by aluminium salts; however, later studies showed that this did not
translate to morphological transformation of Syrian hamster embryo cells. In these cells,
AlCl3 and Al2(SO4) at concentrations up to 20 μg/mL medium neither caused morphological
transformation nor enhanced their transformation induced by a simian adenovirus SA7 (Casto
et al., 1979; Di Paolo & Casto, 1979). In the L5178Y mouse lymphoma assay, AlCl3, 500-620
μg/mL, did not induce forward mutations at the thymidine kinase locus (Oberly et al., 1982).
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Chromosome aberrations have been reported in spermatocytes of grasshoppers (Phloeoba
antennata) 48 – 60 hr post aluminium chloride (10 mg/0.21 g b.w.; Manna & Parida, (1965))
and in mammalian peritoneal cells (Nashed, 1975). Aberrations in the bone marrow cells of
mice injected with aluminium chloride (0.1M aluminium chloride 1 mL/30 g b.w., acute ip.
dose) have also been reported in a single study (Manna & Das, 1972).
Aluminium is known to act as a cross-linking agent for various cellular filaments. Using ascites
hepatoma cells from Sprague-Dawley rats, Wedrychowski et al. (1986a; 1986b) reported that
AlCl3 could serve as a stimulator for the crosslinking of chromosomal proteins. However, in
an Epstein-Barr virus-transformed Burkitts human lymphoma cell line, AlCl3 showed no
ability to crosslink DNA protein at either cytotoxic or non-cytotoxic concentration levels
(Costa et al., 1996). Human blood lymphocytes showed positive responses for both micronuclei
formation (Migliore et al., 1999; Roy et al., 1990) and sister chromatin exchange (Roy et al.,
1990) at AlCl3 levels from 11.6 μmol/mL (Roy et al., 1990) to 500 - 4000 μM (Migliore et al.,
1999). Roy et al. (1990) reported that the increase in micronuclei formation was significant
only in cells obtained from adult donors, and sister chromatin exchange was significant only
in cells from females. The chromatid aberrations reported in the Roy et al. (1990) study were
limited to an increase in gaps and breaks and the study was done in phosphate-free media. One
additional study (Alfaro Moreno et al., 1997) conducted using BALB/c mouse 3T3 cells
reported anaphasic alterations as a possible step in the process of chromosomal dysfunction
following exposure to Mexicali dust (98% potassium aluminium silicates and 2% sodium
dioxide- 0.67 mMl/L). The work of Karlik et al. (1980a; 1980b) suggested that interactions of
aluminium with DNA would be dependent upon pH.
During the 1990s, a number of investigators conducted experiments to determine the genotoxic
potential of aluminium compounds administered to the whole animal. Short-term studies
examining changes occurring within the first 24 - 48hr of systemic dosing with aluminium
compounds showed contradictory results. Isolated DNA from the liver of male Wistar rats
showed no changes in the formation of 8-hydroxydeoxyguanosine (Umemura et al., 1990)
following a high dose of aluminium nitrilotriacetate complex (7 mg Al/kg [259 μmol/kg] i.p.).
Takagi et al. (1990) exposed F-344 rats to 1.2% aluminium clofibrate in the diet; within 1-12
months of exposure the rats showed an elevation in hepatic peroxisomal beta-oxidation enzyme
activity. One early preliminary study using high levels of aluminium chloride (0.01 - 0.1 mol/
mouse, i.p.) reported the induction of chromosomal aberrations (Manna & Das, 1972). Two
later published studies used high dose levels of aluminium sulphate (100 - 500 mg/kg bw (0.3
- 1.5 mmol Al/kg b.w.)) as a known inducer of either micronucleated polychromatic peripheral
erythrocyte (mnPCE) formation (Roy et al., 1992) or SCEs (Dhir et al., 1993) in murine bone
marrow cells. As expected, a significant increase in mnPCEs was induced 24 hrs after a second
aluminium dose of 500mg/kg b.w. in Swiss albino mice. No changes were seen at the 250 mg/
kg b.w. dose level (Roy et al., 1992). The work of Dhir et al. (1993) showed an induction of
SCEs in bone marrow from male Swiss albino mice in a dose-related fashion 24 hr after a single
dose of aluminium sulphate. The induction of SCEs was detected by bromodeoxyuridine
(BrdU) pre-labelling (50 mg BrdU paraffin-coated tablet implanted subcutaenously) followed
by a single dose of aluminium sulphate (100, 200, or 400 mg/kg b.w.) and a single i.p. injection
of colchicine (4 mg/kg b.w.) 22 hrs later.
Studies in which in either male rats (Rattus norvegicus) or sheep were exposed to complex
mixtures containing aluminium were indicative of positive changes. Bauer et al. (1995)
reported mnPCE formation in male and female Wistar rats that received vacuum pump oils
contaminated by waste products from a BC13/C12 aluminium plasma etching process (dose
of 1000 mg/kg/day in a gavage dosing volume of 0.54 mL/kg/day). Numerous compounds and
elements were identified in the waste; however, the aluminium contribution to the waste was
at approximately 2000 ppb. MnPCE formation in bone marrow was not detected until the
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animals had been exposed for 28 days. In another mixture study, the emissions of aluminium
and other ionic forms of metals from an aluminium refining plant were administered orally in
distilled water for one year to sheep (Sivikova & Dianovsky, 1995). The total calculated
concentration of aluminium delivered was 1.1 or 2.4 mmol Al/animal/day. A significant
increase in SCEs was found in the cultured lymphocytes of the high dose group only. A mitotic
delay in both dose groups was reported by the authors based upon differences in cell metaphases
relative to that seen in the controls. Spotheim-Maurizot et al. (1992) reported on the
antigenotoxicity of aluminium. The in vitro frequency of single- and double-stranded breaks
in plasmid DNA, as induced by radiation, was significantly inhibited by low concentrations of
aluminium chloride. A 50% reduction in double-stranded breaks occurred with 0.2 mM
aluminium chloride. A similar reduction was seen in single-stranded breaks with 0.04 mM
concentration levels. The authors speculated that the reduction was due to structural changes
occurring in the DNA that prevented the access of OH+ radicals.
Carcinogenicity
Overall, experimental animal studies have failed to demonstrate carcinogenicity attributable
solely to aluminium compounds (for reviews, see ATSDR, 1999; Furst, 1971; Furst & Haro,
1969; Haddow & Hornig, 1960; IPCS, 1997; Shubik & Hartwell, 1969). The data that exist
for aluminium compounds support the relevance of the physical characteristics of aluminium
in relation to the adverse endpoint under study as was suggested by Krueger et al. (1984). As
an example, in a very early study, O’Gara & Brown (1967) reported an increase in sarcomas
(8 out of 18 rats) in NIH black rats implanted s.c. with 0.05 mm thick aluminium foil. However,
intrapleural or i.p. administration of 3.5 μm diameter aluminium fibres to rats showed no
indication of carcinogenicity (Pigott & Ishmael, 1981; 1992; Stanton, 1974). It has been
proposed that the results of these studies support the hypothesis put forth by Bischoff & Gyson
(1964) that the dimension of the implant rather than chemical composition is related to
carcinogenicity (for review, see Krueger et al. (1984)). A similar pattern is evident in inhalation
studies. Steinhagen et al. (1978) reported a dose-related increase in lung lesions in both rats
(Fischer 344 males and females) and guinea pigs (Hartley) following inhalation of aluminium
chlorhydrate for six months. Fifty-percent of the animals showed lesions following exposure
to 2.5 mg/Al/m3 increasing to 100% of animals that had been exposed to 25 mg Al/m3. In
guinea pigs, approximately 10% showed an increase in AM at a low dose of 0.25 mg Al/m3.
The pathology was characterized by an increase in mononuclear inflammatory cells and large
macrophages in alveoli around the termination of air passageways. These data suggest a
progression in the inflammatory response of the lungs with aluminium chlorohydrate exposure
that may be related to the tissue response to foreign bodies and the associated irritant response.
A later study showed no increased tumour incidence in rats (male and female Wistar) following
inhalation of alumina fibres (2.18 or 2.45 mg/m3; Al2O3 and approx. 4% silica) of a similar
diameter for 86 weeks (Pigott & Ishmael, 1981). When Al2O3 dust was intratracheally instilled
in hamsters, Stenback et al. (1973) concluded that Al2O3 was not carcinogenic for the
respiratory system. Of two additional early studies Schroeder & Mitchner (1975a) reported an
increased incidence in gross tumours of approximately 52% as compared to 16% in control
male Long-Evans rats exposed to aluminium (KAl(SO4)2) at a concentration of 5 ppm in
drinking water for approximately 2-2.5 yr. This was observed in males only. In the second
study, no increase in the incidence of neoplasms in either male or female Wistar rats exposed
to aluminium phosphide/ammonium carbamate in the diet for 2 years was reported
(Hackenberg,1972).
A limited number of studies have been conducted in mice. Two studies examined the effects
of oral exposure to aluminium potassium sulphate in male and female mice. Schroeder &
Mitchener (1975b) reported an increase in the incidence of gross tumours in female Swiss
Webster mice (46 vs. 30%) following exposure to 5 ppm aluminium in drinking water (1.2 mg/
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kg b.w./day for 2-2.5 years). A more recent study by Oneda et al. (1994) showed no increase
in the incidence of gross tumours, neoplastic lesions, or other proliferative lesions in
B6C3F1 mice following dietary exposure to up to 979 mg Al/kg/day for 20-24 months.
Interestingly, in all groups, the incidence of spontaneous hepatocellular carcinoma was
significantly decreased in the females. This was also significantly decreased in the high-dose
group males (5.5 vs. 20.5% in controls) and the incidence of myocardial eosinophilic cytoplasm
showed a dose-dependent decrease with aluminium exposure. When the route of delivery was
changed and an i.p. injection of Al2O3 was given in male and female mice at 2 and 3 months
of age, examination at the end of normal lifespan showed an increase in mesothelioma in the
peritoneum (Frash et al., 1992).
Aluminium compounds have been proposed as possible chemotherapeutic agents.
Experimental animal studies showed that aluminium nitrate (50 - 400 mg/kg; optimal dose:
150mg/kg b.w.) could significantly reduce the growth of i.p. transplanted Walker 256
carcinosarcomas in female Sprague-Dawley rats (Adamson et al., 1975; Hart & Adamson,
1971). A similar effect was not evident against P388 leukaemia cells, L1210 leukaemia, K1964
leukaemia, YPC-1 plasma cells, or Ehrlich ascites carcinoma cells. These effects may be related
to differential uptake of aluminium by these cells (Adamson et al., 1975) or, alternatively, by
direct alterations of the immune response (Pauwels et al., 1979). Pretreatment with a s.c.
injection of 0.1 mL 0.2% aluminium chloride (AlCl3 - 6H2O) reduced the number of developing
nodules induced by dimethyl nitrosamine (Yamane & Ohtawa, 1979).
Interactions Between Aluminium and Other Agents
With additional investigation, the roles of social, environmental, and biological factors as either
modifiers of potential risk or susceptibility factors for adverse effects from chemical exposure
are becoming more evident. With regards to genetic factors, Fosmire et al. (1993) examined
the level of aluminium in the brains of 5 strains of inbred mice following dietary exposure to
260 mg Al/kg b.w. for 28 days. While no difference could be detected between the A/J, BALB/
c, and C57BL/6 strains, higher levels of aluminium were seen in the brains of DBA/2 and C3H/
2 strains. Interestingly, the C3H/HeJ and the C57BL/6 strain differ in bone density (Beamer
et al., 1996) and calcium metabolism which is thought to occur partially via the vitamin D and
PTH endocrine systems’ regulatory influence on extracellular calcium (Chen & Kalu, 1999),
both of which can be influenced by aluminium. Tf plays a significant role in the biological
availability of aluminium to organ systems. The ability to saturate Tf with iron was reported
to be approximately 10 times greater in C57BL/6 and BALB/c mice than in DBA/2 and AKR
mice; however, serum Tf levels were equivalent across these strains (Leboeuf et al., 1995). For
a discussion of other potentially modifying factors such as age, and interactions with other
chemical species, see Toxicokinetics.
EFFECTS ON HUMANS
Case Reports
Although the majority of human cases of aluminium toxicity have been reported in either
preterm infants or patients with renal failure, several case reports of aluminium toxicity have
been documented in other populations (Nieboer et al., 1995). Reports specifically related to
infants and renal impaired patients are included in the Effects on Humans, Subpopulations at
Special Risk section. Case reports allow for potentially important adverse consequences to be
identified; however, this information is not collected in a controlled, systematic manner and,
in general, includes data obtained from small sample sizes. Therefore case reports can not be
generalized to support causal associations and are not subject to statistical verification for
biological relevance.
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A case of osteomalacia was reported subsequent to chronic antacid use in a patient with normal
renal function (Woodson, 1998). The 39 year old female patient consumed approximately 70g
of a commercial antacid daily for approximately 8 years, which is equivalent to consumption
of over 18 kg of elemental aluminium. The daily dose ingested by this individual exceeded the
manufacturer=s recommended maximum daily dose for this antacid. The patient developed
severe osteomalacia due to phosphate depletion. However, the patient=s condition improved
after cessation of antacid use and supplementation with calcium, phosphate and vitamin D.
Severe osteomalacia secondary to ingestion of large amounts of an aluminium- containing
antacid was also found in a 75-year old woman (Kassem et al., 1991). This patient presented
with symptoms of severe osteopoenia, muscle pain and elevated levels of serum alkaline
phosphatase activity. Medical records revealed that she consumed 70-85 mL of antacid daily,
which is equivalent to 8-9 g of aluminium hydroxide. The patient=s condition improved after
cessation of antacid use and treatment with vitamin D2, calcium, phosphate and sodium
fluoride.
Gilbert-Barness et al. (1998) reported the case of a 9-year-old female who was found not to be
progressing developmentally at the age of 2 months. At the age of 4 months the child was
diagnosed with a neurodegenerative disorder with severe mental retardation. Congenital
metabolic disorders were considered as a manifestation; however, all enzyme levels related to
these disorders were within the normal range. The infant had a high Apgar score at birth and
there was no recorded neonatal distress. The patient’s condition progressively worsened,
resulting in death at the age of 9 years. Autopsy revealed CNS cortical atrophy, small basal
ganglia, and hypomyelination of the spinal cord, cerebral cortex, subcortex and cerebellar white
matter. Following autopsy it was discovered that the mother had taken an average of 75
Maalox® tablets (containing 200 mg of aluminium hydroxide per tablet) each day during the
pregnancy. These results suggested that the high levels of aluminium intake by the mother,
during critical periods of the foetus’ brain development, resulted in neurological damage to the
infant. It should also be considered that concurrent ingestion of aluminium-containing antacids
with acid-containing foodstuffs can results in enhanced GI absorption of aluminium (Tytgat
et al., 2003). Pregnant women may be more likely to consume these types of foods (e.g. orange
juice, yogurt), further adding to the concern of aluminium-containing antacid use during
pregnancy.
Reusche et al. (2001b) reported a case of fatal aluminium encephalopathy following
reconstructive otoneurosurgery in which bone reconstruction was performed with aluminium-
containing cement. Six weeks after the surgery the 52 year old female patient experienced
disturbances of consciousness, subacute coma, and grand-mal seizures. The patient died 6
weeks after presentation of these symptoms, due to septic complications. The role played by
aluminium in this fatality remains unclear. Two similar cases of encephalopathy following the
surgical use of aluminium-containing bone cement were reported by Hantson et al. (1994). A
29 year old man died from brain dysfunction following surgery for Meniere’s disease in which
aluminium containing bone cement was used to bridge bone defects. The same operation was
conducted on a 54 year old female. This patient developed confusion, alterations of
consciousness, and grand-mal seizures and the patient died 80 days after surgery. In both cases
the bone cement came in contact with CSF (Hantson et al., 1994).
Several cases of adverse reactions to aluminium in vaccines were reported. MMF is a type of
inflammatory myopathy characterized by muscular infiltrate of macrophages containing
aluminium inclusions (Di Muzio et al., 2004). Several cases of macrophagic myofaciitis were
observed following i.m. injection of aluminium containing vaccines in both adult (Authier et
al., 2001; Gherardi et al., 2001) and paediatric populations (Di Muzio et al., 2004; Gherardi et
al., 2001; Lacson et al., 2002; Nevo et al., 2004). Clinical features of this condition include
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diffuse muscle pain, muscle weakness, fever, and in some cases overt CNS manifestations are
apparent (Authier et al., 2001; Di Muzio et al, 2004). Authier et al. (2001) reported 7 cases of
MMF accompanied by demyelinating CNS symptoms. All of these patients received an
aluminium-containing vaccine 3-78 months before the presentation of symptoms. Gheradi et
al. (2001) recorded information regarding immunizations for 50 patients presenting with
macrophagic myofaciitis. All patients received aluminium hydroxide-containing vaccines 3-96
months before biopsy. The low prevalence of this disorder in relation to the number of
individuals who were vaccinated with aluminium-containing adjuvants suggests that there is
inter-subject variability in the elimination of aluminium. This would account for differences
in the occurrence of MMF in only a predisposed subset of individuals with impaired ability to
eliminate aluminium from muscle (Nevo et al., 2004). MMF has been linked to aluminium
hydroxide-containing vaccines due to the detection of aluminium hydroxide crystals within
MMF lesions, a temporal relationship between vaccination and occurrence of MMF, and
location of the lesions at the same site where aluminium hydroxide-containing vaccine was
administered (Gherardi et al., 2001). However, due to the invasiveness of the biopsy procedure,
cases of MMF have not been compared with asymptomatic controls (Netterlid et al., 2004) and
the pathogenic mechanisms through which aluminium induces this disorder is currently
unknown (Authier et al., 2001).
Contact allergic reactions to aluminium following injection of aluminium-adsorbed vaccines
have also been documented (Akyol et al., 2004; Bergfors et al., 2003; Cox et al., 1988a;
1988b, Netterlid et al., 2004) (see also Effects on Humans, Effects from Non-Occupational
Exposure, Irritation, Irritation after Injection of Aluminium-Adsorbed Proteins (Vaccines and
Hyposensitization Regimens)). This reaction is usually manifested by symptoms including
itching nodules or granulomas at the injection site (Bergfors et al., 2003). Hypersensitivity to
aluminium is considered to be a rare occurrence (Akyol et al., 2004; Bergfors et al., 2003).
Netterlid et al. (2004) conducted a prospective cluster randomized surveillance study to
estimate the extent of late local reactions and contact allergic reactions to aluminium in 22,365
Swedish 10-year olds following vaccination with an aluminium-containing diphtheria-tetanus
vaccine. The presence of local itching nodules persisting for at least 2 months was detected in
3-6 per 10,000 children (Netterlid et al., 2004).
Effects from Occupational Exposure
Respiratory tract effects
Aluminium smelter (potroom) workers: There have been numerous reports of the effects of
working in the aluminium industry on the respiratory tract, particularly in aluminium potroom
(or smelter) workers. Asthma-like symptoms, known as “potroom asthma” have been reported
in several studies. The exact cause of potroom asthma has not been conclusively established,
but hydrogen fluoride and particulate fluoride have been implicated (Barnard et al., 2004;
Soyseth & Kongerud, 1992). Radon et al. (1999) further suggested that lung function
impairment may be only partly due to fluoride exposure and that working in aluminium carbon
plants (with exposure to carbon dusts) may cause acute lung function changes. A detailed
review of studies (in chronological order) follows.
A cross-sectional respiratory survey of white males conducted from October 1979 to May 1980
at an aluminium smelter in British Columbia (Chan-Yeung et al., 1983) compared the results
in 797 potroom workers, 495 with high exposure (who spent more than 50% of their working
time in the potroom) and 302 with medium exposure (who spent less than 50% of their working
time in the potroom), with 713 men with no significant exposure to air contaminants (who
worked in the office and casting departments). There were two components to the study, a
health study and an industrial hygiene survey. For the health study, trained interviewers
administered a questionnaire using a standardized technique; data on smoking habits and
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detailed occupational history were collected. A limited physical examination was conducted,
including respiratory symptoms, and tests for common skin allergens. Chest roentgenograms
were obtained (from 60% of workers), and pulmonary function tests were conducted. To
determine if work place exposure to contaminants had acute effects on the airways, pre-shift
and post-shift spirometry was conducted on a subset of the medium and high exposure groups.
In addition, pre-shift, post-shift and end of the work week urine samples were collected to
measure urinary fluoride levels. The industrial hygiene survey involved personal sampling on
representative workers of different job categories for levels of air contaminants, including total
airborne particulates, gaseous and particulate fluoride, carbon monoxide, sulphur dioxide and
benzo-alpha-pyrene. Highly exposed potroom workers were significantly younger, were
employed for significantly shorter periods of time, and were more likely to smoke than the
control group. Potroom workers had a greater prevalence of cough, sputum, and wheeze
compared with the control group; these results were statistically significant for the high
exposure group but not for the medium exposure group. Less than 10% of the workers who
had a chest radiograph exhibited abnormal findings; most of these changes were determined
to have resulted from previous pulmonary tuberculosis. Chest radiographs revealed the
presence of diffuse reticulonodular shadows in 28 workers with no association with any
particular group. When pulmonary function was adjusted for age, height, duration of
employment and smoking, potroom workers in the high exposure category were found to have
significantly lower mean FEV1 and lower maximal mid-expiratory flow rate. The same result
was observed in the medium exposure group, but was not statistically significant. Pulmonary
function was lower when measured post-shift as compared to the pre-shift measurement in
both potroom and control workers. Urinary fluoride levels increased in potroom workers after
one shift, while the control group exhibited a slight decrease in urinary fluoride levels after
one shift. Results from personal samplers revealed that potroom workers were exposed to
higher levels of air contaminants (total particulate, fluoride, carbon monoxide, sulphur dioxide,
and benzo-alpha-pyrene) than the controls. These results suggest that the increased frequency
of adverse pulmonary effects seen in the potroom workers, compared with the controls, may
be a result of the irritant properties of the air contaminants on the potline. Although no cases
of asthma were detected in the potroom workers, five workers in the control group indicated
that they left the potroom as a result of asthma. In interpreting the results of this study, it must
be considered that only 60% of the sample received chest radiographs. In addition, the article
states that many of the workers had previously been miners which could have had an impact
on the workers= current pulmonary status.
The possible role of atopy in the occurrence of acute bronchoconstrictive impairment was
investigated in a cross-sectional study of 227 workers using the Alu-Swiss process for the
electrolytic extraction of aluminium (Saric et al., 1986). Subjects underwent an examination
which consisted of an interview regarding respiratory symptoms and history of atopy,
measurement of FEV1, and intradermal skin testing with common allergens. Bronchial
hyperreactivity was assessed using non-specific bronchoprovocative tests with histamine or
methacholine. The fraction of workers diagnosed with atopy was within the expected range.
Seven workers exhibited signs of paroxysmal wheezing and dyspnoea. Three of these workers
had a positive skin test, but only one worker had increased IgE levels. Bronchoprovocative
tests with histamine or methacholine indicated the presence of bronchial hyperreactivity in five
of these workers. These results suggest that bronchial hyperreactivity is an important
mechanism in the occurrence of acute respiratory impairment. Atopy did not appear to be
associated with the asthma-like symptoms.
O’Donnell et al. (1989) reported on 57 cases of potroom asthma at an aluminium smelter from
early 1971 to the end of 1986. Beginning in 1982, subjects’ symptoms were diagnosed at
biennial medical examinations. When asthma was suspected, the subject underwent skin tests
to assess background atopy, blood eosinophil count, serum IgE concentration, a progressive
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incremental exercise test, and the measurement of nonspecific bronchial reactivity to
methacholine. All employees had regular chest X-rays. Thirty-one subjects had been diagnosed
with asthma prior to the study commencement in 1982, when these employees were assessed
in detail for the first time. All subjects were transferred from potrooms to other areas of the
smelter after diagnosis. From 1982, subjects underwent annual physical examination,
spirometry and assessment of non-specific bronchial reactivity. Subjects were followed until
the end of 1986. Seventeen of the 57 subjects tested positive for atopy, and 34 subjects exhibited
nonspecific bronchial hyperreactivity to methacholine. The majority of workers showed
improvement of symptoms during the first 2 years after diagnosis and transfer from the
potrooms. However, deterioration of symptoms, as assessed by return to abnormal nonspecific
bronchial reactivity, was noted in several subjects. Forty-three subjects were available for
review in 1986. Twelve reported frequent or persistent symptoms of asthma, and a further 11
were taking some regular medication for intermittent symptoms of asthma. Persistence of
symptoms may be a reflection of the severity of the asthma. It is possible that workers affected
more severely also experienced persistent epithelial damage or continuing inflammatory
changes due to irritant particulate in the airways. It should be noted that 16 of the 31 subjects
diagnosed with asthma had been transferred from potroom work prior to the detailed functional
assessment in 1982. These patients had time to recover from the potroom exposure, and the
baseline symptom measurements may not reflect their symptoms at the time of diagnosis. This
was essentially a monitoring of the respiratory health of potroom workers with a view to moving
those who were adversely affected to different jobs, rather than an epidemiological study.
Mackay et al. (1990) conducted a case control study to test the hypothesis that immunological
determinants and certain genetic markers are related to the risk of developing asthma in
aluminium smelter employees. Data were collected from 33 asthmatic (23 prevalent cases, 10
incident cases) and 127 non-asthmatic potroom workers stratified by age and length of service.
Subjects were tested for atopy (positive wheal and flare response to environmental antigens),
serum Ig levels, autoantibodies, and antinuclear antibodies. The genetic markers assessed
included typing for ABO blood groups, and standard microcytotoxicity for A and B locus
human leucocyte antigens for histocompatibility testing. Sixty-four percent of the asthmatic
workers had a background of atopy while the remaining 36% of the group did not. Of the
asthmatics who were atopic, 48% had elevated IgE levels; however, the difference in frequency
of IgE levels greater than 100 IU/mL was not significant between the asthmatic and the
nonasthmatic group. No other major differences in Ig levels, genetic markers, frequency of
antinuclear or other autoantibodies were noted between the case and control groups. The results
of this study suggest that the immune parameters and genetic markers assessed did not have a
significant impact on the risk of developing aluminium smelter-related asthma.
Respiratory symptoms and lung function were examined in 1,679 male and 126 female potroom
workers from seven Norwegian aluminium reduction plants (Kongerud et al., 1990; 1994;
Kongerud & Samuelsen, 1991). This longitudinal study began in 1986 and the active work
force was examined each year for a period of four years. All subjects leaving their occupation
and all new employees were recorded until the end of 1989. Self-administered questionnaires
were employed to record workers= symptoms of dyspnoea, wheezing and cough during the
previous year. Information about allergy, smoking habits, former work exposure, length of
employment in the potrooms, duration of symptoms and use of airway protection was also
recorded. FEV1 and FVC was measured by spirometry. Personal samplers were used to obtain
measurements of total airborne dust and total fluorides. A total of 9 exposure categories was
established within each plant. Subjects within the same exposure category were assigned
identical exposures based on the average level of total airborne dust and total fluorides for the
previous year.
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Kongerud et al. (1990) reported the results of a cross-sectional survey from this Norwegian
cohort covering the period from the beginning of September to the end of October, 1986 in the
7 aluminium reduction plants. This analysis, which covered 1,760 members of the active work
force during this period, demonstrated a significant association between length of potroom
employment and the presence of work-related asthma. Work-related asthmatic symptoms
occurred in 15% of the workers with an exposure period of 10 years or more, and in 8% of the
workers who had been employed for less than 5 years. The odds ratio (OR) for asthmatic
symptoms was 3.44 (95% CI: 2.06-5.76) for workers employed for 10 years or more compared
to workers exposed for less than five years after controlling for sex, age, familial disposition
for asthma, allergy, smoking, and use of airway protection. Airflow limitation was also
significantly higher for workers employed for over 10 years as compared to those employed
for less than 5 years (OR= 2.6, 95% CI: 1.68-3.85).
A prospective study of the respiratory health in Norwegian aluminium potroom workers was
also conducted of newly enrolled workers who were examined on at least 2 occasions from
January 1, 1986 to December 31, 1989 (Kongerud & Samuelsen, 1991). Dyspnoea and
wheezing were reported by 105 of the 1301 workers during the follow-up. Symptomatic and
asymptomatic workers did not differ in FEV1 or FVC measurements. The probability of
developing symptoms was 7% for people who had never smoked, and 23% for those who
currently smoked, during the first 2 years of employment. Smoking and total fluoride exposure
were determined to be the most important predictors of development of dyspnoea and
wheezing, based on proportional hazards regression analysis. The incidence of respiratory
symptoms was highest in the first year of work and appeared to decrease after two years of
exposure. The estimated probability for the development of symptoms was approximately 20%
after 4 years of exposure. Proportional hazard ratios by smoking status compared to those who
never smoked were: ex-smokers 4.39 (95% CI: 1.30-14.82), low 2.19 (1.23-3.91), and high
3.29 (1.72-6.29). Compared to the lowest level of fluoride exposure of 0-0.4 mg/m3, the hazard
ratio for 0.41-0.8 mg/m3 was 3.35 (1.51-7.41), and for >0.8 mg/m3 was 5.20 (2.02-13.34).
Some of these CIs are broad, indicating small numbers which give a less stable estimate of the
risk.
To investigate whether chronic exposures in potrooms decrease pulmonary function, Kilburn
& Warshaw (1992) compared the pulmonary function status of aluminium refinery workers to
that of regional controls who worked as pipefitters. Selection criteria included having had initial
occupational exposure to asbestos at least 15 years previously, and a duration of exposure of
5 years. The controls were volunteers who may not have been representative of their
occupation, but their age, height, weight and smoking status were well matched with the
aluminium refinery workers. Both groups were exposed to asbestos. The referent group was
also exposed to ferrous metal welding and copper brazing, but not aluminium. Six hundred and
seventy aluminium workers and 659 controls were included in this analysis. Subjects
completed health questionnaires, received a physical chest examination, and chest radiograph.
Spirometry was performed and alveolar carbon monoxide was measured. The prevalence of
reported asthma was 13.5% in the aluminium exposed group as compared to 8.7% in the
comparison group (p < 0.05). Wheezing heard at the physical examination was also
significantly higher in the aluminium workers (32%) as compared to the pipefitters (11.8%).
The prevalence of chronic bronchitis was equal between the two groups. The occurrence of
irregular opacities in the lung was higher in the aluminium workers, and the pattern of these
irregularities differed from that of the regional controls. The prevalence of asthma in non-
smoking workers was 7.6% for the aluminium group and 4.0% for the controls; wheezing was
detected in 21.4% of non-smoking aluminium workers compared to 2.4% of non-smoking
controls. Asthma prevalence was 16.4% for aluminium workers who were current smokers vs.
9.4% in the referent group, and wheezing was heard in 43.7% of aluminium workers who were
current smokers compared with 21.1% in the controls. These results suggest that aluminium
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workers had significantly more asthma, wheezing, airway obstruction and pulmonary
parenchymal abnormalities than did a control group of a similar socio-economic status and
type of employment not involving exposure to aluminium. Due to the lack of industrial hygiene
measurements of exposure to gases, fumes, and other particulates, it is difficult to speculate
on whether a specific agent was responsible for the higher occurrence of asthma in the
aluminium workers. The differences in mean pulmonary function values were not attributed
to asbestos because both groups had similar rates of exposure and prevalence of asbestosis. It
is possible that systematic differences in terms of lifestyle and other previous exposures
between the two groups of workers might have been responsible for the differences in
respiratory symptoms.
Sorgdrager et al. (1995) conducted a nested case control study in two Dutch aluminium
production plants in order to identify workers with an increased risk of developing potroom
asthma. The cases and controls from this study were drawn from two aluminium smelter plants.
The first group contained workers employed in plant A between 1978 and 1988; the second
consisted of workers from plant B employed between 1971 and 1991. Cases were defined as
potroom workers who were unable to work because of respiratory symptoms, and who met
clinical criteria for potroom asthma. These cases were identified through worker consultation
with the occupational health officer for respiratory complaints, or through periodic medical
examinations. Cases were matched to controls (co-workers who did not have potroom asthma)
based on age and year of employment commencement. In Plant A, 57 out of 300 workers were
diagnosed with potroom asthma, while 174 of 1,208 employees were diagnosed with potroom
asthma in plant B. After the matching process, 182 case-control pairs were identified from the
two plants combined and included in the analysis. Subjects underwent pre-employment
examinations which included spirometry, bronchial responsiveness, and blood eosinophil
count. Leucocyte count was also obtained from workers in plant B. Lung function did not differ
between the cases and controls in plant A. In plant B only, FEV1/FVC was significantly lower
in cases than in controls at pre-employment examination. Pre-employment eosinophil counts
were significantly higher in cases than in controls in the workers of both plants (OR = 1.28,
p = 0.0002 controlling for childhood respiratory problems, positive family history, smoking
and lung function). These results suggest that the development of potroom asthma is not related
to lung function or bronchial responsiveness before employment. Elevated blood eosinophil
count may be a risk factor for potroom asthma for workers without clinical signs of respiratory
disease prior to employment. The authors suggested that the combined effects of fluoride
exposure with elevated eosinophil counts might induce an immunological or cytotoxic process.
Three hundred and seventy aluminium potroom workers in a Norwegian plant participated in
a cross-sectional survey to assess bronchial responsiveness, lung function, and respiratory
symptoms in relation to occupational exposure to air contaminants in the potroom (Soyseth &
Kongerud, 1992). Three hundred and thirty-seven subjects completed a questionnaire
regarding respiratory symptoms within the previous year, familial asthma, smoking habits, and
years of employment in the potrooms. Work related asthmatic symptoms were defined as
dyspnoea and wheezing which improved during absence from work. Lung function tests and
methacholine challenge for bronchial responsiveness were conducted. An estimate of exposure
to dust and fluorides was made for each worker based on job specific exposure measurements
and personal sampling equipment. Adjusted ORs were statistically significantly elevated for
subjects exposed to total fluorides above 0.5 mg/m3 compared to workers exposed to total
fluorides at concentrations less than 0.5 mg/m3, for dyspnoea only, dyspnoea and wheezing,
cough and work-related asthmatic symptoms. The equivalent ORs for dust exposure were not
elevated. These findings suggest that exposure to fluorides may be an important determinant
of work related asthmatic symptoms in potroom workers. However, it should be considered
that bronchial responsiveness and spirometry, which are more objective measures of
respiratory function, were not associated with exposure to fluorides or dust. Therefore, it is
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possible that the positive association between exposure to fluoride and respiratory symptoms
is a spurious result because of over-reporting of symptoms in the high exposure group,
misclassification of exposure, or selection bias.
Søyseth et al. (1994) examined the relationship between plasma fluoride levels and bronchial
responsiveness in the same 26 aluminium potroom workers described above. Subjects were
tested for bronchial responsiveness and blood samples were obtained and analysed for fluoride
levels every third month for two years. A positive association was found between bronchial
responsiveness and plasma fluoride levels. This result contrasts with the finding of a negative
association between fluoride exposure and bronchial responsiveness from the previous cross-
sectional survey in the same plant (Soyseth & Kongerud, 1992). The differences between these
two studies may be a reflection of their study designs. Selection bias is a concern in cross-
sectional studies; in a longitudinal design subjects serve as their own controls which allows
selection bias to be minimized. However, the small size of the longitudinal study may limit its
value; for example, such a small subset of aluminium potroom workers may not be
representative of potroom workers in general. It is also possible that fluoride levels serve as a
marker for another non-fluoride containing agent that is present in the potroom and correlated
with fluoride levels.
The bronchial responsiveness of the 26 members of the index group was also compared to that
of 12 aluminium potroom workers who were relocated due to their work-related asthmatic
symptoms (Soyseth et al., 1995). A decrease in bronchial responsiveness during the follow-up
visits occurred in both groups; however, the decline appeared to be greater for the relocated
workers. Subjects who were most reactive at inclusion experienced the largest improvement
in bronchial responsiveness during the follow-up. The results of this study indicate that removal
of potroom workers from the exposure causes a decrease in bronchial responsiveness.
However, the subjects who were relocated were more likely to have more severe symptoms
than the non-relocated workers. Thus the observed decrease in bronchial responsiveness may
be, in part, due to regression to the mean. This phenomenon refers to the tendency of severe
symptoms to naturally decline towards normal levels. Again, the small number of participants
in this study may mean that the results cannot be generalised to other potroom workers.
Søyseth et al. (1996) expanded their cross-sectional survey into a longitudinal study to compare
the variation in bronchial responsiveness over time between potroom workers reporting work-
related asthmatic symptoms and asymptomatic workers. Of the 379 potroom workers who
completed a respiratory questionnaire in the cross-sectional survey, 26 men met the inclusion
criteria for the study which was age under 60 years and normal lung function during symptom
free periods. A reference group was comprised of new male employees who reported no
respiratory symptoms on the questionnaire. The subjects were examined at regular intervals
over a period of two years. At each interval, subjects were asked to record the frequency and
severity of dyspnoea, wheezing and coughing. FEV1 and bronchial responsiveness was also
measured. Eight subjects in the index group shifted between bronchial hyperresponsiveness
and normal bronchial responsiveness, while the degree of bronchial response did not vary for
any of the subjects in the reference group. In addition, it was found that the variability of
bronchial responsiveness was positively associated with mean symptom scores. One possible
limitation of this study is the difference between the index group and the reference group in
age (mean of 38.1 in the index group vs. 25.3 in the reference group), duration of employment,
and smoking habits. However, the authors stated that neither age nor duration of employment
were determinants of bronchial responsiveness in a previous experiment. The observations
from this small longitudinal study indicate that severity of symptoms in aluminium potroom
workers with work related asthma reflects the variability in bronchial responsiveness.
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The effect of exposure to potroom pollutants on the development of lung function in potroom
workers was investigated in an additional longitudinal study by Søyseth et al. (1997). All
employees working in potrooms at the Hydro Aluminium Plant in Årdal, Norway, in September
1986 or later were invited to participate in this study. Employees starting work in the potrooms
during the follow up were also recruited to the cohort. The workers were examined annually
during the period 1986-1992; 265 were included in the final analyses. Pulmonary function was
measured by spirometry Measurement of exposure was conducted by dividing the potrooms
into several job categories. Each year a randomly selected number of workers were asked to
wear samplers for 8 hr shifts to calculate annual mean exposures in each job category. Exposure
to particulates increased the decline in FEV1. It was found that the decline in FEV1 accelerated
with age and smoking. This study suggests that potroom workers may be at increased risk of
developing chronic obstructive lung disease due to the decline in FEV1 as a result of particulate
exposure. This contrasts with the previous findings of Søyseth & Kongerud (1992) and Søyseth
et al. (1994) which demonstrated that respiratory symptoms and bronchial responsiveness were
associated with fluoride levels but not with exposure to particulates. This may be explained by
differences in exposure classification and participant loss to follow-up between the different
studies, as well as to the small number of participants in some of the analyses.
Sorgdrager et al. (1998) conducted a study to investigate whether reduction of exposure and
the introduction of the histamine provocation test (HPT) as a worker selection instrument
resulted in a lower incidence of potroom asthma. The data used for this analysis originated
from employment history, clinical history and some exposure measurements for 179 potroom
workers (contributing 2,845 person years) who developed work-related respiratory disease
between 1970 and 1990. This period was divided into three segments. No exposure data were
available during period 1, (1970-1975). For period 2, (1976-1981), exposure data based on
determination of fluoride in urine samples were available. In the third period (1982-1990) the
HPT was incorporated in the pre-employment medical examination. After the introduction of
the HPT as a selection tool in pre-employment screening, the incidence density of potroom
asthma decreased from 11.6 (period 2) to 2.5 (period 3). However, potroom asthma was also
shown to occur in employees with normal bronchial responsiveness. In addition, there was no
difference in time lag for the cases occurring before and after introduction of the HPT. This
suggests that potroom exposure acts as an inducer of hyper-responsiveness. The decrease in
fluoride levels in the aluminium plant between period 2 and period 3 may have contributed to
the decrease of potroom asthma observed.
Fritschi et al. (1999) conducted a cross-sectional study of 1,529 male participants in an attempt
to compare the prevalence of work-related respiratory symptoms and levels of lung function
in different departments within two different aluminium smelters. Employees of two Australian
aluminium smelters were interviewed to obtain information regarding demographics,
respiratory symptoms, and occupational history. Information was collected about symptoms
of wheeze, dyspnoea, chest tightness, and rhinitis. Subjects who indicated that symptoms were
improved at the beginning of the working week, on days when away from work, or when on
holidays, were considered to have a work-related symptoms. Spirometry was performed on all
subjects; FEV1 and FVC were recorded. Skin prick tests to common allergens were also
performed to determine atopic status. Employees were divided into groups according to the
type and area of work at the time of the survey. Employees in administrative type jobs were
considered to be unexposed. Mean time-weighted averages were available for some job titles
from the two different plants. Multiple logistic regression analysis was performed with each
of the four work-related symptoms (wheeze, chest tightness, shortness of breath, and rhinitis)
as outcomes. The participants from the two smelters completed an interview. Workers in the
ingot process group in Smelter A had about 5 times greater odds (after adjusting for smoking
and age) of reporting each of the work-related symptoms compared to the administration group.
The odds of reporting work-related wheeze and chest tightness was approximately three times
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greater in the anode and potroom groups than in the administration group. The ingot workers
in Smelter B had approximately 3 times greater odds of work-related wheeze, and potroom
employees had 3.5 times the odds of work-related rhinitis, compared to the unexposed group.
Rhinitis was the only symptom reported more commonly by the potroom employees than by
the administration employees in smelter B. The likelihood of reporting work-related symptoms
increased with duration of work in the potrooms, while ingot mill workers and anode process
workers were more likely to report symptoms within the first year of work. The differences in
results between the potrooms in the two different smelters may be a reflection of the age of the
smelter, the type of respiratory equipment used, or the selection process for employees at the
two different plants. Another major difference between the two smelters was that Smelter A
produced alloy while Smelter B did not. The results of cross-sectional studies must be
interpreted cautiously as selection and survival bias is often inherent in this type of design.
Subjects who left the company as a result of their symptoms would not have participated in
this study.
Radon et al. (1999) conducted a cross-sectional survey in a German aluminium smelter to
investigate the combined influence on respiratory health of smoking and exposure in an
aluminium potroom. Seventy-eight smelter employees participated in this survey (23 never
smokers, 38 current smokers, and 17 ex-smokers). Fifty-seven laboratory, workshop and gate
workers (18 non-smokers, 22 current smokers, and 17 ex-smokers) from within the plant served
as controls. Information regarding respiratory symptoms during the preceding year, smoking
habits, medical and occupational history was collected in standardized interviews. Spirometry
tests were preformed for all subjects. Potroom workers who were current smokers at the time
had the lowest prevalence of respiratory symptoms, while, respiratory symptoms in controls
tended to be highest in those who were smokers. No effects of potroom work on the prevalence
of respiratory symptoms could be detected. The highest spirometric values in the potroom
workers were found in ex-smokers. In contrast, the spirometric results were lower in ex-
smokers than in never smokers and lowest in smokers of the control group. Therefore, it appears
that the effect of workplace exposure was greatest in subjects who did not smoke, and the
consequence of smoking was only found in non-exposed subjects. This indicates the lack of a
combined effect of smoking and occupational exposure. Due to the cross-sectional design of
this study, workers who left the job due to airway symptoms or disease and other factors related
to respiratory function could not be captured. Therefore, it is important to recognize the impact
of selection processes in cross-sectional studies of occupational exposures; ignoring these
effects can lead to underestimation of the health effects of the hazard. For example, in this
study, comparison of only the workers who were current smokers in both the exposed and
control group revealed an inverse effect of potroom work on respiratory symptoms. The results
likely reflect the increased probability for least susceptible subjects to continue to smoke and
work in an atmosphere with respiratory irritants.
An Australian nested case-control study assessed employee risk factors for occupational
asthma in primary aluminium smelting (Barnard et al., 2004). The study included 545 workers
employed in areas with moderate to high levels of smelting dust and fume. Workers were
included in the study if they had had their first employment medical examination between 1982
and 1995; the cohort was followed until December 31, 2000. Cases of potroom asthma were
diagnosed by a set of standard criteria during regular medical surveillance of the cohort; some
cases were self-referred. Subjects with chronic obstructive pulmonary disease due to welding
or metal fume were excluded. Forty-five subjects were diagnosed with occupational asthma of
aluminium smelting, or potroom asthma. Four controls per case were matched for the same
year of employment-commencement and age within 5 years. The pre-employment medical
questionnaires were examined and information regarding demographics, details of allergic
symptoms, respiratory symptoms, and spirometric data were extracted. Follow-up data were
collected to obtain information regarding hay fever and family history of asthma, full work
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history while at the smelter, and tobacco smoking history at termination, diagnosis or at
cessation of the study. The investigators were blinded to the status (case or control) of the
subject. Occupational hygiene monitoring was used to obtain the mean concentrations of
respirable dust, fluorides, and sulphur dioxide in all areas. This allowed for the creation of five
different exposure categories ranging from grade 4 (potrooms and potroom services) to grade
0 (areas of low air contamination). A cumulative exposure index for each individual was
calculated based on the years worked in a specific area. The mean exposure index for cases
was 21.21 and, for controls, was 17.84. Forty three of the 45 cases were working in potroom
areas at the time of diagnosis. Subjects who were diagnosed with hay fever at the initial medical
examination or during the follow-up period had an increased risk of developing potroom
asthma (adjusted OR = 3.58, 95% CI: 1.57-8.21). Higher forced expiratory ratio at employment
reduced the risk of developing potroom asthma (adjusted OR = 0.93, 95% CI: 0.88-0.99). These
results suggest that individuals with hay fever may be more susceptible to developing asthma
upon exposure to airborne irritants found in aluminium smelting potrooms. The authors
proposed that this may have been a result of reduced nasal filtration and increased bronchial
hyper-responsiveness in these individuals.
Welders working with aluminium (n=64), stainless steel (n=46) and railroad track workers
(n=149) were studied by Sjögren & Ulfvarson (1985) in relation to an age matched referent
group of nonwelding industrial workers and railroad workers. Welding fume samples were
measured by filters placed inside the welding helmets of the subjects. Participants were
interviewed based on a questionnaire regarding respiratory symptoms. FVC and FEV1 were
measured at lest three times for each subject. All three groups of welders reported higher
frequencies of chronic bronchitis and other respiratory symptoms than their respective
referents. Ozone appeared to be more highly correlated with the observed respiratory symptoms
than aluminium particles among the aluminium welders. Pulmonary function, as assessed by
FVC and FEV1, did not differ between the three groups of welders, or between the welders
and the control group. Subjects with long exposure periods did not exhibit decreased pulmonary
function variables.
Nielsen et al. (1993) studied 25 welders exposed to aluminium. The exposed workers were
matched for age and smoking habits to 25 males employed in a warehouse for wines. Subjects
were interviewed by a physician to obtain information regarding symptoms of conjunctivitis,
rhinitis, pharyngitis, and asthma. The subjects were asked if these symptoms were related to
work (worsened during the work week). History of chronic bronchitis and bronchial
hyperreactivity was also obtained. A physical examination was performed, including
pulmonary auscultation. Allergic status was inferred from information obtained about the
subjects= histories of atopic symptoms, and the administration of a skin prick test to common
allergens. Air sampling analysis was conducted in the breathing zones of 19 welders and a
urine sample was collected from each welder on Friday after the workshift and on the following
Monday morning before work. Lung function tests were conducted to measure vital capacity,
FEV1, and the maximum expiratory flow. The air sampling analysis indicated that the exposure
to welding fumes was lower than PELs. However, the welders showed an increase in urinary
aluminium, indicating a significant uptake. A higher prevalence of work-related eye and
airways symptoms was noted in the welders than in the controls. There did not appear to be an
association between allergic status and the development of symptoms. Welders who had been
employed for less than 2.5 years experienced more symptoms than did long-term welders. This
may reflect a selection for long term workers who are not susceptible to the work-related
effects. Long-term welders exhibited a steeper slope of the alveolar plateau and a slight increase
in volume of trapped gas as compared to the controls, following a methacholine inhalation test.
These observations indicate that welding fumes may cause increased reactivity of the small
airways. The welders in this study were exposed to both aluminium and stainless steel, so it is
not known to which welding fume the effects were attributable, or if the effects were a result
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of a combination of these fumes, or other air contaminants in the plant. However, the authors
stated that aluminium welding was far more frequent than stainless steel welding in this group
of workers.
Occupational exposure to aluminium dust: Pulmonary function of workers exposed to
different types of aluminium dust has not been extensively studied epidemiologically. A small
case-control study was conducted in Turkey (55 aluminium workers, 30 controls) to investigate
the effects of aluminium dust on pulmonary function and to look for the existence of a dose-
response relationship (San et al., 1997). The authors found that the mean serum aluminium
levels of workers (72.7 ± 9.9 ng/mL) were significantly higher than those of controls, and
reflected a range of aluminium exposures considered toxic. Spirometric parameters correlated
negatively with both exposure time and serum aluminium levels. The authors stated that
protective masks were not consistently worn by the aluminium workers; use of masks and
working fewer hr would reduce exposure levels (San et al., 1997). Case reports presented by
Mitchell et al. (1961) implicated very fine aluminium powder (finely divided aluminium) used
for fireworks as a cause of pulmonary fibrosis (also discussed in Effects on Humans, Effects
from Occupational Exposure, Irritation, Inhalation Exposure). The authors concluded that
duration of exposure, particle size, density of the dust, and presence or absence of stearin
(thought to be protective) as well as individual characteristics were all relevant to the
development of pulmonary fibrosis due to aluminium exposure.
It seems that most respiratory problems experienced by aluminium workers – potroom workers,
foundry workers, welders – were not due to exposure to aluminium compounds, but rather to
other substances in the work place. The exception appears to be workers who were exposed to
very fine aluminium dust, who developed pulmonary fibrosis; based on reports in the literature,
this seems to have occurred relatively rarely – precise figures are not available.
Neurotoxicity—Sjögren et al. (1990) studied neuropsychiatric symptoms among welders
exposed to potentially neurotoxic metals including aluminium, chromium, lead, manganese
and nickel. They found that welders (n=78) exposed to aluminium welding fumes for at least
10 years had significantly more neuropsychiatric symptoms than the referent group which was
defined as welders aged 20-29 (n=23). The composition of the referent group could have
affected the authors’ conclusions, since some neuropsychiatric measures differ by age, e.g.,
memory problems.
Hosovski et al. (1990) compared psychomotor and intellectual abilities of 87 aluminium
foundry workers with non-exposed workers matched on age, job seniority and social status.
Exposure to aluminium was assessed by measuring levels in whole blood and urine. Total body
burden of aluminium was assessed following the administration of desferroxamine. They found
slower psychomotor reaction, dissociation of oculomotor coordination, reduced memory
ability and disturbed emotional balance in the exposed workers. They concluded that these
differences could be due to long-term toxic effects of aluminium.
Neurological symptoms of 25 patients, who had worked in an aluminium smelting plant for
more than a decade, were described by White et al. (1992). Fifteen of the patients were working
at the time of examination, and 10 had taken early retirement or medical leave due to their
symptoms. The patients received a standardized evaluation which included the completion of
a health questionnaire, a neurological examination, and neuropsychological evaluation. An
exposure index based on level and duration of exposure in the potroom was calculated for each
worker. The most common symptoms reported by the patients were frequent loss of balance
(88%) and memory loss (84%). Signs of incoordination in 84% were revealed by neurological
examination, and neuropsychological tests showed a substantial impairment of memory
function for 70-75% of the subjects. The degree of exposure in the potroom was graded for
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different job categories, level 1 represented the lowest exposure to dust and fumes from the
potline, and level 4 represented the highest degree of exposure. The exposure index was
significantly associated with signs and symptoms of incoordination. Workers were exposed to
several contaminants in the potroom including; alumina, aluminium fibres, fluorides, calcium
and cryolite. The neurotoxic properties of aluminium suggest that this particular potroom
exposure may be responsible for the neurological symptoms described in these workers. It
should be noted that this was not an epidemiological study, but rather a case report of a fairly
large number of cases. There was no referent group which could have demonstrated the
differences between the cases and controls. However, this study has been frequently quoted as
the basis for conducting further studies of the possible neurological effects of working in an
aluminium smelting plant.
Salib & Hillier (1996) conducted a case-control study to examine the association between AD
and occupational aluminium exposure. Patients with a clinical diagnosis of probable or possible
AD (n=198) were compared to two control groups with respect to their occupational history.
The first control group was comprised of patients with dementias other than AD (n=164); the
second control group consisted of individuals with no dementia (n= 176). Informants of both
cases and controls were interviewed using a structured questionnaire. The subjects=
occupational histories and other personal variables were obtained. Twenty-two of the 198 cases
with AD had been exposed to aluminium at some point in their occupational history, compared
to 39 of the 340 controls. The OR obtained for Alzheimer=s cases compared to all controls
was 0.98 (95% CI: 0.53-1.75). The OR was 0.95 (95% CI: 0.5-1.8) when the cases were
compared to only the other dementias group, and similarly an OR of 0.95 (95% CI: 0.5-1.9)
was observed when the non-demented subjects were used as the comparison group. These
results suggest that there is no association between previous occupational aluminium exposure
and the risk of AD. A limitation of this study is the lack of detail of the occupational exposure
information. The questionnaire contained a broad classification of occupation by industry type
and it is likely that the variation of the extent and type of aluminium exposure in specific
occupational settings was not adequately captured in this study.
Another case control study examining the occupational risk factors for AD was conducted by
Gun et al. (1997). A wide range of physical and chemical agents was assessed including
hydrocarbon solvents, lead, mercury, organophosphates, aluminium, asbestos, vibrations,
physical inactivity, and aluminium. One hundred and seventy cases with possible or probable
AD from two Sydney hospitals were compared to an equal number of age and sex matched
controls recruited from general practices. Informants were interviewed about the subjects=
occupational histories and about other suspected risk factors. The industry and occupation titles
of every job for each participant were entered into the Job-Exposure Matrix (JEM) database
which is maintained by NIOSH. This database provided an estimate of the probability of
exposure to specific chemicals in each occupation for each subject. Occupational hygienists
used the JEM information and their own knowledge of likely exposures to assess the probability
of exposure of each subject to each of the substances of interest in the study. This information
was used to generate a lifetime cumulative exposure record for each subject. The lifetime
exposure status, total time of any exposure, average daily duration of exposures, and the
average intensity of exposure were determined for each specific exposure of interest. The
estimated OR associated with possible or probable exposure to aluminium was 0.33 (95% CI:
0.01-4.16). No statistically significant associations were found among any of the exposures
and the occurrence of AD. Although the exposure estimate was more detailed than the case-
control study conducted by Salib & Hillier (1996) exposure sampling measurements were not
available. This study is also limited by the small number of patients with significant exposure
to the agents of interest.
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Two studies of miners exposed to McIntyre powder (a finely ground aluminium powder),
formerly used as a prophylactic measure against the development of silicosis, have been
conducted to examine a possible association with cognitive impairment or AD. Rifat et al.
(1990) initially reported poorer performance on a battery of cognitive tests by workers exposed
to McIntyre powder than by workers who were not exposed. In a second report which examined
a number of possible confounders, Rifat (1992) found interaction between mother tongue and
exposure, and some effect of education and place of residence, but the observed effect still
held. Nieboer et al. (1995) noted that a weakness of the study was the absence of information
on exposure to other underground substances. A further report did not confirm the earlier
findings (Occupational Disease Panel (Industrial Disease Standards Panel), 1998) and
concluded that the results did not allow any definitive conclusion to be reached regarding the
safety of historical exposure to McIntyre powder. A study of Cornish tin miners compared
mortality of workers in two tin mines, one of which used McIntyre powder as described above
(McDonald et al., 1996). The study did not support a link between inhalation of aluminium in
powder form and AD.
In two studies designed to test specific cognitive functions, differences between workers
exposed and unexposed to aluminium were seen (Akila et al., 1999; Polizzi et al., 2002;
Riihimäki et al., 2000). In the earlier analysis of cognitive performance in Finnish metal inert
gas welders exposed to aluminium, Akila et al. (1999) compared 28 welders with low
aluminium exposure and 24 with high exposure (based on urinary aluminium concentrations)
to a reference group of 28 mild steel workers. The mean urinary aluminium concentrations
were 0.46 μmol/l in the reference group, 2.25 μmol/l in the low exposure group and 9.98 in the
high exposure group. Blood lead levels were measured to exclude one possible confounder and
were all in the normal range (0.1 – 0.4 μmol/l). Information on age, education, smoking and
alcohol consumption was taken into account. The interview also included occupational history,
past and present exposure to neurotoxic agents, past and present diseases, injuries, clinical
symptoms, medication (including antacids containing aluminium) and questions about general
health. A comprehensive neuropsychological examination was administered to assess
psychomotor function, simple visual reaction time, attention related taskes, verbal and visual,
or visuospatial abilities, as well as verbal and visual learning and mamory. No differences were
seen on the finger tapping, Santa Ana dexterity, simple visual reaction times, verbal memory
tasks, the similarities subtest of the Wechsler adult intelligence scale, or the Stroop task.
However, the low exposed group performed more poorly on the memory for designs and on
more difficult block design items. An exposure-response relationship was seen for the time
limited synonym task, embedded figures, digit symbol speed, and the backward counting
component of the divided attention task. In summary, the performance difficulties were mainly
in tasks demanding complex attention, requiring working memory, and particularly in time
limited tasks involving visually presented material. The more recent analysis included
essentially the same study population (Riihimäki et al., 2000) (65 metal inert-gas welders vs.
52 in the earlier analysis, and 25 mild steel workers vs. 28) with referents, low-exposure and
high-exposure groups’ mean serum aluminium levels of 0.08, 0.14 and 0.46 μmol/l respectively
and the corresponding values for urine-aluminium being 0.4, 1.8 and 7.1 μmol/l. They
expanded their findings, showing subjective symptoms including exposure-related increases
in fatigue, mild depression, and memory and concentration problems. In addition to the findings
based on neuropsychological testing, visual EEG analysis showed pathological findings only
for aluminium welders. Mild diffuse abnormalities were seen in 17 percent of the low exposure
group and 27 percent of the high exposure group; mild to moderate epileptiform abnormalities
were found at a frequency of 7 percent and 17 percent respectively. Riihimäki et al. (2000)
concluded that both objective neurophysiological and neuropsychological testing as well as
subjective symptomatology indicated mild but unequivocal findings with a dose-response
relationship with the level of aluminium body burden. The strength of this study was its detailed
neuropsychological assessment of very specific functions; a weakness is the lack of
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measurement in blood or urine of possible additional exposures (other than lead) that could
have affected the results. However, the authors conducted site visits to rule out confounding
exposures such as solvents, and collected occupational histories of the workers, including past
and present exposure to neurotoxic agents.
Letzel et al. (2000) conducted a cross-sectional study with a follow-up five years later at a
German aluminium powder plant to evaluate possible cognitive decline. In the first analysis,
53 exposed workers were compared with 30 controls who were comparable in age, education
and smoking habits. Some members of the exposed group had higher levels of alcohol
consumption and were also less likely to participate in the follow-up. Therefore comparisons
were made separately with the exposed group that was available for follow-up at both phases
of the study (n = 21); this was the exposed group on which the comparisons noted below were
based. The investigation included a standardized medical history, biological monitoring of
aluminium concentration in urine, in creatinine and in plasma as well as measurement of post
prandial blood glucose levels and serum gamma-glutathione levels. The neuropsychological
tests included a multiple choice vocabulary test, three subtests of the Wechsler Adult
Intelligence Survey, German version, (digit span (verbal short-term memory), digit symbol
(visuomotor speed), and block design (constructive abilities)); the trail making test (visuomotor
speed); syndrome short test (SKT-D, visuoverbal short- and long-term memory, attention), and
a visual discriminative reaction task (sustained attention). Statistically significant differences
were found in the levels of aluminium in urine (median value of 98.8ug/L (range 5.0 – 336.6)
in the exposed group that was followed up vs. 7.6 (2.6 – 73.8) in controls), creatinine (77.1 ug/
g (4.6 – 321.4) vs. 9.0 (1.9 – 51.8)) and in plasma (8.5 ug/L (5.4 – 25.0) vs. 4.3 (1.6 – 7.1)) of
the exposed in relation to the controls at the first phase of the study, and at the second phase,
in urine (24.1 ug/L (3.4 – 218.9) vs. 6.5 (2 – 25.4)) and creatinine (19.8 ug/g (3 – 202.7) vs.
4.5 (2.2 – 15.9)), but not in the plasma. Differences due to consumption of medication
containing aluminium were ruled out. No significant differences were seen in the results of the
neuropsychological tests. There was no dose-effect relationship for the length of exposure of
internal aluminium concentrations in plasma or urine and any of the primary neurologic
variables. The study was small and the participants were generally younger than those at higher
risk of cognitive problems.
Pollizi et al. (2002) conducted a cross-sectional case-control study of 64 workers formerly
exposed to aluminium dust and 32 demographically similar controls. Participants were required
to have retired at least 10 years before the beginning of the study (no rationale was given).
They excluded people on continuous medication containing aluminium, with renal failure, past
head trauma, on centrally acting drugs, or diagnosed with other psychiatric, somatic and
neurological disorders, as well as with profound hearing loss or blindness. The controls were
matched for age, professional training, economic status, educational and clinical features. They
administered the Mini-Mental State Exam (MMSE), the Clock Drawing Test (CDT), and the
auditory evoked Event-Related Potential (ERP-P300). To detect mild cognitive impairment,
the time taken to conduct the MMSE and the CDT was also recorded. The former aluminium
workers had significantly higher levels of serum aluminium and blood iron. There was a
negative relationship between serum aluminium levels and MMSE score and CDT score; there
was a positive relationship between serum aluminium levels and MMSE time and CDT time.
There was a significant difference in the latency of P300, MMSE score, MMSE time, CDT
score and CDT time between the exposed and the control population. The authors controlled
for potential confounders including age, height, weight, blood pressure, schooling, alcohol and
consumption, and smoking. The neurological testing in this study was not as comprehensive
as in the Finnish study (Akila et al., 1999), but is consistent with its results. This study measured
blood levels of a greater number of other potential neurotoxins; specifically blood levels of
Mn, Pb and Fe, and serum levels of Cu and Zn. These studies provide evidence of very specific
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forms of mild cognitive impairment in workers exposed to aluminium as measured in their
serum.
Doll (1993), in his review of AD and environmental aluminium, concluded that, while there
was evidence that aluminium is neurotoxic and defects of coordination were pronounced,
cognitive impairment was less evident, and there was no evidence of occupational aluminium
exposure leading to AD.
Irritation—One mineral form of aluminium oxide, a hexagonally, very closely packed form,
corundum, is extensively used as an abrasive and polisher in sandpaper, emery, etc. This can
cause abrasion of the skin, eyes or any other tissue against which it is rubbed.
Skin and eye: Foreign body entry into the eye of material containing bentonite resulted in
anterior segment inflammation. Based on a similar response to bentonite, introduction into
animal eyes, it was concluded that bentonite was the causative agent (Austin & Doughman,
1980).
Inhalation exposure: Several lung diseases have been associated with work in the aluminium
industry: pulmonary fibrosis, alveolar proteinosis, granulomatosis, chronic obstructive lung
disease, asthma, and lung cancer. There have been numerous reports of diffuse pulmonary
fibrosis and interstitial emphysema, but without nodule formation. Some cases were fatal,
attributed to inhalation of metallic aluminium dust in workers in aluminium processing or
manufacturing. Most of the exposures that resulted in the more severe outcomes occurred in
Germany during World War II, in industrial environments that were heavily contaminated with
airborne aluminium flake powder (used in explosives), and where there was unsatisfactory
ventilation due to blackout. It is estimated that the highest air levels of aluminium occurred
during production of pyro powders in the 1940s when concentrations reached 50 to 100 mg/
m3. This lead to a fibrotic lung disease, aluminosis (Sjögren, 2000). The case reports and studies
are summarized in Table 22.
These observations led to the conduct of studies in animals, reviewed above, to further
understand the causes and conditions of the aluminium-associated pulmonary diseases. The
apparently contradictory findings in some of the studies may be explained by the different types
of aluminium, as noted by Corrin (1963b) (see also Effects on Laboratory Mammals and In
Vitro Test Systems, Irritation, In Vitro Test Systems).
A review and historical perspective of the outcomes of these exposures to high concentrations
of airborne aluminium follows. Four men who worked for 1.5 to 16 years in an aluminium
powder factory demonstrated dyspnoea, lymphocytosis and lung x-rays similar to those seen
in silicosis (Goralewski, 1941). Goralewski (1939; 1940; 1941; 1943) studied 700 workers
who made a stamped aluminium powder that comprised 98% aluminium coated with a thin
film of paraffin-like substance. Some workers had a dry cough and radiographs with focal
shadows in the apical region, 4 had spontaneous pneumothorax and 1, on autopsy, had
collagenous fibres enclosing phagocytes containing granular particles. Similar effects were
produced in animals (Jötten & Eickhoff, 1942). It was suggested that aluminium dissolved in
the lung and then co-precipitated with protein to cause this problem (Goralewski, 1947;
1948; Jäger & Jäger, 1941). It has also been suggested that the paraffinic substances were the
causal agents (Perry, 1947), although Van Marwyck & Eickhoff (1950) found paraffin-coated
aluminium dust produced less diffuse interstitial fibrosis than uncoated dust (see Effects on
Laboratory Mammals and In Vitro Test Systems, Irritation, Inhalation Exposure).
Shaver & Riddell (1947) described a lung disease seen in 23 furnace feeders and ore bin
operators, who had worked for 23 months to 15 years in a facility manufacturing the aluminium
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oxide abrasive, corundum. These workers were exposed to fumes containing considerable
amounts of very fine aluminium oxide as well as silica and smaller quantities of many other
substances. The disease was characterized by dyspnoea, sudden attacks of extreme
breathlessness, pneumothorax, and diffuse, irregular, lace-like, granular shadows rapidly
progressing to a non-nodular fibrosis. This became known as Shaver’s disease, a pulmonary
fibrosis seen in workers in bauxite refining or exposed to finely divided aluminium powders,
especially flake (pyro) powders. The fumes were shown to contain 30% silicon dioxide and
55% aluminium oxide; the silicon particle size (0.02 to 05 μm) was smaller than that associated
with classical silicosis (Anon, 1956). More, similar, cases were described by Riddell (1948)
who was not able to identify the cause and Wyatt & Riddell (1949) who found the majority of
the fume particles to be amorphous and ≤ 0.5 μm in diameter. They believed the initial lesion
was intracellular oedema with fibroblastic proliferation, followed by inflammatory cell
infiltration within the thickened alveolar walls and then by collagen deposition. They
hypothesized that intense exposure to amorphous aluminium dust may play a role in this
disorder.
A fatal case described by Mitchell (1959) concerned exposure for 2.75 years to finely divided
aluminium powder having a wide range of particle sizes, with ~ 10 mg/m3 being < 5 μm
diameter (pyro powder). The powder was stearine coated and produced by a stamping machine.
Mitchell et al. (1961) also described another fatal case of a worker who performed the same
job for 3.5 years after the first case. These two workers were exposed to 615 and 685 mg/m3
of pyro powder and ~ 50 mg/m3 of respirable (< 10 μm) dust. Four additional cases identified
among the 27 workmen of this small factory were investigated (Mitchell et al., 1961). The case
described by Jordan (1961) worked for 5 years as a “flash filler”, hand filling fireworks with
pyro powder, then frequently sweeping the floor, raising a considerable amount of dust.
Pneumoconiosis was seen in 5 workers exposed to aluminium pyrotechnic flake powder in an
aluminium powder mill (Swensson et al., 1962). One of these men died 6 years after exposure
due to pulmonary oedema caused by cor pulmonale and aluminosis, another died 20 years after
exposure due to respiratory insufficiency due to aluminosis, and another died 34 years later
with pulmonary fibrosis. When the remaining 2 survivors were studied 40 years later they had
no respiratory symptoms and had no further vital lung capacity deterioration (Sjögren et al.,
1996b). McLaughlin et al. (1962) provided a frequently cited report of a 49 year old who
worked for 13.5 years in the ball-mill room of an aluminium powder factory and who died with
interstitial and nodular fibrosis and dementia. Two samples of dust in the workroom contained
0.94 and 1.46 mg/m3 total dust, of 71 and 60% aluminium, and 0.24 and 0.38/m3 respirable
dust, of 48 and 42% aluminium. Chen et al. (1978) described an aluminium welder who they
claimed to be the first reported case having pulmonary granulomatosis associated with
aluminium inhalation, but not associated with aluminium processing. The case presented as a
diffuse interstitial infiltrate and mild dyspnoea. Microscopic examination of material from an
open lung biopsy showed extensive interstitial granulomas composed of macrophages, foreign
body giant cells, and crystals containing aluminium.
Pneumoconiosis has been attributed to kaolin and montmorillonite exposure (Gough et al.,
1956; Lynch & McIver, 1954; Sakula, 1961). A case of multiple kaolin-induced granulomas
was reported (Herman et al., 1982) in which large amounts of kaolinite were found in a
pneumoconiotic lesion of a worker exposed to kaolin. The presence of silica could not be
detected (Lapenas & Gale, 1983). Pulmonary interstitial inflammation, fibrosis and
granulomatosis have also been reported in those exposed to aluminium silicates (Musk et al.,
1980; Sherwin et al., 1979); this was later concluded not to be caused by the aluminium silicates
(Musk et al., 1988). The prevalence of simple and complicated pneumoconiosis in kaolin
workers was 3.2 and 0.63%, respectively (Morgan et al., 1988). China clay workers who had
a high quartz content of the dust recovered from the lung demonstrated nodular fibrosis whereas
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those who had a high content of kaolinite dust in the lungs had interstitial fibrosis (Wagner et
al., 1986).
Desquamative interstitial pneumonia, a non-specific response to inhaled particles, was
observed in an aluminium welder. Lung biopsy showed large amounts of particles containing
aluminium, particularly in AM (Herbert et al., 1982).
Aluminium oxide refinery workers exposed to some low temperature transitional aluminas
demonstrated little evidence of pulmonary fibrosis and pneumoconiosis. The noted adverse
effects were consistent with non-specific chronic industrial bronchitis associated with
excessive, prolonged exposures to nuisance dust (Townsend et al., 1985). The aluminium lung
concentrations in 4 workers exposed to aluminium oxide for 10 to 37 years were 400 to 1080
mg/kg, respectively and correlated well with the extent of fibrosis (Gaffuri et al., 1985). About
1/3 of 197 workers engaged in electrolytic reduction of aluminium oxide, exposed > 3 years
to dust ranging in size from 0.5 to 5 μm and in concentration from 0.4 to 3.1 mg/m3, and to
gaseous fluoride at concentrations of 0.13 to 0.96 mg/m3 (below the TLV-TWA for fluorides
of 2.5 mg/m3 (ACGIH, 2005), demonstrated bronchitis. X-rays indicated a slowly evolving
pneumoconiosis (Clonfero et al., 1978). Similarly, the incidence of chronic bronchitis increased
with duration of occupational exposure in aluminium foundry workers, to 38% in those with
> 20 years exposure. Dust, fluoride and sulphate levels were half of their TLVs (Clonfero et
al., 1980a). This group provided a case report of aluminium smelter workers who developed
lung fibrosis or fibronodular changes, a pneumoconiosis (Clonfero et al., 1980b). An
aluminium arc welder for 17 years presented with fibrotic nodules with seemingly necrotic
centres in his lungs (Vallyathan et al., 1982). A 44 year old who had worked for 6 years as an
aluminium rail grinder, often in an extremely dusty work environment, presented with
shortness of breath, diffuse x-rays infiltrates and restrictive lung disease. Lung tissue was found
to contain > 342,000,000 particles/g dry weight, of which 94.8% were pure aluminium. It was
concluded that the inhaled aluminium particles caused the pulmonary alveolar proteinosis
(Miller et al., 1984). Similarly, a 50 year old who had worked for 14 years in a potroom and
died 3 years later of respiratory insufficiency had ~ 1,300,000,000 fibrous particles containing
aluminium oxide/g dry lung and 15,000,000,000 non-fibrous Al-containing particles/g dry
lung, respectively. The Al present was α Al oxide, not γ Al oxide or Al metal. This is ~ 1000-
fold more aluminium in the lung than seen in the general population. The authors speculated
that the fibres themselves may have played a role in aluminium-induced fibrosis/
pneumoconiosis in cases of massive aluminium exposure (Gilks & Churg, 1987). Avolio et al.
(1989) reported 13 cases of lung disease in workers in bauxite refining, preparation of
aluminium oxide abrasives, cold grinding of aluminium and other jobs which exposed them
to airborne dust. They felt their cases supported the possibility that exposure to aluminium can
cause interstitial fibrosis but noted that this was associated with a relatively benign lung
condition.
Population studies of aluminium smelter operators suggested minimal (Saia et al., 1981) or no
fibronodular disease (Chan et al., 1983; Discher & Breitenstein, 1976) or increased mortality
associated with pneumoconiosis (Gibbs, 1985). Doese et al. (1938) found no effects in 70
workers in an aluminium foundry or in 16 in a fabricating plant. However, it was noted that
aluminium and aluminium bronze dusts produced upper respiratory tract lesions manifested as
a head cold, irritation and atrophy of the nasal mucosa and septal perforation. Crombie et al.
(1944) studied 125 workers in an aluminium stamp mill who had been exposed for 6 to 23
years and found no chest radiographic evidence of abnormalities attributable to dust inhalation.
The authors concluded that grinders of aluminium airplane propellers, exposed to a mixture of
3 mg/m3 aluminium dust (1/3 between 2 and 7 μm and 2/3 > 7 μm diameter) and aluminium
oxide (mostly < 7 μm diameter) and workers in a factory making aluminium powder showed
no evidence of adverse effects (Hunter et al., 1944). In a study of 9 workers who had abnormal
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chest x-rays and a mean exposure of 25 years to aluminium oxide in the production of
aluminium oxide abrasives, biopsies from 3 indicated interstitial fibrosis, an absence of silicotic
nodules and aluminium levels several orders of magnitude above background. Aluminium
constituted > 90% of the metals in the lung. This suggested that aluminium oxide was the cause
of the pulmonary fibrosis (Jederlinic et al., 1990).
In reviewing the experimental studies and clinical reports on aluminium oxide, Dinman
(1988) suggested that increased thermodynamic instability and enhanced bioreactivity occurs
as particle surface area increases, contributing to pulmonary fibrogenicity, and that the
thermodynamically active catalytic activity of the low temperature transitional forms also
contributes to pulmonary bioreactivity. In their review of evidence for a relationship between
work in the aluminium industry and lung disease, Abramson et al. (1989) concluded that
pulmonary fibrosis had not been shown to be a significant problem. The difficulty of
determining whether the pulmonary fibrosis and pleural abnormalities associated with working
with aluminium are due to aluminium and/or asbestos was discussed (Kilburn & Warshaw,
1992).
Nemery presented a case of aluminium exposure causing a sarcoid-like lung granulomatosis
and suggested that this might be evidence that aluminium causes a cell-mediated immune
response (Nemery, 1990). A 32 year old aluminium polisher who was extensively exposed to
metallic aluminium, aluminium oxide powders and other metals for 8 years developed severe
lung fibrosis with T-lymphocyte alveolitis and sarcoid-like epitheloid granulomas which
contained aluminium. Aluminium comprised ~ 1/3 and silicon ~ ¼ of the mineral species in
his lung. The aluminium particles were 0.5 to 5 μm in diameter (De Vuyst et al., 1986). A case
of pneumoconiosis in a stoneworker was presented with a high lymph node aluminium content
that was attributed to aluminium oxide inhalation (Sunami et al., 1997). Assessment of
bronchial and dermal responsiveness was conducted in 127 aluminium smelter workers.
Hypersensitive reactions to pure aluminium and aluminium smelter dust were seen in some
workers, but bronchial hyperresponsiveness to aluminium aerosol was not seen. The authors
suggested that these changes might be have been due to an immunological disturbance in the
aluminium smelter workers who had experienced long exposures to toxic compounds, mainly
those of aluminium (Hosovski et al., 1998).
Observations in guinea pigs exposed to aluminium hydroxide (Gardner et al., 1944) led to
issuing a warning that large amounts of aluminium inhalation may lower the resistance of
patients to tuberculosis (Council on Industrial Health, 1946).
In reviewing metal-induced pulmonary toxicity, Nemery (1990) suggested that the rarely-
observed pulmonary granulomatous fibrosis seen following aluminium exposure (aluminosis),
is a form of induced pneumoconiosis, similar to that from exposure to beryllium and its
compounds; it was also suggested that this may also be a cell-mediated immune response. This
was also suggested by De Vuyst et al. (1986).
Observations that aluminium inhalation reduced the ability of quartz to produce lung fibrosis
in some experimental animals lead to its application in humans. Initially a number of
uncontrolled studies were conducted. Crombie et al. (1944) treated 34 silicotic coal miners
with 200 to 300 inhalations of a fine aluminium powder, initially for 5 minutes, then increasing
to 30 minutes. Clinical improvement was reported in 19 cases, evidenced by lessening or
disappearance of shortness of breath, cough, chest pain and fatigue, whereas 6 of 9 control
cases that did not receive aluminium reported progression of their disease. There were no
apparent adverse effects, leading the investigators to conclude that inhalation of fine particulate
aluminium powder is not harmful to human lung. Aluminium treatment was reported to produce
symptomatic improvement in 135 of 143 industrial workers who had developed silicosis from
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exposure to siliceous dust (Hannon, 1944). Symptomatic improvement was reported in 49 non-
ferrous metal workers treated with metallic aluminium. Forty-three percent of those treated
with hydrated aluminium oxide reported improvement compared to 30% of those treated with
metallic aluminium oxide. There was no objective measure of improvement in these cases
(Bamberger, 1945). Improvement was reported in 56% of 75 silicosis patients treated with
metallic aluminium powder (Johns & Petronella, 1945). In 1946, E. J. King & C. L. Sutherland
(as noted in Berry, 1948) reviewed the evidence for the use of aluminium to prevent or treat
silicosis and concluded that there was no definitive evidence that aluminium prevented further
development or caused reversal of established disease. It was concluded, after reviewing the
reports to that time, that the improvements reported by many silicotics were subjective and that
there had been no adequately controlled studies (Berry, 1948). Twenty-six silicotic patients
inhaled a dust containing 300,000,000 particles of hydrated aluminium oxide per cubic foot or
air, equivalent to 35 mg/m3, for 20 minutes daily, 5 days weekly for 4 week periods alternating
with 4 week periods of no inhalation, for up to 1 year; comparison was made with 16 controls
who inhaled room air. All subjects were blinded. Subjective improvement was seen in both
groups. No objective improvement was seen in those inhaling aluminium, suggesting the
beneficial effects were psychological (Berry, 1948). It was noted that the observation of
improved function coincided with improved dust control in these industries (Anon, 1956).
Carefully planned and properly controlled studies were recommended (Kennedy, 1956). This
led to an investigation that was conducted in pottery workers and coal miners of the efficacy
of inhalation of 50 mg pure metallic aluminium dust, of which > 90% was respirable, for 15
minutes, 3 times weekly, for up to 3.5 years; comparison was made with inhalation of 5 mg of
carbon black containing 1 mg/kg aluminium powder (Kennedy, 1956). No regression of the x-
ray picture or improvement of functional capacity was seen. It was claimed that no nodulation
was seen in 11 workers in a refractory plant who inhaled aluminium for 11 years, whereas this
was seen in 11 of 12 controls (Hannon, 1953). Five percent of 164 workers who inhaled
aluminium for 5 minutes a week in a foundry manufacturing large castings showed a reduction
of respiratory function after 6 years; 9% of 125 who originally had functional incapacity
deteriorated while 90% improved (Osmond, 1955).
Asthma was seen in workers in the aluminium industry, but this has been largely attributed to
the presence of fluorine and substances other than aluminium. However, there are a number
of reports suggesting that aluminium can cause asthma and related symptoms.
An airway obstruction called potroom asthma was seen in workers in the aluminium industry
(Chan-Yeung et al., 1983; Frostad, 1936; Kongerud et al., 1994). Exposure to emissions from
aluminium industry pots was thought to be the cause of bronchoconstriction among susceptible
workers (Field, 1984). As the pot emissions contained aluminium oxide, carbon dusts,
particulate polycyclic organics, gaseous and particulate fluorides, carbon monoxide, carbon
dioxide, sulphur dioxide and nitrogen oxides, it has so far not been possible to identify the
causative agent(s) of potroom asthma; however, fluoride compounds have been implicated
(Söyseth et al., 1994). Determination of the contribution of fluoride, inspirable dust, sulphur
dioxide, oil mist and the benzene-soluble fraction of coal tar pitch volatiles to respiratory
symptoms in aluminium smelter workers suggested the first two were causative agents (Fritschi
et al., 2003). Respirable sodium aluminium tetrafluoride fibres were found in the work
environment of the primary aluminium industry (Gylseth et al., 1984). Fibres found in the lungs
of previous workers in the aluminium industry who had pulmonary problems were similar and
evidently persisted in the lung for years (Voisin et al., 1996).
Occupational airway hyperreactivity and nocturnal asthma were seen in 16 young male
workers, representing 20% of workers, exposed to aluminium fluoride and in 3 exposed to
aluminium sulphate in another plant. Although inhalation challenge tests were negative in 3
workers, intracutaneous injections produced positive responses in 3 of 8 workers. The authors
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concluded that the aluminium salts were the most likely cause of the occupational nocturnal
asthma (Simonsson et al., 1985). Increased bronchial hyperreactivity in aluminium welders
was attributed to the aluminium (Nielsen et al., 1993). Park et al. (1996) described a worker
who had been exposed for 5 years to aluminium powder and who developed dyspnoea, cough
and sputum production which began 1 hr after beginning work. These symptoms and a
decreased FEV1 were seen to a challenge with 10 mg aluminium powder and 10 mg/mL of
aluminium chloride solution. The worker’s neutrophil chemotactic activity increased during
the challenge. Skin tests to aluminium chloride produced no immediate reaction. The authors
suggested that aluminium powder might have produced bronchoconstriction mediated by a
non-immunological mechanism that could have involved neutrophils. A welder who had
intermittently welded aluminium for 4 years developed symptoms of asthma 1 to 4 hr after
ceasing welding (Vandenplas et al., 1998). Although skin tests with aluminium sulphate and
nitrate did not show an immediate reactivity, the worker exhibited a large decrease in FEV1
following aluminium welding. As positive skin tests to aluminium usually appear after 24 to
48 hr (see Effects on Humans, Effects from Occupational Exposure, Irritation, Dermal
Exposure) the absence of immediate reactivity may not rule out hypersensitivity to aluminium.
Asthmatic symptoms in this subject appeared after aluminium welding in the absence of
detectable fluorides. A positive response was seen to a bronchial provocation test with
aluminium chloride in a foundry worker who had 19 years exposure to molten aluminium and
who experienced potroom asthma (Burge et al., 2000). An aluminium soldering flux containing
potassium aluminium tetrafluoride has been shown to cause a potroom asthma reaction
(Hjortsberg et al., 1994).
Dermal exposure: Four cases of contact dermatitis to dural, an alloy of 95 to 95.5% aluminium,
3.5 to 4% copper, 0.5% manganese and 0.5% magnesium, and 2 cases of contact dermatitis to
aluminium were seen in 202 cases of contact dermatitis among aircraft workers (Hall, 1944).
Itching from an irritant dermatitis that has been reported among potroom workers in factories
using recycled aluminium was probably due to aluminium dust mixed with sulphur dioxide
and traces of other metals (Johannessen & Bergan-Skar, 1980).
The use of a compressed air pistol to accidently impel newly milled narrow aluminium particles
into the hand for 1.5 years of a worker resulted in erythema, hyperkeratosis, fissuring and partial
desquamation of the hand. Patch testing was positive for aluminium filings in petroleum
lubricant. Testing was not conducted with aluminium alone, so it is not known if this reaction
was due to aluminium (Peters et al., 1998).
Corrosivity—Skin, eye and upper respiratory tract contact with trimethyl and triethyl
aluminium can produce thermal burns, redness and swelling (Roychowdhury, 1993).
Organo-aluminium compounds have an aluminium-carbon bond in which the carbon atom
forms part of an organic radical. Most aluminium alkyls are liquids and react with oxygen and
oxygen-containing compounds. This is particularly true for the lower alkylaluminiums such
as the alkylaluminium chlorides and hydrides that are violently reactive with oxygen,
spontaneously flammable in air, and explosive on contact with water, or when mixed with
strong oxidizing agents or halogenated hydrocarbons. They are extremely destructive to living
tissue producing an immediate reaction that results in deep, painful burns with subsequent
scarring if not immediately treated. Contacted areas should be immediately flushed with much
water and covered with a burn ointment (Anderson, 1963). Skin, eye and upper respiratory
tract contact with trimethyl and triethyl aluminium can produce thermal burns, redness and
swelling (Roychowdhury, 1993).
Effects on the endocrine system—In a report on several biological monitoring studies
of aluminium workers in Italy, Alessio et al. (1989) compared 22 workers exposed to
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aluminium with 12 non-exposed workers. They noted that thyroid-stimulating hormone and
prolactin levels were depressed 8 months after starting exposure to aluminium, but
subsequently returned to normal. No other epidemiological studies have been published on this
topic.
Immunotoxicity/immunosuppression—No epidemiological studies investigating the
effects of occupational aluminium exposure on immune parameters in workers have been
published on this topic. There is some evidence describing a potential immunosuppressive
effect of aluminium in renal transplant patients (see Effects on Humans, Effects from Non-
Occupational Exposure, Immunotoxicity/Immunosuppression).
Renal—No epidemiological studies have been published on occupational aluminium
exposure and its effects on the renal system. There is extensive literature describing the role
of renal insufficiency in the development of aluminium induced toxicity (see Effects on
Humans, Case Reports and Effects on Humans, Subpopulations at Special Risk).
Bone—No information was found specifically describing occupational aluminium exposure
and adverse effects of the skeletal system. For a description of non-occupational aluminium
exposure and bone toxicity see Effects on Humans, Effects from Non-Occupational Exposure,
Bone.
Anaemia—No information was found specifically describing aluminium induced anaemia as
a result of an occupational exposure. For a description of non-occupational related aluminium
exposure and anaemia see Effects on Humans, Effects from Non-Occupational Exposure,
Anaemia.
Cancer—The potential for carcinogenic effects from exposure specifically to aluminium or
its compounds in the workplace has not been studied. However, according to IARC, processes
used in the production of aluminium are carcinogenic in humans (IARC 1984; 1985; 1987;
Straif et al., 2005). See below for further discussion on research papers relevant to the IARC
ranking.
A synthesis of different epidemiological studies from 5 countries on the risk of cancer from
occupational to aluminium is presented in Table 23. These studies show excess cancers at
multiple sites, especially the bladder and the lung. In the occupational environment, certain
PAHs, such as tar-pitch volatiles, which are emitted when organic matter is burned, are
established carcinogens. However, uncertainty exists regarding the exposure-response
relationship with respect to PAH. Two review articles have been published on epidemiological
studies in which the relationship between exposure to PAH and lung and bladder cancers in
occupationally exposed subjects was investigated (Armstrong et al., 2004;Mastrangelo et al.,
1996).
In Canada, a significant excess of mortality or morbidity from lung or bladder cancers has been
observed in three studies (Armstrong et al., 1994; Gibbs, 1985; Spinelli et al., 1991). Gibbs
(1985), in a study of 5,406 Canadian aluminium smelter workers, found that mortality from
malignant neoplasms of the bladder and the lung was meaningfully related to the number of
tar-years (an exposure index calculated for each year 1950-1977, which corresponds to a
weighted sum of the total number of years in the tar-exposed occupation) and number of years
of exposure (Gibbs, 1985).
Edling et al. (1987) in Sweden found no significant increase in cancer morbidity or mortality
in 521 workers exposed to aluminium oxide in an abrasive-manufacturing plant and the cohort
was followed up between 1958 and 1983. Selden et al. (1997) in Sweden investigated the risk
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of developing cancers at different sites in workers employed in secondary aluminium (scrap)
smelters. They obtained significantly increased risk estimates for specific sites or organ-
systems such as the rectum and anus (standardized incidence ratio (SIR) =2.13, 95% CI:
1.47-2.99), the nose and paranasal sinuses in a small number of cases (SIR= 4.70, 95% CI:
1.28-12.01), and the lung and pleura (SIR=1.49, 95% CI: 1.11-1.96). They also observed an
increase in anorectal cancer, but this was not etiologically related to occupational determinants
of risk. In contrast to previous findings in primary aluminium smelters, there was no overall
increase in urinary bladder cancer in this study including workers from secondary aluminium
smelters.
Two mortality studies on this topic have been conducted in France. In the first, Mur et al.
(1987) investigated workers at 11 plants of the Aluminium Pechiney Company; the follow-up
period was from 1950 to 1976. A slight but non-significant lung cancer excess of 1.14 was
found based on 37 observed deaths. The second study conducted by the French National
Institute for Research and Safety by request of the Aluminium Pechiney Company was an
update of the mortality study of workers in the largest plant from the previous study (Moulin
et al., 2000). An improvement in the study design was made by collecting the causes of death
from death certificates over the period 1968-1994. The statistical analysis, based on 7 deaths,
showed a non-significant excess of mortality from bladder cancer (standardized mortality ratio
(SMR) =1.7, 95% CI: 0.71-3.64) and the observed mortality from lung cancer (19 deaths) was
significantly lower than expected (SMR=0.63, 95% CI: 0.38-0.98).
The most recent Norwegian studies showed no elevated risk of lung cancer even among the
most heavily PAH-exposed workers (Romundstad et al., 2000a; Ronneberg et al., 1999).
However, these investigators obtained inconsistent results regarding bladder cancer.
Limitations in study size have been problematic in interpreting the results of these studies and
the latter one (Romundstad et al., 2000b) was initiated to clarify possible associations between
PAH exposure and the incidence of lung, bladder, kidney and pancreatic cancers in a combined
update of 6 Norwegian aluminium cohorts, i.e., 11,103 workers including 130 with bladder
and 189 with lung cancers. This study showed an association between bladder cancer and
exposure to PAH, but gave no support to an association with lung, kidney or pancreatic cancers.
Higher than expected mortality from other cancers, including lymphoreticular and
genitourinary malignancies (Rockette & Arena, 1983) or brain cancer (Spinelli et al., 1991)
have also been reported in aluminium reduction plants but again concomitant exposure to PAHs
was likely to have been involved in these plants.
Occupational exposure to aluminium occurs not only in the primary refining of this metal but
also in user industries such as automobile manufacturing. For example, inhalation exposure
can occur during metalworking. In a nested case-control study of 667 cases (members of the
cohort (n=45,000) who died before January 1, 1985) and 3,041 matched controls, Schroeder
et al. (1997) analyzed the effect of aluminium machining on the risk of lung cancer.
Semiquantitative estimates, based on years of exposure, were available for additives including
sulphur and biocides, for the metals, steel, iron and aluminium, and for nitrosamines. A positive
association between exposure to aluminium and lung cancer mortality was observed,
particularly after an exposure period of 20 years. There was no evidence of a dose-response
relationship between years of exposure and the outcome. However, ORs from these models
indicate there are risks from exposure to aluminium together with soluble oils (a class of
machining fluid), rather than from exposure specifically to aluminium. The likelihood that Al
exposure is causally related to lung cancer in this cohort is small.
Armstrong et al. (2004) has reviewed the risk of lung cancer from inhalation exposure to PAHs
in different aluminium-related industries. Meta-analysis of the data from eight of these
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industries showed the risk of lung cancer to be equivalent to 1.16 (95% CI: 1.05-1.28) for
exposure to 100 μg/m3 benzo(a)pyrene.
Several epidemiological studies have shown that workers in the aluminium industry have an
increased risk of developing lung cancer or bladder cancer; however, in all these studies this
risk has been attributed to exposure to the PAHs generated during aluminium production, rather
than to exposures to aluminium compounds. Benke et al. (1998) recommended that more
attention be given to exposures to other contaminants and agents such as aromatic amines and
nitro compounds, asbestos, heat stress and magnetic fields in future studies of cancer in
aluminium smelter workers.
Genotoxicity—A case control study was conducted by Arnaiz et al. (2003) to examine
whether genetic polymorphisms associated with asthma in the general population were also
associated with the development of the asthma-like condition among aluminium potroom
workers. The genotype at beta2-adrenoreceptor 16 and 27 and the high affinity IgE receptor
181 and 183 amino acid positions were studied. Only 52 cases agreed to participate; 13 were
identified as new cases. The study did not show any association between genotype and the
development of asthma for workers employed in a potroom. However this study might not
have been of sufficient power to detect an association because of the limited number of subjects.
Reproductive toxicity
Effects on fertility: Epidemiological investigations of the effects of aluminium on fertility
have not been published. A demographic analysis of fertility in French aluminium industry
workers was conducted, but the aim of this study was to evaluate the potential effects of
occupational exposure to heat and static magnetic fields (Mur et al., 1998). A comparison was
made between the number of live births in the group of male workers (n=692) exposed to heat
and magnetic fields from 11 aluminium producing factories with that in workers in the same
factories who were not exposed to these factors (n=588); the workers were mainly employed
as maintenance operators and had never worked in potrooms. In the passageways where
potroom workers mainly stay, the maximum level of the magnetic fields to which exposures
occurred was 20 mT2. The index taken for estimating the fertility of these workers was the
number of live births since marriage, after the start of occupational exposure. They observed
a significantly greater birthrate in the “exposed” group (3.11 ± 1.74) than in the “control” group
(2.63 ± 1.34) 30 years after marriage, for instance. However, in this study, factors which could
have influenced the results had not been taken into account, that is the contraceptive practices
of couples and non-occupational factors influencing the fertility of the man and/or woman (e.g.,
smoking, which can alter male fertility, was more frequent in the “exposed” than in the “non-
exposed” group; this could have been a bias). Comparison with a national reference (the average
number of live births in the French population is 2.28) also reveals that the fertility of
(“exposed” and “control”) subjects from these aluminium industries is greater than that of the
population as a whole. However other factors can explain the disparities in fertility rates,
especially the fertility of the socio-professional category of the subjects studied here (blue
collar workers) which is higher than that of other socio-professional categories included in the
national reference. This study has too many drawbacks to reach any conclusion on an
association between occupational exposure to aluminium and fertility.
Developmental effects: No published epidemiological studies of the effects of occupational
aluminium on developmental effects were found. There is at least one case report of severe
developmental retardation in a child whose mother had taken high doses of aluminium
containing antacids during pregnancy (see Effects on Humans, Case Reports).
2milliTesla: the strength of the magnetic field.
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Modifying factors
Gene-environment interactions: As described above in Effects on Humans, Effects from
Occupational Exposure, Genotoxicity, Arnaiz et al. (2003) examined whether genetic
polymorphisms associated with asthma in the general population are also associated with the
development of an asthma-like condition among aluminium potroom workers. No associations
between genotype and the development of asthma in workers in a potroom were found.
Confounding factors: The major weakness of studies of occupational exposures to Al is the
lack of information required to rule out exposure to other toxic substances as the cause of the
observed effect. Most of these studies involved a cohort of workers with a small number of
cases which resulted in inconsistent results. Also confounding factors such as smoking
histories, or other occupational exposure to dust or substances such as asbestos have not always
been controlled for. Armstrong et al. (1994), in a case-cohort study, adjusted for smoking
histories from the medical records of the company. They obtained a clear excess of lung cancer
risk in men who had worked in the Søderberg potrooms and in jobs in which there were
generally high exposures to coal tar-pitch volatiles. Linear modelling predicted a rate ratio of
1.25 for lung cancer after 40 years at the TLV for coal tar pitch volatiles of 0.2 mg/m3 (ACGIH,
2005) matter, implying a lifetime absolute excess risk of 2.2 percent. Furthermore, they showed
that the risk was not due to confounding by smoking. In only 4 of the 12 studies reported in
Table 23 has an adjustment been made in the analyses for smoking habits. However, Armstrong
et al. (2004) have noted that confounding is unlikely, where comparisons are being generally
made between groups with only moderately differing smoking habits (particularly different
groups of manual workers).
Producing aluminium leads to the release of a chemically complex mixture including both
gases and particulates of varying chemical composition. Most attention has been focused on
the effects of the particulate phase of the coal-tar-pitch volatiles (CTPV), principally because
CTPV contain carcinogenic PAHs and other carcinogenic constituents (e.g., arylamines and
nitro-PAH). Differences in duration, level and chemical composition of exposure may in part
explain the conflicting results. Earlier studies (Rockette & Arena, 1983; Spinelli et al., 1991)
were not as detailed in their exposure assessments as those of Armstrong et al. (1994) and
Ronneberg et al. (1999).
Explosivity, flammability, oxidizing potential—Aluminium is a reactive chemical
element with a natural affinity for oxygen. Metallic aluminium is produced commercially from
its ores by the breakage of the aluminium-oxygen bonds (see Sources of Human Exposure,
Anthropogenic Sources, Production Levels and Processes). This requires energy and if it
recombines with oxygen in water or air this energy will in turn be released. Within the industrial
environment, explosions continue to be reported as a result of the combination of molten
aluminium and water when water turns to steam as it is trapped between the molten metal and
a solid. Such a rapid expansion and rise in temperature has lead to a number of different types
of steam-related explosions, producing a significant amount of damage. In the mid-1980’s the
Aluminium Association initiated a reporting program for incidents of three different types of
explosions. Defined as level of Force 1, 2, or 3 they cover steam explosions (less than 10 pounds
of metal dispersed less than 15 feet), violent steam explosions (metal dispersed 15 to 50 feet);
and catastrophic explosions resulting from reactions with air or water and the metal is dispersed
more than 50 feet with little remains of the metal, respectively. A recent review outlines these
types of industrial accidents and provides incident data by type of operation over the last 20
years (Epstein, 2005). As expected, the majority of the incidents are within the Force 1 level
however, there has been relatively consistent number of Force 2 incidents over the years. While
Force 1 incidents are associated with burn related injuries, Force 2 incidents represent the
majority of fatalities and serious injuries.
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When assessed, the explosibility of metallic dusts dispersed in air showed that minimum
explosive concentrations of aluminium dusts ranged from 70 to 90 g/m3 when ignited by a
1000 J system up to a maximum of 350 g/m3 at 5000 J. The maximum adiabatic flame
temperature is 3550 °K and the limit flame temperature is 2150 °K. It has been suggested that,
in such cases, aluminium combustion depends on metal evaporation in order to support flame
propagation (Hertzberg et al., 1991).
Mixtures of aluminium and halogenated organic compounds in which the aluminium
concentration can have high reactivity and present an explosion hazard depend on the reactivity
limits (RL). Most mixtures with iodinated compounds are not very reactive and many mixtures
of aluminium with fluorinated hydrocarbons do not have a lower RL. In the presence of heptane,
ternary mixtures of aluminium with fluoro-, chloro-, or bromo-substituted compounds have a
decreased range of reactivity (Cardillo & Nebuloni, 1992).
Effects from Non-Occupational Exposure
Neurotoxicity—It has been shown that aluminium is neurotoxic, based on the literature on
dialysis encephalopathy (see Effects on Humans, Subpopulations at Special Risk, Individuals
with Impaired Renal Function). This section reviews studies, in chronological order, of
aluminium exposure and cognitive impairment, and dementia, including AD.
Aluminium in drinking water: A number of studies have examined the effects of aluminium
in drinking water on cognitive impairment and dementia including AD, as well as other
neurological conditions such as Parkinson=s disease and amyotrophic lateral sclerosis. These
studies are listed in Table 24.
Martyn et al. (1989) conducted an ecological study of the incidence of AD in men and women
aged 40-69 in 88 county districts from the records of 7 CT scanning units to which patients
had been referred for diagnosis, in relation to levels of aluminium in drinking water over the
previous 10 years. CT scans covered a 3-year period, either 1983-85 or 1984-86. There was a
wide range of water aluminium concentrations. Rates were adjusted to compensate for different
rates of referral according to the distance from the nearest CT scanning unit. Dementia was
classified as probable AD (242 men, 203 women), possible AD (112 men, 109 women),
cerebrovascular dementia (162 men, 111 women) and other dementia (154 men, 92 women).
To examine differences in referral practices in different areas, a group of 2,936 epilepsy patients
was also included. The risk of probable AD was 1.5 times higher in districts where the mean
aluminium concentration exceeded 0.11 mg/L than in districts with concentrations of <0.01
mg/L. There was no evidence of a dose-response relationship where there were intermediate
levels of aluminium in water. There was no evidence of a relationship between other types of
dementia or epilepsy and aluminium concentrations in water. It should be noted that this study
included an unusually young population in relation to risk of AD (rates increase dramatically
from ages 65-69 - the oldest people in this study – to those aged 85 and over). The authors
justified exclusion of older age groups in which AD is more common on the basis that younger
people presenting with clinical symptoms of dementia would more likely be more aggressively
assessed and more likely to have a CT scan. The study was not population-based, i.e. not all
people developing AD had an equal probability of being included in the analysis, only those
under age 70 receiving a CT scan. It is not known how this sample differed from all AD cases
in the area studied, but it was not representative.
Flaten (1990) examined geographical associations in Norway between aluminium in drinking
water and death rates (underlying or contributing cause) from dementia including AD, as well
as Parkinson=s disease and amyotrophic lateral sclerosis. Water samples were collected
seasonally from October 1982 to August 1983 from 384 Norwegian waterworks supplying
70.9% of the Norwegian population, covering 193 municipalities. Death rates were
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standardized to the 1979 Norwegian population, for 3 5-year periods (1969-73, 1974-78,
1979-1983) and for the 10-year period, 1974-83. Municipalities were grouped into low,
medium and high levels of aluminium (<0.05 mg/L, 0.05-0.2 mg/L and >0.2mg/L respectively),
and correlation and regression analyses were conducted. Age-adjusted rates per 100,000
population (1974-1983) grouped by aluminium concentration in water showed relative risks
(RR) for dementia in males of 1.00, 1.15 and 1.32 for low, medium and high levels of
aluminium, respectively; for women, the corresponding values were 1.00, 1.19 and 1.42. This
relationship did not hold true for mortality from Parkinson=s disease or amyotrophic lateral
sclerosis. Flaten appropriately cautioned that these associations were ecological, serving to
generate hypotheses for further study. The study has the strength of being population-based.
The association could be stronger than reported if there was under-reporting of dementia on
death certificates; however, since both underlying and contributing causes were used, this
problem would be reduced. Typically, report of dementia on death certificates is specific but
not as highly sensitive; that is, where dementia is recorded, it is highly likely that the decedent
had dementia, but where it is not recorded, it will have been missed in some proportion of the
death records.
Frecker (1991) examined the 1985-86 dementia mortality in Newfoundland to determine if
there were unusual geographic distributions of disease. Data included age, sex, birth place,
place of death, cause of death and surname of parents, as well as aluminium concentration, pH
and colour of water. Two areas of high aluminium levels in drinking water had different rates
of dementia mortality. No conclusive evidence of family clustering was found.
Neri & Hewitt (1991) conducted a case-control analysis, using hospital discharge records of
2,344 people aged 55 or over, hospitalized for AD or presenile dementia, and 2,232 people
with non-psychiatric diagnoses, matched by age and sex to the cases. Drinking water data
included the level of aluminium in treated municipal water. They found an OR of 1.46 for
aluminium concentrations of ≥ 0.200 mg/L compared to <0.01 mg/L. While the analysis was
conducted as a case-control study, the study was really ecological in that it did not have any
data on potential confounders or effect modifiers.
In the Ontario Longitudinal Study of Aging (Forbes et al., 1991), 2,000 men were followed
for about 30 years and, of the 782 who remained in the study in 1991, 400 demonstrated mental
impairment at age 76. Aluminium and fluoride levels in drinking water were obtained from
provincial sources and allocated by place of residence of the study participants. In their first
publication, Forbes et al. (1991) noted only that ‘low’ and ‘high’ referred to below and above
the 50th percentile; there was no mention of what concentrations of aluminium or fluoride were
considered to be ‘low’ and ‘high’. They found that men living in areas with high fluoride were
more likely to be cognitively normal; men in areas with high aluminium were less likely to be
cognitively normal. The combination of high aluminium and low fluoride gave the lowest
likelihood of being cognitively normal (OR=0.37); conversely, the OR for low aluminium and
high fluoride was 1.5. No CIs or levels of statistical significance were given. Two further papers
in 1992 and 1994 expanded on the first report (Forbes & Agwani, 1994a; Forbes et al.,
1992). The median concentration of aluminium in drinking water was 0.0847 mg/L, and, for
fluoride, 0.88 mg/L in treated drinking water. Drinking water levels were classified as “high”
if the concentration aluminium or fluoride was greater than, or equal to, the median value, and
“low” if it was less than the median value. The OR was 2.72 (p < 0.01) for subjects in areas
with high concentrations of aluminium and low levels of fluoride in the drinking water,
compared to those exposed to low aluminium and high fluoride concentrations. An analysis of
the risk of impaired mental functioning according to pH, in addition to aluminium and fluoride,
levels resulted in small numbers, which makes interpretation difficult (Forbes et al., 1994).
There was a lower risk of impaired mental functioning with a neutral pH, between 7.85 and
8.05. Additional caveats include that the sample was not representative of the general
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population (a sample of males aged 45 in 1959), the possibility that those with mental
impairment were more likely to drop out of the study, and the difficulty of accurately
identifying impaired mental functioning based on a brief screening test and subjective
impressions of the responses to the overall interview.
Wettstein et al. (1991) conducted a well-designed population-based study of 805 residents,
aged 81 to 85, living for more than 15 years in districts with high (98 μg/L) or low (4 μg/L)
aluminium concentrations in their drinking water. They measured memory skills using the
Mini Mental Status test. Mnestic and naming skills did not differ between the high and low
exposure groups. Urinary aluminium and serum aluminium levels were measured in 10
clinically diagnosed Alzheimer=s patients and 10 controls in both areas; no significant
difference was found, adding strength to the negative findings. However, the highest
concentration of aluminium in drinking water was below 100 μg/L. Perhaps it would be more
accurate to say that no association was seen between memory loss (or cognitive impairment)
and low and medium levels of exposure.
There have been reports of adverse neurological effects resulting from the accidental
contamination of drinking water in the Camelford area in Cornwall, England in 1988 (Altmann,
1999; McMillan et al., 1993). The water aluminium concentrations recorded at the time of the
contamination event ranged from 30 to 620 mg/L (Eastwood et al., 1990). McMillan et al.
(1993) reported evidence of memory impairment in 10 individuals; this was not an
epidemiological study, but a description of 10 cases referred by their general practitioners.
Altmann et al. (1999) reported on a self-selected group of 55 adults who were considering
litigation due to the alleged effects of the water contamination three years after the incident.
A control group consisted of 15 siblings (all who were available) who had not lived in the
Camelford area since before the water contamination incident. An additional control group of
42 similarly aged adults underwent the same psychological tests. Subjects completed the
national adult reading test as a method of assessing IQ, and the Bexley Maudsley automated
psychological screening to measure cognitive impairment. All affected participants
complained of short term memory loss and impaired concentration. The mean pre-morbid IQ
as assessed by the national adult reading test was above average. The IQ measure of the affected
subjects was similar to their unaffected siblings. Affected subjects performed poorly on the
symbol digit coding test as compared to the 42 unrelated controls. The symbol digit coding
test is thought to be a measure of organic brain disease. The 15 unexposed siblings had
significantly better symbol digit coding test results and flash-pattern differences than did their
affected siblings. Many methodological issues must be considered in interpreting the results
of this study. The cases were self selected and were pursuing litigation for cerebral damage
claimed to be a result of the Camelford incident. It is possible that these cases may have already
had unexplained symptoms and cognitive problems, and the incident served to highlight a
potential cause (David, 2000). In addition, individuals who believed that they had suffered
damage as a result of the incident may have been more likely to have shown errors in
psychological tests which they knew were designed to detect abnormalities (Esmonde, 2000).
The level of aluminium in tap water in the period following the incident and the current levels
of aluminium in the tap water were not reported in the study. There was also no indication of
aluminium concentrations in the drinking water of the controls (Esmonde, 2000).
Jacqmin et al. (1994) investigated the relationship between aluminium, fluorine, calcium, and
pH in drinking water and the risk of cognitive impairment. This investigation used data
collected from the population-based Paquid study. The study sample included 3,777 individuals
65 years of age and older. To assess their cognitive status, subjects completed the MMSE.
Seventy-eight areas of distribution of drinking water were defined and aluminium, calcium,
fluorine, and pH were measured in two separate surveys. A weighted mean of exposure was
calculated for each water supply. Of the 3,697 subjects who competed the MMSE, 24.5% were
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defined as cognitively impaired. A mixed effects logistical regression was performed to
estimate the association between the exposure variables and cognitive impairment while
adjusting for age, sex, educational level, and occupation of the participants. Higher calcium
levels in drinking water appeared to have a protective effect for cognitive impairment; the OR
was 0.8 (p = 0.015, CI not provided) for a calcium concentration of 75 mg/L or greater compared
to less than 75mg/L. The association between aluminium levels and cognitive impairment was
not significant when pH was ignored. A weak interaction was detected between aluminium
and pH levels. The association between aluminium and cognitive impairment was reported to
be positive up to a pH of 7.0, and negative above that pH level. For example an OR of 1.35
was calculated for a concentration of aluminium of 100 ug/L compared to 5 ug/L at a pH of
7.0, while an OR of 0.5 was obtained at the same concentration level with a pH of 8.5. The CIs
for these measures of association were not reported; thus the stability and significance of these
results is not known.
In a subsequent analysis, the effect of silica in water on cognitive impairment was assessed in
3,450 participants in 71 parishes (Jacqmin-Gadda et al., 1996). A weighted mean of the
measures obtained from two different surveys of each component of drinking water (pH, and
concentrations of aluminium, calcium, and fluorine) was computed for each of the 71 areas.
Three categories of silica levels were used (low, medium and high), defined by the first and
last quartiles of the distribution. The prevalence of cognitive impairment for each of the
categories was 24.0 (n=775), 21.8 (n=1,828), and 28.3% (n=847), respectively. In the
regression model, in which first quartiles of exposure for the different water components were
used as cut points, a significant relationship between silica, aluminium, and cognitive
impairment was detected. In this model, when the level of silica and the pH were both low,
subjects exposed to an aluminium concentration of 3.5 ug/L or more were more likely to have
cognitive impairment compared to subjects in the lowest quartile of aluminium exposure
(OR=3.94, 95% CI: 1.39-11.2). This CI is wide, indicating that the results were based on small
numbers. ORs were calculated for eight different categories defined by the distributions of
aluminium, pH, and silica. Low aluminium, high silica, and high pH was chosen as the
reference category. An OR for cognitive impairment of 1.30 (95% CI: 0.75-2.24) was obtained
for water districts with high aluminium, but low silica levels, and low pH. A lower OR (0.74,
95% CI: 0.53-1.02) was obtained for subjects living in areas with high aluminium levels, low
pH, and high silica. These results support the hypothesis of a protective effect of silica in the
development of cognitive impairment.
Forster et al. (1995) conducted a case control study to investigate the relationship between
presenile dementia of the Alzheimer type (PDAT), family history, medical history, cigarette
smoking, and exposure to aluminium. Cases had been diagnosed between 1981 and 1989 as
having dementia before the age of 65 years, and were referred for specialist hospital services.
Subjects were required to meet the DSM-III-R criteria for dementia (American Psychiatric
Association, 1987), and the NINCDS-ADRDA criteria for AD (McKhann et al., 1984).
Subjects completed the MMSE (Folstein et al., 1975); those scoring from 17 to 24 underwent
another test (Geriatric Mental State Examination) to exclude any possible non-organic
psychiatric conditions. Each case was paired with a control randomly selected from the
population matched for age and sex. Informants of both cases and controls answered
questionnaires designed to obtain information on general health, demographic factors, possible
risk factors for AD, and family history of dementia. Historical data on aluminium levels in the
drinking water were related to the place of residence at which the individual had lived the
longest in the 10 years before the onset of symptoms of dementia. A total of 109 case-control
pairs, for which there were available data on aluminium concentrations, were included in the
analysis. The levels of aluminium in drinking water examined were <50 ug/L, 50-99 ug/L,
100-149 ug/L and 150 ug/L and over. No significant relationship was detected between the
mean aluminium concentration in drinking water at place of residence and the onset of
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dementia. This study did not examine the effects of other water constituents, such as silica,
fluoride, calcium or pH on the risk estimate.
Silicon-containing compounds in drinking water are thought to reduce the bioavailability of
aluminium, and is therefore considered to be protective against the development of AD. Taylor
et al. (1995) conducted an analysis of the same 109 case-control pairs included in the study
described above in order to determine if an inverse relationship exists between dissolved silicon
and aluminium in the drinking water. Water samples were collected from the tap water in the
residences of the 109 cases and 109 controls. Historical data of the silicon levels in water were
not available; therefore the case-control pairs were compared based on the current levels of
silicon at their residences. An inverse relationship between aluminium and dissolved silicon
was found. Silicon values at the residences of the cases were not significantly different than in
the controls (p = 0.65). The aluminium levels in the current water samples were also not
significantly different (p = 0.60). Using a threshold value for soluble silicon of 3 mg/L or above,
the OR in the case-control pairs was calculated as 0.8 (95% CI: 0.34-1.83). It must be
considered that the potential protective effect of silicon was measured after the onset of
presenile dementia of the Alzheimer=s type, however, silicon levels in the same water source
are thought to be relatively stable over time.
McLachlan et al. (1996) found an elevated risk of AD where levels of aluminium in drinking
water were ≥100 μg/L, based on 296 neuropathologically confirmed cases of AD and two series
of controls (n = 125 with no pathology and 170 with other neurodegenerative diseases).
Municipal drinking water data were obtained from the Ontario Ministry of Environment and
Energy=s Drinking Water Surveillance Program. Residential histories were collected from
next of kin; one analysis was based on drinking water at the last place of residence before death
(OR = 1.7, p < 0.05), and a second analysis, on the weighted residential histories (OR = 2.5,
p < 0.05). This is the only study based on neuropathologically confirmed cases of AD, which
is a strength. However, there were two weaknesses: only aluminium levels (not fluoride, silica
or pH) in drinking water were obtained, and the analysis did not control for possible
confounders or effect modifiers.
Sohn et al. (1996) conducted a cross-sectional study to investigate the relationship between
aluminium, calcium and magnesium and cognitive impairment in a sample of elderly
individuals living in rural communities in Korea. Two hundred and forty-nine men and 309
women aged 60 years and older participated in this study. The MMSE was used to measure
cognitive status. The geographic region from which the participants were selected was divided
into 66 areas, and the levels of aluminium, calcium, and magnesium were measured in two
separate surveys. The mean concentrations of the 3 drinking water components, as well as the
pH, were determined for each area. No significant correlation was detected between cognitive
impairment and the concentrations of the drinking water components or the pH level of the
drinking water. The cross-sectional design of this study is a weakness; no information was
available on residential history or change in the levels of the drinking water components over
time.
Martyn et al. (1997) conducted a case-control study to investigate the effects of aluminium and
silicon in drinking water on the risk of AD. Subjects were identified from the computerized
tomographic records of eight neuroradiology centres in England and Wales. Male patients with
a possible diagnosis of dementia or primary brain cancer were selected from the files. For each
possible case of dementia the next male patient in the file who was born during the same 5-
year period and had a diagnosis other than dementia (brain tumour, epilepsy, or chronic
disabling disease) was also selected. One hundred and six men with AD were identified for
inclusion in the study. Ninety-nine men with other dementing illnesses, 226 men with brain
cancer, and 441 men with other diseases of the nervous system were included in the analysis
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as controls. Subjects or informants completed a questionnaire which was designed to obtain
information regarding residential history. The response rate was 58% due to failure to obtain
permission from the general practitioner to approach the patient or next of kin (303 subjects),
difficulty in tracing the patient or next of kin (112 subjects), and refusal of the patient or next
of kin (209 subjects). The average aluminium and silica concentration for each address and
period of residence was calculated by obtaining data from the water plants supplying each area.
Aluminium levels in the water supplies ranged from 0.004 to 0.481 mg/L, with a median level
of 0.043 mg/L. Cases were compared to each of the control groups to examine the relationship
between aluminium and silica levels and AD. The risk of AD did not appear to increase with
increasing aluminium concentration. The average levels of silicon in the water ranged from
1.2 to 23.0 mg/L and were inversely related to the average aluminium concentrations. No
significant association for AD risk was found for subjects living in areas where the
concentration of silica was above 6 mg/L as compared to men exposed to silica concentrations
below this threshold. In summary, this study did not find an association between the risk of
AD and aluminium in drinking water (at an average concentration of up to about 0.2 mg/L),
and the concentration of silica in drinking water did not appear to exert a protective effect. The
low response rate was a weakness of the study; its effect on the results is unknown.
Gauthier et al. (2000) conducted a study (68 cases, 68 matched controls) in the Saguenay-Lac-
Saint-Jean region of Quebec to examine aluminium speciation in drinking water and genetic
characteristics in relation to AD. AD diagnosis was established through a three shage process.
Subjects were first screened for cognitive impairment, those screening positive underwent a
standardized clinical interview by a nurse, and finally the diagnosis of dementia was established
according to DSM IV criteria by two external evaluators. Municipal water data collected in
1995-1996 was used to estimate long term exposure to aluminium species in the drinking water.
On average, the subjects had lived 44 years in the residence they occupied at the time of disease
onset. They found that only exposure to organic monomeric aluminium at the onset of disease
was associated with AD (OR = 2.678, 95% CI: 1.04-6.90) after adjusting for education, family
history of AD and the apoliprotein E gene (ApoE) ε4. They did not see any effect of silica or
fluoride, as has been hypothesized (Jacqmin-Gadda et al., 1996; Kraus & Forbes, 1992; Taylor
et al., 1995).
Rondeau et al. (2000) conducted an analysis of the Paquid data to examine the effect of
aluminium and silica in drinking water on the risk of dementia and AD. The analysis included
2,698 participants aged 65 and over living in the community in 75 civil parishes in Gironde
and Dordogne in south-western France, for whom drinking water data and covariates were
available. The mean length of residence in the same parish was 41 years. Over an 8-year follow-
up, 253 incident cases of dementia, including 182 with AD, were identified. The effect of
consumption of bottled water was examined separately (data collected at the 3-year follow-
up). The RR of dementia adjusted for age, gender, educational level, place of residence and
wine consumption was 1.99 (95% CI: 1.20 - 3.26) for those exposed to an aluminium
concentration >0.1 mg/L. For AD the adjusted RR was 2.14 (95% CI: 1.21 - 3.80). There was
an inverse association with silica (RR = 0.74, p = 0.021) (see also Effects on Humans, Effects
from Non-Occupational Exposure, Modifying Factors). There was no statistically significant
interaction between aluminium and silica concentrations or between aluminium and mineral
water consumption.
Overall, many of the studies of aluminium in drinking water and risk of cognitive impairment,
dementia and/or AD have had methodological weaknesses. Early studies were ecological,
taking into account only the level of cognitive impairment, dementia, or AD in relation to
aluminium in drinking water. Most of the case-control and cohort studies took few or no
possible confounders or effect modifiers into account in their analyses. The exception to this
is the analysis by Rondeau et al. (2000), which is by far the strongest methodologically of the
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epidemiological studies conducted to date. However, one limitation of this study is a lack of
an intermediate exposure category, and therefore the inability to examine the possibility of a
dose-response relationship.
Aluminium in antacids and antiperspirants: Graves et al. (1990) conducted a case-control
study to investigate the association between exposure to aluminium, from the lifetime use of
antiperspirants and antacids, and the risk of AD. Subjects diagnosed with AD were selected
from one of two clinics. Selection of cases was limited to those who were married at the time
of diagnosis since the spouse served as an informant. Friends of the case and/or informant were
selected as controls; when this was not possible, a non-blood relative of the case was identified.
The controls were within 10 years of age of the cases and did not suffer from memory loss.
Case and control informants were interviewed about the subjects’ antiperspirant/deodorant use
and antacid use. Subjects were defined as an antiperspirant/deodorant user if they were reported
to have used these products at least once a month for one year prior to the reference year.
Frequency, duration, and the name of the most common brands used were also obtained. A
subject was considered to have been exposed to antacids if he or she had used antacids daily
or almost daily for at least one year prior to the reference year. One hundred and thirty case-
control pairs were included in this analysis. The age-adjusted OR for use of aluminium-
containing antiperspirants vs. no use of antiperspirant was 1.7 (95% CI: 1.1-2.4). This
component of the analysis included only 63 matched pairs as a result of missing information.
There was a statistically significant dose-response relationship between the lifetime use of
aluminium-containing antiperspirants and the risk of AD, adjusted for age (p = 0.01). The age-
adjusted OR for antacid use vs. no use was 3.1 (95% CI: 1.3-7.5). A dose-response gradient
was found for any antacid use (p = 0.009), and the adjusted OR for the highest level of exposure
was 11.66 (95% CI: 1.28-106.4). However, no association was found when only aluminium-
containing antacids were considered (OR=0.8, 95% CI: 0.3-2.1). There are some
methodological issues which should be considered in interpreting the results of this study. The
necessary use of surrogate informants may have resulted in misclassification of exposure data
and a high frequency of missing information. Also the small numbers of subjects in the
exposure categories, especially in the subanalyses, may have led to unstable estimates of the
ORs.
Flaten et al. (1991) compared the rate of mortality from dementia (as an underlying or
contributory cause) of a cohort of 4,179 patients who had surgery for gastro-duodenal ulcer
disease between 1911 and 1987 to national rates. It was assumed that the majority of the patients
operated on after 1963 were heavy users of antacids containing aluminium, although no precise
exposure information was available. No statistically significant results were seen. The SMR
for dementia was 1.10 (95% CI: 0.85 – 1.40, n=64) for all patients, and for those operated on
in the period 1967-78 it was 1.25 (95% CI: 0.66 – 2.13, n=13). Limitations of the study include
misclassification both in diagnosis and exposure; in addition, the observation period may have
been too short to detect an effect. Thus the possibility of an effect cannot be ruled out based
on this study.
The Canadian Study of Health and Aging included a prospective analysis of risk factors for
AD (Lindsay et al., 2002). The baseline population of this study was comprised of 6,434
subjects aged 65 years or older in 1991. Of these, 4,615 subjects participated in the follow-up
study in 1996. The analysis included 194 AD cases, and 3,894 cognitively normal controls.
Detailed information regarding a variety of risk factors was obtained through a self-
administered questionnaire completed by the subjects at baseline. No association was found
between the regular use of antiperspirants OR=0.77 (95% CI: 0.55-1.08), or antacid use
OR=0.91 (95% CI: 0.65-1.26) and the risk of AD.
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In addition to investigating the relationship between PDAT and exposure to aluminium in
drinking water, Forster et al. (1995) also investigated the effects of aluminium exposure from
medicinal sources. In an analysis of 109 case-control pairs matched for age and sex, there was
no significant association between use of antacids for 6 months or more and PDAT (OR=1.6,
95% CI: 0.77-3.51).
Exley (1998) suggested that little is known about absorption of aluminium from antiperspirants,
and that more study is required. There have been no epidemiological studies showing an
association between antacid consumption and AD (Doll, 1993).
Aluminium in food: Although the main source of exposure to aluminium for most people
probably is food, it is believed that very little is absorbed (Marcus et al., 1992) (see also
Toxicokinetics, Absorption, Studies in Humans, Oral Administration). There have only been a
few epidemiological studies of the effects of aluminium in food in the general population. A
small study (23 cases, 23 matched controls) reported positive results (Rogers & Simon,
1999). While they reported on some aspects of medical history, there is no indication that they
considered possible differences between cases and controls in renal function or vitamin
deficiencies relevant to cognitive decline. A comprehensive review of the role of diet in
cognitive decline (Solfrizzi et al., 2003) referred to the possibility of a link between aluminium
in the diet and AD as “controversial” (see Effects on Humans, Subpopulations at Special
Risk).
Aluminium in vaccines: Verreault et al. (2001) examined the association between past
exposure to conventional vaccines and the risk of AD in order to determine if changes to the
immune system could be a factor in the development of this condition. The study population
in this investigation consisted of subjects 65 years of age or older who participated in the
Canadian Study of Health and Aging, which is a prospective cohort study of dementia. Subjects
were screened for dementia at baseline, and cognitively normal subjects completed a risk factor
questionnaire which included information about exposure to vaccines. Respondents were asked
whether they had ever received vaccinations for tetanus, diphtheria, poliomyelitis, or
influeneza. Subjects were screened again for dementia 5 years later. Multivariate logistic
regression models were used to determine the association between vaccine exposure and the
risk of AD, and to adjust for a variety of other suspected risk factors. One hundred and eighty
three subjects, with information about past exposure to vaccines, were diagnosed with probable
or possible AD during the 5 year follow up period; 3,682 subjects remained cognitively normal
at follow-up. A statistically significant lower risk of AD was demonstrated for subjects who
reported at least one vaccination against diptheria/tetanus (OR=0.40, 95% CI: 0.25-0.65), and
at least one vaccination against poliomyelitis (OR=0.54, 95% CI: 0.30-0.97). Exposure to
influenza vaccine was also associated with a lower risk of AD but did not reach statistical
significance (OR= 0.81, 95% CI: 0.55-1.19). These results suggest that past exposure to
vaccines may protect against the development of AD.
Irritation—Corundum, one of the mineral forms of aluminium oxide, a hexagonally, very
closely packed form, is extensively used as an abrasive and polisher in sandpaper, emery, etc.
This can obviously cause abrasion of the skin, eyes or any other tissue against which it is
rubbed.
Oral exposure: Oral exposure to aluminium hydroxide gel has been implicated as a
contributing factor in porphyria cutanea tarda, a vesiculobullous disorder, seen in chronic renal
failure patients on haemodialysis (Fisher, 1984). This suggestion has been supported by the
clinical observations of Gafter et al. (1996), King et al. (1983), McColl et al. (1986), Peserico
(1979), Suga & Ikezawa (1995) but not by the findings of Tercedor et al. (1997).
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The accidental introduction of 20 tons of concentrated aluminium sulphate into a treated water
reservoir in the Camelford area of Cornwall, England in 1988 resulted in a finished water
serving ~ 20,000 people that had low pH and high aluminium concentrations for 3 days. Some
people experienced GI disturbances and oral ulceration. In addition to the low pH and elevated
aluminium in the water, copper, zinc and lead, that were dissolved from domestic plumbing,
were also elevated, making it difficult to attribute the irritation solely to aluminium (Coggon,
1991; Altmann, 1999).
Dermal application: Contact sensitivity to aluminium is very rare. Sensitization has been
reported during continuous application of aluminium-containing antiperspirants, after injection
of aluminium-adjuvant containing vaccines and pollen extracts, topical aluminium application,
and occupational exposure to aluminium dust and filings (see below).
Two types of reaction patterns have been described: recurrent eczema from topical application
of antiperspirants, and persistent granuloma at the injection site. Sensitization is more common
after injection of aluminium-adsorbed vaccines and hyposensitization extracts than from
topical application of antiperspirants and medications (Peters et al., 1998). Fifty reported cases
of aluminium contact sensitivity were reviewed by Böhler-Sommeregger & Lindemayr
(1986), showing that granulomas, eczema and nodules had been reported in 26, 15 and 5 of
the cases, respectively. Only one case that was positive to follow-up tests with aluminium was
discovered among 853 people who were working in a hard metal manufacturing plant (Fischer
& Rystedt, 1982). During the 4.5 years of seeing patients, Veien et al. (1986) encountered 13
children and 1 adult who had positive aluminium patch tests. Moderate positive aluminium
patch test reactions were seen in 4 of 1922, primarily adult, patients (Hemmer et al., 1996).
Other studies found no positive cases among 25 children with ectopic dermatitis and 251 adults
with suspected contact dermatitis (Frost et al., 1985).
Aluminium applied as a nearly saturated solution of aluminium chloride in absolute alcohol to
the axillary region to treat hyperhidrosis produced irritation and soreness, particularly at the
beginning of a regimen of nightly applications for 1 week, alternate nightly applications for 1
week, then twice weekly for 2 weeks (Ellis & Scurr, 1979). Similarly, daily application of 20%
aluminium chloride hexahydrate in ethanol to the palm produced skin irritation in 4 of 12
patients, which disappeared in 3 of these patients after 1 week (Goh, 1990).
Contact sensitivity has been attributed to the use of aluminium-containing antiperspirants. A
patient who experienced itchy axillary dermatitis while using an antiperspirant demonstrated
contact sensitivity to the aluminium disc used in routine patch testing (Finn Chamber®). He
showed a 2+ positive reaction to 2 and 5% aluminium chloride, a positive response to
intracutaneous 0.1% aluminium hydroxide, but not a positive reaction to aluminium foil, or to
1% aluminium acetoacetate (Fischer & Rystedt, 1982). Positive patch tests to aluminium were
seen in two adults who had used topical aluminium acetotartrate (Meding et al., 1984). Positive
reactions were seen to aluminium metal and aluminium chloride, but not to aluminium
subacetate (Kotovirta et al., 1984). Two brothers who had suffered from a scaling eruption on
their faces and limbs since infancy similarly showed a reaction to the aluminium Finn Chamber
and a subsequent aluminium chloride patch test (Dwyer & Kerr, 1993). Cox et al. (1988b)
reported four cases of sensitivity to the aluminium Finn Chamber, and one to aluminium salts
as well, which they believe was induced by diphtheria toxoid, TT and pertussis (DTP)
vaccination. Similar cases of aluminium contact sensitivity demonstrated by positive reactions
to aluminium chambers and aluminium salts were reported in children and adults by (Akyol
et al., 2004; Bajaj et al., 1997; Castelain et al., 1988; Clemmensen & Knudsen, 1980; Cosnes
et al., 1990; Dwyer & Kerr, 1993; Fawcett et al., 1985; Fischer & Rystedt, 1982; Hyry & Hook-
Nikanne, 2004; Kalveram et al., 1980; Kotovirta et al., 1984; O’Driscoll et al., 1991; Stables
et al., 1996; Tosti et al., 1990; Veien et al., 1986). Hemmer et al. (1996) further described the
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use of patch testing with aluminium chloride, aluminium hydroxide and potassium aluminium
sulphate in patients suspected of having a cutaneous hypersensitivity to aluminium chloride
hexahydrate. An acutely inflamed axillary mass of ~ 1 year duration developed following use
of an aluminium zirconium tetrachloridehydrex glycerine antiperspirant for several years. The
authors attributed this foreign body-hypersensitivity reaction to the aluminium zirconium
complex (Skelton et al., 1993).
Not all cases of hypersensitivity to aluminium result in clinical problems. In presenting a case
of aluminium sensitivity revealed by the use of the aluminium-containing Finn Chambers,
Kotovirta et al. (1984) suggested that a patient’s sensitivity to aluminium, as well as those in
some previous cases (Meding et al., 1984), had no clinical relevance, and was only discovered
as an accidental finding of the testing procedure.
Use of 5% aluminium acetate ear drops resulted in a 2 year history of eczema (contact
sensitivity) to aluminium in a 9 year old which resolved when use of the eardrops was
discontinued (O’Driscoll et al., 1991). The aluminium allergy was believed to have been caused
by DTP vaccination. Similarly, three 2 to 3 year olds experienced pruritic infiltrates in response
to toothpaste containing aluminium oxide that resolved 4 to 6 weeks after discontinuation of
use of this toothpaste. Two of the 3 showed return of symptoms when challenged with the
toothpaste. All showed positive patch tests to aluminium (Veien et al., 1993).
Application of lotions containing 1 or 3% aluminium starch octenylsuccinate resulted in
“slight” irritation potential and no evidence for potential to induce allergic sensitization (Nair
& Yamarik, 2002).
Irritation after injection of aluminium-adsorbed proteins (vaccines and hyposensitization
regimens): Aluminium adjuvants are used in vaccines which are given i.m. and s.c., and in
allergen immunotherapy injections which are given s.c. Reports of a workshop on this topic
appear in a 2002 issue of Vaccine (20:S1-S64). Aluminium hydroxide and/or phosphate is used
as an adjuvant in all DTP (including acellular pertussis; DTaP), some Haemophilus influenza
type B, and in most hepatitis A and B, meningococcal, pneumococcal, tick-borne encephalitis,
some rabies, and anthrax vaccines. On the other hand, inactivated poliovirus vaccines, measles,
mumps, rubella, some rabies, yellow fever, Japanese encephalitis, adenovirus, typhoid, plague,
cholera, bacillus calmette-guerin (BCG), meningococcal, and some Haemophilus influenza
type B do not contain aluminium (Baylor et al., 2002; Bergfors, 2005; Eickhoff & Myers,
2002). Erythema is occasionally associated with aluminium adsorbed vaccines (Gupta,
1998). Booster injections containing aluminium-adsorbed vaccines produced more local
reactions, including redness, swelling and itching, in children who had primary immunization
with aluminium-adsorbed vaccine than in children who received un-adsorbed primary vaccines
(Gupta, 1998). Immediate, inflammatory reactions that produce palpable s.c. nodules are
commonly seen with subsequent injections in hyposensitized patients; these reactions usually
heal without treatment after a few weeks (Garcia-Patos et al., 1995; Lopez et al., 1994). About
20 to 30% of patients develop s.c. nodules at the injection site after the acute local reaction
dissipates, whereas the nodules persist in ~ 4% of patients (Lopez et al., 1994). This occurs
more commonly after s.c. than i.m. injection (Hutteroth & Quast, 1990). The most common
reactions are a necrotizing granulamatoma with associated fibrosis and chronic inflammation,
seen in ~ 60% of cases, and a mixed inflammation with fibrous and histocytic or lymphocytic
proliferation, seen in ~ 40% of cases (Miliauskas et al., 1993).
Aluminium adjuvants occasionally produce sterile abscesses, s.c. nodules and dermal
granulomatous inflammation at the injection site (Böhler-Sommeregger & Lindemayr, 1986).
The incidence of transient nodules lasting weeks has been estimated to be 5 to 10% (Fiejka &
Aleksandrowicz, 1993), 2 to 19% (Orfan et al., 1995) and 20 to 30% (Vogelbruch et al.,
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2000) whereas the incidence of persistent nodules that may last for years is less common
(estimated to be 0.1% or lower (Bernier et al., 1981) and 0.5 to 6% (Garcia-Patos et al.,
1995)).
Erythema and swelling were seen in the first 24 to 48 hr after s.c. injection of vaccine containing
aluminium phosphate at a concentration of 10 mg/mL but not in those who received the vaccine
without aluminium. Induration at the injection site was seen in 33% of those receiving the
aluminium-containing vaccine vs. 10 to 14% of those receiving vaccine without aluminium
(Medical Research Council, 1955). Voss & Tolki (1960) reported a granuloma removed ~ 1
year after vaccination with aluminium oxide adsorbed vaccine showed the presence of
aluminium in the granuloma, using a stain. Orell (1962) reported 15 s.c. lesions after influenza
vaccination. By injecting adult guinea pigs with each component of the vaccine he found that
fine aluminium oxide, as used in the vaccine, produced a granulomatous nodule, whereas
injection of commercial aluminium oxide did not, leading him to conclude that particle size
was important. Persisting nodules, histologically characterized as a nonspecific chronic
perivascular inflammatory infiltrate and degenerated collagen, were seen at the site of tetanus
vaccination, and attributed to the aluminium in the vaccine (Lenz, 1966). Deep s.c.
immunization of children with triple vaccine containing aluminium hydroxide at a
concentration of 2.5 mg/0.5 mL resulted in s.c. nodules in 17 to 21% of the children, and 1
sterile abscess; none occurred in the absence of aluminium (Butler et al., 1969). Erdohazi &
Newman (1971) reported 2 cases of post-immunization granuloma that persisted for months
after injection of aluminium hydroxide vaccine. Aluminium was identified in the lump by stain
and x-ray crystallography in the one case in which it was looked for. Three children developed
painful s.c. nodules 1 month to 2 years after injection of aluminium hydroxide-adsorbed DTP
vaccine (Slater et al., 1982). Another case of aluminium hydroxide-induced granuloma that
persisted for 8 years was reported (Savage, 1973). A foreign body granuloma, which developed
in the injection area of a 16-year old after hyposensitization therapy, was found to contain
aluminium hydroxide (Linse et al., 1979).
Aluminium was found in histiocytes in a granulomatous inflammatory infiltrate of an 8-month
old child. The lesion was seen 2 weeks after i.m. vaccine injection in rats (Mrak, 1982). Three
children developed itching, eczema and circumscribed hypertrichosis over nodules following
immunization with aluminium hydroxide-adsorbed vaccines (Pembroke & Marten, 1979).
Cases in which two similar patients also developed hyperpigmentation and itching, that lasted
for 2 years in one, were described (Orlans & Verbov, 1982). Standard patch testing of a patient
who developed eczema during hyposensitization injections with an aluminium-adsorbed
allergen, and who developed a contact dermatitis to aluminium-containing antiperspirants,
revealed positive reactions to the aluminium Finn Chamber discs used for testing. The patch
tests were negative in 53 controls and 9 patients who had received hyposensitization injections
with aluminium-precipitated allergens. The patient showed a positive response to patch tests
with aluminium salts in plastic disks and prick and intradermal testing with aluminium
hydroxide. The eczema disappeared when hyposensitization was discontinued (Clemmensen
& Knudsen, 1980). Three more cases of injection site granulomas associated with pruritus or
tenderness which developed 2 to 9 months after injection of aluminium-adsorbed vaccine were
reported by Fawcett & Smith (1984) who demonstrated the presence of aluminium in the
nodules by stain. In another case, a positive test to the Finn Chambers and aluminium chloride
hexahydrate and a moderate response to aluminium acetate and aluminium powder were shown
(Fawcett et al., 1985). These authors produced a similar response in rats by injecting
aluminium-adsorbed vaccine. A case of a patient with a positive patch test reaction to
aluminium hydroxide who had been sensitized by aluminium-adsorbed vaccine was reported
(Böhler-Sommeregger & Lindemayr, 1986). Thirteen children and one adult, who had received
hyposensitization therapy with aluminium-bound pollen extracts or childhood immunizations
with aluminium-bound vaccine and who had pruritic, excoriated papules, had positive patch
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tests to 2% aluminium chloride. One child developed axillary eczema after antiperspirant use
(Veien et al., 1986). Two additional cases of aluminium sensitivity were seen in adults which
was attributed to inoculation of aluminium-precipitated pollen or dust extracts for
hyposensitization (Castelain et al., 1988). Persistent nodular lesions were noted by Fernandez
et al. (1990) and Hutteroth & Quast (1990) who described a case of palpable, ~ 3 cm diameter,
itchy nodules 3 years after inoculation. Cosnes et al. (1990) reported 2 adult cases of pruritic
nodules and contact allergy to aluminium attributed to aluminium-adsorbed vaccine. A follow-
up study of 202 children who received hyposensitization with aluminium-containing allergens
showed that 13 had severe itching for 1 to 3 years, and persisting, s.c. nodules. Excised nodules
from 6 showed infiltration with lymphocytes, macrophages, plasma cells, mast cells and some
eosinophils. Aluminium was found in nodules from 5 children. Four showed positive patch
tests to aluminium (Frost et al., 1985). Twenty one children had cutaneous granulomas
following aluminium hydroxide-vaccine immunization and positive tests to aluminium
chloride and/or an aluminium Finn Chamber. Clearing of symptoms was experienced by 5,
improvement by 11 and no change by 5 over a period of 1 to 8 years (Kaaber et al., 1992). Two
of 4 children patch-tested again 4 years later showed negative responses.
All children who were referred to 2 private dermatological practices over 6 years and who had
pruritus and s.c. infiltrates in the areas of immunization with an aluminium hydroxide-
containing DTP vaccine were patch tested with an aluminium Finn Chamber or with 2%
aqueous aluminium chloride. Contact allergy to aluminium was demonstrated in 32 children.
Patch testing with 2% aluminium chloride occluded with an aluminium Finn Chamber proved
to be the most sensitive (Nielsen et al., 1992). Aluminium was demonstrated by x-ray
microanalysis in necrotic foci of 4 patients who developed s.c. nodules 4 to 22 months after
vaccine injection (Miliauskas et al., 1993), of 2 patients who developed localized nodular
reactions at the site of prior TT injections (Cominos et al., 1993), and of 3 children who
developed s.c. nodules with necrotizing granulomatous reactions at the site of DTPT (DTP +
poliovirus) injections (Bordet et al., 2001). Similarly it was demonstrated in the macrophages
of itching nodules that developed following immunization with aluminium hydroxide-
adsorbed vaccine in 2 patients (Nagore et al., 2001). Garcia-Patos et al. (1995) concluded that
60 to 80% of patients with delayed hypersensitivity reaction to aluminium show a positive
response to patch tests or aluminium Finn Chambers. Positive responses to patch tests with
aluminium salts in plastic van der Bend chambers were demonstrated in 4 patients who
developed pruritic, painful nodules and papules after vaccination (Skowron et al., 1998). Fiejka
& Aleksandrowicz (1993) suggested that nodules that persist > 6 weeks after injection of
aluminium-adsorbed proteins may indicate aluminium hypersensitivity. The prevalence of
aluminium sensitivity was studied in 40 patients who had received aluminium-containing
antigens, 20 of whom had persistent s.c. nodules of > 2 months duration, and in 20 controls.
The only positive aluminium chloride patch tests were in 4 patients who had persistent nodules
(Lopez et al., 1994). Ten patients who developed persistent s.c. nodules 1 month to 6.5 years
following immunotherapy were studied. Patch tests with 2% aluminium chloride were positive
in 5. Histopathological examination revealed 2 different patterns. Some lesions of < 9 months
duration showed a pure foreign body histiocytic reaction. Other lesions showed a delayed
hypersensitivity granulomatous reaction in association with an histiocytic foreign body
response, suggesting that 2 characteristic histopathological patterns may be produced by
injection of aluminium-adsorbed proteins (Garcia-Patos et al. 1995). A case was reported of
apparently permanent local fibrosis and disfigurement due to alum-precipitated
hyposensitization injections in a woman who showed a positive patch test to 2% aluminium
chloride and itchy eczematous axillary rash to aluminium-containing antiperspirants (Orfan et
al., 1995). Persistent intra-dermal granulomas developed after inappropriate intradermal
injections of aluminium-containing hyposensitization solutions (Vogelbruch et al., 2000). An
unexpectedly high frequency of persistent itching nodules at the vaccination site was observed
from aluminium hydroxide-adsorbed DTP vaccines, leading to a longitudinal observational
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study of the incidence of aluminium sensitization (Bergfors et al., 2003). The authors estimated
that only ~ 100 cases had been described in the previous 40 years. Itching nodules were found
in 645 children following 76,000 s.c. and i.m. vaccinations (0.8%); these appeared in 28, 117,
494, 1 and 6 children after the 1st, 2nd and 3rd, 4th and 6th vaccination, respectively. By 2005,
740 cases had been observed (Bergfors, 2005). The onset averaged 3 months, ranging from 2
weeks to 5 years. Hypertrichosis, hyperpigmentation and/or local eczematous reactions were
seen in 32%. Although the symptoms decreased and the nodules resolved over time, 75% of
the children had symptoms after a mean of 4 years.
Similarly, large injection site reactions were more frequent after the fifth DTaP immunization
than after the previous four (Pichichero et al., 2000). Seventy-seven per cent of the children
with itching nodules had positive patch tests to 2% aluminium chloride using a plastic IQ
chamber and the metallic aluminium of the aluminium Finn Chamber as compared with 8%
of their symptom-less siblings (Bergfors et al., 2003), consistent with the conclusion of Garcia-
Patos et al. (1995) that a delayed hypersensitivity granulomatous reaction occurs in 0.5 to 6%
of cases. In contrast to the Swedish experience described by Bergfors et al. (2003), itching
nodules were reported in only 30 children in Denmark during 1997 to 2003 when 3,600,000
doses of vaccines containing the same aluminium hydroxide-adsorbant were administered
(Thierry-Carstensen & Stellfeld, 2004). It was suggested that the use of i.m. injections in
Denmark, which are claimed to produce this reaction less frequently than s.c., may explain the
difference (Thierry-Carstensen & Stellfeld, 2004) but the Swedish group doubts this (Trollfors
et al., 2005), leaving the cause of this difference unresolved.
Epicutaneous tests demonstrated hypersensitivity to aluminium in 77% (393 of 512) of children
who had persistent itching s.c. nodules at the injection site of the vaccine, aluminium
hydroxide-adsorbed DTP (Bergfors, 2005). The aluminium hypersensitivity was manifest in
local dermatitis after application of aluminium-containing antiperspirants and sun protection
lotions. Eight percent (17 of 221) of children who had received the same vaccinations but who
did not experience any local reaction also demonstrated positive aluminium tests, whereas a
positive reaction was not seen in any of 54 children who earlier had received an aluminium
phosphate-adsorbed vaccine. In contrast to the experience with aluminium hydroxide-adsorbed
vaccines, no cases of persistent nodules were reported among 1.7 million Swedish children
who received aluminium phosphate-adsorbed DT vaccine from 1979 to 1996 (Bergfors,
2005).
A follow-up study was conducted of 22,365 pupils who received i.m. aluminium hydroxide-
or aluminium phosphate-adsorbed diphtheria and tetanus vaccines. The results revealed 405
reports of itching and nodules from the parents. Seventy-five reports were positive for both
itching and nodules, sixty-five had immediate symptoms with a duration of < 3-4 weeks, and
ten had a persistent itching nodule persisting for > 2 months involving both aluminium
adjuvants (Netterlid et al., 2004).
The above reviewed reports suggest persistent adverse effects associated with aluminium
adjuvants are much more frequent following use of aluminium hydroxide than aluminium
phosphate adjuvants. The s.c. injection site seems to cause these problems more frequently
than that of i.m. injection.
An apparently new medical condition, termed MMF, characterized by myalgia, arthralgia,
muscle weakness, asthenia and fever has been described (Gherardi & Cherin, 1998). A study
of 50 patients revealed all had received aluminium hydroxide-containing vaccines, 3 to 96
(median 36) months prior to muscle biopsy with an onset of mylagia 11 months (median) after
vaccine injection. Muscle biopsy showed macrophage infiltration. X-ray microanalysis of
inclusions showed aluminium in each of the 8 cases tested; nuclear microanalysis showed
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elevated levels of aluminium in macrophages and EAAS showed elevated aluminium levels.
A similar syndrome was produced in rats after aluminium hydroxide-containing vaccine
injection (Gherardi et al., 2001). Although aluminium can persist after i.m. injection as a
vaccine adjuvant, there does not appear to be strong evidence that it causes a diffuse
inflammatory muscle disease (Siegrist, 2005).
The only vaccine licensed in the U.S. containing aluminium hydroxide that is administered
s.c., rather than i.m., is anthrax vaccine, adsorbed. However, when given i.m. it produced less
erythema and induration than when injected s.c. (Pittman, 2002).
It has been suggested that subsequent injection of aluminium-containing vaccine in a patient
who developed an aluminium-induced granuloma from previous injection runs the risk of a
similar outcome (Hutteroth & Quast, 1990). This risk needs to be weighed against the benefit
to be derived from the subsequent injection.
Microscopic examination of 4 cases of aluminium-induced injection site reactions suggested
manifestations in addition to the commonly seen histiocyte sheets and necrotizing
granulomatous reaction with associated fibrosis and chronic inflammation or mixed
inflammatory reaction with fibrosis and histiocyte or lymphocyte proliferation (Culora et al.,
1996).
In Denmark, vaccinations are sometimes given into the upper part of the breast region because
the s.c. tissue there is thought to reduce the discomfort of the injection. Twenty-two cases of
vaccination granulomas in the breast region caused by injection of aluminium-adsorbed
vaccines have been described (Al-Suliman et al., 1999; Nielsen et al., 1991).
A tattoo resulted in a delayed, localized, intermittently pruritic granuloma that developed 4
weeks later. It was shown to contain aluminium and titanium particles but no other inorganics
(McFadden et al., 1989). The patient did not show a positive response to epicutaneous testing
with aluminium Finn Chambers and patch tests with aluminium chlorhydrate, aluminium
chloride or aluminium sulphate but did show an erythematous nodular reaction 2 weeks after
intradermal injection of a 10% aluminium chloride suspension. Schwarze et al. (2000) reported
a case in which a woman developed erythematosquamous lesions that appeared 6 days after
receiving blepharopigmentation (tattooing to create a permanent line along the eyelid margin)
with an aluminium silicate compound. This delayed hypersensitivity granulomatous reaction
was attributed to the aluminium salt.
The mechanism of aluminium adjuvant-induced nodules has been thought to be due to a type-
I immediate hypersensitivity reaction or a specific type IV cell-mediated delayed
hypersensitivity response to aluminium (Frost et al., 1985; Garcia-Patos et al., 1995; Lopez et
al., 1994; Orfan et al., 1995) and to a foreign-body reaction to aluminium (Garcia-Patos et al.,
1995; Turk & Parker, 1977). Aluminium adjuvants attract eosinophils to the injection site
(Walls, 1977) and may induce IgE production (Nagel et al., 1977). As noted in Effects on
Laboratory Mammals and In Vitro Test Systems, Irritation, Injection above, the aluminium-
adsorbed protein may increase IgE production. IgE antibodies were higher in adults who
received aluminium hydroxide-adsorbed TT than in those who received the plain TT (Cogne
et al., 1985). Following primary immunization with aluminium-adsorbed pertussis toxin, the
specific IgE response, and local side effects, were greater in children who received aluminium-
adsorbed than those who received non-aluminium-adsorbed booster immunization (Odelram
et al., 1994). IgE responses, and local side effects, increased much more in children given a
booster who had received primary vaccine containing aluminium-phosphate-adsorbed
diphtheria, tetanus and/or pertussis than in those whose primary vaccine was not aluminium-
adsorbed (Mark et al., 1995). An investigation of the in vitro effects of alum on peripheral
blood mononuclear cells from atopic human donors revealed that it down-regulates the
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allergen-driven Th2 cytokine response, providing more support for its use as an adjuvant in
allergen immunotherapy vaccines (Wilcock et al., 2004).
Contact hypersensitivity is initiated by activation of CD4+ T lymphocytes that are activated
by an antigen bound to a relevant major histocompatibility complex class II protein on the
surface of antigen-presenting cells. Metals, such as chromium, cobalt, nickel and platinum may
combine with serum proteins to act as haptens and become antigens (Park et al., 1996;
Sinigaglia, 1994). It does not appear that the ability of aluminium to similarly serve as a hapten
has been evaluated, nor has it been shown that there is a specific IgE antibody to aluminium
(Park et al., 1996). Park et al. (1996) suggested that aluminium-induced occupational
bronchoconstriction/asthma is mediated by a non-immunologic mechanism. Aluminium has
been shown to increase the delayed-type of hypersensitivity to an infection in mice, suggesting
it damages T system and B system-specific immunity (Simonyte et al., 2004).
Although the British Ministry of Health recommended aluminium-free vaccines in 1957, the
Committee on Control of Infectious Diseases of the American Academy of Pediatrics advised
in 1964 that alum-precipitated DTP or aluminium hydroxide- or aluminium phosphate-
adsorbed vaccines should be used (Baylor et al., 2002). Aluminium compounds are the only
adjuvants used in vaccines in the U.S. The U.S. Food and Drug Administration allows ≤0.85
mg Al/dose in vaccines if the level is assayed, ≤1.14 mg Al/dose if determined by calculation
based on the amount of the aluminium compound added, and ≤1.25 mg Al/dose in biological
products, the last to be consistent with WHO standards (Baylor et al., 2002). In the U.S.,
currently used vaccines that contain aluminium do so as aluminium hydroxide, aluminium
phosphate, or a combination of these. In spite of the above problems, it has been suggested that
the benefits and safety profile of aluminium salts as adjuvants in vaccines will result in their
continued use for some time (Baylor et al., 2002; Clements & Griffiths, 2002). Precipitation
of toxins and toxoids by alum (and cerium nitrate, zinc sulfate, calcium chloride dialyzed iron
and tungstic acid) was found to enhance their antigenic properties and reduce the rate of antigen
absorption and elimination in animals (Glenny et al., 1926; 1931). Addition of alum to
diphtheria toxoid increased the percentage of infants and children showing detectable antitoxin
(Volk & Bunney, 1942; Barr et al., 1952) and aluminium phosphate addition increased the
antitoxin titer to diphtheria and tetanus when given with DPT (Greenberg & Benoit, 1956).
However, some studies produced negative results (Barr et al., 1955; Feldman, 1957). The rate
of adverse reactions to aluminium in vaccines is very small (Clements & Griffiths, 2002).
Implantation exposure: Aluminium oxide ceramic implants did not produce any allergic skin
reactions (cutaneous hypersensitivity) in 250 patients (Thomas et al., 2003).
Effects on the endocrine system—PTH function may be affected by exposure to
aluminium which may, in turn, affect bone metabolism (see Effects on Humans, Effects from
Non-Occupational Exposure, Bone) (Cannata Andía, 2000). No epidemiological studies have
been published on this topic.
Immunotoxicity/immunosuppression—There is little information available regarding
the effects of aluminium exposure on immunological parameters in humans.
There is some evidence of a possible link between aluminium overload and
immunosuppression in renal transplant recipients (Davenport et al., 1989; Garrett, 1989;
Nordal et al., 1988c). Nordal et al. (1988c) followed 94 recipients of kidney allografts for 3
years. Subclinical aluminium toxicity was found in 66 of these patients. Factors potentially
influencing the rejection rate in these patients was analyzed by multivariate analysis. Only the
source of kidney (cadavers v.s. living donors) and aluminium accumulation were found to
influence the rejection rate (Nordal et al., 1988c). In a similar study, Davenport et al. (1989)
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followed 58 patients after successful renal allograft transplantation. The patients were divided
into two groups based on the number of rejection episodes following the transplant. The median
daily urinary excretion of aluminium was greater in the group with one or no rejection episodes
than in the group with two or more. These results suggest that aluminium accumulation in renal
transplant patients exerts an immunosuppressive effect.
Graske et al. (2000) conducted a small experimental study on volunteers to examine the effects
of oral aluminium exposure on the immune system. The study group was comprised of 18
healthy volunteers aged 28-57 years. The 18 subjects were randomly assigned into two groups.
Individuals in the treatment group (n=13) ingested 3 daily doses of 10 mL antacid mixture (Al
content 588 mg/10mL) for 6 weeks, subjects in the control group (n=5) did not ingest any
antacids. Blood samples were taken for analysis of lymphocyte subpopulations, nitrogen
induced lymphocyte proliferation, and in vitro production and circulating plasma concentration
of various immunoglobins. A slightly smaller primed cytotoxic T-cell population in the
exposed individuals was the only noted difference in the immune parameters investigated. CD8
+ cells are thought to play a role in the down-regulation of the immune response. In contrast
to the immunosuppressive effects of aluminium observed in renal transplant patients, these
finding suggest that aluminium exposure may have slight stimulatory effect on the immune
system in healthy subjects. This finding has not been confirmed in a larger study.
Renal—There is extensive literature on the effects of renal insufficiency and renal failure on
the absorption of aluminium (see Effects on Humans, Subpopulations at Special Risk,
Individuals with Impaired Renal Function), but no literature to suggest that aluminium
exposure causes renal damage.
Bone—Renal failure results in inability to eliminate aluminium, so that the absorbed
aluminium, or aluminium introduced directly into blood, e.g. during dialysis, cannot be
eliminated. Absorbtion of this aluminium by bones can result in bone disease (Cannata Andia,
1996; Cannata Andia, 2000; Jeffery et al., 1996). Cannata Andía (2000) described renal
osteodystrophy as representing a wide spectrum of bone derangements, ranging from high bone
turnover to low bone turnover, with two main forms: aluminium-induced and non-aluminium-
induced adynamic bone disease. Aluminium-induced osteomalacia involves low bone
turnover, possibly by indirectly inhibiting PTH function.
Jeffery et al. (1996) reviewed the systemic toxic effects of aluminium on bone in patients
receiving renal dialysis. They noted that some renal dialysis patients developed aluminium-
dependent bone disease, while others did not; the reason for this was not clear. They speculated
that it could have been due to differences in handling and accumulation of aluminium leading
to differences in the bone aluminium load, or to more complex interactions between aluminium
accumulation and factors such as the presence, absence, or degree of, hyperparathyroidism.
Recker et al. (1977) studied aluminium absorption in six subjects with normal renal function,
and examined aluminium content in bones from autopsies of both dialysis and non-dialysis
patients. They concluded that the gut barrier is permeable to heavy aluminium load and they
suggested that bone aluminium occurs in humans with normal renal function.
Eastwood et al. (1990) reported the cases of a 41 year-old woman and 49 year old man who
had acute symptoms of mouth and nasal ulcers following the Camelford contamination
incident. The water aluminium concentrations recorded at the time of the contamination event
ranged from 30 to 620 mg/L. These patients were examined approximately 7 months following
the incident and bone biopsies were obtained. Subjective and objective static and dynamic bone
measurements appeared to be within the normal range. Infrequent lines of positive staining for
aluminium by solochrome azurine were detected within the trabecular and cortical bone of
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these patients; however, in a quantitative analysis, aluminium could only be identified in a
single trabecula in one patient. Aluminium concentrations in the bone specimens were within
the normal range. The authors reported that the local areas of aluminium staining and the
incorporation of these lines into the lamellar structure indicated that these deposits were formed
by a single event of short duration. It was concluded: “..under certain conditions normal
individuals can absorb aluminium via the gut, and that such aluminium can be deposited in
bone.” This is a case report only, involving two patients and no controls; the findings may not
be generalizable. In addition, the amount of aluminium that these individuals were exposed to
during the period of contamination is unknown.
McMillan et al. (1993) presented follow up data on the two patients described previously by
Eastwood et al. one year after their initial bone biopsies. In addition, data from seven additional
individuals who underwent bone biopsies 12-17 months after the accident were presented.
These patients developed musculoskeletal symptoms as well as indications of impaired
memory following the contamination incident. In the two patients previously described, there
was no residual aluminium staining and all quantitative and qualitative measurements were
normal. Three of the new patients exhibited borderline osteopoenia, as detected by cancellous
bone measurements which were reported to be 2-3 standard deviations below that of a control
group. However, the control group was not described, and the data were not presented in the
article. The aluminium content of the patients was normal.
The elevated bone Al seen in premature infants who received Al-contaminated total parenteral
nutrition (Toxicokinetics, Distribution (Including Compartmentalization), Human Studies,
Tissue Aluminium Concentrations, Bone) has been implicated in a metabolic bone disease
characterized by pain and patchy osteomalacia and associated with reduced serum 1,25-
dihydroxyvitamin D, reduced or low-normal serum immunoreactive parathyroid hormone,
hypercalciuria, mild hyperphosphatemia, and mild hypercalcemia (Klein et al., 1982;
McCullough & Hsu, 1987).
There have been no epidemiological studies of the effects of aluminium on bone.
Anaemia—Microcytic anaemia is a feature of aluminium intoxication seen in dialysis
patients, which is reversible with deferoxamine treatment (Swartz et al., 1987; Tielemans et
al., 1985). Severity of anaemia in these patients has been shown to be correlated with
erythrocyte aluminium levels (Yuan et al., 1989), which suggests that there is a dose response
relationship. The physiological basis for aluminium induced anaemia is complex, a discussion
of the mechanisms involved and issues surrounding the treatment of this disorder is provided
in Effects on Laboratory Mammals and In Vitro Test Systems, Effects on Haematopoiesis. No
epidemiological studies have been published on this topic.
Cancer—Aluminium salts are the major constituents of many widely used antiperspirant
products. Aluminium chloride was the first compound to be used for this type of application;
currently, however, the most widely used antiperspirant compound is aluminium
chlorohydrate. However, only a few epidemiological studies have been undertaken of the
possible carcinogenic risks of antiperspirants.
In a case-control study, Mirick et al. (2002) investigated a possible relationship between use
of products applied for underarm perspiration and the risk for breast cancer in Western
Washington State. Case patients (n=810) were women aged 20-74 years who had first been
diagnosed with breast cancer between November 1992 and March 1995. Control subjects
(n=793) were women without breast cancer, identified by random-digit dialling from the same
population as the case patients, who were frequency-matched to the case patients by 5-year
age groups. In-person interviews were used to gather the information. The findings did not
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support the hypothesis that antiperspirant use increases the risk of breast cancer with any of
the following activities:
• antiperspirant (OR=0.9; p=0.23) or deodorant use (OR=1.2; p=0.19);
• product use among subjects who shaved with a blade razor; or;
• application of products within 1 hr of shaving (for antiperspirant, OR=0.9 and p=0.40;
for deodorant, OR=1.2 and p=0.16).
No information pertaining to the time of exposure was collected.
McGrath et al. (2003) used a cohort of 437 women to study the association between
antiperspirant and deodorant usage and the risk of breast cancer. In this retrospective study, a
written questionnaire was sent (1st January, 1993 to 31st December, 2001) to surviving female
breast cancer patients whose mean age was 65.7 years (range: 31 to 94 years). The 437 members
of the cohort comprised those of 1,344 women who had returned their questionnaire. This
cohort was subdivided into usage groups identified by the authors as: “maximum”, “middle”,
“minimum”, “none”, and “all” levels of use. The mean age at which breast cancer had been
diagnosed was also compared between subjects who started using these products before the
age of 16 and those who started at or after the age of 16. The frequency and an earlier onset of
antiperspirant/deodorant usage with underarm shaving were associated with an earlier age of
breast cancer diagnosis. A dose-response relationship was observed with the mean age of breast
cancer diagnosis being progressively lower from the no to the high usage groups. Aluminium
salts from antiperspirants could be absorbed through the dermal barrier, however toxicokinetics
studies have shown that aluminium poorly penetrates the skin (see Toxicokinetics, Absorption,
Animal Studies, Dermal). We do not really know which of the components are responsible for
the observed relationship and we should not exclude the fact that other components of the
products or the characteristics of the women could be confounding factors. This small study
cannot conclusively link a woman’s use of underarm products with breast cancer.
Genotoxicity—The aetiology of AD is complex and both environmental and genetic causes
are involved. Moreover, although highly controversial, it has been suggested that aluminium
could play a role in AD (see Effects on Humans, Effects from Non-Occupational Exposure,
Neurotoxicity). Tf is a major transport protein for both iron and aluminium. The Tf protein has
many variants, but the C1 and C2 variants account for the majority of the population of all
races. Farrar et al. (1990) have suggested that deficiency of aluminium binding to Tf may
increase the amount of unbound aluminium which could cross the BBB thereby increasing the
risk of neurotoxic effects. Defective binding of iron and aluminium to the Tf variant C2 could
be present in AD and individuals carrying the C2 allele could therefore be at a greater risk of
developing AD. Contradictory results have been obtained in case controls studies. Namekata
et al. (1997) obtained a significantly higher C2 allele frequency in AD patients than in age-
matched controls. More recently, however, Hussain et al. (2002) did not find a significant
association between the C2 allele and AD. They obtained a significant excess of the C2 allele
only in AD cases without ε4 allele. In contrast, Namateka et al. (1997) suggested that the C2
allele increases the risk of late onset AD and the C2 allele frequency in AD patients
homozygous for the ApoE ε4 allele was increased compared to patients carrying zero or one
copy of the ε4 allele. Lleo et al. (2002) did not find any association with Tf or with any other
genetic factor.
In a recent cohort study, Rondeau et al. (2006) investigated whether the Tf C2 allele (Tf C2)
might be responsible for susceptibility to AD in a sample of 292 subjects (55 of whom had
AD) aged 75 years and over from south-west France; some of these subjects (n=181) had been
exposed to high levels of aluminium in tap water, (i.e., levels higher than 100 μg/L), and others
(n=111 subjects) to low levels of aluminium. The combined genetic effects of the Tf C2 variant
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and the ε4 allele of ApoE was also examined. Logistic regression analysis showed that neither
Tf C2 itself nor its interaction with aluminium or with the ε4 allele of the ApoE was significantly
associated with the risk of AD. These results could be attributed to a lack of power in the
statistical analyses due to small sample size. This appears to be the only epidemiological study
which addresses the issue of the interaction between aluminium in tap water and the influence
of Tf C2 allele in AD.
Developmental effects—Various developmental effects of aluminium in animals have
been described, particularly in rats and mice (Domingo, 1995) (see also Effects on Laboratory
Mammals and In Vitro Test Systems, Reproductive and Developmental Toxicity,
Developmental Toxicity); however, few studies have been conducted in human populations.
Studies of the effects of aluminium on human pregnancy have been located and a recent review
article describes some results on this topic (Reinke et al., 2003). The report of Weberg et al.
(1986) described women with dyspepsia who could have ingested large amounts of aluminium
from antacids at various times during their pregnancies. They analyzed the concentrations of
aluminium in serum from the mother and her newborn child, in consecutive cases where the
mothers had used antacids during the pregnancy (antacid-use group comprised 9 mothers and
their newborns), and in randomly selected cases where the mother had not used antacids
(control group = 32). The median aluminium concentration in serum was 0.19 (0.04-0.70) in
the control group and 0.26 (0.04-1.59) in their newborns, compared to 0.19 (0.04-0.52) and
0.26 (0.07-0.52) in the antacid-use group. This small study did not show significant differences
in aluminium concentration in serum between those who had consumed antacids and the
controls, or between mothers and newborns within any of the two groups.
Severe developmental retardation has been documented in a child whose mother had taken
high doses of aluminium-containing antacids during pregnancy (Gilbert-Barness et al., 1998)
(see Effects on Humans, Case Reports). In most clinical situations, antacids that contain either
calcium or aluminium are safe when taken at the recommended doses. However caution should
be exercised if using aluminium-containing antacids when large doses are taken for long
periods of time. As a result, a panel of experts has developed algorithms that present healthcare
professionals with treatment options (Tytgat et al., 2003). The Panel recommended, for instance
antacids “on-demand” as the first-line over-the-counter treatment in reflux, and as rescue
medication for immediate relief when reflux breaks through with proton pump inhibitors.
Calcium/magnesium-based antacids would be the treatment of choice for pregnant women
because of their good safety profile.
Toxicokinetics, Distribution (Including Compartmentalization), Human Studies, Tissue
Aluminium Concentrations, Milk, presents reported values of Al in human breast milk. This
would suggest that aluminium may generally reach breast-fed newborns, but toxicity data are
lacking.
Bishop et al. (1997) investigated the effects of perinatal exposure to i.v. aluminium on the
neurological development of 227 infants born prematurely. One group of premature infants
received standard feeding solutions and the other group received aluminium-depleted i.v.
feeding solutions. They were evaluated using the Bayley scales of infant development at 18
months of age. The Bayley index was significantly lower in the 39 infants that received more
than 10 days of intravenous feeding of the standard solution than in the 41 infants that received
more than 10 days of intravenous feeding of the Al-depleted solution (92 ± 20 vs. 102 ± 17
respectively, p = 0.02). The result implies an increased risk of subsequent learning problems
in the former group. The standard and aluminium-depleted solutions delivered median daily
aluminium intakes of 187 and 28 μg respectively. None of these infants were judged to have
neuromotor impairment, which interferes with performance of the Bayley scales. A further
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analysis suggested that infants given intravenous feeding that delivered 45 μg Al/kg/day would
experience a one point reduction of the Bayley index for each day of feeding.
Modifying factors—Increasingly, studies are showing that analyses of possible relationships
between aluminium in drinking water and the risk of AD or cognitive impairment must be
made after adjusting for other water constituents that could play a confounding role by masking
the neurotoxicity of ingested aluminium. Other water components or other characteristics of
the geographical area may influence this possible association. It is thus important to include
diverse geographical areas in epidemiological studies.
In particular, the confounding effect of silicon in tap water has been studied. Silicic acid could
protect against aluminium toxicity by the likely formation of hydroxylaluminosilicate
compounds (Birchall & Chappell, 1989). Edwardson et al. (1993) confirmed this conclusion
in a study of five healthy men which showed that the GI absorption of aluminium administered
in orange juice is reduced if sodium silicate is added to the beverage (see also Toxicokinetics,
Absorption, Studies in Humans, Oral Administration, Factors Influencing Oral Aluminium
Absorption, Silicon-Containing Compounds). From these studies, two hypotheses have been
proposed. The first was suggested by Birchall & Chappell (1989), who pointed out that,
generally, aluminium and silicon concentrations in drinking water are negatively correlated,
confirming that silicon may be a confounding factor in the reported statistical association
between aluminium in drinking water and AD. Taylor et al. (1995) showed a significant inverse
correlation between soluble silicon and soluble aluminium (r = −0.43, p < 0.001). Moreover,
drinking water could be an important source of the daily intake of silcon in a form that is
particularly available for association with aluminium. As a second hypothesis, Birchall &
Chapell (1989) suggested that the low association between aluminium levels in drinking water
and AD might be a consequence of the protective effect of silicon in the water. Silicon in water
might protect populations not only from aluminium in water but also from the effect of intake
of aluminium in the diet. More specifically, Exley & Birchall (1993) suggested that a
concentration of silicic acid, produced when sodium silicate solution is acidified, of >100
μmol/L might prevent the absorption of aluminium from the GI tract and facilitate its excretion
by the kidney.
The results of the Paquid cohort study also showed that high silica levels (≥ 11.25 mg/L) are
associated with a lower risk of dementia (adjusted RR = 0.74, 95% CI: 0.58–0.96) and AD
(adjusted RR = 0.73, 95% CI: 0.55–0.99) (Rondeau et al., 2000) (see also Effects on Humans,
Effects from Non-Occupational Exposure, Neurotoxicity). The same relationship was observed
with cognitive decline (Rondeau et al., 2001). The results are concordant with the hypothesis
of Birchall & Chapell (1989) that failure to detect an association between aluminium levels in
drinking water and AD might be due to a protective effect of silicon. If this assumption is true,
then the exact risk attributable to aluminium is probably underestimated in the Paquid cohort,
which does not consider total daily aluminium intake (which is difficult to measure). On the
other hand, the results obtained by Martyn et al. (1997) in a case-control study on younger
subjects (43-75 years) do not support a protective role of silicon.
Several investigators have described how the pH of drinking water may affect the solubility
of aluminium components. It is plausible that the biological availability of aluminium is higher
for low than for high pH, which would lead to an interaction between pH and aluminium. These
results were not confirmed recently (Rondeau et al., 2000). Another interaction has been
described in the literature by Forbes et al. (1994); they found that a neutral pH, a relatively low
aluminium concentration and relatively high fluoride concentration decreased the odds of
cognitive impairment by a factor of about 5, compared with other type of drinking water.
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Subpopulations at Special Risk
Individuals with impaired renal function—Historically, patients with impaired renal
function were exposed to aluminium via trace amounts of aluminium in the water used to
prepare dialysis solutions, as well as from orally administered aluminium compounds
prescribed as GI phosphate binders (Alfrey, 1993). Patients receiving dialysis treatment are at
higher risk of aluminium toxicity from contaminated dialysate because GI absorption is
bypassed, resulting in direct entry of metal into the circulatory system (Hawkins et al., 1994).
In addition, patients with sub-optimal renal function have decreased ability to eliminate
aluminium from the body as the renal pathway is the main route for the excretion of metals
(Alfrey, 1993).
Encephalopathy in dialysis patients has been well documented (Alfrey, 1993; Foley et al,
1981). The main symptoms of this disorder include alterations in behaviour and memory,
speech disorders, convulsions and myoclonus (Foley et al., 1981). Many outbreaks of
encephalopathy were reported in association with the use of dialysis fluids containing
aluminium; however, aluminium induced encephalopathy was also found in patients with renal
failure, who did not undergo dialysis treatment (Foley et al., 1981; Moreno et al., 1991; Sedman
et al., 1984). Foley et al. (1981) reported the onset of encephalopathy in 5 paediatric patients
who had not undergone dialysis therapy but were receiving chronic administration of
aluminium hydroxide gel. Encephalopathy developed in an 8-year old female after 6 years of
orally administered aluminium therapy before end stage renal failure occurred (Sedman et al.,
1984). A fatal case of encephalopathy was reported in a 59 year old male with severe chronic
renal failure (Zatta et al., 2004). This patient was not undergoing dialysis but had consumed
large doses of aluminium-containing antacids for at least 3 years.
Encephalopathy was also found in patients with renal failure who received DFO therapy to
treat bone aluminium toxicity with chelation therapy (Sherrard et al., 1988). It was proposed
that DFO-aluminium complexes may cross the BBB more readily than the naturally circulating
aluminium which is predominantly bound to serum Tf and albumin (Sherrard et al., 1988).
Aluminium toxicity was also implicated in a variety of haematological disorders (Mahieu et
al., 2000). Yuan et al. (1989) assessed the prevalence of aluminium associated anemia in an
outpatient dialysis population. Anaemia was determined to be a significant problem in
approximately 18% of the haemodialysis population studied. Patients with the highest quartile
of red blood cell aluminium values had significantly lower haematocrit levels compared to
those in the lowest quartile (Yuan et al., 1989). Aluminium-induced microcytosis was
documented following a failure in the water treatment system of a dialysis facility (Caramelo
et al., 1995). Twenty-three haemodialysis patients were exposed to high aluminium
concentrations. The patients exhibited a decrease in the erythrocyte: plasma ferritin ratio which
suggested the existence of a decreased rate of iron uptake, although the plasma ferritin levels
indicated normal stores of iron.
Bia et al. (1989) examined the relationship between haemoglobin concentration and aluminium
overload in dialysis patients, as well as the haematopoietic response to DFO treatment.
Haemoglobin levels significantly decreased as the degree of aluminium burden rose, as
assessed by bone surface aluminium staining. Haemoglobin concentrations increased
significantly in 8 patients following DFO treatment, but did not change for the remaining 11
patients. The lack of response to DFO was not correlated to a greater degree of aluminium
overload; however, the erythropoietin levels were significantly higher in responders than in
non-responders. These results suggest that therapy with DFO significantly reduces anaemia in
patients with sufficient levels of erythropoietin such that there may be stimulation in the
development of mature red blood cells (Bia et al., 1989).
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Aluminium induced microcytosis was reported in a child who had suffered moderate renal
failure when given high doses of aluminium compounds for the treatment of
hyperphosphatemia. The microcytosis reversed in 2 months following the discontinuation of
aluminium treatment (Shah et al., 1990).
Bullous dermatosis is another condition which has been linked to aluminium toxicity in end-
stage renal patients (Gafter et al., 1996). It was suggested that high serum aluminium
concentrations in these patients may disrupt certain enzymes in the haeme biosynthetic pathway
resulting in an overproduction and accumulation of porphyrins. This condition is characterized
by skin lesions which can be very painful and are susceptible to secondary infections (Topi et
al., 1981).
Aluminium was also associated with skeletal toxicity in this susceptible population (Jeffery et
al., 1996; Mathias et al., 1993). Aluminium was found to disrupt PTH secretions, and impair
the conversion of 25-hydroxyvitamin D to its biological active hormone, 1, 25-
dihydroxyvitamin D (Klein, 2003). Aluminium bone toxicity results in either increased bone
remodelling, which produces conditions such as osteitis fibrosa, while some patients exhibit
low bone turnover resulting in osteomalacia (Ng et al., 2004). Mixed osteodystrophy also
occurs as some patients exhibit features of both osteomalacia and osteitis fibrosis (Jeffery et
al., 1996). Aluminium in patients with osteomalacia accumulates in the area between calcified
and non-calcified bone (Alfrey, 1993), preventing further mineralization (Bougle et al.,
1997).
The incidence of aluminium intoxication in dialysis patients has decreased considerably in
recent years due to more thorough treatment of water used in all dialysis solutions, and
replacement of orally administered aluminium hydroxide with calcium containing phosphate
binding agents (Hdez-Jaras et al., 1998). However there have been reports of aluminium
toxicity due to failures in treating the water used in dialysis solutions or due to contamination
of the solutions (Berend et al., 2001; Burwen et al., 1995; Caramelo et al., 1995). Hdez-Jaras
et al. (1998) reported aluminium intoxication in 8 patients undergoing acetate-free biofiltration
with bicarbonate solutions contaminated with aluminium. Serum ferritin and aluminium
concentrations were markedly increased in these patients; however there were no indications
of neurological or skeletal abnormalities. Aluminium intoxication was reported following
contamination of the water system supplying a dialysis centre on the island of Curacao in 1996
(Berend et al., 2001). Aluminium had leached from the cement mortar lining a water
distribution pipe exposing 27 dialysis patients to high levels of aluminium. Ten patients died
from acute aluminium encephalopathy while the remaining 17 patients exhibited only minor
symptoms. The serum aluminium concentrations available for 7 of the non-survivors were
significantly higher than in the survivors.
Infants and children—Infants, especially at the pre-term stage, are at particular risk for
aluminium toxicity due to immaturity of the GI wall, the BBB, and renal system (Hawkins et
al. 1994). The limited capacity of infants to excrete aluminium can result in accumulation of
aluminium to levels which may be toxic (Koo et al., 1986). Pre-term infants receiving parenteral
nutrition are exposed to aluminium as the solutions used have intrinsic aluminium content and
may also become contaminated with aluminium during processing and storage (Advenier et
al., 2003). Cognitive deficits have been reported among premature infants that received
standard feeding solutions in comparison to infants receiving aluminium-depleted i.v. feeding
(total parenteral nutrition) solutions (Bishop et al., 1997 (see also Effects on Humans, Effects
from Non-Occupational Exposure, Developmental Effects)). Elevated bone Al seen in
premature infants who received aluminium-contaminated total parenteral nutrition solutions
has been implicated in a metabolic bone disease (see Effects on Humans, Effects from Non-
Occupational Exposure, Bone). Klein (2003) found that hepatic aluminium concentrations in
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5 children receiving parenteral nutrition were 5 to 27 times higher than normal concentrations.
Therefore, aluminium was implicated in the development of parenteral nutrition-associated
cholestasis in infants; however this association has not been fully elucidated (Arnold et al.,
2003). Some highly modified infant formula and soy formula were reported to contain
significantly more aluminium than breast milk (Goyens & Brasseur, 1990; Hawkins et al.,
1994). Von Stockhausen et al. (1990) determined serum aluminium levels in premature infants
receiving long-term parenteral nutrition. There was a significantly negative correlation
between serum aluminium levels and gestational ages among the 22 premature infants
examined (von Stockhausen et al., 1990). Tsou et al. (1991) investigated plasma aluminium
levels in infants with normal renal function during prolonged use of aluminium-containing
antacids (Tsou et al., 1991). Ten infants who had been receiving antacids for at least one week
were compared with 16 controls. The plasma aluminium level of the treated patients (37.2 ±
7.13 μg/L) was significantly higher than that of the control group (4.13 ± 0.66 μg/L).
The growing bone is a particular target for aluminium in infants and young children (Koo &
Kaplan, 1988). A 3-month old premature infant developed rickets after 6 weeks of therapy with
an aluminium containing antacid (Pattaragarn & Alon, 2001). Bougle et al. (1997) examined
the relationship between aluminium and bone mineralization in healthy premature infants.
Serum aluminium levels appeared to be a more significant variable in determining bone-
mineral density variations than the usual biomarkers of bone metabolism such as calcium and
phosphorus levels (Bougle et al., 1997).
EVALUATION OF HUMAN HEALTH RISKS
General Aspects
This section provides a synthesis of data from the salient studies on potential health effects of
exposure to aluminium for the purpose of quantifying health risks. The discussion follows the
following four-step process specified by the National Research Council (1983).
1. Hazard identification (the qualitative identification of adverse effects by route of
exposure, regardless of level of exposure, and the determination of whether those
effects are likely in humans);
2. Exposure assessment (quantification of human exposure by route);
3. Dose-response assessment (quantification of the relationship between the level of
exposure and the probability of effects identified as part of hazard identification); and
4. Risk characterization (the combination of exposure assessment and dose-response
assessment information to develop an estimate of the probability of adverse outcomes
in actual populations).
Health Effects
Hazard identification—Both animal and human data are used to identify potential human
health hazards. Where plentiful, hazard identification is based primarily on epidemiological
data derived from exposed human populations. However, to the extent that it is useful, hazard
identification may also make use of animal data. The epidemiological information base for
aluminium includes many occupational studies describing a range of health effects at high
levels of inhalation exposure, and non-occupational studies of populations exposed to
aluminium in food and drinking water. In addition, vaccine safety studies document the impact
of exposure to aluminium via injection.
The detailed review of the available literature presented earlier in this report permits the
identification of health effects for which there is sufficient evidence of an adverse effect at
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some level of exposure to warrant investigation of the dose-response relationship (see
Evaluation of Human Health Risks, Health Effects, Exposure Characterization). As described
in Effects on Humans, Case Reports, case studies have documented reported cases of a range
of effects following exposure to aluminium. These include:
• osteomalacia following chronic use of high doses of antacids (Kassem et al., 1991;
Woodson, 1998) and exposure to aluminium-contaminated dialysis solutions;
• mental retardation and death (at nine years of age) following in-utero exposure to
aluminium associated with maternal use of antacids at extremely high doses during
pregnancy (Gilbert-Barness et al., 1998);
• fatal aluminium encephalopathy following the chronic use of high doses of antacids
and exposure to aluminium-contaminated dialysis solutions in patients with reduced
or absent renal function (dialysis encephalopathy/dementia), following short term
exposure to large amounts of alum instilled into the urinary bladder in patients with
reduced renal function (Nakamura et al., 2000; Phelps et al., 1999), and following
reconstructive otoneurosurgery using bone cement containing aluminium (Hantson
et al., 1994; Reusche et al., 2001b), although the role of aluminium in these cases was
not clear;
• contact reactivity to aluminium (see Effects on Humans, Effects from Non-
Occupational Exposure, Irritation, Dermal Application);
• adverse reactions to vaccines containing aluminium (Authier et al., 2001; Di Muzio
et al., 2004; Gherardi et al., 2001; Lacson et al., 2002; Nevo et al., 2004); and
• contact allergic reactions to aluminium following injection of vaccines containing
aluminium (Akyol et al., 2004; Bergfors, 2005; Cox et al.,1988b; Netterlid et al.,
2004).
Although these case reports provide information suggestive of adverse health effects in
humans, they do not involve the collection of data in a controlled and systematic manner from
large samples of the general population. The results of such studies, therefore, cannot be
generalized.
The remainder of this section describes results from more detailed studies of aluminium
exposure in human populations. The discussion is organized by route of exposure for two
reasons. First, information on dose-response and exposure is also organized by route of
exposure. Second, the route of exposure can strongly influence a substance’s toxicity. This
influence stems from differences in terms of the organs exposed and from differences in the
degree of absorption (see Toxicokinetics). Where relevant, we also note the influence of
chemical speciation on toxicity. However, the chemical species of aluminium in vivo is often
unknown. Methods to separate in vivo aluminium species for identification and quantification
are not generally employed, because there is great potential for changes in speciation during
separation of metal complexes from each other due to perturbation of chemical equilibria
during the process. An alternative approach is to use computational models that include the
stability constants of metal-ligand complexes to calculate in vivo metal species concentrations.
As there is not good agreement for the aluminium binding constants for many important ligands
of aluminium, there is often not good agreement among the results of speciation modelling
(Caruso et al., 2005).
Within each exposure route, we consider the following health endpoints: 1) acute toxicity, 2)
irritation, 3) corrosivity, 4) sensitization, 5) repeated dose toxicity, 6) mutagenicity, 7)
carcinogenicity, 8) reproductive toxicity, and 9) other forms of toxicity, as described by the
European Commission (2003). For each outcome and route of exposure, the weight of evidence
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for its potential to occur in humans, as evaluated based on a systematic narrative review (Weed,
2005) and consensus among the papers’ authors, is judged to be strong, modest, limited, or
having no clear evidence. Evaluation of Human Health Risks, Health Effects, Exposure
Characterization seeks to quantitatively evaluate the dose-response relationship information
for outcomes having either strong or modest supporting evidence. For evidence of an effect to
be strong, the preponderance of epidemiological data must be positive, with at least some
coming from multiple studies with modest or large sample size and reasonably sound design.
A study is judged to have a sound design if 1) its sample size is large enough to detect an effect
of moderate magnitude; 2) it controls potential confounding effects sufficiently to ensure that
their introduction of a spurious association is at most modest; and 3) it quantifies exposure to
aluminium among subjects or groups of study subjects. Epidemiological evidence that is mixed
or from studies of limited size or poor design can result in, at most, a modest finding of support
for the existence of an effect. If there are only a small number of positive studies of decent
design and size, evidence can be rated as limited. If there is minimal or no evidence of an effect,
we rate support for it as having no clear evidence. Animal evidence on its own is insufficient
to result in classification of an association as “strong.” Animal evidence can, however, serve
to support epidemiological evidence. Strong animal evidence for an effect can also serve as
the basis for classifying the weight of evidence for an effect as modest.
It is important to keep in mind that with the exception of the injection pathway, this section
confines discussion to members of the population that are not believed to be especially
susceptible to the effects of aluminium exposure. The section on individuals with impaired
renal function (Evaluation of Human Health Risks, Health Effects, Hazard Identification,
Sensitive Subpopulations) considers these individuals. Nor does this section in general place
substantial weight on associations observed at extremely high levels of exposure (e.g.,
following chronic exposure to dialysis fluids containing aluminium), as such extreme
exposures are not informative for the purpose of characterizing risks at exposure levels more
typical of other pathways, which may be orders of magnitude smaller.
Finally, we note risks associated with aluminium’s physico-chemical properties.
Inhalation exposure: Studies investigating the impact of inhalation exposure to aluminium
have considered the following endpoints listed in the introduction to Evaluation of Human
Health Risks, Health Effects, Hazard Identification: (2) irritation; (6) mutagenicity; (7)
carcinogenicity; (8) reproductive/developmental effects; and (9) other effects, including
neurological toxicity.
Endpoint (2) – irritation: The association between respiratory symptoms and occupational
exposure to aluminium among aluminium smelter workers has been investigated in a number
of studies (see Effects on Humans, Effects from Occupational Exposure, Respiratory Tract
Effects). Those studies have reported compromised pulmonary function in exposed subjects.
However, in many cases, the subjects were exposed to other agents, such as particulate fluoride
or carbon dusts, that may have been responsible for this effect.
On the other hand, a series of studies have documented physiological changes attributable to
aluminium powder exposure. These changes have included fibrosis, and have been associated
with severe symptoms, such as dry cough, dyspnoea, and shortness of breath (see Effects on
Humans, Effects from Occupational Exposure, Irritation, Inhalation Exposure). These studies
were generally conducted at least 50 years ago, although the consistency of the findings in
multiple populations lends support to the hypothesis that these exposures are capable of causing
this type of irritation. There have been no studies of these physiological effects in non-
occupationally exposed populations. However, animal data support the existence of this effect
(see Effects on Laboratory Mammals and In Vitro Test Systems, Irritation, Inhalation
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Exposure). On the strength of the occupational cohort studies showing evidence of
physiological changes to the lung and severe associated symptoms, and the supporting animal
data, this evidence is rated as strong.
Endpoint (6) - mutagenicity: Evidence of genotoxicity has not been compelling (see Effects
on Laboratory Mammals and In Vitro Test Systems, Carcinogenicity; Effects on Humans,
Effects from Occupational Exposure, Genotoxicity; and Effects on Humans, Effects from Non-
Occupational Exposure, Genotoxicity), and is judged to be limited.
Endpoint (7) – carcinogenicity: Evidence of an association between aluminium exposure and
cancer in humans derives largely from studies of occupationally exposed populations.
Interpretation of these studies, which are summarized in Table 22, is complicated by the fact
that, in most of them, aluminium exposure is confounded by exposure to PAHs, substances
that have themselves been implicated in causing cancer. Other potential confounders include
aromatic amines, nitro compounds, asbestos, heat stress, and magnetic fields. The International
Agency for Research on Cancer (IARC, 1984;Straif et al., 2005) has designated processes
associated with aluminium production as “carcinogenic in humans”, but did not implicate
aluminium itself as a human carcinogen. Neither non-occupational studies (see Effects on
Humans, Effects from Non-Occupational Exposure, Cancer) nor studies in experimental
animal studies have provided evidence that aluminium is carcinogenic (see Effects on
Laboratory Mammals and In Vitro Test Systems, Interactions between Aluminium and Other
Agents). We therefore conclude that there is no clear evidence of cancer due to inhalation of
aluminium.
Endpoint (8) – reproductive/developmental effects: A study of French aluminium industry
workers identified an increase in fertility among those with a higher exposure index (Mur et
al., 1998). However, this study is inadequate for the purpose of assessing the impact of
aluminium exposure on this endpoint. First, the study was designed to evaluate the influence
of exposure to heat and static magnetic fields. Second, the study did not control for other factors
that may explain the results, especially differences in socio-economic status. We therefore
conclude evidence for this effect is limited.
Endpoint (9) – other effects: Sufficient data exist to evaluate the weight of evidence for
neurotoxicity following inhalation exposure to aluminium.
Studies of an association between inhalation exposure to aluminium and neurological effects
have been limited to occupationally exposed populations. Results among studies of
occupationally exposed populations have been mixed (see Effects on Humans, Effects from
Occupational Exposure, Neurotoxicity). Akila et al. (1999) and Riihimäki et al. (2000) reported
that workers exposed to either low or high levels of aluminium (serum aluminium levels of
0.14 and 0.46 μmol/L, respectively) had lower neuropsychological test scores compared to
referants (serum aluminium level of 0.08 μmol/L). EEG abnormalities were most common in
the high exposure group and second most common in the low exposure group. The study
measured lead exposure in order to rule out its potential confounding influence but did not
assess other possible neurotoxic agents. The most recent publication based on this cohort had
a modest sample size that included 65 metal inert-gas welders and 25 mild steel workers. The
earlier study was smaller.
Pollizi et al. (2002) compared cognitive function in 64 aluminium workers and 32 controls.
They reported an inverse relationship between aluminium exposure and performance on
MMSE and the CDT. This study controlled for a greater range of possible neurotoxins.
Nonetheless, its sample size is modest.
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While Sjögren et al. (1996a) observed an elevated risk of neuropsychiatric symptoms among
welders, those workers were also exposed to chromium, lead, manganese, and nickel. Hosovski
et al. (1990) identified differences in psychomotor and intellectual abilities in aluminium
foundry workers and attributed the differences to aluminium metal exposure. White et al.
(1992) identified a ‘neurological syndrome’ among aluminium smelter workers (exposed to
alumina, aluminium fibres, fluorides, calcium and cryolite), although the sample size was small
(n = 25).
Evidence of an association between occupational exposure to aluminium and risk of AD has
generally been negative, although the strength of the conclusions from these studies has been
tempered by sample size considerations and inadequate characterization of exposure levels. A
review by Doll (1993) concluded there was no evidence that occupational exposure causes AD.
A subsequent case control study conducted by Salib & Hiller (1996) also found no association
between AD and occupational exposure to aluminium. More recent studies (Akila et al.,
1999; Riihimäki et al., 2000; Pollizi et al., 2002) reported cognitive effects. These studies were
all small, however, and the first study (Akila et al., 1999 and Riihimäki et al., 2000) did not
control for agents that might have a neurotoxic effect.
Overall, evidence of an association between inhalation exposure and neurological effects is
limited.
Oral ingestion: Studies of the impact of oral exposure to aluminium compounds have
considered the following endpoints listed in the introduction to Evaluation of Human Health
Risks, Health Effects, Hazard Identification: (2) irritation; (6) mutagenicity; (7)
carcinogenicity; (8) reproductive/developmental effects; and (9) other effects, including
neurological impacts, bone toxicity, and metabolism. For this pathway, no occupational
exposure data were available.
Note that because internal exposure following oral exposure depends on absorption and
retention of aluminium, effects described here depend on health status. For the purpose of this
discussion, we confine our attention to the general population. As noted in the introduction to
this section, Evaluation of Human Health Risks, Health Effects, Hazard Identification,
Sensitive Subpopulations addresses individuals, including infants and children, and individuals
with impaired renal function, with specific factors that increase their susceptibility to
aluminium exposure.
Endpoint (2) – irritation: In 1988, a drinking water treatment error lead to 20,000 individuals
in Cornwall, England being exposed to elevated levels of aluminium sulphate in their drinking
water over a three day period. Although members of the population reported GI disturbances
and oral ulcerations, the role of aluminium could not be isolated because of other associated
changes in water chemistry, including a decrease in pH and elevation in the concentrations of
copper, zinc, and lead (dissolved from domestic plumbing fixtures). Animal data do not support
the potential for oral and GI effects (see Effects on Laboratory Mammals and In Vitro Test
Systems, Irritation, Oral Exposure). We therefore conclude that evidence for these endpoints
is limited.
Endpoint (6) - mutagenicity: See discussion in Evaluation of Human Health Effects, Health
Effects, Hazard Identification, Inhalation Exposure, Endpoint (6) - mutagenicity.
Endpoint (7) – carcinogenicity: There are no human data for this endpoint. Animal data (see
Effects on Laboratory Mammals and In Vitro Test Systems, Interactions between Aluminium
and Other Agents) are negative. We therefore conclude that there is no clear evidence for the
carcinogenicity of aluminium by oral ingestion.
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Endpoint (8) – reproductive/developmental effects: There are no epidemiological data on
reproductive or developmental outcomes following oral exposure to aluminium. However,
Effects on Laboratory Mammals and In Vitro Test Systems, Reproductive and Developmental
Toxicity, describes a substantial number of rodent bioassays investigating the impact of
aluminium exposure via oral administration. The results from the animal studies indicate that
the effects depend strongly on the bioavailability of the aluminium species. Species that are
water soluble have been shown to have adverse effects, including aluminium nitrate (Albina
et al., 2000; Paternain et al., 1988), aluminium chloride (Colomina et al., 1999; Cranmer et al.,
1986; Misawa & Shigeta, 1993), or aluminium lactate (Golub et al., 1987; Gonda et al.,
1996; Poulos et al., 1996), although these effects may be directly related to aluminium exposure
or the result of a secondary consequence.
On the other hand, administration of aluminium hydroxide (Al(OH)3), which is absorbed to a
more limited extent (Colomina et al., 1994; Domingo et al., 1991a), has been reported to have
a more limited impact on reproductive outcomes (Gómez et al., 1991), or no adverse impact
(Domingo et al., 1989). Co-administration of ascorbic acid appears to increase the impact of
aluminium hydroxide on reproductive toxicity (see e.g., (Colomina et al., 1994). Donald et al.
(1989) reported neurological defects following exposure of dams to aluminium lactate during
lactation. Administration of aluminium caused significant reductions in maternal weight.
Based on the animal data, we conclude that evidence for this endpoint is modest, although we
emphasize that it is highly dependent on aluminium species, most likely because of differences
in bioavailability.
Endpoint (9a) – other effects - neurological: Effects on Humans, Effects from Non-
Occupational Exposure, Neurotoxicity of this report describes 15 studies of the association
between aluminium in drinking water and the risk of AD. Nine of these studies report an
elevated risk, although methodological limitations have been identified for most of these
investigations. That of Martyn et al. (1989) was not population based; those of Flaten (1990)
and Neri & Hewitt (1991) were ecological in nature and hence did not control for relevant
confounders. Forbes et al. (1991; 1992) reported that men living in areas with elevated
aluminium concentrations in drinking water were less likely to be cognitively normal.
However, interpretation of this study’s results is complicated by the fact that it evaluated the
joint impact of aluminium and fluoride exposure. Other potential problems with this study
included sample size limitations and lack of representativeness. McMillan et al. (1993) and
Altmann et al. (1999) reported on the impact of a short-term spike in exposure to aluminium
in drinking water following operational problems in a local drinking water treatment facility
in the UK. However, because cases in this study were self-selected and may have been
motivated by the potential for compensatory rewards, the results may be biased. Jacqmin et al.
(1994) and Jacqmin-Gadda et al. (1996) reported the association between cognitive impairment
and aluminium and silica drinking water concentrations considered jointly. (These results
support the hypothesis that silica protects against this condition. Because silica limits exposure
to aluminium, this finding may be supportive of a link between aluminium exposure and
cognitive impairment.) McLachlan et al. (1996) reported an elevated risk of AD among
individuals exposed to higher levels of aluminium in drinking water. However, the study did
not control for fluoride, silica, or pH; nor did it control for other potential confounders. Gauthier
et al. (2000) reported an association between risk of AD and exposure to organic monomeric
aluminium at onset. Finally, in a relatively large study involving 2,698 participants aged 65
and older, Rondeau et al. (2000) reported an association between exposure to aluminium in
drinking water and risk of AD. However, because this study lacked an intermediate exposure
group, it is not possible to determine if there is a dose-response relationship. Six other studies
described in Effects on Humans, Effects from Non-Occupational Exposure, Neurotoxicity,
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Aluminium in Drinking Water reported no association between aluminium exposure and
development of AD or cognitive impairment.
In addition to the studies of neurological effects following exposure to aluminium in drinking
water, there are two other studies that consider this endpoint and its association with oral
aluminium exposure. Graves et al. (1990) reported a positive association between lifetime
antacid use and risk of AD. However, this association vanished when consideration was limited
to antacids containing aluminium. A small study of exposure to aluminium in food (Rogers &
Simon, 1999), which followed only 23 case control pairs, reported positive findings.
Animal models lend some support to the biological plausibility of an association between
aluminium exposure and the development of AD. Several studies report that intake of
aluminium (chemical species not specified) (Pratico et al., 2002), aluminium maltolate (Huang
et al., 1997), aluminium chloride (Zhang et al., 2003), or aluminium sulphate (El-Rahman,
2003) increases expression of amyloid protein in rodent tissues, a step that may be critical to
the development of AD. Kihira et al. (2002) reported that administering aluminium in drinking
water to rats lead to the accumulation of tau immunoreactivity in a pattern resembling AD pre-
tangles. Increased oxidative stress in the brains of rodents exposed to aluminium may have
been noted, but this evidence falls short of demonstrating neuropathology (see Effects on
Laboratory Mammals and In Vitro Test Systems, Neurotoxicity, In Vivo Models, Rodent Models
of Aluminium Toxicity by Oral Exposure). Other studies (e.g., Silva et al., 2002) suggest that
aluminium may decrease amyloid plaque formation. However, there may be other effects on
neurotransmitter systems and synaptic function.
Although many of the epidemiological studies reporting a positive association between
aluminium exposure and the development of AD or other forms of cognitive impairment have
limitations, they provide credibility for the potential for such an association. The autopsy data
cast doubt on the association. In addition, animal study data are mixed. In light of that negative
evidence and only limited epidemiological support, we conclude the strength of the evidence
for neurological effects is modest.
Endpoint (9b) – other effects - bone toxicity: Only a small number of animal studies have
investigated the impact of aluminium exposure via oral intake (or gastric intubation) on bone
toxicity and none has demonstrated an adverse effect. Slanina et al. (1984) reported that
administration of aluminium citrate to rats substantially elevated the concentration of
aluminium in bone compared to controls (by a factor of 40), and that administration of citric
acid increased the concentration of aluminium in the bone of animals receiving diet spiked
with aluminium. Animals receiving aluminium hydroxide did not have elevated concentrations
of aluminium in bone. These findings suggest that the potential for aluminium to affect bone
may be limited by the extent to which it is absorbed. Yasui & Ota (1998) reported that rats
consuming a diet containing 194 mg Al /100 g feed (equivalent to 1.94 g/kg feed) as aluminium
lactate exhibited decreased spinal cord magnesium concentration. Because magnesium is
important to bone metabolism, the authors concluded that their findings suggest the potential
for aluminium to cause bone toxicity.
With the exception of a single case study involving a chronic consumer of antacids, there is
no evidence of bone toxicity in people with normal renal function (see Evaluation of Human
Health Risks, Health Effects, Hazard Identification, Exposure via Injection, Endpoint (9b) –
other – bone toxicity for individuals on dialysis). Among members of the population with
normal kidney function, there is limited evidence that exposures to high levels of aluminium
can result in deposits of aluminium in bone tissue (see Effects on Humans, Effects from Non-
Occupational Exposure, Bone). However, these studies have been limited in size and have not
shown adverse effects. We therefore conclude that there is no clear evidence for this endpoint.
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Endpoint (9c) – other effects - metabolism: As concluded in Effects on Laboratory Mammals
and In Vitro Test Systems, Mineral Metabolism, studies of an association between aluminium
exposure and metabolic impacts are inconsistent in terms of their results, with the possibility
that differences across studies may be due, at least in part, to factors such as the level of
exposure, route of exposure, and age of the animals tested. In addition, other than body weight,
the only effects observed were changes in tissue trace mineral concentrations. Because none
of these changes is indicative of an adverse toxic effect, we conclude the evidence for a toxic
metabolism effect is limited.
Dermal and other external exposure: Studies investigating the impact of dermal and other
external exposure to aluminium have considered endpoint (2) - irritation.
In occupational settings, instillation of aluminium sulphate, potash alum, and ammonium alum
have resulted in conjunctivitis and purulent ophthalmitis (Grekhova et al., 1994). Other forms
of aluminium relevant to cosmetics (aluminium starch octenylsuccinate) have also been shown
to cause mild eye irritation in rabbits, although the authors concluded that this exposure was
unlikely to cause irritation in humans (Nair & Yamarik, 2002). Magnesium aluminium silicate
caused minimal eye irritation in a Draize eye irritation test (Hazelton Laboratories, 1968).
When injected intralamellarly, widespread corneal infiltrates and retrocorneal membranes were
recorded (Austin & Doughman, 1980).
Reports of skin irritation due to contact with aluminium have been limited in extent (e.g., 2 of
202 cases of contact dermatitis among aircraft workers reported by Hall (1944), or not
definitively associated with aluminium (Johannessen & Bergan-Skar, 1980; Peters et al.,
1998). Non-occupational evidence of contact sensitivity to aluminium is generally limited to
case reports (see Effects on Humans, Effects from Non-Occupational Exposure, Irritation,
Dermal Application). We therefore conclude that evidence for this endpoint is limited.
Exposure via injection: Studies investigating the impact of exposure to aluminium via
injection have considered the following endpoints listed in the introduction to Evaluation of
Human Health Risks, Health Effects, Hazard Identification: (2) irritation; (8) reproductive/
developmental effects; and (9) other effects, including neurological effects, bone toxicity, and
metabolism.
Endpoint (2) – irritation: The fact that some vaccines contain aluminium hydroxide and/or
aluminium phosphate adjuvant (all DTP, some Haemophilus influenza type B, most hepatitis
A and B, meningococcal, pneumococcal, tick-born encephalitis, some rabies, and anthrax
vaccines) while others do not (inactivated poliovirus, measles, mumps, rubella, some rabies,
yellow fever, Japanese encephalitis, adenovirus, typohoid, plague, cholera, BCG,
meningococcal, and some Haemophilus influenza type B) affords an opportunity to study the
extent to which aluminium might cause irritation. Effects on Humans, Effects from Non-
Occupational Exposure, Irritation, Irritation after Injection of Aluminium-Adsorbed Proteins
(Vaccines and Hyposensitization Regimens) summarizes the numerous studies that have
reported a range of dermal irritation effects following administration of vaccines containing
aluminium. Animal studies support the existence of this effect (see Effects on Laboratory
Mammals and In Vitro Test Systems, Irritation, Injection). We conclude that evidence for this
evidence is strong.
Endpoint (8) – reproductive/developmental effects: Llobet et al. (1995) reported that injecting
male mice with aluminium nitrate for four weeks prior to mating decreased pregnancy rates.
Because there is only a single animal study and no epidemiological data, we conclude that there
is no clear evidence for this endpoint.
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Endpoint (9a) – other – neurological effects: As documented in Effects on Laboratory
Mammals and In Vitro Test Systems, Neurotoxicity, In Vivo Models, Rodent Modesl of
Aluminium Toxicity by Direct Injection, a number of animal studies have shown that rodents
suffer a range of adverse nervous system effects following direct injection of aluminium.
Effects include signs of oxidative stress as indicated by increased glutathione (GSH), increased
measures of lipid peroxidation (TBARS), increased levels of oxidized glutathione (GSSG),
and increased superoxide dismutase levels (Esparza et al., 2003); changes to neuronal
morphology (reductions in axonal length (Sreekumaran et al., 2003)); CNS cell death (Yang
et al., 2004); retinal toxicity (Lu et al., 2002); and reductions in neuronal density (Miu et al.,
2003).
Autopsy evidence from individuals who died of encephalopathy following long-term dialysis
treatment argues against a role for aluminium in the development of one particular neurological
effect, namely AD. Those patients are especially susceptible to aluminium exposure (see
Evaluation of Human Health Risks, Health Effects, Hazard Identification, Sensitive
Subpopulations). Nonetheless, those studies show no association between aluminium exposure
and the development of Alzheimer’s-like lesions.
In any case, there are no human data to support the existence of neurological effects following
injection. On the basis of the animal evidence, we rate the evidence for neurological effects as
modest.
Endpoint (9b) – other - bone toxicity: As detailed in Effects on Laboratory Mammals and In
Vitro Test Systems, Effects on Bone, the vast majority of animal studies investigating the
potential for aluminium to cause bone toxicity have used injection as the exposure pathway.
Studies have reported that aluminium exposure decreases bone formation in rats (Goodman,
1984; Goodman et al., 1984a; Ott et al., 1987) and has an adverse impact on the functional
properties of bone (Cointry et al., 2005; Zafar et al., 2004). Effects on various aspects of bone
formation or metabolism have also been observed in other species, including pigs (Sedman et
al., 1987) and dogs (Goodman et al., 1984b; Quarles et al., 1985; 1988; 1989). Experiments in
these larger animals may have greater relevance to the prediction of impacts in humans for this
endpoint than do the ones in rats. On the other hand, in dialysis patients, contaminated solution
(administered either i.v. or via i.p. injection) is responsible for observed bone toxicity. Based
on this evidence, we judge the evidence for bone toxicity via the injection pathway to be modest.
Endpoint (9c) – other - metabolism: Our comments on the oral exposure pathway for this
endpoint are applicable to the injection pathway, as well. We conclude that evidence for a toxic
metabolism effect is limited.
Sensitive subpopulations: Individuals with impaired renal function do not clear aluminium as
effectively as healthy individuals. This population can also be exposed to higher levels of
aluminium that are administered inadvertently via their i.v. feeds. This route of exposure may
be particularly significant because it bypasses the barrier imposed by GI absorption
characteristics.
Researchers have reported cases of encephalopathy among members of this population (Alfrey,
1993; Foley et al., 1981), resulting in alterations to memory and behaviour, speech disorders,
convulsions, and myoclonus. Yuan et al. (1989) noted that, in dialysis patients, haematocrit
levels were lowest in patients with the highest RBC aluminium values. Bia et al. (1989) reported
that haemoglobin levels were significantly lower among individuals with higher aluminium
burdens. Gafter et al. (1996) reported a link between bullous dermatosis and aluminium toxicity
in end-stage renal patients.
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Infants, especially those born pre-term, are especially vulnerable to aluminium exposure due
to immaturity of the GI wall, the BBB, and the renal system (Hawkins et al., 1994). One study
(Bishop, 1997) reported an association between exposure to aluminium (following
administration of i.v. feeding solutions just after birth) and cognitive development measured
using the Bayley Mental Development Index at 18 months. The study used a randomized
design. On the other hand, it is limited in size. Nor has the study been replicated. Other evidence
of a neurological effect in this population is limited to case studies.
We therefore designate evidence for susceptibility to toxicity among renal patients to be strong.
However, among infants and premature infants, we designate the evidence as limited.
Physico-chemical properties: As noted in Effects on Humans, Effects from Occupational
Exposure, Explosivity, Flammability, Oxidizing Potential, aluminium is a reactive agent that
can pose a risk of physical injury in industrial settings. Airborne aluminium powder can pose
an ignition danger, although only at very high concentrations. Finally, mixtures of aluminium
and halogenated organic compounds can pose an explosion hazard under certain conditions.
Summary: Table 25 summarizes our findings for the strength of the evidence for each pathway
and health effect. There is strong evidence that aluminium can cause irritation following
exposure via either inhalation or injection. Modest evidence of an effect exists for reproductive
toxicity following oral exposure, for neurological toxicity following either oral or injection
exposure, and for bone toxicity following injection exposure. All other effects were judged to
be supported by either limited evidence or no clear evidence at all.
Dose response
This section identifies quantitative benchmarks of toxicity for the health effects for which there
is modest or strong supporting evidence (see Evaluation of Human Health Risks, Health Effects,
Hazard Identification). The discussion is organized by exposure pathway.
Inhalation exposure—For the inhalation pathway, irritation is the only health effect for
which there is strong or modest supporting evidence. Epidemiological findings quantifying
exposures associated with this effect are limited to occupationally exposed cohorts, and this
information draws heavily on the experience of German workers from the World War II era
(see Effects on Humans, Effects from Occupational Exposure, Irritation, Inhalation
Exposure). Those workers are thought to have been exposed to airborne aluminium powder
concentrations as high as 50 to 100 mg/m3. Sjögren (2000) reports that these exposures lead
to aluminosis, a fibrotic disease of the lung.
Animal bioassays confirm the potential for airborne aluminium to cause frank effects at
exposures in the order of 100 mg/m3 or more. Effects included constriction of pulmonary air
flow following exposure of rats to airborne aluminium concentrations of 380 mg/m3 or of
guinea pigs to airborne aluminium concentrations of 580 mg/m3 (Robillard & Alarie, 1963a);
acute bronchopneumonia and moderate thickening of the alveolar walls following exposure of
Syrian Golden hamsters to airborne aluminium chloride hydroxide concentrations of 164 mg/
m3 (Drew et al., 1974); and similar effects in rabbits following their exposure to airborne
aluminium chloride hydroxide concentrations of 212 mg/m3 (Drew et al., 1974).
At exposures approximately one to two orders of magnitude lower, frank effects are not often
reported. On the other hand, physiological changes have been observed, including development
of granulomatous pneumonia in rats following exposure to airborne aluminium concentrations
of either 2.5 or 25 mg/m3 (Steinhagen et al., 1978); Type II alveolar cell effects in rats following
exposure to airborne aluminium concentrations of 1.3 or 1.8 mg/m3 (Finelli et al., 1981), and
an influx of polymorphonuclear neutrophils into bronchopulmonary lavage fluid following
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exposure of rats to airborne aluminium concentrations as low as 10 mg/m3 (Thomson et al.,
1986). While some of these effects persisted after cessation of exposure (e.g., Thomson et al.
(1986) reported effects 6 months after exposure ended), there are no reports indicating that
these responses were more than temporary, or that they lead to any long term risk of disease.
On the strength of the occupational exposure studies and the supporting findings from the
animal studies, we identify an airborne aluminium powder concentration of 50 mg/m3 as a
level at which adverse effects have been observed. Although physiological effects have been
observed in animal studies at lower exposure levels, there is no evidence of effects at these
levels in humans. Nor is there any evidence that these effects lead to a permanent decline in
functional status.
Oral exposure
Neurological effects: If there is an association between aluminium exposure and risk of either
AD or other forms of dementia, the results of positive studies of exposure to aluminium in
drinking water and these health effects would serve to characterize the nature of the dose
response relationship. Martyn (1989) reported that individuals consuming drinking water with
aluminium concentrations exceeding 0.11 mg/L had a 1.5-fold greater risk for AD than those
who consumed water with aluminium concentrations less than 0.01 mg/L. Flaten (1990)
reported RRs for subjects consuming drinking water with aluminium concentrations > 0.2 mg/
L and those consuming drinking water with aluminium concentrations from 0.05 to 0.2 mg/L.
The comparator group included individuals consuming water with aluminium concentrations
< 0.05 mg/L. For the high exposure group, the RRs were 1.32 (male) and 1.42 (female). For
the mid-exposure group, RRs were 1.15 (male) and 1.19 (female). Neri & Hewitt (1991)
reported a RR of 1.46 for individuals consuming drinking water with aluminium concentrations
> 0.2 mg/L, when compared to individuals consuming drinking water with concentrations
below 0.01 mg/L. Rondeau et al. (2000) reported an elevated risk of AD among individuals
consuming water with aluminium concentrations exceeding 100 μg/L. Recall that these studies
have a number of limitations, as described in Evaluation of Human Health Risks, Health Effects,
Hazard Identification, Oral Ingestion, Endpoint (9a) – other effects - neurological.
Interpretation of other drinking water studies for this health endpoint is complicated by the fact
that other water chemistry characteristics were considered in conjunction with aluminium
exposure.
For the purpose of dose-response analysis, we limit our attention to the studies described in
the preceding paragraph. Those studies collectively suggest that relative to very low levels of
aluminium exposure, drinking water concentrations amounting to 0.2 mg/L elevate AD risk
by approximately a factor of 1.3 to 1.5 (see Flaten (1990) and Neri & Hewitt (1991)). The study
by Martyn (1989) suggests the risk may be somewhat higher, while the mid-exposure group
results from the Flaten (1990) study are consistent with this estimate. The Rondeau et al.
(2000) study finding of a risk associated with aluminium concentrations exceeding 100 μg/L
serves as the basis for the level of concern identified here.
Reproductive toxicity effects: Human data for this endpoint are limited to extremely high
exposures (due to chronic high doses of antacids) studied in a very small number of individuals
(see Effects on Humans, Effects from Occupational Exposure, Reproductive Toxicity,
Developmental Effects). Effects on Laboratory Mammals and In Vitro Test Systems,
Reproductive and Developmental Toxicity, Reproductive Toxicity describes seven animal
bioassays that studied the association between reproductive toxicity and the impact of oral
exposure to aluminium. Two of these studies investigated administration of Al(OH)3 alone
(Domingo et al., 1989; Gómez et al., 1990); neither reported any effects. The Domingo et al.
(1989) study evaluated the impact of exposures to Al(OH)3 on gestation days 6-15 as high as
Krewski et al. Page 212
J Toxicol Environ Health B Crit Rev. Author manuscript; available in PMC 2009 November 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
266 mg/kg b.w/day in mice. Gómez et al. (1990) evaluated the impact of exposures as high as
768 mg/kg b.w./day on gestation days 6-15.
On the other hand, studies of the concurrent administration of Al(OH)3 and citric acid (Gómez
et al., 1991), lactate (Colomina et al., 1992), or ascorbic acid (Colomina et al., 1994) did report
reproductive toxicity effects. Gómez et al. (1991) reported delayed ossification following
administration of 384 mg/kg b.w./day in dams along with 62 mg/kg b.w./day citric acid, with
no effects when either of these substances was administered alone. On the other hand, there
was no treatment related impact on pre- or post-implantation sites, number of live foetuses per
litter, or gender ratio. Colomina et al. (1992) reported that administration of 627 mg aluminium
lactate/kg b.w./day and 570 mg lactic acid/kg b.w./day to dams on gestation days 6-15
decreased maternal body weight and foetal body weight, increased the incidence of cleft palate,
and delayed occification. Colomina et al. (1994) found that concurrent administration of
ascorbic acid and aluminium (300 mg/kg b.w./day) had no impact on reproductive toxicity.
The available results suggest that, when consumed alone, even high oral doses of aluminium
(in particular, Al(OH)3) are insufficient to cause reproductive toxicity. However, when
consumed concurrently with acid, which increases absorption (see Toxicokinetics, Absorption,
Animal Studies, Oral Administration, Factors Influencing Oral Aluminium Absorption,
Carboxylic Acids), there is sufficient internal exposure to result in toxicity. Even with
concurrent administration of acid, these effects have been documented only at maternal
exposures of approximately 400 mg/kg body weight/day or higher.
Dermal exposure—The available evidence for this exposure route’s health effects did not
achieve a modest or strong level of support.
Exposure via injection
Irritation: As described in Effects on Humans, Effects from Non-Occupational Exposure,
Irritation, Irritation after Injection of Aluminium-Adsorbed Proteins (Vaccines and
Hyposensitization Regimens), the quantities of aluminium in vaccine adjuvents are sufficient
to trigger localized irritation in humans.
Neurological effects: Doses were reported in terms of mg/kg body weight/day in three of the
studies that investigated the association between neurological effects and exposure to
aluminium via injection. Esparza et al. (2003) reported that administration of 5 or 10 mg
aluminium lactate/kg body weight/day via injection for 8 weeks (5 times per week) resulted in
signs of oxidative stress in the hippocampus. Changes in these markers remained well below
two-fold despite the fact that this exposure was 1,000 times normal. Gómez et al. (2005)
administered 7 mg/kg body weight/day aluminium lactate via injection for 11 weeks (5 times
per week). Exposed animals experienced 30% reductions in body weight. Some signs of
oxidative stress in the hippocampus (elevations of approximately 50% in mitochondrial SOD
mRNA) were also reported. Finally, Miu et al. (2003) injected rats with 0.85 mg aluminium
gluconate/kg b.w./day for 6 months (3 times per week). The study reported evidence of
reductions in neuronal density in the hippocampus, intracellular accumulations of aluminium
in dense granules, and thickening of the meningeal blood vessels.
Exposure characterization
Human Exposure comprehensively reviews the available data quantifying human exposure to
aluminium in the environment.
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Ambient respirable exposures for the general population average as much as nearly 2 μg/m3
(PM2.5 fraction) to 7 μg/m3 (PM10 fraction) of aluminium in ambient dust fractions (see Table
13). Occupational exposures for this route average as much as 1 to 6 mg/m3 (see Table 15).
Table 16 summarizes estimated intake rates for food, drinking water, ambient air (followed by
swallowing), antacid use, buffered aspirin use, and from antiperspirants. The exposures
associated with each of the exposure routes listed span approximately five orders of magnitude.
The largest exposures are associated with the use of antacids (7,200 mg/day) and aspirin (1,000
mg/day). The smallest exposures are associated with inhalation of ambient air and consumption
of drinking water. Using that information, Table 26 estimates body weight normalized
aluminium uptake. Differences in bioavailability for the various routes of exposure change the
ranking of the exposure routes, but only to a limited degree.
The values in this table indicate that intake of aluminium from food dominates that from
drinking water. Even inhalation contributes more aluminium than does consumption of
drinking water. As expected, occupational exposures exceed general population exposures by
more than two orders of magnitude. However, consumption of medications containing
aluminium makes the greatest potential contribution to internal aluminium exposure.
Contributions from these two sources exceed the contribution from food by a factor of about
100 (aspirin) or 1,000 (antacid). The contribution of anti-perspirant use to aluminium uptake
could potentially be of the same order of magnitude as the contribution of diet, although the
degree to which aluminium in anti-perspirants is absorbed has not been well demonstrated (see
Toxicokinetics, Absorption, Studies in Humans, Dermal Exposure).
Risk characterization
Table 27 summarizes the level of concern values identified in Evaluation of Human Health
Risks, Health Effects, Dose Response and the exposure levels listed in Evaluation of Human
Health Risks, Health Effects, Exposure Characterization. The table also reports “margin of
exposure” values, representing the ratio of each level of concern and the corresponding
exposure level. Separate values are reported for occupational and general populations, where
appropriate. For the general population, the margins of exposure are generally large, with the
exception of the estimated margin of exposure associated with drinking water consumption
(margin of exposure equal to approximately unity), and exposure via injection (margin of
exposure less than unity). In particular, aluminium exposures accompanying a single injection
may result in irritation, a relatively minor health effect. Neurological health effects are also
possible, although for typical injections (e.g., for vaccination), only following daily injections
over a period of many months. In the past, dialysis patients were exposed to very high levels
of aluminium due to contamination of dialysis fluid and/or use of aluminium phosphate binders.
Such contamination is possible now, but occurs only rarely. For the general population, health
effects associated with injections containing aluminium are not likely. For the occupational
population, only one margin of exposure value could be estimated. For inhalation exposure in
occupational settings, we estimated a margin of exposure value of approximately eight for the
irritation endpoint.
Although we judge the available toxicity information for aluminium as inadequate to develop
dose response relationships that could be used to estimate the probability of adverse outcomes,
it is sufficient to identify those exposure pathways and health outcomes that are of greatest
concern. Comparing the exposure levels of concern to established exposure limits (summarized
in Table 28) further informs this characterization.
For the general population, the evidence suggests that exposure levels to airborne aluminium
are well below plausible levels of concern. The identified exposure level for the general
population (0.007 mg/m3) is approximately a factor of 300 below the lowest of the occupational
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exposure limits for airborne exposure listed in Table 28. Although these limits are not
established for the general population, the 0.007 mg/m3 concentration is also nearly four orders
of magnitude below the concern level identified for aluminium powder in this assessment (see
Table 27). Occupational exposure is below the level of concern we identified (by approximately
a factor of 8), although the exposure level we identified does exceed some of the exposure
limits listed in Table 28. In any case, it appears that airborne exposure to aluminium is generally
below levels where health effects have been identified, and in the case of the general population,
there is a large margin of exposure.
For oral exposure, we identified two health effects. For reproductive toxicity, there is a margin
of exposure of nearly 3000. On the other hand, for neurological effects (in particular, an
increased risk for the development of AD), exposure to aluminium in drinking water (0.1 mg/
L) may be similar to the level of concern we identified. This level of 0.1 mg/L is less than the
recommended limits established by the WHO, the European Union, and Australia (see Table
28). Secondary drinking water regulations in the U.S. establish a limit of 0.05 to 0.2 mg/L for
aluminium (Table 28).
The implication of the comparisons outlined here is that health effects associated with oral
exposure to aluminium in general, and the neurological (AD) health endpoint in particular,
deserve the greatest scrutiny. Limitations to the epidemiological evidence (confounding,
uncertain exposure levels, and so forth) complicate its use for establishing toxicity benchmarks
(such as a reference dose).
As pointed out by Nieboer et al. (1995), the epidemiological evidence for a possible association
between aluminium in drinking water and AD must be viewed in the context that this disease
has a complex genetic trait. It is considered multifactorial, involving multiple genes that interact
with multiple environmental (including life-style) factors. Early onset AD is strongly linked
to mutations in 3 genes, with autosomal-dominant inheritance patterns (Bertram & Tanzi,
2004; 2005). By contrast, the more frequent late onset (at or older than age 65) AD, only one
genetic risk factor has been consistently established and involves polymorphism of the ApoE
gene; its epsilon-4 allele constitutes a risk factor (Bertram & Tanzi, 2004; 2005). Many other
genetic loci have been implicated, but “no other genetic risk factor has been found to
consistently confer susceptibility to ‘late onset’ AD” (Bertram & Tanzi, 2004). Identification
of specific environmental factors has been more elusive, but age, low-level education, head
trauma, and vascular risk factors (including cardiovascular genetic susceptibility factors) are
plausible candidates (Bertram & Tanzi, 2005; De la Torre, 2002; Kivipelto et al., 2005; Lindsay
et al., 2002). In a recent study of twins, heritability for AD was estimated to be between 58-79%
(Gatz et al., 2006). This evidence for a genetic contribution to the aetiology of AD does not
preclude the possibility of an environmental contribution. However, positive findings in
epidemiological studies completed to date need to be interpreted carefully in light of possible
confounding and inherent study weaknesses.
A chronic exposure animal bioassay might help to provide information on the neurological
impact of oral exposure to aluminium. If such a study is conducted, it should expose animals
via the relevant exposure route (oral exposure), rather than by other routes (e.g., injection).
Before committing the time and resources to such a study, however, the limitations inherent
to such a study need to be considered. First, while a laboratory animal study can identify
alterations in the nervous system and neurobehavioural function, clinical relevance to
neurological effects in humans, especially those related to a cognitive disease, are not clear.
Second, such a study would likely necessitate use of high doses, making downward
extrapolation to environmentally relevant doses and maintained neurobehavioural dysfunction
necessary. While standard algorithms can be used to develop a point of departure (e.g., a
benchmark dose) and identify appropriate adjustment factors (for calculation of a reference
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dose, for example), the implications of the resulting exposure value for human risk may not be
clear. It should be noted that the exposure level of concern estimated here for aluminium in
drinking water (100 μg/L) suggests that absorption of 6.9 × 10-6 mg/kg-day aluminium is of
concern. If that is the case, then exposures associated with food intake (uptake of 1 × 10-4 mg/
kg-day) or inhalation (1.7 × 10-5 mg/kg-day) would also be of concern (see Table 26). This
possibility underlines the need to better understand the robustness of the causal association
between neurological effects and exposure to aluminium, i.e., the effect associated with
exposure via drinking water intake.
RESEARCH NEEDS
Research Needs for Risk Assessment
The following research needs were identified as important research requirements to further
improve risk assessments on aluminium:
• Studies should be conducted to quantify peak and cumulative air-borne aluminium
exposure of workers in the aluminium industry and to characterize aluminium-
containing aerosols in terms of particle composition and size. Concomitant
assessments of the bioavailability of the inhaled aerosols are crucial.
• In many occupational studies of aluminium workers, it was not known whether
respiratory tract illness was due to exposure to aluminium or other substances. There
have been very few studies of neurological effects of occupational exposure via
inhalation to aluminium and aluminium compounds (as measured in serum), and it is
not known if the very specific neurological deficits observed lead to more severe
illness such as AD. Therefore, large-scale, longitudinal, studies of occupational
exposure to aluminium and aluminium compounds via inhalation, with precise
methods of exposure measurement, are needed to assess the risks of respiratory tract
disease and neurological effects due to aluminium and aluminium compounds.
• Further studies are needed to settle the debate over the link between aluminium in
drinking water and neurological disorders and cognitive impairment. Ideally,
individual level data on drinking water exposure as well as other relevant risk factors
would be obtained; in the absence of this, replication of the Rondeau et al. (2000)
analysis in other study populations, with the ability to control for important
confounders and effect modifiers, is needed to assess this potential risk.
Scientific Data Gaps
The following data gaps represent areas of scientific interest to further understanding on the
human health implications of aluminium exposure:
• At present, there is no long-term animal bioassay focusing on the neurotoxic effects
of aluminium. Although this represents a major scientific data gap, the Panel
questioned whether the availability of such a study would greatly improve our ability
to establish human exposure guidelines for aluminium, given the availability of direct
epidemiological evidence in this regard. If such a study were to be conducted for the
purpose of informing human health risk assessment, careful consideration should be
given to the neurological endpoints that would be of most relevance to humans, the
most appropriate animal species and route of exposure, and the detailed experimental
design, including the number of animals tested, and number and selection of doses.
The Panel also noted the lack of data on neurodevelopmental effects in animals, but
was unclear on the need for additional data in this regard for risk assessment purposes.
• Quantify aluminium absorption through the skin in humans after repeated application
of an aluminium-containing antiperspirant.
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• Given the high degree of inhalation exposure to aluminium, further examination of
aluminium uptake from the nasal cavity and distribution directly to the brain, rather
than secondary via the circulatory system in the rat or non-human primate, would
provide information on the potential for inhalation exposure to contribute to
aluminium neurotoxicity by this route.
• Develop a better understanding of the significance of ligands associated with
aluminium on its absorption, distribution, biotransformation and elimination, and
aluminium-induced effects. This would include determination if aluminium
complexes with fluoride or natural organic ligands such as phytates, humic acids and
phenols in water, infant formula or food are stable in vivo, and if not, the rate they
biotransform and the aluminium species formed. The experimental approach will
probably include computational modelling. This work would also address whether
the aluminium species significantly affects aluminium pharmacokinetics, such as oral
bioavailability, and aluminium-induced effects, such as the association between
aluminium consumption and cognitive loss. The pharmacokinetic studies are probably
best conducted using 26Al as a tracer.
• Develop a physiologically-based pharmacokinetic (PBPK) model in the human for
aluminium that would reduce the need for further pharmacokinetic studies necessary
to predict the risk from various aluminium exposures.
• One of the most difficult tasks is to relate the level of exposure of the animal to the
human. For rodent studies, the general rule is that the metabolic rate of rodents is
about 10 times that of humans. Therefore, in testing the efficacy or toxicity of a given
compound, doses that are at least 10 times the normal human dose are usually used.
However, in gauging the relative exposure of the rodent to aluminium, it would be
preferable to document the steady-state level of aluminium in serum as a marker of
exposure. This measure would provide information on absorption, which would be
one variable to consider in assessing differences in metabolism between species.
Internal biomarkers of exposure and target tissue body burdens are important for
assessing neurotoxicity data on any chemical. Unfortunately, relatively few studies
in the existing literature provide this important piece of information. As described in
Toxicokinetics, the steady-state level of aluminium in serum of the average adult
human is 1-2 μg/L. Most of this aluminium is bound to transferrin. Therefore, a study
of rodents in which levels of aluminium in serum were maintained at 10-20 μg/L
would be viewed as a reasonable approximation of normal human exposure. Studies
that achieved higher steady-state levels (5 and 10 times normal serum levels or 50-100
μg/L to 100-200 μg/L) could be viewed as more rigorous tests of toxicity and would
provide very useful information regarding the potential long-term effects of Al on
various organ systems. From the data reviewed here, there is evidence that high levels
of aluminium are toxic to the nervous system, can affect bone, and may affect
hematopoiesis. There remains however, an incomplete understanding of the threshold
of aluminium exposure required to induce toxicity in vulnerable tissues.
• It should be determined if aluminium can serve as a hapten to produce contact
hypersensitivity and if there is a specific IgE antibody to aluminium.
• As the results from some, but not all, epidemiological and dietary studies suggest
silica species can reduce aluminium oral absorption and/or enhance aluminium
excretion and protect against aluminium-induced adverse effects, further studies are
needed to investigate this, focusing on the identity of the silica species, their molar
ratio to aluminium, and the magnitude of the observed effects.
• There is a need for further epidemiological studies that look at all aluminium
components of ingestion. The regular ingestion of aluminium-containing antacids
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represents a major source of exposure to aluminium. However, very few studies have
related their use to the development of AD. Epidemiological studies on aluminium
exposure from food or on the consumption of food-containing aluminium additives
are also uncommon, although food is a more significant source of aluminium ingestion
than water.
APPENDIX A
Summary of the toxic effects of aluminium on laboratory animals and in vitro.
Reference Compound, dose, duration Species End-points examined Results
SINGLE/ACUTE EXPOSURE
Intratracheal/intrapleural exposure
Lindenschmidt et al. (1990) Animals were instilled with
silica (0.2, 1.0, or 5.0 mg/100 g
b.w.), titanium dioxide (1.0 or 5
mg/100 g b.w.), aluminium
oxide (1.0 or 5.0 mg/100g b.w.)
or saline.
Male Fischer- 344 rats Endpoints were
assessed following
termination at 1, 7, 14,
28, and 63 days
following instillation.
BAL performed on 5
rats/group. Levels of
lactate dehydrogenase,
B-glucuronidase, N-
acetyglucosaminidase,
and total protein were
measured. The lungs of
3 rats from each group
were examined for
increased collagen at
the end of the study
period.
Biochemical and
cellular parameters
increased in a dose-
related fashion at the
earlier time points for all
groups, the magnitude
of change was greatest
for silica. The response
for silica dust steadily
increased, while the
levels for the other two
groups decreased
toward normal values.
Minimal histological
changes were seen for
the aluminium oxide or
titanium dioxide groups.
Pigott & Ishmael (1992) Groups of 24 male and 24
female rats were dosed by single
intrapleural injection of
refractory alumina fibres
(Saffil) as manufactured or after
extensive thermal ageing or of
one of two types of
aluminosilicate fibres with
different diameters. Asbestos
and saline were used as positive
and negative controls,
respectively
Male and female albino
rats of the Alpk: AP
(Wistar derived) strain
Rats were maintained
to 85% mortality and
were closely examined
for the presence of
mesothelioma.
Malignant
mesothelioma was
diagnosed in 7 rats
dosed with asbestos, and
3 dosed with
aluminosilicate fibre B.
Mesothelioma was not
detected in any rat dosed
with Saffil or in negative
controls.
Tornling et al. (1993) Single intratracheal instillation
of aluminium oxide (n=21) (40
mg), or aluminium oxide with
adsorbed fluorides (n=21) (40
mg).
Sprague Dawley rats BAL performed 1.4
and 12 months after
exposure.
Cells in BAL fluid were
increased significantly
by secondary alumina
(adsorbed fluorides) but
not with primary
alumina. Fibronectin
concentrations were
increased one year after
exposure in both groups.
Dalbey & Pulkowski (2000) Groups of 15 rats were
administered a single
intratracheal instillation (50
mg) of Bayer pseudoboehmite,
Bayer gamma-Al2O3, Ziegler
pseudoboehmite, or Ziegler
gamma-Al203. Positive controls
were instilled with quartz, and
negative controls with glass
beads.
Male Sprague Dawley
rats
6 months after
administration animals
were evaluated for lung
volumes, pulmonary
pressure- volume
curves, pulmonary
hydroxyproline
content, lung weights
and histopathology.
Rales were noted in the
rats in the four groups
receiving aluminas but
not in the groups given
glass beads or quartz.
Lung lobe weight
significantly increased
with quartz and all
groups given aluminas.
Areas of granulomatous
inflammation and early
collagenization were
noted in the alumina
treatment groups. None
of the aluminas caused a
reaction as severe as
quartz.
Alberquerque et al. (2002) Male rats were instilled once
intrapleurally with saline or Al
(OH)3 (0.15 g/mL). Animals
Male Wistar rats Respiratory system,
lung, and chest wall
elastic, resistive, and
viscelastic/
Chest wall elastic and
viscoelastic pressures
increased after Al(OH)3
instillation. An increase
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were studied 7 or 30 days after
the instillation.
inhomogeneous
pressures were
measured.
Inflammation and
collagen deposition
was assessed.
in the type I/type III
collagen ratio was
present 30 days after
instillation. No
differences in lung
parenchyma among the
groups were noted.
In Vitro
Gusev et al. (1993) Rabbit alveolar macrophages
and monocytes, and human
monocytes and granulocytes
were incubated with different
amounts of quartz, silica, and
alumina dust.
Rabbit alveolar
macrophages and
moncytes, human
granulocytes and
monocytes
Active oxygen total
generation by cells was
measured. The
intensity of generation
of superoxide radicals
by cells was conducted.
Cells incubated with
quartz dust exhibited a
significant increase in
total generation of active
oxygen. Silica dust and
alumina dust at the same
concentrations caused
much less of an increase
in active oxygen
production.
Warshawsky et al. (1994) The cytotoxicity of various
particles, including aluminium
oxide, to alveolar macrophages
obtained from hamsters and rats
was assessed.
Hamster and rat alveolar
macrophage
Cytotoxicity was
measured at 24 and 48
h using dye exclusion
procedures.
The cells treated with
aluminium oxide
showed minimal to no
changes in viability.
Oral exposure
More et al. (1992) One group of 42 rats was
sacrificed 1, 3, 6, 12, 24, 48, and
96 hr after a single (300 mg/kg
b.w.) oral administration of
aluminium hydroxide. A second
group (n=30) received daily the
same dose of aluminium
hydroxide and were sacrificed
after 3, 4, 5, 6, and 7 days of
treatment.
Male Sprague Dawley
rats
Intracellular binding of
aluminium was
examined in the
mucosa of the stomach,
duodenum, jejunum,
and ileum of adult rats.
Aluminium deposits
occurred only in the
antral gland of the
stomach and in rats
treated for at least 3
days.
Injection
Gherardi et al. (2001) 4 rats received an i.m. injection
of an aluminium hydroxide
containing vaccine.
Sprague Dawley rats Animals were
sacrificed at 7, 14, 21,
and 28 days post-
injection and muscles
close to, and remote
from, the site of
injection were
examined by electron
microscopy.
The vaccine induced a
large necrotic area
containing damaged
muscle fibres and
neutrophils surrounded
by abundant
lymphocytes and
macrophages.
Crystalline inclusions
similar to those of MMF
were discovered.
Shi et al. (2001) 42 rats received s.c. injections of
1 of 4 treatments: (1) 0.9%
NaCl, (2) Endotoxin solution,
(3) Endotoxin and aluminium
phosphate adjuvant, (4)
Endotoxin and aluminium
hydroxide adjuvant. The dose of
endotoxin was 1 μg, and the
dose of aluminium was 0.85 mg.
Female Sprague Dawley
rats
To measure systemic
response, the levels of
TNFα, and IL-6 were
measured in the serum.
TNFα and IL-6 were
observed in the group
which received an
endotoxin solution or
endotoxin and
aluminium phosphate
adjuvant. No TNFα or
IL-6 was detected n the
group that received
endotoxin and Al(OH)3
adjuvant.
Valtulini et al. (2005) Investigation followed repeated
reports of up to 65% of pigs
from one particular farm having
one or more nodules in the
muscles of the neck. In total, 45
pigs were assigned to: the
original vaccine, the adjuvant
alone, distilled water, or with
the adjuvant and distilled water
Pigs (cross between
Italian Landrace and
Italian Large White)
Areas of muscular-
cutaneous tissue were
sampled from the neck
of the slaughtered pigs.
Granulomas
underwent histological
and histochemical
analysis.
All groups administered
the vaccine, adjuvant or
adjuvant/water
developed granulomas.
No granulomas were
found in the group
administered water
alone.
Verdier et al. (2005) 2 groups of 12 monkeys
received an i.m. injection of
vaccines which were adjuvanted
with either aluminium
hydroxide or aluminium
phosphate.
Cynomolgus monkeys 4 monkeys from each
group were sacrificed
3, 6, or 12 months after
vaccination.
Histopathological
examination and
aluminium assays were
performed on the
Histopathological
lesions similar to the
MMF described in
humans were observed
and persisted 3 months
after aluminium
phosphate and 12
months after aluminium
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quadriceps muscle
sections.
hydroxide
administration.
Increased aluminium
concentration in the area
of the lesion was also
observed.
Dermal Exposure
Lansdown (1973) Topically applied solutions of
six aluminium salts were
administered to the skin of mice,
rabbits, and pigs. The animals
were treated for 5 consecutive
days at various concentrations.
Female albino mice,
New Zealand white
rabbits, and pigs (large
white strain).
Animals were killed 24
hr after the final
treatment and the skin
was examined for
erythema, thickening,
and scaling.
Epidermal changes
consisting of
hyperplasia,
microabscess formation,
and dermal
inflammatory cell
infiltration were evident
in all three species
treated with aluminium
chloride (10%) or nitrate
(10%), but not with
aluminium sulphate
(10%), aluminium
hydroxide (10%),
acetate (10%), or
chlorhydrate (10% and
25%)
REPEATED EXPOSURE
Inhalation/intratracheal instillation exposure
Christie et al. (1963) Rats and hamsters were exposed
to powder or fume produced
from aluminium. Powder was
blown into the experimental
chambers hourly and fume
every two hr throughout an 8 hr
day. The quantity recovered in
one period was 100 mg from the
powder chamber and 92 mg
from the fume chamber.
Male hamsters and male
Wistar rats
Lungs were examined
for gross abnormalities
and microscopic
examination was also
conducted. Aluminium
content of the lung was
also measured.
Weights of wet lung, ash
and aluminium oxide
content of lungs were
greater in the lungs of
exposed rats than
controls. In rats and
hamsters exposed to
aluminium powder and
alumina fume the initial
response was a
proliferation of
macrophages within
alveolar spaces. After
long exposure to
aluminium powder, rats
showed focal deposits of
hyaline material in
alveolar walls.
Gross et al. (1973) Rats, guinea pigs, and hamsters
were exposed to 3 different
types of aluminium powder
(British pyro powder- flake like
particles, American powder
with flake like particles, and
powder comprised of atomized
spherical particles) in inhalation
chambers at varying
concentrations. Animals were
exposed for 6 hr/day, 5 days/
week, for 6 months; some
animals were exposed for 1
year.
Rats, hamsters, and
guinea pigs
Histological
examination of the
lungs
Scattered small scars
resulted from foci of
lipid pneumonitis in rats
in the treatment group.
Alveolar proteinosis
developed in all three
species that inhaled
aluminium dust, and
was most pronounced in
the rats. These
symptoms resolved
spontaneously and the
accumulated dust
deposits cleared rapidly
from the lungs after
cessation of the
exposure.
Pigott et al. (1981) Rats were exposed to refractory
alumina fibre (Saffil) as
manufactured or aged; asbestos
was used as a positive control.
Rats were placed in inhalation
chambers and were exposed to
fibres 5 days/week for 6 hr
period. Exposures were
terminated after 86 weeks for
the Saffil group and 77 weeks
for the asbestos group. Animals
were maintained until a
Wistar Albino rats Histopathological
examination of all
grossly abnormal tissue
and of the major organs
was conducted.
Pulmonary reaction to
both forms of alumina
fibre was minimal. The
asbestos group
exhibited the most
severe fibrosis.
Pulmonary tumours
were confined to rats
dosed with asbestos.
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mortality rate of 85% was
reached.
Ess et al. (1993) Fibrogenicity of 7 alumina
samples was tested in rats by
intratracheal instillation. Quartz
was used as a positive control.
The total dose (50 mg for each
of the alumina samples and 25
mg for quartz) was administered
by 5 instillations over a period
of 2 weeks.
Female Sprague Dawley
rats
Groups of 5 animals
were sacrificed 60, 90,
180, and 360 days after
exposure. Histological
examinations were
carried out and BAL
was performed on the
rats.
Fibrogenic potential
was not noted for any of
the 5 aluminas used for
primary aluminium
production; a chemical
grade and laboratory
produced sample
induced fibrotic lesions.
Oral exposure
Berlyne et al. (1972a) Groups of nephrectomised rats
were administered 1% or 2%
AlCl3 or Al2(SO4)3 in drinking-
water or oral Al(OH)3 (150 mg
of elemental aluminium/kg
b.w./day) by gavage. Groups of
non-nephrectomised rats
received the same treatments.
The duration of the treatment
was not indicated.
Male rats Weizmann
Institute strain
Plasma and tissue
levels of aluminium
were assessed.
Histological
examination of the
cornea, lungs, liver,
and other major organs
was conducted.
Periorbital bleeding was
noted in all of the oral
treatment groups in the
nephrectomised rats,
except for the Al(OH)3
group.
Thurston et al. (1972) Groups of 6 rats were assigned
to (a) a control diet, (b) diet with
Al(OH)3 3.2 g/kg, (c) diet with
Al(OH)3 + 10 g/kg disodium
hydrogen phosphate. An
additional group of rats
underwent partial nephrectomy
and received diet (b).
Rats Line test for rachitic
change was carried out
on the skeleton of each
animal. Histological
examination was
conducted and the
skeletal aluminium
content assessed.
Al(OH)3 impaired the
growth rate of normal
rats and produced
rachitic bone changes;
this effect could have
been corrected by
phosphate supplements.
Arieff et al. (1979) Normal rats and rats with renal
failure were given oral Al
(OH)3 (300 mg daily for 5
months). A group of mongrel
dogs also received the same
dose and frequency of
treatment. An additional group
of rats and dogs served as
controls.
Sprague Dawley rats,
and mongrel dogs
Aluminium levels were
measured in the liver,
skeletal muscle and
cerebral cortex of the
rats. In the dogs,
aluminium was
measured in the
cerebral cortex and
subcortical white
matter. EEGs were
conducted on the dogs.
EEGs were normal in
the aluminium treated
dogs.
Thorne et al. (1986) Rats were fed diets with no
added aluminium, or with at
doses of added Al(OH)3 1500,
2500 or 3500 mg/kg b.w./day.
These diets were maintained for
30 days, after the treatment
period animals were fed a basal
diet.
Male Long Evans rats A variety of
behavioural tests was
conducted. Brain
aluminium content was
measured.
Brain aluminium
content correlated with
the amount of
aluminium in the diet.
Elevated brain
aluminium correlated
with relatively poor
performance on two of
the behavioural tests.
Sugawara et al. (1988) 22 weanling rats, and 19 adult
rats were fed either a control
diet, a diet with 2000 ppm Al
(OH)3 or 2000 ppm AlK(SO4)2
for 67 days.
Male Wistar rats Blood samples were
taken to determine
haematocrit and
haemoglobin. Serum,
liver, epididymal
adipose tissue, femur,
and intestine were
analyzed for
aluminium and lipids.
No aluminium induced
anaemia or
hyophosphatemia was
observed. Serum
triglyceride was
decreased by
aluminium. Neither
serum cholesterol nor
phospholipids was
affected by aluminium
ingestion.
Bilkei-Gorzo (1993) Rats were treated orally once a
day with NaCl + citric acid,
AlCl3 (30 or 100 mg/kg), Al
(OH)3 (100 mg/kg) + citric acid,
or Al(OH)3 (300 mg/kg). The
treatment was maintained for 90
days.
Long Evans rats Learning ability was
determined by the
labyrinth test at day 90.
Choline-acetyl
transferase,
acetylcholinesterase
activity and aluminium
content of the brains
were measured.
Learning ability was
impaired in the groups
which received AlCl3 or
Al(OH)3 + citric acid.
Aluminium content of
the brain was elevated in
all treatment groups,
most significantly in the
AlCl3 (100 mg/kg)
group. Choline-
acetyltransferase
activity decreased in all
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groups except the Al
(OH)3 treated group.
Ecelbarger et al. (1994b) Rats were fed diets containing
0.4 or 36.8 μmol Al/g diet as
aluminium hydroxide for 8
months until 23 months of age.
Sprague Dawley rats Urine and tissue
samples were collected
for aluminium
analysis.
The rats exhibited little
evidence of aluminium
toxicity as body weight,
feed intake, or changes
in the relative size of
tissues.
Dlugazek et al. (2000) Aluminium was administered in
drinking water as aluminium
chloride, dihydroxyaluminium
sodium carbonate or aluminium
hydroxide. Animals were
exposed to a total dose of 700
mg aluminium for each
compound. The treatment
period was 159 days for Al
(OH)3.
Female mice (Pzh:SFIS) Concentrations of Al,
Ca, Mg, Zn, Cu, and Fe
in the stomach,
kidneys, bone and liver
of the animals were
analyzed.
In the Al(OH)3 treated
group an increase in Mg
concentration in bones,
a decline in the Fe
concentration in the
stomach, and a decline
in Cu in liver and kidney
was observed.
Injection
O’Gara & Brown (1967) Aluminium foil was implanted
s.c. into rats.
NIH black male rats Rats were examined
grossly and
microscopically for
lesions
8 of 18 rats developed
sarcomas following
implantation. The
smooth surface of the
implant is likely
responsible for the
induction of sarcomas.
Levaditi et al. (1968) Injections of Al(OH)3 s.c. were
given weekly to rabbits and
guinea pigs for a duration of 5 or
10 months.
Rabbits and guinea pigs Animals were
examined for visceral
alterations.
Limited local
inflammatory lesions
were observed.
Bugiani & Ghetti (1982) The cisterna magna of 31 rabbits
were injected with 0.3 mL of a
1% suspension of (metallic)
aluminium powder. 11
additional rabbits served as
controls.
Male New Zealand
Albino rabbits
Neurological
examinations were
conducted. Sections of
the spinal cord were
examined for the
number of nerve cells,
and neurons with
neurofibrillary
degeneration.
The injection induced a
slowly progressing
encephalomyelopathy.
The large neurons of the
anterior horns showed
the most severe
neurofibrillary
degeneration and axonal
swellings. Neurogenic
muscular atrophy
appeared in animals
killed in the 2nd and 3rd
month after injection.
Fiejka et al. (1996) Mice received 1 mg Al, as Al
(OH)3, i.p. every two weeks;
another group received an i.p.
injection of 0.1 mg elemental
aluminium in the form of Al
(OH)3 5 days/week. 10 animals
from each group were killed
after treatment with 2, 4 and 6
mg of elemental aluminium.
Mice (strain Pzh:SFIS) Al concentrations in
liver, bone and brain
were evaluated. Liver
tissue was examined
histologically.
Development of
resorption granulomas
was observed in the
liver.
Mahieu et al. (1998) Rats were given Al(OH)3 (80
mg/kg b.w.) i.p. 3 time per week
for a duration of 6 months. The
diet was supplemented with
calcium and phosphorus.
Control rats received i.p.
injections of saline.
Male Wistar rats Phosphate tubular
transport capacity was
evaluated and
parathyroid gland
function was assessed.
The fractional excretion
of P and Na were
significantly lower in
treated animals than in
control animals.
Calcemia recovery
following a
hypocacaemic stimulus
and the nephrogenic
excretion of cAMP were
diminished.
Mahieu et al. (2000) Rats were treated 3 times a wk
with an i.p. injection of Al
(OH)3 (80 g/kg b.w.) for a
period of 6 months.
Male Wistar rats Haematological
parameters, and the
osmotic resistance of
red cells were
determined in blood.
aluminium and Fe
concentrations as well
as Tf saturation rate
were determined in
serum. Urea and
Animals in the
aluminium treatment
group developed
progressive
microcytosis which
became more prominent
with time. The
haematocrit levels were
significantly reduced
during months 1, 3, and
4 for the treated animals.
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creatine plasma levels
were also measured.
The haemoglobin levels
decreased on months 3
and 4, and then began to
increase in months 5 and
6.
Platt et al. (2001) Rats received
intracerebroventricular
injections of aluminium (0.68
μg or 5.4 μg over a period of 5
days). Animals were left for a
period of either 7 days or 6
weeks.
Male Wistar rats The brain of the
animals was
histologically
examined.
A greater inflammatory
response was noted in
Al-injected animals
compared with controls.
Damage of the
cingulated bundle in Al-
treated animals led to a
severe anterograde
degeneration of
cholinergic terminals in
the cortex and
hippocampus.
Bazzoni et al. (2005) 7 rats were injected i.p. with Al
(OH)3 (80 mg/kg b.w) 3 times a
week for three months. A
control group (n=7) was
injected with saline at the same
frequency and duration.
Male Wistar rats Blood samples were
collected to examine
various haematological
parameters.
Significant decreased in
haematocrit and blood
haemoglobin
concentrations were
found in the treatment
group. Erythrocytes
became more resistant to
hypotonic haemolysis.
Erythrocyte aggregation
rate decreased in the
treatment group.
Cointry et al. (2005) 14 rats received i.p. doses of 27
mg/day aluminium as Al(OH)3
for 26 weeks.
Female Wistar rats Femur diaphyses were
studied
tomographically and
mechanically tested in
bending.
Treatment reduced the
cortical bone
mineralization, and had
a negative impact on the
bending stiffness and the
yield stress of cortical
bone.
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ABBREVIATIONS
dae aerodynamic diameters
ATW alum-treated water
AM alveolar macrophages
AD Alzheimer’s disease
ACGIH American Conference of Governmental Industrial Hygienists
APP amyloid precursor protein
ALS amyotrophic lateral sclerosis
ApoE apoliprotein E gene
AA atomic absorption
BCG bacillus calmette-guerin
BBB blood-brain barrier
BrdU bromodeoxyuridine
BALF bronchoalveolar lavage fluid
Bτ body content
CNS central nervous system
CSF cerebrospinal fluid
CAS Chemical Abstracts Service
CC16 clara cell protein 16
CDT clock drawing test
CTPV coal-tar-pitch volatiles
CT computerized tomographic
CI confidence interval
DFO desferrioxamine
DAE dialysis associated encephalopathy
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DNP dinitrophenol
DTP diphtheria toxoid, tetanus toxoid, and pertussis
EEG electroencephalogram
EAAS electrothermal atomic absorption spectrometry
EDX energy dispersive (electron probe) x-ray microanalysis
EDXS energy dispersive x-ray spectrometry
CFU-E erythroid colony forming units
EDTA ethylenediaminetetraacetic acid
EEC European Economic Union Council
EINECS European Inventory of Existing Commercial Substances
ERP-P300 event-related potential
ECF extracellular fluid
FA fatty acid
FAO Food and Agriculture Organization
FEV1 forced expiratory volume
FVC forced vital capacity
i.g. gastric intubation
GI gastrointestinal
GFR glomerular filtration rate
G6PDH glucose-6-phosphate dehydrogenase
GSH glutathione
t½ half life
HBV hepatitis B virus
HPT histamine provocation test
Ig immunoglobulin
ICP-MS inductively-coupled plasma mass spectrometry
IQ intelligence quotient
IL interleukin
IARC International Agency for Research on Cancer
IPCS International Programme on Chemical Safety
i.m. intramuscular
i.p. intraperitoneal
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i.v. intravenous
JEM job-exposure matrix
LDH lactate dehydrogenase
LAMMA laser microprobe mass analysis
LMMS laser microprobe mass spectroscopy
VME limit values for average exposure
MMF macrophagic myofasciitis
MMA manual metal
MOE margin of exposure
MMAD mass median aerodynamic diameter
MCL maximum contaminant level
MAK maximum workplace concentration
Mt mega tonnes
MIG metal inert-gas
PIXE μbeammicro-beam proton-induced X-ray emission
mnPCE micronucleated polychromatic peripheral erythrocyte
MMSE mini-mental state exam
MRL minimal risk level
MCT-1 monocarboxylate-1
INAIL National Institute for Insurance Against Occupational Accidents
NIOSH National Institute for Occupational Safety and Health
NFD neurofibrillary degeneration
NFT neurofibrillary tangle
NAA neutron activation analysis
OR odds ratio
GSSG oxidized glutathione
PTH parathyroid hormone
PTX parathyroidectomy
PD Parkinsonism-dementia
PM particulate matter
PEL permissible exposure limit
PBPK physiologically based pharmacokinetic
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AUC plasma aluminium concentration
PAH polycyclic aromatic hydrocarbons
PDAT presenile dementia of the Alzheimer type
PTWI provisional tolerable weekly intake
RL reactivity limit
REL recommended exposure limit
RSW reconstituted soft water
RR relative risk
R risk phrase
S safety phrase
SEM scanning electron microscopy
SIMS secondary ion mass spectrometry
STEL short term exposure limit
SALP sodium aluminium phosphate
SIR standardized incidence ratio
SMR standardized mortality ratio
s.c. subcutaneous
TT tetanus toxoid
TBARS thiobarbituric acid reactive substances
TLV threshold limit value
TPTX thyroparathyroidectomized
TWA time-weighted average
TPN total parenteral nutrition
TSP total suspended particles
Tf transferrin
TfR-ME transferrin-receptor mediated endocytosis
TEM transmission electron microscopy
TIG tungsten inert-gas
TNF tumor necrosis factor
EPA U.S. Environmental Protection Agency
OSHA U.S. Occupational Safety and Health Administration
Vd volume of distribution
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WDX wavelength dispersive X-ray microanalysis
WHO World Health Organization
ZAG zirconium aluminium glycinate.
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Figure 1.
Distribution of soluble, mononuclear aluminium ion species in aqueous solutions. Ordinate:
mole fraction of aluminium ion occurring as each designated species. At any pH the individual
mole fractions sum to unity. Reprinted with permission from Martin (1986). Copyright 1986
American Association for Clinical Chemistry.
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Figure 2.
Mole fraction of Al(III) v.s. pH distribution curves (solids) for a solution containing 0.1 mM
citrate, 3 mM Ca2+, and 1 pM total Al(III). The distribution is only very weakly dependent on
the concentrations of the three components. The dashed line labelled pX refers to the scale on
the right, where pX= -log(mole fraction of free Al3+). Thus we have, at pH 7.4, pX = 7.7. Since
we also have pAl = pX - log [Al(III)], for 1 μM total Al(III), pAl = 7.4 + 6.0 = 13.7. Reprinted
with permission from Martin (1994). Copyright 1994 American Chemical Society. Note that
LH denotes the citrate tri-anion, with all three of its three carboxylate groups deprotonated;
LH-1 denotes the tetra-anion of citrate, which involves a further loss of a proton from its lone
alcohol functional group. Also pAl= -log (concentration of free Al3+) and Al(III) represents
Al3+ in all of its forms.
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Figure 3.
Mole fraction of total Al(II1) v.s. pF = -log [F-], where [F-] is the ambient fluoride molar
concentration; for fluoride complexes of aluminium at two pH values, dashed curves for pH 4
and solid curves for pH 7.5. Symbols on curves designate number of fluoride (F) or hydroxy
groups (h) bound to Al(III). Thus h4 represents Al(OH)4-, F4, AlF4-, and hF3, (HO)AlF3-.
Reprinted with permission from Martin (1994). Copyright 1994 American Chemical Society.
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Figure 4.
Trends in aluminium production by country. Data from USGS (2004).
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Figure 5. Estimates of aluminium consumption (by year)
a) Based on daily consumption reported for adults in the period 1965-2001: Biego et al.
(1998); CFASD (1984); Delves et al. (1993); Ellen et al. (1990); FASEB (1975); Greger
(1985); Greger & Baier (1983); Gramiccioni et al. (1996); Gorsky et al. (1979); Hamilton &
Minski (1972/1973); Jorhem & Haegglund (1992); Knutti & Zimmerli (1985); Liu et al.
(1992); Liu & Chung (1992); MAFF (1985; MAFF 1993); Matsuda et al. (2001); Müller et al
(1997); Neelam et al. (2000); NFA (1993); Pennington (1988); Pennington & Jones (1989);
Pennington & Schoen (1995); Santaroni (1990); Soliman & Zikovsky (1999); Teraoka et al.
(1981); Tipton et al. (1966); Tripathi et al. (2002); Varo & Koivistoinen (1980); Ysart et al.
(2000); Zook & Lehmann (1965).
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Table 1
Chemical identity of aluminium and its compounds – industrial compoundsa,b.
Compound[CAS No]c Chemical Formula Common Synonyms
Aluminium [7429-90-5] Al -
Aluminium alkyls [R3Al]2, R3Al2X3, [R2AlX]2,
[RAlX2]2, [RnAlX3-n]2 with R=alkyl
groups and X=halides
Trialkylaluminium compounds; alkylaluminium
halides
Aluminium alkoxides
[555-75-9; ethoxide]
[556-91-2; tert-butoxide]
[555-31-7; isopropoxide]
Al(OR)3 R=alkyl group Aluminium t-alkoxides
Aluminium antimonide [25152-52-7] AlSb -
Aluminium basic acetate [142-03-0] [8000-61-1] Al(OH)(CH3CO2
−)2 Aluminium bis(acetato-0) hydroxy; aluminium
diacetate
Aluminium borate [11121-16-7] Al2O3•B2O3 Mineral: eremeyevite or jeremejevite
Aluminium borohydride [16962-07-5] Al(BH4)3 -
Aluminium bromide [7727-15-3] Al(Br)3 Aluminium tribromide
Aluminium calcium hydride [16941-10-9] Ca(AlH4
−)2 -
Aluminium carbide [1299-86-1] Al4C3 -
Aluminium chlorate [15477-33-5] Al(ClO3
−)3 -
Aluminium chloride [7446-70-0] AlCl3 Aluminium trichloride; trichloroaluminium
Aluminium chloride hexahydrate [7748-13-6] AlCl3•6H2O Hydrated aluminium chloride
Aluminium fatty-acid salts:
[688-37-9], oleate;
[555-35-1], palmitate;
[637-12-7], stearate;
[645-17-0], linoleate
Al(FA)3 Fatty acid (FA), aluminium salt
Aluminium fluoride [7784-18-1] AlF3 Aluminium trifluoride
Aluminium hexafluorosilicate [17099-70-6] Al2(SiF6)3 Aluminium flurosilicate; aluminium silicofluoride
Aluminium hydride [7784-21-6] AlH3 -
Aluminium hydroxide [21645-51-2] Al(OH)3 Aldrox; alumina hydrate; gibbsite
Aluminium hypophosphite [7784-22-7] Al(H2PO2
−)3 -
Aluminium iodide [7784-23-8] AlI3 Aluminium triiodide
Aluminium lactate [18917-91-4] Al[CH3(OH)CO2
−]3 Aluctyl
Aluminium lithium hydride [16853-85-3] Li(AlH4
−) Lithium aluminium hydride; lithium
tetrahydroaluminate
Aluminium magnesium silicate [12511-31-8] MgAl2(SiO4
4−)2 Magnesium aluminium silicate; colerainite and other
mineral forms
Aluminium nitrate [13473-90-0] Al(NO3
−)3 -
Aluminium nitride [24304-00-5] AlN -
Aluminium oxalate [814-87-9] Al2(C2O4
2−)3 Aluminium salt
Aluminium oxide [1344-28-1] Al2O3 Aloxite; alumina; α-alumina (corundum)
Aluminium phosphate [7784-30-7] Al(PO4) Aluminium orthophosphate; phosphoric acid,
aluminium salt
Aluminium phosphide [20859-73-8] AlP Aluminium monophosphide; trade names: celphos,
phostoxin, quickphos
Aluminium potassium sulphate [10043-67-1] KAl(SO4
2−)2 Alum
Aluminium potassium sulphate dodecahydrate [7784-24-9] KAl(SO4
2−)2•12H2O Potassium alum
Aluminium selenide [7784-24-9] Al2Se3 -
Aluminium silicate [12141-46-7] Al2SiO5•nH2O Aluminium silicate n-hydrate
Aluminium sodium sulphate [10102-71-3] NaAl(SO4
2−)2 Sodium alum; soda alum
Aluminium sodium sulphate dodecahydrate [10102-71-3] NaAl(SO4
2−)2•12H2O Hydrated sodium alum
Aluminium sulphate [10043-01-3] Al2(SO4
2−)3 Sulphuric acid, aluminium salt; cake alum
Aluminium sulphate octadecahydrate [7784-31-8] Al2(SO4
2−)3•18H2O
Aluminium sulphide [1302-81-4] Al2S3 -
Aluminium tartrate [815-78-1] Al(C4H4O6
−)3 -
Aluminium terachloroaluminate [7784-16-9] NaAlCl4 Sodium chloroaluminate
Aluminium thiocyanite [538-17-0] Al(CNS)3 -
Ammonium hexafluoroaluminate [7784-19-2] (NH4
+)3(AlF6
3−) Ammonium cryolite; ammonium aluminium fluoride
Ammonium tetrachloroaluminate [7784-14-7] (NH4
+)(AlCl4
−) Aluminium ammonium chloride; ammonium
chloroaluminate
Calcium aluminosilicate [1327-39-5] CaAl2S2O8, Ca2Al2SiO7 -
Cryolite [15096-52-3] Na3(AlF6
3−) Sodium aluminium fluoride; trisodium
hexafluoroaluminate (3-)
Dihydrobis (2-methoxyethanolate-O,O) aluminate (1-) sodium
[22722-98-1]
NaAlH2(C3H7O2
−)2 Sodium bis(methoxyethoxy) aluminium hydride;
vitride (R) T reducing agent
Fosetyl aluminium [39148-24-8] Al(CH3OPHO2
−)3 Aluminium tris(ethyl hydrogen phosphonate);
phosphonic acid, monoethyl ester; efosite aluminium
Hydrated magnesium-aluminium-iron silicate [1318-00-9] - Vermiculite
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Compound[CAS No]c Chemical Formula Common Synonyms
Indium gallium aluminium phosphide [108424-49-3;
108730-13-8]
InGaAlP -
Potassium aluminate [1302-63-2] K2Al2O4 Aluminium potassium oxide
Quanidenium aluminium sulphate hexahydrate [10199-21-0] N3H6
+ [Al(SO4
2−)2]•6H2O -
Sodium aluminate [1302-42-7] NaAlO2 Aluminium sodium dioxide
Tris(8-hydroxyquinoline) aluminium [2085-33-8] Al(C9H6NO
−)3 Aluminium tris(8-hydroxyquinoline)
a
Major sources: Lie (1990/1991); The Merck Index (2001); Office of the Federal Register (2003); ChemFinder.com
(http://chemfinder.cambridgesoft.com).
b
See Table 2 for non-industrial compounds.
c
Chemical Abstracts Service (CAS)
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Table 2
Chemical identity of aluminium and its compounds used in pharmaceuticals, food additives, cosmetics and
household productsa, b.
Compound [CAS No] Chemical Formula Common Synonyms
Acetylglycerrhetinic acid, aluminium salt [29728-34-5]AlC96H141O15 Glycyrrhetic acid, aluminium salt; almacet
Aluminium [7429-90-5] Al Aluminium powder or foil
Aluminium acetate [8006-13-1] Al(CH3CO2
−)3 -
Aluminium ammonium sulphate
[7784-25-0] anhydrous
[7784-26-1] dodecahydrate
NH4Al(SO4
2−)2
NH4Al(SO4
2)2•12H20
Alum, ammonium
Aluminium basic acetate [142-03-0] [8000-61-1] Al(OH)(CH3CO2
−)2 Aluminium subacetate; bis(acetato-O)
hydroxyaluminium
Aluminium benzoate [555-32-8] Al(C7H6O2
−)3 Aluminium tribenzoate
Aluminium bis(acetylsalicylate) [23413-80-1] Al(OH)(C9H7O4
−)2 Aluminium diaspirin
Aluminium bromohydrate [39431-98-6] Al2(OH)5Br Dialuminium bromide pentahydroxide
Aluminium butyrate [2269-22-9] Al(C4H9O
−)3 Aluminium sec-butoxide
Aluminium carbonate basic [1339-92-0] Al(OH)(CO3
2−) Basic aluminium carbonate
Aluminium chloride hexahydrate [7748-13-6] AlCl3•6H2O Hydrated aluminium chloride
Aluminium chlorohydrex [53026-85-0] [68953-68-4] - Aluminium chlorohydroxy propyleneglycol complexes
Aluminium citrate [31142-56-0] (NH4
+)5[Al3(H-1Cit)3(OH)(H2O)[NO3
−]•6H2O
Aluminium di(2-ethylhexoate) [1336-25-0] Al(OH)(C7H14CO2
2−)2 2-Ethylexanoic acid aluminium salt
Aluminium fatty-acid saltsc Al(FA)3 FA, aluminium salt
Aluminium glycinate [13682-92-3] Al(OH)(CH2NH2CO2
2−) Dihydroxy aluminium aminoacetate
Aluminium hexaurea sulphate triiodide [15304-14-0] Al[CO(NH2)2]6[SO4I3] -
Aluminium hydroxide [21645-51-2] Al(OH)3 Alumina hydrate
Aluminium hydroxychloride [1327-41-9] Al2(OH)5Cl•2H20 Aluminium chlorhydroxide; basic aluminium chloride
Aluminium lactate [18917-91-4] Al[CH3(OH)CO2
−]3 Aluctyl
Aluminium magnesium silicate [12511-31-8] MgAl2(SiO4
4−)2 Magnesium alumino-silicate
Aluminium metal silicates Ca [1327-39-5]; Na
[1344-00-9]; Na and Ca [1344-01-0]
Na12[(AlO2)12(SiO2)12]•27H2O (sodium) -
Aluminium methanedisulphonate [52667-15-9] Al2(CH2S2O6
2−)3 Methionic acid, aluminium salt
Aluminium nicotinate - Nicalex
Aluminium nitrate [13473-90-0] Al(NO3
-)3 -
Aluminium phenolsulphonate [1300-35-2] Al(C6H5OSO3
−)3 Aluminium tris(hydroxybenzene-sulphonate)
Aluminium phosphate [7784-30-7] Al(PO4) Aluminium orthophosphate; phosphoric acid,
aluminium salt
Aluminium potassium silicate [1327-44-2] anhydrous Al2O3K2O•6SiO2 Potassium aluminium silicate
[12001-26-2] hydrated KAl2(AlSiO3O10)(OH)2 Mica; soapstone
Aluminium potassium sulphate [10043-67-1] KAl(SO4
2−)2 Potassium alum
Aluminium potassium sulphate dodecahydrate
[7784-24-9]
KAl(SO4
2−)2•12H2O
Aluminium silicate [12141-46-7] anhydrous Al2SiO5 Sillimanite; andalusite
[1332-58-7] hydrated Al2O3SiO2•2H2O China clay; kaolin
Aluminium sodium carbonate hexitol complex - Alexitol sodium; sodium polyhydroxoxyaluminium
monocarbonate hexitol complex
Aluminium sodium sulphate [10102-71-3] NaAl(SO4
2−)2 Sodium alum; soda alum
Aluminium sodium sulphate dodecahydrate
[10102-71-3]
NaAl(SO4
2−)2•12H2O
Aluminium sulphate [10043-01-3] Al2(SO4
2−)3 Sulphuric acid, aluminium salt; Cake alum; anti-
infectiveAluminium sulphate octadecahydrate [7784-31-8] Al2(SO4
2−)3•18H2O
Basic aluminium clofibrate [24818-79-9] Al(OH)(C9H10ClOHCO2
−)2 Aluminium 2-(4-chlorophenoxy)-2-methylpropanate
Basic aluminium salicylates [not available] (C7H5O3)nAl(OH)3-n•xH20 Aluminium salicylates, basic
Basic aluminium-magnesium carbonate tetrahydrate
[66827-12-1]
Al2Mg6(OH)14(CO3)2•4H20 Almagate; almax
Basic aluminium-magnesium sulphate dihydrate
[74978-16-8]
Al5Mg10(OH)31(SO4)2•2H20 Magaldrate; magnesium aluminate hydrate
Basic sodium aluminium phosphate [7785-88-8] Na8Al2(OH)2(PO4)4 Kasal phosphate
Bismuth aluminate [12284-76-3] Bi2(Al2O4)3 Aluminium bismuth oxide
Dihydroxy aluminium sodium carbonate [539-68-4] NaAl(OH)2(CO3
2−) [Carbonato(1)-O]di-hydroxyaluminium monosodium
salt; Aluminium sodium carbonate hydroxide
Dihydroxyaluminium allentoinate [5579-81-7] Al(OH)2[C4H5N4O4
−] Aldoxia
Dihydroxyaluminium acetylsalicylate [53230-06-1] Al(OH)2(C9H7O4
−) Dihydroxyaluminium aspirin
Polyhydroxyaluminium acetylsalicylate [9014-67-9] Al2O3[C6H5OCOCH3
−]5 Aloxiprin
Sodium aluminium chlorohydroxy lactate
[97660-24-7] [8038-93-5]
- Aluminium chlorohydroxy lactate sodium complexes
Sucrose octakissulphate aluminium salt [54182-58-0] R-(CH2OSO3
−)8[Al2(OH)5
+ ]8
R = sucrose
Sucralfate
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Compound [CAS No] Chemical Formula Common Synonyms
a
Major sources: Lie (1990/1991); The Merck Index (2001); Office of the Federal Register (2003); ChemFinder.com
(http://chemfinder.cambridgesoft.com).
b
See Table 1 for list of compounds used industrially
c
Some specific FA are identified in Table 1
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Table 6
Summary of industrial uses of aluminium and its compounds – industrial compoundsa.
Compoundb Common Usesc
Aluminium Metal and alloys; foils; in propellants and pyrotechnics
Aluminium alkyls Catalysts
Aluminium alkoxides: ethoxide; tert-butoxide; isopropoxide Oxidizing agents; catalysts
Aluminium antimonide Semiconductor research
Aluminium basic acetate Dyeing agent; water-/fire-proofing agent
Aluminium borate Polymerization catalyst; component of glass
Aluminium borohydride Reducing agent and jet fuel
Aluminium bromide Acid catalyst
Aluminium calcium hydride Reducing agent
Aluminium carbide Reducing agent; source of methane
Aluminium chlorate Disinfectant; bleaching agent
Aluminium chloride Acid catalyst
Aluminium chloride hexahydrate Preserver; disinfectant; dyeing agent
Aluminium fatty-acid salts: oleate, palmitate, stearate, linoleate Ingredients of high temp lubricants, lacquers, waterproofing materials;
protective cover
Aluminium fluoride In ceramics; metallurgical flux; inhibitor of fermentation; catalyst
Aluminium hexafluorosilicate In construction materials; glass manufacture
Aluminium hydride Reducing agent; catalyst
Aluminium hydroxide Adsorbent; emulsifier; dyeing mordant; manufacture of glass;
lubricants; detergents; waterproofing fabrics
Aluminium hypophosphite Polymer fibre finishing agent
Aluminium iodide Catalyst
Aluminium lactate Fire extinguishing foam
Aluminium lithium hydride Reducing agent
Aluminium magnesium silicate Thickening agent
Aluminium nitrate Tanning agent; corrosion inhibitor; nitrating agent
Aluminium nitride Semiconductor component
Aluminium oxalate Dyeing mordant
Aluminium oxide Adsorbent; abrasive; in lubricants; water-proofing agent
Aluminium phosphate Cement component; ceramic flux
Aluminium phosphide Fumigant; semiconductor research
Aluminium potassium sulphate/ aluminium potassium sulphate dodecahydrate In manufacture of dyes; specialty cements; tanning agent; staining
mordant
Aluminium selenide Semiconductor research
Aluminium silicate In glass; manufacture of ceramics; semiprecious stones; enamels; paint
filler
Aluminium sodium sulphate/ aluminium sodium sulphate dodecahydrate As for potassium alum
Aluminium sulphate/ aluminium sulphate octadecahydrate Tanning agent; dyeing mordant; fire/waterproofing agent; decolorizing
and clarifying agent
Aluminium sulphide -
Aluminium tartrate Textile dyeing agent
Aluminium terachloroaluminate Catalyst
Aluminium thiocyanite Dyeing mordant
Ammonium hexafluoroaluminate Synthetic agent
Ammonium tetrachloroaluminate Fur processing agent
Calcium aluminosilicate Constituent of cement and refractories
Cryolite Used in aluminium refining
Dihydrobis (2-methoxyethanolate- O,O) aluminate (1-) sodium Reducing agent
Fosetyl aluminium Agricultural fungicide
Hydrated magnesium-aluminium-iron silicate Catalyst; insulation; filler/packing material
Indium gallium aluminium phosphide Use in optical/information processing systems
Potassium aluminate Cement set accelerator
Quanidenium aluminium sulphate hexahydrate -
Sodium aluminate Manufacture of dyes: milk, soap, glass; stone hardener; water softener
Tris(8-hydroxyquinoline) aluminium Active organic light-emitting diode component
a
Major sources: Lie et al. (1990/1991); The Merck Index (2001); Office of the Federal Register (2003); ChemFinder.com
(http://chemfinder.cambridgesoft.com)
b
CAS Numbers are listed in Table 1
c
For some of the compounds listed, uses as pharmaceuticals, cosmetics, and household products are provided in Table 7.
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Table 7
Summary of uses of aluminium and its compounds - pharmaceuticals, food additives, cosmetics and other
household productsa.
Compoundb Common Usesc
Acetylglycerrhetinic acid, aluminium salt Antiulcerative
Aluminium Aluminium foil; colour ingredient: topical drugs, food packaging
Aluminium acetate Astringent; antiseptic; in food packaging
Aluminium ammonium sulphate (anhydrous and dodecahydrate Astringent; food additive
Aluminium basic acetate Antiseptic; antiperspirant
Aluminium benzoate Antimicrobial
Aluminium bis(acetylsalicylate) Analgesic, antipyretic
Aluminium bromohydrate Antiperspirant
Aluminium butyrate Food packaging ingredient
Aluminium carbonate - basic Antacid; phosphate binder
Aluminium chloride hexahydrate Antiperspirant
Aluminium chlorohydrate Antiperspirant
Aluminium chlorohydrex Topical drug: acne
Aluminium citrate Antiperspirant
Aluminium di(2-ethylhexoate) Food packaging ingredient
Aluminium fatty-acid salts Food packaging ingredient
Aluminium glycinate Antacid
Aluminium hexaurea sulphate triiodide Drinking water antiseptic
Aluminium hydroxide Antacid; antidiarrheal; food colouring agent; topical drugs: diaper rash, anti-
fungal, acne; food packaging ingredient; vaccine adjuvant
Aluminium hydroxychloride Astringent; anti-hyperphosphatemic
Aluminium lactate Antiseptic; in dental impression material
Aluminium magnesium silicate Antacid; topical acne
Aluminium metal silicates (sodium and/or calcium) Food Anticaking agent
Aluminium methanedisulphonate Astringent
Aluminium nicotinate Antihyperlipoproteinemic; source of niacin
Aluminium nitrate Antiperspirant
Aluminium phenolsulphonate Antiperspirant; antimicrobial agent
Aluminium phosphate Antacid; vaccine adjuvant; dental cement
Aluminium potassium silicate (anhydrous) Food packaging ingredient
Aluminium potassium silicate (hydrated) Drug colouring agent; cosmetic ingredient
Aluminium potassium sulphate/Aluminium potassium sulphate
dodecahydrate
Astringent; antiperspirant; water purification agent; baking powder; topical:
diaper rash, anti-fungal; food additive; in preparation of vaccine adjuvants
Aluminium silicate (anhydrous Dental cement; food packaging ingredient
Aluminium silicate (hydrated) Food packaging ingredient
Aluminium sodium carbonate hexitol complex Antacid
Aluminium sodium sulphate/aluminium sodium sulphate dodecahydrate As for potassium alum
Aluminium sulphate/aluminium sulphate octadecahydrate Antiperspirant; topical: diaper rash, anti-fungal; food additive
Basic aluminium clofibrate Antilipimic
Basic aluminium salicylates Antidiarrheal
Basic aluminium-magnesium carbonate tetrahydrate Antacid
Basic aluminium-magnesium sulphate dihydrate Antacid
Basic sodium aluminium phosphate Food additive; leavening agent
Bismuth aluminate Antacid
Dihydroxy aluminium sodium carbonate Antacid
Dihydroxyaluminium allentoinate Astringent; antiulcerative
Dihydroxyaluminium acetylsalicylate Analgesic, antipyretic
Polyoxyaoluminum acetylsalicylate Analgesic
Sodium aluminium chlorohydroxy lactate Antiperspirant; cosmetic products
Sucrose octakissulphate aluminium salt Antiulcerative
a
Major sources: Lie et al. (1990/1991); The Merck Index (2001); Office of the Federal Register (2003); ChemFinder.com
(http://chemfinder.cambridgesoft.com)
b
CAS Numbers are listed in Table 2
c
For some of the compounds listed, industrial uses are provided in Table 6.
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Table 8
Global markets for aluminium productsa.
Market Sector Market Share (%)
Building/Construction 23
Transport-Auto and light truck 18
Transport-Truck, bus, train, ship 9
Packaging-cans 10
Packaging-foil and container 6
Electrical-cable 9
Electrical-other 1
Machinery and Equipment 7
Consumer Durables 7
Aerospace 1
Other 9
a
Data from E. Nordheim, personal communication (2005)
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Table 9
Major (U.S.) markets for aluminium products in 1997a.
Market Sector Market Share (%)
Transportation 34
Containers/Packaging 25
Building/Construction 15
Electrical 8
Consumer Products 8
Other (e.g., machinery/equipment) 10
a
From USGS (1997) in ATSDR (1999)
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Table 10
U.S. occupational exposure limits for aluminium.
Organization Substance Value Reference
OSHA-PELb Total dust 15 mg/m3 – 8 hr TWA NIOSH (2005)
OSHA-PEL Respirable fraction 5 mg /m3 - 8h hr TWA NIOSH (2005)
ACGIH TLVd Metal dust 10 mg /m3 TWA ACGIH (2005)
ACGIH TLV Welding fume 5 mg /m3 TWA ACGIH (1996)a
NIOSH RELc Total dust 10 mg /m3 - TWA NIOSH (2005)
NIOSH REL Respirable fraction 5 mg /m3 - TWA NIOSH (2005)
NIOSH REL Welding fumes 5 mg /m3 - TWA NIOSH (1992)a
a
From ATSDR (1999)
b
Permissible Exposure Limit
c
Recommended Exposure Limit
d
Threshold Limit Value
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Table 11
Limits for occupational exposure to aluminium oxide in Europe, Australia and the U.S.a
Country Occupational Exposure Limit Date
Austria MAKb 0.25 fibers/cm3 Jan, 2006
Belgium 10 mg/m3 – TWAc Jan, 1993
Denmark 10 mg(Al)/m3 – TWA Oct, 2002
France VMEd 10 mg/m3 Jan, 1999
Germany MAK 1.5 mg/m3, respirable fume 2005
Netherlands MAC-TGGe 10 mg/m3 2003
Norway 2 mg(Al)/m3 – TWA
MAC 2 mg/m3 – TWA
Jan, 1999
Poland MAC 16 mg/m3 – STELf Jan, 1999
Russia 6 mg/m3 - TWA Jun, 2003
Sweden 4 mg(Al)/m3, respirable dust – TWA Jan, 1999
Sweden 10 mg(Al)/m3, total dust – TWA Jan, 1999
Switzerland MAK- week 2 mg(Al)/m3 Jan, 1999
United Kingdom 10 mg/m3, total inhalable dust – TWA 2005
United Kingdom 4 mg/m3, respirable dust – TWA 2005
Australia 10 mg/m3 TWA Jan, 1993
U.S. PELg 15 mg/m3, total dust-TWA 1994
U.S. PEL 5 mg/m3, respirable fraction - TWA 1994
a
From RTECS (2006)
b
Maximum workplace concentration
c
Time weighted average
d
Limit values for average exposure
e
Maximum allowable concentration averaged over working life
f
Short term exposure limit
g
Permissable exposure limit
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Table 12
Limits for aluminium in general environments.
Country/Organization Nature of Limit Value
FAO / WHO Provisional Tolerable Weekly Intake 1 mg/kg b.w.
U.S. MRL (intermediate duration-oral) 2 mg/kg/day
WHO Drinking Water Guideline a
EU Drinking Water Directive 0.2 mg/L
United States Secondary Drinking Water Regulation 0.05-0.2 mg/L
Australia Drinking Water Guideline (aesthetic) 0.2 mg/L
Canada Drinking Water Guideline b
U.S. Association for the Advancement of Medical
Instrumentation
Water for dialysate solution <10 μg/L
a
“Practicable levels” of ≤0.1 and ≤0.2 mg/L for large and small facilities, respectively, based on optimization of the coagulation process.
b
Where aluminium-based coagulants are used in conventional treatment plants, the operational guidance level is <0.1mg/L (based on a 12 month running
average of monthly samples); for other types of treatment systems using such coagulants, the operational guidance value is <0.2 mg/L.
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Table 15
Mean concentrations of total aluminium (μg/L) and proportion of constituent fractions % in drinking water (after
purification treatment).
Aluminium Fraction Driscoll & Letterman (1995) Schintu et al. (2000)
Number of plants (country) 3 (U.S.) 3 (Italy)
Collection period Dec 1990 – Jan 1992 Oct 1995 – Feb 1996
Total (unfiltered, acidified), μmol/L (μg/L) 4.7-6.3 (128-169) 3.7-6.7 (100-180)
Total dissolved (after filtrationa; organic, inorganic and colloidal), %
of total
- 53-96
Total monomeric, % of total 21-82 40-62
Organic monomeric, % of total monomeric 15-51 -
Organic (monomeric, tightly bound and colloidal), % of total dissolved - 12-59
Inorganic monomeric, % of total monomeric 49-85 -
Inorganic (monomeric, tightly bound and colloidal), % of total
dissolved
- 41-88
Particulate (suspended plus colloidal)b, % of total 19-83c 19 (mean)
a
0.4 μm filter (Driscoll & Letterman, 1995) and 0.22 μm filter (Schintu et al., 2000)
b
Particulate aluminium is defined as the total (that available on acidifying unfiltered water) minus total dissolved (that available on acidifying after
filtration)
c
Individual values were 19, 59 and 83 %.
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Table 16
Estimates of daily aluminium intakea.
Source Aluminium Concentration Daily Intake (mg) Bioavailabilityh (uptake) (%)
Foodb 0.001 – 40 mg/100 g 7.2 ± 0.3 (females, 14 and older)
8.6 ± 0.7 (males, 14 and older)
0.05 - 0.1
Drinking Water ≤ 200 μg/L 0.16 (mean)c 0.3
Ambient Aira 0.6-7.0 μg/m3 (PM10) [occupational: 1-6 mg/
m3 ‘total’]g
<0.06f [3.5-21.0]g 1.0 - 2.0 (depends on water- solubility)
Antacidsa,d 60-160 mg/5 mL or 110-174 mg/tablet 120-7200 0.3
Buffered Aspirina,d --- 200-1000 0.3
Anti-perspirantse As powder or solution (25% by w.t.) ? ?
a
Based on: Van Oostdam et al. (1990).
b
Source: Pennington & Schoen (1995). It includes contributions from contact with aluminium foil or cookware; values for younger children are lower.
Recent determinations of aluminium in foods have confirmed that the highest concentration reported here is typical of some processed foods (Saiyed &
Yokel, 2005).
c
Mean value in drinking water of 107μg/L and a daily intake of 1.5L (Nieboer et al., 1995 and Human Exposure, General Population Exposures, Drinking
Water).
d
From Ott (1990) and ATSDR (1999). Based on the daily recommended dose of 400 milliequivalents neutralizing capacity, typical intake of aluminium
ranges 3500-5200 mg/day (Brunton, 1996).
e
From Hem & White (1989). The active ingredient is aluminium chlorohydrate, Al(OH)5Cl or aluminium chloride hexahydrate, AlCl3•6H2O. Other
formulations have been reported (Yokel & McNamara, 2001). Based on the published literature, it remains uncertain whether there is absorption of Al
through the skin. Therefore, a value for bioavailability could not be defined.
f
Intake 23 m3/day of air and 35% particle retention (Van Oostdam et al., 1990).
g
Intake of 10m3 per 8-hr shift and particle retention of 35% (Van Oostdam et al., 1990; ATSDR, 1999); the occupational air levels shown are typical for
a work area with significant exposures to both water-insoluble and soluble aluminium such as those experienced in primary and secondary refining (see
Table 14), or for exposures to small-sized particles such as for aluminium welders (see Human Exposure, Occupational Exposure, User Industries).
Typical occupational ‘total’ exposure limits are: 10 mg/m3 (metal dust and aluminium oxide); 5 mg/m3 (pyro powders); and 2 mg/m3 (soluble salts)
(ACGIH, 2005).
h
Based on estimates reported in Nieboer et al. (1995) and in Toxicokinetics, Absorption, Studies in Humans.
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Table 17
Summary of the influence of factors that affect oral aluminium absorption from studies in animals.
Factor Influence on absorption Reference(s)
Solubility Greater solubility, increased
absorption.
Froment et al. (1989a); Yokel & McNamara (1988)
pH Greater absorption at pH 4 than 7. Van der Voet & De Wolff (1986-1987)
Carboxylic acids (citrate) Increased Deng et al. (1998; 2000); Drüeke et al. (1997); Froment et al. (1989a); Partridge
et al. (1989; 1992); Schönholzer et al. (1997); Sutherland & Greger (1998);
Van der Voet et al. (1989); Yokel & McNamara (1988)
Carboxylic acids (acetate, oxalate,
lactate, malate, tartrate, gluconate,
ascorbate, or carbonate)
Increased, but less than produced
by citrate.
Colomina et al. (1994); Domingo et al. (1991a; 1993; 1994); Gómez et al.
(1994); Nestel et al. (1994)
Silicon-containing compounds May reduce absorption. Bellés et al. (1998); Quartley et al. (1993)
Fluoride May enhance. Allain et al. (1996); Xiao et al. (1992)
Iron Inverse correlation between
dietary iron, and iron status, and
aluminium absorption.
Brown & Schwartz (1992); Cannata et al. (1991); Fernández et al. (1989);
Fernandez Menendez et al. (1991); Florence et al. (1994); Winklhofer et al.
(2000)
Calcium Inverse correlation between
dietary calcium, and calcium
status, and aluminium absorption.
Feinroth et al. (1982); Provan & Yokel (1990); Taneda (1984)
Sodium Reduction increased aluminium
uptake.
Van der Voet & de Wolff (1987a)
Ethanol May increase aluminium
absorption or decrease elimination.
Flora et al. (1991)
Uraemia Enhanced absorption. Ittel et al. (1987; 1988; 1991b; 1997); Olaizola et al. (1989); Yokel &
McNamara (1988)
Foods and dietary Components Results suggest both that food does
and does not inhibit aluminium
absorption.
Drüeke et al. (1997); Jouhanneau et al. (1997a); Schönholzer et al. (1997);
Yokel et al. (2001b)
Aluminium dose Increased dose increased
aluminium bioavailability from
soluble aluminium species.
Ittel et al. (1993b); Yokel & McNamara (1985)
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Table 18
Summary of the influence of factors that affect oral aluminium absorption from studies in humans.
Factor Influence on absorption Reference(s)
Solubility Aluminium absorption is greater
from water than aluminium
hydroxide or sucralfate, and from
sucralfate suspension than tablet.
Haram et al. (1987); Schönholzer et al. (1992); Weberg & Berstad (1986) whereas
from drinking water was ~ 0.22 and 0.35% (Conway et al., 1994; Priest et al.,
1998; Stauber et al., 1999)
pH Greater absorption at lower
gastric pH.
Olaizola Ottonello et al. (1991); Rodger et al. (1991)
Carboxylic acids (citrate) Increased Coburn et al. (1991); Fairweather- Tait et al. (1994); Lindberg et al. (1993); Mauro
et al. (2001); Nestel et al. (1994); Nolan et al. (1990); Nordal et al. (1988a); Priest
et al. (1996); Rudy et al. (1991); Slanina et al. (1986); Walker et al. (1990);
Weberg & Berstad (1986)
Silicon-containing compounds May reduce absorption. Edwardson et al. (1993)
Iron Inverse correlation between iron
status and aluminium absorption
and serum aluminium.
Cannata et al. (1993); Huang et al. (1992)
Uraemia Increased Ittel et al. (1991a)
Dementia Increased absorption has been
suggested in AD and Down’s
subjects, but the reported results
could be due to differences in
aluminium distribution or
elimination.
Moore et al. (1997; 2000); Roberts et al. (1998); Taylor et al. (1992)
Aluminium dose Increased dose; decreased
aluminium bioavailability from
aluminium hydroxide.
Weberg & Berstad (1986)
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Table 19
Comparison of aluminium in the bulk brain samples from AD subjects with those of controls. Adopted and
modified from Yokel (2000).
Referencea Methodb # of Subjects Results
AD Control
Crapper et al. (1973) EAAS 5 3 Heterogeneous distribution within subjects.
Some overlap of AD & control values.
Grand mean AD 4 times controls.
Crapper et al. (1976) EAAS 10 7 Continuation of above 28% of AD values > 3 SD above control
value mean.
Trapp et al. (1978) EAAS 4 4 Grand mean AD 1.4 times controlsc.
McDermott et al. (1979) EAAS 10 9 No difference AD vs. control.
Crapper et al. (1980) EAAS Aluminium in nuclear and heterochromatin fractions of AD 2
times control values.
Yase (1980) NAA 3 3 Non-significant, 1.4 times, elevation in AD.
Traub et al. (1981) EAAS 7 4 4 of 7 AD considered in normal range.
Mean of normal 1.375, of AD 3.07 μg/g, significantly different.
Markesbery et al. (1981) NAA 12 28 Mean and median of control 1.3 times AD, maximum AD value
> max. control value.
Yoshimasu et al. (1985) NAA 4 6 Significant elevation in AD (average = 33.5 vs. 19.4 μg/g dry
weight)
Ward & Mason (1987) NAA 28 30 Canadian samples: mean AD 8-10 times controlsc.
30 30 UK samples: mean AD 3 times controlsc.
Jacobs et al. (1989) EAAS 6 4 Control mean 2 times AD mean.
Lukiw et al. (1991) EAAS Aluminium in a chromatin subcompartment, the dinucleosome
fraction, 3 times control values.
Xu et al. (1992c) EAAS 10 10 Approx. 2 times as much in hippocampus, inferior parietal lobule
and temporal gyri of AD than controlc.
Edwardson et al. (1992) EAAS 8 8 Control mean 1.2 times AD mean.
Yoshida et al. (1993);
Yoshida & Yoshimasu
(1996)
NAA 10 8 Aluminium concentrations reported to be above age-matched
controls.
Andrasi et al. (1995) ICP-AES & NAA 9 20 10 brain regions: AD 2.4-8.1 times control, overall AD 3.8 times
controlc.
Bjertness et al. (1996) EAAS 16 14 No difference.
Srivastava & Jain (2002) ICP-MS 4 4 Aluminium significantly higher in parietal cortex but not
cerebellum.
Andrási et al. (2005) ICP-AES & INAA 3 3 AD brain had significantly higher Al concentrations. Five brain
regions were studied.
a
in chronological order of publication
b
inductively coupled plasma atomic emission spectrometry
c
statistically significant
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Table 20
Comparison of aluminium in NFTs from AD subjects with those in controls, determined by microprobe analysis
or staining. Adopted and modified from Yokel (2000).
Referencea Methodb # of subjects Results
AD CONTROL
Terry & Pena (1965) EDX 1 Aluminium not detected.
Perl & Brody (1980) EDX 3 3 Aluminium seen in nucleus & cytoplasm of NFT-positive
cells in AD (91 & 29%) and controls (90 & 11%), but not
in non-NFT-bearing neurons (2 - 6%).
Masters et al. (1985) EDX Excessive Aluminium seen.
Candy et al. (1986) EDX Aluminium and silicon were co-localized in plaque cores in
AD and mentally-normal subjects.
Kobayashi et al. (1987) WDX 1 Aluminium not detected.
Jacobs et al. (1989) EDX 7 Aluminium not detected.
Schuurmans Stekhoven et al.
(1990)
EDX n=5 LMMS n=3 5 Aluminium not detected.
Moretz et al. (1990) EDX 3 Unable to demonstrate significant aluminium.
Chafi et al. (1991) WDX SIMS 7 Aluminium not detected.
Good et al. (1992) LMMS 10 4 In neurons with NFTs, Aluminium in NFTs > cytoplasm,
nucleus & neuropil.
Sparkman (1993) EDX Aluminium detected in NFTs, but not consistently in paired
helical filaments.
Lovell et al. (1993) LMMS 7 5 Grand mean [Al] AD cytoplasm of NFT-bearing neurons
(2.9 μg/gm), non-NFT-bearing neurons (2.3); control
neuron cytoplasm (1.85)
[Al] > 3 σ above control means: AD neurons 9.6-14.3%,
control 1.3-1.5%.
Bouras et al. (1997) LMMS 4 3 Aluminium in nuclei of NFT-free neurons and in the
neuropil in hippocampus and inferior temporal cortex was
2.2 to 3.4 fold higher than in controls
Reusche (1997) LMMS Aluminium not detected.
Makjanic et al. (1998) Nuclear microscopy Aluminium seen in neurons and neuropil of fixed,
osmicated tissue.
Aluminium not see in unstained, untreated tissue.
Kasa et al. (1995) solachrone azurine 10 5 Weak staining of cortical and hippocampal NFTs.
a
in chronological order of publication
b
EDX = Energy dispersive (electron probe) X-ray microanalysis; WDX = wavelength dispersive X-ray microanalysis; SIMS Secondary ion mass
spectrometry; LMMS = Laser microprobe mass spectroscopy
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Table 21
Determination of aluminium in plaques by microprobe methods or staining. Adopted and modified from Yokel
(2000).
Referencea Method # of Subjects Results
AD Control
Nikaido et al. (1972) EDX Aluminium not detected.
Duckett & Galle (1980) EDX 18 3 Highest aluminium seen in plaques &
lipofuscin granules in degenerating cells of all
brains.
Masters et al. (1985) EDX Aluminium & silicon in isolated, intact plaque
cores.
Candy et al. (1986) EDX Aluminium & silicon in plaques of AD and
mentally normal – aluminium 4-19% of plaque
core.
Candy et al. (1986) SIMS 3 Aluminium in in situ plaque cores.
Stern et al. (1986) LMMS 3 Unable to see aluminium in purified plaque
cores.
Mori et al. (1988) EDX Modest increase in some plaque cores & rims.
Jacobs et al. (1989) EDX 7 Aluminium not detected.
Larsson et al. (1990) Proton microprobe Aluminium not detected.
Moretz et al. (1990) EDX No significant difference in AD brain.
Chafi et al. (1991) WDX 7 Aluminium not detected.
Landsberg et al. (1992) Proton (nuclear) microscopy
techniques
5/4 2/2 Studied stained and unstained tissue. <10% of
plaque cores had aluminium. Aluminium
detected in background and control tissue.
Aluminium not detected in plaque cores of
unstained tissue, at stated sensitivity of 15
ppm.
Smith et al. (1992; 1994) EDX, SIMS 4 3 No difference between AD and control brain.
No evidence for significant, > 2-fold,
aluminium in AD pyramidal neurons.
Landsberg et al. (1993) Proton (nuclear) microscopy
techniques
6 2 Aluminium occurred at ≥ 50 ppm in the cores
of 20% of the senile plaques of stained tissue
Senitz & Bluthner (1990) Morin 3 Aluminium detected in dense core of plaque.
Favarato et al. (1992) Morin 5 Staining of plaque core.
Kasa et al. (1995) Solachrome azurine 10 5 Moderate-intense staining of core and/or rim
of some, not all, plaques.
a
in chronological order of publication
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Table 22
Inhalation exposures to aluminium in the workplace – case studies.
Exposure conditions Subjects described in the
report
Outcomes Comments References
Cases of severe lung
fibrosis due to aluminium
exposure in Germany in
the 1930s & 1940s
Cited by others as reporting the
first case of pulmonary fibrosis in
an aluminium worker.
Doese (1938)
Aluminium powder factory: ~ 4 billion
particles/g dust (an explosive
concentration of aluminium dust).
700 workers making
aluminium powder (98%
metallic aluminium) by a
stamping process just
before and during World
War II.
Dry cough, dyspnoea,
lymphocytosis X-rays similar
to those seen in silicosis, rapid
spread of diffuse hyaline
degeneration, spontaneous
pneumothorax was common,
loss of elastic tissue. 26% of
628 workers judged to be
uncomplicated cases of
pulmonary aluminosis. 4 men
with 1.5 to 16 years exposure
had spontaneous
pneumothorax. One fatal case
had collagenous fibres
enclosing phagocytes which
contained particles.
Goralewski (1941) stated: “
aluminium lung is a specific
disease entity.” Paraffin-like
substances were used due to a
shortage of stearine in war-time
Germany. The author believed
the increase of serious cases of
aluminium dust disease was due
to omission of stearine.
Goralewski (1939;
1940; 1941; 1943;
1948) (most of the
information was
obtained from Perry
(1947))
Cases of severe lung
fibrosis due to aluminium
exposure in Germany in
the 1930s & 1940s.
Koelsch (1942)
28 cases of aluminium
dust poisoning
Severe fibrosis of the lung due
to aluminium exposure.
The action of the dust is partly
mechanical, partly chemical.
Meyer & Kasper
(1942a; 1942b)
Aluminum Company of America -
Pittsburg plant - making aluminium
powder.
125 with 6 to 23, an
average of 12, years of
exposure.
Health better than 3,000
workers in other parts of the
plant in New Kensington.
Concluded inhalation of finely
particulate aluminium powder is
not harmful to human lung.
Crombie et al. (1944)
Grinding duralumin (95% aluminium,
3.5 to 4.5% copper, traces of other metals,
≤0.7 % silicon) and in a factory making
aluminium powder.
92 of 97 workers exposed
to aluminium dust.
Grinding process:
Average aluminium
concentration 3 to 5 mg l/
m3, 1/3 was 2 to 7 μm
diameter, 2/3 was ≥7 μm.
Alumina particles mostly
< 1 μm diameter.
Polishing process:
Average aluminium
concentration 50 to 100
mg /m3, 95 mg/ m3 of 7 to
40 μm, 1.4 mg/ m3 of 2 to
7 μm, 2.7 mg/ m3 of < 0.4
to 2 μm diameter.
X-rays in 7 showed shadows
in peripheral parts of their
lungs. 27 claimed to have
some cough, 10 were
somewhat short of breath.
X-ray changes and reported
symptoms were not thought to be
significant because they worked
without obvious effects on their
health. There was no evidence
that the dust caused any disease of
the trachea, bronchi or lungs. It
was noted by Mitchell et al.
(1961) that nearly all respirable
particles were alundum abrasive
and that the aluminium particles
were generally > 7 μm diameter.
Hunter et al. (1944)
Mostly furnace feeding, with some crane
operations, in the manufacture of an
abrasive, corundum, an aluminium oxide,
from bauxite. Most fume particles were
amorphous and < 0.5 μm in diameter.
23 cases 23 months to 15
years employment
X-rays showed shadows
accompanied by
pneumothorax, dyspnoea, and
sudden attacks of extreme
breathlessness. Some cases
showed diffuse non-nodular,
interstitial fibrosis. Some
were fatal.
Has features resembling the
condition attributed to dust
inhalation by Goralewski (1943).
The hypothesis is that intense
exposure to amorphous
aluminium dust may play a
dominant role.
Stated by McLaughlin et al.
(1962) that they were also
exposed to fumes of amorphous
silica.
Riddell (1948); Shaver
& Riddell (1947);
Wyatt & Riddell
(1949)
Aluminium smelting 97 workers were studied. Heavy damage to the lungs of
18 operators in smelting and
alloying departments who had
been employed an average of
6 years.
Aluminosis in 8, 1 with fibrosis,
and other changes caused by
aluminium compounds in 4.
Mödder and Schmitt
(1951)
Aluminium pulverizing A single case report Died 3 years after terminating
3 years employment.
Death attributed to aluminium
dust
Ueda et al.(1958)
Stamping of aluminium powder. Average
dust concentration 4 to 50 mg/m3, most <
4 μm diameter.
5 cases among a group of
35 workers.
Breathlessness after 2 to 4
years, and 13 years exposure
in one worker. Exposure was
terminated; 3 recovered, 2 did
not, 1 died, showing non-
specific lung inflammation,
fibrosis and emphysema.
Edling (1961)
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Exposure conditions Subjects described in the
report
Outcomes Comments References
Flash filler (filling fireworks with
aluminium powder [many particles < 5
μm] and potassium perchlorate by hand).
A case report of a 26 year
old female who had 5
years exposure.
Dyspnoea and gross
pulmonary fibrosis were seen.
She appeared to have had
tuberculosis.
Similar to cases reported by
Goralewski (1947), Shaver
(1948) and Mitchell (1959)
Jordan (1961)
Pyro stamping. Total dust concentration
(means of 5 & 7 samples): 615 & 685 mg/
m3. Respirable dust: 51 & 52 mg/m3.
Stamping, screening and weighing room
mean respirable dust concentration: 19 to
114 mg/m3; mean daily exposure time to
dusty work: 3.5 hr. 70% of particles < 5
μm diameter. 81% free aluminium, 17%
aluminium oxides and hydroxides, 0.5%
stearine (½ palmitic, ½ stearic acid),
0.5% silicon.
Examined 27 of 30
workers at risk. 12 were
exposed to fine
aluminium powder (2
died, 2 were affected). 15
worked with coarser
powder (2 had
radiological symptoms).
6 had pulmonary fibrosis.
There were 2 fatal cases where
pulmonary fibrosis was
conclusive, in 3 cases it was
sufficient and in 1 suggestive.
A follow-up of Mitchell (1959),
case report.
Concluded that finely divided
aluminium was responsible for
the lung damage.
Mitchell et al. (1961)
A ball mill operator in an aluminium flake
powder factory that incorporated 1.5 to 5
% stearic acid. Average concentrations
from 2 sites: total dust 0.94 and 1.46 mg/
m3 (60 & 71% aluminium) Respirable
dust concentration: 0.24 and 0.38 mg/
m3 (42 & 48% aluminium)
A case report of 49 year
old male with 13.5 years
exposure.
Lung shadows, adhesions in
pleural cavities, diffuse
fibrosis of upper lobes. 20 μm
aluminium flakes were seen in
his lungs, which had 340 &
430 mg Al/kg lung (wet
weight).
Histological picture similar to
that described by Mitchell et al.
(1961)
McLaughlin et al.
(1962)
Aluminium welder Case report Diffuse interstitial infiltrate
and mild dyspnoea.
Microscopic examination of
material from lung biopsy
showed extensive interstitial
granulomas composed of
macrophages, foreign body
giant cells and crystals
containing Al.
Chen et al. (1978)
Aluminium welding Case report Desquamative interstitial
pneumonia
Lung biopsy showed large
amounts of particles
containing Al, particularly in
alveolar macrophages.
A nonspecific response to inhaled
particles.
Herbert et al. (1982)
Welding with exposure exclusively to
aerosols of oxidized aluminium
A case report of a 35 year
old male with 17 years
exposure who was a 60
pack per year smoker.
Shortness of breath.
X-ray showed ill-defined
nodular, infiltrative lesions,
especially in the upper airway.
Fibrous pleural adhesions
were present.
Vallyathan et al.
(1982)
Aluminium rail grinding, often in an
extremely dusty work environment
Case report of a 44 year
old with 6 years exposure.
Shortness of breath X-ray
showed diffuse infiltrates and
restrictive lung disease. Lung
tissue contained >
342,000,000 particles/g dry
weight, of which 94.8% were
pure aluminium.
Concluded the inhaled aluminium
particles caused this pulmonary
alveolar proteinosis.
Miller et al. (1984)
Exposure to aluminium dust A case report. Developed
first symptoms of cough,
sputum after 3 years
exposure, diagnosis of
pneumoconiosis made 13
years after initiation of
exposure at age 33.
Pneumoconiosis,
characterized by intensive
lung fibrosis with an
hyperelastogenic reaction X-
ray showed extensive,
defacing fibrosis in both lungs
and pseudo-tumoral shadows.
Dyspnoea, which was
attributed to fibrosis, which
led to fatal chronic cor
pulmonale.
Aluminium concentration 50 to
70 mg/kg in mediastinal lymph
nodes and 0.4 to 2.2 mg/kg in lung
parenchyma
Freour et al. (1966)
Metal polishing A case report of a 61 year
old male with 20 years
exposure who was a 45
pack per year smoker.
Shortness of breath, dry
cough, and dyspnoea.
X-ray showed dense, diffuse
interstitial infiltrate, which
was denser in upper lung.
Bronchoalveolar lavage, lung
& lymph node particles ~ 1/3
aluminium, ~ ¼ silicon.
Large amount of 0.5 to 5 μm
particles in lung.
Diagnosis of pneumoconiosis
based on severe, diffuse, fibrosis;
massive dust deposits and no
specific sign of other lung
disease.
No silicotic nodules were seen.
De Vuyst et al. (1986)
Bauxite refining for aluminium oxide
production (8 cases), cold grinding of
13 males, mean 53 years
old. Awarded
compensation by Turin
X-ray showed irregular
opacities and nodular fibrosis.
Relatively benign character of
modern aluminium lung.
Avolio et al. (1989)
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Exposure conditions Subjects described in the
report
Outcomes Comments References
aluminium (3 cases), other occupations (2
cases)
branch of INAIL
(National Institute for
Insurance against
Occupational Accidents)
19 males, mean 54.7 years
old, mean 16 year dust
inhalation. Awarded
compensation by Venice
branch of INAIL.
X-ray showed 10 cases had
signs of fibrosis, 9 cases of
chronic obstructive
pulmonary disease.
Confirmation of aluminium
pneumoconiosis with moderate
functional alterations.
Lorusso et al. (1992)
Aluminium production A case report of a 62 year
old male industrial
engineer with 23 years
exposure.
Exertional dyspnoea. X-ray
showed bilateral interstitial
infiltrates. Pulmonary
function tests were consistent
with severe restrictive
ventilatory defect.
Al-Masalkhi &
Walton (1994)
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N
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Table 28
Established exposure limits for aluminiuma.
Pathway Exposure Limit Source of standard
Occupational Inhalation 2 mg/m3 Aluminium oxide – Poland, TWA MAC
Aluminium oxide – Switzerland, 2 week TWA
4 mg/m3 Respirable dust – Sweden, TWA
Respirable dust – UK, TWA
5 mg/m3 Respirable fraction – OSHA-PEL, 8 hr TWA
Respirable fraction – NIOSH REL, 10 hr TWA
6 mg/m3 Aluminium oxide – Russia, TWA
10 mg/m3 Metal dust – ACGIH TLV, 8 hr TWA
Welding fume – ACGIH, TWA
Aluminium oxide – ACGIH, TWA
Total dust – NIOSH REL – 10 hr TWA
Aluminium oxide – Belgium – TWA
Aluminium oxide – Denmark – TWA
Aluminium oxide – France – VME
Total dust – Sweden – TWA
Total inhalable dust – UK – TWA
15 mg/m3 Total dust – OSHA-PEL – 8 hr TWA
16 mg/m3 Aluminium oxide – Poland, STEL MAC
General Population Oral Intake 1 mg/kg-week FAO/WHO PTWI
2 mg/kg-day U.S. MRL (intermediate duration)
Population Drinking Water 0.05 to 0.2 mg/L U.S. Secondary Drinking Water Regulation
0.2 mg/L WHO – Drinking Water Guideline
European Union – Drinking Water Directive
Australia – Drinking Water Guideline
Injection Fluids 10 μg/L U.S. Association for the Advancement of Medical Instrumentation
a
Source: Tables 10, 11, and 12 of this report
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